import React, { useEffect } from 'react';
import * as SQLite from "expo-sqlite"
import { cos } from 'react-native-reanimated';

const db = SQLite.openDatabase('db.db')

const ExecuteQuery = (sql, params = []) => new Promise((resolve, reject) => {
      db.transaction((trans) => {
            trans.executeSql(sql, params, (trans, results) => {
                  resolve('Treatments Succesfully inserted into the database', results);
            },
                  (error) => {
                        reject('Failed to inserts Treatments into the database!', error);
                  });
      });
});

const insertTreatmentsToDatabaseAsync = async () => {
   let data =[
      {
          "id": 1,
          "drug_id": 1,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Reduction of hyperglycemia",
          "common_combinations": "High-fiber diet;SC insulin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:15:11.000000Z",
          "updated_at": "2020-09-16T00:15:11.000000Z"
      },
      {
          "id": 2,
          "drug_id": 1,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Reduction of hyperglycemia",
          "common_combinations": "High-fiber diet;SC insulin",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:15:13.000000Z",
          "updated_at": "2020-09-16T00:15:13.000000Z"
      },
      {
          "id": 3,
          "drug_id": 1,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Reduction of hyperglycemia",
          "common_combinations": "High-fiber diet;SC insulin",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:15:16.000000Z",
          "updated_at": "2020-09-16T00:15:16.000000Z"
      },
      {
          "id": 4,
          "drug_id": 2,
          "indication_name": "Feline immunodeficiency virus",
          "expected_effects": "Lower neutrophil count\r\nLess sepsis\r\nHigher lymphocyte count with treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:15:19.000000Z",
          "updated_at": "2020-11-04T01:53:13.000000Z"
      },
      {
          "id": 5,
          "drug_id": 2,
          "indication_name": "Feline immunodeficiency virus",
          "expected_effects": "Lower neutrophil count\r\nLess sepsis\r\nHigher lymphocyte count with treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:15:21.000000Z",
          "updated_at": "2020-11-04T01:53:13.000000Z"
      },
      {
          "id": 6,
          "drug_id": 2,
          "indication_name": "Feline leukemia virus",
          "expected_effects": "71% survival at 12 weeks, with significant increase in appetite, and significant reduction in incidence of sepsis.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:15:24.000000Z",
          "updated_at": "2020-11-04T01:53:13.000000Z"
      },
      {
          "id": 7,
          "drug_id": 2,
          "indication_name": "Feline leukemia virus infection with severe illness (lymphoma, leukopenia, etc.)",
          "expected_effects": "In 33% of dogs/cats, tumors decrease in volume before surgery (amount of volume reduction = 29-85%); histo shows tumor inflammation/necrosis",
          "common_combinations": "Surgical excision, radiation therapy, or both",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:15:26.000000Z",
          "updated_at": "2020-11-04T01:53:13.000000Z"
      },
      {
          "id": 8,
          "drug_id": 3,
          "indication_name": "Premedication",
          "expected_effects": "Mild tranquilization at 20 minutes, peaking at 30 minutes",
          "common_combinations": "Other premedications (e.g., opiate, benzodiazepine);Induction (e.g., propofol, ketamine-diazepam);Maintenance inhalants (e.g., isoflurane)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:15:29.000000Z",
          "updated_at": "2020-09-16T00:15:29.000000Z"
      },
      {
          "id": 9,
          "drug_id": 3,
          "indication_name": "Premedication",
          "expected_effects": "Tranquilization evident at 15 minutes",
          "common_combinations": "Dexmedetomidine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:15:31.000000Z",
          "updated_at": "2020-09-16T00:15:31.000000Z"
      },
      {
          "id": 10,
          "drug_id": 3,
          "indication_name": "Antiemetic",
          "expected_effects": "Mild decrease in nausea",
          "common_combinations": "18% incidence of vomiting if given 15 minutes before opioid (vs. 45% if coadministered with opioid, or 55% if given 15 minutes after opioid)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:15:34.000000Z",
          "updated_at": "2020-11-04T01:57:44.000000Z"
      },
      {
          "id": 11,
          "drug_id": 3,
          "indication_name": "Airline flight sedative",
          "expected_effects": "Quieter behavior, but unchanged level of stress",
          "common_combinations": "Initial decrease in activity level; stress leukogram and higher cortisol levels unchanged with treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:15:36.000000Z",
          "updated_at": "2020-11-04T01:57:44.000000Z"
      },
      {
          "id": 12,
          "drug_id": 3,
          "indication_name": "Urethral obstruction",
          "expected_effects": "Tranquilization, relief of urethral spasm; elimination of obstruction on 73% of cats, with remaining 27% refractory to this treatment/euthanized",
          "common_combinations": "Buprenorphine 0.075 mg PO q 8h, medetomidine 0.1 mg, IM, q 24h, decompressive cystocentesis, SC fluids PRN",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:15:38.000000Z",
          "updated_at": "2020-11-04T01:57:44.000000Z"
      },
      {
          "id": 13,
          "drug_id": 3,
          "indication_name": "Urethral obstruction",
          "expected_effects": "Tranquilization, relief of urethral spasm; elimination of obstruction on 73% of cats, with remaining 27% refractory to this treatment/euthanized",
          "common_combinations": "Buprenorphine 0.075 mg PO q 8h, medetomidine 0.1 mg, IM, q 24h, decompressive cystocentesis, SC fluids PRN",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:15:41.000000Z",
          "updated_at": "2020-11-04T01:57:45.000000Z"
      },
      {
          "id": 14,
          "drug_id": 3,
          "indication_name": "Analgesia (mild, superficial)",
          "expected_effects": "Mild superficial analgesia",
          "common_combinations": "Tramadol",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:15:43.000000Z",
          "updated_at": "2020-09-16T00:15:43.000000Z"
      },
      {
          "id": 15,
          "drug_id": 3,
          "indication_name": "Tranquilization",
          "expected_effects": "Mild tranquilization",
          "common_combinations": "Propofol",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:15:45.000000Z",
          "updated_at": "2020-09-16T00:15:45.000000Z"
      },
      {
          "id": 16,
          "drug_id": 3,
          "indication_name": "Analgesia (visceral)",
          "expected_effects": "No difference in visceral anesthesia compared with placebo control",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:15:47.000000Z",
          "updated_at": "2020-11-04T01:57:45.000000Z"
      },
      {
          "id": 17,
          "drug_id": 5,
          "indication_name": "Glaucoma",
          "expected_effects": "Reduction of intraocular pressure by approximately 20%",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:15:50.000000Z",
          "updated_at": "2020-11-04T02:01:14.000000Z"
      },
      {
          "id": 18,
          "drug_id": 5,
          "indication_name": "Chiari malformation",
          "expected_effects": "Reduction of cerebrospinal fluid pressure -- not substantiated",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:15:52.000000Z",
          "updated_at": "2020-11-04T02:01:14.000000Z"
      },
      {
          "id": 19,
          "drug_id": 6,
          "indication_name": "Antidote: acetaminophen toxicosis",
          "expected_effects": "Reduced/averted toxic effects\r\nImproved recovery from intoxication",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:15:54.000000Z",
          "updated_at": "2020-11-04T02:01:58.000000Z"
      },
      {
          "id": 20,
          "drug_id": 6,
          "indication_name": "Antidote: acetaminophen toxicosis",
          "expected_effects": "Reduced/averted toxic effects",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:15:57.000000Z",
          "updated_at": "2020-11-04T02:01:58.000000Z"
      },
      {
          "id": 21,
          "drug_id": 6,
          "indication_name": "Antidote: reduction of severity of Heinz body anemia (onion powder, propylene glycol)",
          "expected_effects": "Minimal impact\r\nSome GSH sparing that could be beneficial against mild oxidative stress",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:15:59.000000Z",
          "updated_at": "2020-11-04T02:01:58.000000Z"
      },
      {
          "id": 22,
          "drug_id": 6,
          "indication_name": "Acute spinal injury",
          "expected_effects": "No effect",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:16:03.000000Z",
          "updated_at": "2020-11-04T02:01:58.000000Z"
      },
      {
          "id": 23,
          "drug_id": 7,
          "indication_name": "Anti-inflammatory",
          "expected_effects": "Reduction of clinical signs caused by inflammation",
          "common_combinations": "Gastric protectants (misoprostol, famotidine, omeprazole)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:05.000000Z",
          "updated_at": "2020-09-16T00:16:05.000000Z"
      },
      {
          "id": 24,
          "drug_id": 7,
          "indication_name": "Antiplatelet",
          "expected_effects": "Reduced risk of thromboembolism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:16:08.000000Z",
          "updated_at": "2020-11-04T02:02:41.000000Z"
      },
      {
          "id": 25,
          "drug_id": 7,
          "indication_name": "Anti-inflammatory",
          "expected_effects": "Reduction of clinical signs caused by inflammation",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:16:10.000000Z",
          "updated_at": "2020-11-04T02:02:41.000000Z"
      },
      {
          "id": 26,
          "drug_id": 7,
          "indication_name": "Antiplatelet",
          "expected_effects": "Reduced risk of thromboembolism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:16:12.000000Z",
          "updated_at": "2020-11-04T02:02:41.000000Z"
      },
      {
          "id": 27,
          "drug_id": 7,
          "indication_name": "Antiplatelet",
          "expected_effects": "Reduced risk of thromboembolism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:16:15.000000Z",
          "updated_at": "2020-11-04T02:02:41.000000Z"
      },
      {
          "id": 28,
          "drug_id": 7,
          "indication_name": "Antiplatelet",
          "expected_effects": "Reduced risk of thromboembolism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:16:17.000000Z",
          "updated_at": "2020-11-04T02:02:41.000000Z"
      },
      {
          "id": 29,
          "drug_id": 8,
          "indication_name": "Diagnostic testing for hypo- or hyperadrenocorticism",
          "expected_effects": "Stimulation of adrenal cortisol secretion, causing increase in serum cortisol concentration (normal, hyperadrenocorticism) or no increase (hypoadrenocorticism, well-controlled hyperadrenocorticism, or injection error)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:20.000000Z",
          "updated_at": "2020-09-16T00:16:20.000000Z"
      },
      {
          "id": 30,
          "drug_id": 8,
          "indication_name": "Diagnostic testing for hypo- or hyperadrenocorticism",
          "expected_effects": "Stimulation of adrenal cortisol secretion, causing increase in serum cortisol concentration (normal, hyperadrenocorticism) or no increase (hypoadrenocorticism, well-controlled hyperadrenocorticism, or injection error)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:16:22.000000Z",
          "updated_at": "2020-09-16T00:16:22.000000Z"
      },
      {
          "id": 31,
          "drug_id": 9,
          "indication_name": "Diagnostic testing for hypo- or hyperadrenocorticism",
          "expected_effects": "Stimulation of adrenal cortisol secretion",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:24.000000Z",
          "updated_at": "2020-11-04T02:16:27.000000Z"
      },
      {
          "id": 32,
          "drug_id": 9,
          "indication_name": "Diagnostic testing for hypo- or hyperadrenocorticism",
          "expected_effects": "Stimulation of adrenal cortisol secretion",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:16:27.000000Z",
          "updated_at": "2020-11-04T02:16:27.000000Z"
      },
      {
          "id": 33,
          "drug_id": 9,
          "indication_name": "Diagnostic testing for hypo- or hyperadrenocorticism",
          "expected_effects": "Stimulation of adrenal cortisol secretion",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:16:30.000000Z",
          "updated_at": "2020-11-04T02:16:27.000000Z"
      },
      {
          "id": 34,
          "drug_id": 10,
          "indication_name": "Lymphoma (relapsed/resistant)",
          "expected_effects": "Remission of lymphoma",
          "common_combinations": "Prednisone/prednisolone, other antineoplastic drugs in chemotherapy protocols",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:32.000000Z",
          "updated_at": "2020-09-16T00:16:32.000000Z"
      },
      {
          "id": 35,
          "drug_id": 11,
          "indication_name": "Intoxications (numerous), including most pesticides and most human and veterinary medications",
          "expected_effects": "Reduction or avoidance of signs of toxicosis",
          "common_combinations": "Sorbitol and propylene glycol (in liquid preparations)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:35.000000Z",
          "updated_at": "2020-09-16T00:16:35.000000Z"
      },
      {
          "id": 36,
          "drug_id": 11,
          "indication_name": "Intoxications (numerous), including most pesticides and most human and veterinary medications",
          "expected_effects": "Reduction or avoidance of signs of toxicosis",
          "common_combinations": "Sorbitol and propylene glycol (in liquid preparations)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:16:37.000000Z",
          "updated_at": "2020-09-16T00:16:37.000000Z"
      },
      {
          "id": 37,
          "drug_id": 12,
          "indication_name": "Feline herpesviral keratitis",
          "expected_effects": "Resolution of clinical signs",
          "common_combinations": "Topical chlortetracycline against coinfection with Chlamydophila species, l-lysine PO",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:39.000000Z",
          "updated_at": "2020-09-16T00:16:39.000000Z"
      },
      {
          "id": 38,
          "drug_id": 12,
          "indication_name": "Canine herpesvirus",
          "expected_effects": "Lack of clinical efficacy in dogs with neonatal canine herpesvirus infection",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:16:42.000000Z",
          "updated_at": "2020-09-16T00:16:42.000000Z"
      },
      {
          "id": 39,
          "drug_id": 12,
          "indication_name": "Feline systemic viral infections",
          "expected_effects": "",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:16:45.000000Z",
          "updated_at": "2020-09-16T00:16:45.000000Z"
      },
      {
          "id": 40,
          "drug_id": 13,
          "indication_name": "Induction of parturition",
          "expected_effects": "Parturition, with first pup being born 32-56h after 1st injection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:16:47.000000Z",
          "updated_at": "2020-11-04T02:19:08.000000Z"
      },
      {
          "id": 41,
          "drug_id": 13,
          "indication_name": "Pyometra (open cervix)",
          "expected_effects": ">96% efficacy (compared to 88.5% with classical protocol involving 3 doses at days 0, 1, and 6) without recurrence for >2 years; post-treatment onset of estrus = 128 +/- 32 days (interestrous interval)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:16:50.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 42,
          "drug_id": 13,
          "indication_name": "Pregnancy termination",
          "expected_effects": ">99% termination of pregnancy by day 6 of treatment (aglepristone SC + intravaginal misoprostol) vs. 57% (aglepristone monotherapy), 86% (intravaginal misoprostol + aglepristone SC + cabergoline PO), and 43% (aglepristone SC + cloprostenol SC)",
          "common_combinations": "Intravaginal misoprostol (200 µg/DOG if body weight ≤ 20 kg, or 400 µg/DOG if body weight >20 kg) increases abortion rate to 100% within 6 days of start of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:16:52.000000Z",
          "updated_at": "2020-09-16T00:16:52.000000Z"
      },
      {
          "id": 43,
          "drug_id": 13,
          "indication_name": "Pyometra",
          "expected_effects": "90% of queens cured by day 21 after start of treatment\r\nNo recurrence in 2 years",
          "common_combinations": "Cotreatment with trimethoprim/sulfa 15 mg/kg SQ q 24h for 7 days",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:16:54.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 44,
          "drug_id": 13,
          "indication_name": "Mammary fibroepithelial hyperplasia",
          "expected_effects": "Visible regression of hyperplasia within 3-5 days, and complete normalization within 5 weeks",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:16:57.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 45,
          "drug_id": 13,
          "indication_name": "Pregnancy termination (early pregnancy)",
          "expected_effects": "87% successful abortion within 4-9 days after start of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:17:00.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 46,
          "drug_id": 13,
          "indication_name": "Pregnancy termination (mid-pregnancy)",
          "expected_effects": "88.5% successful abortion (50% within 3 days of treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:17:02.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 47,
          "drug_id": 13,
          "indication_name": "Pregnancy prevention",
          "expected_effects": ">99% effective at pregnancy prevention",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:17:05.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 48,
          "drug_id": 14,
          "indication_name": "Giardiasis",
          "expected_effects": "Complete elimination of Giardia cysts from feces",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:07.000000Z",
          "updated_at": "2020-11-04T02:21:15.000000Z"
      },
      {
          "id": 49,
          "drug_id": 14,
          "indication_name": "Filaroides hirthi",
          "expected_effects": "Full elimination of F. hirthi from pups of treated dams (0% infected), vs. 84% infected pups of nontreated dams",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:10.000000Z",
          "updated_at": "2020-11-04T02:21:15.000000Z"
      },
      {
          "id": 50,
          "drug_id": 14,
          "indication_name": "Trichinosis",
          "expected_effects": "Marked reduction in muscle larva burden",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:17:12.000000Z",
          "updated_at": "2020-11-04T02:21:15.000000Z"
      },
      {
          "id": 51,
          "drug_id": 14,
          "indication_name": "Oslerus (formerly Filaroides) osleri",
          "expected_effects": "Resolution of clinical signs after 30 days of treatment\r\nBronchial nodules may persist",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:17:15.000000Z",
          "updated_at": "2020-11-04T02:21:15.000000Z"
      },
      {
          "id": 52,
          "drug_id": 14,
          "indication_name": "Paragonimiasis",
          "expected_effects": "Elimination of Paragonimus ova in feces 9 days after start of treatment\r\nElimination of live flukes from lungs 4-5 weeks after start of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:17:17.000000Z",
          "updated_at": "2020-11-04T02:21:15.000000Z"
      },
      {
          "id": 53,
          "drug_id": 15,
          "indication_name": "Bronchoconstriction (e.g., feline bronchial disease/asthma)",
          "expected_effects": "Reduction of bronchoconstriction, leading to improved respiratory effort and rate",
          "common_combinations": "With or without Ipratropium bromide (40 µg Inhaled) and/or corticosteroids, either by inhaled aerosol (e.g., fluticasone) or systemic (e.g., prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:20.000000Z",
          "updated_at": "2020-09-16T00:17:20.000000Z"
      },
      {
          "id": 54,
          "drug_id": 15,
          "indication_name": "Acute and reversible airway inflammation",
          "expected_effects": "Improved respiratory function (not evident in experimental dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:22.000000Z",
          "updated_at": "2020-09-16T00:17:22.000000Z"
      },
      {
          "id": 55,
          "drug_id": 15,
          "indication_name": "Chronic sterile bronchitis",
          "expected_effects": "42% of dogs cough less according to owners, 50% are unchanged, and 8% cough more",
          "common_combinations": "Environmental modification",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:17:24.000000Z",
          "updated_at": "2020-09-16T00:17:24.000000Z"
      },
      {
          "id": 56,
          "drug_id": 16,
          "indication_name": "Osteosarcoma- palliation",
          "expected_effects": "Apparent pain palliation for 10 and 12 months in 2 reported cases of unresected limb osteosarcoma",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:27.000000Z",
          "updated_at": "2020-11-04T02:23:05.000000Z"
      },
      {
          "id": 57,
          "drug_id": 16,
          "indication_name": "Tooth resorption",
          "expected_effects": "Radiographic improvement leading to clinical improvement",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:29.000000Z",
          "updated_at": "2020-11-04T02:23:05.000000Z"
      },
      {
          "id": 58,
          "drug_id": 16,
          "indication_name": "Idiopathic hypercalcemia",
          "expected_effects": "Reduction in >89% of cases (magnitude of effect: 13-18% reduction in serum calcium concentration); normal serum concentrations at some point in first 6 months of treatment in 75% of cases.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:17:31.000000Z",
          "updated_at": "2020-11-04T02:23:05.000000Z"
      },
      {
          "id": 59,
          "drug_id": 17,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "General anesthesia",
          "common_combinations": "Routine premedication (if premed, reduce alfaxalone dose by 50% in dogs)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:35.000000Z",
          "updated_at": "2020-09-16T00:17:35.000000Z"
      },
      {
          "id": 60,
          "drug_id": 17,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "General anesthesia",
          "common_combinations": "Routine premedication (if premed, no change in alfaxalone dose in cats)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:37.000000Z",
          "updated_at": "2020-09-16T00:17:37.000000Z"
      },
      {
          "id": 61,
          "drug_id": 17,
          "indication_name": "Maintenance of general anesthesia",
          "expected_effects": "General anesthesia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:17:39.000000Z",
          "updated_at": "2020-09-16T00:17:39.000000Z"
      },
      {
          "id": 62,
          "drug_id": 18,
          "indication_name": "Urate urolithiasis prevention",
          "expected_effects": "Complete dissolution of urate uroliths (33%), partial dissolution (33%), or no dissolution (33%)",
          "common_combinations": "Balanced, low-purine diet (low/no organ meats)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:42.000000Z",
          "updated_at": "2020-09-16T00:17:42.000000Z"
      },
      {
          "id": 63,
          "drug_id": 18,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Long-term (up to 65 months) resolution of clinical and clinicopathologic signs of leishmaniasis (when combined with meglumine antimoniate)",
          "common_combinations": "Meglumine antimoniate",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:44.000000Z",
          "updated_at": "2020-09-16T00:17:44.000000Z"
      },
      {
          "id": 64,
          "drug_id": 18,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Complete resolution of ocular and hematologic abnormalities within 2 months in one feline case",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:17:47.000000Z",
          "updated_at": "2020-11-04T01:55:07.000000Z"
      },
      {
          "id": 65,
          "drug_id": 19,
          "indication_name": "Fear/anxiety/panic associated with car trips, veterinary visits",
          "expected_effects": "Decrease in intensity, frequency, or both, of problem behavior\nRapid onset of action (1-2 hours)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:49.000000Z",
          "updated_at": "2020-09-16T00:17:49.000000Z"
      },
      {
          "id": 66,
          "drug_id": 19,
          "indication_name": "Storm phobia",
          "expected_effects": "Improvement in signs of phobia in 94% of dogs, including complete resolution of phobia in 6% of dogs",
          "common_combinations": "Clomipramine given concurrently to storm-phobic dogs: 2 mg/kg PO q 12h for 3 months, then 1 mg/kg PO q 12h for 2 weeks, then 0.5 mg/kg PO q 12h for 2 weeks or longer",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:52.000000Z",
          "updated_at": "2020-09-16T00:17:52.000000Z"
      },
      {
          "id": 67,
          "drug_id": 20,
          "indication_name": "Chronic kidney disease",
          "expected_effects": "Reduction of serum phosphate level",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:17:54.000000Z",
          "updated_at": "2020-09-16T00:17:54.000000Z"
      },
      {
          "id": 68,
          "drug_id": 20,
          "indication_name": "Chronic kidney disease due to renal dysplasia",
          "expected_effects": "Reduction of serum phosphate level",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:17:57.000000Z",
          "updated_at": "2020-09-16T00:17:57.000000Z"
      },
      {
          "id": 69,
          "drug_id": 20,
          "indication_name": "Primary hypoparathyroidism",
          "expected_effects": "Reduction of serum phosphate level",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:18:00.000000Z",
          "updated_at": "2020-09-16T00:18:00.000000Z"
      },
      {
          "id": 70,
          "drug_id": 21,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Significant improvement in osteoarthritis-associated lameness that was persisting despite NSAID treatment",
          "common_combinations": "Meloxicam",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:02.000000Z",
          "updated_at": "2020-09-16T00:18:02.000000Z"
      },
      {
          "id": 71,
          "drug_id": 22,
          "indication_name": "Necrotizing fasciitis (and other systemic infections)",
          "expected_effects": "Elimination of infection",
          "common_combinations": "Ampicillin 22 mg/kg IV q 8h and/or other as appropriate for broad-spectrum coverage",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:05.000000Z",
          "updated_at": "2020-09-16T00:18:05.000000Z"
      },
      {
          "id": 72,
          "drug_id": 22,
          "indication_name": "Susceptible infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:07.000000Z",
          "updated_at": "2020-11-04T02:23:40.000000Z"
      },
      {
          "id": 73,
          "drug_id": 22,
          "indication_name": "Septic peritonitis",
          "expected_effects": "Elimination of infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:18:10.000000Z",
          "updated_at": "2020-11-04T02:23:40.000000Z"
      },
      {
          "id": 74,
          "drug_id": 23,
          "indication_name": "Degenerative myelopathy",
          "expected_effects": "Improvement (or delay in deterioration) did not occur, and treatment was considered minimally effective",
          "common_combinations": "Prednisone (1 mg/DOG q 24-48h);Acetylcysteine (23 mg/DOG q 8h);Vitamins B, C, and E",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:12.000000Z",
          "updated_at": "2020-09-16T00:18:12.000000Z"
      },
      {
          "id": 75,
          "drug_id": 23,
          "indication_name": "Prevention of postoperative hemorrhage in greyhounds",
          "expected_effects": "3 times less postoperative bleeding after ovariohysterectomy or gonadectomy compared to placebo (100 retired racing greyhounds)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:15.000000Z",
          "updated_at": "2020-11-04T02:26:49.000000Z"
      },
      {
          "id": 76,
          "drug_id": 24,
          "indication_name": "Vomiting/diarrhea",
          "expected_effects": "Decreased nausea/vomiting",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:17.000000Z",
          "updated_at": "2020-09-16T00:18:17.000000Z"
      },
      {
          "id": 77,
          "drug_id": 24,
          "indication_name": "Vomiting or regurgitation (suboptimal)",
          "expected_effects": "Decreased nausea/vomiting",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:20.000000Z",
          "updated_at": "2020-09-16T00:18:20.000000Z"
      },
      {
          "id": 78,
          "drug_id": 25,
          "indication_name": "Collapsing trachea",
          "expected_effects": "Reduction in cough",
          "common_combinations": "Antitussives (e.g., hydrocodone, butorphanol);Weight loss;Environmental control to reduce airborne irritants",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:23.000000Z",
          "updated_at": "2020-09-16T00:18:23.000000Z"
      },
      {
          "id": 79,
          "drug_id": 25,
          "indication_name": "Acute airway obstruction",
          "expected_effects": "Improvement in respiratory effort and rate from alleviation of bronchoconstriction",
          "common_combinations": "Oxygen therapy;intubation or tracheostomy may be needed if severe upper airway obstruction",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:25.000000Z",
          "updated_at": "2020-09-16T00:18:25.000000Z"
      },
      {
          "id": 80,
          "drug_id": 25,
          "indication_name": "Respiratory distress due to lower airway disease",
          "expected_effects": "Improvement in respiratory effort and rate from alleviation of bronchoconstriction",
          "common_combinations": "Oxygen therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:18:27.000000Z",
          "updated_at": "2020-09-16T00:18:27.000000Z"
      },
      {
          "id": 81,
          "drug_id": 26,
          "indication_name": "Atrial fibrillation",
          "expected_effects": "Reduction in resultant heart rate (ventricular response rate) of >20% in 76% of dogs\r\nConversion to sinus rhythm in 35% of dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:30.000000Z",
          "updated_at": "2020-11-04T02:27:44.000000Z"
      },
      {
          "id": 82,
          "drug_id": 26,
          "indication_name": "Atrial fibrillation: pretreatment before electrical cardioversion",
          "expected_effects": "Maintenance of normal sinus rhythm for median 120-150 days after electrical cardioversion",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:32.000000Z",
          "updated_at": "2020-11-04T02:27:44.000000Z"
      },
      {
          "id": 83,
          "drug_id": 27,
          "indication_name": "Demodicosis",
          "expected_effects": "Resolution of mite infestation and of skin lesions",
          "common_combinations": "Treatment of inciting cause or underlying illness (demodicosis is often opportunistic)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:35.000000Z",
          "updated_at": "2020-09-16T00:18:35.000000Z"
      },
      {
          "id": 84,
          "drug_id": 27,
          "indication_name": "Demodicosis",
          "expected_effects": "Resolution of mite infestation and of skin lesions",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:37.000000Z",
          "updated_at": "2020-09-16T00:18:37.000000Z"
      },
      {
          "id": 85,
          "drug_id": 28,
          "indication_name": "Separation anxiety",
          "expected_effects": "Improvement in separation anxiety behavior (success rate in dogs: 41%)",
          "common_combinations": "Behavior modification training;Benzodiazepine (clorazepate or alprazolam) or buspirone may be added if necessary",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:40.000000Z",
          "updated_at": "2020-09-16T00:18:40.000000Z"
      },
      {
          "id": 86,
          "drug_id": 28,
          "indication_name": "Idiopathic cystitis/feline lower urinary tract disease, refractory",
          "expected_effects": "Reduction in signs of lower urinary tract disease occurs in 60% of treated cats that failed to respond to other medications",
          "common_combinations": "Environmental enrichment",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:42.000000Z",
          "updated_at": "2020-09-16T00:18:42.000000Z"
      },
      {
          "id": 87,
          "drug_id": 28,
          "indication_name": "Psychogenic alopecia",
          "expected_effects": "Reduction in licking and increase in hair regrowth. Noticeable return of clinical signs if dosage is decreased or stopped in cats that were responding to treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:18:45.000000Z",
          "updated_at": "2020-09-16T00:18:45.000000Z"
      },
      {
          "id": 88,
          "drug_id": 29,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Decrease in blood pressure to ≤ 150 mmHg systolic and ≤ 95 mmHg diastolic (leading to decrease in magnitude, severity, and likelihood of target organ damage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:18:47.000000Z",
          "updated_at": "2020-09-16T00:18:47.000000Z"
      },
      {
          "id": 89,
          "drug_id": 29,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Decrease in blood pressure (typical goal: decrease by 20%)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:18:50.000000Z",
          "updated_at": "2020-09-16T00:18:50.000000Z"
      },
      {
          "id": 90,
          "drug_id": 29,
          "indication_name": "Degenerative mitral valve disease",
          "expected_effects": "Decreased afterload, prolonging disease-free interval during treatment for heart failure (unproven efficacy)",
          "common_combinations": "Diuretic;ACE inhibitor;Pimobendan",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:18:53.000000Z",
          "updated_at": "2020-09-16T00:18:53.000000Z"
      },
      {
          "id": 91,
          "drug_id": 29,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Decrease in blood pressure, typically of 40-55 mmHg (systolic) in moderately to severely hypertensive cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:18:55.000000Z",
          "updated_at": "2020-09-16T00:18:55.000000Z"
      },
      {
          "id": 92,
          "drug_id": 29,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Decrease in blood pressure (typical goal: decrease by 20%)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:18:57.000000Z",
          "updated_at": "2020-09-16T00:18:57.000000Z"
      },
      {
          "id": 93,
          "drug_id": 29,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Decrease in blood pressure (typical goal: decrease by 20%)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:19:00.000000Z",
          "updated_at": "2020-09-16T00:19:00.000000Z"
      },
      {
          "id": 94,
          "drug_id": 30,
          "indication_name": "Urinary acidification",
          "expected_effects": "Acidification of blood, plasma, and urine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:02.000000Z",
          "updated_at": "2020-09-16T00:19:02.000000Z"
      },
      {
          "id": 95,
          "drug_id": 30,
          "indication_name": "Diagnostic test for distal renal tubular acidosis",
          "expected_effects": "In normal dogs, urine pH decreases to 5.5 or less 3-4 hours after dosing. Failure to acidify urine this way suggests distal renal tubular acidosis.",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:19:05.000000Z",
          "updated_at": "2020-09-16T00:19:05.000000Z"
      },
      {
          "id": 96,
          "drug_id": 30,
          "indication_name": "Struvite urolithiasis",
          "expected_effects": "Decrease in content of struvite crystals in urine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:19:07.000000Z",
          "updated_at": "2020-09-16T00:19:07.000000Z"
      },
      {
          "id": 97,
          "drug_id": 31,
          "indication_name": "Gram-positive aerobic bacterial infections (e.g., pyoderma)",
          "expected_effects": "Elimination of signs of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:10.000000Z",
          "updated_at": "2020-09-16T00:19:10.000000Z"
      },
      {
          "id": 98,
          "drug_id": 31,
          "indication_name": "Leptospirosis",
          "expected_effects": "Elimination of leptospiremia and associated clinical signs",
          "common_combinations": "Ampicillin 22 mg/kg IV q 6-8h initially (before starting amoxicillin), then amoxicillin PO for 2 weeks, then doxycycline 5 mg/kg PO q 12h for 2 weeks to eliminate the organism from renal tissue",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:19:12.000000Z",
          "updated_at": "2020-09-16T00:19:12.000000Z"
      },
      {
          "id": 99,
          "drug_id": 31,
          "indication_name": "Helicobacteriosis",
          "expected_effects": "100% elimination of Helicobacter on gastroscopy/biopsy",
          "common_combinations": "Part of triple therapy including clarithromycin 25 mg/kg PO q 12h and lansoprazole 1 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:19:15.000000Z",
          "updated_at": "2020-09-16T00:19:15.000000Z"
      },
      {
          "id": 100,
          "drug_id": 31,
          "indication_name": "Cat bite abscesses",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:19:17.000000Z",
          "updated_at": "2020-09-16T00:19:17.000000Z"
      },
      {
          "id": 101,
          "drug_id": 31,
          "indication_name": "Helicobacteriosis",
          "expected_effects": "Transient suppression but no eradication (some resistance)",
          "common_combinations": "Part of quadruple therapy with omeprazole (0.7 mg/kg PO q 8h), metronidazole (20 mg/kg PO q 12h) and clarithromycin (7.5 mg/kg PO q 12h)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:19:20.000000Z",
          "updated_at": "2020-09-16T00:19:20.000000Z"
      },
      {
          "id": 102,
          "drug_id": 32,
          "indication_name": "Urinary tract infection",
          "expected_effects": "88% resolution of clinical signs\r\n81% of cultures negative 1 week after end of treatment (both results similar to treatment with high-dose enrofloxacin for 3 days)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:22.000000Z",
          "updated_at": "2020-11-04T16:52:26.000000Z"
      },
      {
          "id": 103,
          "drug_id": 32,
          "indication_name": "Skin infections",
          "expected_effects": "Elimination of signs of infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:19:25.000000Z",
          "updated_at": "2020-11-04T16:52:26.000000Z"
      },
      {
          "id": 104,
          "drug_id": 32,
          "indication_name": "Gastrointestinal disease with potential for bacterial translocation (e.g., hemorrhagic gastroenteritis)",
          "expected_effects": "May benefit if signs of sepsis (e.g., fever, leukocytosis/leukopenia, hyperdynamic shock)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:19:27.000000Z",
          "updated_at": "2020-11-04T16:52:26.000000Z"
      },
      {
          "id": 105,
          "drug_id": 32,
          "indication_name": "Pyometra (adjunctive treatment)",
          "expected_effects": "Reduction of severity/risk of sepsis",
          "common_combinations": "Definitive surgical or medical treatment of pyometra",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:19:30.000000Z",
          "updated_at": "2020-09-16T00:19:30.000000Z"
      },
      {
          "id": 106,
          "drug_id": 32,
          "indication_name": "Skin diseases with bacterial component (including feline eosinophilic plaque)",
          "expected_effects": "Significant reduction in lesion size",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:19:32.000000Z",
          "updated_at": "2020-11-04T16:52:26.000000Z"
      },
      {
          "id": 107,
          "drug_id": 32,
          "indication_name": "Chlamydophila psittaci",
          "expected_effects": "Elimination of infection and associated clinical signs. Effect is difficult to rationalize since beta-lactam antibacterials like amoxicillin are cell wall synthesis inhibitors and Chlamydophila does not have a cell wall\r\nPossible effects on secondary bacterial infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:19:35.000000Z",
          "updated_at": "2020-11-04T16:52:26.000000Z"
      },
      {
          "id": 108,
          "drug_id": 32,
          "indication_name": "Mastitis",
          "expected_effects": "Elimination of infection and associated clinical signs",
          "common_combinations": "Surgical drainage of abscesses, if any",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:19:38.000000Z",
          "updated_at": "2020-09-16T00:19:38.000000Z"
      },
      {
          "id": 109,
          "drug_id": 33,
          "indication_name": "Blastomycosis",
          "expected_effects": "65.2% cured, 17.4% improved but relapsed, 1.4% mortality rate",
          "common_combinations": "Itraconazole or fluconazole;IV fluid therapy to ensure fluid diuresis and minimize risk of nephrotoxicosis",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:40.000000Z",
          "updated_at": "2020-09-16T00:19:40.000000Z"
      },
      {
          "id": 110,
          "drug_id": 33,
          "indication_name": "Cryptococcosis",
          "expected_effects": "Significant improvement or clinical cure in all cases (6/6), with retreatment being successful if new lesions (or rising titers) are noted",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:19:42.000000Z",
          "updated_at": "2020-09-16T00:19:42.000000Z"
      },
      {
          "id": 111,
          "drug_id": 33,
          "indication_name": "Blastomycosis (central nervous system)",
          "expected_effects": "Elimination of infection",
          "common_combinations": "Fluconazole 10 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:19:45.000000Z",
          "updated_at": "2020-09-16T00:19:45.000000Z"
      },
      {
          "id": 112,
          "drug_id": 34,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Excellent palliation: treated dogs have significant clinical improvement, but lymph nodes remain positive for Leishmania on aspirates\nSuperior clinical efficacy if given 4 doses (q 24h on days 1, 2, 3, 4) or 5 doses (q 24h on days 1, 2, 3, 4, 10)",
          "common_combinations": "IV fluid therapy to ensure fluid diuresis and minimize risk of nephrotoxicosis",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:47.000000Z",
          "updated_at": "2020-09-16T00:19:47.000000Z"
      },
      {
          "id": 113,
          "drug_id": 34,
          "indication_name": "Xylohypha bantiana mycosis",
          "expected_effects": "Palliation of disease with fewer renal adverse effects than standard amphotericin B",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:19:50.000000Z",
          "updated_at": "2020-09-16T00:19:50.000000Z"
      },
      {
          "id": 114,
          "drug_id": 35,
          "indication_name": "Blastomycosis",
          "expected_effects": "73% cured, 27% improved but relapsed",
          "common_combinations": "IV fluid therapy to ensure fluid diuresis and minimize risk of nephrotoxicosis",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:53.000000Z",
          "updated_at": "2020-09-16T00:19:53.000000Z"
      },
      {
          "id": 115,
          "drug_id": 35,
          "indication_name": "Paecilomycosis",
          "expected_effects": "Remission or cure",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:19:56.000000Z",
          "updated_at": "2020-09-16T00:19:56.000000Z"
      },
      {
          "id": 116,
          "drug_id": 36,
          "indication_name": "Deep bacterial infections with potential for sepsis (e.g., pyothorax)",
          "expected_effects": "Elimination of infection and associated signs",
          "common_combinations": "Can coadminister metronidazole for increased coverage against anaerobic bacteria",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:19:58.000000Z",
          "updated_at": "2020-09-16T00:19:58.000000Z"
      },
      {
          "id": 117,
          "drug_id": 36,
          "indication_name": "Leptospirosis",
          "expected_effects": "Elimination of leptospiremia and associated clinical signs",
          "common_combinations": "Follow with amoxicillin 22 mg/kg PO q 8h for 2 weeks, then doxycycline 5 mg/kg PO q 12h for 2 weeks to eliminate the organism from renal tissue",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:20:00.000000Z",
          "updated_at": "2020-09-16T00:20:00.000000Z"
      },
      {
          "id": 118,
          "drug_id": 36,
          "indication_name": "Perioperative antibiotic treatment",
          "expected_effects": "No appreciable benefit\nWith aseptic procedure, infection rate is no different with ampicillin perioperatively as with placebo",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:20:03.000000Z",
          "updated_at": "2020-09-16T00:20:03.000000Z"
      },
      {
          "id": 119,
          "drug_id": 36,
          "indication_name": "Bacterial pneumonia",
          "expected_effects": "Resolution of infection and associated clinical signs",
          "common_combinations": "Amoxicillin replacement when patient is eating and stable, for continuation/termination of course of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:20:06.000000Z",
          "updated_at": "2020-09-16T00:20:06.000000Z"
      },
      {
          "id": 120,
          "drug_id": 37,
          "indication_name": "Post-operative bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:08.000000Z",
          "updated_at": "2020-09-16T00:20:08.000000Z"
      },
      {
          "id": 121,
          "drug_id": 37,
          "indication_name": "Infected wounds",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:20:10.000000Z",
          "updated_at": "2020-09-16T00:20:10.000000Z"
      },
      {
          "id": 122,
          "drug_id": 38,
          "indication_name": "Coccidiosis",
          "expected_effects": "Elimination of coccidia from fecal analyses\nResolution of diarrhea",
          "common_combinations": "Cotreatment with sulfadimethoxine 25 mg/kg PO q 24h for 4 days",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:13.000000Z",
          "updated_at": "2020-09-16T00:20:13.000000Z"
      },
      {
          "id": 123,
          "drug_id": 39,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Triggers vomiting within 15 min in 90.6% (IV administration) of cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:16.000000Z",
          "updated_at": "2020-09-16T00:20:16.000000Z"
      },
      {
          "id": 124,
          "drug_id": 39,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Triggers vomiting within 15 min in 83.5% (topical conjunctival application) of cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:20:18.000000Z",
          "updated_at": "2020-09-16T00:20:18.000000Z"
      },
      {
          "id": 125,
          "drug_id": 39,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Fails to produce emesis at this dosage (which is emetogenic in dogs and other species)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:20:21.000000Z",
          "updated_at": "2020-09-16T00:20:21.000000Z"
      },
      {
          "id": 126,
          "drug_id": 40,
          "indication_name": "Heinz body hemolytic anemia prevention",
          "expected_effects": "Ineffective: glutathione levels no different, no evidence of clinically significant antioxidant effect",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:23.000000Z",
          "updated_at": "2020-09-16T00:20:23.000000Z"
      },
      {
          "id": 127,
          "drug_id": 40,
          "indication_name": "Feline perforating dermatitis",
          "expected_effects": "Significant improvement in cutaneous lesions",
          "common_combinations": "Methylprednisolone acetate for this type of feline dermatopathy",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:20:26.000000Z",
          "updated_at": "2020-09-16T00:20:26.000000Z"
      },
      {
          "id": 128,
          "drug_id": 41,
          "indication_name": "Lymphoma - CHOP protocol",
          "expected_effects": "Rapid (hours/few days) reduction in tumor burden",
          "common_combinations": "Part of CHOP protocol (also includes cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:28.000000Z",
          "updated_at": "2020-09-16T00:20:28.000000Z"
      },
      {
          "id": 129,
          "drug_id": 41,
          "indication_name": "Lymphoma - modified UWM protocol",
          "expected_effects": "Rapid (hours/few days) reduction in tumor burden",
          "common_combinations": "Part of modified UWM protocol (also includes cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:20:31.000000Z",
          "updated_at": "2020-09-16T00:20:31.000000Z"
      },
      {
          "id": 130,
          "drug_id": 41,
          "indication_name": "Lymphoma - VELCAP-S protocol",
          "expected_effects": "Rapid (hours/few days) reduction in tumor burden",
          "common_combinations": "Part of VELCAP-S protocol (also includes cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:20:34.000000Z",
          "updated_at": "2020-09-16T00:20:34.000000Z"
      },
      {
          "id": 131,
          "drug_id": 41,
          "indication_name": "Relapsed lymphoma",
          "expected_effects": "Rapid (hours/few days) reduction in tumor burden",
          "common_combinations": "Part of LAP protocol (also includes lomustine and prednisone/prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:20:36.000000Z",
          "updated_at": "2020-09-16T00:20:36.000000Z"
      },
      {
          "id": 132,
          "drug_id": 41,
          "indication_name": "Lymphoma - modified UWM protocol",
          "expected_effects": "Rapid (hours/few days) reduction in tumor burden",
          "common_combinations": "Part of modified UWM protocol (also includes cyclophosphamide, chlorambucil, doxorubicin, methotrexate, vincristine, and prednisone/prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:20:38.000000Z",
          "updated_at": "2020-09-16T00:20:38.000000Z"
      },
      {
          "id": 133,
          "drug_id": 41,
          "indication_name": "Lymphoma - VELCAP-C protocol",
          "expected_effects": "Rapid (hours/few days) reduction in tumor burden",
          "common_combinations": "Part of VELCAP-C protocol (also includes cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:20:42.000000Z",
          "updated_at": "2020-09-16T00:20:42.000000Z"
      },
      {
          "id": 134,
          "drug_id": 42,
          "indication_name": "Subaortic stenosis (moderate/severe)",
          "expected_effects": "Reduction of peak heart rate during sympathetic stimulation\r\nBenefit for longevity unsubstantiated",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:44.000000Z",
          "updated_at": "2020-11-04T02:28:02.000000Z"
      },
      {
          "id": 135,
          "drug_id": 42,
          "indication_name": "Dynamic left ventricular outflow tract obstruction",
          "expected_effects": "Reduction of peak heart rate during sympathetic stimulation\r\nBenefit for longevity unsubstantiated",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:20:46.000000Z",
          "updated_at": "2020-11-04T02:28:02.000000Z"
      },
      {
          "id": 136,
          "drug_id": 42,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Reduction of systolic arterial blood pressure\r\nRarely effective as monotherapy",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:20:49.000000Z",
          "updated_at": "2020-11-04T02:28:02.000000Z"
      },
      {
          "id": 137,
          "drug_id": 42,
          "indication_name": "Reduction of tachycardia",
          "expected_effects": "Reduction of exam-room heart rate by 27%: from 204 ± 32 beats/minute to 144 ± 20 beats/minute",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:20:51.000000Z",
          "updated_at": "2020-11-04T02:28:02.000000Z"
      },
      {
          "id": 138,
          "drug_id": 42,
          "indication_name": "Reduction of tachycardia",
          "expected_effects": "Reduction of exam-room heart rate by 27%: from 204 ± 32 beats/minute to 144 ± 20 beats/minute",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:20:53.000000Z",
          "updated_at": "2020-11-04T02:28:03.000000Z"
      },
      {
          "id": 139,
          "drug_id": 42,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Reduction of systolic arterial blood pressure\r\nRarely effective as monotherapy",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:20:56.000000Z",
          "updated_at": "2020-11-04T02:28:03.000000Z"
      },
      {
          "id": 140,
          "drug_id": 43,
          "indication_name": "Reversal of dexmedetomidine sedation",
          "expected_effects": "Rapid reversal of sedation: median arousal time of 3-5 min, median walking time of 6-10 min (vs. >30 min with placebo for both)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:20:58.000000Z",
          "updated_at": "2020-11-04T02:28:14.000000Z"
      },
      {
          "id": 141,
          "drug_id": 43,
          "indication_name": "Reversal of dexmedetomidine sedation",
          "expected_effects": "Reversal of sedative effects apparent in 5 min and complete (back to baseline) in 15 min",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:01.000000Z",
          "updated_at": "2020-11-04T02:28:14.000000Z"
      },
      {
          "id": 142,
          "drug_id": 44,
          "indication_name": "Babesiosis (Babesia gibsoni)",
          "expected_effects": "80% elimination of B. gibsoni DNA on PCR of post-treatment samples",
          "common_combinations": "Azithromycin (10 mg/kg PO q 24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:04.000000Z",
          "updated_at": "2020-09-16T00:21:04.000000Z"
      },
      {
          "id": 143,
          "drug_id": 44,
          "indication_name": "Babesiosis (Babesia conradae)",
          "expected_effects": "Complete elimination of infection (elimination of Babesia DNA on PCR)",
          "common_combinations": "Azithromycin (10-12.5 mg/kg PO q 24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:06.000000Z",
          "updated_at": "2020-09-16T00:21:06.000000Z"
      },
      {
          "id": 144,
          "drug_id": 44,
          "indication_name": "Cytauxzoonosis",
          "expected_effects": "60% survival rate with this treatment (vs. 26% with imidocarb)",
          "common_combinations": "Azithromycin (10 mg/kg PO q 24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:21:08.000000Z",
          "updated_at": "2020-09-16T00:21:08.000000Z"
      },
      {
          "id": 145,
          "drug_id": 45,
          "indication_name": "Adjunct to anesthesia",
          "expected_effects": "Flaccid paralysis\nDrug-dependent, reversible loss of peripheral neuromuscular activity",
          "common_combinations": "Muscle relaxation function",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:11.000000Z",
          "updated_at": "2020-09-16T00:21:11.000000Z"
      },
      {
          "id": 146,
          "drug_id": 45,
          "indication_name": "Uncontrolled myoclonus (e.g., intoxications)",
          "expected_effects": "Reduction/termination of myoclonus during infusion, and then spontaneously as intoxication dissipates",
          "common_combinations": "Has been coadministered with continuous IV infusions of propofol (1 mg/kg/h) and diazepam (0.25 mg/kg/h) when myoclonus is severe",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:13.000000Z",
          "updated_at": "2020-09-16T00:21:13.000000Z"
      },
      {
          "id": 147,
          "drug_id": 46,
          "indication_name": "Premedication before general anesthesia",
          "expected_effects": "Prevention of bradycardia and prevention of excessive respiratory secretions during general anesthesia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:16.000000Z",
          "updated_at": "2020-09-16T00:21:16.000000Z"
      },
      {
          "id": 148,
          "drug_id": 46,
          "indication_name": "Premedication before general anesthesia",
          "expected_effects": "Prevention of bradycardia and prevention of excessive respiratory secretions during general anesthesia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:19.000000Z",
          "updated_at": "2020-09-16T00:21:19.000000Z"
      },
      {
          "id": 149,
          "drug_id": 46,
          "indication_name": "Bradycardia",
          "expected_effects": "Immediate increase in heart rate if bradycardia is of vagal origin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:21:21.000000Z",
          "updated_at": "2020-09-16T00:21:21.000000Z"
      },
      {
          "id": 150,
          "drug_id": 46,
          "indication_name": "Atropine response test",
          "expected_effects": "Increase in heart rate >135 beats/minute, 15-30 min after administration, in >80% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:21:23.000000Z",
          "updated_at": "2020-09-16T00:21:23.000000Z"
      },
      {
          "id": 151,
          "drug_id": 47,
          "indication_name": "Gastroenteritis",
          "expected_effects": "Resolution of vomiting and diarrhea in 90% of treated dogs",
          "common_combinations": "Bismuth subcarbonate and kanamycin (together as Amforol veterinary product)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:26.000000Z",
          "updated_at": "2020-09-16T00:21:26.000000Z"
      },
      {
          "id": 152,
          "drug_id": 47,
          "indication_name": "Gastroenteritis",
          "expected_effects": "Resolution of vomiting and diarrhea in 90% of treated dogs",
          "common_combinations": "Bismuth subcarbonate and kanamycin (together as Amforol veterinary product)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:29.000000Z",
          "updated_at": "2020-09-16T00:21:29.000000Z"
      },
      {
          "id": 153,
          "drug_id": 48,
          "indication_name": "Immune-mediated disease (idiopathic polyarthritis, pemphigus foliaceus)",
          "expected_effects": "Improvement or resolution of clinical signs",
          "common_combinations": "Prednisone 1 mg/kg PO q 24-48h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:31.000000Z",
          "updated_at": "2020-09-16T00:21:31.000000Z"
      },
      {
          "id": 154,
          "drug_id": 49,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "Resolution of clinical signs on aurothioglucose monotherapy in 27% of dogs",
          "common_combinations": "With or without prednisone 1.1 mg/kg PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:33.000000Z",
          "updated_at": "2020-09-16T00:21:33.000000Z"
      },
      {
          "id": 155,
          "drug_id": 49,
          "indication_name": "Plasma cell stomatitis-pharyngitis",
          "expected_effects": "82% of cats improve with treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:36.000000Z",
          "updated_at": "2020-09-16T00:21:36.000000Z"
      },
      {
          "id": 156,
          "drug_id": 50,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "92% of dogs with IMHA were improved when rechecked while taking azathioprine",
          "common_combinations": "Concurrent predniso(lo)ne beginning at 2 mg/kg PO q 24h and tapering to zero gradually over a 2-month period",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:38.000000Z",
          "updated_at": "2020-09-16T00:21:38.000000Z"
      },
      {
          "id": 157,
          "drug_id": 50,
          "indication_name": "Meningoencephalomyelitis, sterile (e.g., granulomatous, necrotizing, steroid-responsive, etc.)",
          "expected_effects": null,
          "common_combinations": "Concurrent prednisone 1 mg/kg PO q 12h for 4 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:40.000000Z",
          "updated_at": "2020-11-04T02:28:48.000000Z"
      },
      {
          "id": 158,
          "drug_id": 50,
          "indication_name": "Immune-mediated neutropenia/thrombocytopenia",
          "expected_effects": "Control of neutropenia (normalization of neutrophil count while being treated)",
          "common_combinations": "Concurrent prednisone 1-2.2 mg/kg PO q 12h initially, rapidly tapering over a few weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:21:43.000000Z",
          "updated_at": "2020-09-16T00:21:43.000000Z"
      },
      {
          "id": 159,
          "drug_id": 50,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "55% remission rate (time to remission: 2-29 months [mean: 11.7 months]) and 27% improvement (but not in remission) rate",
          "common_combinations": "Prednisolone (0.1-4 mg/kg/day PO)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:21:46.000000Z",
          "updated_at": "2020-09-16T00:21:46.000000Z"
      },
      {
          "id": 160,
          "drug_id": 51,
          "indication_name": "Babesiosis (B. gibsoni, B. conradae)",
          "expected_effects": "Complete elimination of B. conradae (assessed via PCR) with treatment in >80% of dogs",
          "common_combinations": "Atovaquone (13.3 mg/kg PO q 8h)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:21:48.000000Z",
          "updated_at": "2020-09-16T00:21:48.000000Z"
      },
      {
          "id": 161,
          "drug_id": 51,
          "indication_name": "Borreliosis/Lyme Disease",
          "expected_effects": "Decrease in titers\r\nImprovement in acute disease",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:21:51.000000Z",
          "updated_at": "2020-11-04T02:29:14.000000Z"
      },
      {
          "id": 162,
          "drug_id": 51,
          "indication_name": "Rocky Mountain spotted fever",
          "expected_effects": "Nonspecific improvement in general demeanor, platelet count, and hypoalbuminemia\r\nSlower resolution of fever compared to treatment with doxycycline or trovafloxacin\r\nFailure to eradicate the organism (rickettsial DNA detectable in some dogs 13 days after end of treatment)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:21:53.000000Z",
          "updated_at": "2020-11-04T02:29:14.000000Z"
      },
      {
          "id": 163,
          "drug_id": 51,
          "indication_name": "Papillomatosis (oral or cutaneous)",
          "expected_effects": "Complete resolution of papillomas in 10-15 days, vs. persistence to >50 days in most untreated cases (rare spontaneous regression)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:21:56.000000Z",
          "updated_at": "2020-11-04T02:29:14.000000Z"
      },
      {
          "id": 164,
          "drug_id": 51,
          "indication_name": "Cytauxzoonosis",
          "expected_effects": "60% survival rate with this treatment (vs. 26% with imidocarb)",
          "common_combinations": "Atovaquone (15 mg/kg PO q 8h)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:21:58.000000Z",
          "updated_at": "2020-09-16T00:21:58.000000Z"
      },
      {
          "id": 165,
          "drug_id": 51,
          "indication_name": "Chlamydophila infection",
          "expected_effects": "Excellent control of clinical signs but failure to eliminate organism, allowing relapses",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:22:01.000000Z",
          "updated_at": "2020-11-04T02:29:15.000000Z"
      },
      {
          "id": 166,
          "drug_id": 52,
          "indication_name": "Congestive heart failure due to myxomatous mitral valve disease",
          "expected_effects": "Median of 158 days until recurrence of congestive heart failure or death/euthanasia (10% of dogs alive at 800 days)",
          "common_combinations": "Furosemide 1.5-3.2 mg/kg PO q 12h in one clinical trial",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:03.000000Z",
          "updated_at": "2020-11-04T16:00:36.000000Z"
      },
      {
          "id": 167,
          "drug_id": 52,
          "indication_name": "Myxomatous mitral valve disease - preclinical/compensated",
          "expected_effects": "Longer time to cardiac events (e.g., congestive heart failure) and longer survival in 1 study",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:22:06.000000Z",
          "updated_at": "2020-11-04T16:00:36.000000Z"
      },
      {
          "id": 168,
          "drug_id": 52,
          "indication_name": "Dilated cardiomyopathy - occult/preclinical, with or without atrial fibrillation",
          "expected_effects": "Median 32.8 months until onset of congestive heart failure or of death; pimobendan 0.24-0.26 mg/kg PO q 12h (median: 65.4 months) or methyldigoxin 0.005 mg/kg PO q 12h (median: 41.5 months) confer a longer disease-free interval than benazepril",
          "common_combinations": "Diltiazem if needed to control rapid atrial fibrillation",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:22:08.000000Z",
          "updated_at": "2020-11-04T16:00:36.000000Z"
      },
      {
          "id": 169,
          "drug_id": 52,
          "indication_name": "Chronic kidney disease",
          "expected_effects": "Improvement in glomerular filtration rate, proteinuria, and health status score",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:22:11.000000Z",
          "updated_at": "2020-11-04T16:00:36.000000Z"
      },
      {
          "id": 170,
          "drug_id": 52,
          "indication_name": "Chronic kidney disease",
          "expected_effects": "Delay in deterioration of clinical status (IRIS stage)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:22:14.000000Z",
          "updated_at": "2020-11-04T16:00:36.000000Z"
      },
      {
          "id": 171,
          "drug_id": 52,
          "indication_name": "Hypertrophic cardiomyopathy - preclinical",
          "expected_effects": "Minimal improvement (possible remodeling of some of LV) if any\r\nNo convincing long-term benefit",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:22:16.000000Z",
          "updated_at": "2020-11-04T16:00:36.000000Z"
      },
      {
          "id": 172,
          "drug_id": 52,
          "indication_name": "Systemic hypertension",
          "expected_effects": "Reduction of blood pressure (modest if any)",
          "common_combinations": "Amlodipine",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:22:19.000000Z",
          "updated_at": "2020-09-16T00:22:19.000000Z"
      },
      {
          "id": 173,
          "drug_id": 53,
          "indication_name": "Urinary retention",
          "expected_effects": "Improved ability to evacuate bladder, but only temporary (loss of efficacy over time)",
          "common_combinations": "Phenoxybenzamine if urethral spasm",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:21.000000Z",
          "updated_at": "2020-09-16T00:22:21.000000Z"
      },
      {
          "id": 174,
          "drug_id": 53,
          "indication_name": "Bethanechol challenge to identify if urinary retention is due to detrusor laxity",
          "expected_effects": "Assess bladder diameter immediately pre-injection (by palpation, or preferably, ultrasonographically).  If positive response, dog shows improved efficacy at spontaneous emptying of the bladder 30 min after dose administration (bladder smaller than when urinating without bethanechol)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:22:23.000000Z",
          "updated_at": "2020-09-16T00:22:23.000000Z"
      },
      {
          "id": 175,
          "drug_id": 53,
          "indication_name": "Dysautonomia",
          "expected_effects": "Marked improvement in demeanor, appetite, and autonomic functions within 24 hours of starting treatment (case report)",
          "common_combinations": "Metoclopramide",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:22:26.000000Z",
          "updated_at": "2020-09-16T00:22:26.000000Z"
      },
      {
          "id": 176,
          "drug_id": 53,
          "indication_name": "Reflex dyssynergia",
          "expected_effects": "Temporary improvement (normal micturition for 5 weeks, single case report only)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:22:28.000000Z",
          "updated_at": "2020-09-16T00:22:28.000000Z"
      },
      {
          "id": 177,
          "drug_id": 54,
          "indication_name": "Colonic evacuation",
          "expected_effects": "Stool softening",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:31.000000Z",
          "updated_at": "2020-09-16T00:22:31.000000Z"
      },
      {
          "id": 178,
          "drug_id": 55,
          "indication_name": "Helicobacteriosis",
          "expected_effects": "86% reduction in frequency of vomiting with triple or quadruple therapy",
          "common_combinations": "Metronidazole and amoxicillin (triple therapy);Metronidazole, amoxicillin, and famotidine (quadruple therapy)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:33.000000Z",
          "updated_at": "2020-09-16T00:22:33.000000Z"
      },
      {
          "id": 179,
          "drug_id": 56,
          "indication_name": "Gastroenteritis",
          "expected_effects": "Resolution of vomiting and diarrhea in 90% of treated dogs",
          "common_combinations": "Attapulgite and kanamycin (together as Amforol veterinary product);Metronidazole",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:36.000000Z",
          "updated_at": "2020-09-16T00:22:36.000000Z"
      },
      {
          "id": 180,
          "drug_id": 56,
          "indication_name": "Gastroenteritis",
          "expected_effects": "Resolution of vomiting and diarrhea in 90% of treated dogs",
          "common_combinations": "Attapulgite and kanamycin (together as Amforol veterinary product);Metronidazole",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:22:38.000000Z",
          "updated_at": "2020-09-16T00:22:38.000000Z"
      },
      {
          "id": 181,
          "drug_id": 57,
          "indication_name": "Acanthomatous ameloblastoma and other discrete/focal tumors",
          "expected_effects": "Complete resolution of tumor within 4 months (median: within 1.5 months) in 6/7 cases, lasting for >2 years",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:41.000000Z",
          "updated_at": "2020-11-04T16:07:57.000000Z"
      },
      {
          "id": 182,
          "drug_id": 57,
          "indication_name": "Acanthomatous ameloblastoma (acanthomatous epulis)",
          "expected_effects": "Reduction in size of mass (often dramatic in first 3 weeks)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:22:43.000000Z",
          "updated_at": "2020-11-04T16:07:57.000000Z"
      },
      {
          "id": 183,
          "drug_id": 57,
          "indication_name": "Seminoma with cutaneous metastasis",
          "expected_effects": "Cytoreduction: decrease in lesion size (by 50% in the first week), allowing surgical excision or simply palliative",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:22:45.000000Z",
          "updated_at": "2020-11-04T16:07:57.000000Z"
      },
      {
          "id": 184,
          "drug_id": 57,
          "indication_name": "Squamous cell carcinoma",
          "expected_effects": "Complete resolution of mass in 78% of cats (lasting >3 years)",
          "common_combinations": "Local electrical wave therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:22:48.000000Z",
          "updated_at": "2020-09-16T00:22:48.000000Z"
      },
      {
          "id": 185,
          "drug_id": 58,
          "indication_name": "Seizure reduction/prevention",
          "expected_effects": "Decrease in seizure frequency (52% reduction, vs. 85% for phenobarbital)",
          "common_combinations": "Phenobarbital, pregabalin, or other anticonvulsant drugs",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:51.000000Z",
          "updated_at": "2020-09-16T00:22:51.000000Z"
      },
      {
          "id": 186,
          "drug_id": 58,
          "indication_name": "Seizure reduction/prevention",
          "expected_effects": "Decrease in seizure frequency",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:22:53.000000Z",
          "updated_at": "2020-11-04T16:29:23.000000Z"
      },
      {
          "id": 187,
          "drug_id": 59,
          "indication_name": "Pseudocyesis",
          "expected_effects": "Termination of behavioral signs (80% of cases) and lactation (81% of cases) in 10-16 days of treatment",
          "common_combinations": "Antiemetic (e.g., metoclopramide 0.5 mg/kg PO 30 minutes before bromocriptine dose)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:22:55.000000Z",
          "updated_at": "2020-09-16T00:22:55.000000Z"
      },
      {
          "id": 188,
          "drug_id": 59,
          "indication_name": "Estrus induction",
          "expected_effects": "Triggering onset of estrus",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:22:58.000000Z",
          "updated_at": "2020-09-16T00:22:58.000000Z"
      },
      {
          "id": 189,
          "drug_id": 59,
          "indication_name": "Hyperadrenocorticism",
          "expected_effects": "Ineffective (e.g., positive therapeutic effect in only 1 of 7 dogs)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:23:00.000000Z",
          "updated_at": "2020-09-16T00:23:00.000000Z"
      },
      {
          "id": 190,
          "drug_id": 59,
          "indication_name": "Prevention of pregnancy",
          "expected_effects": "100% prevention of pregnancy (0/15 dogs whelped) when combined with PGF2-alpha",
          "common_combinations": "Prostaglandin F2-alpha 250 µg/kg SC q 12h for 5 days",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:23:03.000000Z",
          "updated_at": "2020-09-16T00:23:03.000000Z"
      },
      {
          "id": 191,
          "drug_id": 59,
          "indication_name": "Pregnancy termination",
          "expected_effects": ">99% efficacy in pregnancy termination within 3-6 days",
          "common_combinations": "Cotreatment with either dinoprost 0.1-0.2 mg/kg SC q 24h or cloprostenol 1 µg/kg SC q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:23:06.000000Z",
          "updated_at": "2020-09-16T00:23:06.000000Z"
      },
      {
          "id": 192,
          "drug_id": 60,
          "indication_name": "Inflammatory bowel disease",
          "expected_effects": "78% remission rate, which is not significantly different from results with prednisone treatment; similar incidence of adverse effects as prednisone",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:23:08.000000Z",
          "updated_at": "2020-11-04T17:23:32.000000Z"
      },
      {
          "id": 193,
          "drug_id": 60,
          "indication_name": "Inflammatory bowel disease (severe) - ineffective",
          "expected_effects": "Efficacy variable and limited at best: mild improvement in clinical signs in a minority of dogs after 30 days of treatment and no improvement in others (all dogs with severe signs remained severely affected despite treatment in 1 clinical trial)\r\n for 30 days",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:23:11.000000Z",
          "updated_at": "2020-11-04T17:23:32.000000Z"
      },
      {
          "id": 194,
          "drug_id": 61,
          "indication_name": "Echinococcosis/hydatid cyst disease",
          "expected_effects": "Decreases prevalence of fecal Echinococcus shedding in dogs (from 7.9% to 0.1% in 12 months in one study)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:23:14.000000Z",
          "updated_at": "2020-09-16T00:23:14.000000Z"
      },
      {
          "id": 195,
          "drug_id": 62,
          "indication_name": "Dual femoral and sciatic nerve block for stifle surgery",
          "expected_effects": "Significantly less urine retention and significantly less opiate requirement post-operatively compared to epidural",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:23:16.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 196,
          "drug_id": 62,
          "indication_name": "Retrobulbar block during enucleation",
          "expected_effects": "Adequate analgesia in 82% of cases, compared to 19% of cases without bupivacaine block",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:23:18.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 197,
          "drug_id": 62,
          "indication_name": "Retrobulbar block during enucleation",
          "expected_effects": "Adequate analgesia in 82% of cases, compared to 19% of cases without bupivacaine block",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:23:21.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 198,
          "drug_id": 62,
          "indication_name": "Mandibular analgesia via mental nerve block",
          "expected_effects": "Limited and variable region of effective local analgesia in the dog",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:23:23.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 199,
          "drug_id": 62,
          "indication_name": "Intrathoracic infusion",
          "expected_effects": "Analgesia",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:23:26.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 200,
          "drug_id": 62,
          "indication_name": "Intercostal nerve block",
          "expected_effects": "Superior analgesia compared to morphine epidural",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:23:28.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 201,
          "drug_id": 62,
          "indication_name": "Intercostal nerve block",
          "expected_effects": "Superior analgesia compared to morphine epidural",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:23:31.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 202,
          "drug_id": 62,
          "indication_name": "Intraarticular analgesia",
          "expected_effects": "Significantly lower pain level compared to intraarticular morphine or no intraarticular analgesia",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:23:33.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 203,
          "drug_id": 62,
          "indication_name": "Incisional infiltration after laparotomy",
          "expected_effects": "No difference in analgesia between bupivacaine and saline when an otherwise comprehensive analgesic plan is used (including systemic analgesia, e.g., 1 dose hydromorphone at extubation and buprenorphine q 6h for 24h, then carprofen q 12h for 3 days)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:23:36.000000Z",
          "updated_at": "2020-11-04T18:19:22.000000Z"
      },
      {
          "id": 204,
          "drug_id": 62,
          "indication_name": "Epidural anesthesia - post-op (orthopedic surgery)",
          "expected_effects": "Substantial analgesia: lower pain scores and fewer doses of rescue analgesia needed (if any) compared to placebo control",
          "common_combinations": "With or without coadministration of morphine 0.1 mg/kg epidural",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:23:38.000000Z",
          "updated_at": "2020-09-16T00:23:38.000000Z"
      },
      {
          "id": 205,
          "drug_id": 62,
          "indication_name": "Intratesticular for castration",
          "expected_effects": "Highly effective analgesia: 6% of dogs require intraoperative fentanyl for rescue analgesia with this protocol, vs. 29% with morphine epidural + hydromorphone IM + carprofen SC, or 65% with hydromorphone IM and carprofen SC\r\nPain control also apparent via intra-op serum cortisol levels, which are lowest with intratesticular bupivacaine vs. morphine epidural vs. systemic hydromorphone + carprofen",
          "common_combinations": "Hydromorphone 0.1 mg/kg IM;Carprofen 4.4 mg/kg SC",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:23:41.000000Z",
          "updated_at": "2020-11-04T18:21:10.000000Z"
      },
      {
          "id": 206,
          "drug_id": 62,
          "indication_name": "Epidural anesthesia - bupivacaine-morphine combination",
          "expected_effects": "16-hour mean duration of analgesia (bupivacaine-morphine combination)\r\nNo significant respiratory or cardiovascular depression (vs. mild changes seen in similarly-treated dogs)",
          "common_combinations": "Morphine chlorhydrate 0.1-0.4 mg/kg coadministered epidurally",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:23:43.000000Z",
          "updated_at": "2020-11-04T18:21:10.000000Z"
      },
      {
          "id": 207,
          "drug_id": 62,
          "indication_name": "Onychectomy (4-point forelimb block)",
          "expected_effects": "No difference in pain levels compared to surgery performed without bupivacaine block",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:23:46.000000Z",
          "updated_at": "2020-11-04T18:21:10.000000Z"
      },
      {
          "id": 208,
          "drug_id": 63,
          "indication_name": "Premedication for routine surgical procedures",
          "expected_effects": "Sedation\r\nMild analgesia",
          "common_combinations": "Either with medetomidine 5-10 µg/kg IM or acepromazine 0.03 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:23:48.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 209,
          "drug_id": 63,
          "indication_name": "Pre-emptive analgesia (intraoperative - ovariohysterectomy)",
          "expected_effects": "Significantly lower pain scores (less than half pain scores compared to controls) post-op",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:23:50.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 210,
          "drug_id": 63,
          "indication_name": "Pre-emptive analgesia (intraoperative - ovariohysterectomy)",
          "expected_effects": "Significantly lower pain scores (less than half pain scores compared to controls) post-op",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:23:53.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 211,
          "drug_id": 63,
          "indication_name": "Postoperative analgesia - ovariohysterectomy",
          "expected_effects": "Analgesia for average of 16 hours post-operatively",
          "common_combinations": "Anesthetic induction with propofol;Maintenance with isoflurane",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:23:55.000000Z",
          "updated_at": "2020-09-16T00:23:55.000000Z"
      },
      {
          "id": 212,
          "drug_id": 63,
          "indication_name": "Postoperative analgesia - ovariohysterectomy",
          "expected_effects": "Analgesia for an average of 7 (low-dose) to 20 (high-dose) hours post-operatively",
          "common_combinations": "Anesthetic induction with propofol;Maintenance with isoflurane",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:23:58.000000Z",
          "updated_at": "2020-09-16T00:23:58.000000Z"
      },
      {
          "id": 213,
          "drug_id": 63,
          "indication_name": "Sedation for diagnostic and therapeutic procedures",
          "expected_effects": "Prompt and lasting sedation (30 min), in all likelihood largely due to medetomidine given rapid reversal of effects with atipamezole",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:24:00.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 214,
          "drug_id": 63,
          "indication_name": "Management of urethral obstruction in male cats without urethral catheterization",
          "expected_effects": "73% success in normal urination and discharge from hospital without urethral catheterization",
          "common_combinations": "Acepromazine 0.25 mg IM, or 2.5 mg PO, q 8h;Medetomidine 0.1 mg IM q 24h;Decompressive cystocentesis;SC administration of fluids as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:24:03.000000Z",
          "updated_at": "2020-09-16T00:24:03.000000Z"
      },
      {
          "id": 215,
          "drug_id": 63,
          "indication_name": "Postoperative analgesia - ovariohysterectomy",
          "expected_effects": "Significant analgesia\r\nOnly 4/25 (16%) of IM-dosed cats and 6/25 (24%) of IV-dosed cats required additional analgesia, compared to 52% (SC) and 68% (oral transmucosal)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:24:06.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 216,
          "drug_id": 63,
          "indication_name": "Pre-emptive analgesia - ovariohysterectomy",
          "expected_effects": "Significant analgesia, similar to single SC doses of 0.12 mg/kg sustained-release buprenorphine",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:24:08.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 217,
          "drug_id": 64,
          "indication_name": "Intercat aggression",
          "expected_effects": "Promotes assertive and outgoing behavior in victim cat, reducing victimization",
          "common_combinations": "Behavioral modification",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:24:11.000000Z",
          "updated_at": "2020-09-16T00:24:11.000000Z"
      },
      {
          "id": 218,
          "drug_id": 64,
          "indication_name": "Intercat aggression",
          "expected_effects": "Promotes assertive and outgoing behavior in victim cat, reducing victimization",
          "common_combinations": "Behavioral modification",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:24:13.000000Z",
          "updated_at": "2020-09-16T00:24:13.000000Z"
      },
      {
          "id": 219,
          "drug_id": 65,
          "indication_name": "Sedation/premedication for ovariohysterectomy",
          "expected_effects": "Reduction in postoperative pain (similar to meperidine)",
          "common_combinations": "Acepromazine 0.02 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:24:16.000000Z",
          "updated_at": "2020-09-16T00:24:16.000000Z"
      },
      {
          "id": 220,
          "drug_id": 65,
          "indication_name": "Analgesia",
          "expected_effects": "Provides 30-45 min of visceral analgesia without altering heart rate or blood pressure",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:24:18.000000Z",
          "updated_at": "2020-11-04T20:18:42.000000Z"
      },
      {
          "id": 221,
          "drug_id": 65,
          "indication_name": "Analgesia",
          "expected_effects": "Provides 23-53 min of visceral analgesia without altering blood pressure but with a decrease in heart rate",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:24:21.000000Z",
          "updated_at": "2020-11-04T20:18:42.000000Z"
      },
      {
          "id": 222,
          "drug_id": 65,
          "indication_name": "Induction and maintenance of anesthesia (dexmedetomidine-ketamine-butorphanol cocktail)",
          "expected_effects": "Produces general anesthesia (sufficient to allow intubation) 10 min after administration",
          "common_combinations": "Dexmedetomidine 0.015 mg/kg IM;Ketamine 3 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:24:23.000000Z",
          "updated_at": "2020-09-16T00:24:23.000000Z"
      },
      {
          "id": 223,
          "drug_id": 65,
          "indication_name": "Sedation of systemically healthy dogs",
          "expected_effects": "Moderate sedation",
          "common_combinations": "Medetomidine 0.02 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:24:26.000000Z",
          "updated_at": "2020-09-16T00:24:26.000000Z"
      },
      {
          "id": 224,
          "drug_id": 65,
          "indication_name": "Antitussive - cough due to collapsing trachea",
          "expected_effects": "Improvement in cough but rarely full resolution from butorphanol treatment alone",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:24:28.000000Z",
          "updated_at": "2020-11-04T20:18:42.000000Z"
      },
      {
          "id": 225,
          "drug_id": 65,
          "indication_name": "Antiemetic: prevention of cisplatin-induced vomiting",
          "expected_effects": "Highly effective: 19% rate of vomiting (compared to 89% in placebo group)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:24:31.000000Z",
          "updated_at": "2020-11-04T20:18:42.000000Z"
      },
      {
          "id": 226,
          "drug_id": 65,
          "indication_name": "Reversal (partial) of oxymorphone-induced sedation",
          "expected_effects": "Partial reversal of opiate-induced mentation and posture changes",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:24:33.000000Z",
          "updated_at": "2020-11-04T20:18:42.000000Z"
      },
      {
          "id": 227,
          "drug_id": 65,
          "indication_name": "Sedation",
          "expected_effects": "Mild sedation (if any) with butorphanol-midazolam\r\nModerate sedation with mild cardiovascular effects (25% decrease in arterial blood pressure\r\nDecrease in LV stroke volume on echo) when using butorphanol-midazolam-ketamine",
          "common_combinations": "Midazolam 0.4 mg/kg IM;Ketamine 3 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:24:36.000000Z",
          "updated_at": "2020-11-04T20:18:42.000000Z"
      },
      {
          "id": 228,
          "drug_id": 65,
          "indication_name": "Anesthetic induction (part of ketamine-midazolam-butorphanol cocktail)",
          "expected_effects": "Induces general anesthesia sufficient to allow tracheal intubation",
          "common_combinations": "Midazolam 0.3 mg/kg IV;Ketamine 3 mg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:24:38.000000Z",
          "updated_at": "2020-09-16T00:24:38.000000Z"
      },
      {
          "id": 229,
          "drug_id": 66,
          "indication_name": "Anestrus (primary or secondary)",
          "expected_effects": "Estrus triggered in 85% of dogs (similar to treatment with pregnant mare serum gonadotropin, PMSG)\r\nInterval to treatment response of 19-31 days\r\nPregnancy rate of 94% (18/19)\r\nWhelping rate of 100% (18/18)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:24:41.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 230,
          "drug_id": 66,
          "indication_name": "Pregnancy termination",
          "expected_effects": "Cervical dilation in 2-5 days\r\nAbortion of fetuses in 83% of cases if cabergoline is combined with alfaprostol, and 100% of cases if cabergoline is combined with alfaprostol and intravaginal misoprostol",
          "common_combinations": "Alfaprostol (10 µg/kg, SC), either as a single injection 72h after beginning cabergoline treatment, or 2 injections 72h apart, beginning with start of cabergoline treatment;With or without intravaginal misoprostol (400 µg/DOG if body weight ≤ 20 kg, or 600 µg/DOG if body weight > 20 kg) q 48h, which increases efficacy to >99%",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:24:43.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 231,
          "drug_id": 66,
          "indication_name": "Reduction/cessation of lactation",
          "expected_effects": "Abrupt reduction in milk production, with overall 50-70% reduction in milk production during 5 days following treatment (mirroring decrease in circulating prolactin levels)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:24:46.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 232,
          "drug_id": 66,
          "indication_name": "Pyometra",
          "expected_effects": "Termination of pyometra in 86-95% of cases in 10-13 days\r\n7/11 (64%) mated at next estrus become pregnant\r\n19% rate of recurrence of pyometra after next estrus",
          "common_combinations": "Cloprostenol 5 µg/kg SC q 72h every third day;Potentiated sulfa antibiotic q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:24:48.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 233,
          "drug_id": 66,
          "indication_name": "Shortening of interestrous intervals",
          "expected_effects": "Significantly shorter treatment with cabergoline treatment (interestrus interval of 181 days) compared to untreated (interestrus interval of 239 days)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:24:51.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 234,
          "drug_id": 66,
          "indication_name": "Hyperadrenocorticism",
          "expected_effects": "60% of dogs show beneficial response, with reduction/elimination of clinical signs and no significant adverse effects. Of those responders, 2/3 maintain a long-term improvement and 1/3 have recurrence of clinical signs requiring alternative treatment (e.g., trilostane, o,p'DDD, or ketoconazole)\r\n90% of dogs vomit within 1 hours of receiving the first dose, then 10% vomit after the second dose, and none vomit after the third dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:24:53.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 235,
          "drug_id": 66,
          "indication_name": "Pregnancy termination",
          "expected_effects": "Termination of pregnancy in 100% of cases (second trimester) or less (third trimester)\r\nHigher rate of efficacy in third trimester with prostaglandin co-treatment",
          "common_combinations": "Alone or in combination with alfaprostol (10 µg/kg SC q 48h)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:24:56.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 236,
          "drug_id": 66,
          "indication_name": "Control of feral cat population",
          "expected_effects": ">99% termination of pregnancy",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:24:58.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 237,
          "drug_id": 67,
          "indication_name": "Hypercalcemia caused by cholecalciferol-class rodenticides",
          "expected_effects": "Decrease in serum calcium levels to normal range within 24-48h",
          "common_combinations": "Prednisone 0.5 mg/kg PO q 24h, taper over 1 week;Furosemide",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:01.000000Z",
          "updated_at": "2020-09-16T00:25:01.000000Z"
      },
      {
          "id": 238,
          "drug_id": 67,
          "indication_name": "Bone resorption induced by loss of ovarian function",
          "expected_effects": "Decrease in bone resorption (clinical significance unproven)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:04.000000Z",
          "updated_at": "2020-09-16T00:25:04.000000Z"
      },
      {
          "id": 239,
          "drug_id": 68,
          "indication_name": "Renal secondary hyperparathyroidism due to chronic kidney disease",
          "expected_effects": "Improved survival (all-cause mortality of 28% with calcitriol treatment, 63% with placebo)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:06.000000Z",
          "updated_at": "2020-11-04T20:40:43.000000Z"
      },
      {
          "id": 240,
          "drug_id": 69,
          "indication_name": "Prevention of hypocalcemia after surgical correction of hyperparathyroidism",
          "expected_effects": "Maintenance of serum calcium concentration within normal range",
          "common_combinations": "Vitamin D (ergocalciferol) 4000-6000 IU/kg PO q 24h for 7 days, then 1000-2000 IU/kg PO q 24h as long as needed to maintain normal serum calcium level",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:08.000000Z",
          "updated_at": "2020-09-16T00:25:08.000000Z"
      },
      {
          "id": 241,
          "drug_id": 69,
          "indication_name": "Hypocalcemia",
          "expected_effects": "Normalization of serum calcium level",
          "common_combinations": "Dihydrotachysterol 0.02-0.13 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:11.000000Z",
          "updated_at": "2020-09-16T00:25:11.000000Z"
      },
      {
          "id": 242,
          "drug_id": 70,
          "indication_name": "Severe hypocalcemia",
          "expected_effects": "Normalization of serum calcium",
          "common_combinations": "Lidocaine 1% (for intratesticular injection)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:13.000000Z",
          "updated_at": "2020-09-16T00:25:13.000000Z"
      },
      {
          "id": 243,
          "drug_id": 70,
          "indication_name": "Electromechanical dissociation/cardiac arrest (adjunct to cardiopulmonary resuscitation)",
          "expected_effects": "Ineffective as adjunct to CPR: same rate of return to spontaneous circulation as placebo, and inferior to epinephrine treatment",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:16.000000Z",
          "updated_at": "2020-11-04T20:44:24.000000Z"
      },
      {
          "id": 244,
          "drug_id": 70,
          "indication_name": "Sterilization of male cats",
          "expected_effects": "Marked atrophy of treated testes, significant decrease in circulating testosterone concentration (but not as low as control group undergoing orchiectomy)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:25:18.000000Z",
          "updated_at": "2020-11-04T20:44:24.000000Z"
      },
      {
          "id": 245,
          "drug_id": 71,
          "indication_name": "Lead toxicosis",
          "expected_effects": "Reduction of blood lead levels to below the minimum threshold (results of 14-32 µg/dL, with 35 µg/dL as the upper limit of normal range)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:21.000000Z",
          "updated_at": "2020-09-16T00:25:21.000000Z"
      },
      {
          "id": 246,
          "drug_id": 71,
          "indication_name": "Lead toxicosis",
          "expected_effects": "Clinical improvement within 1-2 days and sharp decrease in blood lead levels (within 2-48h of starting treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:23.000000Z",
          "updated_at": "2020-09-16T00:25:23.000000Z"
      },
      {
          "id": 247,
          "drug_id": 72,
          "indication_name": "Severe hypocalcemia",
          "expected_effects": "Normalization of serum calcium concentration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:25.000000Z",
          "updated_at": "2020-09-16T00:25:25.000000Z"
      },
      {
          "id": 248,
          "drug_id": 72,
          "indication_name": "Periparturient hypocalcemia/eclampsia",
          "expected_effects": "Improvement/full resolution of clinical signs\nMean duration of hospitalization of 4 hours (range: 0.5-19)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:28.000000Z",
          "updated_at": "2020-09-16T00:25:28.000000Z"
      },
      {
          "id": 249,
          "drug_id": 72,
          "indication_name": "Reversal of calcium channel blocker overdose",
          "expected_effects": "Return to normal sinus rhythm and normal arterial blood pressure",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:25:30.000000Z",
          "updated_at": "2020-09-16T00:25:30.000000Z"
      },
      {
          "id": 250,
          "drug_id": 72,
          "indication_name": "Parathormone response testing",
          "expected_effects": "Decreases serum parathormone from 84 pg/mL at time zero to 14 and 12 pg/mL at 15 and 60 min, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:25:32.000000Z",
          "updated_at": "2020-09-16T00:25:32.000000Z"
      },
      {
          "id": 251,
          "drug_id": 72,
          "indication_name": "Preparturient hypocalcemia",
          "expected_effects": "Resolution of clinical signs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:25:35.000000Z",
          "updated_at": "2020-09-16T00:25:35.000000Z"
      },
      {
          "id": 252,
          "drug_id": 72,
          "indication_name": "Hypoparathyroidism",
          "expected_effects": "Survival to discharge (and long-term oral maintenance therapy with vitamin D and calcium) in >80% of cases",
          "common_combinations": "Vitamin D (dihydrotachysterol) 0.004-0.04 mg/kg PO q 24h;Either calcium carbonate 23-42 mg/kg PO q 8h or calcium lactate 74-118 mg/kg PO q 8h",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:25:37.000000Z",
          "updated_at": "2020-09-16T00:25:37.000000Z"
      },
      {
          "id": 253,
          "drug_id": 72,
          "indication_name": "Sodium fluoroacetate intoxication",
          "expected_effects": "75% survival rate (vs. 37.5% if untreated)",
          "common_combinations": "Sodium succinate 240 mg/kg dilute to 10 mL in 0.9% NaCl and given after each dose of calcium gluconate",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:25:39.000000Z",
          "updated_at": "2020-09-16T00:25:39.000000Z"
      },
      {
          "id": 254,
          "drug_id": 73,
          "indication_name": "Congestive heart failure due to mitral regurgitation or dilated cardiomyopathy",
          "expected_effects": "Well-tolerated: no significant renal changes biochemically, appetite unchanged",
          "common_combinations": "Furosemide;Digoxin;Low-sodium diet",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:42.000000Z",
          "updated_at": "2020-09-16T00:25:42.000000Z"
      },
      {
          "id": 255,
          "drug_id": 73,
          "indication_name": "Mitral regurgitation",
          "expected_effects": "Improvement in hemodynamic parameters: lower total peripheral resistance, higher forward ejection fraction",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:44.000000Z",
          "updated_at": "2020-09-16T00:25:44.000000Z"
      },
      {
          "id": 256,
          "drug_id": 74,
          "indication_name": "Pseudomonas osteomyelitis",
          "expected_effects": "Eradication of infection",
          "common_combinations": "Wound care;External fixation;Bone grafting",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:46.000000Z",
          "updated_at": "2020-09-16T00:25:46.000000Z"
      },
      {
          "id": 257,
          "drug_id": 75,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "Normalization of serum T4 levels and resolution of clinical signs of hyperthyroidism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:49.000000Z",
          "updated_at": "2020-11-04T20:47:21.000000Z"
      },
      {
          "id": 258,
          "drug_id": 75,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "Normalization of serum T4 levels and resolution of clinical signs of hyperthyroidism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:25:52.000000Z",
          "updated_at": "2020-11-04T20:47:21.000000Z"
      },
      {
          "id": 259,
          "drug_id": 75,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "Normalization of serum T4 levels and resolution of clinical signs of hyperthyroidism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:25:54.000000Z",
          "updated_at": "2020-11-04T20:47:21.000000Z"
      },
      {
          "id": 260,
          "drug_id": 75,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "4-fold decrease in T4 levels after 10 days of treatment, maintained at 1 year",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:25:57.000000Z",
          "updated_at": "2020-11-04T20:47:21.000000Z"
      },
      {
          "id": 261,
          "drug_id": 76,
          "indication_name": "Osteosarcoma",
          "expected_effects": "Median disease-free interval = 291 days; median survival time = 284 days; frewer adverse effects than protocols that include doxorubicin",
          "common_combinations": "Amputation of affected limb",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:25:59.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 262,
          "drug_id": 76,
          "indication_name": "Osteosarcoma",
          "expected_effects": "Median survival time: 365 days\r\n53% rate of reversible myelotoxicosis (mild-moderate)",
          "common_combinations": "Amputation of affected limb",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:26:01.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 263,
          "drug_id": 76,
          "indication_name": "Malignant melanoma",
          "expected_effects": "Clinical response in 28% of dogs, mainly consisting of reduction in tumor size by at least 50% and occasionally elimination of tumor\r\nMedian duration of response of 6 months",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:26:04.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 264,
          "drug_id": 76,
          "indication_name": "Melanoma (oral)",
          "expected_effects": "Median time to detectable metastases of 311 days\r\nMedian survival time of 363 days",
          "common_combinations": "Megavoltage radiation therapy 6 Gy q 1 week for 6 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:26:06.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 265,
          "drug_id": 76,
          "indication_name": "Carcinomatosis, sarcomatosis, mesothelioma",
          "expected_effects": "Median survival time of 332 days (vs. 25 days for untreated dogs)",
          "common_combinations": "Mitoxantrone (5-5.5 mg/m², diluted 1:1 with 0.9% NaCl and then further diluted with 0.9% NaCl to 0.22 mg/mL, intracavitary) given in the same treatment session in some cases;IV doxorubicin or IV mitoxantrone in some cases replacing intracavitary treatment every other session (clinician's preference)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:26:09.000000Z",
          "updated_at": "2020-09-16T00:26:09.000000Z"
      },
      {
          "id": 266,
          "drug_id": 76,
          "indication_name": "Carcinoma",
          "expected_effects": "13% positive response rate: individual complete or partial remissions with single cases of metastatic prostatic carcinoma, intestinal carcinoma, and tonsillar adenocarcinoma\r\n32% rate of palliation/stable disease for median of 72 days",
          "common_combinations": "Gemcitabine 2 mg/kg as slow (20- to 30- minute) IV infusion 4 hours after carboplatin, on days 1 and 8 (carboplatin on day 1 and q 21 days thereafter)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:26:11.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 267,
          "drug_id": 76,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "65% improvement in clinical signs; 35% unchanged clinical signs; median progression-free interval = 74 days, which is not significantly different from mitoxantrone treatment",
          "common_combinations": "Piroxicam 0.3 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:26:13.000000Z",
          "updated_at": "2020-11-04T21:22:46.000000Z"
      },
      {
          "id": 268,
          "drug_id": 76,
          "indication_name": "Oral squamous cell carcinoma",
          "expected_effects": "Median survival of 163 days (range: 53-770 days), including 13% of cats living 2 years or more",
          "common_combinations": "Radiation therapy: 3.5 Gy given for 14 doses over a 9-day period (twice daily, 6 hours apart)",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:26:16.000000Z",
          "updated_at": "2020-09-16T00:26:16.000000Z"
      },
      {
          "id": 269,
          "drug_id": 76,
          "indication_name": "Facial squamous cell carcinoma",
          "expected_effects": "Complete clinical tumor clearance in 67% of cases\r\nMean progression-free survival of 16 ± 3.3 months",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:26:18.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 270,
          "drug_id": 76,
          "indication_name": "Neoplasia (cutaneous hemangiosarcoma, injection site sarcoma, lymphoma, squamous cell carcinoma, etc.)",
          "expected_effects": "Best responses for cutaneous hemangiosarcoma and vaccine-site sarcoma",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:26:20.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 271,
          "drug_id": 76,
          "indication_name": "Mesothelioma",
          "expected_effects": "Reduction of abdominal fluid production by 90%\r\nProgressive disease leading to euthanasia/death in 1 case report",
          "common_combinations": "Piroxicam 0.3 mg/kg PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:26:23.000000Z",
          "updated_at": "2020-11-04T20:51:24.000000Z"
      },
      {
          "id": 272,
          "drug_id": 77,
          "indication_name": "Lymphoma",
          "expected_effects": "Complete remission in 86% of dogs\nMedian duration of remission: 183 days\nMedian survival time: 224 days",
          "common_combinations": "Vincristine 0.75 mg/m² IV q 1 week for 4 weeks, then q 3 weeks;Prednisone 40 mg/m² PO q 24h for 1 week, then 20 mg/m² PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:26:25.000000Z",
          "updated_at": "2020-09-16T00:26:25.000000Z"
      },
      {
          "id": 273,
          "drug_id": 78,
          "indication_name": "Carnitine deficiency",
          "expected_effects": "Improvement in left ventricular systolic function, reduction in left ventricular diameter, and ability to wean dogs from some or all other cardiac medications in some cases",
          "common_combinations": "Taurine 500 mg PO q 8h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:26:27.000000Z",
          "updated_at": "2020-09-16T00:26:27.000000Z"
      },
      {
          "id": 274,
          "drug_id": 78,
          "indication_name": "Weight loss",
          "expected_effects": "Greater weight loss occurs with weight-loss diet plus carnitine supplementation compared to weight-loss diet alone (23.7% weight lost, vs. 19.6% in 18 weeks)",
          "common_combinations": "Calorie-restricted diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:26:30.000000Z",
          "updated_at": "2020-09-16T00:26:30.000000Z"
      },
      {
          "id": 275,
          "drug_id": 79,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Marked (3- to 4-fold) improvement in clinical signs of osteoarthritis",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:26:32.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 276,
          "drug_id": 79,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Improvement in lameness noted by owners and veterinarians in 92.4% of cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:26:34.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 277,
          "drug_id": 79,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Dosage reduction to 3.5 mg/kg PO q 24h was possible by week 12 (signifcantly lower than in non-omega-3-supplemented dogs)",
          "common_combinations": "Omega 3 fatty acids (from fish oil) comprising 3.5% of diet, compared to control diet (0.1% omega-3 fatty acids)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:26:37.000000Z",
          "updated_at": "2020-09-16T00:26:37.000000Z"
      },
      {
          "id": 278,
          "drug_id": 79,
          "indication_name": "Intraocular inflammation",
          "expected_effects": "Equivocally less intraocular inflammation (marginally lower aqueous humor prostaglandin concentrations) with carprofen compared to placebo",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:26:40.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 279,
          "drug_id": 79,
          "indication_name": "Perioperative orthopedic analgesic",
          "expected_effects": "Pain relief for 24h after cruciate surgery (similar degree of effect as meloxicam)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:26:42.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 280,
          "drug_id": 79,
          "indication_name": "Post-operative analgesia (ovariohysterectomy)",
          "expected_effects": "Significantly better pain control both in degree (lower pain scores) and duration (20 hours post-op) with carprofen compared to placebo or pethidine\r\nBetter pain control with carprofen 4 mg/kg than with 2 mg/kg or 1 mg/kg",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:26:45.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 281,
          "drug_id": 80,
          "indication_name": "Myxomatous mitral valvular disease",
          "expected_effects": "Improved quality of life (based on owner-provided responses to a questionnaire in a blinded, controlled study) and lower resting arterial blood pressure",
          "common_combinations": "\"Conventional tx of heart disease\" including \"digoxin, benazepril, a reduced sodium diet, codeine, and a diuretic when indicated\"",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:26:47.000000Z",
          "updated_at": "2020-09-16T00:26:47.000000Z"
      },
      {
          "id": 282,
          "drug_id": 80,
          "indication_name": "Mitral regurgitation",
          "expected_effects": "Beta-blockade (as evidenced by blunting of response to isoproterenol IV infusion) lasts 36h in dogs, indicating an extensive effect after the drug is eliminated (peak plasma concentration of carvedilol in dogs 1-4 hours after oral dosing, virtually entirely eliminated by 8 hours after dosing)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:26:50.000000Z",
          "updated_at": "2020-09-16T00:26:50.000000Z"
      },
      {
          "id": 283,
          "drug_id": 80,
          "indication_name": "Beta-blockade in normal dogs",
          "expected_effects": "Mean peak serum carvedilol concentration 20 times higher with this IV dose than with oral carvedilol 1.5 mg/kg in the same study of normal dogs (476 vs. 24 ng/mL)\nElimination half-life 3.5 times longer with IV than oral (282 vs. 82 min)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:26:52.000000Z",
          "updated_at": "2020-09-16T00:26:52.000000Z"
      },
      {
          "id": 284,
          "drug_id": 81,
          "indication_name": "Systemic aspergillosis",
          "expected_effects": "Clinical improvement and resolution of lymphadenopathy during initial treatment (6 weeks), maintenance of clinical remission (with dosage adjustments) for 1 year",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:26:54.000000Z",
          "updated_at": "2020-09-16T00:26:54.000000Z"
      },
      {
          "id": 285,
          "drug_id": 82,
          "indication_name": "Prophylaxis against bacterial infection after renal transplantation",
          "expected_effects": "Prevention of opportunistic bacterial infection during acute stages of post-transplant immunosuppression",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:26:57.000000Z",
          "updated_at": "2020-09-16T00:26:57.000000Z"
      },
      {
          "id": 286,
          "drug_id": 83,
          "indication_name": "Pyoderma",
          "expected_effects": ">99% elimination of lesions and signs of superficial pyoderma with 3-week treatment\r\nRecurrent pyoderma typically requires 5 weeks of treatment, and deep pyoderma may require up to 9 weeks of treatment",
          "common_combinations": "Treatment of inciting or concurrent dermatologic disorder",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:00.000000Z",
          "updated_at": "2020-11-04T21:46:11.000000Z"
      },
      {
          "id": 287,
          "drug_id": 83,
          "indication_name": "Pyoderma",
          "expected_effects": "Good to excellent response in 97% of cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:27:02.000000Z",
          "updated_at": "2020-11-04T21:46:11.000000Z"
      },
      {
          "id": 288,
          "drug_id": 83,
          "indication_name": "Pyoderma",
          "expected_effects": null,
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:27:04.000000Z",
          "updated_at": "2020-11-04T21:46:11.000000Z"
      },
      {
          "id": 289,
          "drug_id": 83,
          "indication_name": "Pyoderma",
          "expected_effects": "91% of cats have a successful response to treatment when assessed after a 2-week treatment period and a 2-week washout period (no treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:27:07.000000Z",
          "updated_at": "2020-11-04T21:46:11.000000Z"
      },
      {
          "id": 290,
          "drug_id": 84,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:09.000000Z",
          "updated_at": "2020-09-16T00:27:09.000000Z"
      },
      {
          "id": 291,
          "drug_id": 85,
          "indication_name": "Perioperative antimicrobial prophylaxis",
          "expected_effects": "Significantly fewer postoperative infections in 1 clinical study (compared to control group that received placebo (study was terminated early due to marked benefit of cefazolin)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:12.000000Z",
          "updated_at": "2020-11-04T21:48:53.000000Z"
      },
      {
          "id": 292,
          "drug_id": 85,
          "indication_name": "Perioperative antimicrobial prophylaxis for total hip replacement",
          "expected_effects": "Expected reduction in (or elimination of) postoperative infections",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:27:14.000000Z",
          "updated_at": "2020-11-04T21:48:53.000000Z"
      },
      {
          "id": 293,
          "drug_id": 85,
          "indication_name": "Perioperative antimicrobial prophylaxis for total hip replacement",
          "expected_effects": "Expected reduction in (or elimination of) postoperative infections",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:27:17.000000Z",
          "updated_at": "2020-11-04T21:48:53.000000Z"
      },
      {
          "id": 294,
          "drug_id": 85,
          "indication_name": "Perioperative antimicrobial prophylaxis",
          "expected_effects": "Expected reduction in (or elimination of) postoperative infections",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:27:19.000000Z",
          "updated_at": "2020-11-04T21:48:53.000000Z"
      },
      {
          "id": 295,
          "drug_id": 86,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:21.000000Z",
          "updated_at": "2020-09-16T00:27:21.000000Z"
      },
      {
          "id": 296,
          "drug_id": 87,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:24.000000Z",
          "updated_at": "2020-09-16T00:27:24.000000Z"
      },
      {
          "id": 297,
          "drug_id": 88,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:27.000000Z",
          "updated_at": "2020-09-16T00:27:27.000000Z"
      },
      {
          "id": 298,
          "drug_id": 89,
          "indication_name": "Septicemia",
          "expected_effects": "83% recovery or cure from septicemia, including dogs with severe (moribund) clinical status at start of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:29.000000Z",
          "updated_at": "2020-09-16T00:27:29.000000Z"
      },
      {
          "id": 299,
          "drug_id": 90,
          "indication_name": "Susceptible systemic infections including E. coli, Staphylococcus, and many Gram-negative and Gram-positive bacteria",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:32.000000Z",
          "updated_at": "2020-09-16T00:27:32.000000Z"
      },
      {
          "id": 300,
          "drug_id": 90,
          "indication_name": "Susceptible systemic infections including E. coli, Staphylococcus, and many Gram-negative and Gram-positive bacteria",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:27:34.000000Z",
          "updated_at": "2020-09-16T00:27:34.000000Z"
      },
      {
          "id": 301,
          "drug_id": 91,
          "indication_name": "Bacterial dermatitis/pyoderma",
          "expected_effects": "92.4% of cases are treatment successes (defined as all dermatologic clinical signs and cutaneous lesions reduced to being mild or absent)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:37.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 302,
          "drug_id": 91,
          "indication_name": "Urinary tract infection caused by E. coli",
          "expected_effects": "Infection eliminated by cefovecin in 79.1% of cases (vs. 36.4% in dogs treated with cephalexin 15 mg/kg PO q 12h for 2 weeks)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:27:39.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 303,
          "drug_id": 91,
          "indication_name": "Infected wounds/cat bite abscesses",
          "expected_effects": "97% of wound infections and abscesses resolve in the 4 weeks following the injection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:27:42.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 304,
          "drug_id": 91,
          "indication_name": "Urinary tract infection",
          "expected_effects": "78% of cats with history/signs suggesting urinary tract infection (UTI) had no bacteria/no infection at baseline. For the remaining cats, cefovecin was as effective as cephalexin at eliminating bacturia",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:27:44.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 305,
          "drug_id": 92,
          "indication_name": "Systemic bacterial infection (e.g., prophylaxis against bacterial infection after renal transplantation)",
          "expected_effects": "Reduction/prevention of infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:47.000000Z",
          "updated_at": "2020-11-05T19:53:24.000000Z"
      },
      {
          "id": 306,
          "drug_id": 93,
          "indication_name": "Bacterial dermatitis/pyoderma",
          "expected_effects": "96.8% of cases are treatment successes (defined as all dermatologic clinical signs and cutaneous lesions reduced to being mild or absent) vs. 93.9% with cephalexin",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:49.000000Z",
          "updated_at": "2020-11-05T20:30:51.000000Z"
      },
      {
          "id": 307,
          "drug_id": 94,
          "indication_name": "Pseudomonas aeruginosa infection",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:27:52.000000Z",
          "updated_at": "2020-09-16T00:27:52.000000Z"
      },
      {
          "id": 308,
          "drug_id": 94,
          "indication_name": "Pseudomonas aeruginosa infection",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:27:54.000000Z",
          "updated_at": "2020-09-16T00:27:54.000000Z"
      },
      {
          "id": 309,
          "drug_id": 94,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:27:57.000000Z",
          "updated_at": "2020-09-16T00:27:57.000000Z"
      },
      {
          "id": 310,
          "drug_id": 95,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:00.000000Z",
          "updated_at": "2020-09-16T00:28:00.000000Z"
      },
      {
          "id": 311,
          "drug_id": 96,
          "indication_name": "Septic arthritis",
          "expected_effects": "Elimination of infection",
          "common_combinations": "Ampicillin;Amikacin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:03.000000Z",
          "updated_at": "2020-09-16T00:28:03.000000Z"
      },
      {
          "id": 312,
          "drug_id": 96,
          "indication_name": "Borreliosis",
          "expected_effects": "Palliation/elimination of infection",
          "common_combinations": "Imidocarb;Amoxicillin",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:28:05.000000Z",
          "updated_at": "2020-09-16T00:28:05.000000Z"
      },
      {
          "id": 313,
          "drug_id": 96,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:28:07.000000Z",
          "updated_at": "2020-09-16T00:28:07.000000Z"
      },
      {
          "id": 314,
          "drug_id": 97,
          "indication_name": "Pyothorax",
          "expected_effects": "Elimination of infection",
          "common_combinations": "Metronidazole (post-op)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:10.000000Z",
          "updated_at": "2020-09-16T00:28:10.000000Z"
      },
      {
          "id": 315,
          "drug_id": 98,
          "indication_name": "Pyoderma",
          "expected_effects": ">99% elimination of lesions and signs of superficial pyoderma with 3-week treatment\r\nRecurrent pyoderma typically requires 5 weeks of treatment, and deep pyoderma may require up to 9 weeks of treatment",
          "common_combinations": "Treatment of inciting or concurrent dermatologic disorder (e.g., mite infestation, atopic dermatitis, etc)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:12.000000Z",
          "updated_at": "2020-11-05T20:32:27.000000Z"
      },
      {
          "id": 316,
          "drug_id": 98,
          "indication_name": "Urinary tract infection",
          "expected_effects": "Elimination of urinary tract infection in 36% of cases (vs. 79% with single injection of cefovecin)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:28:14.000000Z",
          "updated_at": "2020-11-05T20:32:27.000000Z"
      },
      {
          "id": 317,
          "drug_id": 98,
          "indication_name": "Urinary tract infection",
          "expected_effects": "Elimination of urinary tract infection in 63% of cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:28:17.000000Z",
          "updated_at": "2020-11-05T20:32:27.000000Z"
      },
      {
          "id": 318,
          "drug_id": 99,
          "indication_name": "Perioperative antimicrobial prophylaxis",
          "expected_effects": "Intended reduction in postoperative infections",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:19.000000Z",
          "updated_at": "2020-09-16T00:28:19.000000Z"
      },
      {
          "id": 319,
          "drug_id": 100,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Good to excellent response (reduction in pruritus by 50-100%) in 18% of treated dogs",
          "common_combinations": "Treatment of complicating factors (e.g., Malassezia dermatitis, mite infestation, pyoderma)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:22.000000Z",
          "updated_at": "2020-09-16T00:28:22.000000Z"
      },
      {
          "id": 320,
          "drug_id": 100,
          "indication_name": "Eosinophilic airway inflammation",
          "expected_effects": "No difference in bronchoalveolar lavage results with treatment vs. placebo",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:28:24.000000Z",
          "updated_at": "2020-11-05T20:34:51.000000Z"
      },
      {
          "id": 321,
          "drug_id": 101,
          "indication_name": "Hyperphosphatemia due to chronic kidney disease",
          "expected_effects": "Improved appetite, lower serum phosphorus and urea concentrations",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:28.000000Z",
          "updated_at": "2020-09-16T00:28:28.000000Z"
      },
      {
          "id": 322,
          "drug_id": 102,
          "indication_name": "Lymphoma (COAP protocol: maintenance after induction of remission)",
          "expected_effects": "Maintenance of remission (median duration in dogs receiving COAP protocol: 94 days)",
          "common_combinations": "Part of multidrug protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:30.000000Z",
          "updated_at": "2020-09-16T00:28:30.000000Z"
      },
      {
          "id": 323,
          "drug_id": 102,
          "indication_name": "Mast cell tumor",
          "expected_effects": "Complete (14%) or partial (24%) remission in 38% of treated dogs\r\nMedian progression-free time in treatment responders: 533 days\r\nMedian overall survival in dogs: 140 days",
          "common_combinations": "Prednisolone 40 mg/m² PO q 24h for 14 days, then 20 mg/m² PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:28:32.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 324,
          "drug_id": 102,
          "indication_name": "GI lymphoma (small-cell)",
          "expected_effects": "96% clinical response\r\nMedian duration of clinical remission: 786 days",
          "common_combinations": "Prednisolone 1-2 mg/kg PO for 1 week, then 1 mg/kg PO q 48h until relapse/loss of remission",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:28:35.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 325,
          "drug_id": 102,
          "indication_name": "Lymphoma (University of Wisconsin Madison protocol)",
          "expected_effects": "Maintenance of remission",
          "common_combinations": "Part of multidrug protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:28:38.000000Z",
          "updated_at": "2020-09-16T00:28:38.000000Z"
      },
      {
          "id": 326,
          "drug_id": 103,
          "indication_name": "Rocky Mountain spotted fever ",
          "expected_effects": "Elimination of infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:40.000000Z",
          "updated_at": "2020-09-16T00:28:40.000000Z"
      },
      {
          "id": 327,
          "drug_id": 103,
          "indication_name": "Urinary tract infection",
          "expected_effects": "Elimination of 51% (E. coli), 63% (Proteus mirabilis), 82% (Streptococcus spp.), and 84% (Staphylococcus aureus) of canine urinary tract infections [note: data from 1978 - substantial efficacy differences are expected with evolution of antibiotic resistance over time]",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:28:42.000000Z",
          "updated_at": "2020-09-16T00:28:42.000000Z"
      },
      {
          "id": 328,
          "drug_id": 103,
          "indication_name": "Decrease fecal shedding of Campylobacter jejuni",
          "expected_effects": "Elimination of C. jejuni from fecal shedding by day 4 of treatment\nRecurrence of shedding within 9 days of cessation of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:28:45.000000Z",
          "updated_at": "2020-09-16T00:28:45.000000Z"
      },
      {
          "id": 329,
          "drug_id": 104,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "50% or greater reduction in polydipsia in some cases, but inconsistent",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:47.000000Z",
          "updated_at": "2020-09-16T00:28:47.000000Z"
      },
      {
          "id": 330,
          "drug_id": 104,
          "indication_name": "Congestive heart failure",
          "expected_effects": "Extensive diuretic effect: loss of 12% of total body weight (in fluid, i.e., resorption of voluminous ascites) over 5-day period in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:28:49.000000Z",
          "updated_at": "2020-09-16T00:28:49.000000Z"
      },
      {
          "id": 331,
          "drug_id": 104,
          "indication_name": "Calcium-sparing diuretic",
          "expected_effects": "No benefit: calciuresis unchanged or paradoxically increased (with higher dosage)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:28:52.000000Z",
          "updated_at": "2020-09-16T00:28:52.000000Z"
      },
      {
          "id": 332,
          "drug_id": 105,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "58% of treated dogs show an improvement of at least 25% in pruritus and lesions within 2 weeks of starting treatment, i.e., clearly beneficial when compared to placebo, but unlikely to fully eliminate signs",
          "common_combinations": "Hydroxyzine 2.1 mg/kg PO q12h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:28:54.000000Z",
          "updated_at": "2020-11-07T18:33:07.000000Z"
      },
      {
          "id": 335,
          "drug_id": 106,
          "indication_name": "Nausea",
          "expected_effects": "Prevents vomiting as effectively as maropitant if centrally-triggered (e.g., apomorphine) but less effectively if peripherally-triggered (e.g., ipecac, hydrogen peroxide)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:02.000000Z",
          "updated_at": "2020-09-16T00:29:02.000000Z"
      },
      {
          "id": 336,
          "drug_id": 107,
          "indication_name": "Primary adipsia",
          "expected_effects": "Subjective increase in spontaneous water intake in 1 case, but not sufficient to meet the patient's complete needs",
          "common_combinations": "Addition of water to encourage water intake and mitigate effects of adipsia",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:05.000000Z",
          "updated_at": "2020-09-16T00:29:05.000000Z"
      },
      {
          "id": 337,
          "drug_id": 107,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "Marked and sustained improvement in clinical signs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:29:07.000000Z",
          "updated_at": "2020-09-16T00:29:07.000000Z"
      },
      {
          "id": 338,
          "drug_id": 108,
          "indication_name": "Male infertility due to oligozoospermia",
          "expected_effects": "Marked improvement in semen quality for 2-4 weeks after single injection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:09.000000Z",
          "updated_at": "2020-11-07T18:45:08.000000Z"
      },
      {
          "id": 339,
          "drug_id": 108,
          "indication_name": "Mast cell tumor",
          "expected_effects": "Reduction in tumor size was no different from reduction in tumor size obtained with vinblastine treatment, but there were more adverse effects with vinblastine",
          "common_combinations": "BCG (bacille Calmette-Guérin) 1.35 ng/dose given in same injection q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:29:12.000000Z",
          "updated_at": "2020-09-16T00:29:12.000000Z"
      },
      {
          "id": 340,
          "drug_id": 108,
          "indication_name": "Induction of ovulation",
          "expected_effects": "95.6% ovulation rate\r\nConception rate dependent on insemination timing and technique",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:29:14.000000Z",
          "updated_at": "2020-11-07T18:45:08.000000Z"
      },
      {
          "id": 341,
          "drug_id": 108,
          "indication_name": "Detection of ovarian remnant",
          "expected_effects": "Change in serum progesterone levels from baseline (0.2-0.8 ng/dL) to 1 week post-injection (5-32 ng/mL) if ovarian remnant\r\nFully spayed cats show no change (baseline: 0.3-0.4 ng/mL, 1 week post-injection: 0.2-0.5 ng/mL)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:29:17.000000Z",
          "updated_at": "2020-11-07T18:45:08.000000Z"
      },
      {
          "id": 342,
          "drug_id": 108,
          "indication_name": "Detection of cryptorchid testis",
          "expected_effects": "Normal response in castrated male: serum testosterone concentration less than doubles after hCG injection (vs. pre-hCG serum testosterone 0.68 ng/mL, 30 min post 5 ng/mL, and 120 min post 10.5 ng/mL in cryptorchid cat case)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:29:19.000000Z",
          "updated_at": "2020-11-07T18:45:08.000000Z"
      },
      {
          "id": 343,
          "drug_id": 109,
          "indication_name": "Gastritis",
          "expected_effects": "May produce reduction in gastric acid secretion, but omeprazole is significantly more effective",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:22.000000Z",
          "updated_at": "2020-09-16T00:29:22.000000Z"
      },
      {
          "id": 344,
          "drug_id": 109,
          "indication_name": "Gastritis",
          "expected_effects": "May reduce number and degree of gastric erosions caused by nonsteroidal anti-inflammatory drugs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:29:24.000000Z",
          "updated_at": "2020-09-16T00:29:24.000000Z"
      },
      {
          "id": 345,
          "drug_id": 110,
          "indication_name": "Bacterial prostatitis (susceptible bacteria)",
          "expected_effects": "Good tissue penetration and expected efficacy based on pharmacokinetic studies in healthy dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:27.000000Z",
          "updated_at": "2020-11-07T18:48:00.000000Z"
      },
      {
          "id": 346,
          "drug_id": 111,
          "indication_name": "Prevention of gastroesophageal reflux under anesthesia",
          "expected_effects": "Significantly fewer episodes of perioperative gastroesophageal reflux (11% with cisapride + omeprazole pretreatment, vs. 38% with placebo)",
          "common_combinations": "Esomeprazole 1 mg/kg IV twice, at same time as cisapride",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:30.000000Z",
          "updated_at": "2020-09-16T00:29:30.000000Z"
      },
      {
          "id": 347,
          "drug_id": 111,
          "indication_name": "Gastrointestinal motility disorders",
          "expected_effects": "Improved gastrointestinal tract motility",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:29:32.000000Z",
          "updated_at": "2020-11-07T18:50:01.000000Z"
      },
      {
          "id": 348,
          "drug_id": 112,
          "indication_name": "Osteosarcoma",
          "expected_effects": "Mean survival with cisplatin + doxorubicin + amputation of the affected limb: 415 days -- significantly longer than survival after amputation alone (mean: 218 days)",
          "common_combinations": "Amputation of affected limb;Doxorubicin 30 mg/m² IV CRI, 21 days apart from cisplatin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:29:35.000000Z",
          "updated_at": "2020-09-16T00:29:35.000000Z"
      },
      {
          "id": 349,
          "drug_id": 112,
          "indication_name": "Squamous cell carcinoma of the head/neck",
          "expected_effects": "Partial improvement for 2-15 weeks in 60% of dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:29:38.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 350,
          "drug_id": 112,
          "indication_name": "Squamous cell carcinoma of the head/neck",
          "expected_effects": "Partial improvement for 2-15 weeks in 60% of dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:29:40.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 351,
          "drug_id": 112,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "Partial improvement lasting 31 weeks in 13% of cases\r\nStabilization of disease for 12-34 weeks in 50% of cases\r\nNo response in 38% of cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:29:42.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 352,
          "drug_id": 112,
          "indication_name": "Transitional cell carcinoma - normal renal function",
          "expected_effects": "Remission rate = 13% (versus 57% when combined with a COX-2 inhibiting drug like firocoxib 5 mg/kg PO q 24h); all partial remissions, no complete remissions",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:29:45.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 353,
          "drug_id": 112,
          "indication_name": "Melanoma (oral)",
          "expected_effects": "Median time to detectable metastases of 311 days\r\nMedian survival time of 363 days",
          "common_combinations": "Megavoltage radiation therapy 6 Gy, weekly with every dose of cisplatin as pretreatment, for 6 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:29:48.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 354,
          "drug_id": 112,
          "indication_name": "Mesothelioma, carcinomatosis",
          "expected_effects": "Complete resolution of malignant effusion for 129-306+ days (pleural mesothelioma) and of malignant abdominal effusion for 255-807 days in 2 dogs with carcinomatosis",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:29:52.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 355,
          "drug_id": 112,
          "indication_name": "Soft tissue sarcoma of extremities",
          "expected_effects": "9/19 dogs lived 758-1463 days post-op\r\nOf the 9 dogs that died, only 1 died of tumor-related causes\r\nDuring treatment, there was an 84% rate of complications requiring implant removal",
          "common_combinations": "Surgical reduction of tumor burden",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:29:55.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 356,
          "drug_id": 112,
          "indication_name": "Transitional cell carcinoma of bladder",
          "expected_effects": "Median progression-free interval: 78 days (range: 20-112)\r\nMedian survival: 307 days\r\nModerate/severe nephrotoxicosis in 36% of dogs and moderate/severe gastrointestinal toxicosis in 57% of dogs",
          "common_combinations": "Piroxicam (0.3 mg/kg PO q 24h)",
          "is_contraindicated": 1,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:29:57.000000Z",
          "updated_at": "2020-11-07T18:52:34.000000Z"
      },
      {
          "id": 357,
          "drug_id": 113,
          "indication_name": "Osteosarcoma",
          "expected_effects": "Median disease-free survival of 156 days, not significantly different from carboplatin treatment",
          "common_combinations": "Amputation of the affected limb",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:30:00.000000Z",
          "updated_at": "2020-09-16T00:30:00.000000Z"
      },
      {
          "id": 358,
          "drug_id": 114,
          "indication_name": "Mycobacterium avium infection (disseminated)",
          "expected_effects": "Clinical improvement or cure in approximately 50% of cases (includes those with lifelong ongoing treatment due to recrudescence when treatment is stopped)",
          "common_combinations": "2 additional drugs: either clofazimine (25-50 mg/CAT PO q 24h) or rifampin (75 mg/CAT PO q 24h), and either ciprofloxacin (125 mg/CAT PO q 12h) or doxycycline (50 mg/CAT PO q 12-24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:30:03.000000Z",
          "updated_at": "2020-09-16T00:30:03.000000Z"
      },
      {
          "id": 359,
          "drug_id": 114,
          "indication_name": "Helicobacter pylori gastric infection",
          "expected_effects": "Suppression, but not eradication, of H. pylori in 64% of treated cats",
          "common_combinations": "Omeprazole 0.7 mg/kg PO q 8h, amoxicillin 20 mg/kg PO q 12h, and metronidazole 20mg/kg PO q 12h (\"quadruple therapy\")",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:30:10.000000Z",
          "updated_at": "2020-09-16T00:30:10.000000Z"
      },
      {
          "id": 360,
          "drug_id": 114,
          "indication_name": "Rhodococcus equi cellulitis",
          "expected_effects": "Eradication of infection and healing of lesion in 1 case report",
          "common_combinations": "Rifampin 75 mg/CAT PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:30:13.000000Z",
          "updated_at": "2020-11-07T18:56:54.000000Z"
      },
      {
          "id": 361,
          "drug_id": 114,
          "indication_name": "Ulcerative skin lesion due to Mycobacterium terrae-type organism",
          "expected_effects": "Elimination of infection and resolution of lesion",
          "common_combinations": "Enrofloxacin 5 mg/kg PO q 24h;Rifampin 10 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:30:15.000000Z",
          "updated_at": "2020-09-16T00:30:15.000000Z"
      },
      {
          "id": 362,
          "drug_id": 115,
          "indication_name": "Allergic diseases (e.g., atopic dermatitis)",
          "expected_effects": "Excellent antipruritic effect (based on owner assessment) in 10% of dogs, good in 19% of dogs, and poor in 71% of dogs",
          "common_combinations": "Omega-3 fatty acid supplement",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:30:17.000000Z",
          "updated_at": "2020-09-16T00:30:17.000000Z"
      },
      {
          "id": 363,
          "drug_id": 115,
          "indication_name": "Antipruritic",
          "expected_effects": "Elimination of pruritus in 50% of treated cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:30:20.000000Z",
          "updated_at": "2020-09-16T00:30:20.000000Z"
      },
      {
          "id": 364,
          "drug_id": 116,
          "indication_name": "Periodontal disease",
          "expected_effects": "Reduction in subsequent plaque accumulation 2-6 weeks after procedure, and in periodontal pocket depth, but no difference in gingivitis (compared to no antibacterial treatment)",
          "common_combinations": "Dental prophylaxis",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:30:22.000000Z",
          "updated_at": "2020-09-16T00:30:22.000000Z"
      },
      {
          "id": 365,
          "drug_id": 116,
          "indication_name": "Pyoderma",
          "expected_effects": "81-94% response to treatment, similar or superior to treatment with twice-daily lincomycin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:30:25.000000Z",
          "updated_at": "2020-09-16T00:30:25.000000Z"
      },
      {
          "id": 366,
          "drug_id": 116,
          "indication_name": "Neospora caninum infection",
          "expected_effects": "Improvement in clinical signs in affected, treated puppies (e.g., reduced hindlimb weakness) but incomplete elimination of the organism",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:30:28.000000Z",
          "updated_at": "2020-09-16T00:30:28.000000Z"
      },
      {
          "id": 367,
          "drug_id": 116,
          "indication_name": "Babesiosis (Babesia gibsoni)",
          "expected_effects": "Significant reduction of parasitemia and improvement in clinical signs during and immediately after treatment, but loss of treatment benefit 3-4 weeks after end of 2-week treatment (suggesting parasite suppression but incomplete elimination)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:30:31.000000Z",
          "updated_at": "2020-09-16T00:30:31.000000Z"
      },
      {
          "id": 368,
          "drug_id": 116,
          "indication_name": "Osteomyelitis (experimentally-induced, Staphylococcus aureus)",
          "expected_effects": "Significant elimination of bacteria (94%, vs. 46% when untreated)\nImproved overall clinical recovery (94%, vs. 31% when untreated)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:30:33.000000Z",
          "updated_at": "2020-09-16T00:30:33.000000Z"
      },
      {
          "id": 369,
          "drug_id": 116,
          "indication_name": "Hepatozoonosis",
          "expected_effects": "81% survival, including 41% elimination of all clinical signs",
          "common_combinations": "Co-treatment: trimethoprim-sulfadiazine 15 mg/kg PO q 12h and pyrimethamine 0.25 mg/kg PO q 24h, all for 14 days, followed by decoquinate 10-20 mg/kg PO (mixed in food) q 12h (lifelong treatment)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:30:35.000000Z",
          "updated_at": "2020-09-16T00:30:35.000000Z"
      },
      {
          "id": 370,
          "drug_id": 116,
          "indication_name": "Toxoplasmosis",
          "expected_effects": "Complete resolution of all extraocular signs, and resolution of ocular signs in some but not all cats",
          "common_combinations": "Prednisone 0.25 mg/kg PO q 12h if evidence of anterior uveitis",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:30:38.000000Z",
          "updated_at": "2020-09-16T00:30:38.000000Z"
      },
      {
          "id": 371,
          "drug_id": 116,
          "indication_name": "Toxoplasma gondii oocyst shedding",
          "expected_effects": "Complete elimination of shedding of Toxoplasma oocysts",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:30:40.000000Z",
          "updated_at": "2020-09-16T00:30:40.000000Z"
      },
      {
          "id": 372,
          "drug_id": 117,
          "indication_name": "Mycobacterium avium infection (disseminated)",
          "expected_effects": "Clinical improvement in essentially all cases, with full resolution in 33%",
          "common_combinations": "Clarithromycin 62.5 mg/CAT PO q 12h;Ciprofloxacin 125 mg/CAT PO q 12h or doxycycline 50 mg/CAT PO q 12-24h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:30:42.000000Z",
          "updated_at": "2020-09-16T00:30:42.000000Z"
      },
      {
          "id": 373,
          "drug_id": 117,
          "indication_name": "Feline leprosy",
          "expected_effects": "Clinical cure",
          "common_combinations": "Clarithromycin 50 mg/CAT PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:30:45.000000Z",
          "updated_at": "2020-09-16T00:30:45.000000Z"
      },
      {
          "id": 374,
          "drug_id": 118,
          "indication_name": "Separation anxiety",
          "expected_effects": "Improvement in clinical signs (destruction, urination, defecation) that is 3 times faster than placebo/no treatment",
          "common_combinations": "Behavioral therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:30:47.000000Z",
          "updated_at": "2020-09-16T00:30:47.000000Z"
      },
      {
          "id": 375,
          "drug_id": 118,
          "indication_name": "Anxiety related to travel",
          "expected_effects": "Decreased serum cortisol levels (compared to placebo-treated dogs) and subjective improvement in anxious behavior (moving, drooling, panting)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:30:50.000000Z",
          "updated_at": "2020-09-16T00:30:50.000000Z"
      },
      {
          "id": 376,
          "drug_id": 118,
          "indication_name": "Storm phobia",
          "expected_effects": "Improvement in signs of phobia in 94% of dogs, including complete resolution of phobia in 6% of dogs",
          "common_combinations": "Alprazolam 0.02 mg/kg PO 1 hour before anticipated storm, and q 4h thereafter as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:30:52.000000Z",
          "updated_at": "2020-09-16T00:30:52.000000Z"
      },
      {
          "id": 377,
          "drug_id": 118,
          "indication_name": "Compulsive disorders (e.g., acral lick dermatitis)",
          "expected_effects": "Treatment is effective (marked reduction or elimination of compulsive behavior) in 46% of dogs, somewhat effective in 23% of dogs, and ineffective in 31% of dogs\nOverall, 4 times better improvement in compulsive behavior with treatment than without",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:30:55.000000Z",
          "updated_at": "2020-09-16T00:30:55.000000Z"
      },
      {
          "id": 378,
          "drug_id": 118,
          "indication_name": "Urine spraying",
          "expected_effects": "3-4 -fold reduction in number of spraying events and number of days with spraying events",
          "common_combinations": "Environmental management (recommended)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:30:57.000000Z",
          "updated_at": "2020-09-16T00:30:57.000000Z"
      },
      {
          "id": 379,
          "drug_id": 118,
          "indication_name": "Psychogenic alopecia",
          "expected_effects": "Decreased frequency of licking and visible regrowth of hair",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:31:00.000000Z",
          "updated_at": "2020-09-16T00:31:00.000000Z"
      },
      {
          "id": 380,
          "drug_id": 118,
          "indication_name": "Obsessive-compulsive and anxiety-related disorders",
          "expected_effects": "Improvement or resolution in >99% of cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:31:02.000000Z",
          "updated_at": "2020-09-16T00:31:02.000000Z"
      },
      {
          "id": 381,
          "drug_id": 119,
          "indication_name": "Anticonvulsant",
          "expected_effects": "Rapid loss of anticonvulsant activity (medication tolerance)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:05.000000Z",
          "updated_at": "2020-09-16T00:31:05.000000Z"
      },
      {
          "id": 382,
          "drug_id": 120,
          "indication_name": "Immune mediated hemolytic anemia",
          "expected_effects": "Similar effects in clopidogrel-treated and ultra-low-dose-treated dogs\r\nNo appreciable toxic effects",
          "common_combinations": "May combine with ultra-low-dose aspirin (0.5 mg/kg PO q 24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:07.000000Z",
          "updated_at": "2020-11-07T19:08:50.000000Z"
      },
      {
          "id": 383,
          "drug_id": 120,
          "indication_name": "Management of post-traumatic arterial thrombus",
          "expected_effects": "Visible improvement in arterial perfusion within 48h of clopidogrel + IV CRI heparin, and full resolution within 5 weeks, in 1 case report",
          "common_combinations": "Unfractionated heparin 25 IU/kg/h IV CRI X 48h, then low-molecular weight heparin (dalteparin 130 IU/kg SC q 12h X 5 weeks (with change from IV heparin to SC dalteparin mirroring improvement in perfusion and resolution of signs of pain)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:10.000000Z",
          "updated_at": "2020-11-07T19:08:50.000000Z"
      },
      {
          "id": 384,
          "drug_id": 120,
          "indication_name": "Prevention of recurrence of aortic thromboembolism",
          "expected_effects": "Significantly longer median time to recurrence of embolic disease compared to aspirin treatment: 443 vs. 192 days.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:31:13.000000Z",
          "updated_at": "2020-11-07T19:08:50.000000Z"
      },
      {
          "id": 385,
          "drug_id": 121,
          "indication_name": "Pyometra",
          "expected_effects": "Termination of pyometra in 86-95% of cases in 10-13 days\n7/11 (64%) mated at next estrus become pregnant\n19% rate of recurrence of pyometra after next estrus",
          "common_combinations": "Cabergoline 5 µg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:15.000000Z",
          "updated_at": "2020-09-16T00:31:15.000000Z"
      },
      {
          "id": 386,
          "drug_id": 121,
          "indication_name": "Pregnancy termination",
          "expected_effects": ">99% efficacy in pregnancy termination within 3-6 days",
          "common_combinations": "Cotreatment with bromocriptine 15 µg/kg PO q 12h on day 1, 20 µg/kg PO q 12h on days 2 and 3, and 30 µg/kg PO q 12h thereafter",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:18.000000Z",
          "updated_at": "2020-09-16T00:31:18.000000Z"
      },
      {
          "id": 387,
          "drug_id": 121,
          "indication_name": "Cystic endometrial hyperplasia-pyometra complex",
          "expected_effects": "100% resolution of pyometra by day 15 (75%) or day 29 (25%) after start of treatment",
          "common_combinations": "Aglepristone 10 mg/kg SC on days 1, 2 and 8;Amoxicillin-clavulanate concurrently at 12.5 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:31:20.000000Z",
          "updated_at": "2020-09-16T00:31:20.000000Z"
      },
      {
          "id": 388,
          "drug_id": 122,
          "indication_name": "Seizure control",
          "expected_effects": "Pharmacokinetic study: serum concentrations of nordiazepam (the active metabolite) are detected for 85 +/- 36 minutes after dosing",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:23.000000Z",
          "updated_at": "2020-11-07T19:12:24.000000Z"
      },
      {
          "id": 389,
          "drug_id": 123,
          "indication_name": "Nasal aspergillosis",
          "expected_effects": "67% improvement or full resolution, 2/3 of which occur with a single treatment",
          "common_combinations": "With or without frontal sinus infusion (using 1% topical solution, 10 mg/mL)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:25.000000Z",
          "updated_at": "2020-09-16T00:31:25.000000Z"
      },
      {
          "id": 390,
          "drug_id": 123,
          "indication_name": "Nasal aspergillosis",
          "expected_effects": "High rate of clinical cure (free of signs 2-4 years post-treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:31:28.000000Z",
          "updated_at": "2020-11-07T19:17:21.000000Z"
      },
      {
          "id": 391,
          "drug_id": 123,
          "indication_name": "Urinary tract infection - fungal (Candida spp.)",
          "expected_effects": "Complete elimination of fungal cystitis even in cat with diabetes mellitus",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:31:31.000000Z",
          "updated_at": "2020-11-07T19:17:21.000000Z"
      },
      {
          "id": 392,
          "drug_id": 124,
          "indication_name": "Hypocobalaminemia associated with chronic enteropathy",
          "expected_effects": "Significant improvement in clinical signs and marked increase in serum cobalamin concentration both associated with cobalamin supplementation, and both noted to regress with discontinuation of supplementation (suggesting longer-duration treatment should be considered)",
          "common_combinations": "Dietary changes, probiotic administration, and ancillary treatment at clinician's discretion",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:33.000000Z",
          "updated_at": "2020-11-08T14:15:22.000000Z"
      },
      {
          "id": 393,
          "drug_id": 124,
          "indication_name": "Hypocobalaminemia (whether confirmed or suspected) associated with exocrine pancreatic insufficiency",
          "expected_effects": "Well-tolerated",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:36.000000Z",
          "updated_at": "2020-11-08T14:15:22.000000Z"
      },
      {
          "id": 394,
          "drug_id": 125,
          "indication_name": "Cough suppression",
          "expected_effects": "Effective cough suppression, with either marked reduction or complete elimination of cough depending on inciting cause",
          "common_combinations": "Environmental management and treatment of the underlying cause of cough",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:38.000000Z",
          "updated_at": "2020-09-16T00:31:38.000000Z"
      },
      {
          "id": 395,
          "drug_id": 125,
          "indication_name": "Analgesia",
          "expected_effects": "Post-operative analgesia similar to analgesia achieved with tramadol, ketoprofen, or combinations thereof\r\nSome sedation for up to 24h post-op",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:40.000000Z",
          "updated_at": "2020-11-08T14:17:16.000000Z"
      },
      {
          "id": 396,
          "drug_id": 126,
          "indication_name": "Delay of fibrous stricture re-formation (e.g., endoscopic dilation of an obstructive vaginal membrane)",
          "expected_effects": "Absence of stricture formation",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:43.000000Z",
          "updated_at": "2020-11-08T14:19:08.000000Z"
      },
      {
          "id": 397,
          "drug_id": 126,
          "indication_name": "Prophylaxis against restenosis (e.g., with tracheal stenting)",
          "expected_effects": "Reduction or elimination of granulation tissue in trachea (avoiding restenosis)",
          "common_combinations": "Weight loss (if patient with collapsing trachea is obese);Butorphanol (as antitussive, if collapsing trachea)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:45.000000Z",
          "updated_at": "2020-09-16T00:31:45.000000Z"
      },
      {
          "id": 398,
          "drug_id": 126,
          "indication_name": "Hepatic fibrosis - prevention/delay of worsening",
          "expected_effects": "Resolution of overt signs of hepatocutaneous syndrome",
          "common_combinations": "Egg yolks (as amino acid source);Omega-3 fatty acid supplementation;Zinc sulfate",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:31:48.000000Z",
          "updated_at": "2020-09-16T00:31:48.000000Z"
      },
      {
          "id": 399,
          "drug_id": 126,
          "indication_name": "Amyloidosis/familial Mediterranean fever of Shar Pei dogs",
          "expected_effects": "Improvement in clinical signs and lower liver enzyme levels",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:31:50.000000Z",
          "updated_at": "2020-11-08T14:19:08.000000Z"
      },
      {
          "id": 400,
          "drug_id": 126,
          "indication_name": "Systemic amyloidosis",
          "expected_effects": "No convincing benefit",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:31:53.000000Z",
          "updated_at": "2020-11-08T14:19:08.000000Z"
      },
      {
          "id": 401,
          "drug_id": 127,
          "indication_name": "Lymphoma - COP protocol",
          "expected_effects": "Remission of lymphoma in 95-97% of cases (53-57% complete remission, 38-44% partial remission) lasting 4-88 weeks (median: 12 weeks)",
          "common_combinations": "Vincristine, prednisone/prednisolone, methotrexate (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:31:55.000000Z",
          "updated_at": "2020-09-16T00:31:55.000000Z"
      },
      {
          "id": 402,
          "drug_id": 127,
          "indication_name": "Lymphoma - modified UWM protocol (canine)",
          "expected_effects": "Remission of lymphoma in 94.2% of cases (92.3% complete remission, 1.9% partial remission)\r\nMedian disease-free interval: 282 days\r\nMedian survival: 397 days",
          "common_combinations": "L-asparaginase, doxorubicin, predniso(lo)ne, vincristine (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:31:58.000000Z",
          "updated_at": "2020-11-08T14:44:37.000000Z"
      },
      {
          "id": 403,
          "drug_id": 127,
          "indication_name": "Lymphoma relapse - CHOP protocol (canine)",
          "expected_effects": "Reinduction: 78% 2nd remission rate, with duration of 150-1457 days (mean: 289 days)",
          "common_combinations": "L-asparaginase, doxorubicin, prednisone/prednisolone, vincristine (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:32:01.000000Z",
          "updated_at": "2020-09-16T00:32:01.000000Z"
      },
      {
          "id": 404,
          "drug_id": 127,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "No convincing effect of cyclophosphamide benefit: wide range of survival (1-2600 days) with 45% of cases dead or euthanized due to IMHA",
          "common_combinations": "Prednisone 2.2-4.4 mg/kg/day PO as single or divided dose(s);Some dogs also receive azathioprine and/or other immunosuppressants",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:32:03.000000Z",
          "updated_at": "2020-09-16T00:32:03.000000Z"
      },
      {
          "id": 405,
          "drug_id": 127,
          "indication_name": "Soft tissue sarcoma - adjunctive therapy",
          "expected_effects": "Dose-dependent reduction of angiogenesis and T-regulatory cells",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:32:06.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 406,
          "drug_id": 127,
          "indication_name": "Lymphoma - UWM protocol (feline)",
          "expected_effects": "Remission of lymphoma in 84% of cats (47% complete remission, 37% partial remission) lasting < 8-1150 days (median duration of remission of 654 days if complete remission achieved at first, vs. 114 days if partial remission only)",
          "common_combinations": "L-asparaginase, doxorubicin, prednisolone, vincristine (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:32:08.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 407,
          "drug_id": 127,
          "indication_name": "Lymphoma - COP protocol (feline)",
          "expected_effects": "Complete remission in 75% of cats, with median duration of remission of 251 days (51.4% and 37.8% disease-free at 1 and 2 years, respectively)",
          "common_combinations": "Prednisolone, vincristine (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:32:10.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 408,
          "drug_id": 128,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "Rise in hematocrit is expected if effective",
          "common_combinations": "Predniso(lo)ne",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:32:13.000000Z",
          "updated_at": "2020-09-16T00:32:13.000000Z"
      },
      {
          "id": 409,
          "drug_id": 128,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "Rise in hematocrit is expected if effective",
          "common_combinations": "Predniso(lo)ne",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:32:15.000000Z",
          "updated_at": "2020-09-16T00:32:15.000000Z"
      },
      {
          "id": 410,
          "drug_id": 128,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "In dogs, severe pruritus decreases from 67% before treatment to 16% after 4 weeks of treatment. By contrast, 66% and 61% of control dogs are severely pruritic before and after 4 weeks of placebo treatment, respectively.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:32:18.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 411,
          "drug_id": 128,
          "indication_name": "Perianal fistula, with ketoconazole treatment (to lower necessary dosage of cyclosporine)",
          "expected_effects": "36-71% less expensive than cyclosporine monotherapy, with similar results (improvement in >99% of dogs and complete clinical remission in 75% of dogs)",
          "common_combinations": "Ketoconazole 5.1-11 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:32:20.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 412,
          "drug_id": 128,
          "indication_name": "Inflammatory bowel disease (glucocorticoid-resistant)",
          "expected_effects": "Improvement of clinical signs in 86% of cases, and fourfold decrease in inflammatory cell infiltrate on biopsies",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:32:23.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 413,
          "drug_id": 128,
          "indication_name": "Sebaceous adenitis",
          "expected_effects": "29% improvement in lesion (scales) at 4 months, but 70% improvement if combined cyclosporine and topical therapy",
          "common_combinations": "Topical therapy: sulfur-salicylic acid wash/ethyl lactate wash, baby oil soaks, and 70% propylene glycol in water",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:32:25.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 414,
          "drug_id": 128,
          "indication_name": "Necrotizing meningoencephalitis",
          "expected_effects": "Mean survival of 306 days (compared to 58 days when treated with prednisolone alone)",
          "common_combinations": "With or without prednisolone 1 mg/kg PO q 12h tapered to 0.5 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:32:28.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 415,
          "drug_id": 128,
          "indication_name": "Organ transplantation",
          "expected_effects": "Survival of 0.5-4014 days\r\n15-day survival rate of 50% and 100-day survival rate of 36%",
          "common_combinations": "Methylprednisolone;Prednisolone;Azathioprine or leflunomide",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:32:30.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 416,
          "drug_id": 128,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Marked improvement in skin lesions during treatment (65% with cyclosporine versus 9% with placebo)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:32:32.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 417,
          "drug_id": 128,
          "indication_name": "Pure red cell aplasia",
          "expected_effects": ">80% remission achieved in median of 31 days and lasting a median of 406 days",
          "common_combinations": "Prednisolone at tapering dosage",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:32:35.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 418,
          "drug_id": 129,
          "indication_name": "Antidote for 5-hydroxytryptophan intoxication",
          "expected_effects": "Improvement in clinical signs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:32:37.000000Z",
          "updated_at": "2020-09-16T00:32:37.000000Z"
      },
      {
          "id": 419,
          "drug_id": 129,
          "indication_name": "Antipruritic",
          "expected_effects": "0% difference in clinical signs of pruritus compared to placebo",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:32:40.000000Z",
          "updated_at": "2020-09-16T00:32:40.000000Z"
      },
      {
          "id": 420,
          "drug_id": 129,
          "indication_name": "Hyperadrenocorticism",
          "expected_effects": "Little to no improvement in clinical or biochemical abnormalities",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:32:42.000000Z",
          "updated_at": "2020-09-16T00:32:42.000000Z"
      },
      {
          "id": 421,
          "drug_id": 129,
          "indication_name": "Urine spraying",
          "expected_effects": "Improvement (subjectively, 50-75% reduction in signs) and increased appetite all within a few days of starting treatment, based on owner observation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:32:44.000000Z",
          "updated_at": "2020-09-16T00:32:44.000000Z"
      },
      {
          "id": 422,
          "drug_id": 129,
          "indication_name": "Antipruritic",
          "expected_effects": "Satisfactory control of pruritus in 45% of treated cats, based on owner opinion",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:32:46.000000Z",
          "updated_at": "2020-09-16T00:32:46.000000Z"
      },
      {
          "id": 423,
          "drug_id": 129,
          "indication_name": "Eosinophilic airway inflammation",
          "expected_effects": "Treatment produced no change in airway inflammation (cytologically) or markers of inflammatory response",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:32:49.000000Z",
          "updated_at": "2020-09-16T00:32:49.000000Z"
      },
      {
          "id": 424,
          "drug_id": 130,
          "indication_name": "Lymphoma (stage V - bone marrow)",
          "expected_effects": "89% rate of remission (vs. 25% for protocol without cytosine arabinoside)\r\nSurvival time: 73-635 days (median: 243 days), significantly longer than without cytosine arabinoside (median survival: 72 days)",
          "common_combinations": "L-asparaginase, doxorubicin, cyclophosphamide, vincristine (per protocol);Granulocyte colony stimulating factor and erythropoietin as prophylaxis against cytopenias;Amoxicillin-clavulanate and enrofloxacin as prophylaxis against opportunistic infection;Metoclopramide with or without ondansetron for vomiting",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:32:51.000000Z",
          "updated_at": "2020-11-08T18:41:40.000000Z"
      },
      {
          "id": 425,
          "drug_id": 130,
          "indication_name": "Lymphoma (relapsed)",
          "expected_effects": "16% complete remission and 27% partial remission; median overall progression-free survival = 24 days (range: 2-303 days)",
          "common_combinations": "Dexamethasone, melphalan, actinomycin D (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:32:53.000000Z",
          "updated_at": "2020-11-08T18:41:40.000000Z"
      },
      {
          "id": 426,
          "drug_id": 130,
          "indication_name": "Lymphoma (relapsed)",
          "expected_effects": "72% rate of remission (44% complete remission, 28% partial remission), lasting 2-467+ days (median: 61 days)",
          "common_combinations": "Dexamethasone, melphalan, actinomycin D (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:32:56.000000Z",
          "updated_at": "2020-09-16T00:32:56.000000Z"
      },
      {
          "id": 427,
          "drug_id": 130,
          "indication_name": "Lymphoma (CNS)",
          "expected_effects": "Mild to marked improvement in clinical signs (and CSF cellularity) in some dogs, vs. minimal change (or complications such as tentorial herniation) in others",
          "common_combinations": "Whole-brain irradiation",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:32:58.000000Z",
          "updated_at": "2020-09-16T00:32:58.000000Z"
      },
      {
          "id": 428,
          "drug_id": 130,
          "indication_name": "Meningoencephalitis",
          "expected_effects": "Survival of 46-1025 days (median: 531 days)",
          "common_combinations": "Prednisone 1-2 mg/kg PO q 12h tapering over 3 month period but continued at low dosage if recurrent clinical signs",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:33:00.000000Z",
          "updated_at": "2020-11-08T18:41:40.000000Z"
      },
      {
          "id": 429,
          "drug_id": 130,
          "indication_name": "Lymphoma (renal) - maintenance of remission",
          "expected_effects": "61% complete remission, lasting 20-2542 days (median: 127 days)",
          "common_combinations": "Vincristine, methotrexate, and prednisolone (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:33:03.000000Z",
          "updated_at": "2020-11-08T18:41:40.000000Z"
      },
      {
          "id": 430,
          "drug_id": 130,
          "indication_name": "Lymphoma (renal) - maintenance of remission",
          "expected_effects": "61% complete remission, lasting 20-2542 days (median: 127 days)",
          "common_combinations": "Vincristine, methotrexate, and prednisolone (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:33:06.000000Z",
          "updated_at": "2020-11-08T18:41:40.000000Z"
      },
      {
          "id": 431,
          "drug_id": 130,
          "indication_name": "Lymphoblastic leukemia",
          "expected_effects": "Remission induced successfully, lasted 10 weeks in 1 cat",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:33:09.000000Z",
          "updated_at": "2020-11-08T18:41:41.000000Z"
      },
      {
          "id": 432,
          "drug_id": 131,
          "indication_name": "Lymphoma (relapsed)",
          "expected_effects": "Reinduction of remission in 35% of dogs (complete remission 3%, partial remission 32%)",
          "common_combinations": "Protocols may include combinations of doxorubicin and/or dactinomycin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:11.000000Z",
          "updated_at": "2020-09-16T00:33:11.000000Z"
      },
      {
          "id": 433,
          "drug_id": 131,
          "indication_name": "Lymphoma (resistant)",
          "expected_effects": "Reinduction of remission in 23% of dogs (median duration: 83 days)",
          "common_combinations": "Lomustine 40 mg/m² PO",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:14.000000Z",
          "updated_at": "2020-09-16T00:33:14.000000Z"
      },
      {
          "id": 434,
          "drug_id": 132,
          "indication_name": "Immune-mediated thrombocytopenia",
          "expected_effects": "Normalization of platelet count and decrease in circulating antiplatelet antibody concentrations 2 weeks after beginning treatment in 1 dog",
          "common_combinations": "Prednisone 1 mg/kg PO q 12h, tapered",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:16.000000Z",
          "updated_at": "2020-09-16T00:33:16.000000Z"
      },
      {
          "id": 435,
          "drug_id": 132,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "No appreciable benefit",
          "common_combinations": "Predniso(lo)ne",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:19.000000Z",
          "updated_at": "2020-09-16T00:33:19.000000Z"
      },
      {
          "id": 436,
          "drug_id": 133,
          "indication_name": "Malignant hyperthermia",
          "expected_effects": "Reversal of hyperthermia begins 40-60 min after start of treatment and temperature returns to baseline by 1-3 hours after start of treatment\nHypercarbia (the first abnormality, which precedes hyperthermia) starts to decline 10 min after start of treatment and end-tidal CO2 has returned to normal by 30 min after start of treatment",
          "common_combinations": "Immediate cessation of inhalant anesthesia;Oxygen therapy and cooling measures are essential",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:21.000000Z",
          "updated_at": "2020-09-16T00:33:21.000000Z"
      },
      {
          "id": 437,
          "drug_id": 133,
          "indication_name": "Rhabdomyolysis causing respiratory and myocardial failure",
          "expected_effects": "Improvement in skeletal muscle tone and reduced signs of pain (efficacy of drug for these effects is unproven in dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:23.000000Z",
          "updated_at": "2020-09-16T00:33:23.000000Z"
      },
      {
          "id": 438,
          "drug_id": 133,
          "indication_name": "Urethral spasm",
          "expected_effects": "Minimal (13% and 13-20%) decrease in postprostatic (penile) urethral pressure with dantrolene and dantrolene-prazosin injections, respectively",
          "common_combinations": "Prazosin 0.03 mg/kg IV single dose",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:33:26.000000Z",
          "updated_at": "2020-09-16T00:33:26.000000Z"
      },
      {
          "id": 439,
          "drug_id": 134,
          "indication_name": "Pruritic dermatitis",
          "expected_effects": "Visible improvement in pruritus in 1-4 weeks in most cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:28.000000Z",
          "updated_at": "2020-09-16T00:33:28.000000Z"
      },
      {
          "id": 440,
          "drug_id": 135,
          "indication_name": "Anemia associated with chronic kidney disease",
          "expected_effects": "PCV ≥30% in 85% of treated dogs (median time required: 29 days); PCV increase by ≥10% in 67% of treated dogs. No sustained benefit if interdose interval >21 days. Survival >500 days in some dogs. Systemic hypertension in 36% of treated dogs, pure red cell aplasia in 6%.",
          "common_combinations": "Iron dextran 10 mg/kg IM monthly for some dogs (clinician's prerogative)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:31.000000Z",
          "updated_at": "2020-11-08T19:04:13.000000Z"
      },
      {
          "id": 441,
          "drug_id": 135,
          "indication_name": "Anemia associated with chronic kidney disease",
          "expected_effects": "Increase in hematocrit (median: 8%) 1-6 weeks after starting treatment (median: 3 weeks) in 59% of treated cats\r\nResponders lived a median of 238 days (vs. 83 days for cats whose hematocrit did not rise despite treatment)",
          "common_combinations": "Iron dextran 50 mg/CAT IM once, can be repeated q 4 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:33.000000Z",
          "updated_at": "2020-11-08T19:04:13.000000Z"
      },
      {
          "id": 442,
          "drug_id": 136,
          "indication_name": "Hepatozoonosis",
          "expected_effects": "81% survival, including 41% elimination of all clinical signs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:35.000000Z",
          "updated_at": "2020-09-16T00:33:35.000000Z"
      },
      {
          "id": 443,
          "drug_id": 137,
          "indication_name": "Aluminum toxicosis",
          "expected_effects": "Clear improvement in clinical signs can be expected 24-48h after initiating therapy with deferoxamine and hemodialysis in kidney disease patient\nLong-term survival is possible",
          "common_combinations": "Hemodialysis; termination of aluminum-based phosphate binder administration",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:38.000000Z",
          "updated_at": "2020-09-16T00:33:38.000000Z"
      },
      {
          "id": 444,
          "drug_id": 137,
          "indication_name": "Iron toxicosis",
          "expected_effects": "Reversal of clinical and biochemical (liver enzyme) abnormalities of iron toxicosis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:40.000000Z",
          "updated_at": "2020-09-16T00:33:40.000000Z"
      },
      {
          "id": 445,
          "drug_id": 138,
          "indication_name": "Benign prostatic hyperplasia",
          "expected_effects": "Complete elimination of clinical signs of benign prostatic hyperplasia in 48% of dogs 2 weeks after treatment, and in 83% of dogs 6 months after treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:43.000000Z",
          "updated_at": "2020-09-16T00:33:43.000000Z"
      },
      {
          "id": 446,
          "drug_id": 138,
          "indication_name": "Suppression of libido",
          "expected_effects": "4-fold decrease in semen volume, 10-fold decrease in sperm number, and 3-fold decrease in libido score 10-12 days after 2nd dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:45.000000Z",
          "updated_at": "2020-09-16T00:33:45.000000Z"
      },
      {
          "id": 447,
          "drug_id": 138,
          "indication_name": "Urine spraying",
          "expected_effects": "Limited efficacy and onset of adverse effects",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:33:48.000000Z",
          "updated_at": "2020-09-16T00:33:48.000000Z"
      },
      {
          "id": 448,
          "drug_id": 139,
          "indication_name": "Tibial plateau leveling osteotomy - postoperative anti-inflammatory",
          "expected_effects": "Improved range of motion with deracoxib treatment, but no superiority over untreated dogs with respect to other parameters of limb function",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:51.000000Z",
          "updated_at": "2020-11-08T19:25:25.000000Z"
      },
      {
          "id": 449,
          "drug_id": 139,
          "indication_name": "Soft tissue surgery - perioperative anti-inflammatory",
          "expected_effects": "Significantly more dogs with significantly lower pain scores",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:33:53.000000Z",
          "updated_at": "2020-11-08T19:25:25.000000Z"
      },
      {
          "id": 450,
          "drug_id": 139,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "17% partial remission, 71% stable disease, 13% progressive disease\r\nMedian survival: 323 days",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:33:55.000000Z",
          "updated_at": "2020-11-08T19:25:25.000000Z"
      },
      {
          "id": 451,
          "drug_id": 140,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "Approximately 5- to 10-fold reduction in water consumption and urine volume, compared to untreated diabetes insipidus control dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:33:58.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 452,
          "drug_id": 140,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "Resolution of polyuria/polydipsia in >99% of treated cases\r\nResolution of urinary incontinence in 82% of cases, of which 18% require cotreatment with phenylpropanolamine",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:34:01.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 453,
          "drug_id": 140,
          "indication_name": "von Willebrand disease",
          "expected_effects": "Increase in serum concentration of active von Willebrand factor",
          "common_combinations": "Fresh frozen plasma transfusion if immediately pre-op",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:34:04.000000Z",
          "updated_at": "2020-09-16T00:34:04.000000Z"
      },
      {
          "id": 454,
          "drug_id": 140,
          "indication_name": "Hemorrhage (temporary reversal of bleeding tendencies caused by ehrlichiosis or other immune-mediated mechanisms)",
          "expected_effects": "Spontaneous bleeding stops within 1h after 1st dose\r\nNormalization of buccal mucosal bleeding time (from 9.6 to 2.3 min), significant increase in platelet count, significant decrease in prothrombin time and partial thromboplastin time",
          "common_combinations": "Treatment of cause of bleeding disorder",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:34:06.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 455,
          "drug_id": 140,
          "indication_name": "Surgical adjuvant w/ advanced mammary carcinoma",
          "expected_effects": "In aggressive mammary tumors (histologic grades 2, 3), median disease-free interval >600 days with treatment compared to 26-85 days without treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:34:08.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 456,
          "drug_id": 140,
          "indication_name": "Hyperadrenocorticism diagnosis: adrenal tumor (AT) vs. pituitary-dependent hyperadrenocorticism (PDH) differentiation",
          "expected_effects": "51% increase in serum [cortisol] at 30 min in dogs with PDH, vs. 1% increase for AT and 7% increase for normal controls\r\nIf a dog's serum [cortisol] increases >10% at 30 min, AT is excluded in 75% of cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:34:11.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 457,
          "drug_id": 140,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "Temporary reduction in polydipsia, but loss of efficacy after <8 weeks (replaced by SC injections)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:34:14.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 458,
          "drug_id": 140,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "30-85% reduction in water intake",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:34:16.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 459,
          "drug_id": 140,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "Excellent and immediate response, including 10-fold reduction in water intake (ineffective at q 24h dosing interval)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:34:19.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 460,
          "drug_id": 141,
          "indication_name": "Hypoadrenocorticism",
          "expected_effects": "Good to excellent response in 86.5% of dogs, fair in 12.5%, poor in 1%\r\nSurvival range with treatment: 7 days to 11.8 years (median survival of 5.8 years)\r\n<1% rate of iatrogenic hyperadrenocorticism",
          "common_combinations": "Prednisone 0.2-0.3 mg/kg (lower dosage later, during gradual taper/as-needed use)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:34:21.000000Z",
          "updated_at": "2020-11-08T19:52:35.000000Z"
      },
      {
          "id": 461,
          "drug_id": 141,
          "indication_name": "Hypoadrenocorticism",
          "expected_effects": "Survival of 3-70 months (median: 33 months)",
          "common_combinations": "Glucocorticoid (e.g., methylprednisolone acetate 10 mg/CAT IM q 1 month)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:34:23.000000Z",
          "updated_at": "2020-09-16T00:34:23.000000Z"
      },
      {
          "id": 462,
          "drug_id": 142,
          "indication_name": "Low-dose dexamethasone suppression test (LDDST)",
          "expected_effects": "Normal (suppression): serum [cortisol] ≤ 1.4 µg/dL on 8h sample\r\nPituitary-dependent hyperadrenocorticism, or PDH (lack of suppression with LDDST): serum [cortisol] > 1.4 mg/dL on 8h sample but 1) serum [cortisol] ≤ 1.4 µg/dL at 4h (42% of dogs with PDH), and/or 2) serum [cortisol] at 4h ≤ 50% of baseline value (73% of dogs with PDH)\r\nWith adrenal tumor-induced hyperadrenocorticism, cortisol levels fail to be suppressed at any point during LDDST",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:34:26.000000Z",
          "updated_at": "2020-11-08T19:55:15.000000Z"
      },
      {
          "id": 463,
          "drug_id": 142,
          "indication_name": "High-dose dexamethasone suppression test",
          "expected_effects": "Normal (suppression): serum [cortisol] ≤ 1.4 µg/dL on 8h sample\r\nAdrenal tumor-dependent hyperadrenocorticism (AT) = lack of suppression with HDDST = serum [cortisol] >1.4 µg/dL on 4h and 8h samples versus serum [cortisol] =<1.4 µg/dL and/or 50% or less of baseline value in 73% of dogs with PDH.  Therefore, suppression during HDDST rules out AT, but failure to suppress does not discriminate between AT and PDH",
          "common_combinations": "Abdominal ultrasound (absence of adrenal mass makes adrenal tumor-dependent hyperadrenocorticism very unlikely)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:34:28.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 464,
          "drug_id": 142,
          "indication_name": "Immunosuppressant (e.g., immune-mediated hemolytic anemia, others)",
          "expected_effects": "Reduction in immune-mediated damage (e.g., less overt blood loss, rising platelet count in immune-mediated thrombocytopenia)",
          "common_combinations": "Non-steroidal immunosuppressants including cyclosporine, azathioprine, etc.",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:34:31.000000Z",
          "updated_at": "2020-09-16T00:34:31.000000Z"
      },
      {
          "id": 465,
          "drug_id": 142,
          "indication_name": "Anaphylaxis prevention/prophylaxis",
          "expected_effects": "Suspect lower rate of allergic reaction",
          "common_combinations": "Diphenhydramine",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:34:33.000000Z",
          "updated_at": "2020-09-16T00:34:33.000000Z"
      },
      {
          "id": 466,
          "drug_id": 142,
          "indication_name": "Pregnancy termination",
          "expected_effects": "93-99% efficacy in terminating pregnancy (abortion or resorption) 7-15 days after start of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:34:36.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 467,
          "drug_id": 142,
          "indication_name": "Antineoplastic (e.g., lymphoma)",
          "expected_effects": "Complete remission in 88% of dogs\r\nMedian progression-free interval: 186 days\r\nMedian survival: 294 days",
          "common_combinations": "Doxorubicin, cyclophosphamide, vincristine (per protocol)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:34:38.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 468,
          "drug_id": 142,
          "indication_name": "Hemorrhagic shock: controversial",
          "expected_effects": "Despite improved acute parameters in this experimental study, dosage approaches 6.4 mg/kg, which is the mean cumulative dosage associated with 100% mortality in 13 dogs with dexamethasone-associated colonic perforation and therefore this treatment cannot be considered to be universally safe or efficacious",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:34:40.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 469,
          "drug_id": 142,
          "indication_name": "Immediate glucocorticoid replacement - post-adrenalectomy",
          "expected_effects": "95% perioperative survival rate",
          "common_combinations": "Trilostane X 2-3 weeks preoperatively in dogs with functional adrenal tumors; phenoxybenzamine X 2-3 weeks preoperatively in dogs suspected of having pheochromocytoma; comprehensive postoperative analgesia",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:34:44.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 470,
          "drug_id": 142,
          "indication_name": "Acute neurologic trauma (e.g., intervertebral disk extrusion): controversial",
          "expected_effects": "No proof of efficacy\r\nEvidence of frequent adverse effects in dogs (3.5-fold increased occurrence of diarrhea, 11.4-fold increased occurrence of urinary tract infection)\r\nSeveral doses approach or exceed 6.4 mg/kg, which is the mean cumulative dosage associated with 100% mortality in 13 dogs with dexamethasone-associated colonic perforation",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:34:46.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 471,
          "drug_id": 142,
          "indication_name": "Low-dose dexamethasone suppression test (\"dexamethasone screening test\")",
          "expected_effects": "Normal serum cortisol in healthy cats changes from 0-3.6 µg/dL (pre) to 0-0.9 µg/dL (post), whereas cats with hyperadrenocorticism change from 3.9-9.4 µg/dL (pre) to 1.8-6.2 µg/dL (post)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:34:49.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 472,
          "drug_id": 142,
          "indication_name": "High-dose dexamethasone suppression test (\"dexamethasone suppression test\")",
          "expected_effects": "Normal serum cortisol in healthy cats changes from 0-3.6 µg/dL (pre) to 0-0.9 µg/dL (post), whereas cats with hyperadrenocorticism change from 3.9-7.1 µg/dL (pre) to 1.5-4.7 µg/dL (post)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:34:51.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 473,
          "drug_id": 142,
          "indication_name": "Immunosuppressant (e.g., immune-mediated hemolytic anemia, others)",
          "expected_effects": "Suspect immune suppression",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:34:54.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 474,
          "drug_id": 142,
          "indication_name": "Anaphylaxis prevention/prophylaxis",
          "expected_effects": "Suspect lower rate of allergic reaction",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:34:56.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 475,
          "drug_id": 142,
          "indication_name": "Hypoadrenal crisis",
          "expected_effects": "Survival of 3-70 months (median: 33 months)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:34:59.000000Z",
          "updated_at": "2020-11-08T19:55:16.000000Z"
      },
      {
          "id": 476,
          "drug_id": 143,
          "indication_name": "Sedation, premedication before general anesthesia",
          "expected_effects": "Compared to acepromazine, dexmedetomidine premedication produced greater sedation and a lower inhalant anesthesia requirement",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:35:01.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 477,
          "drug_id": 143,
          "indication_name": "Post-operative analgesia",
          "expected_effects": "As effective as morphine CRI for post-operative analgesia",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:35:03.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 478,
          "drug_id": 143,
          "indication_name": "Total intramuscular injectable anesthesia protocol for castration",
          "expected_effects": "Induction of anesthesia allowing intubation in all cases\r\n10%, 30% and 40% of dogs require supplemental (inhalant) anesthesia when using buprenorphine, butorphanol, and hydromorphone combinations, respectively",
          "common_combinations": "With ketamine (3 mg/kg IM) and any one of the following: butorphanol (0.2 mg/kg IM), or hydromorphone (0.05 mg/kg IM), or buprenorphine (40 µg/kg IM)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:35:06.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 479,
          "drug_id": 143,
          "indication_name": "Sedation and analgesia",
          "expected_effects": "Adequate sedation for medical procedures in >90% of cases\r\nSedation first apparent after 5 min\r\nPeak sedation at 130 min\r\nSpontaneous recovery by 180 min",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:35:08.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 480,
          "drug_id": 143,
          "indication_name": "Premedication before general anesthesia",
          "expected_effects": "50% reduction in induction dosage of propofol\r\n50% reduction in inhalant anesthesia requirement",
          "common_combinations": "With or without ketamine 5 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:35:10.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 481,
          "drug_id": 143,
          "indication_name": "Sedation",
          "expected_effects": "Sedation sufficient to allow placement of an IV catheter in 75% of shelter cats (vs. 84% when dose given IM instead)",
          "common_combinations": "Buprenorphine 20 µg/kg oral transmucosal",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:35:14.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 482,
          "drug_id": 143,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Emesis occurs in 78% of cats",
          "common_combinations": "With or without buprenorphine 20 µg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:35:16.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 483,
          "drug_id": 144,
          "indication_name": "Protection from cardiotoxicosis caused by doxorubicin or daunorubicin",
          "expected_effects": "Well-tolerated\nClinical benefit remains to be proven in dogs and cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:35:18.000000Z",
          "updated_at": "2020-09-16T00:35:18.000000Z"
      },
      {
          "id": 484,
          "drug_id": 144,
          "indication_name": "Protection from cardiotoxicosis caused by doxorubicin or daunorubicin",
          "expected_effects": "Well-tolerated\nClinical benefit remains to be proven in dogs and cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:35:21.000000Z",
          "updated_at": "2020-09-16T00:35:21.000000Z"
      },
      {
          "id": 485,
          "drug_id": 144,
          "indication_name": "Doxorubicin extravasation",
          "expected_effects": "Well-tolerated\nSubjective reduction in severity of extravasation injury, but severe cases may still require long-term surgical care (possibly including limb amputation)",
          "common_combinations": "Cool compresses to site (q 6h for 21 days);Topical dimethyl sulfoxide",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:35:24.000000Z",
          "updated_at": "2020-09-16T00:35:24.000000Z"
      },
      {
          "id": 486,
          "drug_id": 145,
          "indication_name": "Narcolepsy/cataplexy",
          "expected_effects": "Elimination of episodes in most dogs",
          "common_combinations": "Environmental management (avoidance of situations of risk, e.g., falls, other trauma)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:35:26.000000Z",
          "updated_at": "2020-09-16T00:35:26.000000Z"
      },
      {
          "id": 487,
          "drug_id": 145,
          "indication_name": "Narcolepsy",
          "expected_effects": "Marked improvement according to owner observation",
          "common_combinations": "Environmental management (avoidance of situations of risk, e.g., falls, other trauma)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:35:29.000000Z",
          "updated_at": "2020-09-16T00:35:29.000000Z"
      },
      {
          "id": 488,
          "drug_id": 146,
          "indication_name": "Excessive grooming/chewing associated with chronic dermatitis",
          "expected_effects": "Significant reduction in pruritus, based on owner observations (placebo-controlled, double-blinded)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:35:31.000000Z",
          "updated_at": "2020-09-16T00:35:31.000000Z"
      },
      {
          "id": 489,
          "drug_id": 147,
          "indication_name": "Hypoglycemia",
          "expected_effects": "Resolution of overt signs of hypoglycemia (weakness, muscle fasciculations, seizures)",
          "common_combinations": "Treatment of primary cause (e.g., insulinoma, insulin excess, malnutrition in juveniles)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:35:34.000000Z",
          "updated_at": "2020-09-16T00:35:34.000000Z"
      },
      {
          "id": 490,
          "drug_id": 147,
          "indication_name": "Hyperkalemia due to hypoadrenocortical crisis",
          "expected_effects": "Reduction of serum potassium concentration (likely mild effect)",
          "common_combinations": "Low-dose soluble corticosteroid IV injection (e.g., prednisolone sodium succinate or dexamethasone)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:35:38.000000Z",
          "updated_at": "2020-09-16T00:35:38.000000Z"
      },
      {
          "id": 491,
          "drug_id": 147,
          "indication_name": "Hypoglycemia",
          "expected_effects": "Resolution of overt signs of hypoglycemia (weakness, muscle fasciculations, seizures)",
          "common_combinations": "Treatment of primary cause (e.g., insulinoma, insulin excess, malnutrition in juveniles)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:35:40.000000Z",
          "updated_at": "2020-09-16T00:35:40.000000Z"
      },
      {
          "id": 492,
          "drug_id": 147,
          "indication_name": "Hyperkalemia due to urethral obstruction",
          "expected_effects": "Reduction of serum potassium concentration (likely mild effect)\nTypically diluted 1- to 10-fold with sterile water just before administration (dosages listed here are for undiluted 50% dextrose)",
          "common_combinations": "Relief of urethral obstruction;IV calcium gluconate infusion (under ECG monitoring);Possibly insulin therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:35:43.000000Z",
          "updated_at": "2020-09-16T00:35:43.000000Z"
      },
      {
          "id": 493,
          "drug_id": 148,
          "indication_name": "Seizures",
          "expected_effects": "Acute reduction of seizure activity (within seconds of IV administration)",
          "common_combinations": "Cotreatment of the disorder and/or other anticonvulsant drugs",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:35:45.000000Z",
          "updated_at": "2020-09-16T00:35:45.000000Z"
      },
      {
          "id": 494,
          "drug_id": 148,
          "indication_name": "Seizures",
          "expected_effects": "Significant reduction of number and duration of seizures at home compared to no treatment",
          "common_combinations": "Cotreatment of the disorder and/or other anticonvulsant drugs",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:35:48.000000Z",
          "updated_at": "2020-09-16T00:35:48.000000Z"
      },
      {
          "id": 495,
          "drug_id": 148,
          "indication_name": "Seizures",
          "expected_effects": "Systemic absorption of rectally-administered diazepam in dogs is good (66-80%)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:35:51.000000Z",
          "updated_at": "2020-11-08T20:12:52.000000Z"
      },
      {
          "id": 496,
          "drug_id": 148,
          "indication_name": "Seizures",
          "expected_effects": "Plasma concentrations of diazepam at 80% of equivalent dose given IV",
          "common_combinations": "Cotreatment of the disorder and/or other anticonvulsant drugs",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:35:53.000000Z",
          "updated_at": "2020-09-16T00:35:53.000000Z"
      },
      {
          "id": 497,
          "drug_id": 148,
          "indication_name": "Anesthetic induction (hypovolemic dog)",
          "expected_effects": "Prompt induction of anesthesia (3 min)",
          "common_combinations": "With either propofol 2.2 +/- 0.4 mg/kg or ketamine 4.9 +/- 2.3 mg/kg, IV to effect",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:35:56.000000Z",
          "updated_at": "2020-09-16T00:35:56.000000Z"
      },
      {
          "id": 498,
          "drug_id": 148,
          "indication_name": "Anxiety-related disorders (e.g., thunderstorm phobia, separation anxiety)",
          "expected_effects": "Very (24%) or somewhat (43%) effective at reducing behavior of concern",
          "common_combinations": "Behavioral modification training",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:35:58.000000Z",
          "updated_at": "2020-09-16T00:35:58.000000Z"
      },
      {
          "id": 499,
          "drug_id": 148,
          "indication_name": "Metronidazole toxicosis",
          "expected_effects": "Clinical response is 7.6 times shorter with diazepam treatment than without (13.4 hours vs. 4.25 days) and recovery time is 6.8 times faster with diazepam than without (38.8 hours vs. 11 days)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:36:01.000000Z",
          "updated_at": "2020-11-08T20:12:52.000000Z"
      },
      {
          "id": 500,
          "drug_id": 148,
          "indication_name": "Isoniazid toxicosis",
          "expected_effects": "Reduction in seizure activity",
          "common_combinations": "Vitamin B6 coadministration",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:36:04.000000Z",
          "updated_at": "2020-09-16T00:36:04.000000Z"
      },
      {
          "id": 501,
          "drug_id": 148,
          "indication_name": "Seizures",
          "expected_effects": "Termination of status epilepticus",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:36:06.000000Z",
          "updated_at": "2020-11-08T20:12:52.000000Z"
      },
      {
          "id": 502,
          "drug_id": 148,
          "indication_name": "Seizures",
          "expected_effects": "Termination of seizure activity during infusion",
          "common_combinations": "Phenobarbital 1.5-2 mg/CAT/h IV CRI if inadequate acute seizure control",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:36:09.000000Z",
          "updated_at": "2020-09-16T00:36:09.000000Z"
      },
      {
          "id": 503,
          "drug_id": 148,
          "indication_name": "Chemical restraint",
          "expected_effects": "Effective, safe chemical restraint",
          "common_combinations": "Ketamine 10 mg/CAT IV simultaneously",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:36:12.000000Z",
          "updated_at": "2020-09-16T00:36:12.000000Z"
      },
      {
          "id": 504,
          "drug_id": 148,
          "indication_name": "Appetite stimulation",
          "expected_effects": "92% of anorectic cats eat a meal (mean consumption: 80 kcal) 15-27 sec after treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:36:14.000000Z",
          "updated_at": "2020-11-08T20:12:52.000000Z"
      },
      {
          "id": 505,
          "drug_id": 148,
          "indication_name": "Urine spraying",
          "expected_effects": "55% positive response (45% cessation of spraying, 10% decrease in spraying)\r\n90% recurrence after discontinuation of therapy",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:36:16.000000Z",
          "updated_at": "2020-11-08T20:12:52.000000Z"
      },
      {
          "id": 506,
          "drug_id": 148,
          "indication_name": "Urethral obstruction",
          "expected_effects": "No change in distal intraluminal urethral pressure",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:36:19.000000Z",
          "updated_at": "2020-11-08T20:12:52.000000Z"
      },
      {
          "id": 507,
          "drug_id": 149,
          "indication_name": "Hypoglycemia, e.g., due to insulinoma",
          "expected_effects": "Hypoglycemia controlled in 70% of dogs with insulinoma\nSurvival time: 38-704 days (median: 215 days)",
          "common_combinations": "Prednisone",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:21.000000Z",
          "updated_at": "2020-09-16T00:36:21.000000Z"
      },
      {
          "id": 508,
          "drug_id": 150,
          "indication_name": "Glaucoma",
          "expected_effects": "Decrease in intraocular pressure of 15% (5 mg/kg) to 24% (10 mg/kg)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:24.000000Z",
          "updated_at": "2020-09-16T00:36:24.000000Z"
      },
      {
          "id": 509,
          "drug_id": 151,
          "indication_name": "Trichuris vulpis (whipworm) infestation",
          "expected_effects": "84% efficacy: elimination of whipworms from 47% of dogs with first dose, then from a further 37% of dogs with second dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:26.000000Z",
          "updated_at": "2020-09-16T00:36:26.000000Z"
      },
      {
          "id": 510,
          "drug_id": 152,
          "indication_name": "Heartworm prophylaxis",
          "expected_effects": ">99% prevention of heartworm infection if drug administration and compliance are appropriate",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:28.000000Z",
          "updated_at": "2020-11-08T20:14:10.000000Z"
      },
      {
          "id": 511,
          "drug_id": 152,
          "indication_name": "Crenosoma vulpis infestation",
          "expected_effects": "92% elimination of worms (at necropsy 2 weeks after treatment - experimental dogs)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:36:31.000000Z",
          "updated_at": "2020-11-08T20:14:10.000000Z"
      },
      {
          "id": 512,
          "drug_id": 152,
          "indication_name": "Ancylostoma caninum infestation",
          "expected_effects": "88% efficacy eliminating subclinical hookworm infestations from adult dogs\r\nEfficacy is lower in pups showing gastrointestinal signs due to hookworm disease",
          "common_combinations": "Styrylpyridinium 6.6 mg/kg PO concurrently",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:36:33.000000Z",
          "updated_at": "2020-11-08T20:14:10.000000Z"
      },
      {
          "id": 513,
          "drug_id": 152,
          "indication_name": "Brugia malayi infestation",
          "expected_effects": "87-100% elimination of microfilariae at 2 months post-treatment\r\n99% reduction of microfilaremia at 8 months post-treatment, including amicrofilaremia in 86% of treated cats",
          "common_combinations": "Ivermectin 400 µg/kg PO once",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:36:36.000000Z",
          "updated_at": "2020-11-08T20:14:10.000000Z"
      },
      {
          "id": 514,
          "drug_id": 152,
          "indication_name": "Feline leukemia virus (FeLV)-associated lymphoma prophylaxis",
          "expected_effects": "Median survival of 70-72 weeks with treatment (vs. 0% survival at 52 weeks with placebo)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:36:39.000000Z",
          "updated_at": "2020-11-08T20:14:10.000000Z"
      },
      {
          "id": 515,
          "drug_id": 153,
          "indication_name": "Urethral sphincter mechanism incompetence",
          "expected_effects": "64.5% totally effective (return to continence), 22.6% partially effective (improvement but not resolution), 12.9% ineffective",
          "common_combinations": "Treatment of concurrent urinary tract infection if present;Additional therapy (e.g., alpha-1 adrenergic) may be necessary in some cases",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:41.000000Z",
          "updated_at": "2020-09-16T00:36:41.000000Z"
      },
      {
          "id": 516,
          "drug_id": 153,
          "indication_name": "Estrus induction",
          "expected_effects": "60-75% successful estrus induction in late anestrus or mid-anestrus, respectively",
          "common_combinations": "Follicle stimulating hormone (porcine origin; 10 mg/DOG IM on days 5, 9, and 11 after the onset of vulvar bleeding)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:36:44.000000Z",
          "updated_at": "2020-09-16T00:36:44.000000Z"
      },
      {
          "id": 517,
          "drug_id": 153,
          "indication_name": "Pregnancy termination",
          "expected_effects": "Ineffective: 11/12 treated dogs became pregnant",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:36:46.000000Z",
          "updated_at": "2020-09-16T00:36:46.000000Z"
      },
      {
          "id": 518,
          "drug_id": 154,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Drug concentrations attained in plasma, urine, and skin are lower than with enrofloxacin or marbofloxacin but could be of therapeutic value",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:49.000000Z",
          "updated_at": "2020-09-16T00:36:49.000000Z"
      },
      {
          "id": 519,
          "drug_id": 155,
          "indication_name": "Atrial fibrillation ",
          "expected_effects": "Significant reduction in ventricular response rate in atrial fibrillation, from median 195 beats/minute initially to median 164 beats/minute after 2 weeks of treatment\nSimilar to effect with diltiazem treatment (median: 158 beats/minute) but less effective than digoxin-diltiazem combination (median: 126 beats/minute)",
          "common_combinations": "If heart rate remains persistently high even with digoxin therapy in dogs with atrial fibrillation, improved heart rate reduction can be achieved with addition of diltiazem 3 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:51.000000Z",
          "updated_at": "2020-09-16T00:36:51.000000Z"
      },
      {
          "id": 520,
          "drug_id": 155,
          "indication_name": "Dilated cardiomyopathy",
          "expected_effects": "Reduction in tachycardia\nPossible baroreceptor upregulation\nImproved systolic function\nReduction of neurohormonal abnormalities of congestive heart failure",
          "common_combinations": "Furosemide, ACE inhibitor (enalapril, benazepril, ramipril, or imidapril) and pimobendan if congestive heart failure is present",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:36:54.000000Z",
          "updated_at": "2020-09-16T00:36:54.000000Z"
      },
      {
          "id": 521,
          "drug_id": 155,
          "indication_name": "Dilated cardiomyopathy",
          "expected_effects": "Improvement in several echocardiographic parameters in 67% of cats",
          "common_combinations": "Furosemide (1.2 mg/kg PO q 12h);Aspirin (80 mg/CAT PO q 48h);Commercial low-salt diet",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:36:56.000000Z",
          "updated_at": "2020-09-16T00:36:56.000000Z"
      },
      {
          "id": 522,
          "drug_id": 156,
          "indication_name": "Hypoparathyroidism",
          "expected_effects": "Elimination of hypocalcemia (and of associated clinical signs)",
          "common_combinations": "Calcium supplementation (e.g., calcium carbonate)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:36:59.000000Z",
          "updated_at": "2020-09-16T00:36:59.000000Z"
      },
      {
          "id": 523,
          "drug_id": 156,
          "indication_name": "Prevention of hypocalcemia after surgical correction of hyperparathyroidism",
          "expected_effects": "Maintenance of normal serum calcium concentration",
          "common_combinations": "Calcium carbonate 333-1000 mg/DOG PO q 8h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:37:01.000000Z",
          "updated_at": "2020-09-16T00:37:01.000000Z"
      },
      {
          "id": 524,
          "drug_id": 156,
          "indication_name": "Hypoparathyroidism",
          "expected_effects": "Long-term survival (>37 months) is possible in cats",
          "common_combinations": "Acute treatment: 10% calcium gluconate IV, plus high-dosage oral dihydrotachysterol and calcium (loading);Long-term calcium supplementation at 29-53mg/kg/day (mean, 42 mg/kg/day)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:37:04.000000Z",
          "updated_at": "2020-09-16T00:37:04.000000Z"
      },
      {
          "id": 525,
          "drug_id": 157,
          "indication_name": "Supraventricular or re-entrant tachycardia",
          "expected_effects": "Slowing of heart rate via enhancement of physiologic second-degree AV block",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:06.000000Z",
          "updated_at": "2020-11-08T20:17:12.000000Z"
      },
      {
          "id": 526,
          "drug_id": 157,
          "indication_name": "Supraventricular or re-entrant tachycardia",
          "expected_effects": "Slowing of heart rate via enhancement of physiologic second-degree AV block",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:37:09.000000Z",
          "updated_at": "2020-11-08T20:17:12.000000Z"
      },
      {
          "id": 527,
          "drug_id": 157,
          "indication_name": "Acute kidney injury/anuria caused by leptospirosis",
          "expected_effects": "Serum creatinine decreases 1.76 times faster when diltiazem treatment is added to standard therapy\r\nDiltiazem therapy appears safe (has not lowered arterial blood pressure at this dosage in dogs with leptospirosis)",
          "common_combinations": "IV fluids;With or without furosemide;Antibacterials",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:37:11.000000Z",
          "updated_at": "2020-11-08T20:17:12.000000Z"
      },
      {
          "id": 528,
          "drug_id": 157,
          "indication_name": "Hypertrophic cardiomyopathy",
          "expected_effects": "Improved echocardiographic parameters and reduced clinical signs in 1 study",
          "common_combinations": "Furosemide;ACE inhibitor",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:37:13.000000Z",
          "updated_at": "2020-11-08T20:17:12.000000Z"
      },
      {
          "id": 529,
          "drug_id": 158,
          "indication_name": "Atrial fibrillation - chronic",
          "expected_effects": "Significant reduction in ventricular response rate in atrial fibrillation, from median 195 beats/minute initially to median 158 beats/minute after 2 weeks of treatment\nSimilar to effect with digoxin treatment (median: 164 beats/minute) but less effective than digoxin-diltiazem combination (median: 126 beats/minute)",
          "common_combinations": "Digoxin 0.005 mg/kg PO q 12h for greater reduction in atrial fibrillation ventricular response rate",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:16.000000Z",
          "updated_at": "2020-09-16T00:37:16.000000Z"
      },
      {
          "id": 530,
          "drug_id": 158,
          "indication_name": "Hypertrophic cardiomyopathy",
          "expected_effects": "Variable serum drug concentrations, considered either subtherapeutic or toxic",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:37:19.000000Z",
          "updated_at": "2020-09-16T00:37:19.000000Z"
      },
      {
          "id": 531,
          "drug_id": 159,
          "indication_name": "Antinausea",
          "expected_effects": "60% reduction in incidence of acute vomiting compared to negative control, and when emesis occurs, time to onset is doubled compared to negative control",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:21.000000Z",
          "updated_at": "2020-09-16T00:37:21.000000Z"
      },
      {
          "id": 532,
          "drug_id": 160,
          "indication_name": "Zinc toxicosis",
          "expected_effects": "Improvement in clinical signs",
          "common_combinations": "Physical removal of source of toxin (e.g., laparotomy for removal of pennies in zinc toxicosis cases)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:24.000000Z",
          "updated_at": "2020-09-16T00:37:24.000000Z"
      },
      {
          "id": 533,
          "drug_id": 161,
          "indication_name": "Systemic amyloidosis",
          "expected_effects": "No convincing clinical benefit",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:26.000000Z",
          "updated_at": "2020-09-16T00:37:26.000000Z"
      },
      {
          "id": 534,
          "drug_id": 162,
          "indication_name": "Babesiosis (B. rossi)",
          "expected_effects": "Median hematocrit rises from 28% at admission to 36%, 6 days after treatment",
          "common_combinations": "Blood transfusion if anemia is severe",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:29.000000Z",
          "updated_at": "2020-09-16T00:37:29.000000Z"
      },
      {
          "id": 535,
          "drug_id": 162,
          "indication_name": "Trypanosomiasis (T. brucei brucei)",
          "expected_effects": "Clinical signs and parasitemia eliminated by 7 days post-treatment, but relapse in 33% of dogs 2 weeks later (relapse, when it occurs, can be fatal by 8 weeks post-treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:37:31.000000Z",
          "updated_at": "2020-11-08T20:23:39.000000Z"
      },
      {
          "id": 536,
          "drug_id": 162,
          "indication_name": "Babesiosis (B. gibsoni)",
          "expected_effects": "No improvement in parasitemia or hemoglobinuria, even in splenectomized dogs",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:37:34.000000Z",
          "updated_at": "2020-11-08T20:23:39.000000Z"
      },
      {
          "id": 537,
          "drug_id": 162,
          "indication_name": "Trypanosomiasis (Trypanosoma evansi)",
          "expected_effects": "Resolution of parasitemia and clinical signs in >99% of cats within 24-48h of treatment\r\n85.7% elimination of trypanosomal DNA (by PCR) at day 6 post-treatment\r\nAnemia resolves by 35-49 days post-treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:37:36.000000Z",
          "updated_at": "2020-11-08T20:23:39.000000Z"
      },
      {
          "id": 538,
          "drug_id": 163,
          "indication_name": "Hypersensitivity: treatment of anaphylaxis",
          "expected_effects": "Reduction in severity and duration of signs of hypersensitivity",
          "common_combinations": "Dexamethasone (0.05 mg/kg IM, once) ",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:39.000000Z",
          "updated_at": "2020-09-16T00:37:39.000000Z"
      },
      {
          "id": 539,
          "drug_id": 163,
          "indication_name": "Mast cell tumor",
          "expected_effects": "Reduced likelihood/severity of mast cell degranulation and associated effects",
          "common_combinations": "Prednisone 1 mg/kg PO q 48h and omeprazole 0.7 mg/kg PO q 24h also for 72 hours before initiation of toceranib treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:37:42.000000Z",
          "updated_at": "2020-09-16T00:37:42.000000Z"
      },
      {
          "id": 540,
          "drug_id": 163,
          "indication_name": "Pruritic dermatoses",
          "expected_effects": "Satisfactory response (\"good control of pruritus\" according to owner) in 7% of dogs\r\n\"Moderate\" response (some improvement, but insufficient according to owner) in 16% of dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:37:44.000000Z",
          "updated_at": "2020-11-08T20:27:05.000000Z"
      },
      {
          "id": 541,
          "drug_id": 163,
          "indication_name": "Pre-treatment for antineoplastic chemotherapy (e.g., docetaxel for malignant mammary tumors, L-asparaginase, doxorubicin)",
          "expected_effects": "Reduced likelihood of emesis",
          "common_combinations": "Dexamethasone 0.1 mg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:37:47.000000Z",
          "updated_at": "2020-09-16T00:37:47.000000Z"
      },
      {
          "id": 542,
          "drug_id": 163,
          "indication_name": "Sedation",
          "expected_effects": "Insignificant trend to slight sedation at high dose 30 min after administration",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:37:49.000000Z",
          "updated_at": "2020-11-08T20:27:05.000000Z"
      },
      {
          "id": 543,
          "drug_id": 163,
          "indication_name": "Hypersensitivity: prophylaxis/risk reduction",
          "expected_effects": "Subjectively reduced risk of likelihood/severity of anaphylaxis during procedure involving release of vasoactive substances",
          "common_combinations": "Low-dose glucocorticoids",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:37:52.000000Z",
          "updated_at": "2020-11-08T20:27:05.000000Z"
      },
      {
          "id": 544,
          "drug_id": 164,
          "indication_name": "Overweight/obesity",
          "expected_effects": "Loss of 11.8-14% body weight during 16-week period in overweight/obese clinical dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:54.000000Z",
          "updated_at": "2020-09-16T00:37:54.000000Z"
      },
      {
          "id": 545,
          "drug_id": 165,
          "indication_name": "Myocardial systolic dysfunction",
          "expected_effects": "Increase in LV fractional shortening on echo, proportional to dosage (up to 67-99% [near-doubling] at highest dosage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:37:56.000000Z",
          "updated_at": "2020-09-16T00:37:56.000000Z"
      },
      {
          "id": 546,
          "drug_id": 165,
          "indication_name": "Low cardiac output during general anesthesia",
          "expected_effects": "Cardiac index in healthy cats increases from 1.3 L/min/m² (baseline: 0 µg/kg/min) to 2.4 L/min/m² (2.5 µg/kg/min) to 3.25 L/min/m² (20 µg/kg/min)\nNo effect on mean arterial blood pressure",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:37:59.000000Z",
          "updated_at": "2020-09-16T00:37:59.000000Z"
      },
      {
          "id": 547,
          "drug_id": 166,
          "indication_name": "Nausea/vomiting",
          "expected_effects": "Reduction in frequency and severity of acute vomiting",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:38:01.000000Z",
          "updated_at": "2020-09-16T00:38:01.000000Z"
      },
      {
          "id": 548,
          "drug_id": 167,
          "indication_name": "Hypotension during general anesthesia",
          "expected_effects": "Increase in systolic blood pressure, from baseline (94 mmHg) to 10 µg/kg/min (147 mmHg) but no change at 5 µg/kg/min (104 mmHg)",
          "common_combinations": "Fluid resuscitation, which needs to precede catecholamines when hypotension is due to hypovolemia/dehydration/blood loss",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:38:04.000000Z",
          "updated_at": "2020-09-16T00:38:04.000000Z"
      },
      {
          "id": 549,
          "drug_id": 167,
          "indication_name": "Reduction/prevention of acute renal injury",
          "expected_effects": "Renal vasodilation\r\nHigh urine flow rate\r\nAttenuation of decrease in GFR",
          "common_combinations": "Furosemide 1 mg/kg IV bolus, then 1 mg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:38:06.000000Z",
          "updated_at": "2020-11-08T20:30:23.000000Z"
      },
      {
          "id": 550,
          "drug_id": 167,
          "indication_name": "Hypotension, bradycardia",
          "expected_effects": "With healthy cats under general anesthesia (2.5 µg/kg/min): median heart rate (HR) increases from 156 beats/minute to 180 beats/minute, mean arterial pressure (MAP) increases from 68 to 85 mmHg, cardiac index increases from 1.2 to 1.76 L/min/m²\r\nDosage of 5 µg/kg/min: HR=193/min, MAP=94 mmHg, cardiac index=2.06 L/min/m²\r\nDosage of 20 µg/kg/min: HR= 242/min, MAP= 120 mmHg, cardiac index=2.49 L/min/m²",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:38:08.000000Z",
          "updated_at": "2020-11-08T20:30:23.000000Z"
      },
      {
          "id": 551,
          "drug_id": 168,
          "indication_name": "Spirocerca lupi infection",
          "expected_effects": "57% of dogs cured (full resolution of clinical signs, elimination of esophageal nodules on endoscopy) with 3 doses in 6 weeks\r\n14% have a delayed response (>1 year for resolution) to the 3 biweekly injections\r\nRemaining 29% of dogs are cured after additional treatment (500 µg/kg PO q 24h for 6 weeks after the 3 biweekly injections)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:38:11.000000Z",
          "updated_at": "2020-11-08T20:32:59.000000Z"
      },
      {
          "id": 552,
          "drug_id": 168,
          "indication_name": "Notoedric mange",
          "expected_effects": "Clinical improvement 1 week after treatment, with full resolution of skin lesions by day 15 after treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:38:13.000000Z",
          "updated_at": "2020-11-08T20:32:59.000000Z"
      },
      {
          "id": 553,
          "drug_id": 169,
          "indication_name": "Laryngeal paralysis assessment",
          "expected_effects": "Visible increase in respiratory movement, and 57% increase in surface area of rima glottidis compared to no treatment (normal dogs)",
          "common_combinations": "Butorphanol and acepromazine premedication;Titrated IV boluses of propofol",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:38:15.000000Z",
          "updated_at": "2020-09-16T00:38:15.000000Z"
      },
      {
          "id": 554,
          "drug_id": 169,
          "indication_name": "Apnea",
          "expected_effects": "Increase in respiratory rate and effort",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:38:18.000000Z",
          "updated_at": "2020-11-08T20:35:57.000000Z"
      },
      {
          "id": 555,
          "drug_id": 170,
          "indication_name": "Lymphoma (initial) - modified UMW protocol",
          "expected_effects": "94.2% induction of remission\nMedian disease-free interval: 282 days\nMedian survival: 397 days\n9.4% rate of toxicosis severe enough to warrant hospitalization",
          "common_combinations": "L-asparaginase, cyclophosphamide, vincristine, and prednisone, according to protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:38:20.000000Z",
          "updated_at": "2020-09-16T00:38:20.000000Z"
      },
      {
          "id": 556,
          "drug_id": 170,
          "indication_name": "Lymphoma (relapse) - CHOP protocol",
          "expected_effects": "Median reinduced remission duration of 98-214 days, depending on whether relapse occurred soon (< 289 days) after end of initial 6-month chemotherapy treatment or not (≥ 289 days), respectively",
          "common_combinations": "L-asparaginase, cyclophosphamide, vincristine, and prednisone, according to protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:38:22.000000Z",
          "updated_at": "2020-09-16T00:38:22.000000Z"
      },
      {
          "id": 557,
          "drug_id": 170,
          "indication_name": "Osteosarcoma",
          "expected_effects": "Disease-free interval: 146-258 days (median: 202 days)\nSurvival time: 174-342 days (median: 258 days)",
          "common_combinations": "Carboplatin 300 mg/m² q 3 weeks (alternating/staggered with doxorubicin), and amputation of affected limb",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:38:25.000000Z",
          "updated_at": "2020-09-16T00:38:25.000000Z"
      },
      {
          "id": 558,
          "drug_id": 170,
          "indication_name": "Hemangiosarcoma: no clear benefit",
          "expected_effects": "Median survival of 107-257 days, according to grade of hemangiosarcoma, and without a clear benefit over historical controls not treated with doxorubicin",
          "common_combinations": "Surgical resection of hemangiosarcoma",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:38:27.000000Z",
          "updated_at": "2020-09-16T00:38:27.000000Z"
      },
      {
          "id": 559,
          "drug_id": 170,
          "indication_name": "Soft tissue sarcoma (incompletely resected)",
          "expected_effects": "84% one-year and 81% two- to four-year tumor control rates, respectively\n85%, 79%, and 72% survival for 1, 2, and 3-4 years, respectively",
          "common_combinations": "51 Gy orthovoltage radiation in 17 daily 3 Gy fractions",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:38:29.000000Z",
          "updated_at": "2020-09-16T00:38:29.000000Z"
      },
      {
          "id": 560,
          "drug_id": 170,
          "indication_name": "Malignant mammary tumor",
          "expected_effects": "Survival time: 39-2585 days (median: 231 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:38:32.000000Z",
          "updated_at": "2020-09-16T00:38:32.000000Z"
      },
      {
          "id": 561,
          "drug_id": 170,
          "indication_name": "Lymphoma",
          "expected_effects": "47% induction of remission\nMedian survival time of 654 days when initial response was complete remission, 122 days when initial response was partial remission, and 11 days when there was no response to treatment",
          "common_combinations": "L-asparaginase, cyclophosphamide, vincristine, chlorambucil, methotrexate, and prednisone, according to protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:38:34.000000Z",
          "updated_at": "2020-09-16T00:38:34.000000Z"
      },
      {
          "id": 562,
          "drug_id": 170,
          "indication_name": "Injection-site sarcoma",
          "expected_effects": "33% complete or partial response\nSuperior disease-free interval (median: 388 days) compared to treatment with surgery alone (median of historical controls: 93 days)",
          "common_combinations": "Surgical resection of mass lesion",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:38:36.000000Z",
          "updated_at": "2020-09-16T00:38:36.000000Z"
      },
      {
          "id": 563,
          "drug_id": 171,
          "indication_name": "Ehrlichiosis",
          "expected_effects": "94% rate of response to treatment in dogs with naturally-occurring ehrlichiosis, most within 3 days of starting treatment (E. canis titer >1:2560 +/- presence of cutaneous lesions possibly associated with >1 week delay to treatment response)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:38:39.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 564,
          "drug_id": 171,
          "indication_name": "Borreliosis/Lyme disease",
          "expected_effects": "Prevention or elimination of infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:38:42.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 565,
          "drug_id": 171,
          "indication_name": "Leptospirosis",
          "expected_effects": "Elimination of leptospiremia, leptospirosis organisms in renal tissue, and associated clinical signs",
          "common_combinations": "May precede with ampicillin 20 mg/kg IV q 6h or Na/K penicillin G 25000-40000 IU/kg slow IV q 12h (dose reduction for either/both drugs if patient is azotemic)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:38:44.000000Z",
          "updated_at": "2020-09-16T00:38:44.000000Z"
      },
      {
          "id": 566,
          "drug_id": 171,
          "indication_name": "Heartworm/D. immitis infection - pretreatment before adulticide",
          "expected_effects": "2.5-fold reduction in severity of pulmonary arterial lesions when pre-melarsomine treatment with doxycycline, and 4-fold reduction with doxycycline + ivermectin",
          "common_combinations": "Ivermectin 6 µg/kg PO q 1 month and melarsomine 2.5 mg/kg IM when doxycycline treatment is complete (1 dose) and again 4 weeks later (2 doses, 24h apart)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:38:46.000000Z",
          "updated_at": "2020-09-16T00:38:46.000000Z"
      },
      {
          "id": 567,
          "drug_id": 171,
          "indication_name": "Heartworm/D. immitis infection - as adulticide, when melarsomine treatment is not possible",
          "expected_effects": "By day 300 post-treatment, 73% of dogs have a negative heartworm antigen test result and 86% elimination of echocardiographically-visible heartworms\r\n100% elimination of microfilaremia by day 90 of treatment",
          "common_combinations": "Ivermectin 6 µg/kg PO and pyrantel pamoate 14 mg/kg PO (both given at same time, q 2 weeks) for 6 months",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:38:49.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 568,
          "drug_id": 171,
          "indication_name": "Rocky Mountain spotted fever",
          "expected_effects": "Significant reduction in fever within 24h of starting treatment\r\nSignificant increase in platelet count within 48h of starting treatment\r\nAll dogs improve clinically, though rickettsial DNA remains detectable long after resolution of signs (e.g., 10 days after end of treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:38:52.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 569,
          "drug_id": 171,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "38% of dogs controlled with doxycycline-niacinamide treatment regimen chronically",
          "common_combinations": "Niacinamide PO q 8h: 250 mg/DOG if body weight <15 kg or 500 mg/DOG if body weight >15 kg",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:38:54.000000Z",
          "updated_at": "2020-09-16T00:38:54.000000Z"
      },
      {
          "id": 570,
          "drug_id": 171,
          "indication_name": "Lupoid onychodystrophy",
          "expected_effects": "40% excellent response (complete regrowth of normal claws), 20% good response (resolution of pain but abnormal claws persist), 20% partial response (partial persistence of pain and abnormal claw morphology), and 20% poor response (no substantial improvement)",
          "common_combinations": "Niacinamide PO q 8h: 250 mg/DOG if body weight <15 kg or 500 mg/DOG if body weight >15 kg",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:38:57.000000Z",
          "updated_at": "2020-09-16T00:38:57.000000Z"
      },
      {
          "id": 571,
          "drug_id": 171,
          "indication_name": "Endocarditis associated with Bartonella spp.",
          "expected_effects": "Minimally effective in reported case: persistence of clinical signs leading to euthanasia after 17 days of treatment",
          "common_combinations": "Enrofloxacin 306 mg/DOG (approximately 7.5 mg/kg) PO q 12h;Amoxicillin-clavulanate 530 mg/DOG (approximately 12.5 mg/kg) PO q 12h;Treatment for congestive heart failure if present",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:38:59.000000Z",
          "updated_at": "2020-09-16T00:38:59.000000Z"
      },
      {
          "id": 572,
          "drug_id": 171,
          "indication_name": "Ulcerative keratitis",
          "expected_effects": "Insignificant improvement in rate of corneal ulcer healing",
          "common_combinations": "Neomycin;Polymyxin B;Bacitracin topical ointment q 8h",
          "is_contraindicated": 1,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:39:02.000000Z",
          "updated_at": "2020-09-16T00:39:02.000000Z"
      },
      {
          "id": 573,
          "drug_id": 171,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Significant (45%) improvement in lameness score compared to baseline (chondroitin-treated control dogs: 70% improvement)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:39:04.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 574,
          "drug_id": 171,
          "indication_name": "Mycoplasma haemofelis infection",
          "expected_effects": "Significantly better overall demeanor, hematocrit, and resolution of fever with doxycycline compared to untreated control cats",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:39:06.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 575,
          "drug_id": 171,
          "indication_name": "Upper respiratory tract infection with Mycoplasma spp.",
          "expected_effects": "100% elimination of Mycoplasma spp. (and associated clinical signs) with treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:39:09.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 576,
          "drug_id": 171,
          "indication_name": "Chlamydia felis",
          "expected_effects": "Significantly better general condition after 14 days of doxycycline treatment compared to baseline and compared to cats treated with enrofloxacin for 14 days",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:39:11.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 577,
          "drug_id": 171,
          "indication_name": "Plasma cell pododermatitis",
          "expected_effects": "Complete resolution in 23% of cats after 3-4 weeks and a further 12% of cats after an additional 3-4 weeks of treatment\r\n53% show partial improvement after 6-8 weeks of treatment and 12% do not improve with treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-09-16T00:39:14.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 578,
          "drug_id": 171,
          "indication_name": "Bartonellosis",
          "expected_effects": "Bacteremia eliminated in 17% of cases with 14 days of treatment, 50% of cases with 28 days of treatment (vs. 57% and 71%, respectively, with enrofloxacin treatment)\r\nClinical significance of eliminating bacteremia is uncertain because Bartonella are commonly found in otherwise healthy individuals",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-09-16T00:39:16.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 579,
          "drug_id": 171,
          "indication_name": "Mycobacterium avium complex",
          "expected_effects": "Gradual clinical improvement over several weeks\r\nClinically normal 1 year after diagnosis",
          "common_combinations": "Clofazimine 20 mg/kg PO q 24h for 1 month",
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-09-16T00:39:19.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 580,
          "drug_id": 171,
          "indication_name": "Upper respiratory infection associated with Bordetella bronchiseptica",
          "expected_effects": "No change in oronasal shedding of organism",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 18,
          "created_at": "2020-09-16T00:39:21.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 581,
          "drug_id": 172,
          "indication_name": "Myasthenia gravis - diagnostic test",
          "expected_effects": "Positive response consists of dramatic reversal of neuromuscular weakness, typically lasting only a few minutes",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:39:23.000000Z",
          "updated_at": "2020-09-16T00:39:23.000000Z"
      },
      {
          "id": 582,
          "drug_id": 173,
          "indication_name": "Congestive heart failure due to myxomatous mitral valve disease",
          "expected_effects": "Disease-free interval (after the first occurrence of heart failure) is twice as long with furosemide + enalapril as with furosemide + placebo (digoxin optional in either scenario)",
          "common_combinations": "Furosemide 1-4 mg/kg PO q 8-24h;With or without digoxin 0.005 mg/kg PO q 12-24h;With or without pimobendan 0.3 mg/kg PO q 12h;With or without spironolactone 2 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:39:26.000000Z",
          "updated_at": "2020-09-16T00:39:26.000000Z"
      },
      {
          "id": 583,
          "drug_id": 173,
          "indication_name": "Preclinical myxomatous mitral valve disease (prior to congestive heart failure)",
          "expected_effects": "No convincing treatment advantage: apparently small delay to onset of congestive heart failure at certain time points but overall minimal benefit if any",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:39:28.000000Z",
          "updated_at": "2020-11-09T20:20:37.000000Z"
      },
      {
          "id": 584,
          "drug_id": 173,
          "indication_name": "Glomerulonephritis",
          "expected_effects": "50% reduction in urine protein-creatinine ratio after 6 months of treatment (vs. 20% increase with placebo)\r\nImprovement in arterial blood pressure (13 mmHg reduction with enalapril, vs. 6 mmHg increase with placebo)",
          "common_combinations": "Aspirin 0.5-5 mg/kg PO q 12-24h for anticoagulation;Omega-3 fatty acid supplementation",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:39:31.000000Z",
          "updated_at": "2020-11-09T20:20:37.000000Z"
      },
      {
          "id": 585,
          "drug_id": 173,
          "indication_name": "Congestive heart failure due to hypertrophic cardiomyopathy",
          "expected_effects": "Small but significant decrease in left atrial size, left ventricular wall dimensions (significance unclear given cotreatment with other cardiac medications)",
          "common_combinations": "Aspirin;Furosemide;Diltiazem/atenolol",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:39:33.000000Z",
          "updated_at": "2020-09-16T00:39:33.000000Z"
      },
      {
          "id": 586,
          "drug_id": 173,
          "indication_name": "Autosomal dominant polycystic kidney disease",
          "expected_effects": "Decrease in blood pressure 15-17h after enalapril dose (both in normal cats and polycystic kidney disease cats), but no appreciable benefit after 1 week of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:39:35.000000Z",
          "updated_at": "2020-11-09T20:20:37.000000Z"
      },
      {
          "id": 587,
          "drug_id": 174,
          "indication_name": "Nasal aspergillosis",
          "expected_effects": "90% cure rate for aspergillosis confined to the nasal cavity",
          "common_combinations": "Ketoconazole 5 mg/kg PO q 12h for 6 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:39:37.000000Z",
          "updated_at": "2020-09-16T00:39:37.000000Z"
      },
      {
          "id": 588,
          "drug_id": 174,
          "indication_name": "Nasal aspergillosis",
          "expected_effects": "92% cured: 58% after 1 treatment, 27% after 2 treatments, and 7% after 3 treatments",
          "common_combinations": "Endoscopic debridement of visible fungal plaques and necrotic tissue;Ketoconazole 4-6 mg/kg PO q 12h for 4-6 weeks if fungal plaques persist after 3 treatments",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:39:40.000000Z",
          "updated_at": "2020-09-16T00:39:40.000000Z"
      },
      {
          "id": 589,
          "drug_id": 174,
          "indication_name": "Feline dermatophytosis",
          "expected_effects": ">99% cure rate by week 6",
          "common_combinations": "Itraconazole 5 mg/kg PO q 14 days;Treat the environment daily with a 1% bleach solution and once weekly with a 0.6% enilconazole solution",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:39:42.000000Z",
          "updated_at": "2020-09-16T00:39:42.000000Z"
      },
      {
          "id": 590,
          "drug_id": 175,
          "indication_name": "Pyoderma",
          "expected_effects": "Excellent response in 93.3% of dogs (based on veterinarians' examination of lesions)\n25% recurrence 1-4 months after discontinuation",
          "common_combinations": "Treatment of concurrent disorders (e.g., atopy, dietary hypersensitivity, parasitic infestation, etc.)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:39:45.000000Z",
          "updated_at": "2020-09-16T00:39:45.000000Z"
      },
      {
          "id": 591,
          "drug_id": 175,
          "indication_name": "Otitis externa, when bacterial culture confirms enrofloxacin sensitivity",
          "expected_effects": "Systemic administration produces 10- to 30-fold higher enrofloxacin concentrations in vertical ear canal, horizontal ear canal, and middle ear canal tissues than in plasma, indicating favorable tissue-concentrating effects for bacterial otitis\nHigher concentrations achieved with higher dosage, but clinical benefit of higher dosage may not be necessary",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:39:47.000000Z",
          "updated_at": "2020-09-16T00:39:47.000000Z"
      },
      {
          "id": 592,
          "drug_id": 175,
          "indication_name": "Urinary tract infection - high dose short duration protocol",
          "expected_effects": "89% resolution of clinical signs\n77% of cultures negative 1 week after 3-day treatment (both results similar to treatment with amoxicillin-clavulanate for 2 weeks: 81% and 88%, respectively)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:39:49.000000Z",
          "updated_at": "2020-09-16T00:39:49.000000Z"
      },
      {
          "id": 593,
          "drug_id": 175,
          "indication_name": "Prostatitis - bacterial",
          "expected_effects": "Excellent antibacterial penetration into prostatic tissue",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:39:52.000000Z",
          "updated_at": "2020-09-16T00:39:52.000000Z"
      },
      {
          "id": 594,
          "drug_id": 175,
          "indication_name": "Ehrlichiosis",
          "expected_effects": "Limited efficacy: thrombocytopenia begins to resolve during treatment in some dogs (10 mg/kg better than 5 mg/kg), but recurs after end of treatment, whereas doxycycline is universally effective",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:39:54.000000Z",
          "updated_at": "2020-09-16T00:39:54.000000Z"
      },
      {
          "id": 595,
          "drug_id": 175,
          "indication_name": "Pneumonia - bacterial",
          "expected_effects": "Within 4 hours of dosing, enrofloxacin concentration in alveolar macrophages is 10.3 times higher than in plasma, surpassing the minimum inhibitory concentration of most clinically-important susceptible bacteria",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:39:57.000000Z",
          "updated_at": "2020-09-16T00:39:57.000000Z"
      },
      {
          "id": 596,
          "drug_id": 175,
          "indication_name": "Colitis - boxer dog histiocytic ulcerative",
          "expected_effects": "Clinical improvement in lower gastrointestinal clinical signs in >99% of dogs, including 86% persistent absence of clinical signs for 17-62 months after end of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:39:59.000000Z",
          "updated_at": "2020-09-16T00:39:59.000000Z"
      },
      {
          "id": 597,
          "drug_id": 175,
          "indication_name": "Pyometra",
          "expected_effects": "Significant reduction in leukocytosis and serum biochemical abnormalities (when pyometra is managed concurrently)",
          "common_combinations": "Carboprost tromethamine",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:40:02.000000Z",
          "updated_at": "2020-09-16T00:40:02.000000Z"
      },
      {
          "id": 598,
          "drug_id": 175,
          "indication_name": "Sepsis - E. coli septicemia prophylaxis during neutropenia",
          "expected_effects": "Sterilization/elimination of E.coli from feces in 89% of dogs",
          "common_combinations": "Additional antibacterial treatment (e.g., cefoxitin, gentamicin) if resistant E. coli strains emerge",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:40:04.000000Z",
          "updated_at": "2020-09-16T00:40:04.000000Z"
      },
      {
          "id": 599,
          "drug_id": 175,
          "indication_name": "Osteomyelitis",
          "expected_effects": "Minimum inhibitory concentration of enrofloxacin for many organisms is exceeded with this treatment, suggesting reduction/elimination of bacteria with treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:40:06.000000Z",
          "updated_at": "2020-09-16T00:40:06.000000Z"
      },
      {
          "id": 600,
          "drug_id": 175,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Resolution of skin lesions (82% of dogs) and lymphadenopathy (53% of dogs) with enrofloxacin-metronidazole cotreatment, compared to 88% and 75%, respectively, with meglumine antimoniate treatment",
          "common_combinations": "Metronidazole 10 mg/kg PO q 24h for 30 days (coadministered with enrofloxacin)",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:40:09.000000Z",
          "updated_at": "2020-09-16T00:40:09.000000Z"
      },
      {
          "id": 601,
          "drug_id": 175,
          "indication_name": "Endocarditis associated with Bartonella spp.",
          "expected_effects": "Limited benefit if any: persistence of clinical signs leading to euthanasia after 17 days of treatment",
          "common_combinations": "Doxycycline 400 mg/DOG (approximately 10 mg/kg) PO q 12h;Amoxicillin-clavulanate 530 mg/DOG (approximately 12.5 mg/kg) PO q 12h;Treatment for congestive heart failure if present",
          "is_contraindicated": 1,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:40:11.000000Z",
          "updated_at": "2020-09-16T00:40:11.000000Z"
      },
      {
          "id": 602,
          "drug_id": 175,
          "indication_name": "Brucellosis",
          "expected_effects": "Suppression of clinical disease (allowing gestation to term and birth of normal pups) but not eradication of infection\nControversial, since infection is persistent",
          "common_combinations": "Daily cleaning of kennel environment with quaternary ammonium disinfectant",
          "is_contraindicated": 1,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:40:14.000000Z",
          "updated_at": "2020-09-16T00:40:14.000000Z"
      },
      {
          "id": 603,
          "drug_id": 175,
          "indication_name": "Mycobacterial skin/subcutaneous infection (M. smegmatis, M. fortuitum var. fortuitum)",
          "expected_effects": "Visible reduction in drainage and softening of subcutaneous masses after 1-3 weeks of treatment\nComplete resolution with 3-7 weeks of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:40:16.000000Z",
          "updated_at": "2020-09-16T00:40:16.000000Z"
      },
      {
          "id": 604,
          "drug_id": 175,
          "indication_name": "Erosive polyarthritis associated with Mycoplasma gateae",
          "expected_effects": "Marked clinical improvement within 24h of first dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-09-16T00:40:20.000000Z",
          "updated_at": "2020-09-16T00:40:20.000000Z"
      },
      {
          "id": 605,
          "drug_id": 175,
          "indication_name": "Mycoplasma haemofelis infection",
          "expected_effects": "1000-fold reduction in M. haemofelis recovered via polymerase chain reaction after treatment, indicating significant reduction (but incomplete elimination) of organisms",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-09-16T00:40:22.000000Z",
          "updated_at": "2020-09-16T00:40:22.000000Z"
      },
      {
          "id": 606,
          "drug_id": 175,
          "indication_name": "Bartonellosis",
          "expected_effects": "Bacteremia eliminated in 57% of cases with 14 days of treatment, and 71% of cases with 28 days of treatment (vs. 17% and 50%, respectively, with doxycycline treatment)\nClinical significance of eliminating bacteremia is uncertain because Bartonella spp. are commonly found in otherwise healthy individuals",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-09-16T00:40:24.000000Z",
          "updated_at": "2020-09-16T00:40:24.000000Z"
      },
      {
          "id": 607,
          "drug_id": 176,
          "indication_name": "Acute diarrhea",
          "expected_effects": "Significantly shorter time to resolution of diarrhea with treatment (0.5-2.1 days), compared to placebo (1.4 -3.1 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:40:27.000000Z",
          "updated_at": "2020-09-16T00:40:27.000000Z"
      },
      {
          "id": 608,
          "drug_id": 176,
          "indication_name": "Feline herpesvirus-1 chronic infection",
          "expected_effects": "Greater enteric microbial diversity maintained with treatment than with placebo, and possibly fewer episodes of recrudescence of conjunctivitis in some cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:40:29.000000Z",
          "updated_at": "2020-09-16T00:40:29.000000Z"
      },
      {
          "id": 609,
          "drug_id": 177,
          "indication_name": "Cardiopulmonary arrest",
          "expected_effects": "Survival in dogs with naturally-occurring arrest: 60%, 32%, 18% at immediate (return of spontaneous circulation), 20 min, and 60 min time points, respectively\r\n6-fold superiority of epinephrine in 1-hour survival compared to vasopressin",
          "common_combinations": "Cardiopulmonary resuscitation",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:40:32.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 610,
          "drug_id": 177,
          "indication_name": "Calcium channel-blocker overdose",
          "expected_effects": "Substantial improvement in diltiazem overdose-induced second- and third-degree atrioventricular block and restoration of normal sinus rhythm in many dogs, but no effect on hypotension",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:40:34.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 611,
          "drug_id": 177,
          "indication_name": "Severe systemic hypotension (e.g., septic shock)",
          "expected_effects": "Improvement in hemodynamic parameters but negative effects on organ perfusion and decreased survival (compared to norepinephrine or vasopressin)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:40:36.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 612,
          "drug_id": 177,
          "indication_name": "Low cardiac output under general anesthesia",
          "expected_effects": "With infusions of 0.125, 0.25, 0.5, 1, and 2 µg/kg/min, respectively, cardiac index is 58%, 83%, 100%, 110%, and 110% higher than baseline\r\nMean arterial pressure is 83, 88, 119, 134, and 139 mmHg (compared to baseline of 67 mmHg)\r\nHeart rate is 191, 194, 204, 212, and 211 beats/minute (compared to baseline of 163 beats/minute)\r\nPacked cell volume is 39%, 40%, 41%, 42%, and 43% (compared to baseline of 26%)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:40:39.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 613,
          "drug_id": 177,
          "indication_name": "Bronchoconstrictive emergency/asthmatic crisis",
          "expected_effects": "Visible, dramatic improvement in respiratory effort within 15 min",
          "common_combinations": "Atropine IM",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:40:41.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 614,
          "drug_id": 178,
          "indication_name": "Hemangiosarcoma - splenic",
          "expected_effects": "Survival with splenectomy and epirubicin: 74-2717 days (median: 144 days), which is significantly longer than survival with splenectomy alone (14-790 days, median: 87 days)",
          "common_combinations": "Splenectomy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:40:44.000000Z",
          "updated_at": "2020-09-16T00:40:44.000000Z"
      },
      {
          "id": 615,
          "drug_id": 178,
          "indication_name": "Lymphoma",
          "expected_effects": "96% complete response rate\r\nTime to relapse: 40-1264 days (median: 216 days)\r\nSurvival time: 43-2575 days (median: 342 days)",
          "common_combinations": "Cyclophosphamide, vincristine, L-asparaginase, prednisolone +/- methotrexate, chlorambucil, all per protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:40:47.000000Z",
          "updated_at": "2020-11-09T20:40:10.000000Z"
      },
      {
          "id": 616,
          "drug_id": 178,
          "indication_name": "Lymphoma",
          "expected_effects": "96% complete response rate\r\nTime to relapse: 40-1264 days (median: 216 days)\r\nSurvival time: 43-2575 days (median: 342 days)",
          "common_combinations": "Cyclophosphamide, vincristine, L-asparaginase, prednisolone +/- methotrexate, chlorambucil, all per protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:40:49.000000Z",
          "updated_at": "2020-11-09T20:40:11.000000Z"
      },
      {
          "id": 617,
          "drug_id": 179,
          "indication_name": "Pneumonia - Mycoplasma-associated",
          "expected_effects": "Rapid clinical improvement and resolution of infection in majority of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:40:52.000000Z",
          "updated_at": "2020-09-16T00:40:52.000000Z"
      },
      {
          "id": 618,
          "drug_id": 179,
          "indication_name": "Campylobacter jejuni - control of fecal shedding",
          "expected_effects": "Elimination of shedding of C. jejuni in all dogs by day 4 of treatment\nRecurrence of shedding in 89% of dogs by 9 days after end of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:40:54.000000Z",
          "updated_at": "2020-09-16T00:40:54.000000Z"
      },
      {
          "id": 619,
          "drug_id": 179,
          "indication_name": "Dermatitis with pruritus",
          "expected_effects": "Satisfactory response (\"good control of pruritus\" according to owner) in only 4% of dogs\n\"Moderate\" response (some improvement but insufficient according to owner) in 9% of dogs",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:40:57.000000Z",
          "updated_at": "2020-09-16T00:40:57.000000Z"
      },
      {
          "id": 620,
          "drug_id": 179,
          "indication_name": "Gallbladder prokinetic agent",
          "expected_effects": "No significant change in ultrasonographically-determined gallbladder volume",
          "common_combinations": "Feeding a meal",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:40:59.000000Z",
          "updated_at": "2020-09-16T00:40:59.000000Z"
      },
      {
          "id": 621,
          "drug_id": 179,
          "indication_name": "Erosive polyarthritis associated with Mycoplasma gateae",
          "expected_effects": "Persistence of clinical signs and new onset of hemolytic anemia",
          "common_combinations": "Replaced with enrofloxacin for successful outcome",
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:41:01.000000Z",
          "updated_at": "2020-09-16T00:41:01.000000Z"
      },
      {
          "id": 622,
          "drug_id": 180,
          "indication_name": "Anemia",
          "expected_effects": "Target hematocrit of 35-45% reached in majority of treated dogs after 5 weeks of treatment",
          "common_combinations": "Blood transfusion if anemia is severe",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:05.000000Z",
          "updated_at": "2020-09-16T00:41:05.000000Z"
      },
      {
          "id": 623,
          "drug_id": 180,
          "indication_name": "Anemia",
          "expected_effects": "During treatment, owners report improved appetite, increased energy level, weight gain, increased alertness, increased physical strength, and increased playfulness in 91%, 73%, 64%, 45%, 27%, and 18% of cats, respectively\nSurvival time: 54-467 days (most common cause of death: euthanasia due to intractable uremia)",
          "common_combinations": "Treatment for chronic kidney disease",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:07.000000Z",
          "updated_at": "2020-09-16T00:41:07.000000Z"
      },
      {
          "id": 624,
          "drug_id": 180,
          "indication_name": "FIV-associated anemia",
          "expected_effects": "Mean PCV increases from 33% to 46% after 2 weeks of treatment (whether FIV-positive or healthy)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:41:09.000000Z",
          "updated_at": "2020-09-16T00:41:09.000000Z"
      },
      {
          "id": 625,
          "drug_id": 181,
          "indication_name": "To induce transient beta-blockade of the heart",
          "expected_effects": "28% decrease in mean arterial pressure\r\n8% decrease in cardiac output\r\n30% increase in heart rate",
          "common_combinations": "Isoflurane anesthesia (for experimental hemodynamic manipulations)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:12.000000Z",
          "updated_at": "2020-11-09T21:09:11.000000Z"
      },
      {
          "id": 626,
          "drug_id": 181,
          "indication_name": "To induce transient beta-blockade of the heart",
          "expected_effects": "100 and 500 µg/kg/min infusions produce, respectively, 10 and 40% increases in left ventricular end-diastolic pressure, 10 and 25% decreases in LV systolic pressure, but no significant changes in heart rate (baseline = 97 +/- 15 beats/minute, 100 µg/kg/min = 92 +/- 13 beats/minute, 500 µg/kg/min = 96 +/- 7 beats/minute)",
          "common_combinations": "Isoflurane anesthesia (for experimental hemodynamic manipulations)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:15.000000Z",
          "updated_at": "2020-09-16T00:41:15.000000Z"
      },
      {
          "id": 627,
          "drug_id": 181,
          "indication_name": "To induce transient beta-blockade of the heart",
          "expected_effects": "Left ventricular dP/dtmax decreases 15-30% and end-diastolic wall stress increases 35% in healthy cats, but no significant change in heart rate or blood pressure is observed",
          "common_combinations": "Isoflurane anesthesia (for experimental hemodynamic manipulations)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:41:17.000000Z",
          "updated_at": "2020-09-16T00:41:17.000000Z"
      },
      {
          "id": 628,
          "drug_id": 182,
          "indication_name": "Ethylene glycol toxicosis",
          "expected_effects": "50-75% survival depending on amount of ethylene glycol ingested (6-10 mL/kg) and time between ingestion and ethanol treatment (2-6 hours)",
          "common_combinations": "8 mL/kg 5% NaHCO3 intraperitoneally",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:20.000000Z",
          "updated_at": "2020-09-16T00:41:20.000000Z"
      },
      {
          "id": 629,
          "drug_id": 182,
          "indication_name": "Ethylene glycol toxicosis - low-dose protocol",
          "expected_effects": "When administration of ethanol is begun within 1 hour of ingestion, >99% survival and few/no immediate adverse effects in treated dogs",
          "common_combinations": "NaHCO3, 0.9% NaCl",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:22.000000Z",
          "updated_at": "2020-09-16T00:41:22.000000Z"
      },
      {
          "id": 630,
          "drug_id": 182,
          "indication_name": "Ethylene glycol toxicosis",
          "expected_effects": "33% survival if treatment is initiated within 3h of ingestion\r\n<1% survival if treatment is initiated 4h or later after ingestion",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:41:25.000000Z",
          "updated_at": "2020-11-11T18:49:44.000000Z"
      },
      {
          "id": 631,
          "drug_id": 183,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Improvement in weightbearing (superior with higher dosage compared to lower dosage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:27.000000Z",
          "updated_at": "2020-09-16T00:41:27.000000Z"
      },
      {
          "id": 632,
          "drug_id": 184,
          "indication_name": "Squamous cell carcinoma - preneoplastic cutaneous lesions",
          "expected_effects": "Complete resolution of preneoplastic lesions in 20% of treated dogs, partial response in 30%, stable disease in 20%, and progression in 30%",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:30.000000Z",
          "updated_at": "2020-09-16T00:41:30.000000Z"
      },
      {
          "id": 633,
          "drug_id": 184,
          "indication_name": "Pigmented plaques associated with cutaneous papillomavirus infection",
          "expected_effects": "Improvement in pruritus and hyperkeratosis\nSubsequent squamous cell carcinoma",
          "common_combinations": "Chlorhexidine topical therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:32.000000Z",
          "updated_at": "2020-09-16T00:41:32.000000Z"
      },
      {
          "id": 634,
          "drug_id": 185,
          "indication_name": "Exercise-induced gastritis - prevention",
          "expected_effects": "Significantly fewer gastric lesions compared to no treatment (no lesions: 63% of treated dogs vs. 13% of untreated dogs)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:34.000000Z",
          "updated_at": "2020-11-11T18:54:32.000000Z"
      },
      {
          "id": 635,
          "drug_id": 185,
          "indication_name": "Gastric acid suppression",
          "expected_effects": "Significant suppression of gastric acid secretion as evidenced by consistently higher gastric pH (compared to placebo) during treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:37.000000Z",
          "updated_at": "2020-11-11T18:54:32.000000Z"
      },
      {
          "id": 636,
          "drug_id": 185,
          "indication_name": "Helicobacter-associated gastritis",
          "expected_effects": "86% reduction in frequency of vomiting with quadruple therapy",
          "common_combinations": "Bismuth subsalicylate, metronidazole, and amoxicillin (quadruple therapy)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:41:39.000000Z",
          "updated_at": "2020-09-16T00:41:39.000000Z"
      },
      {
          "id": 637,
          "drug_id": 185,
          "indication_name": "Mast cell tumor management (reduction/prevention of histamine-induced gastric ulcers)",
          "expected_effects": "Unproven reduction in histamine-induced gastric ulceration\r\nNo appreciable clinical adverse effects",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:41:42.000000Z",
          "updated_at": "2020-11-11T18:54:32.000000Z"
      },
      {
          "id": 638,
          "drug_id": 185,
          "indication_name": "Chronic kidney disease-associated gastritis - long-term prophylaxis",
          "expected_effects": "No adverse effects reported",
          "common_combinations": "Renal diet;Aluminum hydroxide;Potassium gluconate",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:41:44.000000Z",
          "updated_at": "2020-09-16T00:41:44.000000Z"
      },
      {
          "id": 639,
          "drug_id": 186,
          "indication_name": "Pruritic skin disease",
          "expected_effects": "Significant reduction in pruritus, alopecia, and coat character compared to control group",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:47.000000Z",
          "updated_at": "2020-11-11T18:58:33.000000Z"
      },
      {
          "id": 640,
          "drug_id": 186,
          "indication_name": "Arrhythmogenic right ventricular cardiomyopathy of boxer dogs",
          "expected_effects": "Approximately 50% reduction in number of premature ventricular complexes/24h (Holter monitoring) vs. no such improvement with flax oil or sunflower oil (control group) supplementation",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:50.000000Z",
          "updated_at": "2020-11-11T18:58:33.000000Z"
      },
      {
          "id": 641,
          "drug_id": 186,
          "indication_name": "Idiopathic epilepsy",
          "expected_effects": "85% reduction in seizure frequency in one case report",
          "common_combinations": "Antiepileptic medication as necessary",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:41:52.000000Z",
          "updated_at": "2020-09-16T00:41:52.000000Z"
      },
      {
          "id": 642,
          "drug_id": 187,
          "indication_name": "Whipworm infestation (Trichuris vulpis)",
          "expected_effects": ">99% elimination of parasites (less efficacious at 5 mg/kg or 10 mg/kg dosages)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:41:55.000000Z",
          "updated_at": "2020-09-16T00:41:55.000000Z"
      },
      {
          "id": 643,
          "drug_id": 187,
          "indication_name": "Hookworm infestation (Ancylostoma caninum, Uncinaria stenocephala)",
          "expected_effects": ">99% elimination of parasites (less efficacious at 5 mg/kg or 10 mg/kg dosages)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:41:58.000000Z",
          "updated_at": "2020-09-16T00:41:58.000000Z"
      },
      {
          "id": 644,
          "drug_id": 187,
          "indication_name": "Roundworm infestation in puppies (Toxocara canis)",
          "expected_effects": ">99% reduction in fecal Toxocara egg count",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:42:00.000000Z",
          "updated_at": "2020-09-16T00:42:00.000000Z"
      },
      {
          "id": 645,
          "drug_id": 187,
          "indication_name": "Roundworm infestation in adults (Toxocara canis, Toxascaris leonina)",
          "expected_effects": ">99% elimination of parasites (less efficacious at 5 mg/kg or 10 mg/kg dosages)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:42:03.000000Z",
          "updated_at": "2020-09-16T00:42:03.000000Z"
      },
      {
          "id": 646,
          "drug_id": 187,
          "indication_name": "Tapeworm infestation (Dipylidium caninum) - minimally effective",
          "expected_effects": "Only 14% elimination of worms",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:42:06.000000Z",
          "updated_at": "2020-09-16T00:42:06.000000Z"
      },
      {
          "id": 647,
          "drug_id": 187,
          "indication_name": "Tapeworm infestation (Taenia spp.)",
          "expected_effects": ">99% elimination of parasites (less efficacious at 5 mg/kg or 10 mg/kg dosages)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:42:08.000000Z",
          "updated_at": "2020-09-16T00:42:08.000000Z"
      },
      {
          "id": 648,
          "drug_id": 187,
          "indication_name": "Giardiasis",
          "expected_effects": ">99% elimination of Giardia cysts shed in feces",
          "common_combinations": "Praziquantel (5.4-7 mg/kg) and pyrantel pamoate (26.8-35.2 mg/kg) coadministration as Drontal-Plus product",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:42:10.000000Z",
          "updated_at": "2020-09-16T00:42:10.000000Z"
      },
      {
          "id": 649,
          "drug_id": 187,
          "indication_name": "Hookworm infestation (Ancylostoma caninum)",
          "expected_effects": ">99% elimination of parasites",
          "common_combinations": "Coadministration of 1 mg/kg praziquantel",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:42:13.000000Z",
          "updated_at": "2020-09-16T00:42:13.000000Z"
      },
      {
          "id": 650,
          "drug_id": 187,
          "indication_name": "Roundworm infestation in adults (Toxocara cati)",
          "expected_effects": ">99% elimination of parasites",
          "common_combinations": "Coadministration of 1 mg/kg praziquantel",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:42:16.000000Z",
          "updated_at": "2020-09-16T00:42:16.000000Z"
      },
      {
          "id": 651,
          "drug_id": 187,
          "indication_name": "Tapeworm infestation (Taenia spp.)",
          "expected_effects": ">99% elimination of parasites",
          "common_combinations": "Coadministration of 1 mg/kg praziquantel",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:42:18.000000Z",
          "updated_at": "2020-09-16T00:42:18.000000Z"
      },
      {
          "id": 652,
          "drug_id": 188,
          "indication_name": "Seizures/epilepsy, especially partial complex seizures",
          "expected_effects": "Significant reduction in frequency and/or severity of seizures in most cases (e.g., median of 2 seizures during a period of 2-22 months of treatment, where previously seizures occurred several times weekly or daily)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:42:21.000000Z",
          "updated_at": "2020-09-16T00:42:21.000000Z"
      },
      {
          "id": 653,
          "drug_id": 189,
          "indication_name": "Giardiasis",
          "expected_effects": ">99% elimination of fecal shedding of Giardia cysts in feces after 1 course of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:42:23.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 654,
          "drug_id": 189,
          "indication_name": "Whipworm infestation - Trichuris vulpis",
          "expected_effects": "98-100% elimination of worms",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:42:25.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 655,
          "drug_id": 189,
          "indication_name": "Roundworm infestation - Toxocara canis infestation in greyhounds living in contaminated runs",
          "expected_effects": "Reduction in fecal egg counts of 95.8%, 99.8%, and 99.8% at 10, 31, and 128 days after start of treatment, respectively (vs. significantly lower with pyrantel pamoate: 85.8%, 88.3% and 98.3%)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:42:28.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 656,
          "drug_id": 189,
          "indication_name": "Hookworm infestation - Ancylostoma caninum",
          "expected_effects": "98-100% elimination of worms",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:42:30.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 657,
          "drug_id": 189,
          "indication_name": "Roundworm and hookworm infestation in pregnant bitches - to reduce transmission to puppies",
          "expected_effects": "Pups have 89% lower roundworm burden and 99% lower hookworm burden compared to pups of untreated bitches",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:42:32.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 658,
          "drug_id": 189,
          "indication_name": "Lungworm infestation - Crenosoma vulpis",
          "expected_effects": ">99% elimination of clinical signs and negative findings on Baermann fecal analysis post-treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:42:35.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 659,
          "drug_id": 189,
          "indication_name": "Lung fluke infestation - Paragonimus kellicotti",
          "expected_effects": ">99% elimination of parasite with 10-14 day treatment course (vs. 0% in untreated controls)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:42:37.000000Z",
          "updated_at": "2020-11-11T19:38:13.000000Z"
      },
      {
          "id": 660,
          "drug_id": 189,
          "indication_name": "French heartworm infestation - Angiostrongylus vasorum",
          "expected_effects": "91.3% efficacy of elimination of larvae on Baermann fecal after treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:42:40.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 661,
          "drug_id": 189,
          "indication_name": "Giardiasis",
          "expected_effects": "In cats with coinfections of Giardia spp. and Cryptosporidium parvum, treatment completely eliminated Giardia cysts from feces of 50% of cats, reduced cyst shedding (followed by recrudescence of shedding after the end of treatment) in 38% of cats, and had no effect on Giardia cyst shedding in 12% of cats",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:42:43.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 662,
          "drug_id": 189,
          "indication_name": "Roundworm infestation - Toxocara cati",
          "expected_effects": ">99% elimination of roundworms (vs. 18% for untreated control cats)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:42:45.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 663,
          "drug_id": 189,
          "indication_name": "Hookworm infestation - Ancylostoma tubaeforme",
          "expected_effects": ">99.9% elimination of hookworms (vs. 2% for untreated control cats)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:42:47.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 664,
          "drug_id": 189,
          "indication_name": "Tapeworm infestation - Taenia taeniaeformis",
          "expected_effects": ">99% elimination of tapeworms (vs. 25% for untreated control cats)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-09-16T00:42:50.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 665,
          "drug_id": 189,
          "indication_name": "Bladder worm infestation - Capillaria plica",
          "expected_effects": "Resolution of clinical signs in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-09-16T00:42:52.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 666,
          "drug_id": 189,
          "indication_name": "Lungworm infestation - Aelurostrongylus abstrusus",
          "expected_effects": ">99% elimination of clinical signs, radiographic abnormalities, and fecal shedding, including selamectin-resistant and ivermectin-resistant cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-09-16T00:42:55.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 667,
          "drug_id": 190,
          "indication_name": "Premedication before general anesthesia",
          "expected_effects": "Mask induction with inhalant anesthetic is more rapid, and smoother, and cardiovascular parameters change less during general anesthesia, when fentanyl-midazolam premedication is given",
          "common_combinations": "Midazolam 0.2 mg/kg IM or IV",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:42:57.000000Z",
          "updated_at": "2020-09-16T00:42:57.000000Z"
      },
      {
          "id": 668,
          "drug_id": 190,
          "indication_name": "Anesthetic induction in high anesthetic risk dogs",
          "expected_effects": "Smooth anesthetic induction in 64% of dogs (vs. 36% lifting head, hypersensitive to sound, coughing/swallowing)\r\n10% perioperative deaths in dogs with American Society of Anesthesiologists classification III-V (moderate to high anesthetic risk), including intraoperative euthanasia and post-operative death after intracranial surgery, i.e., not clearly linked to anesthetic protocol",
          "common_combinations": "Coinduction with fentanyl and with diazepam 0.2 mg/kg IV ± propofol 1-2 mg/kg IV to effect if needed, as follows: half of fentanyl dose is given first, then whole diazepam dose, then second half of fentanyl dose, then propofol if needed (1 mg/mL propofol is necessary in 96% of dogs, none needed in 4% of dogs)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:42:59.000000Z",
          "updated_at": "2020-11-11T19:39:56.000000Z"
      },
      {
          "id": 669,
          "drug_id": 190,
          "indication_name": "General anesthesia maintenance in high anesthetic risk dogs",
          "expected_effects": "Heart rate and systolic arterial blood pressure maintained from pre-op to post-op\r\n10% perioperative deaths in dogs with American Society of Anesthesiologists classification III-V (moderate to high anesthetic risk), including intraoperative euthanasia and post-operative death after intracranial surgery, i.e., not clearly linked to anesthetic protocol",
          "common_combinations": "Maintenance with inhalant anesthetic (e.g., isoflurane)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:43:02.000000Z",
          "updated_at": "2020-11-11T19:39:56.000000Z"
      },
      {
          "id": 670,
          "drug_id": 190,
          "indication_name": "Total intravenous anesthesia - fentanyl-propofol infusion",
          "expected_effects": "Mean arterial pressure can remain >70 mmHg for full duration of surgery with this protocol\r\nMean times to extubation, head lift, and sternal recumbency are 33 +/- 15, 43 +/- 20, and 65 +/- 23 minutes, respectively",
          "common_combinations": "Fentanyl (2 µg/kg IV) and atropine (0.04 mg/kg IV) initially given as bolus 5 minutes after propofol induction;Propofol 0.3-0.4 mg/kg/min IV CRI (reduce dosage by 0.1 mg/kg/min if mean arterial pressure <70 mmHg) and fentanyl CRIs are then coadministered continuously",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:43:04.000000Z",
          "updated_at": "2020-11-11T19:39:56.000000Z"
      },
      {
          "id": 671,
          "drug_id": 190,
          "indication_name": "Reduction of isoflurane minimum alveolar concentration",
          "expected_effects": "53% (fentanyl) to 74% (fentanyl-diazepam) reduction in isoflurane requirement",
          "common_combinations": "With or without diazepam 0.5 mg/kg IV bolus over 1 minute, then 0.5 mg/kg/h IV CRI, concurrent with fentanyl CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:43:07.000000Z",
          "updated_at": "2020-09-16T00:43:07.000000Z"
      },
      {
          "id": 672,
          "drug_id": 190,
          "indication_name": "Positive-pressure ventilation - fentanyl-midazolam-propofol infusion",
          "expected_effects": "Dogs successfully ventilated for 24h period, and oxygen delivery, lactate concentration, and arterial base excess remain within reference ranges",
          "common_combinations": "Diazepam or midazolam (0.5 mg/kg/h);Propofol (2.5 mg/kg/h)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:43:09.000000Z",
          "updated_at": "2020-09-16T00:43:09.000000Z"
      },
      {
          "id": 673,
          "drug_id": 190,
          "indication_name": "Epidural analgesia",
          "expected_effects": "Stable cardiovascular and respiratory parameters and sufficient analgesia to perform abdominal surgery (e.g., ovariohysterectomy)",
          "common_combinations": "Propofol 0.2 mg/kg/min IV CRI as needed to maintain immobilization (light plane of anesthesia with reflexes preserved)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:43:12.000000Z",
          "updated_at": "2020-09-16T00:43:12.000000Z"
      },
      {
          "id": 674,
          "drug_id": 190,
          "indication_name": "Postoperative analgesia",
          "expected_effects": "Reduction in pain score",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:43:14.000000Z",
          "updated_at": "2020-11-11T19:39:56.000000Z"
      },
      {
          "id": 675,
          "drug_id": 190,
          "indication_name": "Postoperative analgesia",
          "expected_effects": "Mean 3.07 µg/kg/h IV CRI rate necessary to adequately control signs of post-op pain (e.g., 71% of dogs undergoing forelimb amputation require >2 µg/kg/min)",
          "common_combinations": "Coadministration of ketamine (10 µg/kg/min intra-op and 2 µg/kg/min for 18h post-op) significantly improves post-op analgesia",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:43:16.000000Z",
          "updated_at": "2020-09-16T00:43:16.000000Z"
      },
      {
          "id": 676,
          "drug_id": 190,
          "indication_name": "Analgesia - FLK (fentanyl-lidocaine-ketamine) infusion",
          "expected_effects": "97% reduction in minimum alveolar concentration of isoflurane, i.e., the FLK infusion essentially provides total intravenous anesthesia",
          "common_combinations": "Coadministration with lidocaine 3 mg/kg/h IV CRI and ketamine 0.6 mg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:43:18.000000Z",
          "updated_at": "2020-09-16T00:43:18.000000Z"
      },
      {
          "id": 677,
          "drug_id": 190,
          "indication_name": "Analgesia - fentanyl-ketamine infusion",
          "expected_effects": "Infusion of ketamine and fentanyl provides greater analgesia during immediate post-operative period, and greater degree of physical movement by day 3 post-op, than an infusion of fentanyl alone, in dogs undergoing major surgery (e.g., amputation)",
          "common_combinations": "Ketamine 10 µg/kg/min intra-op and 2 µg/kg/min for 18h post-op",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:43:21.000000Z",
          "updated_at": "2020-09-16T00:43:21.000000Z"
      },
      {
          "id": 678,
          "drug_id": 190,
          "indication_name": "Analgesia - extended duration post-op",
          "expected_effects": "Application of a single transdermal dose 2-4h before orthopedic or soft-tissue surgery provides same level of analgesia (pain score), sedation, and lack of adverse effects, as 16 IM doses of buprenorphine (once pre-op and q 6h for 90h post-op)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:43:23.000000Z",
          "updated_at": "2020-11-11T19:39:56.000000Z"
      },
      {
          "id": 679,
          "drug_id": 190,
          "indication_name": "Analgesia - extended duration post-op",
          "expected_effects": "In dogs undergoing hemilaminectomy, no rescue analgesia is necessary\r\nPlasma fentanyl concentrations are first detected 4h, 8h, 12h, and 18h after patch application in 40%, 20%, 30%, and 10% of dogs, respectively\r\nAnalgesic fentanyl concentrations (≥ 0.23 ng/mL) occur 12h, 24h, and 32h after patch application in 70%, 20%, and 10% of dogs, respectively, and are maintained until after the patch is removed in > 99% of dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:43:26.000000Z",
          "updated_at": "2020-11-11T19:39:56.000000Z"
      },
      {
          "id": 680,
          "drug_id": 190,
          "indication_name": "Analgesia - e.g., for minor procedure",
          "expected_effects": "Nociception is reduced for 5-110 min after administration (peak: 5-35 min after administration, at which time plasma fentanyl concentrations are 1.07-6.2 ng/mL)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:43:28.000000Z",
          "updated_at": "2020-11-11T19:46:17.000000Z"
      },
      {
          "id": 681,
          "drug_id": 190,
          "indication_name": "Analgesia - extended duration post-op",
          "expected_effects": "Plasma fentanyl levels greater than in placebo controls between 12 and 36h after transdermal patch placement",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-09-16T00:43:30.000000Z",
          "updated_at": "2020-11-11T19:46:17.000000Z"
      },
      {
          "id": 682,
          "drug_id": 190,
          "indication_name": "General anesthesia maintenance in injured cats",
          "expected_effects": "Better spontaneous ventilation than propofol, but lower mean arterial blood pressure",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-09-16T00:43:33.000000Z",
          "updated_at": "2020-11-11T19:46:17.000000Z"
      },
      {
          "id": 683,
          "drug_id": 190,
          "indication_name": "Postoperative analgesia",
          "expected_effects": "Reduction in signs of pain",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-09-16T00:43:35.000000Z",
          "updated_at": "2020-11-11T19:46:17.000000Z"
      },
      {
          "id": 684,
          "drug_id": 191,
          "indication_name": "Supportive of erythropoiesis during erythropoietin therapy for anemia",
          "expected_effects": "Provides partial iron supplementation, but treated dogs still show features of iron deficiency\nEither a higher dosage (limitation: inappetence, vomiting) or parenteral injection (e.g., iron dextran) is recommended",
          "common_combinations": "Erythropoietin treatment during chronic kidney disease-associated anemia",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:43:38.000000Z",
          "updated_at": "2020-09-16T00:43:38.000000Z"
      },
      {
          "id": 685,
          "drug_id": 192,
          "indication_name": "Neutropenia associated with canine parvoviral enteritis (recombinant canine G-CSF)",
          "expected_effects": "Neutrophil count significantly higher (vs. placebo) by day 4 of treatment\r\nShorter hospitalization time (5 days with treatment vs. 7.3 days for placebo controls), but with 14% (4/28) mortality in first 7 days in treated dogs vs. 0% (0/34) in placebo control dogs",
          "common_combinations": "Treatment for parvoviral enteritis",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:43:40.000000Z",
          "updated_at": "2020-11-11T20:10:32.000000Z"
      },
      {
          "id": 686,
          "drug_id": 192,
          "indication_name": "Neutropenia associated with canine parvoviral enteritis (recombinant human G-CSF)",
          "expected_effects": "No difference in leukocyte count compared to placebo control\r\nNo survival benefit (68%, vs. 71% with placebo control)",
          "common_combinations": "Treatment for parvoviral enteritis",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:43:43.000000Z",
          "updated_at": "2020-11-11T20:10:32.000000Z"
      },
      {
          "id": 687,
          "drug_id": 192,
          "indication_name": "Neutropenia associated with antineoplastic chemotherapy",
          "expected_effects": "No neutropenia observed during treatment",
          "common_combinations": "Lymphoma protocol based on doxorubicin, cyclophosphamide, vincristine, L-asparaginase, and cytosine arabinoside (anticipation of leukopenia based on incorporation of cytosine arabinoside)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:43:45.000000Z",
          "updated_at": "2020-09-16T00:43:45.000000Z"
      },
      {
          "id": 688,
          "drug_id": 192,
          "indication_name": "Cyclic hematopoiesis",
          "expected_effects": ">10-fold increase in peripheral neutrophil count, fading by day 25 (presumed autoantibody formation)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:43:47.000000Z",
          "updated_at": "2020-11-11T20:10:32.000000Z"
      },
      {
          "id": 689,
          "drug_id": 192,
          "indication_name": "Neutropenia",
          "expected_effects": "3-fold increase in neutrophil count within 24h of beginning treatment\r\nOngoing increase through end of treatment (42 days) at which time neutrophil count is 8-fold higher than baseline",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:43:50.000000Z",
          "updated_at": "2020-11-11T20:10:32.000000Z"
      },
      {
          "id": 690,
          "drug_id": 193,
          "indication_name": "Benign prostatic hyperplasia",
          "expected_effects": "43% decrease in prostatic volume, 20% decrease in prostatic diameter after 16 weeks of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:43:52.000000Z",
          "updated_at": "2020-09-16T00:43:52.000000Z"
      },
      {
          "id": 691,
          "drug_id": 194,
          "indication_name": "Osteoarthritis",
          "expected_effects": "82%, 84%, 96% of treated dogs are reported by owners to have improved with regard to signs of orthopedic disease after 2 weeks, 3 months, and 1 year of treatment, respectively",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:43:55.000000Z",
          "updated_at": "2020-11-11T20:30:28.000000Z"
      },
      {
          "id": 692,
          "drug_id": 195,
          "indication_name": "Malassezia dermatitis",
          "expected_effects": "96% reduction in yeast counts on skin and 56% clinical improvement based on veterinarians' assessment of skin lesions",
          "common_combinations": "Cephalexin 22-30 mg/kg PO q 12h if concurrent bacterial dermatitis",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:43:57.000000Z",
          "updated_at": "2020-09-16T00:43:57.000000Z"
      },
      {
          "id": 693,
          "drug_id": 195,
          "indication_name": "Candida urinary tract infection",
          "expected_effects": "71% elimination of funguria during and/or after treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:44:00.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 694,
          "drug_id": 195,
          "indication_name": "Cryptococcosis - central nervous system",
          "expected_effects": "Gradual clinical improvement (e.g., able to stand after 10 days of treatment, walking without gait deficit after 16 weeks of treatment) and steady decrease in serum antigen titer during treatment in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:44:02.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 695,
          "drug_id": 195,
          "indication_name": "Cryptococcosis - central nervous system",
          "expected_effects": "Slight improvement in demeanor and appetite within 12-24h in 1 case report",
          "common_combinations": "Fluconazole 5 mg/kg PO q 12h (for long-term treatment)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:44:05.000000Z",
          "updated_at": "2020-09-16T00:44:05.000000Z"
      },
      {
          "id": 696,
          "drug_id": 195,
          "indication_name": "Intracranial phaeohyphomycotic fungal granuloma",
          "expected_effects": "Clinical cure after treatment in 1 case report, based on resolution of neurologic deficits and normalization of abnormalities on brain imaging",
          "common_combinations": "Followed by voriconazole 3.4 mg/kg PO q 12h for 10 months",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:44:08.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 697,
          "drug_id": 195,
          "indication_name": "Aspergillosis/penicillosis - nasal",
          "expected_effects": "60% cure rate for both aspergillosis and penicillosis (note: current protocols would likely treat with higher dosages and may be more effective)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:44:10.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 698,
          "drug_id": 195,
          "indication_name": "Cryptococcosis - nasal, cutaneous",
          "expected_effects": "Clinical cure in 97% of treated cats (when no central nervous system involvement)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:44:12.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 699,
          "drug_id": 195,
          "indication_name": "Sporotrichosis - disseminated",
          "expected_effects": "Resolution of infection in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:44:15.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 700,
          "drug_id": 195,
          "indication_name": "Intraocular mycotic infections - coccidioidomycosis",
          "expected_effects": "Visible improvement within first 3 weeks of treatment, continuing and stabilizing over ensuing months (with ongoing treatment), with persistent/permanent corneal and fundic changes expected",
          "common_combinations": "Treatment for uveitis (typically, carefully-titrated dosages of oral and topical ocular corticosteroid)",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:44:17.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 701,
          "drug_id": 195,
          "indication_name": "Aspergillus spp. cystitis",
          "expected_effects": "Marked clinical improvement including weight gain and resolution of azotemia in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:44:21.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 702,
          "drug_id": 195,
          "indication_name": "Candida urinary tract infection",
          "expected_effects": "Elimination of funguria is possible during treatment\r\n recurrence of infection after discontinuation of treatment is very common",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:44:23.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 703,
          "drug_id": 195,
          "indication_name": "Candida urinary tract infection",
          "expected_effects": "Elimination of funguria is possible during treatment\r\n recurrence of infection after discontinuation of treatment is very common",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:44:25.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 704,
          "drug_id": 195,
          "indication_name": "Blastomycosis - cerebral",
          "expected_effects": "Discharge after 12 days of hospitalization, clinical resolution (absence of neurologic deficits) 5.5 months later in 1 case report",
          "common_combinations": "Craniectomy for removal of fungal granuloma;Post-operative amphotericin B 0.25 mg/kg IV q 48h (cumulative dose, 1.75 mg/kg)",
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-09-16T00:44:28.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 705,
          "drug_id": 196,
          "indication_name": "Hypoadrenocorticism",
          "expected_effects": "Response to treatment: 86.5% good to excellent, 12.5% fair, 1% poor\r\nSurvival time: 7 days - 11.8 years (median: 4.7 years)",
          "common_combinations": "Prednisone or prednisolone for glucocorticoid supplementation",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:44:30.000000Z",
          "updated_at": "2020-11-11T20:58:41.000000Z"
      },
      {
          "id": 706,
          "drug_id": 196,
          "indication_name": "Hypoadrenocorticism",
          "expected_effects": "Good clinical response with survival >3 to >70 months (median: 34.1 months) with ongoing treatment",
          "common_combinations": "Prednisone or methylprednisolone acetate for glucocorticoid supplementation",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:44:33.000000Z",
          "updated_at": "2020-09-16T00:44:33.000000Z"
      },
      {
          "id": 707,
          "drug_id": 196,
          "indication_name": "Primary hyperaldosteronism diagnosis",
          "expected_effects": "Urinary aldosterone-to-creatinine ratio (UACR) increases after 4 days of fludrocortisone administration when feline primary hyperaldosteronism is present (1 case report), indicative of primary hyperaldosteronism\r\nUACR decreases by 44–97% (median 78%) in healthy cats that receive the same treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:44:35.000000Z",
          "updated_at": "2020-11-11T20:58:41.000000Z"
      },
      {
          "id": 708,
          "drug_id": 197,
          "indication_name": "Reversal of midazolam-induced respiratory depression",
          "expected_effects": "Reversal of midazolam-induced respiratory depression occurs in 120 +/- 34.5 seconds, vs. 1610 seconds without flumazenil",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:44:38.000000Z",
          "updated_at": "2020-11-11T21:00:58.000000Z"
      },
      {
          "id": 709,
          "drug_id": 197,
          "indication_name": "Reversal of midazolam-induced respiratory depression",
          "expected_effects": "Reversal of midazolam-induced respiratory depression occurs in 262 +/- 94.5 seconds (sublingual), 310 +/- 133.7 seconds (IM), or 342 +/- 84.4 seconds (per rectum), vs. 1610 seconds without flumazenil",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:44:40.000000Z",
          "updated_at": "2020-11-11T21:00:58.000000Z"
      },
      {
          "id": 710,
          "drug_id": 198,
          "indication_name": "Reduction of post-operative inflammation in healthy dogs undergoing elective surgery",
          "expected_effects": "Intermediate level of pain control post-op\nElevation in serum creatinine and liver enzyme (alanine aminotransferase) concentrations",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:44:43.000000Z",
          "updated_at": "2020-09-16T00:44:43.000000Z"
      },
      {
          "id": 711,
          "drug_id": 199,
          "indication_name": "Gastrointestinal adenocarcinoma",
          "expected_effects": "66% complete remission\r\nMedian survival time: 17-35 months in 2 case reports",
          "common_combinations": "Cisplatin cotreatment 60 mg/m² IV q 3 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:44:45.000000Z",
          "updated_at": "2020-11-11T21:01:57.000000Z"
      },
      {
          "id": 712,
          "drug_id": 199,
          "indication_name": "Mammary tumor - malignant (complex carcinoma, carcinosarcoma)",
          "expected_effects": "2-year survival >99% for dogs that received surgery + fluorouracil + cyclophosphamide (vs. 28% with surgery alone)",
          "common_combinations": "Cyclophosphamide 100 mg/m² IV q 1 week",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:44:48.000000Z",
          "updated_at": "2020-09-16T00:44:48.000000Z"
      },
      {
          "id": 713,
          "drug_id": 199,
          "indication_name": "Pancreatic cancer - extremely high dosage used in experimental setting",
          "expected_effects": "Slightly but significantly (50-75%) higher regional drug concentrations via intra-arterial route than intravenous route (may be a modality with reduced systemic toxicity)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:44:50.000000Z",
          "updated_at": "2020-11-11T21:01:57.000000Z"
      },
      {
          "id": 714,
          "drug_id": 200,
          "indication_name": "Separation anxiety",
          "expected_effects": "42% improvement in separation anxiety behaviors within 1 week of treatment initiation\r\n72% improvement over 8 weeks of treatment",
          "common_combinations": "Behavioral modification training",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:44:53.000000Z",
          "updated_at": "2020-11-11T21:06:29.000000Z"
      },
      {
          "id": 715,
          "drug_id": 200,
          "indication_name": "Compulsive behavioral disorder",
          "expected_effects": "70% decrease in owner-reported severity of the compulsive disorder after 6 weeks of treatment\r\nTreated dogs are 8.7 times more likely to have an improvement in their compulsive behavior compared to placebo-treated dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:44:55.000000Z",
          "updated_at": "2020-11-11T21:06:29.000000Z"
      },
      {
          "id": 716,
          "drug_id": 200,
          "indication_name": "Acral lick dermatitis",
          "expected_effects": "Marked improvement in licking behavior and lesion severity according to owners (both parameters) and attending veterinarians (lesion score) when compared to placebo-treated dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:44:58.000000Z",
          "updated_at": "2020-11-11T21:06:29.000000Z"
      },
      {
          "id": 717,
          "drug_id": 200,
          "indication_name": "Scotty cramp - recurrent spasticity, kyphosis, and limb hypertonia induced by exercise",
          "expected_effects": "Ability to walk for 1 hour or more with few/no signs, where prior to treatment, signs were first apparent after 15 seconds of walking\r\nElimination of excitement-triggered signs\r\nSustained remission with ongoing treatment (>1 year), in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:45:01.000000Z",
          "updated_at": "2020-11-11T21:06:29.000000Z"
      },
      {
          "id": 718,
          "drug_id": 200,
          "indication_name": "Dominance aggression",
          "expected_effects": "Significant (e.g., 10-fold for growling behavior) decrease in aggressive responses by 4th week of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:45:03.000000Z",
          "updated_at": "2020-11-11T21:06:29.000000Z"
      },
      {
          "id": 719,
          "drug_id": 200,
          "indication_name": "Urine spraying/inappropriate elimination",
          "expected_effects": "Rapid improvement (mean of 67%) in urine marking after 2 weeks of treatment, then continued, gradual increase in efficacy over subsequent 14 weeks (>90% improvement) and further until 32 weeks of treatment (>95% improvement)\r\nImprovement may temporarily decline after 12-16 weeks of treatment but recovers and increases further thereafter\r\nUrine marking will return in almost all cases if the drug is withdrawn abruptly",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:45:05.000000Z",
          "updated_at": "2020-11-11T21:11:47.000000Z"
      },
      {
          "id": 720,
          "drug_id": 201,
          "indication_name": "Chronic sterile bronchial disease",
          "expected_effects": ">99% of dogs not previously treated with corticosteroids show improvement in clinical signs with fluticasone\r\nOf dogs who were receiving corticosteroids orally and who showed intolerable side-effects from the oral corticosteroids, 56% can show improvement in clinical signs by changing to fluticasone alone, and 45% can show improvement in clinical signs with a combination of fluticasone and lower-dosage oral corticosteroids",
          "common_combinations": "Obesity reduction if relevant;Reduction of environmental triggers for coughing in the home",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:45:08.000000Z",
          "updated_at": "2020-11-11T21:20:11.000000Z"
      },
      {
          "id": 721,
          "drug_id": 201,
          "indication_name": "Asthma",
          "expected_effects": "74, 82, and 81% reduction in airway eosinophilia with 44, 110, and 220 µg/CAT dosage q 12h, respectively",
          "common_combinations": "Beta-2 adrenergic receptor agonist (e.g., albuterol)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:45:11.000000Z",
          "updated_at": "2020-11-11T21:20:11.000000Z"
      },
      {
          "id": 722,
          "drug_id": 201,
          "indication_name": "Airway disease - mild, sterile",
          "expected_effects": "Significant reduction in bronchial responsiveness, airway inflammatory infiltrate, and radiographic evidence of bronchial disease\r\nPeak effect after 10-14 days of treatment (may be longer -- data from 2-week study treatment period)\r\nBenefits maintained for 1 week after end of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:45:13.000000Z",
          "updated_at": "2020-11-11T21:20:11.000000Z"
      },
      {
          "id": 723,
          "drug_id": 202,
          "indication_name": "Cleft palate prevention",
          "expected_effects": "Decrease in prevalence of cleft palate/cleft lip: 5% with supplementation, versus 11-16% in untreated controls; this is matched by 2.5-fold increases in circulating folate concentrations compared to untreated controls",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:45:15.000000Z",
          "updated_at": "2020-11-11T21:15:05.000000Z"
      },
      {
          "id": 724,
          "drug_id": 203,
          "indication_name": "Ethylene glycol intoxication",
          "expected_effects": "89% survival if treatment is begun before azotemia is present at admission (i.e., median 5.5 hours after ethylene glycol ingestion) vs. 5% survival if treatment is begun when azotemia is present at admission (median 14.5 hours after ingestion)",
          "common_combinations": "Fluid therapy and supportive care as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:45:18.000000Z",
          "updated_at": "2020-09-16T00:45:18.000000Z"
      },
      {
          "id": 725,
          "drug_id": 203,
          "indication_name": "Ethylene glycol intoxication",
          "expected_effects": "83% survival if treatment is initiated within 3 hours of ethylene glycol ingestion (vs. 33% with ethanol treatment)\n<1% survival if treatment (regardless of whether fomepizole or ethanol) is initiated 4 hours or more after ingestion\nAll data apply to ingestion of lethal dose of ethylene glycol (1.6-3.3 mL/kg)",
          "common_combinations": "Fluid therapy and supportive care as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:45:20.000000Z",
          "updated_at": "2020-09-16T00:45:20.000000Z"
      },
      {
          "id": 726,
          "drug_id": 204,
          "indication_name": "Thromboembolism prevention and treatment",
          "expected_effects": "Proof-of-concept study shows that healthy cats tolerate treatment and achieve anti-factor Xa plasma levels that are considered therapeutically effective in humans",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:45:23.000000Z",
          "updated_at": "2020-09-16T00:45:23.000000Z"
      },
      {
          "id": 727,
          "drug_id": 205,
          "indication_name": "Congestive heart failure (pulmonary edema) - Acute",
          "expected_effects": "Marked improvement in respiratory comfort, reduction in respiratory rate, and mentation changes from distressed to calm/comfortably asleep",
          "common_combinations": "Oxygen therapy, and sedation (e.g., butorphanol) if anxious",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:45:25.000000Z",
          "updated_at": "2020-09-16T00:45:25.000000Z"
      },
      {
          "id": 728,
          "drug_id": 205,
          "indication_name": "Congestive heart failure (pulmonary edema) - Chronic",
          "expected_effects": "Maintenance of few/no clinical signs, and notably resolution of dyspnea associated with original presentation in acute congestive heart failure",
          "common_combinations": "Angiotensin converting enzyme inhibitor (e.g., enalapril, benazepril, ramipril, imidapril), with or without a second diuretic (e.g., spironolactone or hydrochlorothiazide), with or without pimobendan, and with or without digoxin",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:45:28.000000Z",
          "updated_at": "2020-09-16T00:45:28.000000Z"
      },
      {
          "id": 729,
          "drug_id": 205,
          "indication_name": "Congestive heart failure (pulmonary edema) - Critical/refractory acute",
          "expected_effects": "Improvement in critical dyspnea",
          "common_combinations": "Oxygen therapy, and sedation (e.g., butorphanol) if anxious",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:45:31.000000Z",
          "updated_at": "2020-09-16T00:45:31.000000Z"
      },
      {
          "id": 730,
          "drug_id": 205,
          "indication_name": "Ascites - delay reaccumulation",
          "expected_effects": "Gradual mobilization of ascites over several days and/or indefinite slowing of ascites recurrence if primary cause cannot be eliminated",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:45:33.000000Z",
          "updated_at": "2020-11-11T21:22:30.000000Z"
      },
      {
          "id": 731,
          "drug_id": 205,
          "indication_name": "Hemorrhagic cystitis - risk reduction",
          "expected_effects": "Reduction of risk of hemorrhagic cystitis from 9% (no furosemide) to 1.2% (with furosemide)",
          "common_combinations": "With cyclophosphamide (for treatment of lymphoma)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:45:36.000000Z",
          "updated_at": "2020-09-16T00:45:36.000000Z"
      },
      {
          "id": 732,
          "drug_id": 205,
          "indication_name": "Hypercalcemia",
          "expected_effects": "Normalization of total calcium after 1 day of treatment (including pamidronate and calcitonin), and of ionized calcium after 4 days of treatment, in 1 case report",
          "common_combinations": "Pamidronate;Calcitonin",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:45:38.000000Z",
          "updated_at": "2020-09-16T00:45:38.000000Z"
      },
      {
          "id": 733,
          "drug_id": 205,
          "indication_name": "Acute kidney injury - reduction of severity",
          "expected_effects": "Renal vasodilation, high urine flow rate, and attenuation of decrease in GFR in experimental model\r\nClinical efficacy questioned",
          "common_combinations": "Dopamine 3 µg/kg/min IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:45:41.000000Z",
          "updated_at": "2020-11-11T21:22:30.000000Z"
      },
      {
          "id": 734,
          "drug_id": 205,
          "indication_name": "Craniectomy/durotomy (to decrease intracranial pressure)",
          "expected_effects": "No greater reduction in intracranial pressure when administered (with methylprednisolone sodium succinate and hyperventilation) during craniotomy/durotomy, compared to craniotomy/durotomy alone",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:45:43.000000Z",
          "updated_at": "2020-11-11T21:22:30.000000Z"
      },
      {
          "id": 735,
          "drug_id": 205,
          "indication_name": "Fluid retention (pulmonary edema, pleural effusion)",
          "expected_effects": "Diuresis begins 5 minutes after IV administration and peaks 15 minute after dosing in healthy cats",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:45:46.000000Z",
          "updated_at": "2020-11-11T21:22:31.000000Z"
      },
      {
          "id": 736,
          "drug_id": 205,
          "indication_name": "Ascites",
          "expected_effects": "A single IV dose of 3.1 mg/kg decreases circulating blood volume by 22% in cats (all fluid -- packed cell volume and total protein concentration rise accordingly)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:45:48.000000Z",
          "updated_at": "2020-11-11T21:22:31.000000Z"
      },
      {
          "id": 737,
          "drug_id": 205,
          "indication_name": "Congestive heart failure - iatrogenic",
          "expected_effects": "Marked improvement in respiratory comfort and reduction in respiratory rate, unless anuria",
          "common_combinations": "Oxygen therapy;Sedation (e.g., butorphanol) if anxious",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:45:51.000000Z",
          "updated_at": "2020-09-16T00:45:51.000000Z"
      },
      {
          "id": 738,
          "drug_id": 205,
          "indication_name": "Hypercalcemia",
          "expected_effects": "Normalization of total serum calcium concentration but variable long-term prognosis based on inciting kidney injury and response to treatment (ranging from euthanasia to survival >670 days)",
          "common_combinations": "IV fluids;Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:45:53.000000Z",
          "updated_at": "2020-09-16T00:45:53.000000Z"
      },
      {
          "id": 739,
          "drug_id": 205,
          "indication_name": "Anuric renal failure",
          "expected_effects": "Successful treatment restores urine production, but severe kidney injury may have caused irreversible lesions",
          "common_combinations": "Fluid therapy;Possibly mannitol",
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:45:55.000000Z",
          "updated_at": "2020-09-16T00:45:55.000000Z"
      },
      {
          "id": 740,
          "drug_id": 205,
          "indication_name": "Oral diuretic administration (e.g., control of pleural effusion, pulmonary edema)",
          "expected_effects": "Tolerance of medication\r\nMobilization of extravasated fluid and improvement in clinical signs\r\nDecreased efficacy/\"braking effect\" after 2 weeks of treatment",
          "common_combinations": "Angiotensin converting enzyme inhibitor (e.g., enalapril, benazepril, ramipril, imidapril)",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:45:58.000000Z",
          "updated_at": "2020-11-11T21:22:31.000000Z"
      },
      {
          "id": 741,
          "drug_id": 206,
          "indication_name": "Neuropathic pain",
          "expected_effects": "Responses vary from a dramatic, immediate (1-2 days) improvement in clinical signs as perceived by the owner to no perceptible benefit",
          "common_combinations": "Failure to respond to gabapentin has led to substitution with amitriptyline 1.1-1.4 mg/kg PO q 12h, with similarly variable results: some dogs failing to respond to gabapentin do so dramatically to amitriptyline, and vice-versa",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:46:01.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 742,
          "drug_id": 206,
          "indication_name": "Epilepsy - refractory",
          "expected_effects": "55% of dogs show a positive response (i.e., reduction of at least 50% in weekly number of seizures) after 3 months of treatment",
          "common_combinations": "Phenobarbital;Potassium bromide",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:46:03.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 743,
          "drug_id": 206,
          "indication_name": "Chiari-like malformation and syringomyelia of cavalier King Charles dogs",
          "expected_effects": "19% of dogs stop scratching during treatment, and there is no significant change regarding exercise intolerance, vocalization or facial rubbing\r\nEffects are not proven to be treatment related (vs. natural evolution of disease)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:46:06.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 744,
          "drug_id": 206,
          "indication_name": "Musculoskeletal pain or head trauma",
          "expected_effects": "Subjective decrease in manifestations of chronic pain",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:46:08.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 745,
          "drug_id": 207,
          "indication_name": "Osteosarcoma - pulmonary metastasis",
          "expected_effects": "85% of aerosol gemcitabine-treated dogs show significant (>25% of nodule) necrosis of metastases, compared to 31% of dogs not receiving aerosol gemcitabine",
          "common_combinations": "Carboplatin and/or adriamycin (standard osteosarcoma treatment)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:46:11.000000Z",
          "updated_at": "2020-09-16T00:46:11.000000Z"
      },
      {
          "id": 746,
          "drug_id": 207,
          "indication_name": "Hepatocellular carcinoma",
          "expected_effects": "Median survival time: 983 days, which does not represent an appreciable benefit compared to historical controls treated surgically (partial or complete resection)",
          "common_combinations": "Surgical debulking or removal",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:46:14.000000Z",
          "updated_at": "2020-09-16T00:46:14.000000Z"
      },
      {
          "id": 747,
          "drug_id": 207,
          "indication_name": "Transitional cell carcinoma (urinary bladder)",
          "expected_effects": "5% of dogs have a complete tumor response, 22% have a partial response, 51% have stable disease, and 22% have progressive disease\nMedian survival time: 230 days\nNone of these results is significantly different from historical controls treated with piroxicam alone",
          "common_combinations": "Piroxicam 0.3 mg/kg PO q 24h",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:46:16.000000Z",
          "updated_at": "2020-09-16T00:46:16.000000Z"
      },
      {
          "id": 748,
          "drug_id": 207,
          "indication_name": "Carcinoma - minimally effective if at all",
          "expected_effects": "13% positive response rate: individual complete or partial remissions with single cases of metastatic prostatic carcinoma, intestinal carcinoma, and tonsillar adenocarcinoma\n32% rate of palliation/stable disease for median of 72 days",
          "common_combinations": "Carboplatin 10 mg/kg IV on day 1 and q 21 days thereafter",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:46:18.000000Z",
          "updated_at": "2020-09-16T00:46:18.000000Z"
      },
      {
          "id": 749,
          "drug_id": 207,
          "indication_name": "Mammary carcinoma (malignant)",
          "expected_effects": "Dogs treated with mammary tumor surgery alone or surgery followed by gemcitabine have no difference in local tumor recurrence, rate of metastasis, or overall survival",
          "common_combinations": "Surgical excision of tumor",
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:46:21.000000Z",
          "updated_at": "2020-09-16T00:46:21.000000Z"
      },
      {
          "id": 750,
          "drug_id": 207,
          "indication_name": "Carcinomas",
          "expected_effects": "9% of cats have complete remission\n9% of cats have partial remission",
          "common_combinations": "Carboplatin 10 mg/kg slow IV, 2 weeks on, 1 week off",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:46:24.000000Z",
          "updated_at": "2020-09-16T00:46:24.000000Z"
      },
      {
          "id": 751,
          "drug_id": 207,
          "indication_name": "Squamous cell carcinoma (oral)",
          "expected_effects": "25% of cats have complete response and 50% have partial response to this combined low-dose gemcitabine - megavoltage radiation protocol\nDuration of remission: 11-85 days (median: 42)\nSurvival time: 11-234 days (median: 111.5)",
          "common_combinations": "Megavoltage 6 Gy fraction for 6 treatments, every Tuesday and Friday for 3 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:46:26.000000Z",
          "updated_at": "2020-09-16T00:46:26.000000Z"
      },
      {
          "id": 752,
          "drug_id": 208,
          "indication_name": "Gram-negative sepsis (e.g., parvoviral enteritis)",
          "expected_effects": "93% survival when part of comprehensive treatment protocol",
          "common_combinations": "IV fluid therapy with potassium and dextrose supplementation as needed;Amoxicillin;Metoclopramide;IV colloid as needed;Fenbendazole",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:46:29.000000Z",
          "updated_at": "2020-09-16T00:46:29.000000Z"
      },
      {
          "id": 753,
          "drug_id": 208,
          "indication_name": "Methicillin-resistant staphylococcal infection (e.g., post-operative discospondylitis)",
          "expected_effects": "Both successful resolution of signs and failure to respond to treatment have been recorded in dogs with this protocol",
          "common_combinations": "Trimethoprim-sulfadiazine;Stability of radiographic lesions after 3 months of trimethoprim-sulfa treatment has led to appropriate discontinuation of trimethoprim-sulfa, but if recrudescence occurs, initiation of long-term treatment with chloramphenicol has been successful",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:46:31.000000Z",
          "updated_at": "2020-09-16T00:46:31.000000Z"
      },
      {
          "id": 754,
          "drug_id": 208,
          "indication_name": "Long-term treatment of persistent infection (e.g., Brucella canis-associated panophthalmitis)",
          "expected_effects": "Resolution of ocular clinical signs with long-term treatment (but latent infection inevitably persists with brucellosis)",
          "common_combinations": "Ciprofloxacin;Doxycycline;Rifampin",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:46:34.000000Z",
          "updated_at": "2020-09-16T00:46:34.000000Z"
      },
      {
          "id": 755,
          "drug_id": 208,
          "indication_name": "E. coli endotoxemia",
          "expected_effects": "Minimal nephrotoxicosis\nTissue concentrations consistent with antibacterial effects",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:46:36.000000Z",
          "updated_at": "2020-09-16T00:46:36.000000Z"
      },
      {
          "id": 756,
          "drug_id": 209,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "14% of cats do respond and do not have hypoglycemia\n12% are transient diabetics (do respond but also develop hypoglycemia, requiring discontinuation of glipizide)\n56% of diabetic cats fail to respond and must be changed to insulin treatment\n12% appear to respond clinically (owner opinion) but remain hyperglycemic, and owners refuse to (or cannot) administer insulin\n6% respond initially but efficacy of treatment is lost 16-48 weeks after starting",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:46:38.000000Z",
          "updated_at": "2020-09-16T00:46:38.000000Z"
      },
      {
          "id": 757,
          "drug_id": 209,
          "indication_name": "Diabetes mellitus - transdermal treatment",
          "expected_effects": "N/A",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:46:41.000000Z",
          "updated_at": "2020-09-16T00:46:41.000000Z"
      },
      {
          "id": 758,
          "drug_id": 210,
          "indication_name": "Hypoglycemia",
          "expected_effects": "Median blood glucose (BG) concentration at end of glucagon infusion = 89 mg/dL [4.9 mmol/L] (range: 70-117 mg/dL [3.9-6.5 mmol/L]), which is significantly higher than pre-treatment BG at admission (median = 30 mg/dL [1.7 mg/dL]), after a dextrose bolus (50.5 mg/dL [2.8 mmol/L]), and during IV dextrose CRI (25 mg/dL [1.4 mmol/L]).",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:46:44.000000Z",
          "updated_at": "2020-11-12T19:25:52.000000Z"
      },
      {
          "id": 759,
          "drug_id": 210,
          "indication_name": "Hypoglycemia",
          "expected_effects": "Blood glucose concentration doubles within 10 minutes of administration to healthy dogs and is slightly higher (2.2 times baseline) by 20 minutes after administration, both due to marked (4-fold) elevation in serum insulin concentration within 10 minutes of administration",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:46:46.000000Z",
          "updated_at": "2020-11-12T19:25:52.000000Z"
      },
      {
          "id": 760,
          "drug_id": 210,
          "indication_name": "Hypoglycemia",
          "expected_effects": "Blood glucose concentration doubles within 10 minutes of administration to healthy dogs and is slightly higher (2.2 times baseline) by 20 minutes after administration, both due to marked (4-fold) elevation in serum insulin concentration within 10 minutes of administration",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:46:49.000000Z",
          "updated_at": "2020-11-12T19:25:52.000000Z"
      },
      {
          "id": 761,
          "drug_id": 210,
          "indication_name": "Assessment of beta-cell function in dogs with chronic pancreatitis",
          "expected_effects": "50% of dogs with chronic pancreatitis have a normal insulin secretory response to glucagon, and 50% have markedly depressed response\r\nResults suggest that chronic pancreatitis creates a prediabetic state in some dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:46:51.000000Z",
          "updated_at": "2020-11-12T19:25:52.000000Z"
      },
      {
          "id": 762,
          "drug_id": 210,
          "indication_name": "Calcium-channel blocker overdose",
          "expected_effects": "Substantial improvement in diltiazem overdose-induced second- and third-degree atrioventricular block and restoration of normal sinus rhythm in many dogs, but no effect on hypotension",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:46:54.000000Z",
          "updated_at": "2020-11-12T19:25:52.000000Z"
      },
      {
          "id": 763,
          "drug_id": 210,
          "indication_name": "Diabetes mellitus classification - type I vs. type II",
          "expected_effects": "In response to glucagon injection, serum insulin in lean cats increases (8.2, 17.6, 27.7, 44.2, 26.6, 16.8, 13.8 µU/mL at baseline, 5, 10, 15, 30, 45, and 60 minutes respectively)\r\nSerum insulin increases are also seen in cats that are obese but otherwise healthy, except for insulin levels at baseline and 5 minute post-glucagon injection (15.2 and 30.1 µU/mL, respectively), which are significantly higher than in lean cats\r\n77% of client-owned diabetic cats have no significant response to glucagon (all post-glucagon insulin levels < 14.7 µU/mL), which defines type I diabetes mellitus, whereas 23% of client-owned diabetic cats have an increase (> 14.7 µU/mL) in serum insulin after glucagon injection, indicating insulin antagonism, not absence of insulin production reserve, as the cause of diabetes mellitus (i.e., it is type II)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:46:57.000000Z",
          "updated_at": "2020-11-12T19:25:52.000000Z"
      },
      {
          "id": 764,
          "drug_id": 211,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Well tolerated\r\nImmediate therapeutic benefit (improvement in lameness) is inferior to immediate benefit seen with meloxicam, carprofen",
          "common_combinations": "Chondroitin sulfate;Manganese ascorbate (Cosequin product) or avocado/soybean unsaponifiables (Dasuquin product)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:46:59.000000Z",
          "updated_at": "2020-11-12T20:39:03.000000Z"
      },
      {
          "id": 765,
          "drug_id": 212,
          "indication_name": "Bradycardia (with or without arterial hypotension) during general anesthesia",
          "expected_effects": "Baseline heart rate (52-60 beats/minute) increases to 76-123 beats/minute within 5 min of administration\nTransient tachycardia (≥ 150 beats/minute) occurs in 7.5% of dogs\nConcomitant with increase in heart rate, arterial blood pressure increases from 107/57/73 mmHg (systolic/diastolic/mean) at baseline to 122/73/90 mmHg",
          "common_combinations": "Correction of inciting cause (e.g., decrease plane of anesthesia if too deep)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:01.000000Z",
          "updated_at": "2020-09-16T00:47:01.000000Z"
      },
      {
          "id": 766,
          "drug_id": 212,
          "indication_name": "Premedication for general anesthesia",
          "expected_effects": "Well tolerated (no adverse effects related to glycopyrrolate)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:47:04.000000Z",
          "updated_at": "2020-09-16T00:47:04.000000Z"
      },
      {
          "id": 767,
          "drug_id": 212,
          "indication_name": "Gastric motility reduction",
          "expected_effects": "Reduction in gastric antral for 30-120 min (dosage-related)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:47:06.000000Z",
          "updated_at": "2020-09-16T00:47:06.000000Z"
      },
      {
          "id": 768,
          "drug_id": 212,
          "indication_name": "Premedication for sedation/general anesthesia",
          "expected_effects": "Reduction in degree of bradycardia caused by sedative/anesthetic",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:47:08.000000Z",
          "updated_at": "2020-09-16T00:47:08.000000Z"
      },
      {
          "id": 769,
          "drug_id": 213,
          "indication_name": "Hip dysplasia",
          "expected_effects": "Lameness, range of motion, and joint pain may be mildly improved\nBenefit appears greater with 4.4 mg/kg dosage than either 2.2 mg/kg dosage or 8.8 mg/kg dosage ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:11.000000Z",
          "updated_at": "2020-09-16T00:47:11.000000Z"
      },
      {
          "id": 770,
          "drug_id": 213,
          "indication_name": "Osteoarthritis",
          "expected_effects": "75% of dogs demonstrate improvement in lameness, with concurrent improvement in biomarkers of cartilage health",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:47:13.000000Z",
          "updated_at": "2020-09-16T00:47:13.000000Z"
      },
      {
          "id": 771,
          "drug_id": 214,
          "indication_name": "Determination of neuter status (female dog)",
          "expected_effects": "120 minutes after GnRH administration, plasma estradiol significantly lower in spayed bitches (14 pmol/L, range: 8-19 pmol/L) than in intact bitches (35 pmol/L, range: 24-55 pmol/L)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:16.000000Z",
          "updated_at": "2020-09-16T00:47:16.000000Z"
      },
      {
          "id": 772,
          "drug_id": 214,
          "indication_name": "Determination of neuter status (male dog)",
          "expected_effects": "60 minutes after GnRH administration, plasma testosterone is markedly lower in castrated dogs (0.05 nmol/L, range: 0.05-0.07 nmol/L) than in than in the same dogs before they are castrated (26 nmol/L, range: 16-45 nmol/L). Despite those findings, GnRH stimulation is unnecessary because baseline/resting plasma testosterone levels are also markedly different (baseline intact: 17 nmol/L [range: 7-35 nmol/L], while the same dogs at baseline castrated: 0.06 nmol/L [range: 0.05-0.07 nmol/L])",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:47:18.000000Z",
          "updated_at": "2020-09-16T00:47:18.000000Z"
      },
      {
          "id": 773,
          "drug_id": 214,
          "indication_name": "Identification of functional testicular tissue in intersex conditions",
          "expected_effects": "Baseline testosterone level 2.4 ng/mL and post-GnRH testosterone level 3.31 ng/mL, supporting existence of functional testicular tissue in female (intersex) dog -- testes confirmed at laparotomy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:47:22.000000Z",
          "updated_at": "2020-09-16T00:47:22.000000Z"
      },
      {
          "id": 774,
          "drug_id": 214,
          "indication_name": "Male dog contraception",
          "expected_effects": "Undetectable plasma luteinizing hormone (21 days after implant placement) and testosterone (27 days), decrease in testicular volume by 65% (14 weeks), inability to obtain ejaculate (6 weeks)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:47:24.000000Z",
          "updated_at": "2020-09-16T00:47:24.000000Z"
      },
      {
          "id": 775,
          "drug_id": 214,
          "indication_name": "Ovarian remnant syndrome",
          "expected_effects": "At baseline, plasma LH is higher in spayed bitches (20.2 +/- 3.6 µg/L) than in bitches with remnant ovarian tissue (4.1 +/- 0.7 µg/L) or intact anestrous bitches (0.64 +/- 0.04 µg/L)\n10 minutes after IV GnRH administration, bitches with ovarian remnant syndrome have only a slight increase in LH concentration (amount of increase: 15.5 +/- 1.9 µg/L) compared to spayed bitches (43.6 +/- 10.5 µg/L) or intact anestrous bitches (57.3 +/- 11.1 µg/L). As a result, pre- and post-GnRH measurement of plasma LH levels allows for differentiation of ovarian remnant syndrome from intact anestrus and from complete ovariohysterectomy.",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:47:27.000000Z",
          "updated_at": "2020-09-16T00:47:27.000000Z"
      },
      {
          "id": 776,
          "drug_id": 214,
          "indication_name": "Urethral sphincter mechanism incompetence post-ovariohysterctomy",
          "expected_effects": "Episodes of urinary incontinence decrease by 71% with treatment (compared to 28% with placebo, and 92% with phenylpropanolamine), making gonadotropin-releasing hormone a suitable second-line of treatment after phenylpropanolamine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:47:29.000000Z",
          "updated_at": "2020-09-16T00:47:29.000000Z"
      },
      {
          "id": 777,
          "drug_id": 214,
          "indication_name": "Cryptorchidism treatment",
          "expected_effects": "Azoospermia prior to, and 2 months after, surgery and GnRH treatment\nNormal sperm, and normal litter sired, 7 months and 8 months after combined surgical and medical (GnRH) treatment, respectively",
          "common_combinations": "Surgical correction (orchiopexy)",
          "is_contraindicated": 1,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:47:31.000000Z",
          "updated_at": "2020-09-16T00:47:31.000000Z"
      },
      {
          "id": 778,
          "drug_id": 214,
          "indication_name": "Haircoat change following ovariohysterectomy",
          "expected_effects": "In dogs with post-ovariohysterectomy haircoat changes (typically, development of a wooly, fluffy, non-sleek haircoat), 79% develop a glossier, more normal coat, often limited to the dorsal midline of the torso, 8-16 weeks after GnRH injection\nRegression occurs shortly after results are seen (and therefore, effects of repeated GnRH treatment are under investigation)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:47:34.000000Z",
          "updated_at": "2020-09-16T00:47:34.000000Z"
      },
      {
          "id": 779,
          "drug_id": 214,
          "indication_name": "Induction of fertile estrus in bitches",
          "expected_effects": "Onset of estrus in all bitches, 16 (normal cycles, and GnRH given early, i.e., 120 days earlier than next anticipated estrus) to 23 (prolonged anestrus, GnRH given when normal estrus should have occurred) days after start of GnRH treatment\nBitches bred after onset of estrus have conception rate of 88% and litter size of 4.5 +/- 0.75 puppies",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:47:36.000000Z",
          "updated_at": "2020-09-16T00:47:36.000000Z"
      },
      {
          "id": 780,
          "drug_id": 214,
          "indication_name": "Estrus suppression and contraception in queens",
          "expected_effects": "After implantation, an initial rise in estrogen occurs in 95% of cats (accompanied by behavioral estrus in 14% of cats), but resultant matings are unsuccessful (<1% conception rate) and subsequent episodes of estrus are suppressed for the duration of the impant (e.g., 18 months in 1 study)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:47:38.000000Z",
          "updated_at": "2020-09-16T00:47:38.000000Z"
      },
      {
          "id": 781,
          "drug_id": 215,
          "indication_name": "Cisplatin-induced emesis",
          "expected_effects": ">99% reduction in retching\n75% reduction in vomiting",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:41.000000Z",
          "updated_at": "2020-09-16T00:47:41.000000Z"
      },
      {
          "id": 782,
          "drug_id": 216,
          "indication_name": "Dermatophytosis - Microsporum persicolor",
          "expected_effects": ">99% clinical cure",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:44.000000Z",
          "updated_at": "2020-11-12T20:41:04.000000Z"
      },
      {
          "id": 783,
          "drug_id": 216,
          "indication_name": "\"Dermatophytosis - Microsporum canis",
          "expected_effects": "57% cure rate with griseofulvin only\r\n>99% cure rate when griseofulvin is preceded by lufenuron pretreatment (similar to enilconazole rinse after lufenuron pretreatment [>99% cure rate]\r\nLufenuron therapy alone: 54% cure rate\r\nEnilconazole rinse alone: 20% cure rate)",
          "common_combinations": "Lufenuron pre-treatment (100 mg/kg PO q 15 days for 60 days);With or without enilconazole rinse (0.2% topical rinse q 1 week for 4 weeks)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:47:46.000000Z",
          "updated_at": "2020-11-12T20:41:04.000000Z"
      },
      {
          "id": 784,
          "drug_id": 217,
          "indication_name": "Anemia requiring transfusion - babesiosis",
          "expected_effects": "Similar overall improvement to packed red blood cell transfusion (re. blood gas, acid-base status, blood pressure), although patients receiving packed cells tended to have more rapid normalization of demeanor and appetite",
          "common_combinations": "Treatment of underlying cause",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:49.000000Z",
          "updated_at": "2020-09-16T00:47:49.000000Z"
      },
      {
          "id": 785,
          "drug_id": 217,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "Improved oxygen carrying-capacity has not translated to greater survival in dogs with immune-mediated hemolytic anemia",
          "common_combinations": "Treatment of inciting cause (e.g., predniso(lo)ne, other immunosuppressants, and whole blood/blood product transfusions for immune-mediated hemolytic anemia)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:47:51.000000Z",
          "updated_at": "2020-09-16T00:47:51.000000Z"
      },
      {
          "id": 786,
          "drug_id": 217,
          "indication_name": "Acute blood loss/hemorrhagic shock",
          "expected_effects": "Normalization of cardiac output, mesenteric arterial blood flow, and acid-base variables, but systemic hypertension and lower-than-normal arterial oxygen content and systemic oxygen delivery",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:47:54.000000Z",
          "updated_at": "2020-09-16T00:47:54.000000Z"
      },
      {
          "id": 787,
          "drug_id": 217,
          "indication_name": "Anemia (all causes) - severe",
          "expected_effects": "86% of treated cats improve in at least 1 parameter (blood hemoglobin concentration, body temperature [if hypothermic initially], systemic blood pressure [if hypotensive initially], etc.)",
          "common_combinations": "With or without concurrent packed red blood cell transfusion",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:47:57.000000Z",
          "updated_at": "2020-09-16T00:47:57.000000Z"
      },
      {
          "id": 788,
          "drug_id": 218,
          "indication_name": "Thromboembolism prophylaxis in immune-mediated hemolytic anemia - fixed dosage",
          "expected_effects": "During the initial 40 hours of treatment, only 44% of dogs show adequate anticoagulation at this dosage (based on anti-factor-Xa activity ≥ 0.35 U/mL) and few dogs (<5%) show signs of hemorrhage\r\n83% survival rate to discharge\r\n61% survival rate at 1 year\r\n50% incidence of thrombosis in nonsurvivors",
          "common_combinations": "Aspirin therapy and/or other orally-administered antithrombotics;Immunosuppression (e.g., corticosteroids, cyclosporine, mycophenolate)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:47:59.000000Z",
          "updated_at": "2020-11-12T20:50:11.000000Z"
      },
      {
          "id": 789,
          "drug_id": 218,
          "indication_name": "Thromboembolism prophylaxis in immune-mediated hemolytic anemia - titrated",
          "expected_effects": "Significantly improved survival rate when heparin dosage is adjusted based on circulating anti-factor-Xa level (88% survival of IMHA dogs at 180 days post-diagnosis) compared to when heparin is given at a fixed dosage of 150 IU/kg (14% survival of IMHA dogs at 180 days post-diagnosis)",
          "common_combinations": "Immunosuppression (e.g., corticosteroids, cyclosporine, mycophenolate)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:48:01.000000Z",
          "updated_at": "2020-09-16T00:48:01.000000Z"
      },
      {
          "id": 790,
          "drug_id": 218,
          "indication_name": "Thromboembolism prophylaxis in hypercoagulable states",
          "expected_effects": "High-fixed-dosage heparin (100 IU/kg bolus, then 37.5 mg/kg/h IV CRI) produces transiently effective anticoagulation (based on anti-factor-Xa activity) in 83% of hypercoagulable dogs, but also is associated with hemorrhage in 66% of such dogs\r\nLow-fixed-dosage heparin (12.5 IU/kg/h IV CRI) is safe (no hemorrhage noted) but is ineffective (no dog achieves anti-factor-Xa activity that would be expected to provide anticoagulation)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:48:04.000000Z",
          "updated_at": "2020-11-12T20:50:11.000000Z"
      },
      {
          "id": 791,
          "drug_id": 218,
          "indication_name": "Pyothorax",
          "expected_effects": "Inclusion of heparin in thoracotomy lavage solution confers significantly (P=0.025) better prognosis for short- and long-term survival",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:48:06.000000Z",
          "updated_at": "2020-11-12T20:50:11.000000Z"
      },
      {
          "id": 792,
          "drug_id": 218,
          "indication_name": "Aortic thromboembolism",
          "expected_effects": "45% survival to discharge",
          "common_combinations": "Aspirin therapy 40 mg/CAT PO q 72h (low dosage) or 5 mg/CAT PO q 72h (ultralow dose)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:48:09.000000Z",
          "updated_at": "2020-09-16T00:48:09.000000Z"
      },
      {
          "id": 793,
          "drug_id": 218,
          "indication_name": "Disseminated intravascular coagulation",
          "expected_effects": "33% survival",
          "common_combinations": "Treatment of the underlying cause;Plasma transfusion and additional supportive care as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:48:11.000000Z",
          "updated_at": "2020-09-16T00:48:11.000000Z"
      },
      {
          "id": 794,
          "drug_id": 219,
          "indication_name": "Thromboembolism prophylaxis in hypercoagulable states",
          "expected_effects": "At this dosage and interval, anti-factor-Xa activity (a measure of anticoagulation) does not reach therapeutic levels, i.e., there is insufficient anticoagulation, but no instances of hemorrhage (excessive anticoagulation) are noted either",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:48:18.000000Z",
          "updated_at": "2020-09-16T00:48:18.000000Z"
      },
      {
          "id": 795,
          "drug_id": 219,
          "indication_name": "Thromboembolism prophylaxis in disseminated intravascular coagulation",
          "expected_effects": "The low dosage produces anti-factor-Xa activity levels = 0.27-0.36 IU/mL (subtherapeutic) whereas the higher dosage produces anti-factor-Xa activity levels = 0.62-0.9 IU/mL (therapeutic, but safety/bleeding risk is unknown)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:48:21.000000Z",
          "updated_at": "2020-09-16T00:48:21.000000Z"
      },
      {
          "id": 796,
          "drug_id": 219,
          "indication_name": "Thromboembolism prophylaxis - aortic thromboembolism associated with cardiomyopathy",
          "expected_effects": "17% occurrence of suspected or confirmed thromboembolism during treatment\n9-11% occurrence of hemorrhage during treatment (at home)",
          "common_combinations": "Aspirin 0.2-5.8 mg/kg PO q 2-3.5 days",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:48:23.000000Z",
          "updated_at": "2020-09-16T00:48:23.000000Z"
      },
      {
          "id": 797,
          "drug_id": 220,
          "indication_name": "Infectious respiratory illness causing cough",
          "expected_effects": "Reduction or elimination of bacterial infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:48:26.000000Z",
          "updated_at": "2020-09-16T00:48:26.000000Z"
      },
      {
          "id": 798,
          "drug_id": 221,
          "indication_name": "Systemic hypertension - when adverse reaction to amlodipine",
          "expected_effects": "Reduction of in-clinic arterial blood pressure from >300 mmHg systolic to 120 mmHg systolic\r\nResolution of amlodipine-associated gingival hyperplasia",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:48:28.000000Z",
          "updated_at": "2020-11-12T20:59:50.000000Z"
      },
      {
          "id": 799,
          "drug_id": 221,
          "indication_name": "Congestive heart failure",
          "expected_effects": "After 6 months of treatment, hydralazine + furosemide is associated with less cardiac enlargement, less hyponatremia, and less urinary excretion of potassium and sodium than enalapril + furosemide, but greater circulating angiotensin II and aldosterone levels, higher heart rate, more weight loss, and greater azotemia.",
          "common_combinations": "Furosemide;ACE inhibitor (e.g., enalapril)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:48:31.000000Z",
          "updated_at": "2020-09-16T00:48:31.000000Z"
      },
      {
          "id": 800,
          "drug_id": 221,
          "indication_name": "Mitral regurgitation",
          "expected_effects": "Decrease in mitral regurgitant fraction (extracardiac and long-term effects unknown)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:48:33.000000Z",
          "updated_at": "2020-11-12T20:59:50.000000Z"
      },
      {
          "id": 801,
          "drug_id": 221,
          "indication_name": "Pulmonary hypertension associated with heartworm disease",
          "expected_effects": "57% of treated dogs respond (i.e., have ≥ 20% reduction in pulmonary arterial resistance without increase in mean pulmonary arterial pressure or > 10% increase in heart rate)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:48:35.000000Z",
          "updated_at": "2020-11-12T20:59:50.000000Z"
      },
      {
          "id": 802,
          "drug_id": 221,
          "indication_name": "Selective redistribution of blood flow to enhance selective heating of focal tumors",
          "expected_effects": "Tumor blood flow changes from 39% that of surrounding muscle (no hydralazine) to 6% (with hydralazine), favoring thermal treatment of tumor with fewer effects on surrounding muscle",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:48:38.000000Z",
          "updated_at": "2020-11-12T20:59:50.000000Z"
      },
      {
          "id": 803,
          "drug_id": 221,
          "indication_name": "Hypertension (acute, immediately postoperative after renal transplantation)",
          "expected_effects": "Reduction in systolic blood pressure in 95% of severely hypertensive cats postoperatively to <170 mmHg within 15 min\r\n5% of cats become hypotensive, and 5% do not respond to hydralazine treatment\r\nHydralazine-based control of hypertension significantly reduces incidence of seizures and other post-operative neurologic complications",
          "common_combinations": "Pre- and post-op: cyclosporine, prednisolone (IV) for immunosuppression, beta-blockade (propranolol)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:48:40.000000Z",
          "updated_at": "2020-11-12T20:59:50.000000Z"
      },
      {
          "id": 804,
          "drug_id": 222,
          "indication_name": "Calcium oxalate urolithiasis - prevention",
          "expected_effects": "45% reduction in calcium excretion in urine, but a 30% increase in urine production may require dosage adjustment or be a limiting factor for some clients/households",
          "common_combinations": "Synergistic benefit (re. calciuria) when combined with low-calcium, low-protein balanced diet",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:48:43.000000Z",
          "updated_at": "2020-09-16T00:48:43.000000Z"
      },
      {
          "id": 805,
          "drug_id": 222,
          "indication_name": "Diabetes insipidus - nephrogenic",
          "expected_effects": "5-fold reduction in water intake (from 800 to 980 mL/kg/day without treatment to 170 to 230 mL/kg/day with treatment) and concomitant improvement in polyuric signs, lasting at least 2 years",
          "common_combinations": "Low-sodium diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:48:45.000000Z",
          "updated_at": "2020-09-16T00:48:45.000000Z"
      },
      {
          "id": 806,
          "drug_id": 222,
          "indication_name": "Refractory congestive heart failure",
          "expected_effects": "Reduction in rate of reaccumulation of ascites, pleural effusion, and/or pulmonary edema",
          "common_combinations": "Furosemide;ACE inhibitor;With or without spironolactone;With or without pimobendan;With or without low-salt diet if palatable;With or without digoxin;With or without hydralazine",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:48:47.000000Z",
          "updated_at": "2020-09-16T00:48:47.000000Z"
      },
      {
          "id": 807,
          "drug_id": 222,
          "indication_name": "Calcium oxalate urolithiasis - prevention",
          "expected_effects": "Significant reduction in urinary saturation of calcium oxalate, theoretically beneficial to reducing risk of calcium oxalate urolithiasis occurrence/recurrence",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:48:50.000000Z",
          "updated_at": "2020-09-16T00:48:50.000000Z"
      },
      {
          "id": 808,
          "drug_id": 222,
          "indication_name": "Diabetes insipidus",
          "expected_effects": "Reduction of spontaneous, unrestricted water intake from 900-1200 mL/day (no treatment) to 500 mL/day, and cessation of urinary incontinence",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:48:52.000000Z",
          "updated_at": "2020-09-16T00:48:52.000000Z"
      },
      {
          "id": 809,
          "drug_id": 223,
          "indication_name": "Collapsing trachea",
          "expected_effects": "Nonspecific cough reduction",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:48:54.000000Z",
          "updated_at": "2020-09-16T00:48:54.000000Z"
      },
      {
          "id": 810,
          "drug_id": 224,
          "indication_name": "Hypoadrenocorticism - acute",
          "expected_effects": "Rapid (hours) improvement in demeanor and appetite",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:48:57.000000Z",
          "updated_at": "2020-09-16T00:48:57.000000Z"
      },
      {
          "id": 811,
          "drug_id": 224,
          "indication_name": "Glucocorticoid replacement - acute",
          "expected_effects": "Serum cortisol concentrations at dosage of 0.65 mg/kg/h mimic those of normal healthy dogs, but dosage of 0.32 mg/kg/h produces serum cortisol concentrations that are too low",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:48:59.000000Z",
          "updated_at": "2020-09-16T00:48:59.000000Z"
      },
      {
          "id": 812,
          "drug_id": 224,
          "indication_name": "Post-adrenalectomy - immediate glucocorticoid replacement",
          "expected_effects": "Unremarkable recovery and discharge in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:49:02.000000Z",
          "updated_at": "2020-09-16T00:49:02.000000Z"
      },
      {
          "id": 813,
          "drug_id": 224,
          "indication_name": "Anaphylaxis (e.g., to snake antivenom)",
          "expected_effects": "Resolution of acute respiratory signs (caused by anaphylaxis) within 3 hours following treatment",
          "common_combinations": "Furosemide 2 mg/kg IV once (pulmonary edema)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:49:04.000000Z",
          "updated_at": "2020-09-16T00:49:04.000000Z"
      },
      {
          "id": 814,
          "drug_id": 225,
          "indication_name": "Induction of vomiting after ingestion of toxic substance",
          "expected_effects": "Emesis in 90% of dogs within 14.5 minutes (average) of single-dose administration, and yielding recovery of 48% of the ingested material (vs. apomorphine, which induces emesis in 94% of dogs, within 18.6 minutes [average], yielding 52% of ingested material)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:49:06.000000Z",
          "updated_at": "2020-09-16T00:49:06.000000Z"
      },
      {
          "id": 815,
          "drug_id": 226,
          "indication_name": "Analgesia - post-op (e.g., immediately after orthopedic surgery)",
          "expected_effects": "Manifestations of pain (vocalization, agitation, heart rate, blood pressure, etc.) maintained at or below 3.5 on scales of 1-10 and 1-16 for 24h post-op, with 1 being absence of signs of pain and 10-16 being extreme pain",
          "common_combinations": "Can be supplemented with epidural, local (intra-articular) adjunctive analgesia",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:49:09.000000Z",
          "updated_at": "2020-09-16T00:49:09.000000Z"
      },
      {
          "id": 816,
          "drug_id": 226,
          "indication_name": "Premedication",
          "expected_effects": "Can be expected to reduce need for inhalant anesthetic intra-op",
          "common_combinations": "Acepromazine 0.05 mg/kg IM as part of premedication",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:49:12.000000Z",
          "updated_at": "2020-09-16T00:49:12.000000Z"
      },
      {
          "id": 817,
          "drug_id": 226,
          "indication_name": "Sedation/immobilization",
          "expected_effects": "No appreciable anti-nociceptive effect (compared to saline placebo) during 60 minutes following administration",
          "common_combinations": "Addition of acepromazine provides sedative effects, but these are not significantly different from the sedative effects seen with acepromazine alone",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:49:14.000000Z",
          "updated_at": "2020-09-16T00:49:14.000000Z"
      },
      {
          "id": 818,
          "drug_id": 226,
          "indication_name": "General anesthesia protocol (injectable) - for castration",
          "expected_effects": "Sedation 1-2 minutes after injection\nLateral recumbency 4-6 minutes after injection\nIntubation possible in 40% of cats with IM protocol alone (10 minutes after IM injections)\nSurgical procedure completed successfully and with minimal/no evidence of pain in >99% of cats",
          "common_combinations": "Dexmedetomidine (25 mg/kg IM once) and ketamine (3 mg/kg IM once) administered at same time as hydromorphone",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:49:17.000000Z",
          "updated_at": "2020-09-16T00:49:17.000000Z"
      },
      {
          "id": 819,
          "drug_id": 226,
          "indication_name": "Analgesia",
          "expected_effects": "Systemic analgesia lasting from 35-80 minutes (0.05 mg/kg IV dosage) or 5-200 minutes (0.1 mg/kg IV dosage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:49:19.000000Z",
          "updated_at": "2020-09-16T00:49:19.000000Z"
      },
      {
          "id": 820,
          "drug_id": 226,
          "indication_name": "Analgesia",
          "expected_effects": "Evidence of analgesia up to and including the forelimbs for 180-300 minutes after administration\nNo hyperthermia (vs. systemically-administered hydromorphone in cats)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:49:22.000000Z",
          "updated_at": "2020-09-16T00:49:22.000000Z"
      },
      {
          "id": 821,
          "drug_id": 227,
          "indication_name": "Hypoalbuminemia",
          "expected_effects": "Immediate 25% increase in colloid oncotic pressure associated with treatment, but this effect drops to 10-15% above baseline within 12 hours after administration (no longer significant)\nRepeated doses are needed for a sustained increase in colloid oncotic pressure",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:49:24.000000Z",
          "updated_at": "2020-09-16T00:49:24.000000Z"
      },
      {
          "id": 822,
          "drug_id": 227,
          "indication_name": "Hypotensive hemorrhagic shock - rapid bolus",
          "expected_effects": "Normotension achieved quickly (6 +/- 3 minutes, compared to 19 +/- 3 minutes with IV lactated Ringer's solution) and with a volume of hydroxyethyl starch that is only 1.1 times the volume of blood lost during hemorrhagic/hypotensive shock (vs. lactated Ringer's solution, which must be administered at a dose that is 4.4 times the volume of blood lost in order to achieve the same effect of normotension)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:49:26.000000Z",
          "updated_at": "2020-09-16T00:49:26.000000Z"
      },
      {
          "id": 823,
          "drug_id": 227,
          "indication_name": "Glaucoma - for lowering intraocular pressure rapidly",
          "expected_effects": "Decrease in intraocular pressure of 4-19 mmHg in 86% of dogs, 15-30 minutes after administration (magnitude is similar to effects of mannitol treatment, but mannitol effects occur in 15 minutes or less)\n14% of dogs experience an increase in intraocular pressure, which may be marked (18 mmHg)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:49:29.000000Z",
          "updated_at": "2020-09-16T00:49:29.000000Z"
      },
      {
          "id": 824,
          "drug_id": 227,
          "indication_name": "Hypotension during cardiopulmonary arrest",
          "expected_effects": "Recovery from cardiac arrest caused by 20-fold overdose of ketamine in 1 case report",
          "common_combinations": "Lactated Ringer's solution 25 mL/kg IV and vasopressors (e.g., dopamine) as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:49:32.000000Z",
          "updated_at": "2020-09-16T00:49:32.000000Z"
      },
      {
          "id": 825,
          "drug_id": 228,
          "indication_name": "Erythrocytosis/polycythemia (e.g., due to right-to-left shunting cardiac defects)",
          "expected_effects": "Subjective improvement in clinical signs and reduction in packed cell volume",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:49:34.000000Z",
          "updated_at": "2020-09-16T00:49:34.000000Z"
      },
      {
          "id": 826,
          "drug_id": 228,
          "indication_name": "Mast cell tumor",
          "expected_effects": "28% rate of response, including 4% complete response (full resolution lasting 256-448 days) and 23% partial response (median duration: 46 days, range: 28-189 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:49:37.000000Z",
          "updated_at": "2020-09-16T00:49:37.000000Z"
      },
      {
          "id": 827,
          "drug_id": 228,
          "indication_name": "Meningioma",
          "expected_effects": "Effective palliation: reduction in clinical signs (vision, hearing return after 1 week of treatment) and in tumor size on MRI after 37 days of treatment, and survival for 14 months, in 1 case report",
          "common_combinations": "Dexamethasone",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:49:39.000000Z",
          "updated_at": "2020-09-16T00:49:39.000000Z"
      },
      {
          "id": 828,
          "drug_id": 228,
          "indication_name": "Primary erythrocytosis/polycythemia vera",
          "expected_effects": "Improvement or complete palliation of clinical signs in 1 small case series of dogs with polycythemia vera",
          "common_combinations": "Phlebotomy PRN",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:49:41.000000Z",
          "updated_at": "2020-09-16T00:49:41.000000Z"
      },
      {
          "id": 829,
          "drug_id": 228,
          "indication_name": "Chronic myelogenous leukemia",
          "expected_effects": "Remission induced in most dogs (5/5 in 1 case series) within 1 month of starting treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:49:43.000000Z",
          "updated_at": "2020-09-16T00:49:43.000000Z"
      },
      {
          "id": 830,
          "drug_id": 228,
          "indication_name": "Hypereosinophilic syndrome",
          "expected_effects": "Complete resolution of clinical signs in <7 days\nPeripheral eosinophil count: 0, at day 7 of treatment\nPositive outcome at 16 months of ongoing treatment in 1 case report",
          "common_combinations": "Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:49:46.000000Z",
          "updated_at": "2020-09-16T00:49:46.000000Z"
      },
      {
          "id": 831,
          "drug_id": 228,
          "indication_name": "Primary erythrocytosis",
          "expected_effects": "Resolution of erythrocytosis and clinical signs for up to 6 years with ongoing treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:49:48.000000Z",
          "updated_at": "2020-09-16T00:49:48.000000Z"
      },
      {
          "id": 832,
          "drug_id": 228,
          "indication_name": "Meningioma",
          "expected_effects": "Survival of at least 12-24 months after surgical removal of meningioma and hydroxyurea adjunctive treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:49:50.000000Z",
          "updated_at": "2020-09-16T00:49:50.000000Z"
      },
      {
          "id": 833,
          "drug_id": 229,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Good response (according to owner assessment of clinical signs) in 28% of dogs, moderate response in 38% of dogs, and no response in 34% of dogs\nBetter response in young dogs (age 1-3 years)",
          "common_combinations": "Omega-3 fatty acid supplementation",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:49:53.000000Z",
          "updated_at": "2020-09-16T00:49:53.000000Z"
      },
      {
          "id": 834,
          "drug_id": 229,
          "indication_name": "Pruritic dermatoses",
          "expected_effects": "Satisfactory response (\"good control of pruritus\" according to owner) in 7% of dogs\n\"Moderate\" response (some improvement but insufficient according to owner) in 18% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:49:55.000000Z",
          "updated_at": "2020-09-16T00:49:55.000000Z"
      },
      {
          "id": 835,
          "drug_id": 230,
          "indication_name": "Pyoderma",
          "expected_effects": "74% response rate (as assessed 1 week after end of treatment), maintained for >1 month in 70% (3% relapse rate)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:49:57.000000Z",
          "updated_at": "2020-09-16T00:49:57.000000Z"
      },
      {
          "id": 836,
          "drug_id": 232,
          "indication_name": "Hemangiosarcoma, other soft-tissue sarcomas",
          "expected_effects": "Median survival time: 149 days (longer for cutaneous [241 days] and renal [194 days] hemangiosarcoma, but shorter for splenic hemangiosarcoma [123 days])",
          "common_combinations": "Surgery;Diuresis;Mesna;Doxorubicin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:00.000000Z",
          "updated_at": "2020-09-16T00:50:00.000000Z"
      },
      {
          "id": 837,
          "drug_id": 232,
          "indication_name": "Lymphoma, soft-tissue sarcomas",
          "expected_effects": "Limited benefit, if any: no measurable increase in survival in dogs with splenic hemangiosarcoma, and stable disease/no measurable change for 21-120 days in 44% of lymphoma dogs (versus progressive disease despite ifosfamide in 54% of lymphoma dogs)",
          "common_combinations": "Diuresis;Mesna;Other chemotherapeutic drugs (various)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:50:02.000000Z",
          "updated_at": "2020-11-16T01:35:01.000000Z"
      },
      {
          "id": 838,
          "drug_id": 232,
          "indication_name": "Injection-site sarcoma",
          "expected_effects": "41% overall response rate (100% and ≥ 50% reduction in lesion size in 4% and 37% of cats, respectively)\r\nResponses last from 21-133 days (median: 70 days)",
          "common_combinations": "Diuresis;Mesna;Surgical resection/radiation therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:50:05.000000Z",
          "updated_at": "2020-11-16T01:35:01.000000Z"
      },
      {
          "id": 839,
          "drug_id": 233,
          "indication_name": "Pulmonary hypertension",
          "expected_effects": "40% reduction in pulmonary arterial systolic pressure and improvement in overall clinical status of treated dogs (but also co-treatment with other drugs may have played  a role)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:07.000000Z",
          "updated_at": "2020-11-16T01:38:02.000000Z"
      },
      {
          "id": 840,
          "drug_id": 234,
          "indication_name": "Congestive heart failure",
          "expected_effects": "66% efficacy rate (improvement of clinical signs consistent with congestive heart failure) with cotreatment with diuretics, essentially identical to other ACE inhibitors (e.g., benazepril)",
          "common_combinations": "Furosemide",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:09.000000Z",
          "updated_at": "2020-09-16T00:50:09.000000Z"
      },
      {
          "id": 841,
          "drug_id": 234,
          "indication_name": "Congestive heart failure, kidney disease",
          "expected_effects": "No adverse effects noted",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:50:12.000000Z",
          "updated_at": "2020-09-16T00:50:12.000000Z"
      },
      {
          "id": 842,
          "drug_id": 235,
          "indication_name": "Ehrlichiosis",
          "expected_effects": "94% rate of response to treatment in dogs with naturally-occurring ehrlichiosis, most within 3 days of starting treatment (pretreatment E. canis titer >1:2560 +/- presence of cutaneous lesions possibly associated with >1 week delay to treatment response)",
          "common_combinations": "Doxycycline",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:14.000000Z",
          "updated_at": "2020-09-16T00:50:14.000000Z"
      },
      {
          "id": 843,
          "drug_id": 235,
          "indication_name": "Mixed Ehrlichia and Hepatozoon infection",
          "expected_effects": "Substantial clinical improvement in 48h (return of appetite, resolution of fever), and clinical and parasitologic normalization within 4 weeks, in 1 case report",
          "common_combinations": "Doxycycline 5 mg/kg PO q 12h for 4 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:50:17.000000Z",
          "updated_at": "2020-09-16T00:50:17.000000Z"
      },
      {
          "id": 844,
          "drug_id": 235,
          "indication_name": "Babesiosis - Babesia gibsoni",
          "expected_effects": "84.6% recovery rate in 42 days\r\n15.2% relapse rate",
          "common_combinations": "Diminazene 3.5 mg/kg IM once;Clindamycin 30 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:50:19.000000Z",
          "updated_at": "2020-11-16T01:48:10.000000Z"
      },
      {
          "id": 845,
          "drug_id": 235,
          "indication_name": "Cytauxzoonosis",
          "expected_effects": "26% rate of survival to hospital discharge (vs. 60% with atovaquone-azithromycin)",
          "common_combinations": "IV fluids during hospitalization;Heparin 200 IU/kg SQ q 8h during hospitalization",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:50:22.000000Z",
          "updated_at": "2020-11-16T01:48:10.000000Z"
      },
      {
          "id": 846,
          "drug_id": 235,
          "indication_name": "Hemotropic mycoplasmosis",
          "expected_effects": ">99% elimination of Mycoplasma on blood smear and via PCR during treatment, but recrudescence of infection in some cats >2 weeks after end of treatment, either spontaneously or after stress (e.g., glucocorticoid injection)\r\nTreatment tolerated well without additional supportive care (no atropine, no IV fluids) in cats with Mycoplasma infection, with minimal/no overt clinical signs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:50:25.000000Z",
          "updated_at": "2020-11-16T01:48:10.000000Z"
      },
      {
          "id": 847,
          "drug_id": 235,
          "indication_name": "Ehrlichia-like bodies",
          "expected_effects": "Improved demeanor and appetite after 3 days\r\nNormal appetite and improved body condition after 1 week",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:50:27.000000Z",
          "updated_at": "2020-11-16T01:48:10.000000Z"
      },
      {
          "id": 848,
          "drug_id": 236,
          "indication_name": "Multidrug-resistant E. coli or Enterobacter infection (e.g., bacterial cystitis, peritonitis)",
          "expected_effects": "Complete resolution of the infection by the end of therapy in 2 case studies in dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:30.000000Z",
          "updated_at": "2020-09-16T00:50:30.000000Z"
      },
      {
          "id": 849,
          "drug_id": 236,
          "indication_name": "Pneumonia (aspiration)",
          "expected_effects": "Complete resolution of infection within 1 week in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:50:32.000000Z",
          "updated_at": "2020-09-16T00:50:32.000000Z"
      },
      {
          "id": 850,
          "drug_id": 236,
          "indication_name": "Susceptible infections",
          "expected_effects": "Pharmacokinetic studies support this treatment approach but clinical efficacy remains to be determined in cats with naturally-occurring infections",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:50:34.000000Z",
          "updated_at": "2020-09-16T00:50:34.000000Z"
      },
      {
          "id": 851,
          "drug_id": 237,
          "indication_name": "Cataplexy",
          "expected_effects": "2- to 3-fold improvement in frequency and duration of food-elicited cataplectic events",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:37.000000Z",
          "updated_at": "2020-09-16T00:50:37.000000Z"
      },
      {
          "id": 852,
          "drug_id": 237,
          "indication_name": "Narcolepsy-cataplexy caused by hypocretin deficiency",
          "expected_effects": "Improved ability to finish meals (75% reduction in average eating time after 1 week)\n15% increase in body weight after 9 weeks\nGradual decrease in frequency of narcoleptic events",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:50:39.000000Z",
          "updated_at": "2020-09-16T00:50:39.000000Z"
      },
      {
          "id": 853,
          "drug_id": 237,
          "indication_name": "Heritable nervous behavior in pointer dogs",
          "expected_effects": "Mild short-term improvement but no adequate control of signs long-term",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:50:42.000000Z",
          "updated_at": "2020-09-16T00:50:42.000000Z"
      },
      {
          "id": 854,
          "drug_id": 238,
          "indication_name": "Immune-mediated thrombocytopenia",
          "expected_effects": "Significant reduction in platelet count recovery time (median: 4 days earlier to reach >40,000/µL) and duration of hospitalization (median: 4 days shorter)",
          "common_combinations": "Doxycycline;Prednisone;Famotidine;Sucralfate",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:50:44.000000Z",
          "updated_at": "2020-09-16T00:50:44.000000Z"
      },
      {
          "id": 855,
          "drug_id": 238,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "No significant difference in survival time, length of hospitalization, or transfusion requirements compared to corticosteroid treatment alone",
          "common_combinations": "Dexamethasone IV;Predniso(lo)ne PO",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:50:47.000000Z",
          "updated_at": "2020-09-16T00:50:47.000000Z"
      },
      {
          "id": 856,
          "drug_id": 238,
          "indication_name": "Evans's syndrome when glucocorticoids are contraindicated",
          "expected_effects": "Platelet count doubles within 24h and rest of clinical improvement likely due to cotreatment with leflunomide in 1 case report\r\nCorticosteroid-intolerant disorder (concurrent diabetes mellitus) undisturbed by treatment",
          "common_combinations": "Leflunomide PO",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:50:49.000000Z",
          "updated_at": "2020-11-16T01:50:27.000000Z"
      },
      {
          "id": 857,
          "drug_id": 238,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "Visibly improved lesions, erythema, strength, and appetite within 12h\r\nResolution of fever, anorexia, and hypoglycemia after 5 days\r\nContinued remission for 4 weeks (if relapse, 2 infusions 24h apart and then 4 maintenance infusions q 4-10 weeks, are recommended), all in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:50:52.000000Z",
          "updated_at": "2020-11-16T01:50:28.000000Z"
      },
      {
          "id": 858,
          "drug_id": 238,
          "indication_name": "Adverse cutaneous drug reactions",
          "expected_effects": "Brighter, increase in appetite, regenerative anemia, and areas of healthy granulation tissue on skin lesions noted in 3-7 days, and full healing after several weeks, in 2 case descriptions",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:50:54.000000Z",
          "updated_at": "2020-11-16T01:50:28.000000Z"
      },
      {
          "id": 859,
          "drug_id": 238,
          "indication_name": "Drug-induced Stevens-Johnson syndrome",
          "expected_effects": "Halts progression of cutaneous ulceration within 12h\r\nHealing of lesions, improved demeanor, and weight gain within 7 days",
          "common_combinations": "Enrofloxacin;Topical liquid paraffin ointment",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:50:56.000000Z",
          "updated_at": "2020-11-16T01:50:28.000000Z"
      },
      {
          "id": 860,
          "drug_id": 238,
          "indication_name": "Myasthenia gravis (severe, generalized)",
          "expected_effects": "Improvement in clinical signs in some dogs (may range from mild to marked) within 48-96h of treatment",
          "common_combinations": "Other immunosuppressant therapy (mycophenolate mofetil, azathioprine, pyridostigmine, others);IV fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:50:59.000000Z",
          "updated_at": "2020-09-16T00:50:59.000000Z"
      },
      {
          "id": 861,
          "drug_id": 238,
          "indication_name": "Erythema multiforme",
          "expected_effects": "Rapid healing of lesions, and improved demeanor after 4 days\r\nPulse and respiratory rate within reference ranges, and > 90% resolution of crusts on the skin after 8 days",
          "common_combinations": "Cefadroxil;Topical therapy (lime sulfur, moisturizer)",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:51:01.000000Z",
          "updated_at": "2020-11-16T01:50:28.000000Z"
      },
      {
          "id": 862,
          "drug_id": 239,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Mean blood glucose concentration stays within 100-300 mg/dL range (good control) 24h a day, when blood glucose is monitored by the owner at home",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:03.000000Z",
          "updated_at": "2020-09-16T00:51:03.000000Z"
      },
      {
          "id": 863,
          "drug_id": 239,
          "indication_name": "Hyperglycemia associated with hyperadrenocorticism (insulin antagonism/pre-diabetes mellitus)",
          "expected_effects": "<1% of dogs with hyperadrenocorticism-associated hyperglycemia later develop diabetes mellitus if they receive detemir insulin for the first 4 months of hyperadrenocorticism treatment, vs. 83% if not treated with detemir insulin initially",
          "common_combinations": "Treatment of hyperadrenocorticism (9-cis isotretinoin in 1 study)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:51:06.000000Z",
          "updated_at": "2020-09-16T00:51:06.000000Z"
      },
      {
          "id": 864,
          "drug_id": 239,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "High rate of diabetic remission (67% of cats) beginning 10 days - 5.3 months (median: 1.7 months) after start of treatment and allowing complete termination of insulin administration\nHigh treatment efficacy (median blood glucose at home ≤ 150 mg/dL in 83% of cats, ≤ 200 mg/dL in 17% of cats, and >200 mg/dL [poorly regulated] in <1% of cats)\n6% incidence of hypoglycemia (rarely causing overt clinical signs)",
          "common_combinations": "Low-carbohydrate diet",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:51:08.000000Z",
          "updated_at": "2020-09-16T00:51:08.000000Z"
      },
      {
          "id": 865,
          "drug_id": 240,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Improvement or resolution of polyuria/polydipsia after 24 weeks in 91% of dogs\r\nGood control of hyperglycemia in 58% of dogs after 24 weeks",
          "common_combinations": "Typically, a high-fiber, low-carbohydrate diet is also implemented",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:11.000000Z",
          "updated_at": "2020-11-16T02:02:14.000000Z"
      },
      {
          "id": 866,
          "drug_id": 240,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "High rate of diabetic remission (64% of cats) beginning after glargine treatment and allowing complete suspension of insulin treatment\r\nIn cats not developing remission (or coming out of remission), glargine is highly effective when combined with at-home monitoring of blood glucose by clients to titrate dosage (70% of insulin-dependent cats maintain blood glucose ≤ 150 mg/dL, without signs of hypoglycemia)",
          "common_combinations": "Ultra-low carbohydrate diet (≤ 10% metabolizable energy)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:51:13.000000Z",
          "updated_at": "2020-11-16T02:02:14.000000Z"
      },
      {
          "id": 867,
          "drug_id": 241,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Effective regulation of blood glucose concentration in majority of dogs",
          "common_combinations": "Low-carbohydrate diet",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:15.000000Z",
          "updated_at": "2020-09-16T00:51:15.000000Z"
      },
      {
          "id": 868,
          "drug_id": 241,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "25% of treated cats can stop receiving lente insulin (\"diabetic remission\") a median of 19 days (range: 17-42 days) after having started lente insulin injections, and this diabetic remission (still checked with once-weekly blood glucose measurements at home by the client) lasts at least 3 months. These results compares to a much higher rate of diabetic remission in cats treated with glargine insulin (75%, occurring 28-100 days after start of treatment).",
          "common_combinations": "Low-carbohydrate diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:51:18.000000Z",
          "updated_at": "2020-09-16T00:51:18.000000Z"
      },
      {
          "id": 869,
          "drug_id": 242,
          "indication_name": "Diabetic ketoacidosis",
          "expected_effects": "Resolution of hyperglycemia, acidosis, and ketosis in median of 26h (overall 57% shorter time than with regular insulin, but not significantly different individual resolution times)",
          "common_combinations": "Fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:20.000000Z",
          "updated_at": "2020-09-16T00:51:20.000000Z"
      },
      {
          "id": 870,
          "drug_id": 243,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Duration of effect: 4-10 hours (initial postprandial hyperglycemia occurs 0.6-2.2 hours after meal and insulin dose)\nMean blood glucose suppression: 49.9 ± 17.1% (median: 46%, range: 29-78%)",
          "common_combinations": "Typically, a high-fiber, low-carbohydrate diet is also implemented",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:22.000000Z",
          "updated_at": "2020-09-16T00:51:22.000000Z"
      },
      {
          "id": 871,
          "drug_id": 243,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Peak insulin concentration 2-8 hours after injection\nEffective regulation of blood glucose concentration",
          "common_combinations": "Typically, a high-fiber, low-carbohydrate diet is also implemented",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:51:25.000000Z",
          "updated_at": "2020-09-16T00:51:25.000000Z"
      },
      {
          "id": 872,
          "drug_id": 244,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "10-hour mean blood glucose suppression of 34.6%\n14% decrease in mean serum fructosamine concentration after 60 days\nImprovement of polyuria and polydipsia, and stable or increased body weight in 82% and 94% of dogs, respectively, after 60 days",
          "common_combinations": "Typically, a high-fiber, low-carbohydrate diet is also implemented",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:28.000000Z",
          "updated_at": "2020-09-16T00:51:28.000000Z"
      },
      {
          "id": 873,
          "drug_id": 244,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "9-hour mean blood glucose suppression of 52.3%\n9% increase in mean body weight, and 25.7% decrease in mean serum fructosamine concentration, after 45 days\nImprovement of polyuria and polydipsia and good body condition scores in 79% and 89% of cats, respectively, after 45 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:51:30.000000Z",
          "updated_at": "2020-09-16T00:51:30.000000Z"
      },
      {
          "id": 874,
          "drug_id": 245,
          "indication_name": "Diabetic ketoacidosis",
          "expected_effects": "Decreases blood glucose by 87.6 mg/dL/hour [editor's note: protocol involves a first dose of 0.25 IU/kg IM, but a rate of 87.6 mg/dL/hour for decrease in blood glucose may cause central nervous system damage in some dogs and should not be exceeded. Omitting the 0.25 IU/kg initial dose is preferable, and a lower dosage of insulin may be chosen to ensure a rate of return to normoglycemia that does not exceed 50-75 mg/dL/h.]",
          "common_combinations": "Fluid therapy and supportive care, notably potassium and phosphate supplementation as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:32.000000Z",
          "updated_at": "2020-09-16T00:51:32.000000Z"
      },
      {
          "id": 875,
          "drug_id": 245,
          "indication_name": "Diabetic ketoacidosis",
          "expected_effects": "Blood glucose ≤ 250 mg/dL in a mean of 10 hours (range: 4-24 hours)\r\nMean decrease in blood glucose concentration of 34 mg/dL/h and 28 mg/dL/h in the first 6 and 12 hours, respectively\r\nEffective and consistent reduction in blood glucose, and resolution of acidosis and ketosis",
          "common_combinations": "Fluid therapy and supportive care, notably potassium and phosphate supplementation as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:51:35.000000Z",
          "updated_at": "2020-11-16T02:09:17.000000Z"
      },
      {
          "id": 876,
          "drug_id": 245,
          "indication_name": "Hyperkalemia",
          "expected_effects": "Non-specific rapid decrease in serum potassium concentration",
          "common_combinations": "50% dextrose (average: 1.2 mL) IV simultaneously (recommended to dilute 50% dextrose with 4-6 times greater volume of sterile water before administration)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:51:37.000000Z",
          "updated_at": "2020-09-16T00:51:37.000000Z"
      },
      {
          "id": 877,
          "drug_id": 245,
          "indication_name": "Diabetic ketoacidosis",
          "expected_effects": "Resolution of hyperglycemia, acidosis, and ketosis in median of 43 hours (range: 10-96 hours) for cats that survive the initial hospitalization\r\nRecurrence of diabetic ketosis or ketoacidosis in 42% of cats after median of 4 weeks (range: 3 days to 15 months)",
          "common_combinations": "Fluid therapy and supportive care, notably potassium and phosphate supplementation as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:51:40.000000Z",
          "updated_at": "2020-11-16T02:09:17.000000Z"
      },
      {
          "id": 878,
          "drug_id": 245,
          "indication_name": "Diabetic ketoacidosis",
          "expected_effects": "Normoglycemia (blood glucose < 250 mg/dL) is reached in an average of 7.1-15.1 hours (up to 48 hours)\r\nKetonuria resolves in 49-76 hours",
          "common_combinations": "Fluid therapy and supportive care, notably potassium and phosphate supplementation as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:51:43.000000Z",
          "updated_at": "2020-11-16T02:09:17.000000Z"
      },
      {
          "id": 879,
          "drug_id": 245,
          "indication_name": "Hyperkalemia",
          "expected_effects": "Non-specific rapid decrease in serum potassium concentration",
          "common_combinations": "Dextrose 0.2-5 g/CAT IV (0.4-10 mL of 50% dextrose, recommended to dilute before administration);With or without calcium gluconate;With or without sodium bicarbonate",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:51:45.000000Z",
          "updated_at": "2020-11-16T02:09:17.000000Z"
      },
      {
          "id": 880,
          "drug_id": 246,
          "indication_name": "Diabetes mellitus",
          "expected_effects": "Mean blood glucose < 200 mg/dL (good control) in 15% of cats, and 200-300 mg/dL in 50% of cats (moderate control)\nNo significant difference in glycemic control offered compared to PZI or lente insulin",
          "common_combinations": "Typically, a high-fiber, low-carbohydrate diet is also implemented",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:47.000000Z",
          "updated_at": "2020-09-16T00:51:47.000000Z"
      },
      {
          "id": 881,
          "drug_id": 247,
          "indication_name": "Idiopathic recurrent superficial pyoderma",
          "expected_effects": "Transient improvement in clinical signs after 14 weeks of treatment, compared to untreated dogs\r\n40% of dogs require continued antibiotic therapy, compared to 83% of untreated dogs",
          "common_combinations": "Cephalexin;Benzoyl peroxide or ethyl lactate shampoo",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:51:50.000000Z",
          "updated_at": "2020-11-16T02:13:07.000000Z"
      },
      {
          "id": 882,
          "drug_id": 247,
          "indication_name": "Pigmented epidermal plaques",
          "expected_effects": "Complete resolution of most lesions, with minimal new lesions developing while on continued therapy (18-24 months)",
          "common_combinations": "With treatment of concurrent disease (e.g., hyperadrenocorticism);Laser ablation of plaques",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:51:52.000000Z",
          "updated_at": "2020-09-16T00:51:52.000000Z"
      },
      {
          "id": 883,
          "drug_id": 247,
          "indication_name": "Epitheliotropic lymphoma",
          "expected_effects": "Lesion regression for 10 weeks, then a further 12 weeks of stable disease, in a case report of a dog with relapsed preputial lymphoma (after treatment with cyclophosphamide, vincristine, prednisolone, cytosine arabinoside, and radiation therapy, then recurrence, then interferon treatment)",
          "common_combinations": "Cytosine arabinoside;Epirubicin;Local radiation therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:51:55.000000Z",
          "updated_at": "2020-09-16T00:51:55.000000Z"
      },
      {
          "id": 884,
          "drug_id": 247,
          "indication_name": "Keratoconjunctivitis sicca",
          "expected_effects": "55% of dogs improve with respect to clinical signs\r\n64% of responders (35% of all treated dogs) have an increase in Schirmer tear test of 5 mm/min or greater",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:51:58.000000Z",
          "updated_at": "2020-11-16T02:13:07.000000Z"
      },
      {
          "id": 885,
          "drug_id": 247,
          "indication_name": "Feline leukemia virus infection",
          "expected_effects": "No difference (as monotherapy or with azidothymidine co-treatment) compared to saline placebo",
          "common_combinations": "With or without azidothymidine",
          "is_contraindicated": 1,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:52:00.000000Z",
          "updated_at": "2020-11-16T02:13:07.000000Z"
      },
      {
          "id": 886,
          "drug_id": 247,
          "indication_name": "Feline immunodeficiency virus infection",
          "expected_effects": "96% survival at 6 and 12 months with treatment, vs. 17% survival at 6 months and <1% survival at 1 year with placebo\r\nResolution of fever and lymphadenopathy within 7-10 days of start of treatment\r\nRegression of immunopathological lesions and inflammatory signs after the first 3 weeks\r\nAverage weight gain of 700 g during first 6 months\r\nImproved efficacy of antiparasitics",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:52:03.000000Z",
          "updated_at": "2020-11-16T02:13:07.000000Z"
      },
      {
          "id": 887,
          "drug_id": 247,
          "indication_name": "Feline herpesviral conjunctivitis",
          "expected_effects": "No difference between treatment with interferon (either human IFN-alpha or feline IFN-alpha) and saline placebo",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:52:10.000000Z",
          "updated_at": "2020-11-16T02:13:07.000000Z"
      },
      {
          "id": 888,
          "drug_id": 248,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "After 3 months of treatment: significant (defined as ≥50%) improvement in pruritus score and skin lesions in 56% and 72% of treated dogs, respectively, compared to 75% and 75%, respectively, for dogs treated with cyclosporine (similar benefit for interferon-omega vs. cyclosporine)",
          "common_combinations": "Flea control;Non-medicated shampooing;Ear cleansing;Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:52:13.000000Z",
          "updated_at": "2020-09-16T00:52:13.000000Z"
      },
      {
          "id": 889,
          "drug_id": 248,
          "indication_name": "Parvoviral enteritis",
          "expected_effects": "Significantly (4.4-fold) better survival in treated dogs (93% survival) compared to controls receiving standard care (71% survival)",
          "common_combinations": "Supportive treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:52:15.000000Z",
          "updated_at": "2020-09-16T00:52:15.000000Z"
      },
      {
          "id": 890,
          "drug_id": 248,
          "indication_name": "Stomatitis (chronic)",
          "expected_effects": "Complete resolution and marked improvement in lesions in 10% and 35% of cats, respectively, after 90 days\r\n35% rate of no response to treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:52:18.000000Z",
          "updated_at": "2020-11-16T02:26:49.000000Z"
      },
      {
          "id": 891,
          "drug_id": 248,
          "indication_name": "Feline leukemia virus/feline immunodeficiency virus co-infection",
          "expected_effects": "Significant survival benefit, with 61% 9-month survival in treated cats (vs. 41% with placebo) and 53% 1-year survival with treatment (vs. 41% with placebo)",
          "common_combinations": "Supportive care",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:52:20.000000Z",
          "updated_at": "2020-09-16T00:52:20.000000Z"
      },
      {
          "id": 892,
          "drug_id": 248,
          "indication_name": "Feline leukemia infection",
          "expected_effects": "Nonspecific overall clinical improvement in treated cats after 8 weeks\r\nNo adverse effects noted",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:52:23.000000Z",
          "updated_at": "2020-11-16T02:26:49.000000Z"
      },
      {
          "id": 893,
          "drug_id": 248,
          "indication_name": "Feline immunodeficiency virus infection (PO protocol) - clinical benefit unclear",
          "expected_effects": "Reduction in IL-6 mRNA load with treatment, but no change in viremia and no appreciable overt clinical benefit",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:52:25.000000Z",
          "updated_at": "2020-11-16T02:26:49.000000Z"
      },
      {
          "id": 894,
          "drug_id": 248,
          "indication_name": "Injection-site sarcoma/other fibrosarcoma",
          "expected_effects": "50% disease-free at 1 year (45% local tumor recurrence, 5% pulmonary metastasis)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:52:28.000000Z",
          "updated_at": "2020-11-16T02:26:50.000000Z"
      },
      {
          "id": 895,
          "drug_id": 248,
          "indication_name": "Herpesviral dermatitis",
          "expected_effects": "Rapid reduction of lesion size 48h after first injection, and marked decrease in swelling, resolution of crusts and erosions, and presence of hair regrowth sustained for months after treatment, in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:52:30.000000Z",
          "updated_at": "2020-11-16T02:26:50.000000Z"
      },
      {
          "id": 896,
          "drug_id": 248,
          "indication_name": "Panleukopenia virus Infection prevention",
          "expected_effects": "Ineffective: no difference in occurrence of clinical signs (74% of treated cats vs. 77% of untreated controls) or survival (41% of treated cats vs. 39% of untreated controls)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:52:33.000000Z",
          "updated_at": "2020-11-16T02:26:50.000000Z"
      },
      {
          "id": 897,
          "drug_id": 248,
          "indication_name": "Feline infectious peritonitis",
          "expected_effects": "Ineffective: survival of treated cats was no different than survival of placebo-treated control cats",
          "common_combinations": "Supportive care",
          "is_contraindicated": 1,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:52:35.000000Z",
          "updated_at": "2020-11-16T02:26:50.000000Z"
      },
      {
          "id": 898,
          "drug_id": 249,
          "indication_name": "Sporotrichosis",
          "expected_effects": "Complete resolution of numerous ulcerated cutaneous lesions in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:52:38.000000Z",
          "updated_at": "2020-11-16T02:35:27.000000Z"
      },
      {
          "id": 899,
          "drug_id": 249,
          "indication_name": "Sporothrix-associated externa +/- otitis media",
          "expected_effects": "Complete resolution of head tilt and lethargy after 2-3 weeks of treatment in 1 case report",
          "common_combinations": "Topical antifungal (e.g., griseofulvin drops) and daily topical cleaning/care of affected ear(s)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:52:40.000000Z",
          "updated_at": "2020-09-16T00:52:40.000000Z"
      },
      {
          "id": 900,
          "drug_id": 249,
          "indication_name": "Sporotrichosis",
          "expected_effects": "96% cure rate; 33% rate of adverse effects (typically anorexia, weight loss) responding to suspension fo treatment for 7-20 days before resuming",
          "common_combinations": "Itraconazole 100 mg/CAT PO q 24h",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:52:43.000000Z",
          "updated_at": "2020-11-16T02:35:27.000000Z"
      },
      {
          "id": 901,
          "drug_id": 250,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Effective at eliciting vomiting in 75% of dogs, resulting in 0-5 vomiting episodes (vs. apomorphine: effective in 80% of dogs, resulting in 0-3 vomiting episodes)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:52:45.000000Z",
          "updated_at": "2020-09-16T00:52:45.000000Z"
      },
      {
          "id": 902,
          "drug_id": 250,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Anorexia for several days, aversive to handling, but no vomiting",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:52:48.000000Z",
          "updated_at": "2020-09-16T00:52:48.000000Z"
      },
      {
          "id": 903,
          "drug_id": 251,
          "indication_name": "Nonregenerative anemia",
          "expected_effects": "Improvement/resolution of anemia",
          "common_combinations": "Darbepoetin 0.46 µg/kg SC q 1 week",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:52:51.000000Z",
          "updated_at": "2020-09-16T00:52:51.000000Z"
      },
      {
          "id": 904,
          "drug_id": 251,
          "indication_name": "Nonregenerative anemia",
          "expected_effects": "Correction of relative or absolute iron deficiency when stimulating erythropoiesis",
          "common_combinations": "Darbepoetin 1 µg/kg SC q 1 week",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:52:53.000000Z",
          "updated_at": "2020-09-16T00:52:53.000000Z"
      },
      {
          "id": 905,
          "drug_id": 251,
          "indication_name": "Iron deficiency (neonatal)",
          "expected_effects": "32% fewer microcytic cells, 50% increased packed cell volume, and 30% increased mean corpuscular volume 2-3 weeks after treatment, compared to untreated littermate controls",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:52:55.000000Z",
          "updated_at": "2020-09-16T00:52:55.000000Z"
      },
      {
          "id": 906,
          "drug_id": 252,
          "indication_name": "Bradycardia, decreased cardiac output",
          "expected_effects": "Mean heart rate increases 17% (from 155 to 182 beats/minute)\r\nMean aortic blood pressure decreases 15% (from 124 to 108 mmHg, due to decrease in total peripheral resistance)\r\nCardiac output increases 70% (from 165 to 281 mL/min/kg)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:52:58.000000Z",
          "updated_at": "2020-11-16T02:38:27.000000Z"
      },
      {
          "id": 907,
          "drug_id": 252,
          "indication_name": "Atrioventricular block",
          "expected_effects": "Resolution of bradycardia in individual reported cases: 3rd degree AV block conversion to 2nd degree AV block within 48h, then return to normal sinus rhythm in some dogs in 4-30 days",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:53:00.000000Z",
          "updated_at": "2020-11-16T02:38:27.000000Z"
      },
      {
          "id": 908,
          "drug_id": 252,
          "indication_name": "Bradycardia, decreased cardiac output",
          "expected_effects": "Nonspecific increase in heart rate, eliminated by beta-blocker (atenolol)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:53:03.000000Z",
          "updated_at": "2020-11-16T02:38:27.000000Z"
      },
      {
          "id": 909,
          "drug_id": 253,
          "indication_name": "Congestive heart failure",
          "expected_effects": "Both in normal dogs and dogs with congestive heart failure: treatment produced no differences compared to placebo with respect to distribution of thoracic, abdominal blood flow, heart rate, arterial blood pressure, and packed cell volume (even when serum concentrations are above the minimum \"therapeutic\" concentration)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:53:05.000000Z",
          "updated_at": "2020-09-16T00:53:05.000000Z"
      },
      {
          "id": 910,
          "drug_id": 254,
          "indication_name": "Sebaceous adenitis",
          "expected_effects": ">50% reduction in severity of skin lesions (scaling, alopecia) in 47% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:53:08.000000Z",
          "updated_at": "2020-09-16T00:53:08.000000Z"
      },
      {
          "id": 911,
          "drug_id": 254,
          "indication_name": "Benign cutaneous neoplasia (intracutaneous cornifying epithelioma, inverted papilloma), epidermal cyst",
          "expected_effects": "≥90% reduction in size of ≥90% of tumors in 33% of dogs, and 50-90% reduction in size of 50-90% of tumors in a further 20% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:53:11.000000Z",
          "updated_at": "2020-09-16T00:53:11.000000Z"
      },
      {
          "id": 912,
          "drug_id": 254,
          "indication_name": "Lymphoma - cutaneous",
          "expected_effects": "≥ 50% reduction in erythema, scaling and/or pruritus, with increased quality of life, for at least 4 months, in 38% of dogs\nMean survival time of 10.8 months, compared to 1.3-2.6 months if untreated",
          "common_combinations": "Prednisone",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:53:13.000000Z",
          "updated_at": "2020-09-16T00:53:13.000000Z"
      },
      {
          "id": 913,
          "drug_id": 254,
          "indication_name": "Cornification defect (\"idiopathic seborrhea\")",
          "expected_effects": "100% improvement in skin lesions and pruritus in 13% of dogs in 1 case series, with relapse 2 months after ceasing treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:53:15.000000Z",
          "updated_at": "2020-09-16T00:53:15.000000Z"
      },
      {
          "id": 914,
          "drug_id": 254,
          "indication_name": "Squamous cell carcinoma",
          "expected_effects": "Marked regression and epithelialization of lesions (but not clinical cure) in 1 case report",
          "common_combinations": "Used with controlled localized radiofrequency heating",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:53:18.000000Z",
          "updated_at": "2020-09-16T00:53:18.000000Z"
      },
      {
          "id": 915,
          "drug_id": 255,
          "indication_name": "Blastomycosis",
          "expected_effects": "54% cure\r\n20% improvement but recurrence (OK to retreat)\r\n26% mortality",
          "common_combinations": "Amphotericin B if severe clinical illness",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:53:20.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 916,
          "drug_id": 255,
          "indication_name": "Malassezia dermatitis and otitis externa",
          "expected_effects": "41-54% reduction in Malassezia on cytology, 31-60% improvement in skin lesion size/appearance, and 56-75% improvement in pruritus after 3 weeks of treatment",
          "common_combinations": "Topical therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:53:23.000000Z",
          "updated_at": "2020-09-16T00:53:23.000000Z"
      },
      {
          "id": 917,
          "drug_id": 255,
          "indication_name": "Pythiosis - cutaneous",
          "expected_effects": "Elimination of cutaneous lesion",
          "common_combinations": "Surgical excision;Concurrent terbinafine treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:53:25.000000Z",
          "updated_at": "2020-09-16T00:53:25.000000Z"
      },
      {
          "id": 918,
          "drug_id": 255,
          "indication_name": "Aspergillus-associated bronchopneumonia",
          "expected_effects": "Clinical cure (26 months without recurrence) in 1 case report",
          "common_combinations": "Lung lobectomy;Culture-guided antibacterial therapy (doxycycline, enrofloxacin)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:53:28.000000Z",
          "updated_at": "2020-09-16T00:53:28.000000Z"
      },
      {
          "id": 919,
          "drug_id": 255,
          "indication_name": "Cryptococcosis",
          "expected_effects": "Treatment leads to cure in 57% of cats, improvement in 29% of cats, and no benefit in 14% of cats",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:53:30.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 920,
          "drug_id": 255,
          "indication_name": "Malassezia dermatitis",
          "expected_effects": "70% reduction in pruritus and skin lesions",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:53:33.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 921,
          "drug_id": 255,
          "indication_name": "Blastomycosis",
          "expected_effects": "Clinical improvement in 1 week\r\nRadiographic lung lesions still present after 3 months of treatment but resolved after 5 months of treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:53:35.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 922,
          "drug_id": 255,
          "indication_name": "Sporotrichosis",
          "expected_effects": "Improvement and stabilization (but not eradication) of skin lesions in most cats\r\nClinical cure in some cats\r\nLifelong therapy or change to fluconazole required in some cats\r\nSuperior to iodides because cats with iodide-refractory lesions respond well to itraconazole",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:53:38.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 923,
          "drug_id": 255,
          "indication_name": "Sporotrichosis",
          "expected_effects": "Improvement and stabilization (but not eradication) of skin lesions in most cats\r\nClinical cure in some cats\r\nLifelong therapy or change to fluconazole required in some cats\r\nSuperior to iodides because cats with iodide-refractory lesions respond well to itraconazole",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:53:40.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 924,
          "drug_id": 255,
          "indication_name": "Histoplasmosis",
          "expected_effects": "77% of cats achieve resolution of clinical signs\r\nAfter end of treatment, 32% of cats will have recrudescence of disease requiring retreatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:53:43.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 925,
          "drug_id": 255,
          "indication_name": "Ringworm - Microsporum canis infection",
          "expected_effects": "53-87% cure rate at day 42, depending on concurrent topical treatment (lime sulfur dip most effective)",
          "common_combinations": "Topical therapy (lime sulfur, reformulated odor-free lime sulfur, or combination 0.2% miconazole nitrate and 0.2% chlorhexidine gluconate rinse)",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:53:45.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 926,
          "drug_id": 255,
          "indication_name": "Dermatophytic pseudomycetoma",
          "expected_effects": "Reduction in number and size of nodules",
          "common_combinations": "Amoxicillin PO for first week and/or surgical resection",
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T00:53:48.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 927,
          "drug_id": 256,
          "indication_name": "Sarcoptic acariasis/mange",
          "expected_effects": "Complete elimination of mites in 45% of dogs 14 days after 1st treatment, and in 82% of dogs 28 days after 1st treatment (elimination rates may increase to 64% and >99%, respectively, if vitamin E and selenium are supplemented concurrently)",
          "common_combinations": "Vitamin E (tocopherol) 1.25 mg/kg + selenium 0.0375 mg/kg IM once weekly for 3 doses (concurrent with ivermectin)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:53:50.000000Z",
          "updated_at": "2020-09-16T00:53:50.000000Z"
      },
      {
          "id": 928,
          "drug_id": 256,
          "indication_name": "Demodicosis - generalized",
          "expected_effects": "Topical therapy (e.g., benzoyl peroxide shampoo)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:53:53.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 929,
          "drug_id": 256,
          "indication_name": "Heartworm (Dirofilaria immitis) - monthly prophylaxis",
          "expected_effects": ">99% prevention of larval maturation after mosquito bite",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:53:55.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 930,
          "drug_id": 256,
          "indication_name": "Heartworm (Dirofilaria immitis) - microfilaricide",
          "expected_effects": "90% of dogs become amicrofilaremic by day 21 after treatment and >99% by day 28",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:53:58.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 931,
          "drug_id": 256,
          "indication_name": "Heartworm (Dirofilaria immitis) - slow adulticide",
          "expected_effects": "After 300 days (180 days treatment, then 120 days no treatment), 73% of dogs become heartworm antigen-negative and 86% of dogs with echocardiographically-visible heartworms at baseline no longer have visible worms",
          "common_combinations": "Doxycycline 10 mg/kg PO q 24h for 30 days;Combination product containing pyrantel 14 mg/kg PO q 24h with ivermectin 6 µg/kg (Heartgard Plus)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:54:00.000000Z",
          "updated_at": "2020-09-16T00:54:00.000000Z"
      },
      {
          "id": 932,
          "drug_id": 256,
          "indication_name": "Roundworm infestation - Toxocara canis",
          "expected_effects": "Elimination of 91% of adult and 97% of larval forms of T. canis with 1 treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:54:07.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 933,
          "drug_id": 256,
          "indication_name": "Hookworm infestation - Ancylostoma caninum, A. braziliense",
          "expected_effects": "Elimination of >99% of hookworm burden with 1 treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:54:10.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 934,
          "drug_id": 256,
          "indication_name": "Whipworm infestation - Trichuris vulpis",
          "expected_effects": "Elimination of >99% of whipworm burden with 1 treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:54:12.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 935,
          "drug_id": 256,
          "indication_name": "Nasal mite infestation - Pneumonyssoides caninum",
          "expected_effects": "Elimination of all mites and associated severe nasal signs in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:54:14.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 936,
          "drug_id": 256,
          "indication_name": "Lungworm infestation - Filaroides hirthi",
          "expected_effects": "Elimination of 74% of adult worms and 95% of first-stage larvae (importantly, only 5-10% of dogs are shedding larvae in feces when infected)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:54:17.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 937,
          "drug_id": 256,
          "indication_name": "French heartworm infestation - Angiostrongylus vasorum",
          "expected_effects": "Elimination of cough and fecal larval shedding 7-10 days after end of treatment in 2 of 3 treated cases, and resolution of signs after ivermectin + fenbendazole treatment in the 3rd case",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:54:19.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 938,
          "drug_id": 256,
          "indication_name": "Eyeworm infestation - Thelazia spp.",
          "expected_effects": ">99% elimination of eyeworms by 30 days after 1st dose\r\nPrevalence of 5% with ongoing prophylaxis (repeat dose once monthly), in populations where prevalence in untreated dogs is 18-24%",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:54:22.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 939,
          "drug_id": 256,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "Elimination of all mites in >99% of treated ears by 72 hours post-treatment (vs. 50% with topical selamectin [interscapular skin])",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-09-16T00:54:24.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 940,
          "drug_id": 256,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "Complete elimination of mites and associated signs in 96% of treated cats",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-09-16T00:54:26.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 941,
          "drug_id": 256,
          "indication_name": "Cheyletiellosis",
          "expected_effects": "Complete elimination of mites and associated signs in >99% of treated cats",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-09-16T00:54:29.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 942,
          "drug_id": 256,
          "indication_name": "Hookworm infestation - Ancylostoma spp.",
          "expected_effects": "Elimination of >99% of worm burden with 1 treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-09-16T00:54:31.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 943,
          "drug_id": 256,
          "indication_name": "Roundworm infestation - Toxocara cati",
          "expected_effects": "Elimination of >99% of worm burden with 1 treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 18,
          "created_at": "2020-09-16T00:54:35.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 944,
          "drug_id": 256,
          "indication_name": "Demodicosis (generalized) - Demodex gatoi",
          "expected_effects": "Complete elimination of mites and resolution of associated clinical signs in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 19,
          "created_at": "2020-09-16T00:54:37.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 945,
          "drug_id": 256,
          "indication_name": "Heartworm (Dirofilaria immitis) - monthly prophylaxis",
          "expected_effects": ">99% efficacy (no adult heartworms develop despite exposure to D. immitis-bearing larvae)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 20,
          "created_at": "2020-09-16T00:54:40.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 946,
          "drug_id": 256,
          "indication_name": "Sarcoptic acariasis/mange",
          "expected_effects": "Negative skin scraping and resolution of cutaneous lesions in 7-14 days in reported cases",
          "common_combinations": "With or without topical lime sulfur rinse",
          "is_contraindicated": 0,
          "vdi_display_order": 21,
          "created_at": "2020-09-16T00:54:42.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 947,
          "drug_id": 256,
          "indication_name": "Cutaneous myasis - Calliphora erythrocephala maggot infestation in obese cats",
          "expected_effects": "All visible maggots dead within 2 days of treatment (note: Calliphora/blowfly myiasis is a reportable disease in the U.S. and many other countries)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 22,
          "created_at": "2020-09-16T00:54:44.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 948,
          "drug_id": 256,
          "indication_name": "Nasal myiasis - Oestrus ovis",
          "expected_effects": "Elimination of all clinical signs 2-3 weeks after treatment in 1 case report",
          "common_combinations": "Selamectin single application 1 week after ivermectin treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 23,
          "created_at": "2020-09-16T00:54:47.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 949,
          "drug_id": 256,
          "indication_name": "Lymphatic filariasis - Brugia malayi infestation",
          "expected_effects": "87-100% reduction in microfilariae 2 months after single treatment\r\nBy 8 months post-treatment, microfilaria burden is reduced by 99% and 86% of cats are amicrofilaremic",
          "common_combinations": "Diethylcarbamazine 6 mg/kg PO once",
          "is_contraindicated": 0,
          "vdi_display_order": 24,
          "created_at": "2020-09-16T00:54:49.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 950,
          "drug_id": 256,
          "indication_name": "Lagochilascaris minor infestation",
          "expected_effects": ">99% elimination of nematode (vs. 0% in untreated controls)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 25,
          "created_at": "2020-09-16T00:54:51.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 951,
          "drug_id": 256,
          "indication_name": "Pododermatitis due to Anatrichosoma sp. dermal nematode",
          "expected_effects": "Complete resolution of skin lesions in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 26,
          "created_at": "2020-09-16T00:54:54.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      },
      {
          "id": 952,
          "drug_id": 257,
          "indication_name": "Diarrhea - acute",
          "expected_effects": "Unproven decrease in frequency and urgency of defecation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:54:56.000000Z",
          "updated_at": "2020-09-16T00:54:56.000000Z"
      },
      {
          "id": 953,
          "drug_id": 258,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Tracheal intubation possible in 2.7-4 minutes after dose (coadministration with either diazepam or midazolam)",
          "common_combinations": "Midazolam 0.28 mg/kg IV or diazepam 0.28 mg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:54:59.000000Z",
          "updated_at": "2020-09-16T00:54:59.000000Z"
      },
      {
          "id": 954,
          "drug_id": 258,
          "indication_name": "Castration (ketamine-dexmedetomidine-opiate combination)",
          "expected_effects": "Onset of sedation 1.6-3.6 minutes after injection\nLateral recumbency 4-6 minutes after injection\nIntubation possible in 96% of dogs 3-6 minutes after injection\nAdequate plane of anesthesia for duration of castration obtained without further anesthetic in 90% (K-D-buprenorphine), 70% (K-D-butorphanol), and 60% (K-D-hydromorphone) of dogs\nTime from injection to start of surgery: 20 min, and duration of surgery: 20 minutes, i.e., 40 minutes of adequate anesthesia needed",
          "common_combinations": "Dexmedetomidine 15 µg/kg;Butorphanol 0.2 mg/kg, hydromorphone 0.05 mg/kg, or buprenorphine 0.04 mg/kg (IM, once)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:55:02.000000Z",
          "updated_at": "2020-09-16T00:55:02.000000Z"
      },
      {
          "id": 955,
          "drug_id": 258,
          "indication_name": "Intravenous anesthesia - PLK (propofol-lidocaine-ketamine) combination",
          "expected_effects": "Addition of ketamine-lidocaine confusion reduces the propofol requirement by 37%",
          "common_combinations": "Lidocaine loading dose 1.5 mg/kg IV bolus then 0.25 mg/kg/min IV CRI;Propofol 0.5 mg/kg/min IV CRI (no ketamine-lidocaine) or 0.3 mg/kg/min IV CRI (with ketamine-lidocaine)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:55:04.000000Z",
          "updated_at": "2020-09-16T00:55:04.000000Z"
      },
      {
          "id": 956,
          "drug_id": 258,
          "indication_name": "Analgesia - FLK (fentanyl-lidocaine-ketamine) infusion",
          "expected_effects": "97% reduction in minimum alveolar concentration of isoflurane, i.e., the FLK infusion essentially provides total intravenous anesthesia",
          "common_combinations": "Coadministration with lidocaine 3 mg/kg/h IV CRI and fentanyl 3.6 µg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:55:07.000000Z",
          "updated_at": "2020-09-16T00:55:07.000000Z"
      },
      {
          "id": 957,
          "drug_id": 258,
          "indication_name": "Analgesia - MLK (morphine-lidocaine-ketamine) infusion",
          "expected_effects": "45% reduction in minimum alveolar concentration of isoflurane, i.e., the MLK infusion provides half the requirement for maintenance of general anesthesia",
          "common_combinations": "Coadministration with lidocaine 3 mg/kg/h IV CRI and morphine 0.24 mg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:55:09.000000Z",
          "updated_at": "2020-09-16T00:55:09.000000Z"
      },
      {
          "id": 958,
          "drug_id": 258,
          "indication_name": "Epidural analgesia - thoracotomy",
          "expected_effects": "Analgesia of forelimbs and thorax conferred by single dose for 30 minutes (ketamine only) or 90 minutes (ketamine + lidocaine), moderate motor effects (ataxia) of forelimbs but not hindlimbs (ketamine or ketamine + lidocaine), and no significant change in respiratory rate (ketamine or ketamine + lidocaine)",
          "common_combinations": "With or without lidocaine 0.25 mL/kg epidural once",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:55:11.000000Z",
          "updated_at": "2020-09-16T00:55:11.000000Z"
      },
      {
          "id": 959,
          "drug_id": 258,
          "indication_name": "Sedation - lateral recumbency with head down",
          "expected_effects": "Lateral recumbency with head down in 50%-95% of healthy cats, depending on midazolam dosage\nWith 3 mg/kg ketamine + 0.042 mg/kg midazolam: lateral recumbency with head down lasts 5.5 +/- 4 min, rising and walking with ataxia occurs after 26 +/- 5.7 min, and full recovery occurs at 1.7 +/- 0.4 hours",
          "common_combinations": "Midazolam 0.016-0.054 mg/kg IV 1 minute after ketamine",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:55:14.000000Z",
          "updated_at": "2020-09-16T00:55:14.000000Z"
      },
      {
          "id": 960,
          "drug_id": 258,
          "indication_name": "Deep sedation with analgesia",
          "expected_effects": "Absence of nociception (ulnar nerve stimulation) in 50%-95% of healthy cats, depending on midazolam dosage\nWith 3 mg/kg ketamine + 0.3 mg/kg midazolam: loss of nociception lasts 2.5 +/- 2.2 min, recovery to walking with ataxia occurs at 41.5 +/- 15.2 min, and complete recovery occurs at 3.6 +/- 1.3 hours",
          "common_combinations": "Midazolam 0.29-0.65 mg/kg IV 1 minute after ketamine",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:55:16.000000Z",
          "updated_at": "2020-09-16T00:55:16.000000Z"
      },
      {
          "id": 961,
          "drug_id": 258,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Loss of swallowing reflex in response to laryngoscope placed on back of tongue in 50%-95% of healthy cats, depending on midazolam dosage\nWith 3 mg/kg ketamine + 0.3 mg/kg midazolam: loss of swallowing reflex in response to laryngoscope contact lasts 3.7 +/- 2.3 min, recovery to walking with ataxia occurs at 41.5 +/- 15.2 min, and complete recovery occurs at 3.6 +/- 1.3 hours",
          "common_combinations": "Midazolam 0.27-0.58 mg/kg IV 1 minute after ketamine",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:55:18.000000Z",
          "updated_at": "2020-09-16T00:55:18.000000Z"
      },
      {
          "id": 962,
          "drug_id": 258,
          "indication_name": "Castration - DKO (dexmedetomidine-ketamine-opiate) combination",
          "expected_effects": "Onset of sedation 1.2-2 minutes after injection\nLateral recumbency 2.6-4.6 minutes after injection\n0% incidence of vomiting after drug administration\nIntubation possible in only 50% of cats 10 minutes after injection\nAdequate plane of anesthesia for castration obtained without further anesthetic in 90% (K-D-butorphanol), 80% (K-D-hydromorphone), and 30% (K-D-buprenorphine) of cats\nTime from injection to start of surgery: 10-14 minutes, and duration of surgery: 3-6 minutes, i.e., 13-20 minutes of adequate anesthesia needed",
          "common_combinations": "Dexmedetomidine 25 µg/kg and ketamine 3 mg/kg, combined, IM once;With or without one of the following: butorphanol 0.2 mg/kg, hydromorphone 0.05 mg/kg, or buprenorphine 30 µg/kg",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:55:21.000000Z",
          "updated_at": "2020-09-16T00:55:21.000000Z"
      },
      {
          "id": 963,
          "drug_id": 258,
          "indication_name": "Ovariohysterectomy or castration of feral cats - TKX (tiletamine-zolazepam-ketamine-xylazine) combination",
          "expected_effects": "Lateral recumbency in 4.1 minutes\nAdequate plane of anesthesia for ovariohysterectomy (without supplemental anesthetics) in 92% of cats, with the other 8% requiring a second dose of TKX at the onset of surgery based on signs of insufficient anesthetic depth\nRecovery to sternal recumbency in 72 +/- 42 minutes after reversal of xylazine with yohimbine 0.5 mg/CT IV\n≥ 99% survival rate",
          "common_combinations": "Tiletamine 12.5 mg/CAT, zolazepam 12.5 mg/CAT, and xylazine 5 mg/CAT, all coadministered with ketamine IM once",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:55:23.000000Z",
          "updated_at": "2020-09-16T00:55:23.000000Z"
      },
      {
          "id": 964,
          "drug_id": 258,
          "indication_name": "Immobilization, e.g., for mechanical ventilation - KFMP (ketamine-fentanyl-midazolam-propofol) combination",
          "expected_effects": "Optimal plane of light anesthesia easily maintained with titrated ketamine (+/- propofol) infusion rate",
          "common_combinations": "Fentanyl 0.01 mg/kg/h IV CRI;Midazolam 0.5 mg/kg/h IV CRI;With or without propofol 0.016 mg/kg/h IV CRI PRN",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T00:55:26.000000Z",
          "updated_at": "2020-09-16T00:55:26.000000Z"
      },
      {
          "id": 965,
          "drug_id": 259,
          "indication_name": "Dermatophytosis",
          "expected_effects": "Full clinical recovery in >99% of dogs within an average of 2 months",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:55:28.000000Z",
          "updated_at": "2020-09-16T00:55:28.000000Z"
      },
      {
          "id": 966,
          "drug_id": 259,
          "indication_name": "Pituitary-dependent hyperadrenocorticism",
          "expected_effects": "90% of dogs show some degree of clinical improvement with treatment (90-91% show reduction in polyuria, polydipsia, polyphagia, vs. 24% show improvement in potbellied appearance)\nMedian survival time: 25 months (range: 2-61 months)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:55:31.000000Z",
          "updated_at": "2020-09-16T00:55:31.000000Z"
      },
      {
          "id": 967,
          "drug_id": 259,
          "indication_name": "Reduction of cyclosporine dosage",
          "expected_effects": "36-71% less expensive than cyclosporine monotherapy, with similar results (improvement in >99% of dogs and complete clinical remission in 75% of dogs)",
          "common_combinations": "Cyclosporine 2.5-5.5 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:55:34.000000Z",
          "updated_at": "2020-09-16T00:55:34.000000Z"
      },
      {
          "id": 968,
          "drug_id": 259,
          "indication_name": "Sporotrichosis",
          "expected_effects": "Complete resolution of lesions after 8 weeks of treatment in single reported cases",
          "common_combinations": "Systemic antibacterial treatment (e.g., cephalexin) if concurrent pyoderma",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:55:36.000000Z",
          "updated_at": "2020-09-16T00:55:36.000000Z"
      },
      {
          "id": 969,
          "drug_id": 259,
          "indication_name": "Dermatophytosis",
          "expected_effects": "80% of cats with griseofulvin-resistant dermatophytosis have complete resolution of skin lesions with 4-10 weeks of ketoconazole treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:55:39.000000Z",
          "updated_at": "2020-09-16T00:55:39.000000Z"
      },
      {
          "id": 970,
          "drug_id": 259,
          "indication_name": "Sporotrichosis",
          "expected_effects": "29% of cats show complete resolution of infection, most others require ongoing treatment or succumb to the infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:55:41.000000Z",
          "updated_at": "2020-09-16T00:55:41.000000Z"
      },
      {
          "id": 971,
          "drug_id": 259,
          "indication_name": "Sporotrichosis",
          "expected_effects": "29% of cats show complete resolution of infection, most others require ongoing treatment or succumb to the infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:55:44.000000Z",
          "updated_at": "2020-09-16T00:55:44.000000Z"
      },
      {
          "id": 972,
          "drug_id": 259,
          "indication_name": "Malassezia-associated dermatitis",
          "expected_effects": "Resolution of pruritus within a few days and of all skin lesions without recurrence in 1 case report",
          "common_combinations": "Topical therapy (medicated shampoo)",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:55:46.000000Z",
          "updated_at": "2020-09-16T00:55:46.000000Z"
      },
      {
          "id": 973,
          "drug_id": 259,
          "indication_name": "Cryptococcosis",
          "expected_effects": "Variable: regression of lesions in approximately 50% of treated cats and failure to respond to treatment in the other 50%",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:55:49.000000Z",
          "updated_at": "2020-09-16T00:55:49.000000Z"
      },
      {
          "id": 974,
          "drug_id": 259,
          "indication_name": "Cryptococcosis",
          "expected_effects": "Variable: regression of lesions in approximately 50% of treated cats and failure to respond to treatment in the other 50%",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T00:55:51.000000Z",
          "updated_at": "2020-09-16T00:55:51.000000Z"
      },
      {
          "id": 975,
          "drug_id": 259,
          "indication_name": "Coccidioidomycosis",
          "expected_effects": "30% cure rate\n70% require extended or lifelong treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T00:55:54.000000Z",
          "updated_at": "2020-09-16T00:55:54.000000Z"
      },
      {
          "id": 976,
          "drug_id": 260,
          "indication_name": "Perioperative analgesia (e.g., orthopedic surgery)",
          "expected_effects": "Adequate analgesia as monotherapy (pain control equivalent to that conferred by codeine or tramadol as single agents)",
          "common_combinations": "Opiate (e.g., tramadol 2 mg/kg SC once or codeine 2 mg/kg SC once) or other complementary analgesic",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:55:57.000000Z",
          "updated_at": "2020-09-16T00:55:57.000000Z"
      },
      {
          "id": 977,
          "drug_id": 260,
          "indication_name": "Orthopedic pain - chronic",
          "expected_effects": "Mixed results: lameness is unchanged during treatment (compared to placebo), but 39% of owners report worsening of lameness after discontinuation of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:55:59.000000Z",
          "updated_at": "2020-09-16T00:55:59.000000Z"
      },
      {
          "id": 978,
          "drug_id": 260,
          "indication_name": "Perioperative analgesia (e.g., onychectomy +/- castration)",
          "expected_effects": "Analgesic effects better than saline placebo, comparable to oxymorphone, but significantly inferior to buprenorphine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:56:01.000000Z",
          "updated_at": "2020-09-16T00:56:01.000000Z"
      },
      {
          "id": 979,
          "drug_id": 260,
          "indication_name": "Acute inflammatory disorders (abscess, orthopedic injury, etc.)",
          "expected_effects": "Significant improvement (47% by day 2, 79% by day 4, with 100% being full recovery) in composite of clinical signs including appetite, demeanor, and level of activity",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:56:05.000000Z",
          "updated_at": "2020-09-16T00:56:05.000000Z"
      },
      {
          "id": 980,
          "drug_id": 261,
          "indication_name": "Neutrophil dysfunction (familial)",
          "expected_effects": "Variable, with improvement and near-resolution of signs of opportunistic infection after 2-4 weeks of treatment in some dogs and little visible benefit in others",
          "common_combinations": "Supportive care",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:56:07.000000Z",
          "updated_at": "2020-09-16T00:56:07.000000Z"
      },
      {
          "id": 981,
          "drug_id": 261,
          "indication_name": "Stomatitis (FIV-associated)",
          "expected_effects": "Significant reduction in gingival inflammation, signs of oral pain, and salivation, and improvement in appetite",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:56:09.000000Z",
          "updated_at": "2020-09-16T00:56:09.000000Z"
      },
      {
          "id": 982,
          "drug_id": 261,
          "indication_name": "Enhance neutrophil function",
          "expected_effects": "Significant increase in neutrophil phagocytic function",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:56:12.000000Z",
          "updated_at": "2020-09-16T00:56:12.000000Z"
      },
      {
          "id": 983,
          "drug_id": 262,
          "indication_name": "Hepatic encephalopathy - prevention",
          "expected_effects": "Nonspecific reduction in probability and/or severity of signs of hepatic encephalopathy (unproven)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:56:14.000000Z",
          "updated_at": "2020-09-16T00:56:14.000000Z"
      },
      {
          "id": 984,
          "drug_id": 262,
          "indication_name": "Hepatic encephalopathy - encephalopathic crisis",
          "expected_effects": "Marked clinical improvement within 24h, with some return of appetite\nAlert, normal gait, and normal appetite after 7 days in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:56:16.000000Z",
          "updated_at": "2020-09-16T00:56:16.000000Z"
      },
      {
          "id": 985,
          "drug_id": 262,
          "indication_name": "Stool softening (e.g., post-op colorectal surgery)",
          "expected_effects": "No documented constipation for >4 months",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:56:19.000000Z",
          "updated_at": "2020-09-16T00:56:19.000000Z"
      },
      {
          "id": 986,
          "drug_id": 262,
          "indication_name": "Megacolon - chronic constipation prevention",
          "expected_effects": "Adjusted to create soft but formed stool (e.g., up to 20 mL PO q 8h for chronic management of severe megacolon in a 20 kg dog, based on one case report)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:56:22.000000Z",
          "updated_at": "2020-09-16T00:56:22.000000Z"
      },
      {
          "id": 987,
          "drug_id": 262,
          "indication_name": "Hydrogen breath testing in healthy dogs",
          "expected_effects": "Breath hydrogen concentration of 3.9, 6.6, and 14.9 ppm (vs. baseline fasting: <1 ppm) 2h after ingestion of 12.5, 25, and 50 g/DOG of lactulose, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:56:24.000000Z",
          "updated_at": "2020-09-16T00:56:24.000000Z"
      },
      {
          "id": 988,
          "drug_id": 262,
          "indication_name": "Hepatic encephalopathy - prevention",
          "expected_effects": "Surgical and post-op success in 67% of cats, 17% perioperative mortality, 17% medium-term mortality in 1 case series",
          "common_combinations": "Low-protein diet;Oral antibacterial (e.g., ampicillin)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:56:27.000000Z",
          "updated_at": "2020-09-16T00:56:27.000000Z"
      },
      {
          "id": 989,
          "drug_id": 262,
          "indication_name": "Hepatic encephalopathy - encephalopathic crisis",
          "expected_effects": "Transition from obtunded and seizuring to depressed but ambulatory after 10 hours of treatment in 1 case report",
          "common_combinations": "Acute anticonvulsant treatment (e.g., diazepam, midazolam, phenobarbital PRN)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:56:29.000000Z",
          "updated_at": "2020-09-16T00:56:29.000000Z"
      },
      {
          "id": 990,
          "drug_id": 262,
          "indication_name": "Hydrogen breath testing in healthy cats",
          "expected_effects": "Typical rate of breath hydrogen exhaled 0-180 minutes after oral dosing is 0-4 mL/h in the healthy cat, depending on bacterial flora/antibacterial treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:56:32.000000Z",
          "updated_at": "2020-09-16T00:56:32.000000Z"
      },
      {
          "id": 991,
          "drug_id": 263,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "Excellent response with few/no adverse effects in 83% of treated dogs\nPoor response if underlying myelofibrosis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:56:34.000000Z",
          "updated_at": "2020-09-16T00:56:34.000000Z"
      },
      {
          "id": 992,
          "drug_id": 263,
          "indication_name": "Immune-mediated thrombocytopenia",
          "expected_effects": "Excellent response with few/no adverse effects in 1 small case series",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:56:36.000000Z",
          "updated_at": "2020-09-16T00:56:36.000000Z"
      },
      {
          "id": 993,
          "drug_id": 263,
          "indication_name": "Immune-mediated polyarthritis",
          "expected_effects": "Complete resolution of signs of polyarthritis in 57% of dogs, improvement/incomplete response in 36% of dogs, and no response in 7% of dogs\nIn many responders, signs recur when tapering or stopping leflunomide, indicating the value of tapering and monitoring, and restarting/increasing dosage if signs recur (active disease process)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:56:39.000000Z",
          "updated_at": "2020-09-16T00:56:39.000000Z"
      },
      {
          "id": 994,
          "drug_id": 263,
          "indication_name": "Granulomatous/steroid-responsive meningoencephalitis",
          "expected_effects": "Excellent response with few/no adverse effects in 1 small case series (improvement in neurologic signs in majority of dogs, and mild to marked reduction in lesions seen on MRI)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:56:42.000000Z",
          "updated_at": "2020-09-16T00:56:42.000000Z"
      },
      {
          "id": 995,
          "drug_id": 263,
          "indication_name": "Systemic histiocytosis",
          "expected_effects": "Excellent response for cutaneous and nasal forms, with complete remission of disease\nPoor response (no appreciable efficacy) in 1 case of visceral (splenic, hepatic) histiocytosis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:56:44.000000Z",
          "updated_at": "2020-09-16T00:56:44.000000Z"
      },
      {
          "id": 996,
          "drug_id": 263,
          "indication_name": "Organ transplantation",
          "expected_effects": "Survival time: 0.5-4014 days\n15-day survival: 50%\n100-day survival: 36%",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:56:47.000000Z",
          "updated_at": "2020-09-16T00:56:47.000000Z"
      },
      {
          "id": 997,
          "drug_id": 263,
          "indication_name": "Rheumatoid arthritis",
          "expected_effects": "Marked improvement in 58% of cats, sometimes within 4 weeks",
          "common_combinations": "Methotrexate 7.5 mg/CAT/week (split into three doses of 2.5 mg/CAT PO given on one day: 0, 12, and 24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:56:49.000000Z",
          "updated_at": "2020-09-16T00:56:49.000000Z"
      },
      {
          "id": 998,
          "drug_id": 264,
          "indication_name": "Methotrexate intoxication",
          "expected_effects": "Significant drop in plasma methotrexate concentrations (from 0.05-0.22 µmol/L, to < 0.01 µmol/L), resulting in prevention of toxic effects",
          "common_combinations": "General decontamination procedures if acute ingestion (apomorphine, activated charcoal);Supportive care and diuresis (IV fluids);N-acetylcysteine",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:56:52.000000Z",
          "updated_at": "2020-09-16T00:56:52.000000Z"
      },
      {
          "id": 999,
          "drug_id": 264,
          "indication_name": "Leucovorin rescue",
          "expected_effects": "Limits severe adverse effects of methotrexate 3 g/m² (granulocytopenias evident) but inadequate for methotrexate 6 g/m² dosage",
          "common_combinations": "Methotrexate 3-6 g/m²;IV fluid therapy;Sodium bicarbonate to alkalinize urine (reduces intrarenal precipitation of methotrexate)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:56:54.000000Z",
          "updated_at": "2020-09-16T00:56:54.000000Z"
      },
      {
          "id": 1000,
          "drug_id": 265,
          "indication_name": "Lungworm - Filaroides (Oslerus) osleri",
          "expected_effects": "Resolution of cough 4 days (median) after starting treatment (range: 2-28 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:56:56.000000Z",
          "updated_at": "2020-09-16T00:56:56.000000Z"
      },
      {
          "id": 1001,
          "drug_id": 265,
          "indication_name": "Lungworm - Crenosoma vulpis infestation",
          "expected_effects": ">99% elimination of worms (at necropsy 2 weeks after treatment - experimental dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:56:59.000000Z",
          "updated_at": "2020-09-16T00:56:59.000000Z"
      },
      {
          "id": 1002,
          "drug_id": 265,
          "indication_name": "French heartworm - Angiostrongylus vasorum infestation",
          "expected_effects": "Elimination of lethargy, lameness (with associated joint swelling), and all larvae from >80% of dogs on follow-up fecal exams 5 days after end of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:57:01.000000Z",
          "updated_at": "2020-09-16T00:57:01.000000Z"
      },
      {
          "id": 1003,
          "drug_id": 265,
          "indication_name": "Immunomodulation - systemic lupus erythematosus",
          "expected_effects": "Extended remission (months-years, maximum 9 years) in 56% of dogs, vs. brief remission and long-term corticosteroid therapy when levamisole was not part of the treatment protocol",
          "common_combinations": "Prednisone 1-2 mg/kg/day PO, tapered and stopped over 4-8 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:57:04.000000Z",
          "updated_at": "2020-09-16T00:57:04.000000Z"
      },
      {
          "id": 1004,
          "drug_id": 265,
          "indication_name": "Heartworm (Dirofilaria immitis) - microfilaricide",
          "expected_effects": "Reduction in microfilaremia within 24h, dropping 64-73% over 3-4 days, but returning to a slightly decreased peak within 10 days",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:57:06.000000Z",
          "updated_at": "2020-09-16T00:57:06.000000Z"
      },
      {
          "id": 1005,
          "drug_id": 265,
          "indication_name": "Lungworm - Capillaria aerophila infestation",
          "expected_effects": "Resolution of cough and of Capillaria ova in feces after 2nd injection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:57:09.000000Z",
          "updated_at": "2020-09-16T00:57:09.000000Z"
      },
      {
          "id": 1006,
          "drug_id": 266,
          "indication_name": "Status epilepticus/acute repetitive seizures",
          "expected_effects": "No additional seizures for at least 24h in 56% of dogs receiving diazepam and levetiracetam, compared to 10% of dogs receiving diazepam alone",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:57:12.000000Z",
          "updated_at": "2020-09-16T00:57:12.000000Z"
      },
      {
          "id": 1007,
          "drug_id": 266,
          "indication_name": "Status epilepticus/acute repetitive seizures",
          "expected_effects": "No additional seizures for at least 24h in 56% of dogs receiving diazepam and levetiracetam, compared to 10% of dogs receiving diazepam alone",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:57:14.000000Z",
          "updated_at": "2020-09-16T00:57:14.000000Z"
      },
      {
          "id": 1008,
          "drug_id": 266,
          "indication_name": "Refractory idiopathic epilepsy",
          "expected_effects": "Significant decrease (at least 50% reduction) in seizure frequency in 56% of dogs (vs. 30% in placebo-treated controls)\nOwners report improved quality of life compared to baseline or placebo",
          "common_combinations": "Ongoing treatment with phenobarbital and potassium bromide (With or without zonisamide and/or gabapentin) in most dogs",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:57:16.000000Z",
          "updated_at": "2020-09-16T00:57:16.000000Z"
      },
      {
          "id": 1009,
          "drug_id": 266,
          "indication_name": "Idiopathic epilepsy",
          "expected_effects": "Significant decrease (at least 50% reduction) in seizure frequency in 70% of cats (median of 0.42 seizures/month, compared to 2.1 seizures/month untreated)",
          "common_combinations": "Phenobarbital",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:57:19.000000Z",
          "updated_at": "2020-09-16T00:57:19.000000Z"
      },
      {
          "id": 1010,
          "drug_id": 267,
          "indication_name": "Hypothyroidism (general)",
          "expected_effects": "Resolution of lethargy and mental dullness within 2 weeks in most dogs, and in subsequent weeks in virtually all dogs\nResolution of dermatological signs and mean 10% decrease in body weight within 3 months in most dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:57:22.000000Z",
          "updated_at": "2020-09-16T00:57:22.000000Z"
      },
      {
          "id": 1011,
          "drug_id": 267,
          "indication_name": "Hypothyroidism (severe: myxedema)",
          "expected_effects": "Resolution of distal limb edema, myxedema, abdominal distension, and inappetence after 2 weeks in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:57:24.000000Z",
          "updated_at": "2020-09-16T00:57:24.000000Z"
      },
      {
          "id": 1012,
          "drug_id": 267,
          "indication_name": "Hypothyroidism (comatose) - IV administration",
          "expected_effects": "Clinical improvement over several hours, hospital discharge after 3 days, and normal physical exam (while receiving lifelong oral levothyroxine) 3 months later in 1 case report",
          "common_combinations": "Supportive measures and intense nursing care as dictated by clinical severity",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:57:27.000000Z",
          "updated_at": "2020-09-16T00:57:27.000000Z"
      },
      {
          "id": 1013,
          "drug_id": 267,
          "indication_name": "Hypothyroidism post-thyroidectomy",
          "expected_effects": "Normalization of thyroid status (dosage adjusted based on serum thyroxine monitoring) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:57:30.000000Z",
          "updated_at": "2020-09-16T00:57:30.000000Z"
      },
      {
          "id": 1014,
          "drug_id": 267,
          "indication_name": "Hypothyroidism associated with neurologic dysfunction",
          "expected_effects": "Resolution of lower motor neuron and vestibular signs within 2 months in 97% of dogs\nHighly variable progression of megaesophagus, from marked clinical improvement to severe deterioration (radiographic megaesophagus persists regardless)\nSubstantial improvement in laryngeal paralysis confounded by laryngeal surgery performed in most cases (but single case descriptions indicate that an owner-perceived improvement in laryngeal signs with levothyroxine treatment alone is possible)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:57:32.000000Z",
          "updated_at": "2020-09-16T00:57:32.000000Z"
      },
      {
          "id": 1015,
          "drug_id": 267,
          "indication_name": "Hypothyroidism associated with decreased renal function",
          "expected_effects": "Significant improvement in renal function: glomerular filtration rate ≥ 2 mL/min/kg in 44% of dogs after 1 month and decrease in serum creatine concentration from 1.4 to 1.1 mg/dL after 1 month",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:57:34.000000Z",
          "updated_at": "2020-09-16T00:57:34.000000Z"
      },
      {
          "id": 1016,
          "drug_id": 267,
          "indication_name": "Hypothyroidism associated with retinal dysfunction",
          "expected_effects": "50% decrease in mean photopic a-wave and b-wave peak times, and 42% decrease in mean scotopic b-wave peak times",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:57:37.000000Z",
          "updated_at": "2020-09-16T00:57:37.000000Z"
      },
      {
          "id": 1017,
          "drug_id": 267,
          "indication_name": "Hypothyroidism (after excessive radioiodine treatment for hyperthyroidism)",
          "expected_effects": "Resolution of clinical signs within 1-3 months after starting levothyroxine in >90% of cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:57:39.000000Z",
          "updated_at": "2020-09-16T00:57:39.000000Z"
      },
      {
          "id": 1018,
          "drug_id": 267,
          "indication_name": "Hypothyroidism (congenital)",
          "expected_effects": "Improvement in demeanor within a few days, grater playfulness and resolution of constipation after 6 weeks, and significant growth and normal haircoat within a year of starting treatment, in 1 case report.",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:57:42.000000Z",
          "updated_at": "2020-09-16T00:57:42.000000Z"
      },
      {
          "id": 1019,
          "drug_id": 268,
          "indication_name": "Antiarrhythmic - ventricular tachycardia",
          "expected_effects": "Elimination of ventricular arrhythmia in >90% of dogs",
          "common_combinations": "Treatment of the inciting cause",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:57:45.000000Z",
          "updated_at": "2020-09-16T00:57:45.000000Z"
      },
      {
          "id": 1020,
          "drug_id": 268,
          "indication_name": "Systemic analgesia - FLK (fentanyl-lidocaine-ketamine) infusion",
          "expected_effects": "97% reduction in minimum alveolar concentration of isoflurane, i.e., the FLK infusion essentially provides total intravenous anesthesia",
          "common_combinations": "Coadministration with ketamine 0.6 mg/kg/h IV CRI and fentanyl 3.6 µg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:57:47.000000Z",
          "updated_at": "2020-09-16T00:57:47.000000Z"
      },
      {
          "id": 1021,
          "drug_id": 268,
          "indication_name": "Systemic analgesia - MLK (morphine-lidocaine-ketamine) infusion",
          "expected_effects": "45% reduction in minimum alveolar concentration of isoflurane, i.e., the MLK infusion provides half the requirement for maintenance of general anesthesia",
          "common_combinations": "Coadministration with ketamine 0.6 mg/kg/h IV CRI and morphine 0.24 mg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:57:50.000000Z",
          "updated_at": "2020-09-16T00:57:50.000000Z"
      },
      {
          "id": 1022,
          "drug_id": 268,
          "indication_name": "Atrial fibrillation - acute, vagally-mediated",
          "expected_effects": "Cardioversion to sinus rhythm within approximately 60 seconds in 2 reported cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:57:52.000000Z",
          "updated_at": "2020-09-16T00:57:52.000000Z"
      },
      {
          "id": 1023,
          "drug_id": 268,
          "indication_name": "Anesthesia/analgesia (regional) - castration",
          "expected_effects": "Significantly less post-operative pain, with only 7% of dogs requiring additional analgesia (vs. 47% in control group)",
          "common_combinations": "Buprenorphine 0.02 mg/kg IM once;Carprofen 4 mg/kg IV once;Isoflurane general anesthesia",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:57:55.000000Z",
          "updated_at": "2020-09-16T00:57:55.000000Z"
      },
      {
          "id": 1024,
          "drug_id": 268,
          "indication_name": "Cardiac arrhythmias",
          "expected_effects": "Decreases cardiac sympathetic nerve activity",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:57:57.000000Z",
          "updated_at": "2020-09-16T00:57:57.000000Z"
      },
      {
          "id": 1025,
          "drug_id": 268,
          "indication_name": "Epidural anesthesia",
          "expected_effects": "Analgesia extending to T13-L1 lasting for 69 minutes (lidocaine) or 137 minutes (ketamine + lidocaine), with severe hindlimb ataxia regardless of treatment regimen",
          "common_combinations": "Xylazine 0.1 mg/kg IM once",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:58:00.000000Z",
          "updated_at": "2020-09-16T00:58:00.000000Z"
      },
      {
          "id": 1026,
          "drug_id": 269,
          "indication_name": "Susceptible bacterial infections (e.g., pyoderma)",
          "expected_effects": "71-93% response to treatment, similar or slightly inferior to treatment with once-daily clindamycin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:02.000000Z",
          "updated_at": "2020-09-16T00:58:02.000000Z"
      },
      {
          "id": 1027,
          "drug_id": 270,
          "indication_name": "Mitral regurgitation",
          "expected_effects": "Significant decrease in left-ventricular end-diastolic pressure and pulmonary capillary wedge pressure during treatment of experimentally-created mitral regurgitation in otherwise healthy large-breed dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:04.000000Z",
          "updated_at": "2020-09-16T00:58:04.000000Z"
      },
      {
          "id": 1028,
          "drug_id": 270,
          "indication_name": "To lower arterial blood pressure",
          "expected_effects": "Small but significant decrease is systolic arterial pressure, and increase is heart rate, during treatment with lisinopril and low-sodium diet in otherwise healthy cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:58:07.000000Z",
          "updated_at": "2020-09-16T00:58:07.000000Z"
      },
      {
          "id": 1029,
          "drug_id": 271,
          "indication_name": "Cyclic hematopoiesis",
          "expected_effects": "Marked improvement in peaks and nadirs of all leukocyte lines",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:09.000000Z",
          "updated_at": "2020-09-16T00:58:09.000000Z"
      },
      {
          "id": 1030,
          "drug_id": 271,
          "indication_name": "Estrogen-induced myelosuppression",
          "expected_effects": "Doubling of neutrophil count within 1 week, gradual regeneration of platelets and RBC within 2 weeks, and normal CBC within a month following treatment, all in 1 case report",
          "common_combinations": "Vitamin-mineral supplementation",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:58:12.000000Z",
          "updated_at": "2020-09-16T00:58:12.000000Z"
      },
      {
          "id": 1031,
          "drug_id": 271,
          "indication_name": "Prevention of lomustine chemotherapy-associated myelosuppression",
          "expected_effects": "No appreciable blunting of myelosuppressive effects of other drugs, and additional non-hematologic toxicoses",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:58:14.000000Z",
          "updated_at": "2020-09-16T00:58:14.000000Z"
      },
      {
          "id": 1032,
          "drug_id": 271,
          "indication_name": "Prevention of carboplatin chemotherapy-associated myelosuppression",
          "expected_effects": "Minor increases in platelet numbers and neutrophil count in healthy dogs receiving lithium without chemotherapy, but transient neutropenia and thrombocytopenia in carboplatin-treated dogs are not improved by lithium treatment (e.g., median platelet count changed from 300 X 10[9] at baseline to 137 X 10[9] at day 11 in dogs treated with carboplatin and 101 X 10[9] at day 11 in dogs treated with carboplatin and lithium in 1 study)",
          "common_combinations": "Carboplatin induced thrombocytopenia for which lithium carbonate was ineffective in treating",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:58:17.000000Z",
          "updated_at": "2020-09-16T00:58:17.000000Z"
      },
      {
          "id": 1033,
          "drug_id": 272,
          "indication_name": "Osteosarcoma",
          "expected_effects": "1-year disease-free fraction: 21.8%\n1-year survival: 31.8%",
          "common_combinations": "Surgical resection of lesion (e.g., amputation of affected limb)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:19.000000Z",
          "updated_at": "2020-09-16T00:58:19.000000Z"
      },
      {
          "id": 1034,
          "drug_id": 273,
          "indication_name": "Lymphoma",
          "expected_effects": "Complete remission rate: 85%\nFirst remission lasting 190-444 days (median: 317 days)\n38% lower risk of relapse on a given day of treatment compared to L-CHOP treatment protocol",
          "common_combinations": "Multidrug protocol in L-CHOP and MOPP protocol (L-asparaginase, vincristine, doxorubicin, cyclophosphamide, prednisolone, mechlorethamine, and procarbazine)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:22.000000Z",
          "updated_at": "2020-09-16T00:58:22.000000Z"
      },
      {
          "id": 1035,
          "drug_id": 273,
          "indication_name": "Lymphoma (relapsed/resistant) - dacarbazine/DTIC protocol",
          "expected_effects": "23% of lymphoma-resistant/relapsing dogs had a complete response to treatment and 12% had a partial response, lasting 31-135 days (median: 83 days) and 0-71 days (median: 25 days), respectively",
          "common_combinations": "DTIC 600 mg/m² IV",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:58:24.000000Z",
          "updated_at": "2020-09-16T00:58:24.000000Z"
      },
      {
          "id": 1036,
          "drug_id": 273,
          "indication_name": "Lymphoma (relapsed/resistant) - procarbazine/LOPP protocol",
          "expected_effects": "Median survival time: 98 days (interquartile range: 47-176 days)\nCompared to other lomustine protocols, this approach is associated with lower grade of GI toxicosis, 50% fewer cases of neutropenia, and 15% hospitalization rate (vs. 25%)\n100% and 50% reduction in size of lesions occurs in 36% and 24% of dogs, respectively",
          "common_combinations": "Vincristine;Procarbazine;Prednisone;Alpha-lipoic acid 5 mg/kg PO q 12h during treatment with lomustine, as a hepatoprotectant",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:58:26.000000Z",
          "updated_at": "2020-09-16T00:58:26.000000Z"
      },
      {
          "id": 1037,
          "drug_id": 273,
          "indication_name": "Mast cell tumor (nonresectable)",
          "expected_effects": "1% remission rate, and 10% rate of some degree of benefit, after 14 weeks\nAt this high dosage, 86% incidence of severe neutropenia and 33% rate of severe hepatopathy",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:58:29.000000Z",
          "updated_at": "2020-09-16T00:58:29.000000Z"
      },
      {
          "id": 1038,
          "drug_id": 273,
          "indication_name": "Lymphoma",
          "expected_effects": "Progression-free for 7-708 days (median: 39 days)\nMedian of 21 and 169 progression-free days for large and small/intermediate lymphomas, respectively\nMedian of 25.5 and 180 progression-free days for non-GI and GI lymphomas, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:58:31.000000Z",
          "updated_at": "2020-09-16T00:58:31.000000Z"
      },
      {
          "id": 1039,
          "drug_id": 273,
          "indication_name": "Vaccine-associated sarcoma",
          "expected_effects": "Maximal treatment response achieved in 14-88 days, consisting of 25% response to treatment (4% complete remission, 21% partial remission)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:58:33.000000Z",
          "updated_at": "2020-09-16T00:58:33.000000Z"
      },
      {
          "id": 1040,
          "drug_id": 273,
          "indication_name": "Histiocytic sarcoma",
          "expected_effects": "Survival for 50 additional days, following addition of lomustine to treatment protocol, in 1 feline case report",
          "common_combinations": "Prednisolone;Blood transfusions",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:58:36.000000Z",
          "updated_at": "2020-09-16T00:58:36.000000Z"
      },
      {
          "id": 1041,
          "drug_id": 273,
          "indication_name": "Mast cell tumor",
          "expected_effects": "50% response rate (18% complete response, 32% partial response) lasting 25-727 days (median: 168 days)\n14% incidence of moderate or severe neutropenia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:58:38.000000Z",
          "updated_at": "2020-09-16T00:58:38.000000Z"
      },
      {
          "id": 1042,
          "drug_id": 273,
          "indication_name": "Neoplasms (various) - lymphoma, fibrosarcoma/injection-site sarcoma, multiple myeloma",
          "expected_effects": "25% partial response rate (defined as ≥ 50% reduction in tumor size, with no new tumors, consisting of cats with lymphoma [responders: 40% of lymphoma cases], fibrosarcoma [responders: 40% of fibrosarcoma/injection site sarcoma cases] and multiple myeloma [1 reported case])\n4% incidence of severe neutropenia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T00:58:40.000000Z",
          "updated_at": "2020-09-16T00:58:40.000000Z"
      },
      {
          "id": 1043,
          "drug_id": 274,
          "indication_name": "Diarrhea (e.g., associated with short-bowel syndrome)",
          "expected_effects": "Reduction in frequency of diarrhea in some individual cases\nVariable efficacy for long-term control of diarrhea",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:43.000000Z",
          "updated_at": "2020-09-16T00:58:43.000000Z"
      },
      {
          "id": 1044,
          "drug_id": 275,
          "indication_name": "Pre-anesthetic",
          "expected_effects": "Tranquilizing effects apparent within 5 minutes\nNo change in cardiopulmonary parameters\nSubjectively, enhanced muscle relaxation during surgery (e.g., easier manipulation of fractures compared to muscle tone with other preanesthetic protocols)",
          "common_combinations": "Thiopental",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:45.000000Z",
          "updated_at": "2020-09-16T00:58:45.000000Z"
      },
      {
          "id": 1045,
          "drug_id": 275,
          "indication_name": "Status epilepticus",
          "expected_effects": "Mean 3.4h seizure-free interval, 75% of dogs controlled with lorazepam alone (all findings similar to those of diazepam, i.e., not significantly different)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:58:47.000000Z",
          "updated_at": "2020-09-16T00:58:47.000000Z"
      },
      {
          "id": 1046,
          "drug_id": 276,
          "indication_name": "Flea infestation - preventive",
          "expected_effects": "> 90% efficacy after 4-5 weeks\n> 95% efficacy after 56 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:58:50.000000Z",
          "updated_at": "2020-09-16T00:58:50.000000Z"
      },
      {
          "id": 1047,
          "drug_id": 276,
          "indication_name": "Dermatophytosis or superficial dermatomycoses",
          "expected_effects": ">99% of dogs have a negative fungal culture result within 14.5 days, and resolution of gross lesions within 21 days (compared to ≈8% in untreated controls)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:58:52.000000Z",
          "updated_at": "2020-09-16T00:58:52.000000Z"
      },
      {
          "id": 1048,
          "drug_id": 276,
          "indication_name": "Flea infestation - preventive",
          "expected_effects": "Substantial (72.5%) reduction in flea burden in cats, but other products including fenthion and imidacloprid consistently eliminate a larger proportion of the flea burden",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:58:55.000000Z",
          "updated_at": "2020-09-16T00:58:55.000000Z"
      },
      {
          "id": 1049,
          "drug_id": 276,
          "indication_name": "Dermatophytosis",
          "expected_effects": ">99% cure rate when lufenuron treatment is followed by griseofulvin (vs. 57% cure rate with griseofulvin and no lufenuron pretreatment, or 54% cure rate with lufenuron alone)",
          "common_combinations": "Griseofulvin 50 mg/kg PO q 12h for 40 days (after lufenuron pre-treatment), with or without enilconazole rinse (0.2% topical rinse q 1 week for 4 weeks during griseofulvin treatment)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:58:57.000000Z",
          "updated_at": "2020-09-16T00:58:57.000000Z"
      },
      {
          "id": 1050,
          "drug_id": 277,
          "indication_name": "Feline herpesvirus infection",
          "expected_effects": "Significantly fewer viral shedding episodes with lysine supplementation, but benefit is lost (overridden) by stress of glucocorticoid administration\nLess conjunctivitis with treatment in some but not all cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:59:00.000000Z",
          "updated_at": "2020-09-16T00:59:00.000000Z"
      },
      {
          "id": 1051,
          "drug_id": 278,
          "indication_name": "Acute replacement in hypomagnesemia",
          "expected_effects": "Correction of hypomagnesemia and associated signs\nMay require repeated boluses\nTotal cumulative dose must not exceed 2 mEq/kg (hypotension)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:59:02.000000Z",
          "updated_at": "2020-09-16T00:59:02.000000Z"
      },
      {
          "id": 1052,
          "drug_id": 278,
          "indication_name": "Tetanus",
          "expected_effects": "Substantial improvement in muscle relaxation and comfort within 48 hours of initiating (and escalating) infusion to produce high-normal serum magnesium concentrations in 1 case report",
          "common_combinations": "Diazepam and phenobarbital IV CRIs as needed;Low-dose (0.02-0.03 mg/kg) acepromazine boluses as needed;Intensive supportive care",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:59:05.000000Z",
          "updated_at": "2020-09-16T00:59:05.000000Z"
      },
      {
          "id": 1053,
          "drug_id": 278,
          "indication_name": "Reduction of general anesthesia requirement",
          "expected_effects": "No difference in anesthetic depth, cardiovascular variables, post-operative pain scores, or other variables compared to placebo",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:59:07.000000Z",
          "updated_at": "2020-09-16T00:59:07.000000Z"
      },
      {
          "id": 1054,
          "drug_id": 278,
          "indication_name": "Hypomagnesemia causing refractory hypokalemia",
          "expected_effects": "Return of serum magnesium to within reference range\nAbility to correct previously refractory hypokalemia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:59:11.000000Z",
          "updated_at": "2020-09-16T00:59:11.000000Z"
      },
      {
          "id": 1055,
          "drug_id": 279,
          "indication_name": "Reduction of elevated intracranial pressure",
          "expected_effects": "44% decrease in mean intracranial pressure (16 mmHg [pre] to 9 mmHg [post])\nDecrease in mean intracranial pressure of <3 mmHg in 40% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:59:13.000000Z",
          "updated_at": "2020-09-16T00:59:13.000000Z"
      },
      {
          "id": 1056,
          "drug_id": 279,
          "indication_name": "Reduction of elevated intraocular pressure",
          "expected_effects": "Mean intraocular pressure (IOP) decrease: 3.21 mmHg, during the first 60 min\nDecrease in IOP lasts up to 30 min longer than treatment with hypertonic hydroxyethyl starch",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:59:15.000000Z",
          "updated_at": "2020-09-16T00:59:15.000000Z"
      },
      {
          "id": 1057,
          "drug_id": 279,
          "indication_name": "Unilateral renal obstruction identification",
          "expected_effects": "Mannitol decreases ultrasound-derived resistive index in normal dog kidneys, but mannitol with ureteral obstruction increases the resistive index\nMean renal resistive index of 0.79 and 0.80 in obstructed kidney at 30 and 60 min after treatment, respectively, compared to 0.53 and 0.54 in nonobstructed kidney at the same times\nOverall false-negative rate of 24% when using a renal resistive index of 0.73 as an obstruction-positive level, or 12% when comparing kidneys within the same dog",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:59:18.000000Z",
          "updated_at": "2020-09-16T00:59:18.000000Z"
      },
      {
          "id": 1058,
          "drug_id": 279,
          "indication_name": "Mobilization of body cavity effusion in patient with normal cardiovascular and renal function",
          "expected_effects": "Reduction in ascites by 5 mL/kg after 2h, and 22% increase in plasma volume (vs. reduction in ascites by 23 mL/kg after 2h, and 14% decrease in plasma volume with furosemide 5-10 mg/kg [in experimental dogs])",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:59:20.000000Z",
          "updated_at": "2020-09-16T00:59:20.000000Z"
      },
      {
          "id": 1059,
          "drug_id": 279,
          "indication_name": "Diuretic",
          "expected_effects": "9.5 mL/DOG urine production (vs. 23 mL/DOG with 5-10 mg/kg furosemide single dose [in experimental dogs]) over a 2-hour period",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:59:22.000000Z",
          "updated_at": "2020-09-16T00:59:22.000000Z"
      },
      {
          "id": 1060,
          "drug_id": 279,
          "indication_name": "Reduction of elevated intracranial pressure",
          "expected_effects": "3.5% increase in plasma osmolality (320 to 331.6 mOsm/L)\nNo effect on CSF osmolality or plasma vasopressin concentration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:59:25.000000Z",
          "updated_at": "2020-09-16T00:59:25.000000Z"
      },
      {
          "id": 1061,
          "drug_id": 279,
          "indication_name": "Reduction of elevated intracranial pressure",
          "expected_effects": "53.5% decrease in intracranial pressure after 30 min (from mean of 29.7 mmHg to 13.8 mmHg)\nNo significant effect on serum osmolality",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:59:27.000000Z",
          "updated_at": "2020-09-16T00:59:27.000000Z"
      },
      {
          "id": 1062,
          "drug_id": 279,
          "indication_name": "Protection from acute kidney injury: intraop during renal transplantation",
          "expected_effects": "Nonspecific reduction of risk of acute renal injury\n64% overall survival at 14 days post-op",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T00:59:30.000000Z",
          "updated_at": "2020-09-16T00:59:30.000000Z"
      },
      {
          "id": 1063,
          "drug_id": 280,
          "indication_name": "Pyoderma",
          "expected_effects": "81% response rate (as assessed 1 week after end of treatment), maintained for >1 month in 70% (11% relapse rate) - similar to ibafloxacin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:59:32.000000Z",
          "updated_at": "2020-09-16T00:59:32.000000Z"
      },
      {
          "id": 1064,
          "drug_id": 280,
          "indication_name": "Urinary tract infection",
          "expected_effects": "96.2% bacteriological cure rate\n83.3% clinical cure rate\nFewer relapses after end of treatment compared to amoxicillin-clavulanate",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:59:35.000000Z",
          "updated_at": "2020-09-16T00:59:35.000000Z"
      },
      {
          "id": 1065,
          "drug_id": 280,
          "indication_name": "Urinary tract infection",
          "expected_effects": "96.2% bacteriological cure rate\n83.3% clinical cure rate\nFewer relapses after end of treatment compared to amoxicillin-clavulanate",
          "common_combinations": "Concurrent treatment of underlying cause (e.g., uroliths, prostatic disease, etc.) if present",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:59:37.000000Z",
          "updated_at": "2020-09-16T00:59:37.000000Z"
      },
      {
          "id": 1066,
          "drug_id": 280,
          "indication_name": "Intraocular infection",
          "expected_effects": "Peak marbofloxacin concentration reached in aqueous humor 3.5h after IV injection\nAqueous humor half-life: 780 min\nPenetration into aqueous humor: 38%\nPredicted to be effective against intraocular Pseudomonas aeruginosa, Enterobacteriaceae, and S. pseudintermedius but likely not Streptococcus spp.",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:59:40.000000Z",
          "updated_at": "2020-09-16T00:59:40.000000Z"
      },
      {
          "id": 1067,
          "drug_id": 280,
          "indication_name": "Visceral leishmaniasis",
          "expected_effects": "Complete clinical recovery in a mean of 58 days for 83% of dogs (75% of dogs having been treated with prior anti-leishmanial therapy)\nIncreased efficacy when used after other treatment protocols (57 days vs. 74 days)\n90% decrease in circulating amastigotes (30 per 100 macrophages on day 84, vs. 300 pre-treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T00:59:42.000000Z",
          "updated_at": "2020-09-16T00:59:42.000000Z"
      },
      {
          "id": 1068,
          "drug_id": 280,
          "indication_name": "Upper respiratory infection ",
          "expected_effects": "88% improved or cured after 5 days of treatment (vs. 78% for amoxicillin-clavulanic acid)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T00:59:45.000000Z",
          "updated_at": "2020-09-16T00:59:45.000000Z"
      },
      {
          "id": 1069,
          "drug_id": 280,
          "indication_name": "Mycoplasma haemofelis infection",
          "expected_effects": "10% higher packed cell volume, compared to untreated cats, after 7 days or more\nHematological improvement: non-specific increase in Hb concentration, decrease in mean cell volume, increase in mean cell Hb content, and decrease in red cell distribution width\nDoes not consistently clear M. haemofelis infection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T00:59:47.000000Z",
          "updated_at": "2020-09-16T00:59:47.000000Z"
      },
      {
          "id": 1070,
          "drug_id": 281,
          "indication_name": "Vomiting due to motion sickness - prevention",
          "expected_effects": "86.1% and 76.5% reduction in emesis when given 2h and 10h prior to travel, respectively\nEffective for at least 11h",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T00:59:50.000000Z",
          "updated_at": "2020-09-16T00:59:50.000000Z"
      },
      {
          "id": 1071,
          "drug_id": 281,
          "indication_name": "Vomiting due to various etiologies - prevention",
          "expected_effects": "Control/elimination of vomiting in 78% of dogs, compared to 50% of untreated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T00:59:52.000000Z",
          "updated_at": "2020-09-16T00:59:52.000000Z"
      },
      {
          "id": 1072,
          "drug_id": 281,
          "indication_name": "Vomiting due to various etiologies - prevention",
          "expected_effects": "Control/elimination of vomiting in 78% of dogs, compared to 50% of untreated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T00:59:55.000000Z",
          "updated_at": "2020-09-16T00:59:55.000000Z"
      },
      {
          "id": 1073,
          "drug_id": 281,
          "indication_name": "Vomiting due to chemotherapy (doxorubicin) - prevention",
          "expected_effects": "Vomiting in 8% of dogs, compared to 35% of untreated dogs, and at a reduced severity (3 times per day, or lasting 2 days at most)\nDiarrhea in 33% of dogs, compared to 53% of untreated dogs, and at a reduced severity (at most 2 additional stools in 87.5% of affected dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T00:59:57.000000Z",
          "updated_at": "2020-09-16T00:59:57.000000Z"
      },
      {
          "id": 1074,
          "drug_id": 281,
          "indication_name": "Vomiting due to chemotherapy (cisplatin) - control of active vomiting",
          "expected_effects": "Significantly less vomiting with maropitant (mean: 5 episodes) compared to placebo (mean: 15 episodes), and significantly shorter time to end of vomiting (0.65h vs. 1.65h)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:00:00.000000Z",
          "updated_at": "2020-09-16T01:00:00.000000Z"
      },
      {
          "id": 1075,
          "drug_id": 281,
          "indication_name": "Vomiting due to chemotherapy (cisplatin) - prevention",
          "expected_effects": "2.7, 1.1, and 0.5 emetic events with 1, 2, and 3 mg/kg, respectively, compared to 20.3 emetic events in placebo-treated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:00:03.000000Z",
          "updated_at": "2020-09-16T01:00:03.000000Z"
      },
      {
          "id": 1076,
          "drug_id": 281,
          "indication_name": "Vomiting due to motion sickness or xylazine administration - prevention",
          "expected_effects": "3-fold, 9-fold, and >9-fold reduction in emetic events when given SC, PO, and IV, respectively, compared to placebo\nConversion of 1/3 of vomiting event to milder retching in 1/3 of cats and elimination of emesis altogether in the other 2/3 (none actually vomit)\n24h expected duration of effect",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:00:05.000000Z",
          "updated_at": "2020-09-16T01:00:05.000000Z"
      },
      {
          "id": 1077,
          "drug_id": 282,
          "indication_name": "Parenteral nutrition",
          "expected_effects": "Well tolerated, with faster triglyceride clearance, and slower phospholipid and cholesterol clearance, compared to long-chain triglyceride emulsion\nNo signs of narcosis or encephalopathy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:07.000000Z",
          "updated_at": "2020-09-16T01:00:07.000000Z"
      },
      {
          "id": 1078,
          "drug_id": 282,
          "indication_name": "Protein-losing enteropathy",
          "expected_effects": "Weight gain of 0.5 kg within 18 days",
          "common_combinations": "Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:00:11.000000Z",
          "updated_at": "2020-09-16T01:00:11.000000Z"
      },
      {
          "id": 1079,
          "drug_id": 283,
          "indication_name": "Inhibit spermatogenesis",
          "expected_effects": "Very brief suppression of luteinizing hormone",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:13.000000Z",
          "updated_at": "2020-09-16T01:00:13.000000Z"
      },
      {
          "id": 1080,
          "drug_id": 283,
          "indication_name": "Inhibit spermatogenesis and reduce sperm quality",
          "expected_effects": "Rapid and significant decrease in sperm motility, morphology, and output",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:00:15.000000Z",
          "updated_at": "2020-09-16T01:00:15.000000Z"
      },
      {
          "id": 1081,
          "drug_id": 283,
          "indication_name": "Urine spraying and marking",
          "expected_effects": "Overall efficacy of 30%\nEffective in 48%, 13%, 50%, and 18% of males, females, single-cat homes, and multi-cat homes, respectively - with combined results such as 80% efficacy in male single-cat homes",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:00:18.000000Z",
          "updated_at": "2020-09-16T01:00:18.000000Z"
      },
      {
          "id": 1082,
          "drug_id": 284,
          "indication_name": "Estrus suppression - early proestrus",
          "expected_effects": "Estrus suppression in 92% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:20.000000Z",
          "updated_at": "2020-09-16T01:00:20.000000Z"
      },
      {
          "id": 1083,
          "drug_id": 284,
          "indication_name": "Estrus suppression - anestrus",
          "expected_effects": "Estrus suppression in 97% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:00:23.000000Z",
          "updated_at": "2020-09-16T01:00:23.000000Z"
      },
      {
          "id": 1084,
          "drug_id": 284,
          "indication_name": "Dermatological disease (eosinophilic granuloma complex, neurodermatitis, endocrine alopecia, miliary dermatitis)",
          "expected_effects": "Complete resolution for at least 18 months in 25% of cats after 1 treatment sequence\nDisease control: 75% with 2 treatment sequences and/or maintenance therapy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:00:25.000000Z",
          "updated_at": "2020-09-16T01:00:25.000000Z"
      },
      {
          "id": 1085,
          "drug_id": 284,
          "indication_name": "Urine spraying/marking",
          "expected_effects": "Overall efficacy of 30%\nEffective in 48%, 13%, 50%, and 18% of males, females, single-cat homes, and multi-cat homes, respectively - with combined results such as 80% efficacy in male single-cat homes",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:00:28.000000Z",
          "updated_at": "2020-09-16T01:00:28.000000Z"
      },
      {
          "id": 1086,
          "drug_id": 285,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Remission in 85% of dogs within 3-6 weeks, but 74% relapse rate within 1 year\n75% probability of 4-year survival, after 3-6 weeks of treatment and relapse therapy, in dogs with normal renal function\nEquivalent efficacy if given IV or SC",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:30.000000Z",
          "updated_at": "2020-09-16T01:00:30.000000Z"
      },
      {
          "id": 1087,
          "drug_id": 285,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Resolution of skin lesions (88% of dogs) and lymphadenopathy (75% of dogs) with treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:00:32.000000Z",
          "updated_at": "2020-09-16T01:00:32.000000Z"
      },
      {
          "id": 1088,
          "drug_id": 286,
          "indication_name": "Heartworm adulticide",
          "expected_effects": ">99% elimination of adult worms\nPretreatment with doxycycline also reduces pulmonary arterial lesions 2.5-fold, whereas pretreatment with doxycycline and ivermectin reduces pulmonary arterial lesions 4-fold",
          "common_combinations": "Doxycycline 10 mg/kg PO q 12h for 4 weeks beginning at the time of diagnosis;Ivermectin 6 µg/kg (i.e., monthly preventive dosage) beginning at the time of diagnosis and continued indefinitely",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:35.000000Z",
          "updated_at": "2020-09-16T01:00:35.000000Z"
      },
      {
          "id": 1089,
          "drug_id": 287,
          "indication_name": "Alopecia X",
          "expected_effects": "Mild to moderate hair regrowth in 40% of dogs (half with no change or minimal change to affected area and fine undercoat growth, half with decrease in affected area and moderate undercoat and guard hair growth)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:38.000000Z",
          "updated_at": "2020-09-16T01:00:38.000000Z"
      },
      {
          "id": 1090,
          "drug_id": 287,
          "indication_name": "Hyperadrenocorticism (atypical)/sex steroid disorder",
          "expected_effects": "Intact females after 28 days: mean 27.4%, 60%, and 73.5% decrease in estradiol, testosterone, and dehydroepiandrosterone sulfate concentrations, respectively\nIntact males after 28 days: mean 40.9% and 50% decrease in testosterone and 17-hydroxyprogesterone concentrations, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:00:40.000000Z",
          "updated_at": "2020-09-16T01:00:40.000000Z"
      },
      {
          "id": 1091,
          "drug_id": 287,
          "indication_name": "Inhibit ovarian activity",
          "expected_effects": "Effective suppression of estrous elevations in fecal estrogens after 25 days (interestrous concentrations or below)\nInhibition of endogenous ovarian activity without affecting artificial insemination quality",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:00:42.000000Z",
          "updated_at": "2020-09-16T01:00:42.000000Z"
      },
      {
          "id": 1092,
          "drug_id": 288,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Significant improvement in lameness and joint pain after 1-2 weeks of treatment (mild improvement in placebo-treated dogs, significantly greater [double] in treated dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:00:45.000000Z",
          "updated_at": "2020-09-16T01:00:45.000000Z"
      },
      {
          "id": 1093,
          "drug_id": 288,
          "indication_name": "Anti-inflammatory and analgesia (orthopedic surgery)",
          "expected_effects": "Adequate post-op pain control (no rescue analgesia required) as monotherapy, similar to other NSAIDs (e.g., robenacoxib)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:00:47.000000Z",
          "updated_at": "2020-09-16T01:00:47.000000Z"
      },
      {
          "id": 1094,
          "drug_id": 288,
          "indication_name": "Dermatitis associated with pain",
          "expected_effects": "Significant reduction in signs of pain (28.3% after 2-3 days of treatment, compared to 8.3% in placebo-treated dogs)",
          "common_combinations": "Antibacterial therapy for pyoderma, as indicated (e.g., cephalexin)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:00:50.000000Z",
          "updated_at": "2020-09-16T01:00:50.000000Z"
      },
      {
          "id": 1095,
          "drug_id": 288,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "Survival for 9 months in 1 case report of a dog with TCC affecting the ductus deferens",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:00:53.000000Z",
          "updated_at": "2020-09-16T01:00:53.000000Z"
      },
      {
          "id": 1096,
          "drug_id": 288,
          "indication_name": "Inflammatory disorders of the limbs or spine (osteoarthritis, orthopedic or soft tissue injury, etc.)",
          "expected_effects": "Significant improvement in overall status (demeanor, appetite, lameness, etc): >50% improvement with treatment, similar to other NSAIDs (e.g., ketoprofen)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:00:55.000000Z",
          "updated_at": "2020-09-16T01:00:55.000000Z"
      },
      {
          "id": 1097,
          "drug_id": 288,
          "indication_name": "Analgesia - post-op",
          "expected_effects": "Significant post-operative analgesic effect, similar to carprofen\nVery effective as monotherapy (only 5% of treated cats require rescue analgesia)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:00:58.000000Z",
          "updated_at": "2020-09-16T01:00:58.000000Z"
      },
      {
          "id": 1098,
          "drug_id": 288,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "91% of cats show clinical improvement (resolution of clinical signs for 0-630 days, median: 334 days)\nSurvival is 3 times longer if tumor is COX-2 negative on immunohistochemistry (375 days if COX-2-negative vs. 123 days if COX-2-positive) despite treatment with meloxicam",
          "common_combinations": "Surgical resection if feasible",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:01:00.000000Z",
          "updated_at": "2020-09-16T01:01:00.000000Z"
      },
      {
          "id": 1099,
          "drug_id": 289,
          "indication_name": "Multiple myeloma",
          "expected_effects": "Median survival time: 540 days\nSerum monoclonal Ig concentrations undetectable in 43% of dogs, and decreased by ≥ 50% in 49% of dogs",
          "common_combinations": "Cyclophosphamide;Prednisone",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:02.000000Z",
          "updated_at": "2020-09-16T01:01:02.000000Z"
      },
      {
          "id": 1100,
          "drug_id": 289,
          "indication_name": "Anal sac adenocarcinoma",
          "expected_effects": "Median survival time of 20 and 29.3 months for sublumbar nodal metastasis and localized anal sac tumor, respectively",
          "common_combinations": "Surgical removal of tumor",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:01:05.000000Z",
          "updated_at": "2020-09-16T01:01:05.000000Z"
      },
      {
          "id": 1101,
          "drug_id": 289,
          "indication_name": "Chronic lymphocytic leukemia",
          "expected_effects": "Gradual improvement of clinical signs and hematological findings, typically most apparent after 3 weeks of treatment in 1 small study",
          "common_combinations": "Prednisolone 4.3-30 mg/m²/day",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:01:07.000000Z",
          "updated_at": "2020-09-16T01:01:07.000000Z"
      },
      {
          "id": 1102,
          "drug_id": 289,
          "indication_name": "Lymphoma (relapsed) - DMAC protocol",
          "expected_effects": "Complete remission in 44% of dogs, for a median of 112 days\n≥ 50% decrease in one dimension for all tumors in 28% of dogs, for a median of 44 days\nStable disease in 11% of dogs, for a median of 27 days",
          "common_combinations": "Dexamethasone;Actinomycin D;Cytosine arabinoside",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:01:10.000000Z",
          "updated_at": "2020-09-16T01:01:10.000000Z"
      },
      {
          "id": 1103,
          "drug_id": 289,
          "indication_name": "Melanoma - oral",
          "expected_effects": "No observable impact on the development of metastatic disease, time to first event, or survival in large retrospective study (111 dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:01:12.000000Z",
          "updated_at": "2020-09-16T01:01:12.000000Z"
      },
      {
          "id": 1104,
          "drug_id": 289,
          "indication_name": "Multiple myeloma",
          "expected_effects": "63% response rate (50% complete, 12.5% partial)\nSurvival time: 4-24 months (median: 387 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:01:15.000000Z",
          "updated_at": "2020-09-16T01:01:15.000000Z"
      },
      {
          "id": 1105,
          "drug_id": 290,
          "indication_name": "Analgesia and sedation",
          "expected_effects": "Reliable sedation and analgesia for up to 4 hours",
          "common_combinations": "Acepromazine;Meloxicam",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:19.000000Z",
          "updated_at": "2020-09-16T01:01:19.000000Z"
      },
      {
          "id": 1106,
          "drug_id": 290,
          "indication_name": "Analgesia and sedation - orthopedic surgery",
          "expected_effects": "Adequate post-op analgesia in most dogs (slightly more sedation, and slightly inferior pain control, compared to 1 SC dose of carprofen intra-op)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:01:21.000000Z",
          "updated_at": "2020-09-16T01:01:21.000000Z"
      },
      {
          "id": 1107,
          "drug_id": 290,
          "indication_name": "Analgesia",
          "expected_effects": "No appreciable analgesic effect compared to placebo-treated control (or buprenorphine-treated cats) during post-operative recovery",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:01:23.000000Z",
          "updated_at": "2020-09-16T01:01:23.000000Z"
      },
      {
          "id": 1108,
          "drug_id": 291,
          "indication_name": "Susceptible bacterial infections",
          "expected_effects": "Adequate tissue fluid and urine concentrations to eliminate susceptible bacteria with a minimum inhibitory concentration of 0.12 µg/mL",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:26.000000Z",
          "updated_at": "2020-09-16T01:01:26.000000Z"
      },
      {
          "id": 1109,
          "drug_id": 292,
          "indication_name": "Inflammatory bowel disease (anti-inflammatory)",
          "expected_effects": "Significant improvement in inflammatory infiltrate on biopsies during treatment compared to pretreatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:28.000000Z",
          "updated_at": "2020-09-16T01:01:28.000000Z"
      },
      {
          "id": 1110,
          "drug_id": 293,
          "indication_name": "Premedication in high-risk anesthetic patients",
          "expected_effects": "Mild to moderate sedation\nNo apnea\nMinimal cardiovascular effects\nNo induction of emesis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:31.000000Z",
          "updated_at": "2020-09-16T01:01:31.000000Z"
      },
      {
          "id": 1111,
          "drug_id": 293,
          "indication_name": "Rescue analgesia when routine post-operative analgesia is insufficient",
          "expected_effects": "Brief (2-4 hours) but effective analgesia",
          "common_combinations": "Local or systemic analgesia, e.g., bupivacaine or morphine intra-articular injection (methadone is given if analgesic effects of the other drugs are insufficient)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:01:33.000000Z",
          "updated_at": "2020-09-16T01:01:33.000000Z"
      },
      {
          "id": 1112,
          "drug_id": 293,
          "indication_name": "Postoperative analgesia (e.g., thoracotomy)",
          "expected_effects": "Normal post-op recovery in a short case series of cats with pyothorax",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:01:35.000000Z",
          "updated_at": "2020-09-16T01:01:35.000000Z"
      },
      {
          "id": 1113,
          "drug_id": 294,
          "indication_name": "Glaucoma (to decreases intraocular pressure)",
          "expected_effects": "7.5 +/- 2.6 mmHg decrease in intraocular pressure after 5 days of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:38.000000Z",
          "updated_at": "2020-09-16T01:01:38.000000Z"
      },
      {
          "id": 1114,
          "drug_id": 295,
          "indication_name": "Protection against cisplatin-induced renal disease",
          "expected_effects": "Well tolerated with possibility of emesis (20%)\nHalf-life of 9h compatible with single protective dose prior to cisplatin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:40.000000Z",
          "updated_at": "2020-09-16T01:01:40.000000Z"
      },
      {
          "id": 1115,
          "drug_id": 295,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "84% of cats become euthyroid within 2-3 weeks of initiating treatment\n35% of cats experience adverse effects ranging from subclinical to sufficiently severe that treatment must be stopped",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:01:43.000000Z",
          "updated_at": "2020-09-16T01:01:43.000000Z"
      },
      {
          "id": 1116,
          "drug_id": 295,
          "indication_name": "Hyperthyroidism",
          "expected_effects": ">98% of treated cats show clinical improvement (weight gain and reduced blood pressure), similar to oral carbimazole-treated controls\nHigh compliance due to ease of treatment delivery",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:01:46.000000Z",
          "updated_at": "2020-09-16T01:01:46.000000Z"
      },
      {
          "id": 1117,
          "drug_id": 296,
          "indication_name": "Urine acidifier",
          "expected_effects": "97% decrease in number of struvite crystals per milliliter of urine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:49.000000Z",
          "updated_at": "2020-09-16T01:01:49.000000Z"
      },
      {
          "id": 1118,
          "drug_id": 297,
          "indication_name": "Vacuolar/steroid hepatopathy",
          "expected_effects": "Significantly increases liver total glutathione concentration and appears to favorably influence antioxidant function (redox status) of red blood cells and liver\nDoes not prohibit development of the classic histologic features of glucocorticoid hepatopathy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:01:51.000000Z",
          "updated_at": "2020-09-16T01:01:51.000000Z"
      },
      {
          "id": 1119,
          "drug_id": 297,
          "indication_name": "Acetaminophen intoxication",
          "expected_effects": "Clinical cure in 1 severely affected dog",
          "common_combinations": "Supportive care as needed (e.g., packed red blood cell transfusion, IV fluids);Famotidine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:01:53.000000Z",
          "updated_at": "2020-09-16T01:01:53.000000Z"
      },
      {
          "id": 1120,
          "drug_id": 297,
          "indication_name": "Reduction of chemotherapy-associated hepatotoxicosis (lomustine)",
          "expected_effects": "Fewer SAMe-treated dogs had increased liver enzyme concentrations (68% vs. 84% in untreated/lomustine-only dogs), and the liver enzyme elevations were significantly smaller in SAMe-treated dogs than in dogs not treated with SAMe (lack of dosage and interval information for this application is limiting)",
          "common_combinations": "Silymarin",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:01:56.000000Z",
          "updated_at": "2020-09-16T01:01:56.000000Z"
      },
      {
          "id": 1121,
          "drug_id": 297,
          "indication_name": "Osteoarthritis",
          "expected_effects": "No difference in lameness or pain parameters compared to placebo treatment",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:01:58.000000Z",
          "updated_at": "2020-09-16T01:01:58.000000Z"
      },
      {
          "id": 1122,
          "drug_id": 297,
          "indication_name": "Acetaminophen intoxication",
          "expected_effects": "After single-dose 90 mg acetaminophen intoxication: 6% decrease in packed cell volume (vs. 20% decrease without SAMe) by day 14 after intoxication\nFew differences between SAMe and non-SAMe-treated cats (e.g., 83% survival for both), suggesting that benefit of SAMe treatment may be partial/mild, and likely dependent on acetaminophen dosage and interindividual variation\nNo adverse effects of SAMe treatment noted",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:02:01.000000Z",
          "updated_at": "2020-09-16T01:02:01.000000Z"
      },
      {
          "id": 1123,
          "drug_id": 297,
          "indication_name": "Antioxidant",
          "expected_effects": "Significant increase in erythrocyte reduced glutathione and significant decrease in erythrocyte thiobarbiturate reacting substances and hepatic glycogen, markers suggesting enhanced antioxidant function and liver metabolism, respectively\nTypographic error in abstract (\"did cause overt signs of toxicity\": missing \"not,\" as no toxic effects occurred)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:02:03.000000Z",
          "updated_at": "2020-09-16T01:02:03.000000Z"
      },
      {
          "id": 1124,
          "drug_id": 298,
          "indication_name": "Muscle strain injury",
          "expected_effects": "53% of treated dogs have complete improvement after treatment, 13% have significant improvement, and 7% have some improvement\nLong-term follow-up identifies some degree of recurrence in 2/3 of dogs",
          "common_combinations": "Exercise restriction;Nonsteroidal anti-inflammatory drug",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:02:06.000000Z",
          "updated_at": "2020-09-16T01:02:06.000000Z"
      },
      {
          "id": 1125,
          "drug_id": 298,
          "indication_name": "Intervertebral disk disease - supportive care",
          "expected_effects": "Most dogs with acute intervertebral disk disease-related signs experience a decrease in muscle tone, tension, and associated signs of anxiety promptly (within minutes) of IV administration\nTreatment does not improve the disease substrate (intervertebral disc disease is not improved) but comfort can be enhanced and spontaneous (albeit only temporary) remission may occur",
          "common_combinations": "Exercise restriction",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:02:08.000000Z",
          "updated_at": "2020-09-16T01:02:08.000000Z"
      },
      {
          "id": 1126,
          "drug_id": 298,
          "indication_name": "Tremorgenic mycotoxin intoxication",
          "expected_effects": "Full recovery with intensive nursing care in canine case series",
          "common_combinations": "Phenobarbital;Intensive nursing care (including intubation and positive pressure ventilation for apnea)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:02:11.000000Z",
          "updated_at": "2020-09-16T01:02:11.000000Z"
      },
      {
          "id": 1127,
          "drug_id": 298,
          "indication_name": "Pyrethroid intoxication - IV CRI protocol",
          "expected_effects": "Resolution of most/all tremors, allowing transition to oral methocarbamol (40-60 mg/kg PO q 8h for 2-8 days) at home",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:02:13.000000Z",
          "updated_at": "2020-09-16T01:02:13.000000Z"
      },
      {
          "id": 1128,
          "drug_id": 298,
          "indication_name": "Tetanus",
          "expected_effects": "Gradual but uncomplicated, complete recovery from tetanic crisis in 1 case report (7 days hospitalization)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:02:16.000000Z",
          "updated_at": "2020-09-16T01:02:16.000000Z"
      },
      {
          "id": 1129,
          "drug_id": 298,
          "indication_name": "Permethrin toxicosis",
          "expected_effects": "Low/no need for diazepam or propofol intervention to control muscle fasciculations",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:02:18.000000Z",
          "updated_at": "2020-09-16T01:02:18.000000Z"
      },
      {
          "id": 1130,
          "drug_id": 298,
          "indication_name": "Permethrin toxicosis",
          "expected_effects": "Low/no need for diazepam or propofol intervention to control muscle fasciculations",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:02:20.000000Z",
          "updated_at": "2020-09-16T01:02:20.000000Z"
      },
      {
          "id": 1131,
          "drug_id": 299,
          "indication_name": "Lymphoma (multiagent protocol)",
          "expected_effects": "73% complete remission rate, no different from doxorubicin monotherapy (30 mg/m² IV q 3 weeks for 5 treatments)",
          "common_combinations": "L-asparaginase;Vincristine;Cyclophosphamide;Doxorubicin;Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:02:23.000000Z",
          "updated_at": "2020-09-16T01:02:23.000000Z"
      },
      {
          "id": 1132,
          "drug_id": 299,
          "indication_name": "Protein-losing enteropathy",
          "expected_effects": "Clinical improvement and remission in 1 case report",
          "common_combinations": "Azathioprine;Metronidazole;Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:02:25.000000Z",
          "updated_at": "2020-09-16T01:02:25.000000Z"
      },
      {
          "id": 1133,
          "drug_id": 299,
          "indication_name": "Osteosarcoma",
          "expected_effects": "No identifiable benefit (despite treatment, 80% of dogs develop metastases median 4 months after amputation)\nNeutropenia common at 3g/m² even with leucovorin rescue, 6g/m² dosage not recommended",
          "common_combinations": "Leucovorin (rescue);Vincristine",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:02:28.000000Z",
          "updated_at": "2020-09-16T01:02:28.000000Z"
      },
      {
          "id": 1134,
          "drug_id": 299,
          "indication_name": "Transmissible venereal tumor",
          "expected_effects": "No therapeutic response observed in treated dogs",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:02:30.000000Z",
          "updated_at": "2020-09-16T01:02:30.000000Z"
      },
      {
          "id": 1135,
          "drug_id": 299,
          "indication_name": "Immune-mediated inflammation (e.g., rheumatoid arthritis)",
          "expected_effects": "Marked improvement in 58% of cats, sometimes within 4 weeks",
          "common_combinations": "Leflunomide 70 mg/CAT PO q 24h, tapering to q 3-4 days when clinical improvement is seen",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:02:33.000000Z",
          "updated_at": "2020-09-16T01:02:33.000000Z"
      },
      {
          "id": 1136,
          "drug_id": 300,
          "indication_name": "Evaluate pancreas for insulinoma",
          "expected_effects": "Insulinoma typically shows a different (darker, reddish violet) color against a paler pink background of normal pancreatic tissue, allowing accurate identification and resection (e.g., 4/4 dogs in one case series)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:02:35.000000Z",
          "updated_at": "2020-09-16T01:02:35.000000Z"
      },
      {
          "id": 1137,
          "drug_id": 300,
          "indication_name": "Methemoglobinemia (e.g., hydroxyurea-induced)",
          "expected_effects": ">80% survival after single ingestions of 80-400 mg/kg hydroxyurea (causing severe clinical signs including cyanosis)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:02:37.000000Z",
          "updated_at": "2020-09-16T01:02:37.000000Z"
      },
      {
          "id": 1138,
          "drug_id": 300,
          "indication_name": "Methemoglobinemia (e.g., nitrite-induced)",
          "expected_effects": "Conflicting results suggesting both greater and fewer Heinz bodies simultaneously with treatment\nNo clinical support for use",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:02:40.000000Z",
          "updated_at": "2020-09-16T01:02:40.000000Z"
      },
      {
          "id": 1139,
          "drug_id": 301,
          "indication_name": "Narcolepsy-cataplexy",
          "expected_effects": "Minor improvement in episodes but persistently abnormal",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:02:42.000000Z",
          "updated_at": "2020-09-16T01:02:42.000000Z"
      },
      {
          "id": 1140,
          "drug_id": 301,
          "indication_name": "Narcolepsy-cataplexy",
          "expected_effects": "50% reduction (number/severity) of episodes at this dosage\nUp to 0.384 mg/kg IV does not fully abolish all episodes",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:02:44.000000Z",
          "updated_at": "2020-09-16T01:02:44.000000Z"
      },
      {
          "id": 1141,
          "drug_id": 302,
          "indication_name": "Pruritic dermatitis",
          "expected_effects": "Pruritus well-controlled in 44% of cats after 1 week, and in 88% of cats after 2 weeks\nPruritus control maintained with q 48h treatment in 81% of cats for 6 weeks or longer",
          "common_combinations": "Treatment of inciting cause of pruritus",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:02:47.000000Z",
          "updated_at": "2020-09-16T01:02:47.000000Z"
      },
      {
          "id": 1142,
          "drug_id": 303,
          "indication_name": "Lumbosacral degenerative stenosis",
          "expected_effects": "79% clinical improvement including 53% complete resolution of signs based on owner feedback (Note: signs initially may be worse for first 3 days after treatment)",
          "common_combinations": "Sedation for procedure (methadone, acepromazine, and medetomidine)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:02:49.000000Z",
          "updated_at": "2020-09-16T01:02:49.000000Z"
      },
      {
          "id": 1143,
          "drug_id": 303,
          "indication_name": "Bicipital tenosynovitis",
          "expected_effects": "66% of dogs experience improvement in lameness\n33% either unchanged or deteriorate, requiring surgery",
          "common_combinations": "Carprofen;Exercise restriction",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:02:51.000000Z",
          "updated_at": "2020-09-16T01:02:51.000000Z"
      },
      {
          "id": 1144,
          "drug_id": 303,
          "indication_name": "Immunosuppression",
          "expected_effects": "Nonspecific decrease in immunity",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:02:54.000000Z",
          "updated_at": "2020-09-16T01:02:54.000000Z"
      },
      {
          "id": 1145,
          "drug_id": 303,
          "indication_name": "Uveitis - sterile",
          "expected_effects": "Subjective reduction in corneal edema and lack of progression of synechia in one case report",
          "common_combinations": "Topical treatment as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:02:56.000000Z",
          "updated_at": "2020-09-16T01:02:56.000000Z"
      },
      {
          "id": 1146,
          "drug_id": 303,
          "indication_name": "Pruritic dermatitis",
          "expected_effects": "Substantial improvement in pruritus",
          "common_combinations": "Treatment of underlying condition (food hypersensitivity, parasitic hypersensitivity, etc.)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:02:58.000000Z",
          "updated_at": "2020-09-16T01:02:58.000000Z"
      },
      {
          "id": 1147,
          "drug_id": 303,
          "indication_name": "Feline airway disease/asthma",
          "expected_effects": "47% response to treatment\nRecurrent relapses in remaining 53%",
          "common_combinations": "Bronchodilator (e.g., aminophylline or terbutaline);Environmental modification to reduce inciting causes",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:03:01.000000Z",
          "updated_at": "2020-09-16T01:03:01.000000Z"
      },
      {
          "id": 1148,
          "drug_id": 303,
          "indication_name": "Hypoadrenocorticism",
          "expected_effects": "Survival >3 to >70 months (median: 34.1 months)",
          "common_combinations": "Desoxycorticosterone pivalate (mineralocorticoid replacement)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:03:03.000000Z",
          "updated_at": "2020-09-16T01:03:03.000000Z"
      },
      {
          "id": 1149,
          "drug_id": 303,
          "indication_name": "Oral mast cell tumor",
          "expected_effects": "Complete clinical remission >9 months in one case report",
          "common_combinations": "Lomustine",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:03:06.000000Z",
          "updated_at": "2020-09-16T01:03:06.000000Z"
      },
      {
          "id": 1150,
          "drug_id": 303,
          "indication_name": "Immunosuppression",
          "expected_effects": "52% of cats previously exposed to Toxoplasma gondii begin to shed oocysts during methylprednisolone acetate treatment, and active lesions of toxoplasmosis are found in 83% of treated cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:03:08.000000Z",
          "updated_at": "2020-09-16T01:03:08.000000Z"
      },
      {
          "id": 1151,
          "drug_id": 304,
          "indication_name": "Spinal cord trauma",
          "expected_effects": "Suspected but unproven benefit\n90% incidence of gastrointestinal tract bleeding not prevented by cimetidine, sucralfate, or misoprostol",
          "common_combinations": "Spinal surgery",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:03:11.000000Z",
          "updated_at": "2020-09-16T01:03:11.000000Z"
      },
      {
          "id": 1152,
          "drug_id": 304,
          "indication_name": "Spinal cord trauma",
          "expected_effects": "Resolution of neurologic deficits faster than untreated controls, slower than dogs treated with both methylprednisolone sodium succinate and acupuncture",
          "common_combinations": "Spinal surgery;Acupuncture therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:03:13.000000Z",
          "updated_at": "2020-09-16T01:03:13.000000Z"
      },
      {
          "id": 1153,
          "drug_id": 304,
          "indication_name": "Craniectomy/durotomy (to decrease intracranial pressure)",
          "expected_effects": "No greater reduction in intracranial pressure when administered (with furosemide and hyperventilation) during craniotomy/durotomy, compared to craniotomy/durotomy alone",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:03:16.000000Z",
          "updated_at": "2020-09-16T01:03:16.000000Z"
      },
      {
          "id": 1154,
          "drug_id": 304,
          "indication_name": "Immunosuppression - autoimmune skin disease (pemphigus foliaceus, pemphigus vulgaris, systemic lupus erythematosus)",
          "expected_effects": "Dramatic and rapid improvement in autoimmune skin lesions, without overtly apparent adverse effects using this short-term protocol",
          "common_combinations": "Cotreatment with cimetidine 4 mg/kg PO q 8h;Subsequent long-term oral immunosuppression (e.g., prednisone, azathioprine, gold salts)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:03:18.000000Z",
          "updated_at": "2020-09-16T01:03:18.000000Z"
      },
      {
          "id": 1155,
          "drug_id": 304,
          "indication_name": "Immunosuppression - myasthenia gravis (severe, generalized)",
          "expected_effects": "No improvement in critical clinical signs",
          "common_combinations": "Immunosuppression with mycophenolate mofetil;Immunoglobulin G (human);Supportive care",
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:03:21.000000Z",
          "updated_at": "2020-09-16T01:03:21.000000Z"
      },
      {
          "id": 1156,
          "drug_id": 304,
          "indication_name": "Brain injury - experimental",
          "expected_effects": "Improvement in brain blood flow (vs. no such improvement in untreated control cats)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:03:23.000000Z",
          "updated_at": "2020-09-16T01:03:23.000000Z"
      },
      {
          "id": 1157,
          "drug_id": 304,
          "indication_name": "Bronchoconstrictive emergency/asthmatic crisis",
          "expected_effects": "Response within 30 minutes in some cats (improved respiratory comfort) or failure to respond in others, requiring epinephrine-atropine treatment",
          "common_combinations": "Aminophylline 4 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:03:26.000000Z",
          "updated_at": "2020-09-16T01:03:26.000000Z"
      },
      {
          "id": 1158,
          "drug_id": 305,
          "indication_name": "Estrus suppression in queens",
          "expected_effects": "May prevent estrus for 1 month only",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:03:28.000000Z",
          "updated_at": "2020-09-16T01:03:28.000000Z"
      },
      {
          "id": 1159,
          "drug_id": 306,
          "indication_name": "Nausea/vomiting - prevention",
          "expected_effects": "71% absence of vomiting with treatment, compared to 97% absence of vomiting with maropitant treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:03:31.000000Z",
          "updated_at": "2020-09-16T01:03:31.000000Z"
      },
      {
          "id": 1160,
          "drug_id": 306,
          "indication_name": "Gastroesophageal reflux prevention (intra-op)",
          "expected_effects": "Does not significantly reduce the incidence of gastroesophageal reflux in dogs",
          "common_combinations": "Acepromazine;Propofol;Isoflurane;Meloxicam",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:03:33.000000Z",
          "updated_at": "2020-09-16T01:03:33.000000Z"
      },
      {
          "id": 1161,
          "drug_id": 306,
          "indication_name": "Nausea/vomiting (e.g., caused by alpha-2 agonist drugs) - prevention",
          "expected_effects": "50% reduction in episodes of vomiting (compared to no treatment) at 0.2-0.4 mg/kg\n66% reduction at 0.6 mg/kg\n85% reduction at 0.8-1 mg/kg",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:03:36.000000Z",
          "updated_at": "2020-09-16T01:03:36.000000Z"
      },
      {
          "id": 1162,
          "drug_id": 307,
          "indication_name": "Myxomatous mitral valve disease - early stages and/or arrhythmia",
          "expected_effects": "13% reduction in resting heart rate in exam room (from 136 to 120 beats/minute) after weeks of treatment\nNo significant progression in general status, clinical state of heart disease, or echocardiographic results at initial recheck after starting treatment (median: 40 days), consistent with stabilizing effect of beta-blockers\nSurvival after beginning metoprolol treatment: 4-3147 days (median: 347 days), consistent with the very wide range of survival of the disease in dogs and neither convincingly improved nor harmed by metoprolol",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:03:39.000000Z",
          "updated_at": "2020-09-16T01:03:39.000000Z"
      },
      {
          "id": 1163,
          "drug_id": 307,
          "indication_name": "Dilated cardiomyopathy - early stages and/or arrhythmia",
          "expected_effects": "13% reduction in resting heart rate in exam room(from 136 to 120 beats/minute) after weeks of treatment\nNo significant progression in general status, clinical state of heart disease, or echocardiographic results at initial recheck after starting treatment (median: 40 days), consistent with stabilizing effect of beta-blockers\nSurvival after beginning metoprolol treatment: 4-3147 days (median: 347 days), consistent with the very wide range of survival of the disease in dogs and neither convincingly improved nor harmed by metoprolol",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:03:41.000000Z",
          "updated_at": "2020-09-16T01:03:41.000000Z"
      },
      {
          "id": 1164,
          "drug_id": 307,
          "indication_name": "Sympathetically-mediated ventricular arrhythmias",
          "expected_effects": "Decreases ventricular arrhythmogenicity (specifically, propensity to form premature ventricular complexes in response to epinephrine IV infusion) by at least 3-fold",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:03:43.000000Z",
          "updated_at": "2020-09-16T01:03:43.000000Z"
      },
      {
          "id": 1165,
          "drug_id": 307,
          "indication_name": "Cardiac anti-ischemic",
          "expected_effects": "Significant reduction in myocardial ischemic process compared to atenolol or placebo",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:03:46.000000Z",
          "updated_at": "2020-09-16T01:03:46.000000Z"
      },
      {
          "id": 1166,
          "drug_id": 307,
          "indication_name": "Cardiac anti-ischemic",
          "expected_effects": "Significant reduction in myocardial ischemic process compared to atenolol or placebo",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:03:48.000000Z",
          "updated_at": "2020-09-16T01:03:48.000000Z"
      },
      {
          "id": 1167,
          "drug_id": 308,
          "indication_name": "Anaerobic infections (e.g., pyothorax)",
          "expected_effects": "Generally rapid response to treatment\nSurvival and discharge in >90% of cases",
          "common_combinations": "Correction of the inciting cause (e.g., thoracocentesis, with or without thoracotomy for pyothorax)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:03:51.000000Z",
          "updated_at": "2020-09-16T01:03:51.000000Z"
      },
      {
          "id": 1168,
          "drug_id": 308,
          "indication_name": "Inflammatory bowel disease",
          "expected_effects": "80% clinical improvement, but no significant change in canine inflammatory bowel disease index",
          "common_combinations": "Hypoallergenic diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:03:53.000000Z",
          "updated_at": "2020-09-16T01:03:53.000000Z"
      },
      {
          "id": 1169,
          "drug_id": 308,
          "indication_name": "Helicobacter-associated gastritis",
          "expected_effects": "86% reduction in frequency of vomiting with quadruple therapy",
          "common_combinations": "Bismuth subsalicylate, famotidine, and amoxicillin (quadruple therapy)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:03:56.000000Z",
          "updated_at": "2020-09-16T01:03:56.000000Z"
      },
      {
          "id": 1170,
          "drug_id": 308,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Resolution of skin lesions (82% of dogs) and lymphadenopathy (53% of dogs) with metronidazole-enrofloxacin cotreatment, compared to 88% and 75%, respectively, with meglumine antimoniate treatment",
          "common_combinations": "Enrofloxacin 20 mg/kg PO q 24h for 30 days (coadministered with metronidazole)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:03:58.000000Z",
          "updated_at": "2020-09-16T01:03:58.000000Z"
      },
      {
          "id": 1171,
          "drug_id": 308,
          "indication_name": "Perianal fistula",
          "expected_effects": "Smaller/shallower lesions, and reduced inflammation and discharge, seen rapidly within 2-4 weeks, with little additional improvement after 4-6 weeks",
          "common_combinations": "Azathioprine 50 mg/DOG orally PO q 24 h;Surgical excision of remaining fistulae and/or diseased anal sacs",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:04:01.000000Z",
          "updated_at": "2020-09-16T01:04:01.000000Z"
      },
      {
          "id": 1172,
          "drug_id": 308,
          "indication_name": "Babesiosis",
          "expected_effects": "83% remission rate\nMean recovery time: 24 days\nResults are not significantly different when combined with diminazene diaceturate injections (86% remission rate, mean recovery time: 24 days)",
          "common_combinations": "Doxycycline;Enrofloxacin;With or without diminazene diaceturate",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:04:03.000000Z",
          "updated_at": "2020-09-16T01:04:03.000000Z"
      },
      {
          "id": 1173,
          "drug_id": 308,
          "indication_name": "Giardiasis",
          "expected_effects": ">99% elimination of fecal shedding of oocysts during 15 days following treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:04:06.000000Z",
          "updated_at": "2020-09-16T01:04:06.000000Z"
      },
      {
          "id": 1174,
          "drug_id": 308,
          "indication_name": "Intestinal dysbiosis/antibiotic-responsive diarrhea/small intestinal bacterial overgrowth",
          "expected_effects": "Elimination of anaerobic bacteria from small intestinal fluid samples after treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:04:08.000000Z",
          "updated_at": "2020-09-16T01:04:08.000000Z"
      },
      {
          "id": 1175,
          "drug_id": 309,
          "indication_name": "Ventricular arrhythmia (e.g., arrhythmogenic right ventricular cardiomyopathy)",
          "expected_effects": "After 28 days of treatment, 73% of dogs have significant (>85%) reduction in number of premature ventricular complexes (median 801/24h period in boxers with arrhythmogenic right ventricular cardiomyopathy receiving mexiletine-atenolol cotreatment, vs. median 5814/24h period in same dogs before treatment)\n18% of dogs have significant (>85%) *increase* in number of premature ventricular complexes\nNo appreciable effect of treatment on frequency or severity of syncope, or longevity",
          "common_combinations": "Atenolol 0.3-0.6 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:04:11.000000Z",
          "updated_at": "2020-09-16T01:04:11.000000Z"
      },
      {
          "id": 1176,
          "drug_id": 310,
          "indication_name": "Pseudocyesis/pseudopregnancy",
          "expected_effects": "90%, >99%, 81%, and 78% of dogs with pseudocyesis show psychologic, physical, psychologic or physical, and psychologic and physical improvement with treatment, respectively (compared to  40%, 64%, 24%, and 14%, respectively, of placebo-treated dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:04:13.000000Z",
          "updated_at": "2020-09-16T01:04:13.000000Z"
      },
      {
          "id": 1177,
          "drug_id": 310,
          "indication_name": "Estrus suppression",
          "expected_effects": ">99% effective estrus suppression, with normal return of estrous cycles after discontinuation (mean: estrus onset 39 days after end of treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:04:16.000000Z",
          "updated_at": "2020-09-16T01:04:16.000000Z"
      },
      {
          "id": 1178,
          "drug_id": 311,
          "indication_name": "Sedation/premedication for general anesthesia",
          "expected_effects": "With medetomidine: sternal recumbency within 10 minutes\nWith butorphanol: mild-to-moderate sedation in 90% of dogs within 10 minutes",
          "common_combinations": "Butorphanol 0.1 mg/kg or medetomidine 20 µg/kg;Sevoflurane mask induction",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:04:18.000000Z",
          "updated_at": "2020-09-16T01:04:18.000000Z"
      },
      {
          "id": 1179,
          "drug_id": 311,
          "indication_name": "Anesthetic induction",
          "expected_effects": "Induction with single midazolam-ketamine dose in 57% of dogs\nSecond midazolam-ketamine dose (25% of the original dosage) required in 43% of dogs\nOverall time to induction for all dogs: 2.7 minutes",
          "common_combinations": "Ketamine 5.5 mg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:04:21.000000Z",
          "updated_at": "2020-09-16T01:04:21.000000Z"
      },
      {
          "id": 1180,
          "drug_id": 311,
          "indication_name": "Mechanical ventilation - ongoing sedation protocol",
          "expected_effects": "Light sedation with spontaneous respiration and no signs of anxiety or patient-ventilator asynchrony\nEffects lasting 87% of duration with midazolam-morphine-medetomidine, and 93% of duration with midazolam-fentanyl-propofol",
          "common_combinations": "IV CRI cotreatment with either morphine (0.6 mg/kg/h) and medetomidine (1 µg/kg/h), or with fentanyl (18 µg/kg/h) and propofol (2.5 mg/kg/h);Mouth care, position change, and physical manipulations q 6h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:04:23.000000Z",
          "updated_at": "2020-09-16T01:04:23.000000Z"
      },
      {
          "id": 1181,
          "drug_id": 311,
          "indication_name": "Sedation/premedication for general anesthesia",
          "expected_effects": "Does not produce effective sedation as midazolam-butorphanol combination\nDoes produce effective sedation as midazolam-butorphanol-ketamine combination or midazolam-butorphanol-dexmedetomidine combination",
          "common_combinations": "Butorphanol 0.4 mg/kg IM;With or without ketamine 3 mg/kg IM;With or without dexmedetomidine 5 µg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:04:26.000000Z",
          "updated_at": "2020-09-16T01:04:26.000000Z"
      },
      {
          "id": 1182,
          "drug_id": 311,
          "indication_name": "General anesthesia - for minor procedures",
          "expected_effects": "Re-dosing (half the original dosage) required in 11% of cats\n13 ± 17 hours to return to normal behavior",
          "common_combinations": "Butorphanol 0.3 mg/kg and ketamine 5 mg/kg coadministered IM",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:04:28.000000Z",
          "updated_at": "2020-09-16T01:04:28.000000Z"
      },
      {
          "id": 1183,
          "drug_id": 311,
          "indication_name": "Sedation - lateral recumbency with head down",
          "expected_effects": "Lateral recumbency with head down in 50% (0.016 mg/kg) to 95% (0.054 mg/kg) of healthy cats\nWith IV 0.042 mg/kg midazolam and 3 mg/kg ketamine: lateral recumbency with head down lasts 5.5 +/- 4 minutes, rising and walking with ataxia occurs after 26 +/- 5.7 minutes, and full recovery occurs at 1.7 +/- 0.4 hours",
          "common_combinations": "Ketamine 3 mg/kg given IV 1 min before midazolam",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:04:31.000000Z",
          "updated_at": "2020-09-16T01:04:31.000000Z"
      },
      {
          "id": 1184,
          "drug_id": 311,
          "indication_name": "Deep sedation with analgesia",
          "expected_effects": "Absence of nociception (ulnar nerve stimulation) in 50% (0.29 mg/kg) to 95% (0.65 mg/kg) of healthy cats\nWith IV 0.3 mg/kg midazolam and 3 mg/kg ketamine: loss of nociception lasts 2.5 +/- 2.2 minutes, recovery to walking with ataxia occurs at 41.5 +/- 15.2 minutes, and complete recovery occurs at 3.6 +/- 1.3 hours",
          "common_combinations": "Ketamine 3 mg/kg given IV 1 min before midazolam",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:04:33.000000Z",
          "updated_at": "2020-09-16T01:04:33.000000Z"
      },
      {
          "id": 1185,
          "drug_id": 311,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Loss of swallowing reflex in response to laryngoscope placed on back of tongue in 50% (0.27 mg/kg) to 95% (0.58 mg/kg) of healthy cats\nWith IV 0.3 mg/kg midazolam and 3 mg/kg ketamine: loss of swallowing reflex in response to laryngoscope contact lasts 2.5 +/- 2.2 minutes, recovery to walking with ataxia occurs at 41.5 +/- 15.2 minutes, and complete recovery occurs at 3.6 +/- 1.3 hours",
          "common_combinations": "Ketamine 3 mg/kg given IV 1 min before midazolam",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:04:36.000000Z",
          "updated_at": "2020-09-16T01:04:36.000000Z"
      },
      {
          "id": 1186,
          "drug_id": 311,
          "indication_name": "Status epilepticus (e.g., due to permethrin toxicosis)",
          "expected_effects": "81% survival rate to discharge in cases of permethrin toxicosis",
          "common_combinations": "Propofol IV CRI or intermittent IV boluses for breakthrough tremors/seizures",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:04:39.000000Z",
          "updated_at": "2020-09-16T01:04:39.000000Z"
      },
      {
          "id": 1187,
          "drug_id": 312,
          "indication_name": "Pregnancy termination",
          "expected_effects": "Highly effective (>80%, likely >95%) termination of pregnancy, concomitant with decreased serum progesterone concentration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:04:42.000000Z",
          "updated_at": "2020-09-16T01:04:42.000000Z"
      },
      {
          "id": 1188,
          "drug_id": 312,
          "indication_name": "Pregnancy termination",
          "expected_effects": "Effective pregnancy termination when administered in mid-stage pregnancy (approximately 21-40 days of gestation)\nSeveral instances of inefficacy when administered after day 40 of gestation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:04:44.000000Z",
          "updated_at": "2020-09-16T01:04:44.000000Z"
      },
      {
          "id": 1189,
          "drug_id": 313,
          "indication_name": "Heartworm disease - prophylaxis",
          "expected_effects": ">99% prevention of Dirofilaria immitis survival after inoculation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:04:46.000000Z",
          "updated_at": "2020-09-16T01:04:46.000000Z"
      },
      {
          "id": 1190,
          "drug_id": 313,
          "indication_name": "Hookworm infestation - Ancylostoma caninum",
          "expected_effects": "98% fewer Ancylostoma ova in feces 7 days post-treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:04:49.000000Z",
          "updated_at": "2020-09-16T01:04:49.000000Z"
      },
      {
          "id": 1191,
          "drug_id": 313,
          "indication_name": "Whipworm infestation - Trichuris vulpis",
          "expected_effects": "97% reduction in adult T. vulpis burden and 100% elimination of T. vulpis ova in feces 7 days after treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:04:51.000000Z",
          "updated_at": "2020-09-16T01:04:51.000000Z"
      },
      {
          "id": 1192,
          "drug_id": 313,
          "indication_name": "Demodicosis - generalized",
          "expected_effects": "1 mg/kg: marked improvement in appearance by day 60, 38% effective overall, and 50% effective after doubling dosage for an additional 60-90 days\n2 mg/kg: marked improvement in appearance by day 30, 85% effective overall\nApproximately 7% more effective in juvenile-onset cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:04:54.000000Z",
          "updated_at": "2020-09-16T01:04:54.000000Z"
      },
      {
          "id": 1193,
          "drug_id": 313,
          "indication_name": "Nasal mite infestation - Pneumonyssoides caninum",
          "expected_effects": "No clinical signs within 1 week in 13% of dogs, no signs after second treatment in 51% of dogs, no signs after third treatment in 33% of dogs, and an incomplete clinical response in 3% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:04:57.000000Z",
          "updated_at": "2020-09-16T01:04:57.000000Z"
      },
      {
          "id": 1194,
          "drug_id": 313,
          "indication_name": "Spirocercosis",
          "expected_effects": ">99% elimination of parasites in aorta and esophagus, and of parasitic nodules in esophagus\nVariable, partial reduction (but not elimination) of some aortic nodules/aneurysms, suggesting permanent aortic changes occur in the first 30-45 days of infection\nFecal egg counts very unreliable for assessing treatment efficacy (shed in <10% of samples regardless of treatment or placebo)",
          "common_combinations": "Praziquantel 5 mg/kg (minimum - rounded up if dosage is not exactly 5 mg/kg)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:05:00.000000Z",
          "updated_at": "2020-09-16T01:05:00.000000Z"
      },
      {
          "id": 1195,
          "drug_id": 313,
          "indication_name": "Eyeworm infestation - Thelazia callipaeda ",
          "expected_effects": "87% of dogs cured after 1 treatment, 98% of dogs cured after 2 treatments\nDosage-dependent effects: 29% efficacy at dose < 0.68 mg/kg, 96% efficacy at dose 0.70-0.85 mg/kg, and >99% efficacy at dose ≥ 0.86 mg/kg\nOnce-monthly prophylaxis at same dosage is also highly (>90%) effective",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:05:02.000000Z",
          "updated_at": "2020-09-16T01:05:02.000000Z"
      },
      {
          "id": 1196,
          "drug_id": 313,
          "indication_name": "Heartworm disease - prophylaxis",
          "expected_effects": ">99% prevention of Dirofilaria immitis survival in the cat, provided 2 or more consecutive monthly doses are given (possibility of breakthrough infection if only 1 monthly dose had been given by time of mosquito bite)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:05:04.000000Z",
          "updated_at": "2020-09-16T01:05:04.000000Z"
      },
      {
          "id": 1197,
          "drug_id": 313,
          "indication_name": "Hookworm infestation - Ancylostoma tubaeforme",
          "expected_effects": "Elimination of >99% of both adult worms and fecal ova",
          "common_combinations": "Praziquantel 10 mg/CAT",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:05:07.000000Z",
          "updated_at": "2020-09-16T01:05:07.000000Z"
      },
      {
          "id": 1198,
          "drug_id": 314,
          "indication_name": "Inappetence",
          "expected_effects": "Increased food consumption: 53% of healthy cats eat readily after mirtazapine treatment, compared with 13% of placebo-treated cats\nWhen all placebo-treated cats who refused food are treated with mirtazapine, 89% of them then eat",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:05:09.000000Z",
          "updated_at": "2020-09-16T01:05:09.000000Z"
      },
      {
          "id": 1199,
          "drug_id": 315,
          "indication_name": "Gastric erosion/ulceration prophylaxis (induced by nonsteroidal anti-inflammatory drug treatment)",
          "expected_effects": "Significantly less vomiting and gastric ulceration: in aspirin-treated dogs, vomiting occurs on 7% of treatment days when dogs also are receiving misoprostol, vs. 16% of treatment days with placebo\nSignificantly fewer, and less severe, gastric mucosal lesions on endoscopy when misoprostol is given than when placebo is given",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:05:12.000000Z",
          "updated_at": "2020-09-16T01:05:12.000000Z"
      },
      {
          "id": 1200,
          "drug_id": 315,
          "indication_name": "Gastric erosion/ulceration prophylaxis (induced by high-dose methylprednisolone sodium succinate treatment)",
          "expected_effects": "Does not prevent gastric hemorrhage resulting from high methylprednisolone sodium succinate doses (30 mg/kg + 15 mg/kg at hour 2 and 6, followed by 15 mg/kg q 6h until reaching 48h)\nNo difference in results with misoprostol vs. placebo",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:05:14.000000Z",
          "updated_at": "2020-09-16T01:05:14.000000Z"
      },
      {
          "id": 1201,
          "drug_id": 315,
          "indication_name": "Gastric erosion/ulceration prophylaxis (induced by IV dexamethasone treatment in dogs with intervertebral disk disease)",
          "expected_effects": "No significant effect - no apparent reduction in gastric erosion/ulcer severity on endoscopy",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:05:16.000000Z",
          "updated_at": "2020-09-16T01:05:16.000000Z"
      },
      {
          "id": 1202,
          "drug_id": 315,
          "indication_name": "Pregnancy termination",
          "expected_effects": ">99% termination of pregnancy by day 6 of treatment (intravaginal misoprostol + aglepristone SC) vs. 57% (aglepristone monotherapy), 86% (intravaginal misoprostol + aglepristone SC + cabergoline PO), and 43% (aglepristone SC + cloprostenol SC) termination at 6 days\nFewer side-effects (e.g., no vomiting, vs. cabergoline treatment)",
          "common_combinations": "Aglepristone 10 mg/kg SC q 24h, twice",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:05:19.000000Z",
          "updated_at": "2020-09-16T01:05:19.000000Z"
      },
      {
          "id": 1203,
          "drug_id": 315,
          "indication_name": "Pregnancy termination",
          "expected_effects": ">99% termination of pregnancy by day 6 of treatment (intravaginal misoprostol + aglepristone SC) vs. 57% (aglepristone monotherapy), 86% (intravaginal misoprostol + aglepristone SC + cabergoline PO), and 43% (aglepristone SC + cloprostenol SC) termination at 6 days\nFewer side-effects (e.g., no vomiting, vs. cabergoline treatment)",
          "common_combinations": "Aglepristone 10 mg/kg SC q 24h, twice",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:05:21.000000Z",
          "updated_at": "2020-09-16T01:05:21.000000Z"
      },
      {
          "id": 1204,
          "drug_id": 315,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "30% reduction in pruritus and in severity of skin lesions (vs. 0% in placebo-treated dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:05:24.000000Z",
          "updated_at": "2020-09-16T01:05:24.000000Z"
      },
      {
          "id": 1205,
          "drug_id": 316,
          "indication_name": "Lymphoma - induction/initial treatment",
          "expected_effects": "82% complete remission and 12% partial remission, lasting 1-1500 days (median: 302 days)\n16% severe neutropenia (febrile, requiring hospitalization)\nOverall survival: 1-2200 days (median: 622 days)",
          "common_combinations": "Part of protocol that includes L-asparaginase, cyclophosphamide, doxorubicin, prednisone/prednisolone, and vincristine",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:05:26.000000Z",
          "updated_at": "2020-09-16T01:05:26.000000Z"
      },
      {
          "id": 1206,
          "drug_id": 316,
          "indication_name": "Lymphoma - relapse",
          "expected_effects": "47% of dogs achieve complete reinduction of remission with treatment, lasting a median of 84 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:05:29.000000Z",
          "updated_at": "2020-09-16T01:05:29.000000Z"
      },
      {
          "id": 1207,
          "drug_id": 316,
          "indication_name": "Lymphoma - relapse",
          "expected_effects": "47% of dogs achieve complete reinduction of remission with treatment, lasting a median of 84 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:05:31.000000Z",
          "updated_at": "2020-09-16T01:05:31.000000Z"
      },
      {
          "id": 1208,
          "drug_id": 316,
          "indication_name": "Carcinomatosis, sarcomatosis, mesothelioma",
          "expected_effects": "Median survival time: 332 days (vs. 25 days for untreated dogs)",
          "common_combinations": "Carboplatin (300 mg/m², diluted to volume of 10 mg/mL with 5% dextrose and then further diluted with 5% dextrose to 0.22 mg/mL, intracavitary) given in the same treatment session in some cases;IV doxorubicin;IV mitoxantrone in some cases replacing intracavitary treatment in alternating sessions (clinician's preference)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:05:34.000000Z",
          "updated_at": "2020-09-16T01:05:34.000000Z"
      },
      {
          "id": 1209,
          "drug_id": 316,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "Rapid resolution of lower urinary tract signs\nMedian disease-free interval: 200 days\nMedian survival: 299 days\n25% incidence of minor adverse effects (overall, protocol well-tolerated)",
          "common_combinations": "Piroxicam 0.3 mg/kg PO q 24h;CO2 laser debulking/ablation of mass lesion(s)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:05:36.000000Z",
          "updated_at": "2020-09-16T01:05:36.000000Z"
      },
      {
          "id": 1210,
          "drug_id": 316,
          "indication_name": "Malignant neoplasia",
          "expected_effects": "Complete or partial remission in 18% of cats (many receiving mitoxantrone treatment after being out of remission from previous treatments)\n29% of cats have self-limiting vomiting after treatment\nFatal pulmonary edema in 1-2% of treated cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:05:38.000000Z",
          "updated_at": "2020-09-16T01:05:38.000000Z"
      },
      {
          "id": 1211,
          "drug_id": 317,
          "indication_name": "Analgesia - postoperative ovariohysterectomy",
          "expected_effects": "Adequate analgesia at all time points, using a multiple-point pain scoring system\n15-30% lower heart rate post-op compared to pre-op baseline",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:05:41.000000Z",
          "updated_at": "2020-09-16T01:05:41.000000Z"
      },
      {
          "id": 1212,
          "drug_id": 317,
          "indication_name": "Analgesia - postoperative ovariohysterectomy",
          "expected_effects": "Smooth anesthetic recovery without vocalizing and evidence of discomfort (as seen in equivalent dogs treated with transdermal fentanyl patch)\nEating/appetite in 6-18 hours (median: 6)\nSalivation for the first 30 minutes in 10% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:05:43.000000Z",
          "updated_at": "2020-09-16T01:05:43.000000Z"
      },
      {
          "id": 1213,
          "drug_id": 317,
          "indication_name": "Analgesia - postoperative laparotomy",
          "expected_effects": "Adequate analgesia at all time points, using a multiple-point pain scoring system\n15-30% lower heart rate post-op compared to pre-op baseline",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:05:46.000000Z",
          "updated_at": "2020-09-16T01:05:46.000000Z"
      },
      {
          "id": 1214,
          "drug_id": 317,
          "indication_name": "Analgesia - laminectomy",
          "expected_effects": "50% reduction in IV fentanyl requirement intra-op, indicating analgesic effect\nNo significant bradycardia or hypotension",
          "common_combinations": "Ketamine 5 mg/kg slow IV q 1h;Fentanyl 4-5 µg/kg IV bolus then 1.2 µg/kg/h",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:05:48.000000Z",
          "updated_at": "2020-09-16T01:05:48.000000Z"
      },
      {
          "id": 1215,
          "drug_id": 317,
          "indication_name": "Analgesia - as part of morphine-lidocaine-ketamine infusion protocol",
          "expected_effects": "45% reduction in mean alveolar concentration of isoflurane, indicating extensive anesthetic-reducing effect of infusion",
          "common_combinations": "Lidocaine 3 mg/kg/h IV CRI;Ketamine 0.6 mg/kg/h IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:05:51.000000Z",
          "updated_at": "2020-09-16T01:05:51.000000Z"
      },
      {
          "id": 1216,
          "drug_id": 317,
          "indication_name": "Sedation",
          "expected_effects": "Moderate sedation (less than methadone 0.5 mg/kg IV but more than butorphanol 0.15 mg/kg IV and more than tramadol 2 mg/kg IV)\n83% incidence of retching and/or vomiting (vs. 0% with methadone, butorphanol, or tramadol)\nPeak sedative effect 45 minutes after administration, lasting at least 90 minutes (likely also reflects role of acepromazine)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:05:54.000000Z",
          "updated_at": "2020-09-16T01:05:54.000000Z"
      },
      {
          "id": 1217,
          "drug_id": 317,
          "indication_name": "Analgesia",
          "expected_effects": "Analgesia for 4-6h after treatment, which is longer than analgesia conferred by butorphanol (<30 minutes) or placebo (0 minutes) but shorter than analgesia conferred by buprenorphine (4-12h)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:05:57.000000Z",
          "updated_at": "2020-09-16T01:05:57.000000Z"
      },
      {
          "id": 1218,
          "drug_id": 317,
          "indication_name": "Analgesia",
          "expected_effects": "Thermal antinociception for 16-24 hours",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:05:59.000000Z",
          "updated_at": "2020-09-16T01:05:59.000000Z"
      },
      {
          "id": 1219,
          "drug_id": 317,
          "indication_name": "General anesthesia - MMK (morphine-medetomidine-ketamine) combination",
          "expected_effects": "Lateral recumbency 1.9 minutes after injection, and ability to intubate 4.3 minutes after IM injection\nUnresponsiveness to noxious stimulus for 2 hours (from minute 3 to minute 120 post-injection) in >83% of cats\nPrompt recovery with atipamezole IM after 2 hours",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:06:01.000000Z",
          "updated_at": "2020-09-16T01:06:01.000000Z"
      },
      {
          "id": 1220,
          "drug_id": 318,
          "indication_name": "Mycobacterial infections",
          "expected_effects": "Serum concentrations of moxifloxacin in cats are >10 times higher than the minimum inhibitory concentration of several species of Mycobacterium",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:06:03.000000Z",
          "updated_at": "2020-09-16T01:06:03.000000Z"
      },
      {
          "id": 1221,
          "drug_id": 319,
          "indication_name": "Immune-mediated anemia/aplastic anemia",
          "expected_effects": "Improvements in hematocrit and platelet count after 13-17 days, with normal levels by day 22",
          "common_combinations": "Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:06:06.000000Z",
          "updated_at": "2020-09-16T01:06:06.000000Z"
      },
      {
          "id": 1222,
          "drug_id": 319,
          "indication_name": "Myasthenia gravis",
          "expected_effects": "40% of dogs achieve remission of clinical signs",
          "common_combinations": "Pyridostigmine 1 mg/kg",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:06:09.000000Z",
          "updated_at": "2020-09-16T01:06:09.000000Z"
      },
      {
          "id": 1223,
          "drug_id": 319,
          "indication_name": "Myasthenia gravis (severe, generalized)",
          "expected_effects": "Improvement (ranging from mild to marked) in clinical signs within 24h of treatment in some individual cases",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:06:11.000000Z",
          "updated_at": "2020-09-16T01:06:11.000000Z"
      },
      {
          "id": 1224,
          "drug_id": 319,
          "indication_name": "Autoimmune skin disease",
          "expected_effects": "Visible improvement of lesions after 4 weeks, with near-complete remission for at least 16 months, in 1 case report",
          "common_combinations": "Prednisone 2 mg/kg PO q 12h for 4 weeks, then taper to lowest dosage that remains effective (0.25 mg/kg PO q 48h in 1 case report)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:06:14.000000Z",
          "updated_at": "2020-09-16T01:06:14.000000Z"
      },
      {
          "id": 1225,
          "drug_id": 319,
          "indication_name": "Immunosuppression for kidney transplantation",
          "expected_effects": "Acceptable renal allograft function\nPatient survival: > 200 days\n30% mortality rate (sepsis and gastrointestinal toxicoses primarily)",
          "common_combinations": "Nonmyeloablative total body irradiation (200 cGy);Cyclosporine;Prednisone;With or without bone marrow transplantation",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:06:16.000000Z",
          "updated_at": "2020-09-16T01:06:16.000000Z"
      },
      {
          "id": 1226,
          "drug_id": 319,
          "indication_name": "Immune-mediated hemolytic anemia",
          "expected_effects": "Improved demeanor and strongly regenerative anemia with 3-8 days of treatment\nNormal hematocrit with 2-4 weeks of therapy",
          "common_combinations": "Doxycycline 5 mg/kg PO q 12h and prednisolone 2 mg/kg PO q 12h, with prednisolone taper and continuing as prednisolone monotherapy (e.g., to 0.5 mg/kg PO q 12h after 2 months of treatment)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:06:19.000000Z",
          "updated_at": "2020-09-16T01:06:19.000000Z"
      },
      {
          "id": 1227,
          "drug_id": 320,
          "indication_name": "Opiate reversal (e.g., oxymorphone)",
          "expected_effects": "Effectively, but transiently, reverses effects of IV oxymorphone (for 20-40 minutes with IV naloxone injection)\nThe effects of 4 IV doses of oxymorphone given 20 minutes apart (total: 1 mg/kg oxymorphone over 80 minutes) can last 3-5 hours, and therefore, repeated dosing with naloxone is often necessary",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:06:21.000000Z",
          "updated_at": "2020-09-16T01:06:21.000000Z"
      },
      {
          "id": 1228,
          "drug_id": 320,
          "indication_name": "Opiate reversal (e.g., oxymorphone)",
          "expected_effects": "Effectively, but transiently, reverses effects of IV oxymorphone (for 40-70 minutes with IM naloxone injection)\nThe effects of 4 IV doses of oxymorphone given 20 minutes apart (total: 1 mg/kg oxymorphone over 80 minutes) can last 3-5 hours, and therefore, repeated dosing with naloxone is often necessary",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:06:23.000000Z",
          "updated_at": "2020-09-16T01:06:23.000000Z"
      },
      {
          "id": 1229,
          "drug_id": 320,
          "indication_name": "Compulsive tail-chasing - bull terrier",
          "expected_effects": "Near-complete cessation of tail-chasing behavior within 20 minutes of injection, vs. no response (phenobarbital, epidural lidocaine, diazepam, morphine) or worsening (dextroamphetamine) with other treatments in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:06:27.000000Z",
          "updated_at": "2020-09-16T01:06:27.000000Z"
      },
      {
          "id": 1230,
          "drug_id": 320,
          "indication_name": "Fentanyl reversal",
          "expected_effects": "Reverses fentanyl anesthetic-sparing effect",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:06:29.000000Z",
          "updated_at": "2020-09-16T01:06:29.000000Z"
      },
      {
          "id": 1231,
          "drug_id": 322,
          "indication_name": "Myasthenia gravis - acute treatment",
          "expected_effects": "Clinical improvement and no further regurgitation after 3 days of treatment",
          "common_combinations": "With pyridostigmine bromide",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:06:31.000000Z",
          "updated_at": "2020-09-16T01:06:31.000000Z"
      },
      {
          "id": 1232,
          "drug_id": 322,
          "indication_name": "Myasthenia gravis - diagnostic test",
          "expected_effects": "Unequivocal reversal of clinical signs confirms myasthenia gravis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:06:34.000000Z",
          "updated_at": "2020-09-16T01:06:34.000000Z"
      },
      {
          "id": 1233,
          "drug_id": 322,
          "indication_name": "Reversal of neuromuscular blockade (vecuronium)",
          "expected_effects": "Accelerated resolution of signs of neuromuscular blockade",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:06:37.000000Z",
          "updated_at": "2020-09-16T01:06:37.000000Z"
      },
      {
          "id": 1234,
          "drug_id": 322,
          "indication_name": "Ileus (functional) - induction of intestinal motility",
          "expected_effects": "Defecation after 20 minutes, but effect short-lived",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:06:39.000000Z",
          "updated_at": "2020-09-16T01:06:39.000000Z"
      },
      {
          "id": 1235,
          "drug_id": 322,
          "indication_name": "Analgesia - epidural",
          "expected_effects": "Moderate postoperative analgesia, but not synergistic (neostigmine-morphine epidural combination is not significantly more analgesic than morphine epidural alone), and less analgesic than morphine epidural monotherapy\nWith neostigmine epidural, supplemental analgesia is required in 10% of dogs\nAppetite returns in 8.5h, vs. 3h for neostigmine-morphine epidural combination",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:06:42.000000Z",
          "updated_at": "2020-09-16T01:06:42.000000Z"
      },
      {
          "id": 1236,
          "drug_id": 322,
          "indication_name": "Ivermectin toxicosis",
          "expected_effects": "Full recovery after 5 days in 1 case report of 16-fold ivermectin overdose\nIneffective in 2 other fatal cases (but 125- to 250-fold overdoses)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:06:44.000000Z",
          "updated_at": "2020-09-16T01:06:44.000000Z"
      },
      {
          "id": 1237,
          "drug_id": 323,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "38% of dogs controlled with doxycycline-niacinamide treatment regimen chronically",
          "common_combinations": "Doxycycline 3-18 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:06:47.000000Z",
          "updated_at": "2020-09-16T01:06:47.000000Z"
      },
      {
          "id": 1238,
          "drug_id": 323,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "38% of dogs controlled with doxycycline-niacinamide treatment regimen chronically",
          "common_combinations": "Doxycycline 3-18 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:06:49.000000Z",
          "updated_at": "2020-09-16T01:06:49.000000Z"
      },
      {
          "id": 1239,
          "drug_id": 323,
          "indication_name": "Autoimmune skin disease",
          "expected_effects": "For cutaneous/\"discoid\" lupus erythematosus: > 90% and 50-90% improvement in 40% and 30% of dogs, respectively, after 8 weeks of treatment",
          "common_combinations": "With tetracycline PO (at same body-weight-indexed dosage [mg] and same interval as niacinamide)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:06:52.000000Z",
          "updated_at": "2020-09-16T01:06:52.000000Z"
      },
      {
          "id": 1240,
          "drug_id": 323,
          "indication_name": "Autoimmune skin disease",
          "expected_effects": "For cutaneous/\"discoid\" lupus erythematosus: > 90% and 50-90% improvement in 40% and 30% of dogs, respectively, after 8 weeks of treatment",
          "common_combinations": "With tetracycline PO (at same body-weight-indexed dosage [mg] and same interval as niacinamide)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:06:54.000000Z",
          "updated_at": "2020-09-16T01:06:54.000000Z"
      },
      {
          "id": 1241,
          "drug_id": 323,
          "indication_name": "Lupoid onychodystrophy",
          "expected_effects": "40% excellent response (complete regrowth of normal claws), 20% good response (resolution of pain but abnormal claws persist), 20% partial response (partial persistence of pain and abnormal claw morphology), and 20% poor response (no substantial improvement)",
          "common_combinations": "Doxycycline 5-10 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:06:56.000000Z",
          "updated_at": "2020-09-16T01:06:56.000000Z"
      },
      {
          "id": 1242,
          "drug_id": 323,
          "indication_name": "Lupoid onychodystrophy",
          "expected_effects": "40% excellent response (complete regrowth of normal claws), 20% good response (resolution of pain but abnormal claws persist), 20% partial response (partial persistence of pain and abnormal claw morphology), and 20% poor response (no substantial improvement)",
          "common_combinations": "Doxycycline 5-10 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:06:59.000000Z",
          "updated_at": "2020-09-16T01:06:59.000000Z"
      },
      {
          "id": 1243,
          "drug_id": 324,
          "indication_name": "Urethral obstruction",
          "expected_effects": "30-50% reduction in intraluminal pressure of the feline urethra in the prostatic region only\nSince this is the wider diameter part of the urethra and virtually never the source of obstruction in naturally-occurring urethral obstruction, nifedipine cannot be considered clinically useful\nNo effect on post-prostatic urethral pressure",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:01.000000Z",
          "updated_at": "2020-09-16T01:07:01.000000Z"
      },
      {
          "id": 1244,
          "drug_id": 325,
          "indication_name": "Flea infestation - Ctenocephalides felis",
          "expected_effects": "Highly effective flea kill by 3 h (99% in dogs, 100% in cats) and by 8h (100% in dogs and cats) after administration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:04.000000Z",
          "updated_at": "2020-09-16T01:07:04.000000Z"
      },
      {
          "id": 1245,
          "drug_id": 325,
          "indication_name": "Flea infestation - Ctenocephalides felis",
          "expected_effects": "Highly effective flea kill by 3 h (99% in dogs, 100% in cats) and by 8h (100% in dogs and cats) after administration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:06.000000Z",
          "updated_at": "2020-09-16T01:07:06.000000Z"
      },
      {
          "id": 1246,
          "drug_id": 326,
          "indication_name": "Acute congestive heart failure",
          "expected_effects": "Evidence of vasodilation: 7% increase in splenic volume peaking 14 minutes after application",
          "common_combinations": "Other treatments (e.g., diuretic, oxygen supplementation) as clinically indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:09.000000Z",
          "updated_at": "2020-09-16T01:07:09.000000Z"
      },
      {
          "id": 1247,
          "drug_id": 326,
          "indication_name": "Acute vasodilation during cardiovascular procedures",
          "expected_effects": "Restores mean pulmonary arterial pressure (PAP) to normal range\nDecrease in PAP begins immediately, lasting 3-5 min\nDecreases mean blood pressure by 12-26 mmHg (dose dependent)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:11.000000Z",
          "updated_at": "2020-09-16T01:07:11.000000Z"
      },
      {
          "id": 1248,
          "drug_id": 326,
          "indication_name": "Acute vasodilation during cardiovascular procedures",
          "expected_effects": "In dogs with acute mitral regurgitation: 26% and 28% decrease over 3 minutes, in left ventricular end-diastolic pressure and mean left arterial pressure, respectively, returning 10 minutes after discontinuation\n19% decrease in central venous pressure, returning 20 minutes after discontinuation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:07:14.000000Z",
          "updated_at": "2020-09-16T01:07:14.000000Z"
      },
      {
          "id": 1249,
          "drug_id": 327,
          "indication_name": "Acute congestive heart failure",
          "expected_effects": "Nonspecific reduction in peripheral arterial pressure",
          "common_combinations": "Treatment for acute congestive heart failure as indicated (e.g., diuretics, oxygen supplementation)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:17.000000Z",
          "updated_at": "2020-09-16T01:07:17.000000Z"
      },
      {
          "id": 1250,
          "drug_id": 327,
          "indication_name": "Acute hypertension (e.g., phenylpropanolamine toxicosis)",
          "expected_effects": "Rapid control of hypertension",
          "common_combinations": "Treatment for ventricular arrhythmias, if present (e.g., esmolol, sotalol)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:19.000000Z",
          "updated_at": "2020-09-16T01:07:19.000000Z"
      },
      {
          "id": 1251,
          "drug_id": 327,
          "indication_name": "Intraoperative hypertension (e.g., pheochromocytoma adrenalectomy)",
          "expected_effects": "78% survival to discharge in pheochromocytoma adrenalectomy (5% intra-op mortality: ventricular fibrillation, intractable hemorrhage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:07:22.000000Z",
          "updated_at": "2020-09-16T01:07:22.000000Z"
      },
      {
          "id": 1252,
          "drug_id": 327,
          "indication_name": "Patent ductus arteriosus - intra-op rupture",
          "expected_effects": "Reduction of systolic and mean arterial blood pressure (MAP) by 27-60 mmHg and 14-33 mmHg, respectively, within 5-10 minutes of starting infusion\nNormal MAP within 5 min of discontinuation\nLigation successful in >80% of PDAs that rupture, or where rupture appeared imminent, intra-op (uneventful anesthetic recovery and discharge in all dogs in 1 case series)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:07:24.000000Z",
          "updated_at": "2020-09-16T01:07:24.000000Z"
      },
      {
          "id": 1253,
          "drug_id": 328,
          "indication_name": "Gastroprokinetic",
          "expected_effects": "Mild (approximately 20%) and moderate (approximately 50%) increase in enteric electrical activity after 10 and 20 mg/kg dosages, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:27.000000Z",
          "updated_at": "2020-09-16T01:07:27.000000Z"
      },
      {
          "id": 1254,
          "drug_id": 329,
          "indication_name": "Systemic hypotension in euvolemic dog",
          "expected_effects": "42, 17, and 26 mmHg increases in systolic blood pressure, diastolic blood pressure, and mean blood pressure, respectively, over 10 minutes\nMean decrease in heart rate: 21 beats/minute",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:29.000000Z",
          "updated_at": "2020-09-16T01:07:29.000000Z"
      },
      {
          "id": 1255,
          "drug_id": 329,
          "indication_name": "Severe systemic hypotension due to sepsis (septic shock)",
          "expected_effects": "2-fold greater likelihood of survival with norepinephrine treatment of hypotension (compared to 3-fold greater likelihood of survival when managing critical hypotension with vasopressin, and 6-fold greater likelihood of death with hypotension management using epinephrine) in experimental septic shock in dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:31.000000Z",
          "updated_at": "2020-09-16T01:07:31.000000Z"
      },
      {
          "id": 1256,
          "drug_id": 330,
          "indication_name": "Urinary tract infection",
          "expected_effects": "Excellent response when infection is caused by susceptible organisms: normal urinalysis and no growth in urine culture 1-3 weeks following treatment (isolated urinary tract infection) and normal urinalysis, no bacterial growth in urine and prostate cultures, and a marked decrease in prostate size 1-4 months following treatment (prostatitis)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:34.000000Z",
          "updated_at": "2020-09-16T01:07:34.000000Z"
      },
      {
          "id": 1257,
          "drug_id": 330,
          "indication_name": "Bacterial prostatitis",
          "expected_effects": "Moderate penetration into prostatic tissue, but slightly inferior to ciprofloxacin and to other fluoroquinolones",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:36.000000Z",
          "updated_at": "2020-09-16T01:07:36.000000Z"
      },
      {
          "id": 1258,
          "drug_id": 330,
          "indication_name": "Otitis externa",
          "expected_effects": "92% satisfactory response after 7-14 days of treatment\n21% rate of recurrence during 3 month follow-up",
          "common_combinations": "Ketoconazole 1% in same solution",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:07:39.000000Z",
          "updated_at": "2020-09-16T01:07:39.000000Z"
      },
      {
          "id": 1259,
          "drug_id": 331,
          "indication_name": "Protothecosis",
          "expected_effects": "Elimination of all clinical signs and negative rectal scraping/cytology in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:41.000000Z",
          "updated_at": "2020-09-16T01:07:41.000000Z"
      },
      {
          "id": 1260,
          "drug_id": 331,
          "indication_name": "Fungal enteritis",
          "expected_effects": "Resolution of clinical signs and of fecal fungal shedding",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:43.000000Z",
          "updated_at": "2020-09-16T01:07:43.000000Z"
      },
      {
          "id": 1261,
          "drug_id": 332,
          "indication_name": "Glucagonoma-associated superficial necrolytic dermatitis",
          "expected_effects": "Marked improvement in skin lesion and systemic signs within 5 days\nNear-complete resolution of clinical signs within 10 days\nRapid recurrence of clinical signs on discontinuation",
          "common_combinations": "Mirtazapine;Ondansetron",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:46.000000Z",
          "updated_at": "2020-09-16T01:07:46.000000Z"
      },
      {
          "id": 1262,
          "drug_id": 332,
          "indication_name": "Insulinoma",
          "expected_effects": "Immediate benefit in dogs with insulinoma: pre-treatment blood glucose concentration 41-63 mg/dL\nTreatment increases blood glucose concentration by up to 30 mg/dL (median increase: 12 mg/dL) by 6h after injection\nMedian plasma insulin concentration decreases dramatically into normal range after 1 dose (normal baseline: 43 pmol/L, insulinoma [untreated]: 117 pmol/L, insulinoma [6h after 1st octreotide injection]: 54 pmol/L)\nInsignificant impact on plasma growth hormone, adrenocorticotropic hormone, and cortisol concentrations",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:07:48.000000Z",
          "updated_at": "2020-09-16T01:07:48.000000Z"
      },
      {
          "id": 1263,
          "drug_id": 332,
          "indication_name": "Gastrinoma",
          "expected_effects": "8 µg/kg dosage produces 50% reduction in plasma gastrin levels -- from 10000 to 5000 pg/mL (normal range: 12-74 pg/mL) -- 1h after injection, returning to pretreatment levels 6-8h after injection\n14-month survival in 1 case report",
          "common_combinations": "Supportive gastrointestinal therapy (e.g., famotidine, omeprazole, sucralfate)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:07:50.000000Z",
          "updated_at": "2020-09-16T01:07:50.000000Z"
      },
      {
          "id": 1264,
          "drug_id": 333,
          "indication_name": "Cataract surgery - infection prophylaxis",
          "expected_effects": "≤ 15%, ≤ 15%, 62%, 92%, and >99% of eyes exceed 90% minimum inhibitory concentration for Streptococcus spp., Corynebacterium spp., Staphylococcus spp., Bacillus spp., and E. coli, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:53.000000Z",
          "updated_at": "2020-09-16T01:07:53.000000Z"
      },
      {
          "id": 1265,
          "drug_id": 334,
          "indication_name": "Histiocytic ulcerative colitis",
          "expected_effects": "No improvement of clinical signs in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:55.000000Z",
          "updated_at": "2020-09-16T01:07:55.000000Z"
      },
      {
          "id": 1266,
          "drug_id": 335,
          "indication_name": "Gastritis and gastric ulceration (NSAID-associated) - prevention",
          "expected_effects": "Consistently fewer gastric ulcerations, and of milder degree, with omeprazole treatment compared to cimetidine or to untreated controls",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:07:58.000000Z",
          "updated_at": "2020-09-16T01:07:58.000000Z"
      },
      {
          "id": 1267,
          "drug_id": 335,
          "indication_name": "Gastritis and gastric ulceration (corticosteroid-associated)",
          "expected_effects": "No difference compared to misoprostol or untreated controls",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:08:00.000000Z",
          "updated_at": "2020-09-16T01:08:00.000000Z"
      },
      {
          "id": 1268,
          "drug_id": 335,
          "indication_name": "Gastroesophageal reflux during general anesthesia",
          "expected_effects": "18% of dogs show evidence of acidic gastroesophageal reflux with omeprazole treatment, vs. 52% in untreated controls ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:08:02.000000Z",
          "updated_at": "2020-09-16T01:08:02.000000Z"
      },
      {
          "id": 1269,
          "drug_id": 335,
          "indication_name": "Gastritis and gastric ulceration (exercise-induced, in Alaskan sled dogs)",
          "expected_effects": "3-fold lower incidence of gastric lesions (on endoscopy after 500-km run) compared to famotidine and 4-fold compared to placebo",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:08:05.000000Z",
          "updated_at": "2020-09-16T01:08:05.000000Z"
      },
      {
          "id": 1270,
          "drug_id": 335,
          "indication_name": "Gastrinoma",
          "expected_effects": "Marked clinical improvement within 1-2 days\nResolution of diarrhea and normalization of body weight after 12-14 days\n>2 year survival with no clinical signs, all in 1 case report",
          "common_combinations": "Sucralfate during first week of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:08:07.000000Z",
          "updated_at": "2020-09-16T01:08:07.000000Z"
      },
      {
          "id": 1271,
          "drug_id": 335,
          "indication_name": "Helicobacteriosis",
          "expected_effects": "Transient suppression but no eradication (some resistance)",
          "common_combinations": "Part of quadruple therapy with amoxiciilin 20 mg/kg PO q 12h, metronidazole 20 mg/kg PO q 12h, and clarithromycin 7.5 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:08:10.000000Z",
          "updated_at": "2020-09-16T01:08:10.000000Z"
      },
      {
          "id": 1272,
          "drug_id": 336,
          "indication_name": "Nausea - general/peripheral",
          "expected_effects": "Significant reduction in vomiting (similar to maropitant)\nSignificantly better antiemetic effect compared to metoclopramide or chlorpromazine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:12.000000Z",
          "updated_at": "2020-09-16T01:08:12.000000Z"
      },
      {
          "id": 1273,
          "drug_id": 336,
          "indication_name": "Nausea - associated with parvoviral enteritis in puppies",
          "expected_effects": "No report of adverse effect",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:08:14.000000Z",
          "updated_at": "2020-09-16T01:08:14.000000Z"
      },
      {
          "id": 1274,
          "drug_id": 336,
          "indication_name": "Nausea - associated with alpha-2 adrenergic drugs",
          "expected_effects": "Reduces vomiting associated with alpha-2 adrenergic agonists: vomiting occurs in 33% of cats (and is milder), compared to 78% without ondansetron",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:08:17.000000Z",
          "updated_at": "2020-09-16T01:08:17.000000Z"
      },
      {
          "id": 1275,
          "drug_id": 337,
          "indication_name": "Pituitary-dependent hyperadrenocorticism",
          "expected_effects": "With properly titrated dosage, full resolution of clinical signs can be expected over a period of several weeks in the majority of cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:19.000000Z",
          "updated_at": "2020-09-16T01:08:19.000000Z"
      },
      {
          "id": 1276,
          "drug_id": 337,
          "indication_name": "Adrenal tumor-dependent hyperadrenocorticism",
          "expected_effects": "Good to excellent response in 66% of dogs\nSurvival time: 3 weeks to 5 years (median: 11.5 months) vs. 3.5 months with surgery\nOne or more relapses in 63% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:08:22.000000Z",
          "updated_at": "2020-09-16T01:08:22.000000Z"
      },
      {
          "id": 1277,
          "drug_id": 337,
          "indication_name": "Alopecia X - when melatonin treatment has failed",
          "expected_effects": "Partial to complete hair re-growth in 66% of dogs, and failure to regrow hair in 33% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:08:25.000000Z",
          "updated_at": "2020-09-16T01:08:25.000000Z"
      },
      {
          "id": 1278,
          "drug_id": 337,
          "indication_name": "Hyperadrenocorticism",
          "expected_effects": "No clinical response in 1 reported case",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:08:27.000000Z",
          "updated_at": "2020-09-16T01:08:27.000000Z"
      },
      {
          "id": 1279,
          "drug_id": 338,
          "indication_name": "Superficial and deep pyoderma",
          "expected_effects": "Excellent response to treatment (based on veterinarians' assessments of lesions) in 95.6% of dogs\n18% recurrence rate within 3 months of end of treatment",
          "common_combinations": "Antihistamine if concurrent atopic dermatitis;Antiparasitic if concurrent parasitic skin infestation",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:30.000000Z",
          "updated_at": "2020-09-16T01:08:30.000000Z"
      },
      {
          "id": 1280,
          "drug_id": 338,
          "indication_name": "Penetrating foreign body",
          "expected_effects": "Reduction in signs of infection in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:08:32.000000Z",
          "updated_at": "2020-09-16T01:08:32.000000Z"
      },
      {
          "id": 1281,
          "drug_id": 339,
          "indication_name": "Benign prostatic hyperplasia",
          "expected_effects": "38% reduction in prostate volume by day 14 (vs. 28% with delmadinone)\nComplete elimination of prostate-associated clinical signs in 50% of dogs by day 14, 63% by day 60, and 84% by day 180 of treatment (similar to 48%, 59%, and 83%, respectively, for demadinone)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:34.000000Z",
          "updated_at": "2020-09-16T01:08:34.000000Z"
      },
      {
          "id": 1282,
          "drug_id": 340,
          "indication_name": "Parvoviral enteritis",
          "expected_effects": "Significant avoidance of weight loss during intensive care (2.6% weight gain with oseltamivir, vs. 4.5% weight loss with placebo)",
          "common_combinations": "Intensive treatment for parvoviral enteritis (IV fluids, ampicillin, enrofloxacin, metoclopramide, etc.)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:37.000000Z",
          "updated_at": "2020-09-16T01:08:37.000000Z"
      },
      {
          "id": 1283,
          "drug_id": 341,
          "indication_name": "Fear/anxiety/panic associated with veterinary visits or car trips",
          "expected_effects": "Nonspecific reduction of clinical signs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:39.000000Z",
          "updated_at": "2020-09-16T01:08:39.000000Z"
      },
      {
          "id": 1284,
          "drug_id": 342,
          "indication_name": "Sedation (general)",
          "expected_effects": "Marked sedation, requiring minimal or no restraint, for at least 60 minutes\nAverage 14% decrease in heart rate\nIncreased respiratory rate (up 10-30 breaths/minute) for 20 minutes after injection\nAverage 16% decrease in systolic arterial blood pressure within 20 minutes of injection (of oxymorphone-acepromazine), gradually returning to normal after > 100 min\nAverage of 185 and 209 minutes to stand and walk, respectively",
          "common_combinations": "Acepromazine",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:08:42.000000Z",
          "updated_at": "2020-09-16T01:08:42.000000Z"
      },
      {
          "id": 1285,
          "drug_id": 342,
          "indication_name": "Sedation (preanesthetic)",
          "expected_effects": "Mean sedation score of 4-6 (out of 14, where 14 is general anesthesia), 10-25 minutes after oxymorphone IV, vs. mean sedation score of 7.5-10 (10-25 minutes after oxymorphone-acepromazine injection)\nThree times more panting in dogs with oxymorphone monotherapy as with oxymorphone-acepromazine combination, but oxygen saturation remains within normal limits\n21-36% decrease in heart rate (still within limits) 25 minutes after oxymorphone or oxymorphone-acepromazine\nNo significant change in plasma histamine concentration",
          "common_combinations": "With or without simultaneous acepromazine 0.05 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:08:44.000000Z",
          "updated_at": "2020-09-16T01:08:44.000000Z"
      },
      {
          "id": 1286,
          "drug_id": 342,
          "indication_name": "Analgesia (general)",
          "expected_effects": "Potent analgesia (similar to hydromorphone) with lengthy (mean: 5.5 hours) interval between 1st dose and need for 2nd dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:08:47.000000Z",
          "updated_at": "2020-09-16T01:08:47.000000Z"
      },
      {
          "id": 1287,
          "drug_id": 342,
          "indication_name": "Analgesia (intraoperative)",
          "expected_effects": "Significant analgesic effect of adding oxymorphone to general anesthesia protocol, allowing reduction in inhaled anesthetic concentration (mean minimum alveolar concentration of isoflurane: 0.7% and 1.0%, at 1.5h and 4.5h post-oxymorphone, respectively, vs. 1.2% in placebo-treated control dogs)\nEffect lasts 4h-5h (decreasing after 2h)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:08:50.000000Z",
          "updated_at": "2020-09-16T01:08:50.000000Z"
      },
      {
          "id": 1288,
          "drug_id": 342,
          "indication_name": "Analgesia (post-op for orthopedic surgery)",
          "expected_effects": "Short-term analgesia: very effective during the first 2h post-op (pain score ≤ 1/13)\nAverage pain score ≤ 4/13 for up to 12h post-op\nUp to 40% of dogs require supplemental analgesia 7h after initial oxymorphone dose, compared to only 5% when combined with ketoprofen, or with ketoprofen alone",
          "common_combinations": "Ketoprofen",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:08:52.000000Z",
          "updated_at": "2020-09-16T01:08:52.000000Z"
      },
      {
          "id": 1289,
          "drug_id": 342,
          "indication_name": "Epidural analgesia (thoracotomy)",
          "expected_effects": "Effective analgesia (1/6 multifactorial pain score) for 10h post-op in 88% of dogs, vs. 2h for IM route",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:08:55.000000Z",
          "updated_at": "2020-09-16T01:08:55.000000Z"
      },
      {
          "id": 1290,
          "drug_id": 342,
          "indication_name": "Analgesia (general)",
          "expected_effects": "Monotherapy: mild visceral analgesia apparent with 0.05 mg/kg and 0.1 mg/kg dosages\nCombination therapy with butorphanol: moderate to marked visceral analgesia for 30 minutes, and mild visceral analgesia for up to 60 minutes",
          "common_combinations": "Butorphanol 0.05-0.2 mg/kg combined in same syringe as oxymorphone and given IV",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:08:57.000000Z",
          "updated_at": "2020-09-16T01:08:57.000000Z"
      },
      {
          "id": 1291,
          "drug_id": 343,
          "indication_name": "Ehrlichiosis",
          "expected_effects": "Elimination of E. canis within 24h of first injection\nImprovement of clinical signs within 24h of first injection, especially fever and anorexia, with full resolution of signs 24h after the second injection in 87% of dogs\nSwelling and/or pain at the injection site in 10% of dogs when dosages of piroxicam < 0.8 mg/kg are used",
          "common_combinations": "Piroxicam 15 mg/DOG IM to decrease pain",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:00.000000Z",
          "updated_at": "2020-09-16T01:09:00.000000Z"
      },
      {
          "id": 1292,
          "drug_id": 343,
          "indication_name": "Leptospirosis",
          "expected_effects": "80% survival of dogs with fulminant experimental leptospirosis with treatment (vs. 20% survival in untreated controls)\nMarkedly decreased severity of infection with treatment (e.g., mean duration of icterus in surviving treated dogs: 6 days, vs. 16 days in surviving untreated dogs, and mean peak BUN 45 mg/dL in treated dogs vs. 111 mg/dL in untreated dogs)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:03.000000Z",
          "updated_at": "2020-09-16T01:09:03.000000Z"
      },
      {
          "id": 1293,
          "drug_id": 344,
          "indication_name": "Dystocia without mechanical obstruction",
          "expected_effects": "Delivery of fetus in 23%, 14%, and 5% of dogs within 30, 60, and 90 minutes, respectively",
          "common_combinations": "Calcium gluconate 100 mg/mL: 2-10 mL (based on body weight) slow IV",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:05.000000Z",
          "updated_at": "2020-09-16T01:09:05.000000Z"
      },
      {
          "id": 1294,
          "drug_id": 344,
          "indication_name": "Induce parturition",
          "expected_effects": "Induces parturition in >99% of dogs (when dam is at days 59-61 post-estimated ovulation date and pretreated with aglepristone)\nParturition lasts 9.6h compared to 8h in untreated dogs that continue to term\nFirst pup is delivered a mean of 25.9h after aglepristone injection (range: 21-30h)\nMean of 116 ± 83 min between pups, vs. 68.8 ± 24.5 min in natural whelping group",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:08.000000Z",
          "updated_at": "2020-09-16T01:09:08.000000Z"
      },
      {
          "id": 1295,
          "drug_id": 344,
          "indication_name": "Increase number of spermatozoa",
          "expected_effects": "No significant effect on number of spermatozoa, progressive motility, or percentage of normal spermatozoa, over 18-24 days (6 doses)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:09:10.000000Z",
          "updated_at": "2020-09-16T01:09:10.000000Z"
      },
      {
          "id": 1296,
          "drug_id": 345,
          "indication_name": "Mast cell tumor (nonresectable)",
          "expected_effects": "Resolution of lesions, or marked reduction in lesion size with no new lesions, in 7% of dogs with nonresectable mast cell tumor (vs. 1% with high-dosage lomustine: 70 mg/m²) after 14 weeks of treatment\n19% termination of treatment due to loss of efficacy (vs. 60% for equivalent patients treated with lomustine)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:13.000000Z",
          "updated_at": "2020-09-16T01:09:13.000000Z"
      },
      {
          "id": 1297,
          "drug_id": 346,
          "indication_name": "Osteolysis associated with osteosarcoma",
          "expected_effects": "Pamidronate does not reduce bone pain (associated with osteosarcoma in dogs that do not undergo amputation)\nSome improvement in biomarkers of bone remodeling with pamidronate treatment",
          "common_combinations": "Standard antineoplastic protocol (doxorubicin, deracoxib, radiotherapy)",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:15.000000Z",
          "updated_at": "2020-09-16T01:09:15.000000Z"
      },
      {
          "id": 1298,
          "drug_id": 346,
          "indication_name": "Hypercalcemia (refractory to standard hypercalcemia treatment)",
          "expected_effects": "Serum total or ionized calcium concentrations return to normal range in 24-48h (median: 30h) in >88% of treated dogs/cats\nRecurrence of hypercalcemia variable, with some animals remaining normocalcemic for weeks despite having active disease that could cause recurrent hypercalcemia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:19.000000Z",
          "updated_at": "2020-09-16T01:09:19.000000Z"
      },
      {
          "id": 1299,
          "drug_id": 346,
          "indication_name": "Hypercalcemia (due to cholecalciferol toxicosis)",
          "expected_effects": "With higher dosage (2 mg/kg): 15% decrease in glomerular filtration rate after 3 days, vs. 55% in untreated dogs\nDose-dependent reduction in serum calcium concentrations (average of ≥ 2 mg/dL lower between days 4-14)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:09:21.000000Z",
          "updated_at": "2020-09-16T01:09:21.000000Z"
      },
      {
          "id": 1300,
          "drug_id": 347,
          "indication_name": "Exocrine pancreatic insufficiency",
          "expected_effects": "Complete control of associated GI clinical signs in 47% of dogs\nDespite treatment, good responders may have persisting intermittent signs including high fecal volume, yellow and pulpy feces, and flatulence",
          "common_combinations": "Treatment for intestinal dysbiosis (tylosin, metronidazole, trimethoprim, amoxicillin, possibly B vitamin injections)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:23.000000Z",
          "updated_at": "2020-09-16T01:09:23.000000Z"
      },
      {
          "id": 1301,
          "drug_id": 347,
          "indication_name": "Pancreatic autotransplantation",
          "expected_effects": "After autotransplantation, the canine exocrine pancreatic tissue degenerates, leaving only islets (insulin production)\nEnzyme supplementation keeps these dogs at normal weight and free of clinical signs of exocrine pancreatic insufficiency",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:26.000000Z",
          "updated_at": "2020-09-16T01:09:26.000000Z"
      },
      {
          "id": 1302,
          "drug_id": 347,
          "indication_name": "Exocrine pancreatic insufficiency",
          "expected_effects": "Markedly improved haircoat quality, normalization of body condition (with 400 g weight gain), and normal frequency and consistency of feces, after 6 weeks of treatment in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:09:28.000000Z",
          "updated_at": "2020-09-16T01:09:28.000000Z"
      },
      {
          "id": 1303,
          "drug_id": 348,
          "indication_name": "Gastric acid secretion suppression",
          "expected_effects": "Median 24-hour intragastric pH of 3.11 and 3.68 after 2 and 6 days of treatment, respectively, compared to 1.78 and 1.67 in placebo-treated dogs\nIntragastric pH ≥ 3 for 54-59% of the time, and ≥ 4 for 35-41% of the time, after 2-6 days of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:30.000000Z",
          "updated_at": "2020-09-16T01:09:30.000000Z"
      },
      {
          "id": 1304,
          "drug_id": 349,
          "indication_name": "Leishmaniasis - L. donovani",
          "expected_effects": "Complete recovery in 92% of dogs after 30 days (similar to control dogs treated with sodium stilbogluconate)\nSeronegativity in 50% of dogs after paromomycin treatment for 4 weeks\nDecrease in mean anti-Leishmania antibody titer from 1:360 to 1:36 after 30 days, compared to 1:460 to 1:360 in stilbogluconate-treated dogs\nSerum IgG and circulating immune-complex concentrations return to normal ranges after treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:33.000000Z",
          "updated_at": "2020-09-16T01:09:33.000000Z"
      },
      {
          "id": 1305,
          "drug_id": 349,
          "indication_name": "Leishmaniasis - visceral (L. chagasi)",
          "expected_effects": "Clinical resolution for up to 4 years in 25% of dogs, with mild adverse effects\n42% of initial improvement, but relapse 1-4 months after end of treatment\nLower dosage (20 mg/kg) produces fewer adverse effects, but parasitemia is more persistent and relapse typically occurs within 50-100 days\nHigher dosage (80 mg/kg for 40 days) produces unacceptable degrees of adverse effects",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:35.000000Z",
          "updated_at": "2020-09-16T01:09:35.000000Z"
      },
      {
          "id": 1306,
          "drug_id": 349,
          "indication_name": "Cryptosporidiosis",
          "expected_effects": "Resolution of diarrhea, and of fecal ova shedding in feces, during 4 weeks following treatment in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:09:38.000000Z",
          "updated_at": "2020-09-16T01:09:38.000000Z"
      },
      {
          "id": 1307,
          "drug_id": 350,
          "indication_name": "Social phobias, anxieties concerning social interactions, and related urine marking",
          "expected_effects": "More confidence in interactions with other cats",
          "common_combinations": "Behavioral therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:40.000000Z",
          "updated_at": "2020-09-16T01:09:40.000000Z"
      },
      {
          "id": 1308,
          "drug_id": 351,
          "indication_name": "Idiopathic chronic hepatitis of doberman dogs (and associated hepatic copper accumulation)",
          "expected_effects": "Mean decrease in liver copper concentration: 61% (pre: median 1179 mg/kg [range: 630-1330 mg/kg], post: median 300 mg/kg [range: 195-815 mg/kg], all dry matter basis hepatic tissue)\nNormal histopathological appearance of lesions in > 80% of dogs after treatment\nComplete resolution of subclinical hepatitis in 60% of dogs, with marked improvement in the remaining 40%\nNo detectable adverse effects during treatment",
          "common_combinations": "General treatment of hepatopathy as clinically indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:43.000000Z",
          "updated_at": "2020-09-16T01:09:43.000000Z"
      },
      {
          "id": 1309,
          "drug_id": 351,
          "indication_name": "Lead toxicosis",
          "expected_effects": "Partial decrease in blood lead concentration (pre: median 110 µg/dL [range: 40-390 µg/dL], post: median 80 µg/dL [range: 20-310 µg/dL] - normal ranges variably reported as <40 µg/dL to <5 µg/dL)",
          "common_combinations": "Supportive treatments as required (IV fluid therapy, diazepam and barbiturates, corticosteroids and mannitol, antiemetics)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:45.000000Z",
          "updated_at": "2020-09-16T01:09:45.000000Z"
      },
      {
          "id": 1310,
          "drug_id": 351,
          "indication_name": "Copper storage hepatopathy of Bedlington terriers",
          "expected_effects": "No significant improvement in hepatic copper concentration or liver lesions histopathologically in 2 reported cases",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:09:48.000000Z",
          "updated_at": "2020-09-16T01:09:48.000000Z"
      },
      {
          "id": 1311,
          "drug_id": 352,
          "indication_name": "Urinary tract infection",
          "expected_effects": "50%, 62%, 42%, and >99% efficacy against E. coli, P. mirabilis, Proteus rettgeri, and both staphylococci and streptococci, respectively, in 1 large study (1970s, so bacterial susceptibility patterns likely have changed)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:09:50.000000Z",
          "updated_at": "2020-09-16T01:09:50.000000Z"
      },
      {
          "id": 1312,
          "drug_id": 352,
          "indication_name": "Actinomycosis",
          "expected_effects": "With protracted treatment (months to >1 year of oral penicillin treatment), clinical cure occurs in many cases",
          "common_combinations": "Interpleural (intrathoracic) infusion is given concurrently if chest tube is in place: drain purulent effusion from thoracic cavity and infuse 250000 IU potassium penicillin G (diluted in 500 mL sterile 0.9% saline) q 24h for 5 days",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:09:52.000000Z",
          "updated_at": "2020-09-16T01:09:52.000000Z"
      },
      {
          "id": 1313,
          "drug_id": 352,
          "indication_name": "Leptospirosis",
          "expected_effects": "Reduction/elimination of leptospiremia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:09:55.000000Z",
          "updated_at": "2020-09-16T01:09:55.000000Z"
      },
      {
          "id": 1314,
          "drug_id": 352,
          "indication_name": "Perioperative infection prophylaxis",
          "expected_effects": "No infections in 97% of dogs, compared to 84% of untreated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:09:57.000000Z",
          "updated_at": "2020-09-16T01:09:57.000000Z"
      },
      {
          "id": 1315,
          "drug_id": 352,
          "indication_name": "Dental prophylaxis (bacteremia prevention)",
          "expected_effects": "No difference in incidence of bacteremia with (50%), vs. without (53%), IV penicillin in blood cultures from dogs with periodontal disease (30 minutes after start of dental manipulation)\nLonger-term effect (e.g., bacterial colonization and infection rate hours/days later) unknown",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:10:00.000000Z",
          "updated_at": "2020-09-16T01:10:00.000000Z"
      },
      {
          "id": 1316,
          "drug_id": 352,
          "indication_name": "Anaerobic infections (e.g., pyothorax)",
          "expected_effects": "78% overall survival with no residual clinical signs of illness 2-6 weeks after treatment",
          "common_combinations": "Chest tube placement during initial hospitalization, with recurrent pleural lavage",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:10:03.000000Z",
          "updated_at": "2020-09-16T01:10:03.000000Z"
      },
      {
          "id": 1317,
          "drug_id": 353,
          "indication_name": "Pneumonia (e.g., caused by Streptococcus zooepidemicus in an animal shelter setting)",
          "expected_effects": "Complete resolution of clinical disease in small case series of acutely, severely ill dogs",
          "common_combinations": "Streptomycin 20 mg/kg IM q 12h;IV fluids as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:10:05.000000Z",
          "updated_at": "2020-09-16T01:10:05.000000Z"
      },
      {
          "id": 1318,
          "drug_id": 353,
          "indication_name": "Bacterial endocarditis",
          "expected_effects": "Wax-wane status with overall deterioration, leading to euthanasia 20 days after initial diagnosis, in 1 case report",
          "common_combinations": "Streptomycin 14 mg/kg in 1 case report",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:10:08.000000Z",
          "updated_at": "2020-09-16T01:10:08.000000Z"
      },
      {
          "id": 1319,
          "drug_id": 353,
          "indication_name": "Ehrlichiosis",
          "expected_effects": "Unchanged concentration of leukocyte morulae after treatment compared to untreated control dogs",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:10:10.000000Z",
          "updated_at": "2020-09-16T01:10:10.000000Z"
      },
      {
          "id": 1320,
          "drug_id": 353,
          "indication_name": "Streptococcal infection outbreak in a cattery",
          "expected_effects": "Immediate termination of the outbreak (no new cases for 3 months)",
          "common_combinations": "Benzathine penicillin G given in equal amounts and at the same time as procaine penicillin G",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:10:13.000000Z",
          "updated_at": "2020-09-16T01:10:13.000000Z"
      },
      {
          "id": 1321,
          "drug_id": 354,
          "indication_name": "Status epilepticus",
          "expected_effects": "Seizure control and discharge in 60% of dogs/cats with severe status epilepticus, euthanasia in 30%, and non-euthanasia death in 10% in 1 case series ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:10:16.000000Z",
          "updated_at": "2020-09-16T01:10:16.000000Z"
      },
      {
          "id": 1322,
          "drug_id": 354,
          "indication_name": "General anesthesia",
          "expected_effects": "Effective anesthesia for 2h (mean: 138 minutes) with single dose\n42-80% decreased respiration rate during the first 50 minutes post-administration, possibly requiring positive-pressure ventilation\n58 minutes (mean) from return of consciousness to ability to ambulate",
          "common_combinations": "Xylazine IM 10 min before pentobarbital IV",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:10:19.000000Z",
          "updated_at": "2020-09-16T01:10:19.000000Z"
      },
      {
          "id": 1323,
          "drug_id": 354,
          "indication_name": "Long-term general anesthesia",
          "expected_effects": "Reliable ultra-long-term anesthesia, requiring minimal intervention (up to 3 weeks)\nTolerance develops, requiring dosage adjustment\n47% mortality rate in otherwise healthy dogs (most commonly due to pneumothorax, sepsis, or cardiac arrest, not always associated with the drug administration), with mortality distributed over days 2-18 of anesthesia",
          "common_combinations": "With or without propofol 75 µg/kg/min IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:10:21.000000Z",
          "updated_at": "2020-09-16T01:10:21.000000Z"
      },
      {
          "id": 1324,
          "drug_id": 354,
          "indication_name": "Sedation prior to euthanasia",
          "expected_effects": "Lateral recumbency (mean: 59 minutes after ingestion of tablets) in 86% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:10:23.000000Z",
          "updated_at": "2020-09-16T01:10:23.000000Z"
      },
      {
          "id": 1325,
          "drug_id": 354,
          "indication_name": "Euthanasia",
          "expected_effects": "Mean of 14, 25, 30, and 600 seconds to collapse, final breath, absence of activity on electroencephalogram, and asystole on electrocardiogram, respectively\nConcurrent administration of lidocaine accelerates time to asystole but does not alter other responses",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:10:25.000000Z",
          "updated_at": "2020-09-16T01:10:25.000000Z"
      },
      {
          "id": 1326,
          "drug_id": 355,
          "indication_name": "Osteoarthritis",
          "expected_effects": "50% decrease in orthopedic score (composite assessment including weakness, stiffness, pain, and lameness) after treatment\nResponse lasting 1-6 months after one 4-week course of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:10:28.000000Z",
          "updated_at": "2020-09-16T01:10:28.000000Z"
      },
      {
          "id": 1327,
          "drug_id": 356,
          "indication_name": "Dermatomyositis",
          "expected_effects": "Hair regrowth in a median of 6 weeks\nNo changes in complete blood count serum biochemistry profile, or urinalysis attributable to treatment\nComplete resolution in 40% of dogs, and decrease in lesion score to mild or moderate in 60% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:10:30.000000Z",
          "updated_at": "2020-09-16T01:10:30.000000Z"
      },
      {
          "id": 1328,
          "drug_id": 356,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "8- to 10-fold improvement with 2 months of treatment: complete recovery in 27% of dogs, and 42% of dogs with polyunsaturated fatty acid supplement as co-treatment, after 60 days\n39% and 85% reduction in pruritus after 30 and 60 days, respectively",
          "common_combinations": "Polyunsaturated fatty acid supplement (provides a small and non-significant additive benefit according to 1 clinical trial)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:10:33.000000Z",
          "updated_at": "2020-09-16T01:10:33.000000Z"
      },
      {
          "id": 1329,
          "drug_id": 357,
          "indication_name": "Epilepsy",
          "expected_effects": "Complete resolution of seizures in 85% of dogs during 1st 6 months\nFor persistent seizures, treatment significantly decreases seizure duration (mean reduction: 88%)",
          "common_combinations": "A second anticonvulsant if seizure control is incomplete",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:10:35.000000Z",
          "updated_at": "2020-09-16T01:10:35.000000Z"
      },
      {
          "id": 1330,
          "drug_id": 357,
          "indication_name": "Epilepsy - cotreatment with bromide",
          "expected_effects": "Associated with mean serum phenobarbital concentration of 28 µg/mL (mean bromide serum concentration: 186 mg/dL) and seizure frequency of 1.5-2.2/week in the most medically-resistant seizure patients (dogs receiving phenobarbital + bromide, and referred for further additional treatment)",
          "common_combinations": "Potassium bromide 39 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:10:38.000000Z",
          "updated_at": "2020-09-16T01:10:38.000000Z"
      },
      {
          "id": 1331,
          "drug_id": 357,
          "indication_name": "Epilepsy - cotreatment with gabapentin",
          "expected_effects": "Addition of gabapentin to phenobarbital + potassium bromide increases the interictal interval, and is associated with elimination of seizures in a minority of dogs, but does not reduce the total number of seizures in treated dogs overall",
          "common_combinations": "Potassium bromide 24 mg/kg PO q 24h;Gabapentin 17.5-25 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:10:41.000000Z",
          "updated_at": "2020-09-16T01:10:41.000000Z"
      },
      {
          "id": 1332,
          "drug_id": 357,
          "indication_name": "Brain tumor - seizure prevention",
          "expected_effects": "Effective seizure control in 67% of dogs",
          "common_combinations": "Prednisone at anti-inflammatory dosages, tapered to 0.5 mg/kg PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:10:44.000000Z",
          "updated_at": "2020-09-16T01:10:44.000000Z"
      },
      {
          "id": 1333,
          "drug_id": 357,
          "indication_name": "Status epilepticus - IV loading",
          "expected_effects": "Seizure control and discharge in 60% of dogs/cats with severe status epilepticus, euthanasia in 30%, and non-euthanasia death in 10% in 1 case series ",
          "common_combinations": "With or without pentobarbital 4 mg/kg (up to 3 boluses);With or without pentobarbital 1.6-4.8 mg/kg/min IV CRI - if refractory seizure activity is present",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:10:46.000000Z",
          "updated_at": "2020-09-16T01:10:46.000000Z"
      },
      {
          "id": 1334,
          "drug_id": 357,
          "indication_name": "Status epilepticus post-op portosystemic shunt attenuation",
          "expected_effects": "Complete resolution of seizures indefinitely (several months) in 1 small case series",
          "common_combinations": "Propofol 2-6 mg/kg IV bolus to effect, then 0.1-0.5 mg/kg/min IV if needed for ongoing seizure control (cotreatment with phenobarbital IV CRI)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:10:48.000000Z",
          "updated_at": "2020-09-16T01:10:48.000000Z"
      },
      {
          "id": 1335,
          "drug_id": 357,
          "indication_name": "Epilepsy",
          "expected_effects": "Complete resolution of seizures in 50% of cats\nNon-specific decreased frequency of seizures in 27% of cats",
          "common_combinations": "With dexamethasone or diazepam",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:10:51.000000Z",
          "updated_at": "2020-09-16T01:10:51.000000Z"
      },
      {
          "id": 1336,
          "drug_id": 357,
          "indication_name": "Status epilepticus - IV loading",
          "expected_effects": "Seizure control and discharge in 2 of 3 cats with severe status epilepticus in 1 case series (both: permethrin toxicosis) and euthanasia in the remaining cat (neoplastic brain metastases)",
          "common_combinations": "With or without pentobarbital 4 mg/kg (up to 3 boluses);With or without pentobarbital 1.6-4.8 mg/kg/min IV CRI - if refractory seizure activity is present",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:10:53.000000Z",
          "updated_at": "2020-09-16T01:10:53.000000Z"
      },
      {
          "id": 1337,
          "drug_id": 358,
          "indication_name": "Pheochromocytoma pre-op",
          "expected_effects": "Associated with significant benefit: 13% perioperative mortality rate with phenoxybenzamine pre-treatment, compared to 48% in untreated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:10:55.000000Z",
          "updated_at": "2020-09-16T01:10:55.000000Z"
      },
      {
          "id": 1338,
          "drug_id": 358,
          "indication_name": "Reflex dyssynergia",
          "expected_effects": "No significant improvement in signs of dysuria in 1 case report",
          "common_combinations": "Diazepam",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:10:58.000000Z",
          "updated_at": "2020-09-16T01:10:58.000000Z"
      },
      {
          "id": 1339,
          "drug_id": 358,
          "indication_name": "Urethral obstruction",
          "expected_effects": "In anesthetized, healthy, sexually intact males: 14% decrease in intraurethral pressure in the preprostatic region of the urethra and no significant pressure changes in the prostatic or postprostatic region",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:11:00.000000Z",
          "updated_at": "2020-09-16T01:11:00.000000Z"
      },
      {
          "id": 1340,
          "drug_id": 358,
          "indication_name": "Urethral obstruction",
          "expected_effects": "45% decrease in mean urethral pressure in prostatic/preprostatic urethra (5 cm from the tip of the penis)\nNo effect on areas of the urethra composed entirely of either smooth or striated muscle",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:11:03.000000Z",
          "updated_at": "2020-09-16T01:11:03.000000Z"
      },
      {
          "id": 1341,
          "drug_id": 359,
          "indication_name": "Post-op analgesia/anti-inflammatory (orthopedic surgery)",
          "expected_effects": "Slightly lower pain scores and reduction in lameness for several days post-op\nNo significant effect on post-op swelling, or wound/fracture healing",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:05.000000Z",
          "updated_at": "2020-09-16T01:11:05.000000Z"
      },
      {
          "id": 1342,
          "drug_id": 360,
          "indication_name": "Hypotension - to increase mean arterial blood pressure in euvolemic animal (typically intra-op or critical care)",
          "expected_effects": "Increases systolic arterial blood pressure by 51 mmHg and elicits signs of discomfort associated with hypertension\nLower dosage (repeated if necessary) is preferred",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:08.000000Z",
          "updated_at": "2020-09-16T01:11:08.000000Z"
      },
      {
          "id": 1343,
          "drug_id": 360,
          "indication_name": "Hypotension - to increase mean arterial blood pressure in euvolemic animal (typically intra-op or critical care)",
          "expected_effects": "0.125, 0.25, 0.5, 1, and 2 µg/kg/min infusion rates increase mean arterial blood pressure by 10%, 10%, 45%, 65%, and 110% (all compared to baseline of 66 +/- 10 mmHg)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:11:11.000000Z",
          "updated_at": "2020-09-16T01:11:11.000000Z"
      },
      {
          "id": 1344,
          "drug_id": 361,
          "indication_name": "Urethral sphincter mechanism incompetence",
          "expected_effects": "Significant benefit: by day 7 of treatment, 55% of dogs show no episodes of unconscious urination vs. 26% of placebo-treated control dogs (by day 28: 86% vs. 33%)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:14.000000Z",
          "updated_at": "2020-09-16T01:11:14.000000Z"
      },
      {
          "id": 1345,
          "drug_id": 361,
          "indication_name": "Retrograde ejaculation",
          "expected_effects": "75% and 72.2% decrease in sperm cells found in the urine pre- and post-ejaculation, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:11:17.000000Z",
          "updated_at": "2020-09-16T01:11:17.000000Z"
      },
      {
          "id": 1346,
          "drug_id": 361,
          "indication_name": "Urinary incontinence due to detrusor instability",
          "expected_effects": "No appreciable change in urinary incontinence",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:11:19.000000Z",
          "updated_at": "2020-09-16T01:11:19.000000Z"
      },
      {
          "id": 1347,
          "drug_id": 361,
          "indication_name": "Urethral sphincter mechanism incompetence",
          "expected_effects": "Marked improvement in continence after 3 weeks\nComplete continence after 2 months, with continuous maintenance treatment (q 24h)\nEpisodes of incontinence during periods of discontinued treatment, all in 1 case report",
          "common_combinations": "Treatment of bacterial urinary tract infection",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:11:21.000000Z",
          "updated_at": "2020-09-16T01:11:21.000000Z"
      },
      {
          "id": 1350,
          "drug_id": 363,
          "indication_name": "Congestive heart failure caused by myxomatous mitral valve disease",
          "expected_effects": "Median of 267 days to cardiac death, euthanasia based on heart failure, or failure of the treatment",
          "common_combinations": "Furosemide;ACE inhibitor",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:29.000000Z",
          "updated_at": "2020-09-16T01:11:29.000000Z"
      },
      {
          "id": 1351,
          "drug_id": 363,
          "indication_name": "Congestive heart failure caused by dilated cardiomyopathy in Doberman dogs",
          "expected_effects": "Median of 130 days to treatment failure, compared to only 14 days in placebo-treated dogs",
          "common_combinations": "Furosemide (PO as required);ACE inhibitor (e.g., benazepril 0.5 mg/kg PO q 12h)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:11:31.000000Z",
          "updated_at": "2020-09-16T01:11:31.000000Z"
      },
      {
          "id": 1352,
          "drug_id": 363,
          "indication_name": "Dilated cardiomyopathy in doberman pinschers - occult stage",
          "expected_effects": "In Dobermans with echo-confirmed occult/preclinical dilated cardiomyopathy, as many dogs develop congestive heart failure with pimobendan as with placebo, but dogs receiving pimobendan remain overtly healthy longer (718 days vs. 441 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:11:34.000000Z",
          "updated_at": "2020-09-16T01:11:34.000000Z"
      },
      {
          "id": 1353,
          "drug_id": 363,
          "indication_name": "Dilated cardiomyopathy in doberman pinschers - occult stage",
          "expected_effects": "In Dobermans with echo-confirmed occult/preclinical dilated cardiomyopathy, as many dogs develop congestive heart failure with pimobendan as with placebo, but dogs receiving pimobendan remain overtly healthy longer (718 days vs. 441 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:11:36.000000Z",
          "updated_at": "2020-09-16T01:11:36.000000Z"
      },
      {
          "id": 1354,
          "drug_id": 363,
          "indication_name": "Pulmonary hypertension",
          "expected_effects": "Significantly improved quality of life as assessed by owners (compared to placebo treatment in a blinded study) concurrent with improvements in echocardiographic and blood-borne cardiac biomarker results",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:11:39.000000Z",
          "updated_at": "2020-09-16T01:11:39.000000Z"
      },
      {
          "id": 1355,
          "drug_id": 363,
          "indication_name": "Congestive heart failure caused by restrictive cardiomyopathy",
          "expected_effects": "Median survival time: 151 days (range: 1-870)\nTreatment with several concurrent medications in the study make the effects of pimobendan alone difficult to conclude",
          "common_combinations": "Furosemide (PO as required);ACE inhibitor (e.g., benazepril 0.5 mg/kg PO q 12h);With or without anticoagulation, as indicated",
          "is_contraindicated": 1,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:11:41.000000Z",
          "updated_at": "2020-09-16T01:11:41.000000Z"
      },
      {
          "id": 1356,
          "drug_id": 364,
          "indication_name": "Colonic perforation - antimicrobial prophylaxis",
          "expected_effects": "No peritonitis in 1 case report",
          "common_combinations": "Supportive care, including IV fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:44.000000Z",
          "updated_at": "2020-09-16T01:11:44.000000Z"
      },
      {
          "id": 1357,
          "drug_id": 365,
          "indication_name": "Pneumonia",
          "expected_effects": "Marked clinical improvement in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:46.000000Z",
          "updated_at": "2020-09-16T01:11:46.000000Z"
      },
      {
          "id": 1358,
          "drug_id": 366,
          "indication_name": "Roundworm infestation - Toxocara, Toxascaris (elimination from adult dogs)",
          "expected_effects": "Variable efficacy against immature adult T leonina\nLittle or no useful effect against the larval stages of T canis and T leonina",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:11:48.000000Z",
          "updated_at": "2020-09-16T01:11:48.000000Z"
      },
      {
          "id": 1359,
          "drug_id": 366,
          "indication_name": "Roundworm infestation- Toxocara canis (prevention in puppies)",
          "expected_effects": "97% efficacy when given to unweaned pups at 10, 20 and 30 days of age\n83% efficacy when given once to 30-day-old pups\nIncreased overall weight gains of 18% in puppies between the ages of 10-30 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:11:50.000000Z",
          "updated_at": "2020-09-16T01:11:50.000000Z"
      },
      {
          "id": 1360,
          "drug_id": 366,
          "indication_name": "Roundworm infestation - Toxocara canis (elimination from puppies)",
          "expected_effects": "The efficacy of piperazine alone in eliminating ascarid worms from puppies is 52%\nWhen combined with thenium closylate a 90% efficacy is achieved\nThenium closylate given on its own has a low efficacy (5%)",
          "common_combinations": "Thenium closylate",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:11:53.000000Z",
          "updated_at": "2020-09-16T01:11:53.000000Z"
      },
      {
          "id": 1361,
          "drug_id": 366,
          "indication_name": "Hookworm infestation - Ancylostoma caninum (elimination from adult dogs)",
          "expected_effects": "Low efficacy: elimination of 16% of A. caninum",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:11:55.000000Z",
          "updated_at": "2020-09-16T01:11:55.000000Z"
      },
      {
          "id": 1362,
          "drug_id": 366,
          "indication_name": "Roundworm infestation - Toxocara canis (elimination from adult cats)",
          "expected_effects": "96-98% elimination of total ascarids",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:11:57.000000Z",
          "updated_at": "2020-09-16T01:11:57.000000Z"
      },
      {
          "id": 1363,
          "drug_id": 366,
          "indication_name": "Roundworm infestation - Toxascaris leonina (elimination from adult cats)",
          "expected_effects": "96-98% elimination of total ascarids",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:12:00.000000Z",
          "updated_at": "2020-09-16T01:12:00.000000Z"
      },
      {
          "id": 1364,
          "drug_id": 366,
          "indication_name": "Hookworm infestation - Ancylostoma caninum (elimination from adult cats)",
          "expected_effects": "Low efficacy: elimination of 18% of A. caninum",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:12:02.000000Z",
          "updated_at": "2020-09-16T01:12:02.000000Z"
      },
      {
          "id": 1365,
          "drug_id": 366,
          "indication_name": "Tapeworm infestation - Taenia taeniaformis (elimination from adult cats)",
          "expected_effects": "Low efficacy: elimination of 21% of  T. taeniaformis",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:12:05.000000Z",
          "updated_at": "2020-09-16T01:12:05.000000Z"
      },
      {
          "id": 1366,
          "drug_id": 367,
          "indication_name": "Transitional cell carcinoma - piroxicam monotherapy",
          "expected_effects": "Complete or partial remission in 19% of dogs\n91% of owners report improvement in quality of life regardless of tumor remission\nOverall median survival time: 181 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:12:07.000000Z",
          "updated_at": "2020-09-16T01:12:07.000000Z"
      },
      {
          "id": 1367,
          "drug_id": 367,
          "indication_name": "Transitional cell carcinoma - with mitoxantrone and CO2 laser therapy",
          "expected_effects": "Normal urination within 72h in 75% (piroxicam + mitoxantrone) or >87% (CO2 laser ablation, then piroxicam + mitoxantrone) of dogs\nDisease-free interval: 127 to >700 days (median: 200 days)\nSurvival time: 200-801 days (median: 299 days)",
          "common_combinations": "CO2 laser ablation of masses;Mitoxantrone q 3 weeks (4 doses total)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:12:09.000000Z",
          "updated_at": "2020-09-16T01:12:09.000000Z"
      },
      {
          "id": 1368,
          "drug_id": 367,
          "indication_name": "Malignant melanoma (oral)",
          "expected_effects": "Complete tumor remission in 18% of dogs\nSurvival: 10-370 days (median: 119 days)",
          "common_combinations": "Cisplatin 50 mg/m² IV q 3 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:12:12.000000Z",
          "updated_at": "2020-09-16T01:12:12.000000Z"
      },
      {
          "id": 1369,
          "drug_id": 367,
          "indication_name": "Squamous cell carcinoma (oral)",
          "expected_effects": "Complete tumor remission in 56% of dogs\nSurvival: 41-2010 days (median: 237 days)",
          "common_combinations": "Cisplatin 50 mg/m² IV q 3 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:12:14.000000Z",
          "updated_at": "2020-09-16T01:12:14.000000Z"
      },
      {
          "id": 1370,
          "drug_id": 367,
          "indication_name": "Mesothelioma",
          "expected_effects": "Reduction of abdominal fluid production\nSurvival: 8 to >24 months in 2 published cases",
          "common_combinations": "Cyclophosphamide;Cisplatin;Doxorubicin",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:12:16.000000Z",
          "updated_at": "2020-09-16T01:12:16.000000Z"
      },
      {
          "id": 1371,
          "drug_id": 367,
          "indication_name": "Nasal tumors",
          "expected_effects": "Complete remission and partial remission in 50% and 25% of dogs, respectively\nSurvival: 150-960 days (median: 210 days)",
          "common_combinations": "Carboplatin-doxorubicin protocol;Gastric protectant if adverse GI effects",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:12:19.000000Z",
          "updated_at": "2020-09-16T01:12:19.000000Z"
      },
      {
          "id": 1372,
          "drug_id": 367,
          "indication_name": "Rectal polyps",
          "expected_effects": "Reduction of hematochezia, tenesmus, and fecal mucus production (88% of owners qualify the degree of improvement as good or excellent)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:12:21.000000Z",
          "updated_at": "2020-09-16T01:12:21.000000Z"
      },
      {
          "id": 1373,
          "drug_id": 367,
          "indication_name": "Inflammatory mammary carcinoma",
          "expected_effects": "Marked improvement when tumors are COX-2-positive (as many/most are)\nSurvival with piroxicam treatment ranges between 128-238 days (median: 174 days) vs. 7 day median survival with doxorubicin-based treatment\nSubjectively, significant improvement in quality of life occurs in majority of piroxicam-treated dogs according to owners",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:12:25.000000Z",
          "updated_at": "2020-09-16T01:12:25.000000Z"
      },
      {
          "id": 1374,
          "drug_id": 367,
          "indication_name": "Injection site pain - prophylaxis",
          "expected_effects": "Complete elimination of injection-associated pain in >92% of dogs with this dosage and protocol\nHigher dosage does not reduce pain further (but may confer greater adverse effects)\nLower dosages are less effective: 0.5 and 0.8 mg/kg eliminate injection-associated pain in 10% and 33% of dogs, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:12:27.000000Z",
          "updated_at": "2020-09-16T01:12:27.000000Z"
      },
      {
          "id": 1375,
          "drug_id": 367,
          "indication_name": "Fever",
          "expected_effects": "Elimination of fever in >90% of dogs\nNo apparent benefit to higher dosage: with a lower dosage of 0.5 mg/kg, fever is eliminated in 86% of dogs after 1 dose and >90% of dogs after the second dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T01:12:30.000000Z",
          "updated_at": "2020-09-16T01:12:30.000000Z"
      },
      {
          "id": 1376,
          "drug_id": 367,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "Survival: 84-1545 days in 1 case series",
          "common_combinations": "With or without surgical debulking of tumor (may or may not improve prognosis)",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T01:12:32.000000Z",
          "updated_at": "2020-09-16T01:12:32.000000Z"
      },
      {
          "id": 1377,
          "drug_id": 367,
          "indication_name": "Cystic nasal adenocarcinoma",
          "expected_effects": "Non-specific improvement in clinical signs, with intermittent episodes\nSurvival time: 744 days in 1 case report",
          "common_combinations": "Chemoembolization;Anticonvulsant treatment as required;Misoprostol 4.7 mg/kg PO q 8h as GI protectant",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T01:12:34.000000Z",
          "updated_at": "2020-09-16T01:12:34.000000Z"
      },
      {
          "id": 1378,
          "drug_id": 367,
          "indication_name": "Mesothelioma",
          "expected_effects": "Temporary reduction of abdominal fluid production by 90% (but progressive disease leading to death/euthanasia) in 1 case report",
          "common_combinations": "Tumor debulking;Repeated abdominal drainage/centesis;Intracavitary carboplatin 180 mg/m² q 3 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T01:12:37.000000Z",
          "updated_at": "2020-09-16T01:12:37.000000Z"
      },
      {
          "id": 1379,
          "drug_id": 368,
          "indication_name": "Hypokalemia",
          "expected_effects": "Dosage-dependent increase in serum potassium concentration is expected",
          "common_combinations": "Intravenous fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:12:39.000000Z",
          "updated_at": "2020-09-16T01:12:39.000000Z"
      },
      {
          "id": 1380,
          "drug_id": 368,
          "indication_name": "Hypokalemia",
          "expected_effects": "Dosage-dependent increase in serum potassium concentration is expected",
          "common_combinations": "Intravenous fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:12:41.000000Z",
          "updated_at": "2020-09-16T01:12:41.000000Z"
      },
      {
          "id": 1381,
          "drug_id": 369,
          "indication_name": "Calcium oxalate urolithiasis prevention",
          "expected_effects": "Significant reduction in oxalate content of urine in 50% of treated miniature schnauzers (but no significant reduction other breeds)\nMean increase in urine pH: 0.2",
          "common_combinations": "Dietary modification to reduce risk of urolithiasis",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:12:44.000000Z",
          "updated_at": "2020-09-16T01:12:44.000000Z"
      },
      {
          "id": 1382,
          "drug_id": 369,
          "indication_name": "Urine alkalinization (e.g., in conjunction with other methods to prevent urate urolith recurrence)",
          "expected_effects": "Significant increase in urine pH range, from 6.9-7.3 (baseline, untreated) to 7.6-8.2 (after 10 days of treatment)",
          "common_combinations": "Dietary modification to reduce risk of urolithiasis",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:12:46.000000Z",
          "updated_at": "2020-09-16T01:12:46.000000Z"
      },
      {
          "id": 1383,
          "drug_id": 369,
          "indication_name": "Hypokalemia and/or metabolic acidosis associated with chronic kidney disease",
          "expected_effects": "Improvement or resolution of hypokalemia/acidosis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:12:49.000000Z",
          "updated_at": "2020-09-16T01:12:49.000000Z"
      },
      {
          "id": 1384,
          "drug_id": 370,
          "indication_name": "Hypokalemia",
          "expected_effects": "Resolution of hypokalemia (high-normal potassium) after 5 days of treatment in 1 case report",
          "common_combinations": "Correction/management of the inciting cause",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:12:52.000000Z",
          "updated_at": "2020-09-16T01:12:52.000000Z"
      },
      {
          "id": 1385,
          "drug_id": 370,
          "indication_name": "Hypokalemia",
          "expected_effects": "With supplementation, normokalemia is maintained during chronic kidney disease: serum K 4.4 mEq/L at baseline with mild CKD and 4.2 mEq/L six months later with potassium gluconate supplementation, vs. 4.8 mEq/L (baseline) to 3.6 mEq/L six months later with sodium gluconate supplementation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:12:54.000000Z",
          "updated_at": "2020-09-16T01:12:54.000000Z"
      },
      {
          "id": 1386,
          "drug_id": 371,
          "indication_name": "Hypophosphatemia treatment (e.g., with diabetic ketoacidosis management)",
          "expected_effects": "End of hemolysis and complete clinical recovery in 2-4 days in reported cases when immediate treatment of hypophosphatemia is implemented using potassium phosphate\nHemolysis if severe phosphate deficit (e.g., 0.8-0.9 mg/dL in reported cases) is not corrected promptly",
          "common_combinations": "Potassium chloride if hypokalemia is more severe and/or persists longer than hypophosphatemia (common)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:12:57.000000Z",
          "updated_at": "2020-09-16T01:12:57.000000Z"
      },
      {
          "id": 1387,
          "drug_id": 371,
          "indication_name": "Hypophosphatemia treatment/prevention (e.g., with hepatic lipidosis or diabetic ketoacidosis management)",
          "expected_effects": "Increase in serum phosphate levels to slightly above the reference range in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:12:59.000000Z",
          "updated_at": "2020-09-16T01:12:59.000000Z"
      },
      {
          "id": 1388,
          "drug_id": 371,
          "indication_name": "Hypophosphatemia treatment/prevention (e.g., with hepatic lipidosis or diabetic ketoacidosis management)",
          "expected_effects": "Significant increase and/or normalization of serum phosphate concentration with 6-12h infusion when severe hypophosphatemia initially (undetectable to 1.3 mg/dL)\n83% survival",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:13:02.000000Z",
          "updated_at": "2020-09-16T01:13:02.000000Z"
      },
      {
          "id": 1389,
          "drug_id": 372,
          "indication_name": "Lower urinary tract infection",
          "expected_effects": "Clinical cure (eradication of infection) in >96% of treated cats, vs. 89% with amoxicillin-clavulanate and 87% with doxycycline",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:13:05.000000Z",
          "updated_at": "2020-09-16T01:13:05.000000Z"
      },
      {
          "id": 1390,
          "drug_id": 372,
          "indication_name": "Upper respiratory tract infection caused by Chlamydophila felis or Mycoplasma spp.",
          "expected_effects": "Marked improvement in clinical signs after 1 week of treatment\nAfter 6 weeks of treatment, elimination of Mycoplasma spp. from >95% of cats, and of C. felis from 76% of cats (vs. complete elimination of both organisms with doxycycline treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:13:07.000000Z",
          "updated_at": "2020-09-16T01:13:07.000000Z"
      },
      {
          "id": 1391,
          "drug_id": 372,
          "indication_name": "Hemotropic mycoplasmosis (M. haemofelis infection)",
          "expected_effects": "Recovery from M. haemofelis-associated anemia is complete within 10 days of end of treatment, similar to doxycycline\n67% rate of complete elimination of M. haemofelis (assessed via PCR) vs. 0% for cats treated with doxycycline (i.e., persistence via latent carrier state in cats treated with doxycycline despite clinical response)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:13:09.000000Z",
          "updated_at": "2020-09-16T01:13:09.000000Z"
      },
      {
          "id": 1392,
          "drug_id": 373,
          "indication_name": "Organophosphate toxicosis",
          "expected_effects": "Tripling of red blood cell/plasma acetylcholinesterase activity (from 5% without pralidoxime-atropine to 15% with pralidoxime-atropine) with a single dose, but still below baseline (100%), 30 minutes after treatment",
          "common_combinations": "Atropine 0.14 mg/kg IV once",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:13:12.000000Z",
          "updated_at": "2020-09-16T01:13:12.000000Z"
      },
      {
          "id": 1393,
          "drug_id": 373,
          "indication_name": "Organophosphate toxicosis (chlorpyrifos)",
          "expected_effects": "Survival and complete recovery in 2 reported cases",
          "common_combinations": "Atropine 0.05 mg/kg SC q 6h (at same time as pralidoxime)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:13:14.000000Z",
          "updated_at": "2020-09-16T01:13:14.000000Z"
      },
      {
          "id": 1394,
          "drug_id": 374,
          "indication_name": "Tapeworm infestation - Dipylidium caninum, Taenia spp.",
          "expected_effects": ">99% efficacy against mature Taenia spp. and D. caninum\nNo adverse effects noted",
          "common_combinations": "Emodepside 1 mg/kg as combination (Profender product)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:13:17.000000Z",
          "updated_at": "2020-09-16T01:13:17.000000Z"
      },
      {
          "id": 1395,
          "drug_id": 374,
          "indication_name": "Tapeworm infestation - Dipylidium caninum, Taenia spp., Echinococcus granulosus",
          "expected_effects": ">99% cure rate within 2-3 days of single injection\nNo adverse effects noted",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:13:19.000000Z",
          "updated_at": "2020-09-16T01:13:19.000000Z"
      },
      {
          "id": 1396,
          "drug_id": 374,
          "indication_name": "Echinococcal infestation - mature and immature E. granularis, E. multilocularis",
          "expected_effects": ">99% efficacy against mature and immature E. granulosus and E. multilocularis\nNo adverse effects noted",
          "common_combinations": "Emodepside 1 mg/kg as combination (Profender product)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:13:22.000000Z",
          "updated_at": "2020-09-16T01:13:22.000000Z"
      },
      {
          "id": 1397,
          "drug_id": 374,
          "indication_name": "Salmon poisoning disease - elimination of trematode fluke vector (Nanophyteus salmincola)",
          "expected_effects": "Trematode reduction of >99% in treated animals vs. untreated controls",
          "common_combinations": "Doxycycline co-treatment to eliminate the causative organism, Neorickettsia helminthoeca",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:13:25.000000Z",
          "updated_at": "2020-09-16T01:13:25.000000Z"
      },
      {
          "id": 1398,
          "drug_id": 374,
          "indication_name": "Lung fluke infestation - Paragonimus kellicotti",
          "expected_effects": "Elimination of all ova from feces within 2 days (dogs) or 7 days (cats) after treatment\nComplete resolution of radiographic lesions in all dogs by 2 weeks post-treatment, but only in 71% of cats even 4 weeks after treatment\nEffects on clinical signs uncertain (trivial/very mild clinical signs even in untreated dogs studied in experimentally-induced infections)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:13:28.000000Z",
          "updated_at": "2020-09-16T01:13:28.000000Z"
      },
      {
          "id": 1399,
          "drug_id": 374,
          "indication_name": "Tapeworm infestation - Dipylidium caninum, Taenia spp., Echinococcus granulosus",
          "expected_effects": ">99% cure rate within 2-3 days of single injection\nNo adverse effects noted",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:13:30.000000Z",
          "updated_at": "2020-09-16T01:13:30.000000Z"
      },
      {
          "id": 1400,
          "drug_id": 375,
          "indication_name": "Vasodilation in mitral regurgitation",
          "expected_effects": "Significant reduction in volume of mitral regurgitation (echocardiographic), similar to other vasodilators (enalapril, hydralazine)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:13:32.000000Z",
          "updated_at": "2020-09-16T01:13:32.000000Z"
      },
      {
          "id": 1401,
          "drug_id": 375,
          "indication_name": "Reflex dyssynergia",
          "expected_effects": "Effectiveness in controlling clinical signs (based on owner assessment): good in 64% of dogs, fair in 27% of dogs, and poor in 9% of dogs",
          "common_combinations": "With or without carbachol;With or without surgical pexy procedure",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:13:35.000000Z",
          "updated_at": "2020-09-16T01:13:35.000000Z"
      },
      {
          "id": 1402,
          "drug_id": 375,
          "indication_name": "Systemic hypertension (e.g., acute hypertensive crisis)",
          "expected_effects": "Mean arterial blood pressure 27%, 33%, and 33% lower than baseline at 10, 20, and 40 minutes post-dose, respectively ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:13:37.000000Z",
          "updated_at": "2020-09-16T01:13:37.000000Z"
      },
      {
          "id": 1403,
          "drug_id": 375,
          "indication_name": "Urethral obstruction",
          "expected_effects": "Lowers urethral pressure by 50% (vs. 20% with phenoxybenzamine), predominantly in the prostatic urethra, for >40 minutes after single injection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:13:40.000000Z",
          "updated_at": "2020-09-16T01:13:40.000000Z"
      },
      {
          "id": 1404,
          "drug_id": 375,
          "indication_name": "Urethral obstruction",
          "expected_effects": "20% reduction in urethral pressure in the prostatic region (prazocin-dantrolene combination)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:13:42.000000Z",
          "updated_at": "2020-09-16T01:13:42.000000Z"
      },
      {
          "id": 1405,
          "drug_id": 376,
          "indication_name": "Replacement (i.e., hypoadrenocorticism/glucocorticoid deficiency)",
          "expected_effects": "Response to treatment: 86.5% good to excellent, 12.5% fair, 1% poor\nGlucocorticoid-related adverse effects (e.g., polyuria/polydipsia) in 11% of dogs\nOverall survival time: 7 days - 11.8 years (median: 4.7 years)",
          "common_combinations": "Mineralocorticoid supplement (fludrocortisone or desoxycorticosterone pivalate/DOCP)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:13:45.000000Z",
          "updated_at": "2020-09-16T01:13:45.000000Z"
      },
      {
          "id": 1406,
          "drug_id": 376,
          "indication_name": "Anti-inflammatory",
          "expected_effects": "Histologic evidence of inflammation is lowest with prednisone treatment, intermediate with aspirin treatment and highest with no treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:13:47.000000Z",
          "updated_at": "2020-09-16T01:13:47.000000Z"
      },
      {
          "id": 1407,
          "drug_id": 376,
          "indication_name": "Immunosuppressive - immune-mediated disease",
          "expected_effects": "Variable\nMedian time for effect: 5 days (e.g., for immune-mediated hemolytic anemia: stabilization of packed cell volume)\n86% survival to discharge and 79% survival-and-remission rate at 5 months with only prednisone therapy and intensive supportive care (dogs with immune-mediated hemolytic anemia)",
          "common_combinations": "Additional immunosuppressants (e.g., cyclosporine or mycophenolate) to taper prednisone/prednisolone regimen and reduce glucocorticoid-related adverse effects",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:13:50.000000Z",
          "updated_at": "2020-09-16T01:13:50.000000Z"
      },
      {
          "id": 1408,
          "drug_id": 376,
          "indication_name": "Immunosuppressive - prevention of transplant rejection",
          "expected_effects": "Sufficient immunosuppression to confer long-term survival (>4 months) in 40% of dogs, but frequent opportunistic infections and recurrent thromboembolism suggest excessive immunosuppression and specifically indicate a lower-dosage (or pulse) glucocorticoid protocol may be preferable",
          "common_combinations": "Cyclosporine;Azathioprine",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:13:52.000000Z",
          "updated_at": "2020-09-16T01:13:52.000000Z"
      },
      {
          "id": 1409,
          "drug_id": 376,
          "indication_name": "Antineoplastic (e.g., lymphoma - modified University of Wisconsin Madison protocol)",
          "expected_effects": "Variable\n92% complete remission rate, median disease-free interval of 282 days, and median survival of 397 days in dogs with lymphoma receiving prednisone with combination chemotherapy, for example",
          "common_combinations": "Additional antineoplastic chemotherapeutic drugs (e.g., for lymphoma: cyclophosphamide, doxorubicin, vincristine with or without L-asparaginase)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:13:55.000000Z",
          "updated_at": "2020-09-16T01:13:55.000000Z"
      },
      {
          "id": 1410,
          "drug_id": 376,
          "indication_name": "Replacement (i.e., hypoadrenocorticism/glucocorticoid deficiency)",
          "expected_effects": "Good response to treatment with few/no adverse effects\nMedian survival: 35 months (range: 1.5 to >70 months) with treatment",
          "common_combinations": "Mineralocorticoid supplement (fludrocortisone 0.1 mg/CAT PO q 24h, or desoxycorticosterone pivalate/DOCP injections)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:13:58.000000Z",
          "updated_at": "2020-09-16T01:13:58.000000Z"
      },
      {
          "id": 1411,
          "drug_id": 376,
          "indication_name": "Anti-inflammatory",
          "expected_effects": "Positive response (improvement in lesions and clinical signs) in 36-45% of treated cats, similar to cyclosporine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:14:01.000000Z",
          "updated_at": "2020-09-16T01:14:01.000000Z"
      },
      {
          "id": 1412,
          "drug_id": 376,
          "indication_name": "Immunosuppressive - immune-mediated disease",
          "expected_effects": "Evidence of initial immunosuppressive effect (e.g., stabilization of packed cell volume in cats with immune-mediated hemolytic anemia) in 8-14 days in 18% of cats, 16-24 days in 41% of cats, and 28-42 days in 29% of cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:14:03.000000Z",
          "updated_at": "2020-09-16T01:14:03.000000Z"
      },
      {
          "id": 1413,
          "drug_id": 376,
          "indication_name": "Antineoplastic (e.g., lymphoma - University of Wisconsin Madison protocol)",
          "expected_effects": "Complete remission, partial remission, and no response in 47%, 37%, and 16% of cats treated with this prednisolone-containing protocol, respectively",
          "common_combinations": "Additional antineoplastic chemotherapeutic drugs (e.g., for lymphoma: cyclophosphamide, doxorubicin, vincristine with or without L-asparaginase)",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:14:05.000000Z",
          "updated_at": "2020-09-16T01:14:05.000000Z"
      },
      {
          "id": 1414,
          "drug_id": 377,
          "indication_name": "Hemorrhagic shock",
          "expected_effects": "Limited benefit in hypovolemic shock: IV fluid replacement restores blood pressure and most other hemodynamic parameters\nAddition of prednisolone sodium succinate is associated with a significantly lower heart rate (mean: 90 beats/minute, vs. 110 and 130 beats/minute with only fluid therapy and with no treatment, respectively) by 180 minutes after massive hemorrhage",
          "common_combinations": "Fluid therapy as clinically indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:08.000000Z",
          "updated_at": "2020-09-16T01:14:08.000000Z"
      },
      {
          "id": 1415,
          "drug_id": 377,
          "indication_name": "Prevention of acute transplant rejection",
          "expected_effects": "57% of the dogs survive >2 years after renal transplantation",
          "common_combinations": "Rabbit anti-dog thymocyte serum;Prednisone;Cyclosporine-A;Azathioprine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:10.000000Z",
          "updated_at": "2020-09-16T01:14:10.000000Z"
      },
      {
          "id": 1416,
          "drug_id": 377,
          "indication_name": "Hypoadrenal crisis",
          "expected_effects": "98% survival rate with treatment",
          "common_combinations": "Fluid therapy as clinically indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:14:13.000000Z",
          "updated_at": "2020-09-16T01:14:13.000000Z"
      },
      {
          "id": 1417,
          "drug_id": 377,
          "indication_name": "Suspected asthmatic crisis",
          "expected_effects": "Cyanosis and dyspnea generally resolve within 30 minutes",
          "common_combinations": "Oxygen supplementation;Bronchodilator as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:14:15.000000Z",
          "updated_at": "2020-09-16T01:14:15.000000Z"
      },
      {
          "id": 1418,
          "drug_id": 378,
          "indication_name": "Epilepsy (refractory)",
          "expected_effects": "Significant benefit: in dogs already receiving phenobarbital, potassium bromide, or both, addition of pregabalin further reduced seizure frequency by ≥ 50 in 78% of dogs (median reduction of number of seizures: 58% with addition of pregabalin)\nSedation and ataxia are common, especially in dogs already receiving other anticonvulsants concurrently, and titration of dosage should aim to reduce seizure frequency as much as possible with highest dosage that does not produce sedation or ataxia",
          "common_combinations": "Phenobarbital and/or potassium bromide",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:18.000000Z",
          "updated_at": "2020-09-16T01:14:18.000000Z"
      },
      {
          "id": 1419,
          "drug_id": 378,
          "indication_name": "Neuropathic pain associate with Chiari-like malformation in cavalier King Charles spaniels",
          "expected_effects": "19% of dogs stop phantom scratching, but no significant benefit is apparent for exercise intolerance, vocalization, or facial rubbing\nGradual worsening of severity of signs (by a median of 12%) over 3.4-year study period despite treatment\n75% survival after 3.4 years (17% euthanized due to intractable signs of neuropathic pain despite treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:20.000000Z",
          "updated_at": "2020-09-16T01:14:20.000000Z"
      },
      {
          "id": 1420,
          "drug_id": 379,
          "indication_name": "Ventricular arrhythmias (post-op)",
          "expected_effects": "Reduction or elimination of ventricular arrhythmia in 90% of dogs after 10 minutes of treatment (similar to lidocaine treatment)\nNo evidence of hypotension related to procainamide treatment",
          "common_combinations": "Correction of inciting cause",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:22.000000Z",
          "updated_at": "2020-09-16T01:14:22.000000Z"
      },
      {
          "id": 1421,
          "drug_id": 379,
          "indication_name": "Re-entrant tachycardia",
          "expected_effects": "Termination of arrhythmia, and lack of recurrence despite attempts to induce arrhythmia, in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:25.000000Z",
          "updated_at": "2020-09-16T01:14:25.000000Z"
      },
      {
          "id": 1422,
          "drug_id": 379,
          "indication_name": "Re-entrant tachycardia",
          "expected_effects": "Ineffective at terminating supraventricular tachycardia",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:14:27.000000Z",
          "updated_at": "2020-09-16T01:14:27.000000Z"
      },
      {
          "id": 1423,
          "drug_id": 379,
          "indication_name": "Ventricular arrhythmias (arrhythmogenic right ventricular cardiomyopathy of boxer dogs)",
          "expected_effects": "Ineffective: no difference (compared to pre-treatment) regarding number of premature ventricular complexes on Holter monitored electrocardiogram, nor number of syncopal episodes",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:14:30.000000Z",
          "updated_at": "2020-09-16T01:14:30.000000Z"
      },
      {
          "id": 1424,
          "drug_id": 380,
          "indication_name": "Relapsed/resistant lymphoma - LOPP-UF protocol",
          "expected_effects": "In this cohort of dogs with resistant/relapsed lymphoma, treatment duration ranged from 10-308 days (median: 84 days)\n61% overall response rate (36% complete response, 24% partial response)\nSurvival time: 51-762 days (median: 290 days)",
          "common_combinations": "Lomustine, vincristine, and prednisone, per protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:32.000000Z",
          "updated_at": "2020-09-16T01:14:32.000000Z"
      },
      {
          "id": 1425,
          "drug_id": 380,
          "indication_name": "Relapsed/resistant lymphoma - MPP protocol",
          "expected_effects": "In this cohort of dogs with resistant/relapsed lymphoma, there was a 34% overall response rate (17% complete response, 17% partial response)\nProgression-free survival: 22 to >550 days (median: 238 days) while in clinical remission (i.e., the 17% best responders)",
          "common_combinations": "Mechlorethamine, vincristine, and prednisone, per protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:35.000000Z",
          "updated_at": "2020-09-16T01:14:35.000000Z"
      },
      {
          "id": 1426,
          "drug_id": 380,
          "indication_name": "Granulomatous meningoencephalomyelitis",
          "expected_effects": "Significant treatment benefit: median survival time of 14 months with procarbazine + prednisone treatment, vs. 3 weeks with no treatment",
          "common_combinations": "Prednisone",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:14:37.000000Z",
          "updated_at": "2020-09-16T01:14:37.000000Z"
      },
      {
          "id": 1427,
          "drug_id": 381,
          "indication_name": "Nausea",
          "expected_effects": "Inconsistent results: vomiting prevented in 1 treated dog and not prevented in another",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:40.000000Z",
          "updated_at": "2020-09-16T01:14:40.000000Z"
      },
      {
          "id": 1428,
          "drug_id": 381,
          "indication_name": "Nausea",
          "expected_effects": "Effectively protects against nausea (e.g., induced by apomorphine in 1 study) in ≥ 50% of dogs\n3 times more effective than chlorpromazine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:42.000000Z",
          "updated_at": "2020-09-16T01:14:42.000000Z"
      },
      {
          "id": 1429,
          "drug_id": 382,
          "indication_name": "Sick sinus syndrome/sinus node dysfunction causing syncope",
          "expected_effects": "Highly variable response (some dogs have resolution of signs for 2-5 years, whereas others show no appreciable benefit)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:45.000000Z",
          "updated_at": "2020-09-16T01:14:45.000000Z"
      },
      {
          "id": 1430,
          "drug_id": 382,
          "indication_name": "Urinary incontinence due to detrusor instability",
          "expected_effects": "Successful resolution of incontinence with propantheline monotherapy (used as needed) with or without concurrent phenylpropanolamine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:47.000000Z",
          "updated_at": "2020-09-16T01:14:47.000000Z"
      },
      {
          "id": 1431,
          "drug_id": 383,
          "indication_name": "Anesthetic induction",
          "expected_effects": "Premedicated: effective anesthesia at 2.6 mg/kg in 90% of dogs\nUnpremedicated: effective anesthesia at 5 mg/kg in 80% of dogs\n14% of dogs show signs of excitement during induction if not premedicated with acepromazine, vs. <4% if premedicated",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:14:50.000000Z",
          "updated_at": "2020-09-16T01:14:50.000000Z"
      },
      {
          "id": 1432,
          "drug_id": 383,
          "indication_name": "Anesthesia - total intravenous anesthesia",
          "expected_effects": "With 0.25 µg/kg/min remifentanil: antinociception in 50% and 92% of dogs after 15 and 30 min, respectively\nWith 0.5 µg/kg/min remifentanil: antinociception in 92% and > 99% of dogs after 15 and 30 min, respectively\nStable mean arterial pressure (72-98 mmHg, only passing 90 mmHg after 75 min) throughout anesthesia\nHeart rate average of 56-86 beats/minute from 5-120 min, rising back to 116-167 beats/minute within 15 min after anesthesia end-time",
          "common_combinations": "Remifentanil 0.25-0.5 µg/kg/min IV CRI",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:14:52.000000Z",
          "updated_at": "2020-09-16T01:14:52.000000Z"
      },
      {
          "id": 1433,
          "drug_id": 383,
          "indication_name": "Anesthesia",
          "expected_effects": "Abolishes all movement in response to surgical incision in >50% of dogs (ED50) at this dosage, i.e., may be uptitrated or reduced to effect\n34% average decrease in systolic arterial pressure during 15-60 minutes of anesthesia\n15 minutes after induction: average of 37% and 45% decrease in heart rate and cardiac index, respectively\nAfter termination of 2-hour infusion, average of 20, 41, and 52 minutes to extubation, sternal recumbency, and standing, respectively",
          "common_combinations": "With or without concurrent lidocaine and ketamine CRI (which reduce propofol requirement by 37%)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:14:55.000000Z",
          "updated_at": "2020-09-16T01:14:55.000000Z"
      },
      {
          "id": 1434,
          "drug_id": 383,
          "indication_name": "Status epilepticus - repeated boluses",
          "expected_effects": "Seizure control is achievable in 88% of dogs that were refractory to IV diazepam +/- IV phenobarbital\n1 dog's seizures were refractory to propofol and 1 dog died after propofol administration in 1 case series",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:14:57.000000Z",
          "updated_at": "2020-09-16T01:14:57.000000Z"
      },
      {
          "id": 1435,
          "drug_id": 383,
          "indication_name": "Status epilepticus - IV constant rate infusion",
          "expected_effects": "Seizure control in many dogs not otherwise controlled with diazepam +/- phenobarbital",
          "common_combinations": "With or without phenobarbital 4 mg/kg IV then 1.6-4.8 mg/kg/h IV CRI if seizures are refractory to diazepam IV, then phenobarbital IV, then propofol IV CRI monotherapy",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:15:00.000000Z",
          "updated_at": "2020-09-16T01:15:00.000000Z"
      },
      {
          "id": 1436,
          "drug_id": 383,
          "indication_name": "Portosystemic shunt ligation - post-op seizures refractory to other anticonvulsants",
          "expected_effects": "Resolution of seizure activity in first few hours, lasting up to 6 months before relapse\n55-72 hours before dogs awaken from anesthesia",
          "common_combinations": "Phenobarbital 5 mg/kg IV (switch to PO when conscious and stable);Supportive therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:15:02.000000Z",
          "updated_at": "2020-09-16T01:15:02.000000Z"
      },
      {
          "id": 1437,
          "drug_id": 383,
          "indication_name": "Anesthetic induction",
          "expected_effects": "Successful induction of anesthesia, but with high incidence of transient apnea ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:15:05.000000Z",
          "updated_at": "2020-09-16T01:15:05.000000Z"
      },
      {
          "id": 1438,
          "drug_id": 383,
          "indication_name": "Anesthetic induction - severe hepatobiliary disease/hepatic lipidosis",
          "expected_effects": "No greater incidence of adverse effects, difference in hospitalization, or any other negative parameter in hepatic lipidosis cats anesthetized with propofol compared to similar cats anesthetized with other agents",
          "common_combinations": "Inhalant maintenance anesthesia (isoflurane, sevoflurane)",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:15:07.000000Z",
          "updated_at": "2020-09-16T01:15:07.000000Z"
      },
      {
          "id": 1439,
          "drug_id": 383,
          "indication_name": "Status epilepticus - IV constant rate infusion",
          "expected_effects": "19.5-22h of anesthesia before emerging seizure-free in 2 reported cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:15:10.000000Z",
          "updated_at": "2020-09-16T01:15:10.000000Z"
      },
      {
          "id": 1440,
          "drug_id": 383,
          "indication_name": "Portosystemic shunt ligation - post-op seizures refractory to other anticonvulsants",
          "expected_effects": "Suppression of seizure activity in >99% of cases, but long-term neurological outcome highly variable: despite good post-operative seizure control, 50% of affected cats have permanent neurologic deficits (blindness, obtundation) while 50% have a good outcome (normal neurologic function)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T01:15:12.000000Z",
          "updated_at": "2020-09-16T01:15:12.000000Z"
      },
      {
          "id": 1441,
          "drug_id": 384,
          "indication_name": "Dilated cardiomyopathy and congestive heart failure - after pulmonary edema and pleural effusion have resolved",
          "expected_effects": "Survival: 8-1335 days (median: 126 days)\n34% survival rate at 1 year, 20% at 2 years",
          "common_combinations": "Furosemide;Digoxin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:15.000000Z",
          "updated_at": "2020-09-16T01:15:15.000000Z"
      },
      {
          "id": 1442,
          "drug_id": 384,
          "indication_name": "Supraventricular tachycardia - acute",
          "expected_effects": "Variable - no benefit observed in re-entrant tachycardia case, but reduction of sinus tachycardia and/or sympathetically-driven ventricular tachycardia (e.g., in cats) is expected",
          "common_combinations": "Typically used during anesthesia or intensive care (both contexts: when rapid, uncontrolled tachycardia)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:15:17.000000Z",
          "updated_at": "2020-09-16T01:15:17.000000Z"
      },
      {
          "id": 1443,
          "drug_id": 384,
          "indication_name": "Hypertrophic cardiomyopathy - having reached congestive heart failure, now well-controlled with furosemide",
          "expected_effects": "6-month survival rate of 33% in 1 case series of cats",
          "common_combinations": "Furosemide if pulmonary edema/pleural effusion",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:15:20.000000Z",
          "updated_at": "2020-09-16T01:15:20.000000Z"
      },
      {
          "id": 1444,
          "drug_id": 384,
          "indication_name": "Hyperthyroidism (pre-operative reduction of tachycardia)",
          "expected_effects": "Reduction in severity and duration of tachycardia expected\nFew/no significant adverse effects",
          "common_combinations": "Definitive antithyroid treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:15:22.000000Z",
          "updated_at": "2020-09-16T01:15:22.000000Z"
      },
      {
          "id": 1445,
          "drug_id": 385,
          "indication_name": "Urethral sphincter mechanism incompetence",
          "expected_effects": "Improves urinary continence in 66% of dogs after 28 days of treatment (vs. 75% with phenylpropanolamine, which also produced fewer side-effects and more substantial improvements in urethral pressure profiles)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:25.000000Z",
          "updated_at": "2020-09-16T01:15:25.000000Z"
      },
      {
          "id": 1446,
          "drug_id": 385,
          "indication_name": "Nasal congestion",
          "expected_effects": "Maintenance of > 75% nasal volume for 3-8h (vs. <50% of nasal volume, i.e., nasal congestion, without treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:15:28.000000Z",
          "updated_at": "2020-09-16T01:15:28.000000Z"
      },
      {
          "id": 1447,
          "drug_id": 386,
          "indication_name": "Large-bowel diarrhea",
          "expected_effects": "Normal feces, or rare mild diarrhea in 63% of dogs\nOnly occasional diarrhea, much less severe and frequent than pre-treatment, in 22% of dogs\nPrimarily normal feces, with diarrhea episodes still occurring commonly in 11% of dogs",
          "common_combinations": "Highly digestible diet",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:30.000000Z",
          "updated_at": "2020-09-16T01:15:30.000000Z"
      },
      {
          "id": 1448,
          "drug_id": 387,
          "indication_name": "Roundworm infestation - Toxocara canis, Toxascaris leonina",
          "expected_effects": "94% efficacy in elimination of adult and immature parasites and fecal ova with single dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:32.000000Z",
          "updated_at": "2020-09-16T01:15:32.000000Z"
      },
      {
          "id": 1449,
          "drug_id": 387,
          "indication_name": "Hookworm infestation - Ancylostoma caninum, Uncinaria stenocephala",
          "expected_effects": "94% efficacy in elimination of adult and immature parasites and fecal ova with single dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:15:35.000000Z",
          "updated_at": "2020-09-16T01:15:35.000000Z"
      },
      {
          "id": 1450,
          "drug_id": 387,
          "indication_name": "Vomit worm infestation - Physaloptera spp.",
          "expected_effects": "Resolution of vomiting in 83% of dogs",
          "common_combinations": "Supportive treatment for vomiting (e.g., cimetidine, ivermectin, metoclopramide, fenbendazole)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:15:37.000000Z",
          "updated_at": "2020-09-16T01:15:37.000000Z"
      },
      {
          "id": 1451,
          "drug_id": 387,
          "indication_name": "Roundworm infestation - Toxocara cati",
          "expected_effects": ">99% efficacy in reduction of egg counts and elimination of adults after 1 dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:15:40.000000Z",
          "updated_at": "2020-09-16T01:15:40.000000Z"
      },
      {
          "id": 1452,
          "drug_id": 387,
          "indication_name": "Hookworm infestation - Ancylostoma tubaeformae",
          "expected_effects": "99% (paste formulation) and 98% (granule formulation) efficacy in reducing egg counts and removing adults after 1 dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:15:42.000000Z",
          "updated_at": "2020-09-16T01:15:42.000000Z"
      },
      {
          "id": 1453,
          "drug_id": 388,
          "indication_name": "Myasthenia gravis",
          "expected_effects": "Complete remission in 42% of dogs\nMean of 3.5 months to remission (range: 0.37-10 months)\n33% mortality rate\nResolution of megaesophagus in 27% of dogs",
          "common_combinations": "With or without mycophenolate (benefit unproven)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:45.000000Z",
          "updated_at": "2020-09-16T01:15:45.000000Z"
      },
      {
          "id": 1454,
          "drug_id": 388,
          "indication_name": "Myasthenia gravis (e.g., associated with transdermal methimazole treatment of hyperthyroidism)",
          "expected_effects": "Resolution of neurological signs within 1 week (pyridostigmine treatment provided together with elimination of underlying cause)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:15:47.000000Z",
          "updated_at": "2020-09-16T01:15:47.000000Z"
      },
      {
          "id": 1455,
          "drug_id": 389,
          "indication_name": "Hepatozoonosis",
          "expected_effects": "Survival time: 29 to >53 months (mean: ≥39 months) and 12 months, with and without decoquinate, respectively\n84% and 13% 2-year survival with and without decoquinate, respectively",
          "common_combinations": "Trimethoprim-sulfadiazine (15 mg/kg PO q 12h) and clindamycin (10 mg/kg PO q 8h) for 14 days, followed by decoquinate (10-20 mg/kg in food q 12h) for 3-33 months",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:50.000000Z",
          "updated_at": "2020-09-16T01:15:50.000000Z"
      },
      {
          "id": 1456,
          "drug_id": 389,
          "indication_name": "Toxoplasma gondii - prophylaxis/prevention of fecal shedding",
          "expected_effects": "Suppression of oocyst formation in >99% of cats but specifically with treatment initiation 2 days prior to T. gondii exposure",
          "common_combinations": "Sulfadiazine 60 mg/kg PO q 24h cotreatment",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:15:53.000000Z",
          "updated_at": "2020-09-16T01:15:53.000000Z"
      },
      {
          "id": 1457,
          "drug_id": 390,
          "indication_name": "Atrial fibrillation - acute, vagally-mediated (high vagal tone due to GI, urinary, neurologic, or other disorders +/- opiate or alpha-2 agonist drug treatment)",
          "expected_effects": "Conversion to normal sinus rhythm 1 hour after administration of the second dose (total treatment time <12h) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:15:55.000000Z",
          "updated_at": "2020-09-16T01:15:55.000000Z"
      },
      {
          "id": 1458,
          "drug_id": 390,
          "indication_name": "Atrial fibrillation - chronic, with digoxin cotreatment",
          "expected_effects": "Variable: reported cases have shown rate reduction and reduction of ventricular ectopy, successful electrical cardioversion to sinus rhythm immediately post-quinidine, and persistent/refractory atrial fibrillation, in individual dogs with atrial fibrillation associated with structural heart disease (marked cardiomegaly)",
          "common_combinations": "With or without digoxin",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:15:57.000000Z",
          "updated_at": "2020-09-16T01:15:57.000000Z"
      },
      {
          "id": 1459,
          "drug_id": 390,
          "indication_name": "Atrial fibrillation - chronic, with digoxin cotreatment",
          "expected_effects": "Failure to convert to sinus rhythm initially, and persistence of atrial fibrillation, may produce signs of toxicosis after 4-5 days, requiring reduction or discontinuation of treatment, but such signs coincided with the termination of atrial fibrillation and return of normal sinus rhythm in 1 case report",
          "common_combinations": "Digoxin",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:16:00.000000Z",
          "updated_at": "2020-09-16T01:16:00.000000Z"
      },
      {
          "id": 1460,
          "drug_id": 391,
          "indication_name": "Congestive heart failure - adjunctive treatment",
          "expected_effects": "Improvement in composite clinical cardiac findings over 7-month period, to a degree similar to results with captopril treatment",
          "common_combinations": "Furosemide",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:03.000000Z",
          "updated_at": "2020-09-16T01:16:03.000000Z"
      },
      {
          "id": 1461,
          "drug_id": 391,
          "indication_name": "Delay/prevention of congestive heart failure",
          "expected_effects": "Slight delay (e.g., 2-4 weeks, compared to control) in onset of congestive heart failure in experimental, pacing-induced heart failure model in dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:05.000000Z",
          "updated_at": "2020-09-16T01:16:05.000000Z"
      },
      {
          "id": 1462,
          "drug_id": 391,
          "indication_name": "Hypertrophic cardiomyopathy (delay hypertrophic process)",
          "expected_effects": "No difference between ramipril-treated cats and placebo-treated cats with respect to ventricular hypertrophy, diastolic ventricular function, or myocardial fibrosis",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:16:08.000000Z",
          "updated_at": "2020-09-16T01:16:08.000000Z"
      },
      {
          "id": 1463,
          "drug_id": 392,
          "indication_name": "Increase gastrointestinal motility",
          "expected_effects": "No significant difference in gastric emptying time, small and large bowel transit time, and total GI transit time with ranitidine treatment compared to without",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:10.000000Z",
          "updated_at": "2020-09-16T01:16:10.000000Z"
      },
      {
          "id": 1464,
          "drug_id": 392,
          "indication_name": "Gastric acid reduction",
          "expected_effects": "No significant effect compared to placebo (saline)\nBy the 3rd day of treatment, gastric pH ≥3 for 37-45% of a 24h day and ≥4 for 25-27%",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:13.000000Z",
          "updated_at": "2020-09-16T01:16:13.000000Z"
      },
      {
          "id": 1465,
          "drug_id": 392,
          "indication_name": "Gastroesophageal reflux (perioperative)",
          "expected_effects": "Ineffective - no difference between ranitidine-treated dogs and untreated controls",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:16:15.000000Z",
          "updated_at": "2020-09-16T01:16:15.000000Z"
      },
      {
          "id": 1466,
          "drug_id": 393,
          "indication_name": "Canine leproid granuloma syndrome",
          "expected_effects": "Resolution of the lesions, without serious side effects (6/7 dogs)",
          "common_combinations": "Clarithromycin 2-3 mg/kg PO q 8h, or clofazimine",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:17.000000Z",
          "updated_at": "2020-09-16T01:16:17.000000Z"
      },
      {
          "id": 1467,
          "drug_id": 393,
          "indication_name": "Feline leprosy",
          "expected_effects": "Marked improvement or complete resolution in 66% of treated cats\nPartial response in 17% of treated cats\nDeath or euthanasia due to the disease in 17% of treated cats",
          "common_combinations": "Clarithromycin 62.5 mg/CAT PO q 12h, or clofazimine 25-50 mg/CAT PO q 24h or 50 mg/CAT PO q 48h, or both clarithromycin and clofazimine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:21.000000Z",
          "updated_at": "2020-09-16T01:16:21.000000Z"
      },
      {
          "id": 1468,
          "drug_id": 394,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Significant clinical response (50%, 70% improvement in lameness and clinical signs) after 14 and 28 days of treatment, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:23.000000Z",
          "updated_at": "2020-09-16T01:16:23.000000Z"
      },
      {
          "id": 1469,
          "drug_id": 394,
          "indication_name": "Post-operative analgesia (soft tissue surgery)",
          "expected_effects": "Overall assessment for 22h post-op (posture, incision pain, etc.) significantly better with single robenacoxib injection than with single meloxicam injection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:25.000000Z",
          "updated_at": "2020-09-16T01:16:25.000000Z"
      },
      {
          "id": 1470,
          "drug_id": 394,
          "indication_name": "Osteoarthritis and other causes of orthopedic pain",
          "expected_effects": "Overall assessment of pain, mobility and inflammation similar for robenacoxib and ketoprofen",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:16:28.000000Z",
          "updated_at": "2020-09-16T01:16:28.000000Z"
      },
      {
          "id": 1471,
          "drug_id": 395,
          "indication_name": "Giardiasis",
          "expected_effects": "Effective suppression but incomplete eradication: ronidazole eliminates Giardia spp. (both fecal cysts and fecal antigen) from essentially all dogs during treatment and for at least 26 days post-treatment. Despite these results, >99% of dogs have return of fecal Giardia cysts between 33-54 days post-treatment (kennel setting) despite appropriate hygiene measures",
          "common_combinations": "Chlorhexidine shampooing;Disinfection of kennel",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:30.000000Z",
          "updated_at": "2020-09-16T01:16:30.000000Z"
      },
      {
          "id": 1472,
          "drug_id": 395,
          "indication_name": "Trichomoniasis (Tritrichomonas fetus)",
          "expected_effects": "Elimination of fecal shedding and resolution of diarrhea (indefinitely, for >6 months follow-up) from most cats with 1 or 2 courses of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:32.000000Z",
          "updated_at": "2020-09-16T01:16:32.000000Z"
      },
      {
          "id": 1473,
          "drug_id": 396,
          "indication_name": "Chylothorax (delay of recurrence)",
          "expected_effects": "Not universally effective since many dogs require additional therapy (e.g., pericardectomy, cisterna chyli ablation, thoracic duct ligation) due to persistent chylous pleural effusion",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:35.000000Z",
          "updated_at": "2020-09-16T01:16:35.000000Z"
      },
      {
          "id": 1474,
          "drug_id": 396,
          "indication_name": "To accelerate lymphatic flow and raise cholesterol resorption from the interstitial space",
          "expected_effects": "Nonspecific decrease in concentration of esterified and free cholesterol in serum, and increase in arterial blood cholesterol\nNonspecific increase in concentration of esterified cholesterol in thoracic duct lymph\nNonspecific but significant decrease in total cholesterol in the gastrocnemius muscle, liver, and popliteal lymph node (all in 1 experimental study)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:37.000000Z",
          "updated_at": "2020-09-16T01:16:37.000000Z"
      },
      {
          "id": 1475,
          "drug_id": 396,
          "indication_name": "Chylothorax (delay of recurrence)",
          "expected_effects": "Absence of dyspnea in 75% of cats during treatment in 1 small case series, with complete resolution of effusion in 50% of cats",
          "common_combinations": "Thoraccoentesis;Low-fat diet",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:16:40.000000Z",
          "updated_at": "2020-09-16T01:16:40.000000Z"
      },
      {
          "id": 1476,
          "drug_id": 397,
          "indication_name": "Asthma",
          "expected_effects": "30% decrease in eosinophil percentages in bronchoalveolar lavage fluid, compared to untreated cats\nSuppression of parts of allergic response (complete inhibition of allergen-stimulated airway hyperresponsiveness)",
          "common_combinations": "500 µginhaled fluticasone propionate/dose",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:43.000000Z",
          "updated_at": "2020-09-16T01:16:43.000000Z"
      },
      {
          "id": 1477,
          "drug_id": 398,
          "indication_name": "Heartworm prophylaxis",
          "expected_effects": ">99% effective in preventing heartworm development",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:16:46.000000Z",
          "updated_at": "2020-09-16T01:16:46.000000Z"
      },
      {
          "id": 1478,
          "drug_id": 398,
          "indication_name": "Sarcoptic mange",
          "expected_effects": "Elimination of all mites (on skin scrapings) by day 22 after first treatment, and resolution of most/all skin lesions by 50-64 days after first treatment (similar to imidacloprid-moxidectin combination)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:16:48.000000Z",
          "updated_at": "2020-09-16T01:16:48.000000Z"
      },
      {
          "id": 1479,
          "drug_id": 398,
          "indication_name": "Demodicosis (generalized)",
          "expected_effects": "Complete remission occurs in 20% of treated dogs, in 4-24 weeks (mean: 10 weeks)\nRemission is more likely to occur in juvenile demodicosis (dogs <2 years old) and in dogs with milder skin lesions on initial presentation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:16:51.000000Z",
          "updated_at": "2020-09-16T01:16:51.000000Z"
      },
      {
          "id": 1480,
          "drug_id": 398,
          "indication_name": "Nasal mite - Pneumonyssoides caninum infestation",
          "expected_effects": "100% reduction in nasal mites (vs. 17% reduction in untreated control dogs)\nNo superior benefit of 24 mg/kg dosage over 6 mg/kg, but limited numbers of dogs tested",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:16:53.000000Z",
          "updated_at": "2020-09-16T01:16:53.000000Z"
      },
      {
          "id": 1481,
          "drug_id": 398,
          "indication_name": "Lice infestation (sucking lice - Linognathus setosus)",
          "expected_effects": "Complete elimination of lice by 42 days post-application in 91% of treated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:16:56.000000Z",
          "updated_at": "2020-09-16T01:16:56.000000Z"
      },
      {
          "id": 1482,
          "drug_id": 398,
          "indication_name": "Lice infestation - biting lice (dogs: Trichodectes canis, cats: Felicola subrostratus)",
          "expected_effects": "100% efficacy in eliminating lice by 7 days post-treatment (vs. 24-58% \"efficacy\"/spontaneous reduction with placebo treatment), with corresponding decrease/elimination of associated clinical signs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:16:58.000000Z",
          "updated_at": "2020-09-16T01:16:58.000000Z"
      },
      {
          "id": 1483,
          "drug_id": 398,
          "indication_name": "Flea allergy dermatitis",
          "expected_effects": "Marked reduction/elimination of fleas, and significant reduction in associated signs of flea-bite allergy, in treated dogs and cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:17:01.000000Z",
          "updated_at": "2020-09-16T01:17:01.000000Z"
      },
      {
          "id": 1484,
          "drug_id": 398,
          "indication_name": "Ear mite infestation (Otodectes cynotis)",
          "expected_effects": "90% elimination of ear mites after 2 treatments in dogs (vs. 65% with positive control drug, e.g., Otomite)\n>99% elimination of mites after 1 treatment in cats (vs. 93% with positive control)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:17:03.000000Z",
          "updated_at": "2020-09-16T01:17:03.000000Z"
      },
      {
          "id": 1485,
          "drug_id": 398,
          "indication_name": "Cheyletiellosis",
          "expected_effects": "100% resolution in clinical signs by 60 days after 1st treatment - no relapses noted\nAll skin samples negative for mites by day 30 and all skin and fecal samples negative for mites by day 60",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:17:06.000000Z",
          "updated_at": "2020-09-16T01:17:06.000000Z"
      },
      {
          "id": 1486,
          "drug_id": 398,
          "indication_name": "Roundworm, hookworm infestations (Toxocara cati, Ancylostoma tubaeforme)",
          "expected_effects": "Reduction in fecal ova counts for roundworms of 99.9-100% by 60 days after 1st treatment (vs. 97-100% for pyrantel pamoate or flubendazole)\nReduction in fecal ova counts for hookworms of 100% by 60 days after 1st treatment (vs. 98.9-99.9% for pyrantel pamoate or flubendazole)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T01:17:08.000000Z",
          "updated_at": "2020-09-16T01:17:08.000000Z"
      },
      {
          "id": 1487,
          "drug_id": 399,
          "indication_name": "Cognitive dysfunction syndrome",
          "expected_effects": "80% and 77% of owners report that the dog seems generally improved at 30 days and 60 days of treatment, respectively (positive change in physical activity, orientation, and interaction with family members)\n19% of owners report no change with treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:17:11.000000Z",
          "updated_at": "2020-09-16T01:17:11.000000Z"
      },
      {
          "id": 1488,
          "drug_id": 399,
          "indication_name": "Learning and training (healthy dogs)",
          "expected_effects": "Significant increase in performance of tasks geared towards a motivational cue (i.e., significant evidence of increased concentrating ability) compared to placebo",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:17:13.000000Z",
          "updated_at": "2020-09-16T01:17:13.000000Z"
      },
      {
          "id": 1489,
          "drug_id": 399,
          "indication_name": "Hyperadrenocorticism",
          "expected_effects": "No convincing benefit: after 6 months, improvement, deterioration, and stagnation of clinical signs occurs in 20%, 40%, and 40% of dogs, respectively",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:17:16.000000Z",
          "updated_at": "2020-09-16T01:17:16.000000Z"
      },
      {
          "id": 1490,
          "drug_id": 399,
          "indication_name": "Acromegaly",
          "expected_effects": "No improvement in clinical signs associated with treatment (and euthanasia after 1 year of treatment) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:17:18.000000Z",
          "updated_at": "2020-09-16T01:17:18.000000Z"
      },
      {
          "id": 1491,
          "drug_id": 400,
          "indication_name": "Pulmonary hypertension",
          "expected_effects": "Significant improvement in short- to medium-term quality of life, physical activity/exercise tolerance, and concomitant 25-30 mean reduction in systolic pulmonary arterial pressure",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:17:21.000000Z",
          "updated_at": "2020-09-16T01:17:21.000000Z"
      },
      {
          "id": 1492,
          "drug_id": 400,
          "indication_name": "Eisenmenger's syndrome",
          "expected_effects": "Significant improvement in clinical signs within 1 day of starting therapy, maintained for 1 and 3 months of treatment in 2 reported cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:17:23.000000Z",
          "updated_at": "2020-09-16T01:17:23.000000Z"
      },
      {
          "id": 1493,
          "drug_id": 400,
          "indication_name": "Acute pulmonary embolism (experimentally-induced)",
          "expected_effects": "Mitigates pulmonary hypertension caused by acute pulmonary embolism: mean pulmonary arterial pressure that increases by 24 mmHg with embolization alone increases by 42% less (14 mmHg increase) when sildenafil is administered during ongoing thromboembolism",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:17:26.000000Z",
          "updated_at": "2020-09-16T01:17:26.000000Z"
      },
      {
          "id": 1494,
          "drug_id": 400,
          "indication_name": "Ischemia-induced ventricular arrhythmias",
          "expected_effects": "60-75% fewer cardiac arrhythmias, and arrhythmia severity reduced, with sildenafil compared to controls (in an experimental model of myocardial infarction)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:17:28.000000Z",
          "updated_at": "2020-09-16T01:17:28.000000Z"
      },
      {
          "id": 1495,
          "drug_id": 401,
          "indication_name": "Lomustine hepatotoxicosis - prevention",
          "expected_effects": "Mild hepatoprotectant effect possible: increases in serum liver enzymes occur in 68% of dogs receiving CCNU and sylimarin (vs. 84% of dogs receiving CCNU alone)",
          "common_combinations": "S-adenosylmethionine",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:17:31.000000Z",
          "updated_at": "2020-09-16T01:17:31.000000Z"
      },
      {
          "id": 1496,
          "drug_id": 401,
          "indication_name": "Amanita mushroom intoxication - prevention",
          "expected_effects": "Suppression of serum changes and fall in prothrombin time associated with intoxication, marked reduction in hemorrhagic hepatic necrosis (vs. controls) and marked improvement in survival (>99% with treatment vs. 67% in dogs not treated with silibinin)\nNormal hepatic morphology at 192 hours post-treatment in silibinin-treated dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:17:33.000000Z",
          "updated_at": "2020-09-16T01:17:33.000000Z"
      },
      {
          "id": 1497,
          "drug_id": 401,
          "indication_name": "Carbon tetrachloride intoxication - prevention",
          "expected_effects": "Lower serum liver enzyme levels 12 and 24h after intoxication, and milder liver lesions, vs. untreated controls",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:17:36.000000Z",
          "updated_at": "2020-09-16T01:17:36.000000Z"
      },
      {
          "id": 1498,
          "drug_id": 401,
          "indication_name": "Gentamicin-induced nephrotoxicosis - prevention",
          "expected_effects": "40% increase in serum creatinine concentration with gentamicin alone, vs. 10% decrease when cotreatment with silymarin\nTotal serum antioxidant concentrations also higher in dogs treated with silymarin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:17:38.000000Z",
          "updated_at": "2020-09-16T01:17:38.000000Z"
      },
      {
          "id": 1499,
          "drug_id": 401,
          "indication_name": "Atrial flutter - amiodarone potentiation",
          "expected_effects": "Silymarin + amiodarone has greater antiarrhythmic effect (less inducible atrial flutter) than amiodarone alone in an atrial flutter model in experimental dogs",
          "common_combinations": "Amiodarone 600 mg/DOG PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:17:40.000000Z",
          "updated_at": "2020-09-16T01:17:40.000000Z"
      },
      {
          "id": 1500,
          "drug_id": 401,
          "indication_name": "Acetaminophen-induced hepatotoxicosis - prevention",
          "expected_effects": "Maintains liver enzyme levels within normal limits for at least 72h when coadministered with acetaminophen, or when administered 4h after acetaminophen intoxication (vs. untreated control cats, where liver enzyme levels double by 24h and triple by 72h after intoxication)\nSimilar effect to positive control group (acetylcysteine)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:17:43.000000Z",
          "updated_at": "2020-09-16T01:17:43.000000Z"
      },
      {
          "id": 1501,
          "drug_id": 402,
          "indication_name": "Metabolic acidosis",
          "expected_effects": "From acidemia pre-treatment (venous pH: 7.14, base excess: -11 mEq/L), sodium bicarbonate normalizes values to at or near baseline (venous pH: 7.36, base excess: -1 mEq/L) by end of 30-minute infusion",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:17:46.000000Z",
          "updated_at": "2020-09-16T01:17:46.000000Z"
      },
      {
          "id": 1502,
          "drug_id": 402,
          "indication_name": "Hyperkalemia (bolus)",
          "expected_effects": "Mild reduction in serum potassium: 10% reduction (from 9 to 8.3 mEq/L) by 15 minutes after dosing, and a further 5% (to 8.1 mEq/L) by 30 minutes after dosing - no further reduction",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:17:48.000000Z",
          "updated_at": "2020-09-16T01:17:48.000000Z"
      },
      {
          "id": 1503,
          "drug_id": 402,
          "indication_name": "Hyperkalemia (constant rate infusion)",
          "expected_effects": "Mild but ongoing reduction in serum potassium: 5% reduction (from 8.8 to 8.5 mEq/L) by 15 minutes after dosing, a further 5% (to 8.3 mEq/L) by 30 minutes after dosing, and continued reduction to 6.8 mEq/L by 2h after start (1h after 1h bicarbonate CRI)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:17:51.000000Z",
          "updated_at": "2020-09-16T01:17:51.000000Z"
      },
      {
          "id": 1504,
          "drug_id": 402,
          "indication_name": "Cardiopulmonary resuscitation (extended)",
          "expected_effects": "Fewer defibrillation shocks needed (2 vs. 5), faster return of spontaneous circulation (6 vs. 22 minutes), and higher short-term survival rates (73% vs. 5%) with NaHCO3 treatment during prolonged CPR, compared to same CPR without NaHCO3 (saline control)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:17:53.000000Z",
          "updated_at": "2020-09-16T01:17:53.000000Z"
      },
      {
          "id": 1505,
          "drug_id": 402,
          "indication_name": "Metabolic acidosis",
          "expected_effects": "74% overall survival (with bicarbonate treatment as part of therapeutic approach to severe acidosis in ketotic diabetic cats)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:17:57.000000Z",
          "updated_at": "2020-09-16T01:17:57.000000Z"
      },
      {
          "id": 1506,
          "drug_id": 402,
          "indication_name": "Hyperkalemia and metabolic acidosis in cats with urethral obstruction",
          "expected_effects": "Sodium bicarbonate with IV fluid therapy corrects >95% of cases of severe metabolic acidosis in cats with urethral obstruction (>95% survival rate)\nSerum potassium decreases from 6.9 mEq/L to 3.4 mEq/L with relief of urethral obstruction + fluid therapy + sodium bicarbonate",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:17:59.000000Z",
          "updated_at": "2020-09-16T01:17:59.000000Z"
      },
      {
          "id": 1507,
          "drug_id": 403,
          "indication_name": "Ventricular tachyarrhythmias in boxer dogs (arrhythmogenic right ventricular cardiomyopathy)",
          "expected_effects": "83% reduction in number of PVCs/24h (from median of 5907 to median of 998), compared to 71%, 50%, and 86%, for atenolol, procainamide, and mexiletine + atenolol, respectively\nNo significant reduction in occurrence of syncope with any of these 4 drug protocols, however\nEffect on lifespan not yet determined",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:01.000000Z",
          "updated_at": "2020-09-16T01:18:01.000000Z"
      },
      {
          "id": 1508,
          "drug_id": 403,
          "indication_name": "Ventricular tachyarrhythmias",
          "expected_effects": "Reduction in ventricular arrhythmogenesis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:04.000000Z",
          "updated_at": "2020-09-16T01:18:04.000000Z"
      },
      {
          "id": 1509,
          "drug_id": 403,
          "indication_name": "Inherited ventricular arrhythmias in German shepherds",
          "expected_effects": "22% of dogs achieve a reduction in number of PVCs on Holter with sotalol, compared to 42% with sotalol-mexiletine cotreatment, and 9% with mexiletine alone",
          "common_combinations": "Mexiletine 8 mg/kg PO q 8h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:18:06.000000Z",
          "updated_at": "2020-09-16T01:18:06.000000Z"
      },
      {
          "id": 1510,
          "drug_id": 403,
          "indication_name": "Recurrent syncope associated with paroxysmal supraventricular tachycardia",
          "expected_effects": "No further episodes of syncope 18 months after initiating treatment in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:18:08.000000Z",
          "updated_at": "2020-09-16T01:18:08.000000Z"
      },
      {
          "id": 1511,
          "drug_id": 404,
          "indication_name": "Flea infestation - Ctenocephalides felis ",
          "expected_effects": ">99% of fleas dead within 4h of administration ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:11.000000Z",
          "updated_at": "2020-09-16T01:18:11.000000Z"
      },
      {
          "id": 1512,
          "drug_id": 404,
          "indication_name": "Tick prevention - Rhipicephalus sanguineus",
          "expected_effects": "95 and 97% reduction in tick counts at 24h post treatment with 50 mg/kg and 100 mg/kg dosages, respectively\nEfficacy declines rapidly (no difference between treatment and control groups 9 days after 100 mg/kg) ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:13.000000Z",
          "updated_at": "2020-09-16T01:18:13.000000Z"
      },
      {
          "id": 1513,
          "drug_id": 405,
          "indication_name": "Mitral regurgitation caused by myxomatous mitral valve disease",
          "expected_effects": "Significant reduction in worsening or death (10% in spironolactone group vs. 26% in placebo group) in dogs also receiving an ACE inhibitor and furosemide and/or digoxin if needed",
          "common_combinations": "Furosemide;ACE inhibitor;Digoxin",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:16.000000Z",
          "updated_at": "2020-09-16T01:18:16.000000Z"
      },
      {
          "id": 1514,
          "drug_id": 405,
          "indication_name": "Aldosterone antagonism",
          "expected_effects": "In dogs, inhibition of aldosterone activity by 28, 50, and 88% can be achieved with dosages of 0.08, 1.2, and 2 mg/kg PO q 24h, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:18.000000Z",
          "updated_at": "2020-09-16T01:18:18.000000Z"
      },
      {
          "id": 1515,
          "drug_id": 405,
          "indication_name": "Diuretic (as monotherapy)",
          "expected_effects": "No effect on water or sodium diuresis: no difference in volume of urine produced at any dosage\nReduction in potassium excretion in urine at 1-2 mg/kg",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:18:21.000000Z",
          "updated_at": "2020-09-16T01:18:21.000000Z"
      },
      {
          "id": 1516,
          "drug_id": 405,
          "indication_name": "Hypertrophic cardiomyopathy",
          "expected_effects": "No significant treatment benefit (ventricular wall thicknesses and ventricular wall motion/diastolic properties are unchanged with treatment)\n31% incidence of severe facial ulcerative dermatitis (requiring discontinuation of spironolactone) in Maine Coon cats",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:18:23.000000Z",
          "updated_at": "2020-09-16T01:18:23.000000Z"
      },
      {
          "id": 1517,
          "drug_id": 406,
          "indication_name": "Cachexia reversal/prevention in chronic kidney disease",
          "expected_effects": "In 82% of dogs, lean body mass is greater with stanozolol administration, and stanozolol treatment is associated with a more positive nitrogen balance in 73% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:26.000000Z",
          "updated_at": "2020-09-16T01:18:26.000000Z"
      },
      {
          "id": 1518,
          "drug_id": 407,
          "indication_name": "Visceral leishmaniasis",
          "expected_effects": "Profound suppression (clinical but not parasitological cure) of disease: >99% elimination of clinical signs, and of amastigotes from lymph nodes\nNo relapses in 6-24 months after treatment, although immunofluorescent antibody test results remain positive in all dogs despite treatment",
          "common_combinations": "Allopurinol 15 mg/kg PO q 12 h as pretreatment (until clinical signs improve), then also combined with stilbogluconate for 1 month, then also as monotherapy for 7 months following end of stilbogluconate treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:28.000000Z",
          "updated_at": "2020-09-16T01:18:28.000000Z"
      },
      {
          "id": 1519,
          "drug_id": 408,
          "indication_name": "Aortic thromboembolism",
          "expected_effects": "Effective short-/medium-term resolution of thrombosis in >80% of dogs",
          "common_combinations": "Anticoagulant (heparin or warfarin)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:31.000000Z",
          "updated_at": "2020-09-16T01:18:31.000000Z"
      },
      {
          "id": 1520,
          "drug_id": 408,
          "indication_name": "Aortic thromboembolism",
          "expected_effects": "Return of palpable pulse in ≤ 24h in 54% of cats\nReturn of motor limb function in ≤ 6 days in 30% of cats\n33% survival to discharge",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:33.000000Z",
          "updated_at": "2020-09-16T01:18:33.000000Z"
      },
      {
          "id": 1521,
          "drug_id": 409,
          "indication_name": "To induce diabetes mellitus (experimentally)",
          "expected_effects": "Stable induction of diabetes mellitus, resulting in up to 50% decrease in glucose usage capability\n53% and 71% increase in mean plasma glucose concentration 1 and 2 weeks post-injection, respectively\n2 and 3 times higher percentage of urine glucose excretion 1 and 2 weeks post-injection, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:36.000000Z",
          "updated_at": "2020-09-16T01:18:36.000000Z"
      },
      {
          "id": 1522,
          "drug_id": 409,
          "indication_name": "Insulinoma",
          "expected_effects": "Normoglycemia for 16-309 days (median: 163 days) vs. 0-426 days (median: 90 days) for control dogs",
          "common_combinations": "With or without prednisone;With or without diazoxide",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:38.000000Z",
          "updated_at": "2020-09-16T01:18:38.000000Z"
      },
      {
          "id": 1523,
          "drug_id": 410,
          "indication_name": "Lead poisoning",
          "expected_effects": "Decrease in mean blood lead concentration by 54%, 76%, and 61% after 3, 7, and 20 days, respectively\nMean urine lead concentration of 485, 254, and 28 µg/dL on days 3, 7, and 20, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:41.000000Z",
          "updated_at": "2020-09-16T01:18:41.000000Z"
      },
      {
          "id": 1524,
          "drug_id": 410,
          "indication_name": "Lead poisoning",
          "expected_effects": "Average 58% decrease in blood lead concentration after 2 days, and back to normal limits after 1 week, in 2 reported feline cases",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:43.000000Z",
          "updated_at": "2020-09-16T01:18:43.000000Z"
      },
      {
          "id": 1525,
          "drug_id": 411,
          "indication_name": "Esophagitis",
          "expected_effects": "14% excellent, 59% very good, and 27% good composite result of balloon dilation of esophageal stricture with sucralfate as part of post-procedure treatment protocol",
          "common_combinations": "Cimetidine (or other H2 blocker);Metoclopramide;Prednisone (for post-balloon-dilation of esophageal stricture)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:18:46.000000Z",
          "updated_at": "2020-09-16T01:18:46.000000Z"
      },
      {
          "id": 1526,
          "drug_id": 411,
          "indication_name": "Gastrinoma",
          "expected_effects": "14 month survival in 1 case report",
          "common_combinations": "Famotidine 1 mg/kg PO q 8h;Omeprazole 0.7 mg/kg PO q 24h;Increasing doses of octreotide SC from 1 month after diagnosis",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:18:48.000000Z",
          "updated_at": "2020-09-16T01:18:48.000000Z"
      },
      {
          "id": 1527,
          "drug_id": 411,
          "indication_name": "Gastric ulceration (corticosteroid-induced)",
          "expected_effects": "90% of treated dogs have positive fecal occult blood test results (same as untreated controls)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:18:51.000000Z",
          "updated_at": "2020-09-16T01:18:51.000000Z"
      },
      {
          "id": 1528,
          "drug_id": 411,
          "indication_name": "Gastric ulceration",
          "expected_effects": "Long-term survival (>30 months) in septic peritonitis case report where sucralfate was part of post-operative treatment protocol",
          "common_combinations": "Treatment of the underlying disorder;Cimetidine or other H2 blockers;Omeprazole",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:18:53.000000Z",
          "updated_at": "2020-09-16T01:18:53.000000Z"
      },
      {
          "id": 1529,
          "drug_id": 411,
          "indication_name": "Esophagitis",
          "expected_effects": "100% of cats receiving sucralfate prior to acid insult have normal esophageal endoscopy 24 hours after the last acid exposure, vs. 17% of placebo-treated controls",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:18:56.000000Z",
          "updated_at": "2020-09-16T01:18:56.000000Z"
      },
      {
          "id": 1530,
          "drug_id": 411,
          "indication_name": "Gastroesophageal reflux during anesthesia in the kitten",
          "expected_effects": "No adverse effect reported\nEfficacy unproven",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:18:58.000000Z",
          "updated_at": "2020-09-16T01:18:58.000000Z"
      },
      {
          "id": 1531,
          "drug_id": 412,
          "indication_name": "Urinary tract infection",
          "expected_effects": "Successful resolution of urinary tract infections caused by E. coli (82% of cases), Proteus mirabilis (73%), Klebsiella pneumoniae (67%), Streptococcus spp. (56%), and S. aureus (100%)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:19:01.000000Z",
          "updated_at": "2020-09-16T01:19:01.000000Z"
      },
      {
          "id": 1532,
          "drug_id": 412,
          "indication_name": "Urinary tract infection (single high-dose protocol)",
          "expected_effects": "Infection remains 2 and 7 days after treatment in all dogs (vs. remaining in only 17% of dogs at 7 days during standard q 12h trimethoprim-sulfa treatment for 21 days)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:19:03.000000Z",
          "updated_at": "2020-09-16T01:19:03.000000Z"
      },
      {
          "id": 1533,
          "drug_id": 412,
          "indication_name": "Neutropenia associated with antineoplastic chemotherapy",
          "expected_effects": "Treatment associated with lower hospitalization rates (3% vs. 19% in placebo-treated controls), severe nonhematologic toxicosis rates (16% vs. 56%), severe gastrointestinal toxicosis rates (17% vs. 46%), and altered performance rates (14% vs. 40%) in patients that receive trimethoprim-sulfadiazine automatically post-doxorubicin",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:19:06.000000Z",
          "updated_at": "2020-09-16T01:19:06.000000Z"
      },
      {
          "id": 1534,
          "drug_id": 412,
          "indication_name": "Pyoderma",
          "expected_effects": "Resolution in 39% and 76% (3 weeks and 6 weeks) of cases with 30 mg/kg PO q 24h, and 57% and 79% (3 weeks and 6 weeks) with 30 mg/kg PO q 12h",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:19:08.000000Z",
          "updated_at": "2020-09-16T01:19:08.000000Z"
      },
      {
          "id": 1535,
          "drug_id": 412,
          "indication_name": "Toxoplasmosis (central nervous system)",
          "expected_effects": ">99% of dogs respond to therapy, but many (e.g., 50% in 1 study) need to switch to another drug (e.g., clindamycin) due to adverse effects caused by trimethoprim-sulfadiazine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:19:11.000000Z",
          "updated_at": "2020-09-16T01:19:11.000000Z"
      },
      {
          "id": 1536,
          "drug_id": 412,
          "indication_name": "Polioencephalomyelopathy",
          "expected_effects": "No clinical improvement with treatment, leading to euthanasia, in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:19:19.000000Z",
          "updated_at": "2020-09-16T01:19:19.000000Z"
      },
      {
          "id": 1537,
          "drug_id": 412,
          "indication_name": "Immunization against shedding of Toxoplasma oocysts",
          "expected_effects": "Oocyst formation suppressed in >99% of cats\nAfter challenge, 100% of cats are immune",
          "common_combinations": "Sulfadiazine 60 mg/kg combined with pyrimethamine 1 mg/kg",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:19:21.000000Z",
          "updated_at": "2020-09-16T01:19:21.000000Z"
      },
      {
          "id": 1538,
          "drug_id": 412,
          "indication_name": "Intestinal development of Toxoplasma gondii",
          "expected_effects": "Inhibition of oocyst-excretion in 75% of cats, with no parasites on histological exam for up to 7 days",
          "common_combinations": "Pyrimethamine 2 mg/kg IM",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:19:24.000000Z",
          "updated_at": "2020-09-16T01:19:24.000000Z"
      },
      {
          "id": 1539,
          "drug_id": 413,
          "indication_name": "Coccidiosis - Isospora spp. infection",
          "expected_effects": "99% reduction in fecal oocyst count post-treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:19:27.000000Z",
          "updated_at": "2020-09-16T01:19:27.000000Z"
      },
      {
          "id": 1540,
          "drug_id": 413,
          "indication_name": "Coccidiosis",
          "expected_effects": "Successfully eradicates >99% of infections",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:19:29.000000Z",
          "updated_at": "2020-09-16T01:19:29.000000Z"
      },
      {
          "id": 1541,
          "drug_id": 414,
          "indication_name": "Prevention of coccidiosis",
          "expected_effects": "99.8% elimination of Isospora spp. and significant increase in body weight of treated pups by 14 (vs. untreated controls)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:19:32.000000Z",
          "updated_at": "2020-09-16T01:19:32.000000Z"
      },
      {
          "id": 1542,
          "drug_id": 414,
          "indication_name": "Pyoderma",
          "expected_effects": "75% and >99% resolution of pyoderma after 3 weeks and 6 weeks of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:19:34.000000Z",
          "updated_at": "2020-09-16T01:19:34.000000Z"
      },
      {
          "id": 1543,
          "drug_id": 415,
          "indication_name": "Urinary tract infection",
          "expected_effects": "Successful resolution of urinary tract infections caused by E. coli (82% of cases), Proteus mirabilis (73%), Klebsiella pneumoniae (67%), Streptococcus spp. (56%), and S. aureus (100%)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:19:37.000000Z",
          "updated_at": "2020-09-16T01:19:37.000000Z"
      },
      {
          "id": 1544,
          "drug_id": 415,
          "indication_name": "Bacterial pneumonia",
          "expected_effects": "Initial radiographic improvement in pulmonary infiltrates, but termination of treatment was necessary due to vomiting (once after each drug administration, including via nasogastric tube, X 5 doses, until termination) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:19:39.000000Z",
          "updated_at": "2020-09-16T01:19:39.000000Z"
      },
      {
          "id": 1545,
          "drug_id": 416,
          "indication_name": "Perianal fistula",
          "expected_effects": "Complete resolution or partial improvement in 79% and 21% of dogs, respectively",
          "common_combinations": "Topical disinfection with dilute chlorhexidine once at the start of treatment;Prednisone 2 mg/kg PO q 24h for 2 weeks, then 1 mg/kg PO q 24h for 4 weeks, then 1 mg/kg PO q 48h for 10 weeks;Metronidazole 10 mg/kg PO q 12h for 2 weeks;Stool softener (psyllium-based product or canned pumpkin, PRN);Novel-protein diet",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:19:41.000000Z",
          "updated_at": "2020-09-16T01:19:41.000000Z"
      },
      {
          "id": 1546,
          "drug_id": 416,
          "indication_name": "Atopic dermatitis (focal carpal lesions)",
          "expected_effects": "Lesions (erythema, excoriations, oozing, lichenification) are reduced by 63% with treatment, vs. 3% with placebo\n75% of treated dogs experience significant (≥ 50%) reduction in lesion size with treatment, vs. 0% of placebo-treated control dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:19:43.000000Z",
          "updated_at": "2020-09-16T01:19:43.000000Z"
      },
      {
          "id": 1547,
          "drug_id": 416,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Mild benefit: erythema significantly improved after 4 weeks of treatment according to veterinarian's assessment (but not according to owner's assessment)\nNo appreciable improvement in pruritus",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:19:46.000000Z",
          "updated_at": "2020-09-16T01:19:46.000000Z"
      },
      {
          "id": 1548,
          "drug_id": 416,
          "indication_name": "Autoimmune skin disease (cutaneous/discoid lupus erythematosus, pemphigus erythematosus)",
          "expected_effects": "42% of cases have an excellent response, 42% of cases have a partial response, and 16% of cases do not respond",
          "common_combinations": "With or without tetracycline-niacinamide;With or without oral or topical glucocorticoids;With or without additional immunosuppressants (e.g., azathioprine) on a case-by-case basis",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:19:49.000000Z",
          "updated_at": "2020-09-16T01:19:49.000000Z"
      },
      {
          "id": 1549,
          "drug_id": 416,
          "indication_name": "Prevention of allograft rejection after renal transplantation",
          "expected_effects": "Tacrolimus-treated cats survive twice as long as untreated cats in 1 experimental renal transplantation study",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:19:51.000000Z",
          "updated_at": "2020-09-16T01:19:51.000000Z"
      },
      {
          "id": 1550,
          "drug_id": 416,
          "indication_name": "Necrotizing otitis externa",
          "expected_effects": "Complete resolution (50% of treated cats) or significant improvement (80% reduction in lesional area\n25% of cats) in cats previously refractory to systemic glucocorticoids, systemic antibacterials, and various otic preparations in 1 small case series",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:19:54.000000Z",
          "updated_at": "2020-09-16T01:19:54.000000Z"
      },
      {
          "id": 1551,
          "drug_id": 416,
          "indication_name": "Idiopathic facial dermatitis",
          "expected_effects": "Improvement within 8 weeks of initiating therapy and complete resolution after 6 months of therapy in 1 case report",
          "common_combinations": "Amoxicillin–clavulanate 13.75 mg/kg PO q 12h for 2 weeks;Itraconazole 10 mg/kg PO q 24h for 4 weeks;Topical therapy (bathing with 4% chlorhexidine shampoo) q 3 days",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:19:56.000000Z",
          "updated_at": "2020-09-16T01:19:56.000000Z"
      },
      {
          "id": 1552,
          "drug_id": 417,
          "indication_name": "Pulmonary arterial hypertension",
          "expected_effects": "Decrease in pulmonary arterial pressure within 24h, and up to 26 mmHg decrease in systolic arterial pressure, with rapid resolution of all respiratory and cardiac signs of pulmonary arterial hypertension. Despite treatment, deterioration occurs after 10 days (all in 1 case report)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:19:58.000000Z",
          "updated_at": "2020-09-16T01:19:58.000000Z"
      },
      {
          "id": 1553,
          "drug_id": 418,
          "indication_name": "Phenylephrine-induced intraurethral pressure (IUP) elevation",
          "expected_effects": "Urethral relaxation effect peaks at 1-2h and lasts 6-8h",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:01.000000Z",
          "updated_at": "2020-09-16T01:20:01.000000Z"
      },
      {
          "id": 1554,
          "drug_id": 419,
          "indication_name": "Dilated cardiomyopathy - Cocker spaniels",
          "expected_effects": "Improvement in left ventricular systolic function, reduction in left ventricular diameter, and ability to wean dogs from some or all other cardiac medications in some cases",
          "common_combinations": "Carnitine 1 g/DOG PO q 8-12h;Furosemide;ACE inhibitor;Digoxin if heart failure",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:04.000000Z",
          "updated_at": "2020-09-16T01:20:04.000000Z"
      },
      {
          "id": 1555,
          "drug_id": 419,
          "indication_name": "Dilated cardiomyopathy - various atypical breeds",
          "expected_effects": "Significant improvement in echocardiographic parameters (partial or complete reversal of dilated cardiomyopathy) after median of 3 months of treatment\nSurvival: 1-1460 days (median: 456 days)\nLong-term survivors (58% of dogs) can be weaned completely from all cardiac medications, and receive only taurine",
          "common_combinations": "Furosemide;ACE inhibitor;Digoxin if heart failure",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:06.000000Z",
          "updated_at": "2020-09-16T01:20:06.000000Z"
      },
      {
          "id": 1556,
          "drug_id": 419,
          "indication_name": "Taurine deficient dilated cardiomyopathy/myocardial failure",
          "expected_effects": "Clinical resolution or marked improvement in appetite, activity, and respiratory pattern within 2 weeks\nEchocardiographically normal after 4-6 weeks\n52-fold increase in mean plasma taurine concentration (from 9.7 nmol/mL baseline to mean 505 nmol/mL from weeks 2-12 of treatment)",
          "common_combinations": "Furosemide;ACE inhibitor;Digoxin if heart failure",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:20:09.000000Z",
          "updated_at": "2020-09-16T01:20:09.000000Z"
      },
      {
          "id": 1557,
          "drug_id": 420,
          "indication_name": "Malassezia dermatitis",
          "expected_effects": "87% reduction in mean yeast count after 3 weeks, and significant reduction in pruritus (i.e., >50% improvement) in 75% of dogs",
          "common_combinations": "Cephalexin 22-30 mg/kg PO q 12h for pyoderma",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:12.000000Z",
          "updated_at": "2020-09-16T01:20:12.000000Z"
      },
      {
          "id": 1558,
          "drug_id": 420,
          "indication_name": "Systemic and subcutaneous mycoses",
          "expected_effects": "Plasma drug levels consistent with antimicrobial efficacy for Blastomyces dermatitidis, Histoplasma capsulatum, Microsporum spp., Trichophyton mentagrophytes, Sporothrix schenckii, and Coccidioides immitis\nClinical efficacy and safety unproven",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:14.000000Z",
          "updated_at": "2020-09-16T01:20:14.000000Z"
      },
      {
          "id": 1559,
          "drug_id": 420,
          "indication_name": "Systemic aspergillosis",
          "expected_effects": "No appreciable change in clinical signs",
          "common_combinations": "Itraconazole;Posaconazole;Amphotericin B lipid complex",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:20:17.000000Z",
          "updated_at": "2020-09-16T01:20:17.000000Z"
      },
      {
          "id": 1560,
          "drug_id": 420,
          "indication_name": "Feline dermatophytosis due to Microsporum canis",
          "expected_effects": "27% of cats are clinically and mycologically cured by 30 days after end of treatment, and 92% by 90 days after end of treatment, reflecting the long half-life of terbinafine in feline hair",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:20:19.000000Z",
          "updated_at": "2020-09-16T01:20:19.000000Z"
      },
      {
          "id": 1561,
          "drug_id": 420,
          "indication_name": "Dermatophyte mycetoma (e.g., if adverse drug effects force termination of itraconazole)",
          "expected_effects": "Clinical improvement or resolution in 4-7 weeks, mycological cure in 12-14 weeks\nRecurrence may require persistent pulse therapy",
          "common_combinations": "With or without 2% chlorhexidine/2% miconazole shampoo weekly;Clipping if long-haired",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:20:21.000000Z",
          "updated_at": "2020-09-16T01:20:21.000000Z"
      },
      {
          "id": 1562,
          "drug_id": 421,
          "indication_name": "Collapsing trachea - acute deterioration",
          "expected_effects": "Improvement in respiratory effort in 1 case report",
          "common_combinations": "Butorphanol 0.2 mg/kg IV q 4-6h;Dexamethasone sodium phosphate 0.08 mg/kg IV q 12h;Hydrocodone 0.25 mg/kg PO q 6h;Supplemental oxygen",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:24.000000Z",
          "updated_at": "2020-09-16T01:20:24.000000Z"
      },
      {
          "id": 1563,
          "drug_id": 421,
          "indication_name": "Atrioventricular block/severe bradycardia",
          "expected_effects": "Increase in atrial and ventricular rates to 180 and 90 beats/minute, respectively (from 100 and 50 beats/minute, respectively, before treatment)\nNormal sinus rhythm between 140-170 beats/minute after 45 minutes (periodic, not sustained)\nDiminishing effect from 1-2 weeks onward and not effective long-term, all in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:27.000000Z",
          "updated_at": "2020-09-16T01:20:27.000000Z"
      },
      {
          "id": 1564,
          "drug_id": 421,
          "indication_name": "Asthma",
          "expected_effects": "Severely asthmatic cats: 35% decrease and 45% increase in lung resistance and lung compliance, respectively\nModerately asthmatic cats: 26% decrease and 33% increase in lung resistance and lung compliance, respectively\nAverage of 28% increase in heart rate at peak\nDisproportionately greater bronchodilator effect in asthmatic cats compared to healthy cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:20:29.000000Z",
          "updated_at": "2020-09-16T01:20:29.000000Z"
      },
      {
          "id": 1565,
          "drug_id": 421,
          "indication_name": "Upper respiratory tract infection (Chlamydophila felis)",
          "expected_effects": "Quality of life and vital signs (Karnofsky score) increases mainly based on choice of antibacterial (enrofloxacin superior to doxycycline) and role of terbutaline appears minimal",
          "common_combinations": "Bromhexinhydrochloride 0.5 mg/kg PO q 8h;Enrofloxacin 5 mg/kg SC q 24h for 3 days, then 15 mg/CAT PO q 24h for 11 days, or doxycycline 5 mg/kg SC q 12h for 3 days, then PO for 11 days",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:20:32.000000Z",
          "updated_at": "2020-09-16T01:20:32.000000Z"
      },
      {
          "id": 1566,
          "drug_id": 421,
          "indication_name": "Adjunctive treatment for bronchoscopy",
          "expected_effects": "Bronchoscopic complication rate is 7% with treatment (generally mild), compared to 50% or greater in untreated cats (ranging from mild to fatal)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:20:34.000000Z",
          "updated_at": "2020-09-16T01:20:34.000000Z"
      },
      {
          "id": 1567,
          "drug_id": 422,
          "indication_name": "Inhibition of growth hormone release",
          "expected_effects": "Significant inhibitory effect on the response of canine growth hormone to a growth hormone secretatogue during, and for up to 8 days after, treatment\nNon-specific decrease in plasma concentration of insulin-like growth factor 1 after day 10, lasting up to 8 days post-treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:37.000000Z",
          "updated_at": "2020-09-16T01:20:37.000000Z"
      },
      {
          "id": 1568,
          "drug_id": 422,
          "indication_name": "Modulation of luteinizing hormone releasing hormone (LHRH)",
          "expected_effects": "Mean increase of 14, 24, and 99 pg/mg in LHRH concentration in the ventral, middle, and dorsal hypothalamus, respectively (from baseline values of 1, 12, and 33 pg/mg)\nDiminishing effects",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:39.000000Z",
          "updated_at": "2020-09-16T01:20:39.000000Z"
      },
      {
          "id": 1569,
          "drug_id": 423,
          "indication_name": "Rocky Mountain spotted fever",
          "expected_effects": "Initial improvement in clinical signs 1-2 days after starting treatment in dogs without neurological deficits (1-4 days in dogs with neurologic deficits), and complete recovery 1-4 days after starting treatment in dogs without neurologic deficits (1-13 days in dogs with neurologic deficits)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:41.000000Z",
          "updated_at": "2020-09-16T01:20:41.000000Z"
      },
      {
          "id": 1570,
          "drug_id": 423,
          "indication_name": "Heartworm microfilariae - Dirofilaria immitis",
          "expected_effects": "72, 83, and 91% reduction in microfilariae on days 15, 30, and 115, respectively (with tetracycline treatment occurring from day 1 to day 40), but with recrudescence later (40% at day 160) > 99% elimination of microfilariae after 85 days (45 days post-treatment) and protection against microfilaremia for up to 4 months post-treatment",
          "common_combinations": "Acaciasides (saponins from the Acacia auriculiformis tree) given immediately after tetracycline treatment (10 mg/kg PO q 24h for 7 days) increase speed and extent of microfilaricide, to >99% elimination of microfilariae",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:44.000000Z",
          "updated_at": "2020-09-16T01:20:44.000000Z"
      },
      {
          "id": 1571,
          "drug_id": 423,
          "indication_name": "Ehrlichiosis (both treatment of clinical disease and prophylaxis in seropositive dogs in a highly endemic region)",
          "expected_effects": "Remission in 97% of dogs with clinical signs\nElimination of serum antibody in 60% of seropositive dogs for 2 years using prophylactic protocol (6.6 mg/kg)\nDecrease in number of seropositive reactions by 46% (57% pretreatment, reduced to 11% after treatment)",
          "common_combinations": "Tick control program",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:20:46.000000Z",
          "updated_at": "2020-09-16T01:20:46.000000Z"
      },
      {
          "id": 1572,
          "drug_id": 424,
          "indication_name": "Collapsing trachea",
          "expected_effects": "Tracheal stent placement (with theophylline pretreatment) eliminated all clinical signs in 33% of dogs with severe, medically intractable tracheal collapse and provided significant improvement (but not full resolution) in an additional 61% of dogs, in 1 case series",
          "common_combinations": "Tracheal stent placement in cases of advanced/refractory tracheal collapse;Mucolytic drugs;With or without corticosteroids at anti-inflammatory dosages",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:49.000000Z",
          "updated_at": "2020-09-16T01:20:49.000000Z"
      },
      {
          "id": 1573,
          "drug_id": 424,
          "indication_name": "Bradycardia causing syncope (sick sinus syndrome/sinus node dysfunction)",
          "expected_effects": "No convincing benefit in reported cases\nAnecdotal reports of reduced frequency of syncopal episodes (and improved quality of life) in a minority of dogs",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:52.000000Z",
          "updated_at": "2020-09-16T01:20:52.000000Z"
      },
      {
          "id": 1574,
          "drug_id": 424,
          "indication_name": "General bronchodilation",
          "expected_effects": "Calculated plasma theophylline concentrations that are achieved with this dosage would be in the therapeutic range",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:20:54.000000Z",
          "updated_at": "2020-09-16T01:20:54.000000Z"
      },
      {
          "id": 1575,
          "drug_id": 425,
          "indication_name": "Lungworm - Filaroides (Oslerus) osleri infestation",
          "expected_effects": "Fecal examinations negative for F. osleri after 1 week, lasting for at least 6 months\n>99% resolution of respiratory tract nodules after 2 weeks, and complete resolution after 5 weeks, lasting up to 6 months with only mild inflammation appearing at times after 10 weeks, all in 1 case report",
          "common_combinations": "Prednisone",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:20:56.000000Z",
          "updated_at": "2020-09-16T01:20:56.000000Z"
      },
      {
          "id": 1576,
          "drug_id": 425,
          "indication_name": "Nasal aspergillosis and penicilliosis",
          "expected_effects": "Clinical resolution or marked improvement in 12% and 43% of dogs that are and are not treated surgically, respectively, after 6 months\nResolution of nasal discharge in 26% of dogs\nProgression of disease, leading to euthanasia within 6-37 months in 23% of dogs ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:20:59.000000Z",
          "updated_at": "2020-09-16T01:20:59.000000Z"
      },
      {
          "id": 1577,
          "drug_id": 425,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "20-80% efficacy after 1 day, increasing to >99% efficacy in both ears from day 3-31",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:21:02.000000Z",
          "updated_at": "2020-09-16T01:21:02.000000Z"
      },
      {
          "id": 1578,
          "drug_id": 426,
          "indication_name": "Supplementation",
          "expected_effects": "Effective correction of nutritional thiamine deficiency",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:04.000000Z",
          "updated_at": "2020-09-16T01:21:04.000000Z"
      },
      {
          "id": 1579,
          "drug_id": 426,
          "indication_name": "Supplementation to correct thiamine deficiency",
          "expected_effects": "Neurologically stable after 2-4 days (no further seizures), with ongoing clinical improvement for subsequent weeks until clinically normal within 3 weeks to 4 months, all in a brief case series",
          "common_combinations": "Phenobarbital for seizure control;Balanced diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:21:07.000000Z",
          "updated_at": "2020-09-16T01:21:07.000000Z"
      },
      {
          "id": 1580,
          "drug_id": 427,
          "indication_name": "Anesthesia induction",
          "expected_effects": "Induction of anesthesia unremarkable",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:09.000000Z",
          "updated_at": "2020-09-16T01:21:09.000000Z"
      },
      {
          "id": 1581,
          "drug_id": 427,
          "indication_name": "Anesthesia induction - with propofol",
          "expected_effects": "Rapid recumbency, with minimal coughing, good muscle relaxation and no outward signs of excitement in 90% of dogs (thiopental-propofol combination) vs. 70% (thiopental monotherapy)\nSmooth recovery (righting to sternal recumbency, standing, walking with minimal ataxia) in 70% of dogs with propofol-thiopental vs. 10% with thiopental monotherapy at similar time points",
          "common_combinations": "Propofol 6 mg/kg IV administered over 90 sec",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:21:12.000000Z",
          "updated_at": "2020-09-16T01:21:12.000000Z"
      },
      {
          "id": 1582,
          "drug_id": 427,
          "indication_name": "Anesthesia induction",
          "expected_effects": "Effective induction of anesthesia",
          "common_combinations": "Succinylcholine 1.5 mg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:21:14.000000Z",
          "updated_at": "2020-09-16T01:21:14.000000Z"
      },
      {
          "id": 1583,
          "drug_id": 427,
          "indication_name": "Anesthesia induction",
          "expected_effects": "Effective induction of anesthesia",
          "common_combinations": "Turbocurarine",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:21:17.000000Z",
          "updated_at": "2020-09-16T01:21:17.000000Z"
      },
      {
          "id": 1584,
          "drug_id": 428,
          "indication_name": "Thyroid-stimulating hormone (TSH) response test",
          "expected_effects": "Normal response: within 6 hours, ≥ 3-fold increase in serum thyroxine concentration in >99% of dogs, and 2-fold increase in T3 concentration in 50% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:19.000000Z",
          "updated_at": "2020-09-16T01:21:19.000000Z"
      },
      {
          "id": 1585,
          "drug_id": 428,
          "indication_name": "Increase radioiodine uptake in hyperthyroid cats",
          "expected_effects": "Radioactive iodine uptake (RAIU) of 34, 46, and 47% after 6, 12, and 24 hours, respectively (mean of 7.3% higher than cats without TSH)\nNo significant effect on serum thyroxine concentration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:21:22.000000Z",
          "updated_at": "2020-09-16T01:21:22.000000Z"
      },
      {
          "id": 1586,
          "drug_id": 428,
          "indication_name": "Thyroid-stimulating hormone (TSH) response test",
          "expected_effects": "Within 6 hours: serum T4 concentration >4 µg/dL (range: 4.1-8.4 µg/dL), or an increase in the concentration by 2.5 µg/dL",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:21:24.000000Z",
          "updated_at": "2020-09-16T01:21:24.000000Z"
      },
      {
          "id": 1587,
          "drug_id": 429,
          "indication_name": "Otitis externa complicated by Pseudomonas aeruginosa and ruptured tympanic membrane",
          "expected_effects": "92% of treated dogs respond well, with resolution of otitis and healing of tympanic membrane if it was ruptured (duration of treatment, including topical extending 14 days beyond clinical cure: 14-36 days)",
          "common_combinations": "Ear flushing q 48h until no aural discharge;Prednisone 1-2 mg/kg PO q 24h PRN for inflammation, tapered over 1-2 weeks once inflammation decreases",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:27.000000Z",
          "updated_at": "2020-09-16T01:21:27.000000Z"
      },
      {
          "id": 1588,
          "drug_id": 429,
          "indication_name": "Prophylactic antithrombotic",
          "expected_effects": "Reduction in the incidence of thrombus formation from 89% in the untreated group to 53% in the 250 mg/kg group and 6% in the 750 mg/kg group",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:21:29.000000Z",
          "updated_at": "2020-09-16T01:21:29.000000Z"
      },
      {
          "id": 1589,
          "drug_id": 429,
          "indication_name": "Antithrombotic",
          "expected_effects": "Platelet aggregation is decreased in all evaluated animals receiving ticarcillin, in a dosage-dependent manner\nPlatelet aggregation is significantly decreased within 24 hours at a dose of 20.8-41.2 mg/kg/h, whereas at 10.4 mg/kg/hr, platelet aggregation inhibition becomes apparent at 48 hours\nBleeding times are prolonged at dosages above 31.25 mg/kg/hr",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:21:32.000000Z",
          "updated_at": "2020-09-16T01:21:32.000000Z"
      },
      {
          "id": 1590,
          "drug_id": 430,
          "indication_name": "Susceptible infections",
          "expected_effects": "91% and 65% bioavailability for ticarcillin and clavulanate, respectively\nPeak serum concentrations of ticarcillin (91.45 µg/mL) and clavulanate (2.80 µg/mL) occur at 30 and 15 min post-injection, respectively\nExpected to provide effective treatment for at least 34 strains of ticarcillin-resistant Enterobacteriaceae",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:34.000000Z",
          "updated_at": "2020-09-16T01:21:34.000000Z"
      },
      {
          "id": 1591,
          "drug_id": 431,
          "indication_name": "Anesthesia induction",
          "expected_effects": "Excellent muscle relaxation and analgesia by 10 minutes after injection\nHeart rate increases by 58% 10 minutes after injection and 66% (peak) by 30 minutes after injection",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:37.000000Z",
          "updated_at": "2020-09-16T01:21:37.000000Z"
      },
      {
          "id": 1592,
          "drug_id": 431,
          "indication_name": "Anesthesia induction",
          "expected_effects": "Smooth induction of anesthesia in dogs, providing a plane of anesthesia that is only light in 33% of cases (movement of head and extremities)\nStormy recovery in 17% of dogs, characterized by increased muscle tone, paddling, and curling of the tongue",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:21:39.000000Z",
          "updated_at": "2020-09-16T01:21:39.000000Z"
      },
      {
          "id": 1593,
          "drug_id": 431,
          "indication_name": "Sedation prior to euthanasia",
          "expected_effects": "Mild ataxia initially\nLateral recumbency in 50% of dogs (mean of 62 minutes to reach recumbency)\nWith acepromazine: sternal recumbency in 88% of dogs, progressing to lateral recumbency in 75% of dogs (mean of 48.6 minutes to lateral recumbency)",
          "common_combinations": "Acepromazine 2 mg/kg PO",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:21:42.000000Z",
          "updated_at": "2020-09-16T01:21:42.000000Z"
      },
      {
          "id": 1594,
          "drug_id": 431,
          "indication_name": "Sedation for brief, superficial procedure (e.g., intradermal allergen testing)",
          "expected_effects": "Effective lateral recumbency, requiring little to no restraint, for up to 15 minutes\nSternal recumbency within 30 minutes and walking within 2h\nIncrease in muscle activity and persistent dissociation from the environment during recovery",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:21:44.000000Z",
          "updated_at": "2020-09-16T01:21:44.000000Z"
      },
      {
          "id": 1595,
          "drug_id": 431,
          "indication_name": "Anesthesia induction",
          "expected_effects": "Effective sedation and lateral recumbency within 3-5 minutes\nAnesthesia lasting 70-90 minutes, with 65 minutes of surgical anesthesia\nMaintenance of blood pressure and heart rate within normal ranges\nQuality of recovery increased by inclusion of medetomidine in the protocol (with or without atipamezole reversal of medetomidine)",
          "common_combinations": "Butorphanol 0.15 mg/kg IV;With or without medetomidine 15 µg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:21:47.000000Z",
          "updated_at": "2020-09-16T01:21:47.000000Z"
      },
      {
          "id": 1596,
          "drug_id": 431,
          "indication_name": "Anesthesia for ovariohysterectomy or castration of feral cats - TKX (tiletamine-zolazepam-ketamine-xylazine) combination",
          "expected_effects": "Lateral recumbency in 4.1 minutes\nAdequate plane of anesthesia for ovariohysterectomy (without supplemental anesthetics) in 92% of cats, with the other 8% requiring a second dose of TKX at the onset of surgery based on signs of insufficient anesthetic depth\nRecovery to sternal recumbency in 72 +/- 42 minutes after reversal of xylazine with yohimbine 0.5 mg/CAT IV\nSurvival rate: ≥ 99%",
          "common_combinations": "Ketamine 20 mg/CAT, zolazepam 12.5 mg/CAT, and xylazine 5 mg/CAT, all coadministered with tiletamine IM once",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:21:49.000000Z",
          "updated_at": "2020-09-16T01:21:49.000000Z"
      },
      {
          "id": 1597,
          "drug_id": 433,
          "indication_name": "Pseudomonas respiratory tract infection",
          "expected_effects": "Drug levels appear in bronchial secretions within 5 minutes of the infusion and peak concentrations are reached 2h after infusion\nConcentrations reached in bronchial secretions surpass minimum inhibitory concentration (and should be effective against) >80% of Pseudomonas isolates",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:52.000000Z",
          "updated_at": "2020-09-16T01:21:52.000000Z"
      },
      {
          "id": 1598,
          "drug_id": 433,
          "indication_name": "E. coli fulminant septicemia (single bolus protocol)",
          "expected_effects": "Significant reduction in E. coli blood levels (including compared to lower dosage tobramycin protocols), but with a 0% 7-day survival rate",
          "common_combinations": "With or without methylprednisolone sodium succinate 30 mg/kg",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:21:54.000000Z",
          "updated_at": "2020-09-16T01:21:54.000000Z"
      },
      {
          "id": 1599,
          "drug_id": 433,
          "indication_name": "E. coli fulminant septicemia (repeated infusion protocol)",
          "expected_effects": "Significant reduction in E. coli blood levels\n7-day survival rate: 17%",
          "common_combinations": "With or without  methylprednisolone sodium succinate 30 mg/kg",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:21:56.000000Z",
          "updated_at": "2020-09-16T01:21:56.000000Z"
      },
      {
          "id": 1600,
          "drug_id": 434,
          "indication_name": "Ventricular arrhythmias caused by dilated cardiomyopathy (occult stage) in Doberman dogs",
          "expected_effects": "70% reduction in total number of premature ventricular complexes in majority (80%) of treated dogs\nVentricular tachycardia eliminated in 90% of affected dogs\nSurvival benefit unproven",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:21:59.000000Z",
          "updated_at": "2020-09-16T01:21:59.000000Z"
      },
      {
          "id": 1601,
          "drug_id": 434,
          "indication_name": "Antiarrhythmic (in early subacute post-myocardial infarction phase)",
          "expected_effects": "Median number of spontaneous premature ventricular complexes is reduced immediately from 48% to 8% - returns to 39% 15 minutes after administration",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:01.000000Z",
          "updated_at": "2020-09-16T01:22:01.000000Z"
      },
      {
          "id": 1602,
          "drug_id": 435,
          "indication_name": "Mast cell tumor (higher grade - Patnaik II or III) - after surgical resection if possible",
          "expected_effects": "43% of all dogs responded to treatment (15% complete response, 28% partial response), vs. 8% observed response with placebo",
          "common_combinations": "Surgical excision",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:22:04.000000Z",
          "updated_at": "2020-09-16T01:22:04.000000Z"
      },
      {
          "id": 1603,
          "drug_id": 435,
          "indication_name": "Mast cell tumor (higher grade - Patnaik II or III) - with hypofractionated radiation therapy",
          "expected_effects": "Overall response rate: 76% (59% with complete resolution of lesions, 17% with >30% reduction in lesion size)\nMedian progression-free time: 316 days\nMedian survival time is unknown (>374 days) because the dogs outlived the study in which they were participating",
          "common_combinations": "Radiation therapy (24 Gy divided into 3 or 4 fractions) beginning 1 week after medical therapy;Prednisone;Omeprazole;Diphenhydramine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:07.000000Z",
          "updated_at": "2020-09-16T01:22:07.000000Z"
      },
      {
          "id": 1604,
          "drug_id": 436,
          "indication_name": "Perioperative analgesia",
          "expected_effects": "Significantly less postoperative pain and lower respiratory rates in treated dogs, vs. placebo-treated controls",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:22:09.000000Z",
          "updated_at": "2020-09-16T01:22:09.000000Z"
      },
      {
          "id": 1605,
          "drug_id": 436,
          "indication_name": "Ocular inflammation",
          "expected_effects": "Significantly reduces miosis related to intraocular surgery",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:12.000000Z",
          "updated_at": "2020-09-16T01:22:12.000000Z"
      },
      {
          "id": 1606,
          "drug_id": 436,
          "indication_name": "Inflammation of subcutis",
          "expected_effects": "A single injection of 2 mg/kg or 8 mg/kg reduces inflammation of subcutis by 60% compared to placebo-treated controls in an experimental model of focal panniculitis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:22:14.000000Z",
          "updated_at": "2020-09-16T01:22:14.000000Z"
      },
      {
          "id": 1607,
          "drug_id": 436,
          "indication_name": "Perioperative analgesia - orthopedic surgery",
          "expected_effects": "Effective analgesia (comparable to meloxicam, although tolfenamic acid is significantly less palatable and requires q 12h administration vs. q 24h for meloxicam)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:22:17.000000Z",
          "updated_at": "2020-09-16T01:22:17.000000Z"
      },
      {
          "id": 1608,
          "drug_id": 437,
          "indication_name": "Coccidiosis - Isospora spp. infection",
          "expected_effects": "Fecal oocyst counts are reduced by >99.9% by 3 days after 1 dose",
          "common_combinations": "Emodepside 0.45 mg/kg PO",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:22:20.000000Z",
          "updated_at": "2020-09-16T01:22:20.000000Z"
      },
      {
          "id": 1609,
          "drug_id": 437,
          "indication_name": "Coccidiosis - Isospora spp.",
          "expected_effects": "Elimination of fecal oocysts to undetectable levels within 24h of treatment, and concurrent rapid, complete resolution of clinical signs associated with coccidiosis\nRecurrence is common (30% of kittens), beginning 9 days after treatment and persisting if not retreated",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:22.000000Z",
          "updated_at": "2020-09-16T01:22:22.000000Z"
      },
      {
          "id": 1610,
          "drug_id": 438,
          "indication_name": "Congestive heart failure",
          "expected_effects": "Equal or superior diuretic effect, compared to furosemide: similar control of signs of congestive heart failure, but heightened diuretic effect (lower urine specific gravity) and greater azotemia and electrolyte change",
          "common_combinations": "ACE inhibitor;With or without digoxin;With or without pimobendan;With or without spironolactone, as dictated by case",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:22:25.000000Z",
          "updated_at": "2020-09-16T01:22:25.000000Z"
      },
      {
          "id": 1611,
          "drug_id": 438,
          "indication_name": "Diuretic effect",
          "expected_effects": "In a pharmacokinetic study, torsemide causes a dose-dependent increase in urine flow (significant diuretic effect), an increase in urinary excretion of sodium and potassium, a decrease in renal vascular resistance, and an increase in renal blood flow",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:28.000000Z",
          "updated_at": "2020-09-16T01:22:28.000000Z"
      },
      {
          "id": 1612,
          "drug_id": 438,
          "indication_name": "Pressure overload cardiac hypertrophy",
          "expected_effects": "The diuretic effect of torsemide peaks 4h after administration and persists for 12h (vs. 2-3h and 6h, respectively, for furosemide)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:22:30.000000Z",
          "updated_at": "2020-09-16T01:22:30.000000Z"
      },
      {
          "id": 1613,
          "drug_id": 439,
          "indication_name": "Analgesia - general",
          "expected_effects": "Significant increase in pain threshold 5-6h after administration\nNo other changes expected, including no adverse effects at this dosage",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:22:32.000000Z",
          "updated_at": "2020-09-16T01:22:32.000000Z"
      },
      {
          "id": 1614,
          "drug_id": 439,
          "indication_name": "Perioperative analgesia - ovariohysterectomy",
          "expected_effects": "Post-op analgesia comparable to analgesia achieved with pre-op administration of morphine",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:35.000000Z",
          "updated_at": "2020-09-16T01:22:35.000000Z"
      },
      {
          "id": 1615,
          "drug_id": 439,
          "indication_name": "Perioperative analgesia - ovariohysterectomy",
          "expected_effects": "Similar to morphine (0.2 mg/kg)-induced analgesia, sedation, SpO2, blood pH, blood gases, cardiovascular variables, glucose, catecholamine and cortisol concentrations",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:22:37.000000Z",
          "updated_at": "2020-09-16T01:22:37.000000Z"
      },
      {
          "id": 1616,
          "drug_id": 439,
          "indication_name": "Postoperative analgesia - ovariohysterectomy",
          "expected_effects": "Combination of pre-op morphine and post-op tramadol provides better post-op analgesia than either pre-op morphine or pre-op tramadol as sole therapies",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:22:39.000000Z",
          "updated_at": "2020-09-16T01:22:39.000000Z"
      },
      {
          "id": 1617,
          "drug_id": 439,
          "indication_name": "Postoperative analgesia - orthopedic surgery",
          "expected_effects": "Tramadol alone or combined with ketoprofen provides adequate post-op analgesia, and unlike tramadol, codeine, and ketoprofen monotherapies, tramadol + ketoprofen prevents an increase in blood glucose concentration during the post-op period (suggesting lower immediate post-op stress)",
          "common_combinations": "With or without ketoprofen 2 mg/kg single dose",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:22:42.000000Z",
          "updated_at": "2020-09-16T01:22:42.000000Z"
      },
      {
          "id": 1618,
          "drug_id": 439,
          "indication_name": "Analgesia - ocular",
          "expected_effects": "Associated with fewest instances of refractory ocular pain requiring additional analgesia (20% with tramadol treatment, vs. 50% with placebo control and 80% for topical treatment [nalbuphine])",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:22:44.000000Z",
          "updated_at": "2020-09-16T01:22:44.000000Z"
      },
      {
          "id": 1619,
          "drug_id": 439,
          "indication_name": "Sedation",
          "expected_effects": "No appreciable sedative effect attributable to tramadol",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:22:47.000000Z",
          "updated_at": "2020-09-16T01:22:47.000000Z"
      },
      {
          "id": 1620,
          "drug_id": 439,
          "indication_name": "Analgesia - general",
          "expected_effects": "Significant analgesia at 2, 3, and 4 mg/kg dosages compared to placebo\n4 mg/kg administered q 6h can be expected to maintain analgesia close to the maximum effect of tramadol\nMany/most treated cats show evidence suggesting euphoria (playfulness, kneading, affectionate behavior) ",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:22:49.000000Z",
          "updated_at": "2020-09-16T01:22:49.000000Z"
      },
      {
          "id": 1621,
          "drug_id": 439,
          "indication_name": "Perioperative analgesia - ovariohysterectomy",
          "expected_effects": "Significant analgesia (no additional analgesia necessary) when coadministered with a nonsteroidal anti-inflammatory (e.g., vedaprofen), vs. monotherapy with either tramadol or NSAID, or placebo-treated controls",
          "common_combinations": "With or without vedaprofen 0.5 mg/kg PO 1h pre-op, single dose",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:22:52.000000Z",
          "updated_at": "2020-09-16T01:22:52.000000Z"
      },
      {
          "id": 1622,
          "drug_id": 439,
          "indication_name": "Perioperative analgesia - castration",
          "expected_effects": "Intra-op analgesic effect as evidenced by lower minimum alveolar concentration of inhalant anesthetic, and post-op analgesic effect as evidenced by no need for additional analgesia during recovery",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T01:22:54.000000Z",
          "updated_at": "2020-09-16T01:22:54.000000Z"
      },
      {
          "id": 1623,
          "drug_id": 440,
          "indication_name": "Inhibition of thrombolysis",
          "expected_effects": "85% reduction of circulating D-dimer concentrations from thrombi (suggesting maintenance of organized thrombus) for >24 h after 1 injection\nSubsequent lysis indicates the need for repeated dosing to maintain organized thrombus (vs. plasminogen activator inhibitor-1, which maintains thrombus organization and thrombus growth for 1 week after 1 dose)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:22:57.000000Z",
          "updated_at": "2020-09-16T01:22:57.000000Z"
      },
      {
          "id": 1624,
          "drug_id": 440,
          "indication_name": "Hemorrhage from liver rupture (amyloidosis)",
          "expected_effects": "Rapid clinical improvement in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:22:59.000000Z",
          "updated_at": "2020-09-16T01:22:59.000000Z"
      },
      {
          "id": 1625,
          "drug_id": 441,
          "indication_name": "Local injection to decrease fibrosis (e.g., restenosis) or lesion inflammation (e.g., acral lick granuloma)",
          "expected_effects": "Substantial clinical improvement, including endoscopic improvement and reduced regurgitation severity, in a reported case of esophageal stricture",
          "common_combinations": "Prednisone 1 mg/kg PO q 24h intermittently in 1 case of esophageal stricture post-dilation",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:23:02.000000Z",
          "updated_at": "2020-09-16T01:23:02.000000Z"
      },
      {
          "id": 1626,
          "drug_id": 441,
          "indication_name": "Joint inflammation (experimental)",
          "expected_effects": "Short-term benefit (significantly decreased inflammation) but long-term impact unknown",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:23:04.000000Z",
          "updated_at": "2020-09-16T01:23:04.000000Z"
      },
      {
          "id": 1627,
          "drug_id": 441,
          "indication_name": "Pruritic skin disease",
          "expected_effects": "Pruritus well-controlled in 44% of cats after 1 week, in 90% of cats after 2 weeks\nPruritus control maintained with q 48h treatment in 88% of cats for 6 weeks or longer",
          "common_combinations": "Treatment of inciting cause of pruritus",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:23:06.000000Z",
          "updated_at": "2020-09-16T01:23:06.000000Z"
      },
      {
          "id": 1628,
          "drug_id": 441,
          "indication_name": "Pemphigus foliaceus",
          "expected_effects": "Remission expected in majority of treated cats (>90% in one case series), with fewer side-effects, when compared to prednisone or prednisone + chlorambucil",
          "common_combinations": "Prednisolone and/or chlorambucil",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:23:09.000000Z",
          "updated_at": "2020-09-16T01:23:09.000000Z"
      },
      {
          "id": 1629,
          "drug_id": 442,
          "indication_name": "Hyperadrenocorticism (pituitary-dependent) - standard protocol",
          "expected_effects": "Polyuria/polydipsia completely resolves in 70% of dogs, skin lesions resolve in 62% of dogs, significant reduction in ACTH concentrations occur after a mean of 12 days of treatment\nOverall, mean survival time is 549 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:23:11.000000Z",
          "updated_at": "2020-09-16T01:23:11.000000Z"
      },
      {
          "id": 1630,
          "drug_id": 442,
          "indication_name": "Hyperadrenocorticism (pituitary-dependent) - standard protocol",
          "expected_effects": "Polyuria/polydipsia completely resolves in 70% of dogs, skin lesions resolve in 62% of dogs, significant reduction in ACTH concentrations occur after a mean of 12 days of treatment\nOverall, mean survival time is 549 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:23:13.000000Z",
          "updated_at": "2020-09-16T01:23:13.000000Z"
      },
      {
          "id": 1631,
          "drug_id": 442,
          "indication_name": "Hyperadrenocorticism (pituitary-dependent) - standard protocol",
          "expected_effects": "Polyuria/polydipsia completely resolves in 70% of dogs, skin lesions resolve in 62% of dogs, significant reduction in ACTH concentrations occur after a mean of 12 days of treatment\nOverall, mean survival time is 549 days",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:23:16.000000Z",
          "updated_at": "2020-09-16T01:23:16.000000Z"
      },
      {
          "id": 1632,
          "drug_id": 442,
          "indication_name": "Hyperadrenocorticism (pituitary-dependent) - low dosage protocol",
          "expected_effects": "Favorable effect on clinical signs reported at 61-77% of visits after dosage titration (initially 40%) in dogs with pituitary-dependent hyperadrenocorticism\nFavorable effect in >90% of dogs with an adrenocortical tumor, in preparation for surgical removal of the tumor",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:23:18.000000Z",
          "updated_at": "2020-09-16T01:23:18.000000Z"
      },
      {
          "id": 1633,
          "drug_id": 442,
          "indication_name": "Alopecia X",
          "expected_effects": "Complete hair re-growth in 85-100% of patients within 4-8 weeks",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:23:20.000000Z",
          "updated_at": "2020-09-16T01:23:20.000000Z"
      },
      {
          "id": 1634,
          "drug_id": 442,
          "indication_name": "Hyperadrenocorticism",
          "expected_effects": "Treatment improves clinical signs (typically within 1-2 weeks) and endocrine test results in all treated cats, with survival ranging from 6 days to 20 months (median: 6 months)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:23:23.000000Z",
          "updated_at": "2020-09-16T01:23:23.000000Z"
      },
      {
          "id": 1635,
          "drug_id": 443,
          "indication_name": "Chronic/recurrent diarrhea",
          "expected_effects": "85% of treated dogs have normal fecal consistency after 7 days vs. 29% of dogs receiving placebo",
          "common_combinations": "Fenbendazole 50 mg/kg PO q 24h for 3 days",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:23:25.000000Z",
          "updated_at": "2020-09-16T01:23:25.000000Z"
      },
      {
          "id": 1636,
          "drug_id": 443,
          "indication_name": "Modification of intestinal flora",
          "expected_effects": "Progressive decrease in mean bacterial diversity with treatment, but changes are highly variable between individuals\nEnterococcus-like organisms increase significantly during tylosin administration, without producing overtly apparent clinical effects",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:23:27.000000Z",
          "updated_at": "2020-09-16T01:23:27.000000Z"
      },
      {
          "id": 1637,
          "drug_id": 443,
          "indication_name": "Superficial pyoderma",
          "expected_effects": "73% of dogs show complete remission within 3 weeks of treatment, and a further 7% respond after an additional 2 weeks",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:23:30.000000Z",
          "updated_at": "2020-09-16T01:23:30.000000Z"
      },
      {
          "id": 1638,
          "drug_id": 443,
          "indication_name": "Cryptosporidiosis",
          "expected_effects": "Stools are normal within 7 days of initiating therapy, and all fecal samples assessed for oocysts during and 6 months post-therapy are negative\nResolution of lymphocytic duodenitis after treatment, and clinically normal 2 years post-treatment in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:23:32.000000Z",
          "updated_at": "2020-09-16T01:23:32.000000Z"
      },
      {
          "id": 1639,
          "drug_id": 444,
          "indication_name": "Chronic idiopathic hepatitis",
          "expected_effects": "Overall median survival: 374 days (with ursodeoxycholic acid as one component of multidrug treatment)",
          "common_combinations": "Immunosuppressants (azathioprine, prednisone);GI protectant (famotidine);Antibacterials;Hepatoprotectant (s-adenosylmethionine);Antiencephalopathic treatments",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:23:35.000000Z",
          "updated_at": "2020-09-16T01:23:35.000000Z"
      },
      {
          "id": 1640,
          "drug_id": 444,
          "indication_name": "Gallbladder mucocele (nonobstructive)",
          "expected_effects": "Partial, then complete, resolution of mucocele at 1 and 2 month recheck abdominal ultrasound exams, respectively, and no recurrence at 4 months, in 1 case report",
          "common_combinations": "S-adenosylmethionine;Antibacterials;Omega-3 fatty acids;Famotidine;Levothyroxine;Fenbendazole;Hypoallergenic diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:23:37.000000Z",
          "updated_at": "2020-09-16T01:23:37.000000Z"
      },
      {
          "id": 1641,
          "drug_id": 444,
          "indication_name": "Hepatic copper accumulation",
          "expected_effects": "Marked clinical improvement noted with multidrug therapy (including ursodeoxycholic acid) and survival without overt clinical signs for >2 years in 1 case report",
          "common_combinations": "Amoxicillin-clavulanate;Lactulose;Colchicine;Zinc supplementation;Dietary management",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:23:39.000000Z",
          "updated_at": "2020-09-16T01:23:39.000000Z"
      },
      {
          "id": 1642,
          "drug_id": 444,
          "indication_name": "Cholangiohepatitis complex",
          "expected_effects": "Significantly shorter survival times with ursodeoxycholic acid treatment compared to prednisolone treatment (suggesting both should be used together, as is common practice, rather than individually)",
          "common_combinations": "With or without prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:23:42.000000Z",
          "updated_at": "2020-09-16T01:23:42.000000Z"
      },
      {
          "id": 1643,
          "drug_id": 444,
          "indication_name": "Gallbladder mucocele (nonobstructive)",
          "expected_effects": "Improvement after initiation of treatment (started as part of post-operative medication and continued thereafter) and still alive and well at follow up 7 months post-op in 1 case report",
          "common_combinations": "Cholecystectomy;Antibacterials;Analgesics;Hypoallergenic diet",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:23:45.000000Z",
          "updated_at": "2020-09-16T01:23:45.000000Z"
      },
      {
          "id": 1644,
          "drug_id": 444,
          "indication_name": "Short bowel syndrome",
          "expected_effects": "Intestinal crypt depth is significantly increased (1.3 times that of controls) for treated cats, leading to an improvement in diarrhea, reduction in frequency of defecation, and improvement in fecal consistency",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:23:47.000000Z",
          "updated_at": "2020-09-16T01:23:47.000000Z"
      },
      {
          "id": 1645,
          "drug_id": 446,
          "indication_name": "Methicillin-resistant ocular infection",
          "expected_effects": "Corneal ulcer, discharge and anemia resolve with treatment in 1 case report",
          "common_combinations": "Topical vancomycin (0.5% q 6h) also administered in 1 case report",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:23:49.000000Z",
          "updated_at": "2020-09-16T01:23:49.000000Z"
      },
      {
          "id": 1646,
          "drug_id": 446,
          "indication_name": "Enterococcus faecium cholangiohepatitis",
          "expected_effects": "Palliation (resolution of clinical signs, despite persistence of low-grade infection, after 15 months of treatment) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:23:52.000000Z",
          "updated_at": "2020-09-16T01:23:52.000000Z"
      },
      {
          "id": 1647,
          "drug_id": 446,
          "indication_name": "Ascending biliary infection",
          "expected_effects": "Elimination of fever within 12h, and continued clinical improvement for the following 7 days, in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:23:54.000000Z",
          "updated_at": "2020-09-16T01:23:54.000000Z"
      },
      {
          "id": 1648,
          "drug_id": 447,
          "indication_name": "Cardiopulmonary arrest",
          "expected_effects": "Overall rate of return to spontaneous circulation: 60% (no difference between epinephrine vs. vasopressin)\nOverall survival rate to discharge: 1.7%",
          "common_combinations": "With or without atropine;Defibrillation",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:23:57.000000Z",
          "updated_at": "2020-09-16T01:23:57.000000Z"
      },
      {
          "id": 1649,
          "drug_id": 447,
          "indication_name": "Hemorrhagic shock",
          "expected_effects": "Increase in diastolic arterial pressure from 45 to 91 mmHg within 5 minutes\nNo increase in systolic arterial pressure\nEffects last for >1h",
          "common_combinations": "Rapid crystalloid resuscitation",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:24:00.000000Z",
          "updated_at": "2020-09-16T01:24:00.000000Z"
      },
      {
          "id": 1650,
          "drug_id": 447,
          "indication_name": "Severe systemic hypotension due to sepsis (septic shock)",
          "expected_effects": "3-fold greater likelihood of survival with vasopressin infusion during severe sepsis (compared to norepinephrine, which provides 2-fold, and epinephrine, which confers a worse likelihood of survival than placebo treatment [i.e., harm])",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:24:02.000000Z",
          "updated_at": "2020-09-16T01:24:02.000000Z"
      },
      {
          "id": 1651,
          "drug_id": 448,
          "indication_name": "Supraventricular tachycardia",
          "expected_effects": "86% of dogs convert to sinus rhythm (36% with 1 dose, 36% with 2 doses, and 14% with 3 doses)\n1 reported instance of persistence of arrhythmia during treatment (0.15 mg/kg total in 5-6 minutes), then onset of severe hypotension, prompting termination of treatment without having converted the arrhythmia to sinus rhythm",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:24:05.000000Z",
          "updated_at": "2020-09-16T01:24:05.000000Z"
      },
      {
          "id": 1652,
          "drug_id": 448,
          "indication_name": "Reversal of acute theophylline toxicosis",
          "expected_effects": "Prevents theophylline-induced hypotension, arrhythmias and sudden death (all dogs receiving theophylline overdose without verapamil die as a result of the overdose, whereas all verapamil-treated dogs survive)",
          "common_combinations": "Trandolapril 0.05 mg/kg IV",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:24:07.000000Z",
          "updated_at": "2020-09-16T01:24:07.000000Z"
      },
      {
          "id": 1653,
          "drug_id": 448,
          "indication_name": "Epilepsy as add-on treatment",
          "expected_effects": "All dogs fail to responders to therapy, with verapamil-induced exacerbation strongly suspected (46% of dogs removed from 1 study due to increased seizure frequency or severity)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:24:09.000000Z",
          "updated_at": "2020-09-16T01:24:09.000000Z"
      },
      {
          "id": 1654,
          "drug_id": 448,
          "indication_name": "Hypertrophic cardiomyopathy",
          "expected_effects": "50% survival rate for cats receiving verapamil, vs. 94% survival rate for those receiving diltiazem",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:24:12.000000Z",
          "updated_at": "2020-09-16T01:24:12.000000Z"
      },
      {
          "id": 1655,
          "drug_id": 449,
          "indication_name": "Mast cell tumor",
          "expected_effects": "≥50%, but <100%, reduction in the sum of all tumor volumes for a median of 77 days (range: 48-229 days) in 12% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:24:15.000000Z",
          "updated_at": "2020-09-16T01:24:15.000000Z"
      },
      {
          "id": 1656,
          "drug_id": 449,
          "indication_name": "Mast cell tumor",
          "expected_effects": "≥50%, but <100%, reduction in the sum of all tumor volumes for a median of 28 days (range: 28-78 days) in 23% of dogs\nComplete clinical resolution for 63 days in 1 dog",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:24:17.000000Z",
          "updated_at": "2020-09-16T01:24:17.000000Z"
      },
      {
          "id": 1657,
          "drug_id": 449,
          "indication_name": "Lymphoma (resistant/relapsing)",
          "expected_effects": "Remission (lasting 28-41 days) in 17% of CHOP-resistant lymphoma cases",
          "common_combinations": "Prophylactic antibacterials as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:24:20.000000Z",
          "updated_at": "2020-09-16T01:24:20.000000Z"
      },
      {
          "id": 1658,
          "drug_id": 449,
          "indication_name": "Transitional cell carcinoma of the urinary bladder",
          "expected_effects": "≥50% decrease in tumor volume and <50% change in tumor volume in 36% and 50% of dogs, respectively\nProgression-free interval: median 122 days (range: 28-399 days)\nMedian survival time: 147 days (range: 28-476)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:24:22.000000Z",
          "updated_at": "2020-09-16T01:24:22.000000Z"
      },
      {
          "id": 1659,
          "drug_id": 450,
          "indication_name": "Lymphoma - modified UWM protocol",
          "expected_effects": "Complete and partial remission in 92% and 2% of dogs, respectively\n>99% second remission rate in cases of relapse\nMedian disease-free interval and survival time of 282 and 397 days, respectively\nComparable results to the longer protocol that includes a maintenance phase",
          "common_combinations": "L-asparaginase (400 IU/kg SC, week 1);Cyclophosphamide (250 mg/m² IV, week 2, 7, 13, and 21);Doxorubicin (30 mg/m² IV, week 4, 9, 17, and 25);Prednisone (2 mg/kg PO q 24h for 7 days, then 1.5 mg/kg PO q 24h for 7 days, then 1 mg/kg PO q 24h for 7 days, then 0.5 mg/kg PO q 24h for 7 days, then stop)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:24:25.000000Z",
          "updated_at": "2020-09-16T01:24:25.000000Z"
      },
      {
          "id": 1660,
          "drug_id": 450,
          "indication_name": "Lymphoma - CHOP protocol",
          "expected_effects": "Median remission duration: 289 days (range: 150-1457 days)\n78% second remission rate\nMedian second remission duration: 159 days (range: 121-212 days)",
          "common_combinations": "L-asparaginase (10000 U/m² SC, week 1);Cyclophosphamide (200-250 mg/m² PO/IV, week 2, 6, 12, and 20);Doxorubicin (30 mg/m² IV, week 4, 8, 16, and 24);Prednisone (30 mg/m² PO q 24h for 7 days, then 20 mg/m² PO q 24h for 7 days, then 10 mg/m² PO q 24h for 7 days, then stop)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:24:27.000000Z",
          "updated_at": "2020-09-16T01:24:27.000000Z"
      },
      {
          "id": 1661,
          "drug_id": 450,
          "indication_name": "Transmissible venereal tumor",
          "expected_effects": "50% remission rate after 3 and 7 weeks in cold/dry and hot/rainy months, respectively\n>90% remission rate after 5 and 10 weeks in cold/dry and hot/rainy months, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:24:29.000000Z",
          "updated_at": "2020-09-16T01:24:29.000000Z"
      },
      {
          "id": 1662,
          "drug_id": 450,
          "indication_name": "Immune-mediated thrombocytopenia",
          "expected_effects": "Platelet count ≥40,000/µL in an average of 4.9 ± 1.1 days, compared to 6.8 ± 4.5 days without vincristine\nHospitalization for an average of 5.4 ± 0.3 days, compared to 7.3 ± 0.5 days without vincristine",
          "common_combinations": "Prednisone 1.5-2 mg/kg PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:24:32.000000Z",
          "updated_at": "2020-09-16T01:24:32.000000Z"
      },
      {
          "id": 1663,
          "drug_id": 450,
          "indication_name": "Lymphoma - modified UWM protocol",
          "expected_effects": "Complete and partial (decrease in size of measurable tumors by > 50% but < 100%) remission in 47% and 37% of cats, respectively\nAverage remission duration of 156 days - longer in cats with complete remission (654 days), compared to partial remission (114 days)\nMedian survival time of 210 days - longer in cats with complete remission (654 days) compared to partial remission (122 days)",
          "common_combinations": "L-asparaginase (400 IU/kg SC, week 1);Cyclophosphamide (200 mg/m² IV, week 2 and 7);Doxorubicin (25 mg/m² IV over 20 min, week 4, 9, and 25), chlorambucil (1.4 mg/kg, PO, week 13 and 21);Methotrexate (0.5-0.8 mg/kg IV, week 17);Prednisolone (2 mg/kg PO q 24h for 14 days, then 1 mg/kg PO q 24h for 7 days, then 1 mg/kg PO q 48h until end of treatment)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:24:35.000000Z",
          "updated_at": "2020-09-16T01:24:35.000000Z"
      },
      {
          "id": 1664,
          "drug_id": 450,
          "indication_name": "Lymphoma - COP protocol",
          "expected_effects": "Complete remission in 75% of cats\nOverall 1- and 2-year survival rates of 49% and 40%, respectively (median: 266 days)\n1- and 2-year disease free rates of 51% and 49%, respectively (based on cats with complete remission)",
          "common_combinations": "Cyclophosphamide (300 mg/m² PO, week 1 and 4, then q 3 weeks during remission);Prednisolone (50 mg/m² PO q 24h)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:24:38.000000Z",
          "updated_at": "2020-09-16T01:24:38.000000Z"
      },
      {
          "id": 1665,
          "drug_id": 450,
          "indication_name": "Immune-mediated thrombocytopenia",
          "expected_effects": "Insignificant increase in platelet count",
          "common_combinations": "Dexamethasone sodium phosphate 0.3 mg/kg IV q 12h;Doxycycline 5 mg/kg q 12h;Packed red blood cell transfusions",
          "is_contraindicated": 1,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:24:40.000000Z",
          "updated_at": "2020-09-16T01:24:40.000000Z"
      },
      {
          "id": 1666,
          "drug_id": 451,
          "indication_name": "Vitamin E/selenium deficiency",
          "expected_effects": "Plasma vitamin E concentration within normal range (or > 5 µg/mL) in 88% of dogs after 12h\nPeak vitamin E level in 3-24h",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:24:43.000000Z",
          "updated_at": "2020-09-16T01:24:43.000000Z"
      },
      {
          "id": 1667,
          "drug_id": 451,
          "indication_name": "Adjunctive therapy for sarcoptic mange",
          "expected_effects": "Significantly greater and faster clinical improvement with vitamin E added to treatment\nMarked improvement in lesions after 14 days, with full resolution of lesions by day 28 post-treatment\n14-day and 28-day post-treatment cure rates of 64% and 100%, respectively",
          "common_combinations": "Selenium (directly combined);1% ivermectin (0.2 mg/kg SC)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:24:45.000000Z",
          "updated_at": "2020-09-16T01:24:45.000000Z"
      },
      {
          "id": 1668,
          "drug_id": 451,
          "indication_name": "Prophylaxis/protection from nephrotoxicosis (gentamicin-induced)",
          "expected_effects": "Without silymarin: 36% and 33% decrease in mean serum creatinine and mean serum malondialdehyde (MDA), respectively (at or slightly below healthy baseline value)\nWith silymarin: 46% decrease in mean serum MDA",
          "common_combinations": "With or without silymarin 20 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:24:48.000000Z",
          "updated_at": "2020-09-16T01:24:48.000000Z"
      },
      {
          "id": 1669,
          "drug_id": 451,
          "indication_name": "Panniculitis/steatitis",
          "expected_effects": "Substantial glucocorticoid-sparing effect within 3 weeks, with 50-70% decrease in prednisolone dosage\nResolution of clinical signs within 3 weeks on maintained dosage of 200 IU q 12h, without prednisolone, in 1 reported case",
          "common_combinations": "Prednisolone",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:24:50.000000Z",
          "updated_at": "2020-09-16T01:24:50.000000Z"
      },
      {
          "id": 1670,
          "drug_id": 451,
          "indication_name": "Improved memory in aged dogs",
          "expected_effects": "Average 8% increase from baseline in cognitive performance accuracy, lasting up to 70 days\nAverage 3% increase in cognitive performance accuracy from a placebo diet, which itself provides a 2% increase from baseline",
          "common_combinations": "Each capsule contains phosphatidylserine (25 mg), Gingko biloba extract titrated in gingkosides (50 mg, 24%), and pyridoxine HCl (vitamin B6, 20.5 mg)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:24:53.000000Z",
          "updated_at": "2020-09-16T01:24:53.000000Z"
      },
      {
          "id": 1671,
          "drug_id": 451,
          "indication_name": "Panniculitis/steatitis",
          "expected_effects": "Complete resolution in 90% of cats",
          "common_combinations": "Corticosteroid therapy;Dietary changes",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:24:55.000000Z",
          "updated_at": "2020-09-16T01:24:55.000000Z"
      },
      {
          "id": 1672,
          "drug_id": 452,
          "indication_name": "Brodifacoum toxicosis",
          "expected_effects": "Normal or stable one-stage prothrombin time, activated partial thromboplastin time, activated coagulation time, complete blood count, thrombocyte count, and serum chemistry values within 48h of treatment (all normal by end of treatment)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:24:57.000000Z",
          "updated_at": "2020-09-16T01:24:57.000000Z"
      },
      {
          "id": 1673,
          "drug_id": 452,
          "indication_name": "Anticoagulant rodenticide toxicosis",
          "expected_effects": "Maintenance of normal range coagulation times during treatment\nTrivial increase in one-stage prothrombin time to 9-14 sec (normal 6-8 sec), for up to 6 days post-treatment, before returning to reference range times",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:25:00.000000Z",
          "updated_at": "2020-09-16T01:25:00.000000Z"
      },
      {
          "id": 1674,
          "drug_id": 452,
          "indication_name": "Anticoagulant rodenticide toxicosis",
          "expected_effects": "Normal coagulation time within 1-3 days\nAverage of 50% and 67% reduction in prothrombin time and activated partial thromboplastin time, respectively, after 2 days (both in normal range within 4 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:25:03.000000Z",
          "updated_at": "2020-09-16T01:25:03.000000Z"
      },
      {
          "id": 1675,
          "drug_id": 452,
          "indication_name": "Dietary deficiency",
          "expected_effects": "Average of 63% decrease in clotting time (returns to normal range within 3-6 days)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:25:05.000000Z",
          "updated_at": "2020-09-16T01:25:05.000000Z"
      },
      {
          "id": 1676,
          "drug_id": 452,
          "indication_name": "Congenital deficiency",
          "expected_effects": "Normalization of clotting factor concentrations\nProlonged coagulation times within 2 weeks of cessation of lower dosage therapy (based on 2 cases)",
          "common_combinations": "Blood transfusion if excessive blood loss",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:25:07.000000Z",
          "updated_at": "2020-09-16T01:25:07.000000Z"
      },
      {
          "id": 1677,
          "drug_id": 453,
          "indication_name": "Intracranial phaeohyphomycotic fungal granuloma",
          "expected_effects": "Complete resolution of the granuloma after 4 months (8 months after surgery) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:10.000000Z",
          "updated_at": "2020-09-16T01:25:10.000000Z"
      },
      {
          "id": 1678,
          "drug_id": 453,
          "indication_name": "Aspergillus flavus keratomycosis",
          "expected_effects": "Visual and comfortable eye after 29 days, with mild edema and fibrosis\nNegative fungal culture within 29 days, all in 1 case report",
          "common_combinations": "Ofloxacin ophthalmic solution (0.3%);Atropine sulfate ophthalmic ointment (1%);L-lysine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:25:12.000000Z",
          "updated_at": "2020-09-16T01:25:12.000000Z"
      },
      {
          "id": 1679,
          "drug_id": 454,
          "indication_name": "Decrease risk of thromboembolism",
          "expected_effects": "Average prothrombin time of 17.26 ± 4.21 sec, compared to baseline of 8.76 ±0.34 sec",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:15.000000Z",
          "updated_at": "2020-09-16T01:25:15.000000Z"
      },
      {
          "id": 1680,
          "drug_id": 454,
          "indication_name": "Decrease risk of thromboembolism",
          "expected_effects": "Median survival of 11 months after aortic thromboembolism, vs. median survival of 7.5 months with aspirin therapy, in 1 retrospective study",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:25:18.000000Z",
          "updated_at": "2020-09-16T01:25:18.000000Z"
      },
      {
          "id": 1681,
          "drug_id": 455,
          "indication_name": "Sedation - for electroencephalogram",
          "expected_effects": "Effective level of sedation and general muscle relaxation\nNoise- and artifact-free recording for at least 30 minutes",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:20.000000Z",
          "updated_at": "2020-09-16T01:25:20.000000Z"
      },
      {
          "id": 1682,
          "drug_id": 455,
          "indication_name": "Premedicant - for general anesthesia and ovariohysterectomy",
          "expected_effects": "Greater sedation with xylazine than with nalbuphine\nXylazine-nalbuphine combination superior to either drug alone for immobilization",
          "common_combinations": "With or without nalbuphine",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:25:23.000000Z",
          "updated_at": "2020-09-16T01:25:23.000000Z"
      },
      {
          "id": 1683,
          "drug_id": 455,
          "indication_name": "Analgesia - epidural",
          "expected_effects": "Effective analgesia for up to 3 and >4 hours when administered IM or epidurally, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:25:25.000000Z",
          "updated_at": "2020-09-16T01:25:25.000000Z"
      },
      {
          "id": 1684,
          "drug_id": 455,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Mean recumbency, arousal, and walking times of 2.5, 32, and 49.5 min, respectively",
          "common_combinations": "Midazolam 1 mg/kg IM, 5 minutes after xylazine",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:25:28.000000Z",
          "updated_at": "2020-09-16T01:25:28.000000Z"
      },
      {
          "id": 1685,
          "drug_id": 455,
          "indication_name": "Induction of vomiting",
          "expected_effects": "Average of 1.67 ± 1.21 emetic events within 2 hours",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:25:30.000000Z",
          "updated_at": "2020-09-16T01:25:30.000000Z"
      },
      {
          "id": 1686,
          "drug_id": 455,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Recumbency within 5 minutes for >99% of cats\nEffective anesthesia for 60 and 100 minutes at a dosage of 2.2 and 4.4 mg/kg, respectively",
          "common_combinations": "Ketamine 6.6 mg/kg",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:25:33.000000Z",
          "updated_at": "2020-09-16T01:25:33.000000Z"
      },
      {
          "id": 1687,
          "drug_id": 455,
          "indication_name": "Urethral obstruction",
          "expected_effects": "Average 60% decrease in urethral pressure 4-7 cm from the tip of the penis\nNo effect on urethral pressure in areas of pure smooth muscle or pure striated muscle (i.e., where obstructions occur)",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:25:35.000000Z",
          "updated_at": "2020-09-16T01:25:35.000000Z"
      },
      {
          "id": 1688,
          "drug_id": 456,
          "indication_name": "Reversal of midazolam, xylazine, and butorphanol",
          "expected_effects": "Reversal of all hemodynamic effects within 1 minute",
          "common_combinations": "Flumazenil 0.25 mg/kg IV, once, to reverse benzodiazepine (midazolam)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:37.000000Z",
          "updated_at": "2020-09-16T01:25:37.000000Z"
      },
      {
          "id": 1689,
          "drug_id": 456,
          "indication_name": "Amitraz intoxication",
          "expected_effects": "Complete reversal of all amitraz-induced effects (e.g., bradycardia, hypotension, sedation, loss of reflexes, bradypnea, and mydriasis) but with more tachycardia and tachypnea than equivalent reversal using atipamezole",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:25:40.000000Z",
          "updated_at": "2020-09-16T01:25:40.000000Z"
      },
      {
          "id": 1690,
          "drug_id": 456,
          "indication_name": "Reversal of xylazine-ketamine anesthesia",
          "expected_effects": "Consciousness within 3 minutes, and walking 1-2 minutes later\nComplete reversal of bradycardia and respiratory depression",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:25:44.000000Z",
          "updated_at": "2020-09-16T01:25:44.000000Z"
      },
      {
          "id": 1691,
          "drug_id": 457,
          "indication_name": "Endotoxemia causing hypotension",
          "expected_effects": "Minor benefit: improvement in hypotension (but not cardiac parameters or body temperature) during endotoxemia in 1 experimental study",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:46.000000Z",
          "updated_at": "2020-09-16T01:25:46.000000Z"
      },
      {
          "id": 1692,
          "drug_id": 457,
          "indication_name": "Asthma (model)",
          "expected_effects": "No significant difference in airway inflammation or airway hyperresponsiveness when comparing zafirlukast-treated asthmatic cats to placebo-treated controls",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:25:48.000000Z",
          "updated_at": "2020-09-16T01:25:48.000000Z"
      },
      {
          "id": 1693,
          "drug_id": 458,
          "indication_name": "Feline immunodeficiency virus",
          "expected_effects": "Good clinical condition in > 99% of cats after treatment, compared to good clinical condition in 20% of untreated cats\nAverage of 75% decrease in viral load, compared to a > 50% increase in untreated cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:51.000000Z",
          "updated_at": "2020-09-16T01:25:51.000000Z"
      },
      {
          "id": 1694,
          "drug_id": 459,
          "indication_name": "Zinc-responsive dermatosis",
          "expected_effects": "Partial improvement in cutaneous signs, especially after IV doses",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:53.000000Z",
          "updated_at": "2020-09-16T01:25:53.000000Z"
      },
      {
          "id": 1695,
          "drug_id": 460,
          "indication_name": "Zinc-responsive dermatosis",
          "expected_effects": "Complete resolution of skin lesions in 44% of dogs, and significant (>50%) improvement in 48% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:55.000000Z",
          "updated_at": "2020-09-16T01:25:55.000000Z"
      },
      {
          "id": 1696,
          "drug_id": 461,
          "indication_name": "Zinc-responsive dermatosis",
          "expected_effects": "Complete resolution of skin lesions in 28% of dogs, and significant (>50%) improvement in 62% of dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:25:58.000000Z",
          "updated_at": "2020-09-16T01:25:58.000000Z"
      },
      {
          "id": 1697,
          "drug_id": 462,
          "indication_name": "Refractory idiopathic epilepsy",
          "expected_effects": "Reduction in seizure frequency (mean of 81%) in 58% of dogs\nReduction of concurrently administered anticonvulsants in 75% of dogs",
          "common_combinations": "Felbamate;Gabapentin;Phenobarbital;Clorazepate;Potassium bromide",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:00.000000Z",
          "updated_at": "2020-09-16T01:26:00.000000Z"
      },
      {
          "id": 1698,
          "drug_id": 463,
          "indication_name": "Squamous cell carcinoma (oral)",
          "expected_effects": "50% partial response rate, <8% complete response rate",
          "common_combinations": "Cyclosporine 5 mg/kg PO (to enhance bioavailability)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:03.000000Z",
          "updated_at": "2020-09-16T01:26:03.000000Z"
      },
      {
          "id": 1699,
          "drug_id": 463,
          "indication_name": "Malignant mammary gland tumors",
          "expected_effects": "Median survival time with surgery alone: 390 days. Median survival time with surgery and either docetaxel or doxorubicin: 231 days, with trend toward higher long-term local control and survival rate but no significant difference in recurrence-free interval, time to metastasis, or overall survival.",
          "common_combinations": "Surgical resection",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:26:05.000000Z",
          "updated_at": "2020-09-16T01:26:05.000000Z"
      },
      {
          "id": 1700,
          "drug_id": 464,
          "indication_name": "Parvoviral enteritis",
          "expected_effects": "Significantly greater survival (83% vs. 33%) in parvo puppies receiving or not receiving endotoxin antiserum, respectively",
          "common_combinations": "Supportive care including broad-spectrum antibacterial, antiemetic, analgesic, and fluid therapies as indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:08.000000Z",
          "updated_at": "2020-09-16T01:26:08.000000Z"
      },
      {
          "id": 1701,
          "drug_id": 465,
          "indication_name": "Echinococcus granulosus infection (mature: 28 days post-infection)",
          "expected_effects": "96%, 99.9% and 99.99% efficacy (worm burden reduction) with dosages of 2.5, 5 and 7.5 mg/kg, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:10.000000Z",
          "updated_at": "2020-09-16T01:26:10.000000Z"
      },
      {
          "id": 1702,
          "drug_id": 465,
          "indication_name": "Echinococcus granulosus infection (juvenile: 7 days post-infection)",
          "expected_effects": "94%, 90% and 99.8% efficacy (worm burden reduction) with dosages of 5, 7.5 and 10 mg/kg, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:26:13.000000Z",
          "updated_at": "2020-09-16T01:26:13.000000Z"
      },
      {
          "id": 1703,
          "drug_id": 465,
          "indication_name": "Echinococcus mutilocularis infection",
          "expected_effects": "Worm burden reduced by 99.6% - 99.9% within 4 days of treatment (treatment given 20 days post-infection)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:26:15.000000Z",
          "updated_at": "2020-09-16T01:26:15.000000Z"
      },
      {
          "id": 1704,
          "drug_id": 465,
          "indication_name": "Taenia pisiformis and T. Hydatigena infection",
          "expected_effects": "100% efficacy at 2.5-5 mg/kg dosages",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:26:18.000000Z",
          "updated_at": "2020-09-16T01:26:18.000000Z"
      },
      {
          "id": 1705,
          "drug_id": 465,
          "indication_name": "Dipylidium caninum infection",
          "expected_effects": "100% effective at eliminating worm burden",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:26:21.000000Z",
          "updated_at": "2020-09-16T01:26:21.000000Z"
      },
      {
          "id": 1706,
          "drug_id": 465,
          "indication_name": "Taenia taeniaeformis infection",
          "expected_effects": ">99% effective at eliminating worm burden",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:26:23.000000Z",
          "updated_at": "2020-09-16T01:26:23.000000Z"
      },
      {
          "id": 1707,
          "drug_id": 465,
          "indication_name": "Echinococcus mutilocularis infection",
          "expected_effects": "100% efficacy: worm burden eliminated completely within 4 days of treatment (treatment given 20 days post-infection)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:26:25.000000Z",
          "updated_at": "2020-09-16T01:26:25.000000Z"
      },
      {
          "id": 1708,
          "drug_id": 466,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Effective anesthetic induction, with no significant changes in cardiovascular parameters",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:28.000000Z",
          "updated_at": "2020-09-16T01:26:28.000000Z"
      },
      {
          "id": 1709,
          "drug_id": 466,
          "indication_name": "Induction and maintenance of general anesthesia",
          "expected_effects": "Consistent and complete anesthesia during 60-minute CRI, with minimal changes in hemodynamic values\n time from end of CRI to extubation = 17 +/- 9 min, sternal recumbency = 44 +/- 14 min, standing normally = 54 +/- 12 min, and walking normally = 61 +/- 11 min",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:26:30.000000Z",
          "updated_at": "2020-09-16T01:26:30.000000Z"
      },
      {
          "id": 1710,
          "drug_id": 466,
          "indication_name": "Induction of general anesthesia",
          "expected_effects": "Rapid induction of anesthesia in all cats in 1 study",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:26:33.000000Z",
          "updated_at": "2020-09-16T01:26:33.000000Z"
      },
      {
          "id": 1711,
          "drug_id": 467,
          "indication_name": "Ventricular arrhythmias (experimental)",
          "expected_effects": "Reduces the ratio of ventricular beats/total beats by 80% 5-10 minutes after administration in an experimental dog model",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:35.000000Z",
          "updated_at": "2020-09-16T01:26:35.000000Z"
      },
      {
          "id": 1712,
          "drug_id": 467,
          "indication_name": "Atrial fibrillation (experimental)",
          "expected_effects": "In an experimental dog model, converts atrial fibrillation to sinus rhythm in >83% of dogs after a mean time of 10 min and at a mean plasma concentration of 1.7 + 0.3 mg/L, with termination of atrial fibrillation always occurring during the administration of the loading dose",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:26:38.000000Z",
          "updated_at": "2020-09-16T01:26:38.000000Z"
      },
      {
          "id": 1713,
          "drug_id": 468,
          "indication_name": "Masticatory myositis (acute)",
          "expected_effects": "Resolution of myositis and associated clinical signs over 7 days in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:40.000000Z",
          "updated_at": "2020-09-16T01:26:40.000000Z"
      },
      {
          "id": 1714,
          "drug_id": 469,
          "indication_name": "Sick sinus syndrome/sinus node dysfunction",
          "expected_effects": "Improvement in frequency and severity of syncopal episodes, then gradual recurrence after 8 months, in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:43.000000Z",
          "updated_at": "2020-09-16T01:26:43.000000Z"
      },
      {
          "id": 1715,
          "drug_id": 470,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "Limited efficacy: body weight is stable after 12 weeks of treatment in 44% of cats and there are no significant improvements in owner-monitored parameters (e.g., water consumption, appetite, etc.)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:45.000000Z",
          "updated_at": "2020-09-16T01:26:45.000000Z"
      },
      {
          "id": 1716,
          "drug_id": 471,
          "indication_name": "Hyperthyroidism",
          "expected_effects": "After 4-6 weeks of treatment, 67% of cats respond (increased body weight, decreased heart rate, decreased serum T3 concentration) and 33% fail to respond. No adverse effects noted (important advantage over methimazole)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:48.000000Z",
          "updated_at": "2020-09-16T01:26:48.000000Z"
      },
      {
          "id": 1717,
          "drug_id": 471,
          "indication_name": "Cholecystography",
          "expected_effects": "In dogs, after 2nd dose: contrast enhancement of gallbladder for 1.5 - 2.5 days on plain radiographs and for up to 4 days on CT",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:26:50.000000Z",
          "updated_at": "2020-09-16T01:26:50.000000Z"
      },
      {
          "id": 1718,
          "drug_id": 472,
          "indication_name": "Giardiasis",
          "expected_effects": "Improvement in clinical signs within 15 hours of 1st dose\n decreased fecal shedding of cysts at 39 hours (absence of shedding at 54 hours)\n formed stools at 84 hours",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:53.000000Z",
          "updated_at": "2020-09-16T01:26:53.000000Z"
      },
      {
          "id": 1719,
          "drug_id": 473,
          "indication_name": "Gastroenteritis",
          "expected_effects": "Resolution of vomiting, diarrhea in 90% of treated dogs",
          "common_combinations": "bismuth subcarbonate and attapulgite (as Amforol veterinary product)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:55.000000Z",
          "updated_at": "2020-09-16T01:26:55.000000Z"
      },
      {
          "id": 1720,
          "drug_id": 474,
          "indication_name": "Gastric ulceration and erosion",
          "expected_effects": "Complete healing of gastric ulcerations and erosions occured after 9 +/- 1.2 days of treatment, which was superior to misoprostol, famotidine, or sucralfate, but inferior to seabuckthorn oil, in 1 study",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:26:58.000000Z",
          "updated_at": "2020-09-16T01:26:58.000000Z"
      },
      {
          "id": 1721,
          "drug_id": 474,
          "indication_name": "Helicobacteriosis",
          "expected_effects": "Eradication of Helicobacter from stomachs of >90% of treated dogs, lasting >60 days based on endoscopic histologic re-evaluation",
          "common_combinations": "As part of triple therapy with clarithromycin 25 mg/kg PO q 12h and amoxicillin 50 mg/kg PO q 12 h, all for 7 days",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:27:00.000000Z",
          "updated_at": "2020-09-16T01:27:00.000000Z"
      },
      {
          "id": 1722,
          "drug_id": 474,
          "indication_name": "Adjunct to antineoplastic chemotherapy",
          "expected_effects": "68% of animals treated with chemotherapy + high-dosage lansoprazole display a partial or complete response, versus only 17% of control animals treated with chemotherapy only\n difference is greater with lymphoma",
          "common_combinations": "Tumor-specific chemotehrapy protocol (e.g., modified Madison-Wisconsin for new-onset lymphoma)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:27:03.000000Z",
          "updated_at": "2020-09-16T01:27:03.000000Z"
      },
      {
          "id": 1723,
          "drug_id": 474,
          "indication_name": "Adjunct to chemotherapy",
          "expected_effects": "85.7% of treated cats show benefit, including quality of life scores",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:27:06.000000Z",
          "updated_at": "2020-09-16T01:27:06.000000Z"
      },
      {
          "id": 1724,
          "drug_id": 474,
          "indication_name": "Gastric acid suppression",
          "expected_effects": "Degree of gastric acid suppression is similar to omeprazole-treated cats\n long-lasting (30% gastric acid suppression persists 24 h after lansoprazole dose)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:27:08.000000Z",
          "updated_at": "2020-09-16T01:27:08.000000Z"
      },
      {
          "id": 1725,
          "drug_id": 475,
          "indication_name": "Parenteral nutrition",
          "expected_effects": "Meets or surpasses energy requirements: treated dogs gain weight, with lipid emulsion providing 45% of total caloric requirements",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:10.000000Z",
          "updated_at": "2020-09-16T01:27:10.000000Z"
      },
      {
          "id": 1726,
          "drug_id": 475,
          "indication_name": "Ivermectin intoxication",
          "expected_effects": "Improvement in mentation after 1 h and resolution of several neurologic abnormalities by 8 h of treatment (31 h post-exposure) in 2 case reports",
          "common_combinations": "Supportive care including IV fluids",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:27:14.000000Z",
          "updated_at": "2020-09-16T01:27:14.000000Z"
      },
      {
          "id": 1727,
          "drug_id": 475,
          "indication_name": "Moxidectin intoxication",
          "expected_effects": "Initial improvement in clinical signs within 2 h, and resolution of clinical signs within 24 h in small case series",
          "common_combinations": "Supportive care including IV fluids",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:27:16.000000Z",
          "updated_at": "2020-09-16T01:27:16.000000Z"
      },
      {
          "id": 1728,
          "drug_id": 475,
          "indication_name": "Baclofen intoxication",
          "expected_effects": "Complete resolution of clinical signs 8 h after starting infusion in 1 case report",
          "common_combinations": "Supportive care including IV fluids",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:27:19.000000Z",
          "updated_at": "2020-09-16T01:27:19.000000Z"
      },
      {
          "id": 1729,
          "drug_id": 475,
          "indication_name": "Diltiazem intoxication",
          "expected_effects": "Gradual improvement to discharge 45 h after hospital admission in 1 case report",
          "common_combinations": "High-dose insulin (1 IU/kg/h IV) and dextrose, dopamine PRN for vasopressor support, nursing care",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:27:21.000000Z",
          "updated_at": "2020-09-16T01:27:21.000000Z"
      },
      {
          "id": 1730,
          "drug_id": 475,
          "indication_name": "Bupivacaine intoxication (accidental IV)",
          "expected_effects": ">83% survival with IV lipid as part of acute treatment protocol versus <17% survival with placebo control instead of lipid",
          "common_combinations": "Cardiopulmonar cerebral resuscitation if needed",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:27:23.000000Z",
          "updated_at": "2020-09-16T01:27:23.000000Z"
      },
      {
          "id": 1731,
          "drug_id": 475,
          "indication_name": "Parenteral nutrition",
          "expected_effects": "48% overall survival for critically ill cats receiving lipid emulsion as part of TPN (mortality influenced mainly by underlying diseases)\n weight loss, hyperglycemia at 24 h post-TPN, hypoalbuminemia, and chronic kidney disease are negative prognostic indicators for survival",
          "common_combinations": "Other components of TPN (i.e., dextrose, amino acids, and crystalloid fluid)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:27:26.000000Z",
          "updated_at": "2020-09-16T01:27:26.000000Z"
      },
      {
          "id": 1732,
          "drug_id": 475,
          "indication_name": "Ivermectin intoxication",
          "expected_effects": "96 h post-ingestion of ivermectin and after 1 bolus and 2 CRIs: clinically stable cat discharged from hospital in 1 case report",
          "common_combinations": "Crystalloid fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:27:28.000000Z",
          "updated_at": "2020-09-16T01:27:28.000000Z"
      },
      {
          "id": 1733,
          "drug_id": 475,
          "indication_name": "Permethrin intoxication",
          "expected_effects": "All cats in a small case series show a subjective rapid clinical improvement following treatment, with no adverse reactions",
          "common_combinations": "Methocarbamol 30-50 mg/kg IV or PO PRN, not to exceed 330 mg/kg/day",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:27:31.000000Z",
          "updated_at": "2020-09-16T01:27:31.000000Z"
      },
      {
          "id": 1734,
          "drug_id": 475,
          "indication_name": "Lidocaine intoxication",
          "expected_effects": "Marked improvement in mentation and alertness over the course of CRI (30 minutes) in 1 case report (lidocaine: 20 mg/kg SC, single dose, with signs of toxicosis 15 minutes later)",
          "common_combinations": "Supportive care including oxygen and fluid therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T01:27:33.000000Z",
          "updated_at": "2020-09-16T01:27:33.000000Z"
      },
      {
          "id": 1735,
          "drug_id": 476,
          "indication_name": "Antiemetic",
          "expected_effects": "3-fold reduction in retching/vomiting induced by apomorphine in 1 experimental study",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:35.000000Z",
          "updated_at": "2020-09-16T01:27:35.000000Z"
      },
      {
          "id": 1736,
          "drug_id": 476,
          "indication_name": "Vestibular disease",
          "expected_effects": "No adverse reaction reported in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:27:38.000000Z",
          "updated_at": "2020-09-16T01:27:38.000000Z"
      },
      {
          "id": 1737,
          "drug_id": 477,
          "indication_name": "Cognitive dysfunction, obsessive-compulsive disorder",
          "expected_effects": "64% of treated dogs show improvement by the second week of treatment",
          "common_combinations": "Alone or combined with fluoxetine (1-2 mg/kg PO q 24 h)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:41.000000Z",
          "updated_at": "2020-09-16T01:27:41.000000Z"
      },
      {
          "id": 1738,
          "drug_id": 478,
          "indication_name": "Pituitary-dependent hyperadrenocorticism",
          "expected_effects": "Reduction in baseline and ACTH-stimulated cortisol concentrations, improvement in clinical signs, and stabilization to allow for successful adrenalectomy in 1 case report",
          "common_combinations": "Adrenalectomy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:43.000000Z",
          "updated_at": "2020-09-16T01:27:43.000000Z"
      },
      {
          "id": 1739,
          "drug_id": 478,
          "indication_name": "Pituitary-dependent hyperadrenocorticism",
          "expected_effects": "Subjective clinical improvement and objective improvement in clinicopathologic data following treatment with metyrapone prior to successful resolution of disease with bilateral adrenalectomy",
          "common_combinations": "Adrenalectomy",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:27:46.000000Z",
          "updated_at": "2020-09-16T01:27:46.000000Z"
      },
      {
          "id": 1740,
          "drug_id": 479,
          "indication_name": "Leishmaniasis",
          "expected_effects": "Marked improvement in clinical severity score (47%) by treatment day 28 and 90% improvement by day 196\n 76% and 88% reduction at day 28 and day 196, respectively, in parasite load based on bone marrow PCR\n overall results essentially identical to meglumine antimoniate-treated control group",
          "common_combinations": "Allopurinol 10 mg/kg PO q 12h co-treatment for full duration of miltefosine therapy and for 6 months thereafter",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:48.000000Z",
          "updated_at": "2020-09-16T01:27:48.000000Z"
      },
      {
          "id": 1741,
          "drug_id": 480,
          "indication_name": "Gastrointestinal hypomotility",
          "expected_effects": "20%, 25%, and 30% increase in gastric antral motility with 0.75, 1, and 2 mg/kg dosages, respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:51.000000Z",
          "updated_at": "2020-09-16T01:27:51.000000Z"
      },
      {
          "id": 1742,
          "drug_id": 480,
          "indication_name": "Gastrointestinal hypomotility (vincristine-induced)",
          "expected_effects": "Maintains normal gastric antral motility post-vincristine (versus 40% decrease, and 30% decrease, in motility without mosapride on days 3 and 4 post-vincristine, respectively)\n 50% decrease in GI adverse events",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:27:53.000000Z",
          "updated_at": "2020-09-16T01:27:53.000000Z"
      },
      {
          "id": 1743,
          "drug_id": 480,
          "indication_name": "Gastric ulceration (corticosteroid-induced)",
          "expected_effects": "28% reduction in gastric ulcer severity, 18% decrease in gastrointestinal transit time (faster GI transit), and reduction in incidence of vomiting",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:27:56.000000Z",
          "updated_at": "2020-09-16T01:27:56.000000Z"
      },
      {
          "id": 1744,
          "drug_id": 481,
          "indication_name": "Acral lick dermatitis",
          "expected_effects": "63.6% of treated dogs respond (cessation of licking, re-epithelialization of the lick granuloma)\n relapses occur with drug discontinuation",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:27:59.000000Z",
          "updated_at": "2020-09-16T01:27:59.000000Z"
      },
      {
          "id": 1745,
          "drug_id": 481,
          "indication_name": "Opioid antagonist (e.g., remifentanil)",
          "expected_effects": "Cumulative naltrexone dose of 300 mcg/kg antagonizes dysphoria and restores normal behavior in remifentanil-treated cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:28:01.000000Z",
          "updated_at": "2020-09-16T01:28:01.000000Z"
      },
      {
          "id": 1746,
          "drug_id": 482,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Marked (67%) reduction in owner assessed pruritus after 14 days of treatment, compared to placebo\n 49% reduction in veterinarian-assessed skin lesion severity after 28 days, compared to 4% increase with placebo",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:03.000000Z",
          "updated_at": "2020-09-16T01:28:03.000000Z"
      },
      {
          "id": 1747,
          "drug_id": 483,
          "indication_name": "Urinary incontinence due to detrusor instability/detrusor hyperactivity/\"urge syndrome\"",
          "expected_effects": "Successful resolution of incontinence with oxybutynin monotherapy (used as needed) in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:06.000000Z",
          "updated_at": "2020-09-16T01:28:06.000000Z"
      },
      {
          "id": 1748,
          "drug_id": 483,
          "indication_name": "Urinary incontinence due to detrusor instability/detrusor hyperactivity/\"urge syndrome\"",
          "expected_effects": "Successful resolution of urinary incontinence within 24 hours of commencing oxybutynin in 1 case report, and recurrence upon discontinuation of treatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:28:08.000000Z",
          "updated_at": "2020-09-16T01:28:08.000000Z"
      },
      {
          "id": 1749,
          "drug_id": 484,
          "indication_name": "Neuromuscular blockade",
          "expected_effects": "Provides neuromuscular blockade suitable for ophthalmic surgery for at least 60 minutes in >83% of treated dogs. Caution: reduction of tidal volume and minute ventilation by 40% and 55%, respectively",
          "common_combinations": "Positive-pressure ventilation must be available, may be needed in some",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:11.000000Z",
          "updated_at": "2020-09-16T01:28:11.000000Z"
      },
      {
          "id": 1750,
          "drug_id": 484,
          "indication_name": "Neuromuscular blockade for positive-pressure ventilation",
          "expected_effects": "Successful neuromuscular blockade lasting at least 90 minutes, concomitant with inhalant anesthesia, to facilitate controlled ventilation without changes in the respiratory pattern",
          "common_combinations": "Inhalant anesthesia (e.g., halothane in 1 experiment)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:28:13.000000Z",
          "updated_at": "2020-09-16T01:28:13.000000Z"
      },
      {
          "id": 1751,
          "drug_id": 484,
          "indication_name": "Neuromuscular blockade for positive-pressure ventilation",
          "expected_effects": "Titration of infusion rate in this range reduces muscular twitch strength by 50%",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:28:16.000000Z",
          "updated_at": "2020-09-16T01:28:16.000000Z"
      },
      {
          "id": 1752,
          "drug_id": 484,
          "indication_name": "Ophthalmic surgery",
          "expected_effects": "Profound akinesia of the superior rectus muscle with total absence of muscular contraction for up to 120 minutes (lidocaine-pancuronium coadministration)",
          "common_combinations": "Lidocaine 10 mg total dose, retrobulbar",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:28:19.000000Z",
          "updated_at": "2020-09-16T01:28:19.000000Z"
      },
      {
          "id": 1753,
          "drug_id": 485,
          "indication_name": "Intraoperative reduction of acute systemic hypertension",
          "expected_effects": "Reduction of intraoperative hypertension during pheochromocytoma hypertension in 1 case series",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:21.000000Z",
          "updated_at": "2020-09-16T01:28:21.000000Z"
      },
      {
          "id": 1754,
          "drug_id": 486,
          "indication_name": "Reduction of fibrinolysis",
          "expected_effects": "Suppresses D-dimer release from a blood clot by 80% and effectively suppresses thrombolysis for 24 hours",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:24.000000Z",
          "updated_at": "2020-09-16T01:28:24.000000Z"
      },
      {
          "id": 1755,
          "drug_id": 487,
          "indication_name": "Babesia felis infection",
          "expected_effects": "Rapid elimination of parasitemia (parasitemia <0.1% 6-12 days after first dose), which is significantly more effective than treatment buparvaquone, rifampin, trimethoprim-sulfadiazine, enrofloxacin, or danofloxacin\n however, infection is not fully eradicated and patent state persists",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:26.000000Z",
          "updated_at": "2020-09-16T01:28:26.000000Z"
      },
      {
          "id": 1756,
          "drug_id": 488,
          "indication_name": "Corynebacterium urealyticum",
          "expected_effects": "In 1 case study, resolution of clinical signs and negative culture 7 days of treatment\n normal urinalysis and negative culture after 30 days (15 days after end of treatment), whereas infection had recurred with all other antibacterials",
          "common_combinations": "Methionine for urinary acidification",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:28.000000Z",
          "updated_at": "2020-09-16T01:28:28.000000Z"
      },
      {
          "id": 1757,
          "drug_id": 488,
          "indication_name": "Corynebacterium urealyticum",
          "expected_effects": "Negative urine culture within 10 days of initiating therapy\n no recurrence of infection within 2 months of treatment",
          "common_combinations": "Acetohydroxamic acid for urinary acidification",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:28:31.000000Z",
          "updated_at": "2020-09-16T01:28:31.000000Z"
      },
      {
          "id": 1758,
          "drug_id": 489,
          "indication_name": "Diuresis and natriuresis",
          "expected_effects": "Significant diuretic effect: urine output after 12 days of treatment is 157% greater than pretreatment",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:33.000000Z",
          "updated_at": "2020-09-16T01:28:33.000000Z"
      },
      {
          "id": 1759,
          "drug_id": 490,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Mobility and activity scores improve or remain unchanged, while renal parameters did not worsen over a 7-month period in 1 study, even in dogs with pre-existing IRIS stage 2 or 3 kidney disease",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:36.000000Z",
          "updated_at": "2020-09-16T01:28:36.000000Z"
      },
      {
          "id": 1760,
          "drug_id": 490,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Small but significant reduction in pruritus in 46% of dogs (≥ 50% decrease in 36% of dogs), versus 28% and 16%, respectively, for placebo",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:28:38.000000Z",
          "updated_at": "2020-09-16T01:28:38.000000Z"
      },
      {
          "id": 1761,
          "drug_id": 490,
          "indication_name": "Anterior uveitis",
          "expected_effects": "More effective than carprofen or meloxicam for controlling the production of PGE2 in dogs with experimentally-induced uveitis",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:28:41.000000Z",
          "updated_at": "2020-09-16T01:28:41.000000Z"
      },
      {
          "id": 1762,
          "drug_id": 490,
          "indication_name": "Analgesia, urinary tract pain",
          "expected_effects": "91% of treated cats tolerate it well (have no adverse events)\n urinary protein likely associated with inflammation decreases significantly over the course of the prescription",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:28:43.000000Z",
          "updated_at": "2020-09-16T01:28:43.000000Z"
      },
      {
          "id": 1763,
          "drug_id": 491,
          "indication_name": "TRH stimulation test",
          "expected_effects": "Serum T4 concentration is significantly lower after TRH stimulation than after TSH stimulation, causing false-positive diagnoses\n TRH stimulation is not a useful means of diagnosing hypothyroidism in dogs according to one study",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:28:45.000000Z",
          "updated_at": "2020-09-16T01:28:45.000000Z"
      },
      {
          "id": 1764,
          "drug_id": 491,
          "indication_name": "TRH stimulation test",
          "expected_effects": "Serum T4 increases 3 fold in 70% of clinically normal dogs given TRH IV, versus >90% of dogs given TSH IV",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:28:49.000000Z",
          "updated_at": "2020-09-16T01:28:49.000000Z"
      },
      {
          "id": 1765,
          "drug_id": 491,
          "indication_name": "Cataplexy/narcolepsy",
          "expected_effects": "TRH significantly reduces cataplexy in canine narcolepsy\n at higher dosages (>1000 mcg/kg), nearly complete suppression of cataplexy is observed",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:28:51.000000Z",
          "updated_at": "2020-09-16T01:28:51.000000Z"
      },
      {
          "id": 1766,
          "drug_id": 491,
          "indication_name": "Acanthosis nigricans",
          "expected_effects": "Gradual return to normal skin pigmentation with full resolution of lesions and odor\n change may not be noted for the first 4 weeks of treatment\n discontinuation of therapy results in return of lesions",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:28:53.000000Z",
          "updated_at": "2020-09-16T01:28:53.000000Z"
      },
      {
          "id": 1767,
          "drug_id": 491,
          "indication_name": "TRH stimulation test",
          "expected_effects": "Increase in serum T4 <50% of baseline in 82% cats with suspected hyperthyroidism versus 43% of cats of the control group",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:28:56.000000Z",
          "updated_at": "2020-09-16T01:28:56.000000Z"
      },
      {
          "id": 1768,
          "drug_id": 491,
          "indication_name": "TRH stimulation test",
          "expected_effects": "Good discrimination between thyroid and nonthyroid disease: serum T4 levels increase by >50% in 96% of normal cats and cats with non-thyroidal illness, versus 11% of mildly hyperthyroid cats",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:28:59.000000Z",
          "updated_at": "2020-09-16T01:28:59.000000Z"
      },
      {
          "id": 1769,
          "drug_id": 492,
          "indication_name": "Tolareance of post-surgical confinement at home",
          "expected_effects": "",
          "common_combinations": "Combined with tramadol (4-6 mg/kg PO q 8-12 h X 3 days) for analgesia",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:29:01.000000Z",
          "updated_at": "2020-09-16T01:29:01.000000Z"
      },
      {
          "id": 1770,
          "drug_id": 492,
          "indication_name": "Thunderstorm phobia",
          "expected_effects": "Decreases intensity of anxiety associated with thunderstorm phobias in 1 case study",
          "common_combinations": "Behavior modification and pheremone treatment (DAP collar). Can also be combined with SSRI's or tricyclic antidepressants.",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:04.000000Z",
          "updated_at": "2020-09-16T01:29:04.000000Z"
      },
      {
          "id": 1771,
          "drug_id": 492,
          "indication_name": "Anxiety",
          "expected_effects": "85% of owners report that trazodone improves the signs of disorder very much (72.5%) or somewhat (12.5%)",
          "common_combinations": "Can be combined with clomipramine, amitriptyline, imipramine, SSRI's, benzodiazepines, buspirone, reserpine, and/or melatonin",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:29:06.000000Z",
          "updated_at": "2020-09-16T01:29:06.000000Z"
      },
      {
          "id": 1772,
          "drug_id": 492,
          "indication_name": "Sleep apnea in English bulldogs",
          "expected_effects": "The combination of trazodone and L-tryptophan significantly increases sleep efficiency in all dogs in 1 study",
          "common_combinations": "L-tryptophan",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:29:08.000000Z",
          "updated_at": "2020-09-16T01:29:08.000000Z"
      },
      {
          "id": 1773,
          "drug_id": 493,
          "indication_name": "Contraception, male",
          "expected_effects": "Complete sterility achieved between days 23 and 84 post-implantation.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:29:11.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1774,
          "drug_id": 493,
          "indication_name": "Estrus induction",
          "expected_effects": ">93% of anestrous bitches develop estrus after implantation\r\n 81% ovulate, and 69% become pregnant.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:14.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1775,
          "drug_id": 493,
          "indication_name": "Urethral sphincter mechanism incompetence",
          "expected_effects": "Urinary continence achieved in 93% of dogs after 4 weeks of deslorelin-phenylpropanolamine co-treatment\r\n continence then remains for average 253 days (range: 61-738 days) with deslorelin implant and no phenylpropanolamine",
          "common_combinations": "Phenylpropanolamine 1.5 mg/kg PO q 8h for 1st 4 weeks of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:29:16.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1776,
          "drug_id": 493,
          "indication_name": "Delay onset of puberty in puppies with vaginitis",
          "expected_effects": "Treatment with deslorelin implants in prepubertal female dogs delays puberty for at least 4.5 months and can be sustained with repeated treatments.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:29:19.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1777,
          "drug_id": 493,
          "indication_name": "Benign prostatic hyperplasia",
          "expected_effects": "Serum testosterone undetectable by day 11 post-implantation\r\n 20% decrease in prostatic volume by day 11 post-implantation, maximal at day 52 (70% reduction in volume) which persists while implant is in place\r\n decreased sperm concentration and motility between day 22-37 post-implantation",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:29:21.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1778,
          "drug_id": 493,
          "indication_name": "Contraception, male",
          "expected_effects": "Mean duration of efficacy of implant: 79 (range: 62-101) weeks, defined as low serum testosterone level, absence of libido, and small testes.  After end of efficacy, serum testosterone levels return to normal in 3 weeks\r\n libido and fertility normalize over the next 2-5 months",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:29:23.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1779,
          "drug_id": 493,
          "indication_name": "Contraception, female",
          "expected_effects": "Beginning 20 days after implantation, >90% of queens remain in ovarian quiescence for at least 90 days\r\n fully reversible after removal of the implant",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:29:26.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 1780,
          "drug_id": 493,
          "indication_name": "Urethral sphincter mechanism incompetence",
          "expected_effects": "Continence achieved on day 25 post-implantation and sustained for at least 15 months in 1 case report",
          "common_combinations": "After implant removal: equine chorionic gonadotropin 100 IU/CAT IM followed by human chorionic gonadotropin 100 IU/CAT IM 84 hours later to induce estrus and ovulation, respectively",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:29:29.000000Z",
          "updated_at": "2020-09-16T01:29:29.000000Z"
      },
      {
          "id": 1781,
          "drug_id": 494,
          "indication_name": "Prophylaxis for gastroesophageal reflux under anesthesia",
          "expected_effects": "Significantly increases gastric and esophageal pH (7.7 with esomeprazole vs. 3.9 with placebo)\r\n no effect on number of episodes of perioperative gastroesophageal reflux unless combined with cisapride",
          "common_combinations": "Co-treatment with cisapride (1 mg/kg IV, diluted to 100 mL and given IV over 15 minutes) possible for reducing gastroesophageal reflux",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:32.000000Z",
          "updated_at": "2020-11-11T18:44:40.000000Z"
      },
      {
          "id": 1782,
          "drug_id": 495,
          "indication_name": "Cryptococcosis",
          "expected_effects": "Fourfold reduction in cryptococcal titer after 3 weeks but onset of acute, severe toxic epidermal necrolysis",
          "common_combinations": "Amphotericin B (0.25 mg/kg IV 3 times/week)",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:29:34.000000Z",
          "updated_at": "2020-09-16T01:29:34.000000Z"
      },
      {
          "id": 1783,
          "drug_id": 495,
          "indication_name": "Eumycetoma",
          "expected_effects": "Complete resolution of lesion during treatment in 1 case report",
          "common_combinations": "Itraconazole 5 mg/kg PO q 24 h X 10 weeks, beginning immediately post-op and overlapping with flucytosine for the last 4 weeks of treatment",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:37.000000Z",
          "updated_at": "2020-09-16T01:29:37.000000Z"
      },
      {
          "id": 1784,
          "drug_id": 495,
          "indication_name": "Cryptococcosis",
          "expected_effects": "Resolution of clinical signs and negative fungal cultures within 8 weeks with 250 mg/CAT PO q 12 h, but no improvement with 250 mg/CAT PO q 24 h, in 1 case report",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:29:39.000000Z",
          "updated_at": "2020-09-16T01:29:39.000000Z"
      },
      {
          "id": 1785,
          "drug_id": 496,
          "indication_name": "Vasodilation (e.g., mitral regurgitation)",
          "expected_effects": "In dogs with mitral regurgitation, irbesartan decreases systemic vascular resistance to normal levels",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:29:41.000000Z",
          "updated_at": "2020-09-16T01:29:41.000000Z"
      },
      {
          "id": 1786,
          "drug_id": 496,
          "indication_name": "Vasodilation",
          "expected_effects": "Single 5 mg/kg dose reduces blood pressure for 2-10 hours in healthy dogs",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:44.000000Z",
          "updated_at": "2020-09-16T01:29:44.000000Z"
      },
      {
          "id": 1787,
          "drug_id": 497,
          "indication_name": "Orthopedic implant infection caused by methicillin-resistant Staphylococcus pseudintermedius",
          "expected_effects": "Successful wound healing in 1 case report where infection was resistant to all other antibacterials",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:29:46.000000Z",
          "updated_at": "2020-09-16T01:29:46.000000Z"
      },
      {
          "id": 1788,
          "drug_id": 497,
          "indication_name": "Urinary tract infection due to Corynebacterium urealyticum",
          "expected_effects": "Elimination of infection in 1 case report",
          "common_combinations": "Commercial urinary acidifying diet",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:49.000000Z",
          "updated_at": "2020-09-16T01:29:49.000000Z"
      },
      {
          "id": 1789,
          "drug_id": 498,
          "indication_name": "Roundworm infestation - T. canis and T. leonina",
          "expected_effects": "Efficacies for T. canis and T. leonina are >99% and 98 - >99%. Respectively",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:29:51.000000Z",
          "updated_at": "2020-09-16T01:29:51.000000Z"
      },
      {
          "id": 1790,
          "drug_id": 498,
          "indication_name": "Tapeworm infestation - Taenia spp",
          "expected_effects": "70-90% efficacy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:29:54.000000Z",
          "updated_at": "2020-09-16T01:29:54.000000Z"
      },
      {
          "id": 1791,
          "drug_id": 498,
          "indication_name": "Tapeworm infestation - Dipylidium spp",
          "expected_effects": "<3% efficacy\n >97% of D. caninum persist despite treatment with this drug",
          "common_combinations": "",
          "is_contraindicated": 1,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:29:56.000000Z",
          "updated_at": "2020-09-16T01:29:56.000000Z"
      },
      {
          "id": 1792,
          "drug_id": 498,
          "indication_name": "Hookworm infestation - Ancylostoma caninum",
          "expected_effects": ">99% efficacy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:29:59.000000Z",
          "updated_at": "2020-09-16T01:29:59.000000Z"
      },
      {
          "id": 1793,
          "drug_id": 498,
          "indication_name": "Hookworm infestation - Uncinaria stenocephala",
          "expected_effects": ">98% efficacy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-09-16T01:30:01.000000Z",
          "updated_at": "2020-09-16T01:30:01.000000Z"
      },
      {
          "id": 1794,
          "drug_id": 498,
          "indication_name": "Giardiasis",
          "expected_effects": "75-85% efficacy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-09-16T01:30:04.000000Z",
          "updated_at": "2020-09-16T01:30:04.000000Z"
      },
      {
          "id": 1795,
          "drug_id": 498,
          "indication_name": "Whipworm infestation - T. vulpis",
          "expected_effects": ">98% efficacy",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-09-16T01:30:06.000000Z",
          "updated_at": "2020-09-16T01:30:06.000000Z"
      },
      {
          "id": 1796,
          "drug_id": 498,
          "indication_name": "Thelaziosis",
          "expected_effects": ">67% efficacy: elimination of prasites in 3/3 dogs treated in a small case series",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-09-16T01:30:09.000000Z",
          "updated_at": "2020-09-16T01:30:09.000000Z"
      },
      {
          "id": 1797,
          "drug_id": 498,
          "indication_name": "Hookworm infestation - Ancylostoma tubaeforme",
          "expected_effects": "99% effective",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-09-16T01:30:11.000000Z",
          "updated_at": "2020-09-16T01:30:11.000000Z"
      },
      {
          "id": 1798,
          "drug_id": 498,
          "indication_name": "Roundworm infestation - T.cati",
          "expected_effects": ">99% effective",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-09-16T01:30:14.000000Z",
          "updated_at": "2020-09-16T01:30:14.000000Z"
      },
      {
          "id": 1799,
          "drug_id": 498,
          "indication_name": "Tapeworm infestation - T. taeniaeformis",
          "expected_effects": "50% effective",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-09-16T01:30:16.000000Z",
          "updated_at": "2020-09-16T01:30:16.000000Z"
      },
      {
          "id": 1800,
          "drug_id": 498,
          "indication_name": "Tapeworm infestation - Dipylidium caninum",
          "expected_effects": "89-99% efficacy (higher efficacy with 22 mg/kg dosage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-09-16T01:30:19.000000Z",
          "updated_at": "2020-09-16T01:30:19.000000Z"
      },
      {
          "id": 1801,
          "drug_id": 498,
          "indication_name": "Tapeworm infestation - Spirometra spp",
          "expected_effects": "30-80% efficacy (higher efficacy with *lower* dosage)",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-09-16T01:30:21.000000Z",
          "updated_at": "2020-09-16T01:30:21.000000Z"
      },
      {
          "id": 1802,
          "drug_id": 499,
          "indication_name": "Urinary tract infection (Candida), recurrent/chronic",
          "expected_effects": "Well tolerated but specific efficacy unclear in 1 case report",
          "common_combinations": "Urinary acidifying diet and appropriate antibacterial therapy",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:30:24.000000Z",
          "updated_at": "2020-09-16T01:30:24.000000Z"
      },
      {
          "id": 1803,
          "drug_id": 499,
          "indication_name": "Urinary tract infection (Candida)",
          "expected_effects": "Persistence of Candida infection despite methenamine and ascorbic acid treatment in 1 case report",
          "common_combinations": "Ascorbic acid",
          "is_contraindicated": 1,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:30:26.000000Z",
          "updated_at": "2020-09-16T01:30:26.000000Z"
      },
      {
          "id": 1804,
          "drug_id": 500,
          "indication_name": "Reduction of enteric microflora (pre-operatively)",
          "expected_effects": ">90% eradication of most organisms from small and large intestine (based on biopsy samples cultured and also examined by electron microscopy), including >99% eradication of Enterobacteriaceae",
          "common_combinations": "Erythromycin 500 mg/DOG PO co-administered for 3 treatments; clear liquid diet for 72 h pre-op; 280 g/DOG magnesium citrate PO and tap water enema, both 24 h pre-op",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:30:29.000000Z",
          "updated_at": "2020-09-16T01:30:29.000000Z"
      },
      {
          "id": 1805,
          "drug_id": 500,
          "indication_name": "Reduction of enteric microflora (in immunosuppressed individuals)",
          "expected_effects": "80% of dogs have no culturable bacteria on the skin or in the GI tract after 2-7 days of treatment",
          "common_combinations": "Cephalothin 70-230 mg/kg PO q 8 h cotreatment with neomycin; nystatin 45 000 - 125 000 IU/kg PO q 8h beginning 3-4 days before neomycin and cephalothin; and antiseptic bathing",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:30:32.000000Z",
          "updated_at": "2020-09-16T01:30:32.000000Z"
      },
      {
          "id": 1806,
          "drug_id": 500,
          "indication_name": "Prevention of endotoxemia",
          "expected_effects": "Treatment reduces circulating endotoxin concentration by 50% and is associated with greater survival in experimental canine endotoxemia",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:30:34.000000Z",
          "updated_at": "2020-09-16T01:30:34.000000Z"
      },
      {
          "id": 1807,
          "drug_id": 500,
          "indication_name": "Hepatic encephalopathy",
          "expected_effects": "Reduction in hyperammonemia. Long-term use may be ill-advisable and thus identifying and correcting the underlying cause (hepatic encephalopathy, portosystemic shunt, etc) is important.",
          "common_combinations": "Low-protein, low-fat diet with oral multivitamin supplementation +/- lactulose PO",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-09-16T01:30:36.000000Z",
          "updated_at": "2020-09-16T01:30:36.000000Z"
      },
      {
          "id": 1808,
          "drug_id": 501,
          "indication_name": "Myelomonocytic leukemia",
          "expected_effects": "Complete remission. An improved attitude and appetite and palpably smaller spleen and smaller tonsils are observed with response to therapy. Remission is accomplished when bone marrow aspirates contain less than 5% blast cells and when normal erythropoiesis, granuloytopoiesis, megakaryocytopoiesis begin to occur. ",
          "common_combinations": "Cytosine arabinoside (100 mg/m2 IV or SC), Vincristine (1.5 mg/m2 IV), Doxorubicin (30 mg/m2 IV), Prednisolone (40 mg/m2 PO)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:30:39.000000Z",
          "updated_at": "2020-09-16T01:30:39.000000Z"
      },
      {
          "id": 1809,
          "drug_id": 501,
          "indication_name": "Myeloblastic leukemia",
          "expected_effects": "Remission with the disappearance of abnormal cells by hospital day 10 in 1 case report\n relapses can occur and can be addressed with the same drugs and regimen as needed",
          "common_combinations": "Cytosine arabinoside (100 mg/m2 IV or SC q 12h for 3-4 days), prednisone (20 mg/m2 PO q 12 h for 7 days, then 10 mg/m2 PO q 12 h), Corynebacterium parvum (as an immunoadjuvant) 0.5 mg/kg PO or IV q 7d",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-09-16T01:30:41.000000Z",
          "updated_at": "2020-09-16T01:30:41.000000Z"
      },
      {
          "id": 1810,
          "drug_id": 501,
          "indication_name": "Reticuloendotheliosis",
          "expected_effects": "Improvement in clinical signs and reduction in the number of circulating RE cells in a small case series",
          "common_combinations": "Cytosine arabinoside, prednisone, vitamin-mineral supplement, anabolic steroid, antibacterials, and crystalloid fluids",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-09-16T01:30:44.000000Z",
          "updated_at": "2020-09-16T01:30:44.000000Z"
      },
      {
          "id": 1811,
          "drug_id": 502,
          "indication_name": "Rocky Mountain spotted fever",
          "expected_effects": "Termination of fever within 12 h\n improved demanor, nomal platelet count within 48 h\n rickettsial DNA can still be detected in the blood of some dogs on day 21 post-infection. In i study, trovafloxacin is as efficacious as doxycycline in treating Rocky Mountain Spotted Fever.",
          "common_combinations": "",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-09-16T01:30:46.000000Z",
          "updated_at": "2020-09-16T01:30:46.000000Z"
      },
      {
          "id": 1812,
          "drug_id": 503,
          "indication_name": "Cystinuria - dissolution of uroliths",
          "expected_effects": "Complete dissolution of uroliths in 53% of treated dogs",
          "common_combinations": "In general: increased water intake; urinary alkalinization; dietary modification",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-30T19:33:08.000000Z",
          "updated_at": "2020-10-30T19:33:08.000000Z"
      },
      {
          "id": 1813,
          "drug_id": 504,
          "indication_name": "Hypo-, hyperadrenocorticism",
          "expected_effects": "Appropriate cortisol response, similar to short-acting ACTH analogs: peak [cortisol] after 2-4h; [cortisol] >9 μg/dL in healthy dogs and >5 μg/dL in dogs free of hypoadrenocorticism; return of [cortisol] to baseline after 24h.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-10-30T19:41:08.000000Z",
          "updated_at": "2020-10-30T19:41:08.000000Z"
      },
      {
          "id": 1814,
          "drug_id": 505,
          "indication_name": "Re-entrant tachycardia - ineffective",
          "expected_effects": "No conversion of re-entrant tachycardia to normal sinus rhythm observed in 1 case report, even with dosage up to 0.75 mg/kg cumulatively",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-30T19:50:18.000000Z",
          "updated_at": "2020-10-30T19:50:18.000000Z"
      },
      {
          "id": 1829,
          "drug_id": 507,
          "indication_name": "Dog flea infestation (prevention, elimination) - Ctenocephalides canis",
          "expected_effects": "Elimination of >99% of fleas and flea eggs within 24 hours after single oral dose; prevention of re-infestation and prevention of egg production from new infestations for up to 5 weeks after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1830,
          "drug_id": 507,
          "indication_name": "Cat flea infestation (prevention, elimination) - Ctenocephalides felis",
          "expected_effects": "Elimination of >99.9% of fleas and flea eggs within 24 hours after single oral dose; prevention of re-infestation and prevention of egg production from new infestations for up to 36 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1831,
          "drug_id": 507,
          "indication_name": "Demodicosis (generalized) - Demodex canis",
          "expected_effects": "Reduction of mite count by >99% from 28-56 days after start of treatment; reduction of mite count by 100% at 84 days after start of treatment; improvement in skin condition (decreased crusts, casts, and scales)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1832,
          "drug_id": 507,
          "indication_name": "Sarcoptic acariasis/mange - Sarcoptes scabiei",
          "expected_effects": "2 months; repeat once monthly as clinically required",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1833,
          "drug_id": 507,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "Reduction of mite count by >98% compared to untreated dogs at 28 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1834,
          "drug_id": 507,
          "indication_name": "American dog tick/wood tick infestation - Dermacentor variabilis",
          "expected_effects": "Elimination of 100% of ticks by 48 hours after single oral dose; prevention of re-infestation (>97% efficacy) up to 30 days following single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1835,
          "drug_id": 507,
          "indication_name": "Ornate dog tick infestation - Dermacentor reticulatus",
          "expected_effects": "Elimination of >99% of ticks within 2 days of oral dose; prevention of re-infestation (>96% efficacy) up to 30 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1836,
          "drug_id": 507,
          "indication_name": "Castor bean tick infestation - Ixodes ricinus",
          "expected_effects": "Elimination of >99% of ticks within 2 days of oral dose; prevention of re-infestation (>99% efficacy) up to 30 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1837,
          "drug_id": 507,
          "indication_name": "Australian paralysis tick infestation - Ixodes holocyclus",
          "expected_effects": "Elimination of 100% of ticks within 48 hours of single oral dose; prevention of re-infestation (93-100% efficacy) up to 30 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1838,
          "drug_id": 507,
          "indication_name": "Deer tick infestation - Ixodes scapularis",
          "expected_effects": "Elimination of >98% of ticks within 48 hours of single oral dose; prevention of weekly re-infestations (>94% efficacy) up to 30 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1839,
          "drug_id": 507,
          "indication_name": "Brown dog tick infestation - Rhipicephalus sanguineus",
          "expected_effects": "Elimination of >98% of ticks within 2 days of single oral dose; prevention of re-infestation (>95% efficacy) up to five weeks after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1840,
          "drug_id": 507,
          "indication_name": "Lone Star tick infestation - Amblyomma americanum",
          "expected_effects": "Elimination of 100% of ticks within 24 hours of single oral dose; partial elimination of some ticks (11 - 92%) following reinfestation up to five weeks after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1841,
          "drug_id": 507,
          "indication_name": "Dog tick infestation - Haemaphysalis longicornis",
          "expected_effects": "Elimination of 100% of ticks within 48 hours of single oral dose; prevention of reinfestation (>91% efficacy) up to 30 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1842,
          "drug_id": 507,
          "indication_name": "French heartworm prophylaxis - Angiostrongylus vasorum",
          "expected_effects": "Prevention of infestation (>94% efficacy) up to 90 days after start of treatment; 99.9% prevention of fecal shedding of larvae during treatment",
          "common_combinations": "milbemycin 0.5 mg/kg (as NexGard Spectra product)",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1843,
          "drug_id": 507,
          "indication_name": "Spirocerca lupi infestation",
          "expected_effects": "Elimination of >92% of worms by 168 days after start of treatment; esophageal nodules smaller (but not fewer) with treatment; no effect on aortic nodules",
          "common_combinations": "milbemycin 0.5 mg/kg (as NexGard Spectra product)",
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1844,
          "drug_id": 507,
          "indication_name": "Hookworm infestation - Ancylostoma ceylanicum",
          "expected_effects": "Elimination of >99.9% of worms by 7 days after single oral dose",
          "common_combinations": "milbemycin 0.5 mg/kg (as NexGard Spectra product)",
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1845,
          "drug_id": 507,
          "indication_name": "Mixed GI nematode infestation",
          "expected_effects": "Reduction of fecal egg count by 99.7% (Toxocara roundworms), 99.7% (Toxascaris roundworms), 97.2% (hookworms), 99.7% (Trichuris whipworms), and 99.7% (Capillaria) 9 - 21 days after single oral dose",
          "common_combinations": "milbemycin 0.5 mg/kg (as NexGard Spectra product)",
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-10-30T20:33:00.000000Z",
          "updated_at": "2020-10-30T20:33:00.000000Z"
      },
      {
          "id": 1846,
          "drug_id": 508,
          "indication_name": "Tracheitis associated with collapsing trachea",
          "expected_effects": "As adjunctive treatment for tracheitis noted endoscopically during tracheal stent placement: improvement in clinical signs (96% of dogs, in conjunction with tracheal stenting, saline nebulization, and antibiotic therapy if respiratory tract infection suspected)",
          "common_combinations": "Tracheal stent placement in case series of dogs with severe tracheal collapse, saline nebulization q 12h, and enrofloxacin 5 mg/kg PO q 24h + amoxicillin 15 mg/kg PO q 12h if respiratory tract infection suspected)",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T18:18:17.000000Z",
          "updated_at": "2020-10-31T18:18:17.000000Z"
      },
      {
          "id": 1847,
          "drug_id": 509,
          "indication_name": "Anticoagulation",
          "expected_effects": "Resolution of mitral valve thrombus (1 dog) and prevention of growth of mitral valve thrombus (1 dog) after open-heart ePTFE chordal implantation",
          "common_combinations": "Clopidogrel 4 mg/kg PO q 24h",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T18:20:29.000000Z",
          "updated_at": "2020-10-31T18:20:29.000000Z"
      },
      {
          "id": 1848,
          "drug_id": 510,
          "indication_name": "Neoplasia",
          "expected_effects": "6% partial response (markedly decreased tumor size in 1 dog with transitional cell carcinoma of the bladder that was previously unresponsive to carboplatin and piroxicam), 47% stable disease, and 47% progressive disease in 1 series of dogs with neoplasia previously treated with conventional chemotherapeutic protocols; no adverse effects noted despite careful clinical evaluation for these.",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T18:22:19.000000Z",
          "updated_at": "2020-10-31T18:22:19.000000Z"
      },
      {
          "id": 1849,
          "drug_id": 511,
          "indication_name": "Hyperlipidemia",
          "expected_effects": "Normalization of serum triglyceride and serum cholesterol concentrations in 91% and 67% of dogs, respectively, after 1st 30 days of treatment.",
          "common_combinations": "Control of hyperlipidemia by primary means (e.g., control of underlying disease, if any)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T18:24:09.000000Z",
          "updated_at": "2020-10-31T18:24:09.000000Z"
      },
      {
          "id": 1850,
          "drug_id": 512,
          "indication_name": "Anorexia",
          "expected_effects": "Appetite improvement in 69% of treated dogs, compared to 45% of placebo-treated control dogs",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T18:25:07.000000Z",
          "updated_at": "2020-10-31T18:25:07.000000Z"
      },
      {
          "id": 1855,
          "drug_id": 514,
          "indication_name": "Excretory urography",
          "expected_effects": "Ureteral and ureterovesicular junction anatomy readily assessed with minimal patient preparation",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T18:39:36.000000Z",
          "updated_at": "2020-10-31T18:39:36.000000Z"
      },
      {
          "id": 1856,
          "drug_id": 514,
          "indication_name": "Hepatic angiography",
          "expected_effects": "Hepatic arteries and portal veins clearly visualized in all dogs in 1 study",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-10-31T18:39:36.000000Z",
          "updated_at": "2020-10-31T18:39:36.000000Z"
      },
      {
          "id": 1857,
          "drug_id": 514,
          "indication_name": "Shoulder arthrography - radiographs",
          "expected_effects": "Acceptable delineation of joint structures in all dogs in 1 study; best delineation of articular cartilage with 185 mg iodine/joint; best visualization of bicipital tendon sheet and pouches of the shoulder joint with 750 mg iodine/joint.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-10-31T18:39:36.000000Z",
          "updated_at": "2020-10-31T18:39:36.000000Z"
      },
      {
          "id": 1858,
          "drug_id": 514,
          "indication_name": "Idiopathic renal hematuria - sclerotherapy",
          "expected_effects": "Cessation of gross hematuria in 67% of dogs within 1 week post-treatment; occasional recurrent mild hematuria in 33% of dogs 2-3 weeks after sclerotherapy (resolving in 1 dog after removal of ureteral stent); slight improvement in PCV in all dogs - all in series of 6 cases",
          "common_combinations": "2 povidone iodine-meglumine diatrizoate-D5W renal pelvis infusions followed by 2 renal pelvis infusions of 0.5%-1% silver nitrate solution of same predetermined volume (15-20 minutes each), then ureteral stent placement X 4-6 weeks (ureteral obstruction prophylaxis)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-10-31T18:39:36.000000Z",
          "updated_at": "2020-10-31T18:39:36.000000Z"
      },
      {
          "id": 1859,
          "drug_id": 515,
          "indication_name": "Coccidiosis - Isospora spp infestation",
          "expected_effects": "Reduction of fecal shedding of Isospora oocysts from 75% of puppies pre-treatment to 10% of puppies 7 days post-treatment and 33% 10 days post-treatment",
          "common_combinations": "Hygiene/decontamination of premises",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-10-31T19:12:34.000000Z",
          "updated_at": "2020-10-31T19:12:34.000000Z"
      },
      {
          "id": 1860,
          "drug_id": 515,
          "indication_name": "Coccidiosis - Isospora spp infestation",
          "expected_effects": "Reduction of fecal shedding of Isospora oocysts from 90% of kittens pre-treatment to only one oocyst in the feces of one kitten 7 days post-treatment; however, 24% of kittens pass oocysts again by 10 days post-treatment; diarrhea may continue for 4 - 5 days after singe oral dose despite absence of oocysts in feces.",
          "common_combinations": "Hygiene/decontamination of premises",
          "is_contraindicated": 0,
          "vdi_display_order": null,
          "created_at": "2020-10-31T19:12:34.000000Z",
          "updated_at": "2020-10-31T19:12:34.000000Z"
      },
      {
          "id": 1861,
          "drug_id": 516,
          "indication_name": "Hyperlipidemia",
          "expected_effects": "Significant reduction in plasma lipid concentrations: decreases of 29+/-9% (fasting triglycerides), 30+/-7% (total cholesterol), 30+/-5% (free fatty acids), and 25+/-3% phospholipids) after 15 days of treatment.",
          "common_combinations": "Low-fat diet",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T15:11:33.000000Z",
          "updated_at": "2020-11-03T15:11:33.000000Z"
      },
      {
          "id": 1862,
          "drug_id": 517,
          "indication_name": "Acute kidney injury - ineffective",
          "expected_effects": "39% survival to discharge (not different from historical controls that did not receive fenoldopam)",
          "common_combinations": "Supportive care for acute kidney injury",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T15:13:16.000000Z",
          "updated_at": "2020-11-03T15:13:16.000000Z"
      },
      {
          "id": 1863,
          "drug_id": 517,
          "indication_name": "Acute kidney injury - ineffective",
          "expected_effects": "38% survival to discharge (not different from historical controls that did not receive fenoldopam)",
          "common_combinations": "Supportive care for acute kidney injury",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T15:13:16.000000Z",
          "updated_at": "2020-11-03T15:13:16.000000Z"
      },
      {
          "id": 1864,
          "drug_id": 518,
          "indication_name": "Thallium toxicosis",
          "expected_effects": "Acceleration of thallium elimination in experimentally intoxicated dogs: half-life of 2.5 days with treatment versus 6.5 days in untreated controls",
          "common_combinations": "Disodium EDTA 150 mg/kg PO q 24h X 3 days",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T15:14:06.000000Z",
          "updated_at": "2020-11-03T15:14:06.000000Z"
      },
      {
          "id": 1865,
          "drug_id": 519,
          "indication_name": "Flea infestation (prevention, elimination) - Ctenocephalides spp",
          "expected_effects": "Elimination of >99.8% of fleas by 4, 8, and 12 weeks after single topical dose",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1866,
          "drug_id": 519,
          "indication_name": "Flea infestation (prevention, elimination) - Ctenocephalides spp",
          "expected_effects": "Elimination of >99.8% of fleas by 4, 8, and 12 weeks after single topical dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1867,
          "drug_id": 519,
          "indication_name": "Demodicosis (generalized) - Demodex canis",
          "expected_effects": "Elimination of 99.8% of mites by 28 days and elimination of 100% of mites by 56-84 days after single oral dose; improvement in clinical signs (alopecia, erythematous patches, crusts, casts, scales)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1868,
          "drug_id": 519,
          "indication_name": "Sarcoptic acariasis/mange - Sarcoptes scabiei infestation",
          "expected_effects": "Elimination of 100% of mites within 4 weeks after single oral dose; improvement in clinical signs (erythematous papules, casts, crusts, pruritus, alopecia)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1869,
          "drug_id": 519,
          "indication_name": "Sarcoptic acariasis/mange - Sarcoptes scabiei infestation",
          "expected_effects": "Elimination of 100% of mites within 4 weeks after single topical dose; improvement in clinical signs (erythematous papules, casts, crusts, pruritus, alopecia)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1870,
          "drug_id": 519,
          "indication_name": "American dog tick/wood tick infestation - Dermacentor variabilis",
          "expected_effects": "Elimination of >96% of ticks within 12 hours after infestation and for up to 42 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1871,
          "drug_id": 519,
          "indication_name": "Ornate dog tick infestation - Dermacentor reticulatus",
          "expected_effects": "Elimination of >99% of ticks within 48 hours after infestation and for up to 90 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1872,
          "drug_id": 519,
          "indication_name": "Ornate dog tick infestation - Dermacentor reticulatus",
          "expected_effects": "Elimination of >99% of ticks within 48 hours after infestation and for up to 90 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1873,
          "drug_id": 519,
          "indication_name": "Castor bean tick infestation - Ixodes ricinus",
          "expected_effects": "Elimination of 100% of ticks within 24h after single oral dose; prevention of re-infestation with >98% efficacy up to 12 weeks after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1874,
          "drug_id": 519,
          "indication_name": "Australian paralysis tick infestation - Ixodes holocyclus",
          "expected_effects": "Elimination of 100% of ticks within 24 hours after single oral dose; prevention of re-infestation with 100% efficacy up to 115 days after single oral dose, dropping to 95.7% at 143 days post-dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1875,
          "drug_id": 519,
          "indication_name": "Brown dog tick infestation - Rhipicephalus sanguineus",
          "expected_effects": "Elimination of >91% of ticks within 48 hours after single topical dose; prevention of re-infestation with >95% efficacy up to 12 weeks after single topical dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1876,
          "drug_id": 519,
          "indication_name": "Lone Star tick infestation - Amblyomma americanum",
          "expected_effects": "Elimination of 100% of ticks within 24 hours after single oral dose; prevention of re-infestation with >82% efficacy up to 28 days after single oral dose, then loss of efficacy after 28 days",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1877,
          "drug_id": 519,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "Elimination of 99.8% of mites within 28 days after single oral dose; decreased volume of cerumen",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1878,
          "drug_id": 519,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "Elimination of 99.8% of mites within 28 days after single topical dose; decreased volume of cerumen",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1879,
          "drug_id": 519,
          "indication_name": "Cat flea infestation (prevention, elimination) - Ctenocephalides felis spp",
          "expected_effects": "Elimination of >99% of fleas 4, 8, and 12 weeks after single topical dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1880,
          "drug_id": 519,
          "indication_name": "Ear mite infestation - Otodectes cynotis",
          "expected_effects": "Elimination of 100% of mites within 28 days after single topical dose; decreased volume of cerumen",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-11-03T15:32:28.000000Z",
          "updated_at": "2020-11-03T15:32:28.000000Z"
      },
      {
          "id": 1881,
          "drug_id": 519,
          "indication_name": "Demodicosis (generalized) - Demodex cati infestation",
          "expected_effects": "Negative skin scrapings, partial hair regrowth, and resolution of pruritus within 1 month after single oral dose; full hair regrowth within 2 months",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-11-03T15:32:29.000000Z",
          "updated_at": "2020-11-03T15:32:29.000000Z"
      },
      {
          "id": 1882,
          "drug_id": 519,
          "indication_name": "Feline fur mite infestation - Lynxacarus radovskyi (Hawaii, Australia, Fiji, New Zealand, Brazil, Philippines, Malaysia)",
          "expected_effects": "Elimination of 100% of mites within 28 days after single oral dose; prevention of re-infestation up to 42 days after single oral dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 18,
          "created_at": "2020-11-03T15:32:29.000000Z",
          "updated_at": "2020-11-03T15:32:29.000000Z"
      },
      {
          "id": 1883,
          "drug_id": 520,
          "indication_name": "Hypercholesterolemia - ineffective",
          "expected_effects": "No significant change in serum cholesterol concentration",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T15:54:06.000000Z",
          "updated_at": "2020-11-03T15:54:06.000000Z"
      },
      {
          "id": 1884,
          "drug_id": 521,
          "indication_name": "Osteoarthritis",
          "expected_effects": "Significant but modest improvement in osteoarthritis-associated pain scores: 48.1% of dogs improve with grapiprant vs. spontaneous improvement in 31.3% of placebo-treated controls",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T15:55:28.000000Z",
          "updated_at": "2020-11-03T15:55:28.000000Z"
      },
      {
          "id": 1885,
          "drug_id": 522,
          "indication_name": "Idiopathic epilepsy",
          "expected_effects": "Significant reduction in partial and generalized seizure frequency: 32-47% of dogs free of generalized tonic-clonic seizures after 6 months; imepitoin appears to be very effective for treating partial and complex partial seizures but minimally effective for treating cluster seizures; no apparent tolerance develops to antiepileptic activity of imepitoin during continuous treatment for up to 6 months",
          "common_combinations": "In dogs, phenobarbital +imepitoin achieves >50% reduction in seizure frequency in 36-42% of dogs; for adding imepitoin onto existing phenobarbital regimen, recommended imepitoin dosage is 5 mg/kg PO q 12h initially, with uptitration to 15 mg/kg PO q 12h as needed; for adding phenobarbital onto existing imepitoin regimen (>20 mg/kg PO q 12h), recommended phenobarbital dosage is 1.5 mg/kg PO q 12h",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:00:28.000000Z",
          "updated_at": "2020-11-03T16:00:28.000000Z"
      },
      {
          "id": 1886,
          "drug_id": 522,
          "indication_name": "Anxiety disorders",
          "expected_effects": "Significant improvement in behavioral parameters (beginning after 1 week of treatment), with 76% of owners opting to continue treatment at their own expense after trial completion",
          "common_combinations": "Behavioral modification plan",
          "is_contraindicated": 0,
          "vdi_display_order": null,
          "created_at": "2020-11-03T16:00:28.000000Z",
          "updated_at": "2020-11-03T16:00:28.000000Z"
      },
      {
          "id": 1887,
          "drug_id": 522,
          "indication_name": "Idiopathic epilepsy",
          "expected_effects": "Complete elimination of seizures for 8 week study duration (4 weeks treatment + 4 weeks observation without treatment) in 50% of cats, reduction in seizure frequency in further 13% cats, and no improvement in seizures in remaining 37% of cats",
          "common_combinations": "Addition of phenobarbital (1 mg/kg PO q 12h) (1 cat) and levetiracetam (20-30 mg/kg PO q8h) (1 cat) for cats showing incomplete response to imepitoin in one prospective study",
          "is_contraindicated": 0,
          "vdi_display_order": null,
          "created_at": "2020-11-03T16:00:28.000000Z",
          "updated_at": "2020-11-03T16:00:28.000000Z"
      },
      {
          "id": 1888,
          "drug_id": 523,
          "indication_name": "Myelography - radiographic/fluoroscopic",
          "expected_effects": "Good myelographic quality on radiographs; low incidence of postmyelographic complications (seizures in 7% of dogs), suggesting iohexol is safe for routine use in myelography",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1889,
          "drug_id": 523,
          "indication_name": "Myelography - CT",
          "expected_effects": "Good myelographic quality on CT",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1890,
          "drug_id": 523,
          "indication_name": "Angiography (cardiac) - fluoroscopic",
          "expected_effects": "Identification of ductus arteriosus on fluoroscopy",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1891,
          "drug_id": 523,
          "indication_name": "Angiography (cardiac) - CT",
          "expected_effects": "Good imaging for cardiac angiography; optimal image quality in healthy dogs obtained with scan delay of 13-17 seconds following injection of contrast at 372 mg iodine/kg (800 mg/kg) in 1:2 or 1:3 saline dilutions",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1892,
          "drug_id": 523,
          "indication_name": "Angiography (hepatic) - CT",
          "expected_effects": "Good visualization of hepatic vasculature; optimal time was a 9-sec delay time post IV injection for hepatic arterial phase; then venous phase after completion of arterial phase scanning",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1893,
          "drug_id": 523,
          "indication_name": "Epidurography - CT",
          "expected_effects": "Good visualization of epidural space. Total cranial-caudal dispersion of iohexol optimal with 20-minute injection duration. Disperson similar with T11-L1 and L6-S1 injections, but maximal CT values higher at C7/T1 and T4/T5 with T11-L1 injections and higher at T13/L1 and L4/L5 levels with L6-S1 injection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1894,
          "drug_id": 523,
          "indication_name": "Shoulder arthrography - radiographic",
          "expected_effects": "Good visualization of the joint on radiographs; cartilage flap identified in 89% of cases of humeral osteochondritis dissecans (versus 0% on plain radiographs), and biceps tendon lesions identified in 78% of cases",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1895,
          "drug_id": 523,
          "indication_name": "Shoulder arthrography - CT",
          "expected_effects": "Good delination of articular cartilage; 37.5 mg iodine/mL contrast medium (12.5% dilution) creates the best contrast with least artifact for measurements compared to 75 mg iodine/mL or 150 mg iodine/mL",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-03T16:03:40.000000Z",
          "updated_at": "2020-11-03T16:03:40.000000Z"
      },
      {
          "id": 1896,
          "drug_id": 523,
          "indication_name": "Elbow arthrography - CT",
          "expected_effects": "0.2 mg epinephrine added to iohexol mixture for injection into joint",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-03T16:03:41.000000Z",
          "updated_at": "2020-11-03T16:03:41.000000Z"
      },
      {
          "id": 1897,
          "drug_id": 523,
          "indication_name": "Stifle arthrography - CT",
          "expected_effects": "Good visualization of cranial cruciate ligaments, medial and lateral menisci, long digital extensor tendons, and popliteal tendons; clear images of acute partial ruptures of the cranial cruciate ligament",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-03T16:03:41.000000Z",
          "updated_at": "2020-11-03T16:03:41.000000Z"
      },
      {
          "id": 1898,
          "drug_id": 523,
          "indication_name": "Excretory urography - CT",
          "expected_effects": "Good visualization of renal structures. Iodixanol has a longer contrast effect than iohexol in the renal cortex even with the same iodine dosage; this is because of iodixanol's lower osmolarity",
          "common_combinations": "0.2 mg epinephrine added to iohexol mixture for injection into joint",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-11-03T16:03:41.000000Z",
          "updated_at": "2020-11-03T16:03:41.000000Z"
      },
      {
          "id": 1899,
          "drug_id": 523,
          "indication_name": "Retrograde ureteropyelography - ureteral stenting with fluoroscopy",
          "expected_effects": "Good visualization of ipsilateral ureter and renal pelvis; imaging can allow visualization of ureteral lesion (stricture, urolith) prior to ureteral stent placement",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-11-03T16:03:41.000000Z",
          "updated_at": "2020-11-03T16:03:41.000000Z"
      },
      {
          "id": 1900,
          "drug_id": 524,
          "indication_name": "Atopic dermatitis",
          "expected_effects": "Decrease in pruritus within 1 day, persisting in most dogs for at least 1 month; greater efficacy with 2 mg/kg dosage than with 0.5 mg/kg dosage",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:09:24.000000Z",
          "updated_at": "2020-11-03T16:09:24.000000Z"
      },
      {
          "id": 1901,
          "drug_id": 525,
          "indication_name": "Obesity - ineffective",
          "expected_effects": "Not effective for its intended purpose: over a 3-month period, obese dogs eating a low-fat diet and receiving mitratapide lose 16.1 +/- 5.6% of body weight, compared to dogs eating a low-fat diet and receiving placebo, who lose 16.8 +/- 8.0% of body weight (no signifcant difference).",
          "common_combinations": "Weight-loss (energy-restricted) diet",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:11:35.000000Z",
          "updated_at": "2020-11-03T16:11:35.000000Z"
      },
      {
          "id": 1902,
          "drug_id": 526,
          "indication_name": "Estrogen-induced aplastic anemia",
          "expected_effects": "Estrogen-induced anemia and leukopenia improvement begining 8 days after first nandrolone injection, with return to normal by 60 days after first dose - all in 1 case report (unclear whether predominant influence is drug-associated benefit or spontaneous improvement)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:33:24.000000Z",
          "updated_at": "2020-11-03T16:33:24.000000Z"
      },
      {
          "id": 1903,
          "drug_id": 526,
          "indication_name": "Pure red cell aplasia",
          "expected_effects": "Increase in hematocrit from 17% (baseline) to 26% and improvement in appetite, energy, and body weight 7 days after first dose in 1 case report; improvement continued and sustained after end of weekly treatments (unclear whether nandrolone or other factors responsible for improvement)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T16:33:24.000000Z",
          "updated_at": "2020-11-03T16:33:24.000000Z"
      },
      {
          "id": 1904,
          "drug_id": 526,
          "indication_name": "Enhance bone healing following osteotomy (tibial tuberosity advancement)",
          "expected_effects": "Significantly faster bone consolidation (radiographic): mean 63 days with nandrolone vs. mean 105 days without nandrolone",
          "common_combinations": "Routine post-operative medications (e.g., cephalexin 30 mg/kg PO q 12h X 7 days, carprofen 2.2 mg/kg PO q 12h X 7 days, tramadol 2 mg/kg PO q 8h X 7 days in 1 study)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T16:33:24.000000Z",
          "updated_at": "2020-11-03T16:33:24.000000Z"
      },
      {
          "id": 1905,
          "drug_id": 527,
          "indication_name": "Chagas' disease - Trypanosoma cruzi infection, acute phase",
          "expected_effects": "Complete eliminiation of parasites with 3-4 days of treatment",
          "common_combinations": "Anti-inflammatory dose of corticosteroid given with each dose of nifurtimox. Treatment with nifurtimox alone is associated with severe acute myocarditis and focal necrosis of cardiac fibers, causing irregular changes on ECG; combination of nifurtimox and corticosteroid is associated with less myocardial inflammation",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:34:21.000000Z",
          "updated_at": "2020-11-03T16:34:21.000000Z"
      },
      {
          "id": 1906,
          "drug_id": 528,
          "indication_name": "Chagas' disease - Trypanosoma cruzi infection, acute phase",
          "expected_effects": "Complete eliminiation of parasites with 3-4 days of treatment",
          "common_combinations": "Anti-inflammatory dose of corticosteroid given with each dose of nifurtimox. Treatment with nifurtimox alone is associated with severe acute myocarditis and focal necrosis of cardiac fibers, causing irregular changes on ECG; combination of nifurtimox and corticosteroid is associated with less myocardial inflammation",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:34:56.000000Z",
          "updated_at": "2020-11-03T16:34:56.000000Z"
      },
      {
          "id": 1909,
          "drug_id": 530,
          "indication_name": "Induction of cataplexy - diagnosis of narcolepsy",
          "expected_effects": "Enhancement of signs of narcolepsy: 3- to 4-fold increase in severity of cataplectic events (frequency and duration of cataplexy) during food-elicited cataplexy test in narcoleptic dogs",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T16:37:57.000000Z",
          "updated_at": "2020-11-03T16:37:57.000000Z"
      },
      {
          "id": 1910,
          "drug_id": 530,
          "indication_name": "Prophylaxis against nerve agent poisoning - sarin",
          "expected_effects": "Combination prophylactic treatment (physostigmine 2.5 microg/kg/h + scopolamine 1 microg/kg/h for 48h) confers full protection against 2.5x LD50 IV of sarin",
          "common_combinations": "Scopolamine 1 microg/kg/h IV CRI x 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T16:37:57.000000Z",
          "updated_at": "2020-11-03T16:37:57.000000Z"
      },
      {
          "id": 1911,
          "drug_id": 531,
          "indication_name": "Colonoscopy preparation",
          "expected_effects": "Adequate colon evacuation with this protocol: median colon preparation score of 1.63-2.25, where 1=ideal and 4=unacceptable",
          "common_combinations": "20 mL/kg warm water enema administered following each PEG dose and again immediately before anesthesia",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:07:59.000000Z",
          "updated_at": "2020-11-03T17:07:59.000000Z"
      },
      {
          "id": 1912,
          "drug_id": 531,
          "indication_name": "Constipation",
          "expected_effects": "Soft stools achievable through dose titration in majority of cats (6/6 in one study of non-obstipated cats)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": null,
          "created_at": "2020-11-03T17:07:59.000000Z",
          "updated_at": "2020-11-03T17:07:59.000000Z"
      },
      {
          "id": 1913,
          "drug_id": 532,
          "indication_name": "Hyperphosphatemia",
          "expected_effects": "7-20% decrease in serum phosphorus concentration, and 21-30% decrease in urinary phosphorus concentration, after 28 days in healthy experimental cats",
          "common_combinations": "Low-phosphate diet (e.g., Hills Prescription Diet k/d in 1 study)",
          "is_contraindicated": 0,
          "vdi_display_order": null,
          "created_at": "2020-11-03T17:09:17.000000Z",
          "updated_at": "2020-11-03T17:09:17.000000Z"
      },
      {
          "id": 1914,
          "drug_id": 533,
          "indication_name": "Coccidiosis",
          "expected_effects": "92.9% of treated dogs have no detectable coccidia on fecal evaluation 3-4 days after start of treatment; no significant change in fecal consistency score in this time frame, however.",
          "common_combinations": "Topical hygiene (bathing) and environmental control (cleaning contaminated surfaces of premises with 10% ammonia @ 10 minutes contact time)",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:10:33.000000Z",
          "updated_at": "2020-11-03T17:10:33.000000Z"
      },
      {
          "id": 1915,
          "drug_id": 533,
          "indication_name": "As clinically indicated (28 days in 1 case report)",
          "expected_effects": "No recurrence of conjunctival mass during treatment nor during 6-month follow-up",
          "common_combinations": "Surgical debulking/resection of conjunctival mass",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T17:10:33.000000Z",
          "updated_at": "2020-11-03T17:10:33.000000Z"
      },
      {
          "id": 1916,
          "drug_id": 533,
          "indication_name": "Coccidiosis",
          "expected_effects": "87.5% of treated cats have no detectable coccidia on fecal evaluation 3-4 days after start of treatment; no significant change in fecal consistency score in this time frame, however.",
          "common_combinations": "Topical hygiene (bathing) and environmental control (cleaning contaminated surfaces of premises with 10% ammonia @ 10 minutes contact time)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T17:10:33.000000Z",
          "updated_at": "2020-11-03T17:10:33.000000Z"
      },
      {
          "id": 1917,
          "drug_id": 534,
          "indication_name": "Aspergillosis - disseminated",
          "expected_effects": "Median survival = 241 days (range: 44-516); clinical remission (survival > 1 year) in 4/10 dogs and clinical improvement in 6/10 dogs in 1 case series; recurrence after cessation of treatment is common and cause of death ultimately is progressive disease in most instances",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1918,
          "drug_id": 534,
          "indication_name": "Aspergillosis - sinonasal (refractory)",
          "expected_effects": "Complete clinical remission in 70% of cases and partial clinical remission in 30% of cases, with relapse in 20% of cases after cessation of combination therapy (posaconazole, terbinafine, doxycyline) in 1 case series of 10 dogs with previously refractory disease; all dogs in the series lived >1 year after starting combination therapy",
          "common_combinations": "Frontal sinus trephination and fungal plaque debridement, clotrimazole infusion, and subsequent co-treatment in addition to posaconazole (terbinafine 30 mg/kg PO q 12h and doxycycline 5 mg/kg PO q 12h)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1919,
          "drug_id": 534,
          "indication_name": "Systemic mycosis  - Westerdykella spp.",
          "expected_effects": "Improvement in azotemia, increased appetite, and clinically stability for 11 weeks at q 12h dosing (seemingly ineffective at initial q 24h dosing), followed by deterioration thereafter: dissemination of mycotic infection possibly attributed to treatment change to terbinafine and/or development of resistance to posaconazole",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1920,
          "drug_id": 534,
          "indication_name": "Aspergillosis - sinonasal",
          "expected_effects": "Resolution of epistaxis and stertor, sustained for 13 months after end of treatment in 1 case report; 4 months after discontinuting posaconazole, recurrence of mild nasal discharge attributed to atrophic rhinitis rather than worsening of fungal infection",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1921,
          "drug_id": 534,
          "indication_name": "Aspergillosis - orbital",
          "expected_effects": "Resolution of submandibular lymphadenopathy, reduction in size of oral lesions, and weight gain during 1st 3 weeks of treatment; resolution of oral lesions and of soft-tissue opacities in sinus, orbit, and nasal cavity (CT scan) in 1st 12 weeks of treatment; no recurrence of infection for 20 months after discontinuing posaconazole",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1922,
          "drug_id": 534,
          "indication_name": "Zygomycosis (focal) - Mucor spp.",
          "expected_effects": "Reduction in size of subcutaneous mass in 1st 2 weeks of treatment, with further decrease in size for 3 months; discontinuation of treatment at 5 months when culture and cytology negative (no recurrence X 12 months after end of treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1923,
          "drug_id": 534,
          "indication_name": "Phaeohyphomycosis (focal) - Cladophialophora bantiana",
          "expected_effects": "Clinical stability X 7 months with ongoing posaconazole treatment in 1 case report (euthnasia at 13 months for different problem [hepatocellular carcinoma] with no evidence of recurrent fungal infection at post-mortem)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1924,
          "drug_id": 534,
          "indication_name": "Coelomycosis (focal) - Microsphaeropsis arundinis",
          "expected_effects": "Subcutaneous mass decreased in size noticeably within weeks of starting treatment in 1 case report (elimination of clinical signs for >2 years after discontinuation of posaconazole, then recurrence of nasal swelling)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-03T17:13:57.000000Z",
          "updated_at": "2020-11-03T17:13:57.000000Z"
      },
      {
          "id": 1925,
          "drug_id": 535,
          "indication_name": "Constipation prevention",
          "expected_effects": "Stimulates defecation in 43% of cats within 1 hour of dosing, versus 9% of untreated control cats",
          "common_combinations": "Other, complementary methods of constipation prevention (e.g., laxative[s], high-fiber diet)",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:14:55.000000Z",
          "updated_at": "2020-11-03T17:14:55.000000Z"
      },
      {
          "id": 1926,
          "drug_id": 536,
          "indication_name": "Lymphoma - multicentric",
          "expected_effects": "Overall response rate = 84% (68% complete response, 16% partial response); overall median progression-free interval = 194 days (median 216 days for complete responders, 63 days for partial responders); protocol alternating RAB/DOX generally well tolerated, with progression-free intervals similar to standard DOX-based multi-agent protocols, with fewer treatment visits but adverse effect of pumonary fibrosis is a concern",
          "common_combinations": "Doxorubicin in alternating RAB/DOX protocol: rabacfosadine 1 mg/kg slow IV weeks 0, 6, 12 + doxorubicin 30 mg/m2 IV weeks 3, 9, 15",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:16:19.000000Z",
          "updated_at": "2020-11-03T17:16:19.000000Z"
      },
      {
          "id": 1927,
          "drug_id": 536,
          "indication_name": "Lymphoma - cutaneous T-cell",
          "expected_effects": "Objective response rate=45% (complete response=9% of cases, partial response=36%, stable disease=18%, progressive disease=36%); median progression-free surival=26 to >399 days, median=37.5 days",
          "common_combinations": "Prednisone 1 mg/kg PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T17:16:19.000000Z",
          "updated_at": "2020-11-03T17:16:19.000000Z"
      },
      {
          "id": 1928,
          "drug_id": 536,
          "indication_name": "Multiple myeloma",
          "expected_effects": "Major antitumor responses (reduction of serum paraprotein and resolution of hypercalcemia, peripheral cytopenias and bone marrow plasmacytosis) in 82% of dogs for a median of 172 days; 1 instance of durable stringent complete response (>1047 days) in a dog with melphalan-refractory disease",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T17:16:20.000000Z",
          "updated_at": "2020-11-03T17:16:20.000000Z"
      },
      {
          "id": 1929,
          "drug_id": 537,
          "indication_name": "Routine, various enteropathy medications (e.g., ranitidine 2 mg/kg q 12h X 21 days, metoclopramide 0.3 mg/kg q 12h X 15 days, vitamin B12/cyanocobalamin 250–1000 microg/DOG IM once weekly in 1 case series)",
          "expected_effects": "Complete remission in GI abnormalities (appetite, vomiting, stool consistency and frequency, etc. - Canine IBD Index) in 86% of treated dogs, similar to metronidazole 15 mg/kg PO q 12h X 21 days (80%)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": null,
          "created_at": "2020-11-03T17:17:31.000000Z",
          "updated_at": "2020-11-03T17:17:31.000000Z"
      },
      {
          "id": 1930,
          "drug_id": 538,
          "indication_name": "Anticoagulation",
          "expected_effects": "Marked decrease in anti-factor-Xa activity (median value at baseline = 0.68, median value at peak effect of treatment = 0.06)",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:18:18.000000Z",
          "updated_at": "2020-11-03T17:18:18.000000Z"
      },
      {
          "id": 1931,
          "drug_id": 538,
          "indication_name": "Thromboembolic disease",
          "expected_effects": "Extended period with lack of signs of embolic disease",
          "common_combinations": "Clopidogrel 0.75 mg/kg PO q 12h or 2 mg/kg PO q 24h coadministered to all cases in 1 small retrospective study",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T17:18:18.000000Z",
          "updated_at": "2020-11-03T17:18:18.000000Z"
      },
      {
          "id": 1932,
          "drug_id": 541,
          "indication_name": "Giardiasis - Giardia duodenalis infestation",
          "expected_effects": "Resolution of diarrhea and elimination of 100% of Giardia cysts by 6-8 days post-treatment",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:20:25.000000Z",
          "updated_at": "2020-11-03T17:20:25.000000Z"
      },
      {
          "id": 1933,
          "drug_id": 542,
          "indication_name": "Acral lick dermatitis",
          "expected_effects": "Mean 21% reduction in licking behavior (vs. baseline and vs. placebo) but only 10% rate of clinically meaningful (>50%) reduction in licking; less effective than clomipramine or fluoxetine; limited efficacy could be due to insufficient dosage or duration of treatment (11 weeks) in 1 study",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T17:22:07.000000Z",
          "updated_at": "2020-11-03T17:22:07.000000Z"
      },
      {
          "id": 1934,
          "drug_id": 543,
          "indication_name": "Perioperative - ovariectomy",
          "expected_effects": "Possibly faster skin healing time (7+/-3 days with treatment, compared to 10 +/-2 days in placebo-treated controls, but treatment details nonspecific) and absence of incision site inflammation (versus mild inflammation in 40% of placebo-treated dogs) in one small study",
          "common_combinations": "Lincomycin 5 mg/kg IM, coadministered with each injection",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:17:27.000000Z",
          "updated_at": "2020-11-03T19:17:27.000000Z"
      },
      {
          "id": 1935,
          "drug_id": 544,
          "indication_name": "Oral Porphyromonas spp infection",
          "expected_effects": "Complete elimination of Porphyromonas spp from periodontal tissue, similar to clindamycin and superior to amoxicillin-clavulanate or doxycycline",
          "common_combinations": "Metronidazole 12.5 mg/kg PO q 24h",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:19:33.000000Z",
          "updated_at": "2020-11-03T19:19:33.000000Z"
      },
      {
          "id": 1936,
          "drug_id": 546,
          "indication_name": "Neospora caninum gastrointestinal infection - soft feces",
          "expected_effects": "Resolution of soft stool",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:26:22.000000Z",
          "updated_at": "2020-11-03T19:26:22.000000Z"
      },
      {
          "id": 1937,
          "drug_id": 547,
          "indication_name": "Aortic thromboembolism, acute",
          "expected_effects": "In a dog with signs of thromboembolism for <12h, treatment was associated with improved pulse quality and return of muscle tone and withdrawal response within 3h; aortic thrombus resolved within 2 weeks of treatment",
          "common_combinations": "Deferoxamine mesylateb 10 mg/kg IV q 2-8h (to help prevent reperfusion injury) + aspirin 0.5 mg/kg PO q 12h in 1 case report",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:29:15.000000Z",
          "updated_at": "2020-11-03T19:29:15.000000Z"
      },
      {
          "id": 1938,
          "drug_id": 547,
          "indication_name": "Aortic thromboembolism, chronic - ineffective",
          "expected_effects": "No significant improvement in hindlimb perfusion, then necrosis of hindlimb tissues requiring amputation of a digit in 1 case report of a dog with clinical signs X 4 weeks preceding treatment",
          "common_combinations": "Heparin 100 IU/kg IV or SC q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T19:29:15.000000Z",
          "updated_at": "2020-11-03T19:29:15.000000Z"
      },
      {
          "id": 1939,
          "drug_id": 547,
          "indication_name": "Catheter-associated jugular venous thrombosis",
          "expected_effects": "Acute reduction in size of caval thrombus (from 2.9 cm to 1.4 cm) within 48 hours, and resolution of chylothorax within two weeks, in 1 case report",
          "common_combinations": "Heparin 100 IU/kg IV q 6h + fresh frozen plasma 24 mL/kg IV over 6 hrs",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-03T19:29:15.000000Z",
          "updated_at": "2020-11-03T19:29:15.000000Z"
      },
      {
          "id": 1940,
          "drug_id": 547,
          "indication_name": "Aortic thromboembolism - efficacy questionable",
          "expected_effects": "In cats treated immediately (within 1h of presentation to the hospital) when signs of ATE start <12h before presentation, tPA is associated with restored pulses in 40% (4h) to 53% (24h) of limbs and restored motor function in 33% of limbs (24h); 27% of cats discharged from hospital alive in 1 propective trial (trial terminated prematurely due to high rate of adverse effects)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-03T19:29:15.000000Z",
          "updated_at": "2020-11-03T19:29:15.000000Z"
      },
      {
          "id": 1941,
          "drug_id": 548,
          "indication_name": "Copper storage disease",
          "expected_effects": "Reduction in hepatic [Cu] from 1,215 μg/g dry weight (DW) pre-treatment to 300 μg/g DW after 1 year of treatment in 1 case report",
          "common_combinations": "Low-copper diet",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:30:45.000000Z",
          "updated_at": "2020-11-03T19:30:45.000000Z"
      },
      {
          "id": 1942,
          "drug_id": 549,
          "indication_name": "Nausea - ineffective",
          "expected_effects": "Ineffective at preventing vomiting in dogs given emetic agent protoveratrine",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:35:56.000000Z",
          "updated_at": "2020-11-03T19:35:56.000000Z"
      },
      {
          "id": 1943,
          "drug_id": 549,
          "indication_name": "Nausea - ineffective",
          "expected_effects": "Ineffective at preventing vomiting in cats given emetic agent RU-24969",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T19:35:56.000000Z",
          "updated_at": "2020-11-03T19:35:56.000000Z"
      },
      {
          "id": 1944,
          "drug_id": 550,
          "indication_name": "Nausea - ineffective",
          "expected_effects": "Ineffective at preventing vomiting in dogs given emetic agent protoveratrine",
          "common_combinations": null,
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T19:36:40.000000Z",
          "updated_at": "2020-11-03T19:36:40.000000Z"
      },
      {
          "id": 1945,
          "drug_id": 550,
          "indication_name": "Nausea - ineffective",
          "expected_effects": "Ineffective at preventing vomiting in cats given emetic agent RU-24969",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-03T19:36:40.000000Z",
          "updated_at": "2020-11-03T19:36:40.000000Z"
      },
      {
          "id": 1946,
          "drug_id": 551,
          "indication_name": "Pruritus - atopic dermatitis, flea bite hypersensitivity, idiopathic",
          "expected_effects": "Trimeprazine + prednisolone decreases glucocorticoid dosage by an average of 30% in 75% of dogs; trimeprazine + prednisolone effective in controlling pruritus in 77% of dogs; trimeprazine monotherapy is ineffective for controlling pruritus in a majority of dogs (poor or no response in 97% of treated dogs)",
          "common_combinations": "Prednisolone 2 mg",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T20:25:40.000000Z",
          "updated_at": "2020-11-03T20:25:40.000000Z"
      },
      {
          "id": 1947,
          "drug_id": 552,
          "indication_name": "Prevention of hypocalcemia after surgical correction of hyperparathyroidism",
          "expected_effects": "33% rate of clinical hypocalcemia (tetany) with this treatment post-parathyroidectomy, compared to 64% without treatment",
          "common_combinations": "Calcium carbonate 333-1000 mg/DOG PO q 8h",
          "is_contraindicated": 1,
          "vdi_display_order": 1,
          "created_at": "2020-11-03T20:48:34.000000Z",
          "updated_at": "2020-11-03T20:48:34.000000Z"
      },
      {
          "id": 1948,
          "drug_id": 4,
          "indication_name": "Analgesia (orthopedic surgery) - insufficient effect",
          "expected_effects": "Analgesia similar to that obtained with tramadol 5-7 mg/kg PO q 12h, but either approach is insufficient (25-30% of patients require rescue analgesia)",
          "common_combinations": "Hydrocodone 0.5-0.6 mg/kg PO q 8h with each dose of acetaminophen; morphine 0.25-0.5 mg/kg SC (single dose immediately post-op)",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-11-04T01:58:40.000000Z",
          "updated_at": "2020-11-04T01:58:40.000000Z"
      },
      {
          "id": 1953,
          "drug_id": 4,
          "indication_name": "Universal toxicity in this species - no known safe dosage or treatment indications",
          "expected_effects": null,
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-04T01:59:46.000000Z",
          "updated_at": "2020-11-04T01:59:46.000000Z"
      },
      {
          "id": 1956,
          "drug_id": 5,
          "indication_name": "Paroxysmal dyskinesia",
          "expected_effects": "Elimination of all exercise-associated episodes of muscular stiffness and collapse 3 days after beginning treatment (where 2 weeks of clonazepam treatment had failed), and recovery of normal muscle mass, all in 1 case report of a 12 week-old Golden Retriever puppy.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T02:01:14.000000Z",
          "updated_at": "2020-11-04T02:01:14.000000Z"
      },
      {
          "id": 1957,
          "drug_id": 5,
          "indication_name": "Hydrocephalus - ineffective",
          "expected_effects": "No treatment-associated change in clinical signs or ventricle-brain ratio on MRI",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-04T02:01:14.000000Z",
          "updated_at": "2020-11-04T02:01:14.000000Z"
      },
      {
          "id": 1958,
          "drug_id": 6,
          "indication_name": "Parvoviral enteritis/septicemia",
          "expected_effects": "Significantly earlier improvement in leukopenia (evident by day 3) with addition of acetylcysteine to treatment protocol",
          "common_combinations": "Supportive treatment (IV fluids, antiemetic, antibiotic (e.g., ceftriaxone-tazobactam)",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-04T02:01:58.000000Z",
          "updated_at": "2020-11-04T02:01:58.000000Z"
      },
      {
          "id": 1959,
          "drug_id": 7,
          "indication_name": "Prevention of recurrent aortic thrombosis",
          "expected_effects": "Significantly inferior prevention of recurrent thromboembolism compared to clopidogrel 18.75 mg/CAT PO q 24h",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-04T02:02:41.000000Z",
          "updated_at": "2020-11-04T02:02:41.000000Z"
      },
      {
          "id": 1960,
          "drug_id": 9,
          "indication_name": "Monitoring of trilostane or mitotane treatment",
          "expected_effects": "Similar results to those obtained with higher dosage (5 μg/kg), indicating the lower (1 μg/kg) dosage can be used for monitoring of treatment, but not for initial diagnosis, of hyperadrenocorticism",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-04T02:16:27.000000Z",
          "updated_at": "2020-11-04T02:16:27.000000Z"
      },
      {
          "id": 1961,
          "drug_id": 13,
          "indication_name": "Insulin resistance (progesterone-induced)",
          "expected_effects": "Reduction in insulin requirement by day 19 (but not in first week): median dosage of insulin decrease (from 1.98 U/kg to <1 IU/kg in one study), whereas control dogs are unchanged; serum progesterone concentrations do not change despite aglepristone treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-04T02:19:09.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 1962,
          "drug_id": 13,
          "indication_name": "Mammary carcinoma",
          "expected_effects": "Trend to improved prognosis, especially for tumors that are smaller (<3 cm diameter), single, histologically mixed or complex, of histologic grade I, of TNM stage I or II, and without lymph node metastasis",
          "common_combinations": "Surgical excision of mammary tumor(s)",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-04T02:19:09.000000Z",
          "updated_at": "2020-11-04T02:19:09.000000Z"
      },
      {
          "id": 1963,
          "drug_id": 14,
          "indication_name": "Echinococcosis (alveolar - prostatic)",
          "expected_effects": "Decrease in size of cyst, relieving constipation and stranguria",
          "common_combinations": "Surgical drainage of lesions; praziquantel 7.5 mg/kg PO once",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-04T02:21:15.000000Z",
          "updated_at": "2020-11-04T02:21:15.000000Z"
      },
      {
          "id": 1964,
          "drug_id": 22,
          "indication_name": "Bacterial cystitis (Pseudomonas aeruginosa) associated with permanent cystostomy tube",
          "expected_effects": "Resolution of infection in 1 case, but with onset of casts in urine after 14 days (requiring replacement of cystostomy tube)  and then onset of hematuria at 27 days (which resolved when amikacin was stopped); no abnormalities of serum renal values.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-04T02:23:40.000000Z",
          "updated_at": "2020-11-04T02:23:40.000000Z"
      },
      {
          "id": 1965,
          "drug_id": 23,
          "indication_name": "Pericardial effusion due to bleeding right atrial mass - ineffective",
          "expected_effects": "Median recurrence of clinical signs associated with cardiac tamponade in 1-186 days (median = 12 days), which is not different from untreated controls (1-277 days).",
          "common_combinations": "Yunnan Baiyao 1-2 capsules PO q 12h",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T02:26:49.000000Z",
          "updated_at": "2020-11-04T02:26:49.000000Z"
      },
      {
          "id": 1966,
          "drug_id": 26,
          "indication_name": "Ventricular tachycardia (refractory), ventricular fibrillation",
          "expected_effects": "75% effectiveness for conversion to sinus rhythm in non-cardiac-arrest cases and 75% rate of discharge in these patients; 0% survival rate in dogs treated during cardiac arrest.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T02:27:44.000000Z",
          "updated_at": "2020-11-04T02:27:44.000000Z"
      },
      {
          "id": 1967,
          "drug_id": 42,
          "indication_name": "Hypertrophic cardiomyopathy, subclinical - ineffective",
          "expected_effects": "No significant difference in cardiac or all-cause mortality between cats receiving atenolol and untreated controls",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-04T02:28:03.000000Z",
          "updated_at": "2020-11-04T02:28:03.000000Z"
      },
      {
          "id": 1968,
          "drug_id": 43,
          "indication_name": "Reversal of general anesthesia that includes dexmedetomidine",
          "expected_effects": "Faster resolution of sedation and faster return to sternal recumbency (median = 15 minutes [range = 5-60 minutes] versus median = 60 minutes [range = 15-90 minutes] for placebo) in cats induced with dexmedetomidine-ketamine-hydromorphone IM",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T02:28:14.000000Z",
          "updated_at": "2020-11-04T02:28:14.000000Z"
      },
      {
          "id": 1969,
          "drug_id": 44,
          "indication_name": "Babesiosis (Babesia gibsoni)",
          "expected_effects": "88% improvement in days post-treatment, but 71% rate of relapse in 90 days post-treatment; a second course of treatment can produce a good response in some dogs and no response in others",
          "common_combinations": "Proguanil 7-10 mg/kg PO q 12 h X 10d + doxycycline 5 mg/kg PO q 12h X 30d",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-04T02:28:23.000000Z",
          "updated_at": "2020-11-04T02:28:23.000000Z"
      },
      {
          "id": 1970,
          "drug_id": 44,
          "indication_name": "Babesiosis (B. microti-like isolate)",
          "expected_effects": "Clinical signs fully resolved in 76% of dogs at 90-day follow-up visit, with 82% of dogs showing resolution of clinical laboratory abnormalities; nevertheless, parasitemia persists (via PCR) on days 90 (47% of cases) and 360 (50%) despite atovaquone treatment (versus 68% and 60% persistence with buparvaquone and 94% and 73% persistence with imidocarb, respectively)",
          "common_combinations": "Azithromycin 10 mg/kg PO q 24h X 10d",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-04T02:28:23.000000Z",
          "updated_at": "2020-11-04T02:28:23.000000Z"
      },
      {
          "id": 1971,
          "drug_id": 50,
          "indication_name": "Chronic enteropathy",
          "expected_effects": "Treatment success in 7% of dogs (versus 71% in dogs treated with chlorambucil 4.4 mg/m2 PO q 24h + prednisolone 1.7 mg/kg PO q 24h), median serum albumin increase=36% at 3 weeks (versus 56% for chlorambucil + prednisolone), and median survival=30 days (versus >500 days for chlorambucil + prednisolone), all indicating inferiority of azathioprine compared to chlorambucil for this indication",
          "common_combinations": "Prednisolone 2 mg/kg (range: 1.3-3.8 mg/kg) PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-04T02:28:48.000000Z",
          "updated_at": "2020-11-04T02:28:48.000000Z"
      },
      {
          "id": 1972,
          "drug_id": 50,
          "indication_name": "Pyoderma gangrenosum",
          "expected_effects": "Resolution of skin lesions (leaing residual scarring) during 1st 3 weeks of treatment in 1 case report",
          "common_combinations": "Prednisolone 0.75 mg/kg PO q 12h initially, then tapered after 100 days of treatment (to 0.25 mg/kg prednisolone PO q 72h over 6 months)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-04T02:28:48.000000Z",
          "updated_at": "2020-11-04T02:28:48.000000Z"
      },
      {
          "id": 1973,
          "drug_id": 50,
          "indication_name": "Eosinophilic pulmonary granulomatosis",
          "expected_effects": "Clinical improvement after 2 weeks of treatment, complete resolution of signs after 4 weeks of treatment, and no recurrence for 2 years after end of 6-month course of treatment, all in 1 case report",
          "common_combinations": "Prednisolone 1.1 mg/kg PO q 12h X 2 weeks, then decreased based on clinical improvement to 0.7 mg/kg PO q 12h for weeks 3-4, 0.7 mg/kg PO q 24h for weeks 5-7, 0.7 mg/kg q 48h for weeks 8-10, 0.4 mg/kg PO q 48h for weeks 11-14, and 0.2 mg/kg PO q 48h for weeks 15-17 in 1 case report",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-04T02:28:48.000000Z",
          "updated_at": "2020-11-04T02:28:48.000000Z"
      },
      {
          "id": 1974,
          "drug_id": 51,
          "indication_name": "Babesiosis (B. microti-like isolate)",
          "expected_effects": "Clinical signs fully resolved in 76% of dogs (with atovaquone co-treatment) at 90-day follow-up visit, and with 82% of dogs showing resolution of clinical laboratory abnormalities; nevertheless, parasitemia persists (via PCR) on days 90 (47% of cases) and 360 (50%), versus 68% and 60% persistence with buparvaquone + azithromycin and 94% and 73% persistence with imidocarb treatment, respectively",
          "common_combinations": "Either atovaquone 13.5 mg/kg PO q 8h X 10d or buparvaquone 5 mg/kg IM twice (48h apart)",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-04T02:29:15.000000Z",
          "updated_at": "2020-11-04T02:29:15.000000Z"
      },
      {
          "id": 1975,
          "drug_id": 51,
          "indication_name": "Cyclosporine-induced gingival hyperplasia",
          "expected_effects": "Significant decrease in gingival sulcus depth indicating regression of gingival hyperplasia at week 8, 4 weeks after ending cyclosporine treatment; superior results (and fewer GI adverse effects) with azithromycin (85 mg/g) toothpaste-based formulation, with decreased sulcus depth after only 2 weeks of treatment; gingival overgrowth due to cyclosporine (prompting azithromycin treatment) occurs after 82-2178 days (mean=723 days) of cyclosporin treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-04T02:29:15.000000Z",
          "updated_at": "2020-11-04T02:29:15.000000Z"
      },
      {
          "id": 1976,
          "drug_id": 51,
          "indication_name": "Hemoabdomen due to peliosis hepatis with Bartonella infection",
          "expected_effects": "Marked improvemen in systemic signs during 5-day hospitalization, normal physical examination 1 week after discharge, and full recovery with no recurrence 1 year post-diagnosis in 1 case report",
          "common_combinations": "Surgical resection of bleeding liver lesions and liver biopsy",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-04T02:29:15.000000Z",
          "updated_at": "2020-11-04T02:29:15.000000Z"
      },
      {
          "id": 1977,
          "drug_id": 57,
          "indication_name": "Lymphoma - minimally effective",
          "expected_effects": "Minimally effective: progresssive disease despite bleomycin treatment in 89% of dogs in 1 case series, partial response in 1 case that received 4 treatments (cumulative dose: 2.3 U/kg over 4 weeks) and showed a decrease in lymph node size.",
          "common_combinations": "Pretreatment diphenhydramine and antiemetic (maropitant +/- ondansetron) in some cases, at clinician's preference",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-04T16:18:38.000000Z",
          "updated_at": "2020-11-04T16:18:38.000000Z"
      },
      {
          "id": 1978,
          "drug_id": 57,
          "indication_name": "Squamous cell carcinoma",
          "expected_effects": "19% complete remission, 14% partial remission, 29% stable disease, and 38% progressive disease after a median of 5 treatments; median time to progression (bleomycin alone) = 3.9 months versus 20.6-24.2 months if part of an electrochemotherapy protocol",
          "common_combinations": "+/- electroporation (electrochemotherapy)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-04T16:18:38.000000Z",
          "updated_at": "2020-11-04T16:18:38.000000Z"
      },
      {
          "id": 1979,
          "drug_id": 58,
          "indication_name": "Seizure reduction/prevention - loading dose only",
          "expected_effects": "Therapeutic bromide levels (1-3 mg/mL) noted in 84% of dogs when measured within 24h of completing the protocol",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T16:29:23.000000Z",
          "updated_at": "2020-11-04T16:29:23.000000Z"
      },
      {
          "id": 1980,
          "drug_id": 60,
          "indication_name": "Chronic bronchial disease (feline asthma, feline chronic bronchitis)",
          "expected_effects": "Improvement and complete resolution of clinical signs in 28% and 26% of cats treated for >2 months, respectively.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T17:23:32.000000Z",
          "updated_at": "2020-11-04T17:23:32.000000Z"
      },
      {
          "id": 1981,
          "drug_id": 62,
          "indication_name": "Intratesticular (castration) - ineffective",
          "expected_effects": "Ineffective: no difference in postoperative pain scores or incision site scores compared to saline placebo",
          "common_combinations": "Lidocaine 1 mg/kg mixed with bupivacaine 1 mg/kg and injected simultaneously as mixture",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-11-04T18:21:10.000000Z",
          "updated_at": "2020-11-04T18:21:10.000000Z"
      },
      {
          "id": 1982,
          "drug_id": 62,
          "indication_name": "Intraperitoneal",
          "expected_effects": "Effective analgesia: significantly less rescue analgesia needed compared to placebo controls (and similar analgesia to meloxicam SC, suggesting the possibility of meloxicam SC + bupivacaine IP for higher-level analgesia)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-11-04T18:21:10.000000Z",
          "updated_at": "2020-11-04T18:21:10.000000Z"
      },
      {
          "id": 1983,
          "drug_id": 62,
          "indication_name": "Sciatic and femoral nerve blockade",
          "expected_effects": "Analgesia observed for up to 8 hours after administration, and gait deficits for up to 3 hours after administration, in treated hindlimb",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-11-04T18:21:11.000000Z",
          "updated_at": "2020-11-04T18:21:11.000000Z"
      },
      {
          "id": 1984,
          "drug_id": 62,
          "indication_name": "Mastectomy - surgical wound irrigation",
          "expected_effects": "Significantly greater analgesia (and lower rates of vocalization and aggression) for 4-10 hours potoperatively, compared to cats receiving carprofen alone",
          "common_combinations": "Carprofen 4 mg/kg SC once",
          "is_contraindicated": 0,
          "vdi_display_order": 17,
          "created_at": "2020-11-04T18:21:11.000000Z",
          "updated_at": "2020-11-04T18:21:11.000000Z"
      },
      {
          "id": 1985,
          "drug_id": 62,
          "indication_name": "Perineal urethrostomy - pudendal nerve block",
          "expected_effects": "Significantly less analgesic requirement intra- and posoperatively compared to placebo control",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 18,
          "created_at": "2020-11-04T18:21:11.000000Z",
          "updated_at": "2020-11-04T18:21:11.000000Z"
      },
      {
          "id": 1986,
          "drug_id": 63,
          "indication_name": "Analgesia (orthopedic)",
          "expected_effects": "Inferior analgesia compared to methadone 0.5 mg/kg IM once (79% versus 42% requirement forpostoperative rescue analgesia, respectively)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-04T20:17:15.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 1987,
          "drug_id": 63,
          "indication_name": "Oral pain (gingivostomatitis)",
          "expected_effects": "Significant reduction in oral pain scores evident from 30 to 90 minutes after administration",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-11-04T20:17:15.000000Z",
          "updated_at": "2020-11-04T20:17:15.000000Z"
      },
      {
          "id": 1988,
          "drug_id": 66,
          "indication_name": "Galactorrhea associated with prolactinoma",
          "expected_effects": "Resolution of galactorrhea after 1 week of treatment; serum [prolactin] = 0.42 ng/mL after 4 weeks of treatment; stopping treatment after 4 months triggers return of galactorrhea within 26 days, and serum [prolactin] = 17.9 ng/mL - all drawn from 1 canine case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-04T20:22:04.000000Z",
          "updated_at": "2020-11-04T20:22:04.000000Z"
      },
      {
          "id": 1989,
          "drug_id": 68,
          "indication_name": "Rickets",
          "expected_effects": "Normocalcemia and healing of pathologic fractures after 3 weeks of treatment; clinically normal thereafter (1 feline case report)",
          "common_combinations": "Calcium carbonate 75 mg/kg PO q 8h X 1 year (case report)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-04T20:40:43.000000Z",
          "updated_at": "2020-11-04T20:40:43.000000Z"
      },
      {
          "id": 1990,
          "drug_id": 68,
          "indication_name": "Myocardial failure caused by hypoparathyroidism-asscociated profound hypocalcemia",
          "expected_effects": "Resolution of cardiac chamber dilation and poor systolic function over the first 6 weeks of treatment, allowing permanent discontinuation of all cardiac medications; normal cardiovascular status at 1 year - all in 1 case report",
          "common_combinations": "Calcium carbonate 96 mg/kg PO q 24h X 3 months (tapering to zero in 3rd month) in 1 case report",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T20:40:43.000000Z",
          "updated_at": "2020-11-04T20:40:43.000000Z"
      },
      {
          "id": 1991,
          "drug_id": 70,
          "indication_name": "Medical castration - questionable efficacy",
          "expected_effects": "Azoospermia for at least 12 months in 60% and 80% of dogs receiving the 0.1 and 0.2 mg/mL injections, respectively, with no adverse effects; azoospermia in >90% of dogs receiving the 0.4 and 0.6 mg/mL injections, respectively, but with 20% and 60% rate of adverse effects, respectively (scrotal inflammation, ulceration, and fistula formation)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-04T20:44:24.000000Z",
          "updated_at": "2020-11-04T20:44:24.000000Z"
      },
      {
          "id": 1992,
          "drug_id": 76,
          "indication_name": "Osteosarcoma - accelerated protocol",
          "expected_effects": "Median survival time - 317 days; 1- and 2-year survival = 43.2 and 13.9%, respectively.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-11-04T21:18:44.000000Z",
          "updated_at": "2020-11-04T21:18:44.000000Z"
      },
      {
          "id": 1993,
          "drug_id": 76,
          "indication_name": "Lower urinary tract carcinoma - intraarterial administration",
          "expected_effects": "Greater treatment effect compared to IV administration (e.g., 36% partial remission [≥30% decrese in target lesion diameter] with IA compared to 13% with IV); significantly less anemia, lethargy, and anorexia with IA compared to IV.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-11-04T21:18:44.000000Z",
          "updated_at": "2020-11-04T21:18:44.000000Z"
      },
      {
          "id": 1994,
          "drug_id": 76,
          "indication_name": "Lower urinary tract transitional cell carcinoma",
          "expected_effects": "65% improvement in clinical signs; 35% unchanged clinical signs; median progression-free interval = 74 days, which is not significantly different from mitoxantrone treatment",
          "common_combinations": "Piroxicam 0.3 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-11-04T21:18:44.000000Z",
          "updated_at": "2020-11-04T21:18:44.000000Z"
      },
      {
          "id": 1995,
          "drug_id": 78,
          "indication_name": "Antioxidant/muscle recovery (canine athletes)",
          "expected_effects": "Greater lean body mass, lower serum myoglobin levels, and greater antioxidant activity associated with carnitine supplementation",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-04T21:32:23.000000Z",
          "updated_at": "2020-11-04T21:32:23.000000Z"
      },
      {
          "id": 2000,
          "drug_id": 79,
          "indication_name": "Carprofen",
          "expected_effects": "Significantly greater analgesia compared to tramadol (e.g., rescue analgesia needed in 5% of carprofen-treated dogs vs 29% for tramadol-treated dogs)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-04T21:44:43.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 2001,
          "drug_id": 79,
          "indication_name": "Perioperative analgesia (cutaneous mass removal) - ineffective",
          "expected_effects": "No difference in postoperative pain parameters between placebo or carprofen treatment preoperatively",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-04T21:44:43.000000Z",
          "updated_at": "2020-11-04T21:44:43.000000Z"
      },
      {
          "id": 2002,
          "drug_id": 91,
          "indication_name": "Urinary tract infection prevention in spinal cord injury patients: questionable efficacy",
          "expected_effects": "No significant benefit over intraoperative cefazolin (25% prevalence of UTI with cefovecin vs. 17.4% with intra-op cefazolin)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-05T19:46:43.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 2003,
          "drug_id": 91,
          "indication_name": "Lyme borreliosis (experimental, 75 days post-infection)",
          "expected_effects": "Similar to amoxicillin or doxycycline treatment: significant elimination of Borrelia antigen (noted via PCR on skin biopsy samples); significantly greater reduction/elimination of Borrelia antibody titer compared to no treatment.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-05T19:46:43.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 2004,
          "drug_id": 91,
          "indication_name": "Parvoviral enteritis (outpatient protocol)",
          "expected_effects": "80% survival to discharge (versus 90% with inpatient intensive care); 3.8 +/- 1.6 days to discharge with this protocol versus 4.6 +/- 2 days with inpatient intensive care; 50% of dogs treated with this protocol require dextrose supplementation and 60% of dogs require potassium supplementation",
          "common_combinations": "Initial IV fluid resuscitation for stabilization (15-45 mL/kg crystalloids), initial treatment for hypoglycemia if needed (using 25% dextrose IV), external warming if hypothermia, and general supportive care; then outpatient treatment with cefovecin, SC isotonic crystalloid fluids (30 mL/kg SC q 6h), and maropitant 1 mg/kg SC q 24h; buprenorphine 0.02 mg/kg SC if evidence of pain; ondansetron 0.5 mg/kg SC if ≥3 episodes of vomiting in 6h; 1-5 mL high fructose corn syrup q 4-6h if hypoglycemic.",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-05T19:46:43.000000Z",
          "updated_at": "2020-11-05T19:46:43.000000Z"
      },
      {
          "id": 2007,
          "drug_id": 92,
          "indication_name": "Parvoviral enteritis",
          "expected_effects": "90% survival to discharge (versus 80% with outpatient protocol); 4.6 +/- 2 days to discharge with this protocol versus 3.8 +/- 1.6 days with outpatient treatment",
          "common_combinations": "Initial IV fluid resuscitation for stabilization (15-45 mL/kg crystalloids), initial treatment for hypoglycemia if needed (using 25% dextrose IV), external warming if hypothermia, and general supportive care; then ongoing treatment with cefoxitin, IV isotonic crystalloid fluids (120 mL/kg/day IV with 25 mEq/L KCl, plus ongoing losses), and maropitant 1 mg/kg IV q 24h; buprenorphine 0.02 mg/kg IV if evidence of pain; ondansetron 0.5 mg/kg IV if ≥3 episodes of vomiting in 6h; a 25% dextrose bolus followed by 2.5%-7.5% dextrose IV CRI if hypoglycemic.",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-05T19:53:24.000000Z",
          "updated_at": "2020-11-05T19:53:24.000000Z"
      },
      {
          "id": 2008,
          "drug_id": 100,
          "indication_name": "Atopic dermatitis - ineffective",
          "expected_effects": "Ineffective: cetirizine treatment does not alter clinical signs more than does placebo administration.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-05T20:37:57.000000Z",
          "updated_at": "2020-11-05T20:37:57.000000Z"
      },
      {
          "id": 2009,
          "drug_id": 102,
          "indication_name": "Lymphoma (L-CHOC, prednisolone-free protocol)",
          "expected_effects": "L-asparaginase 10 000 U/m2 IM on day 1 of treatment; doxorubicin 30 mg/m2 IV on days 8, 22, 43, 71, and 92 of treatment; vincristine 0.5-0.7 mg/m2 IV once on day 57 of treatment; cyclophosphamide 200-250 mg/m2 PO on days 60 and 113 of treatment; +/- prednisone PO q 24h at (mg/m2) 50 (starting day 8), 40 (starting day 15), 30 (starting day 22), 25 (starting day 29), 20 (starting at day 43), 15 (starting at day 57), 10 (starting at day 71), 5 (starting at day 85), and 5 q 48h (from days 99-113) of treatment",
          "common_combinations": "L-asparaginase 10 000 U/m2 IM on day 1 of treatment; doxorubicin 30 mg/m2 IV on days 8, 22, 43, 71, and 92 of treatment; vincristine 0.5-0.7 mg/m2 IV once on day 57 of treatment; cyclophosphamide 200-250 mg/m2 PO on days 60 and 113 of treatment; +/- prednisone PO q 24h at (mg/m2) 50 (starting day 8), 40 (starting day 15), 30 (starting day 22), 25 (starting day 29), 20 (starting at day 43), 15 (starting at day 57), 10 (starting at day 71), 5 (starting at day 85), and 5 q 48h (from days 99-113) of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-07T18:25:22.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 2010,
          "drug_id": 102,
          "indication_name": "Chronic enteropathy",
          "expected_effects": "Treatment success in 71% of dogs (versus 7% in dogs treated with azathioprine 1.6 mg/kg PO q 24h + prednisolone 2 mg/kg PO q 24h), median serum albumin increase=56% at 3 weeks (versus 36% for azathioprine + prednisolone), and median survival >500 days (versus 30 days for azathioprine + prednisolone), all indicating superiority of chlorambucil compared to azathioprine for this indication",
          "common_combinations": "Prednisolone 1.7 mg/kg (range: 1-2.4 mg/kg) PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-07T18:25:22.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 2011,
          "drug_id": 102,
          "indication_name": "Transitional cell carcinoma (refractory)",
          "expected_effects": "3% partial remission, 67% stable disease, and 30% progressive disease in one clinical trial of dogs that had previously shown progression during stanrdard chemotherapy; median progression-free interval (time from the start of chlorambucil treatment to the day progressive disease was detected) of 119 days (range, 7-728 days) and median survival time of 221 days (range, 7-747 days).",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-07T18:25:22.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 2012,
          "drug_id": 102,
          "indication_name": "Eosinophilic granuloma of the digits",
          "expected_effects": "Marked improvement/almost complete resolution described in 2 cases",
          "common_combinations": "Prednisolone 1.5-1.8 mg/kg PO q 24h X 2 weeks, then tapered and/or stopped; debulking laser surgery in 1 case; amoxicilliin clavulanate 12.5 mg/kg PO q 12h X 2-4 weeks +/- povidone iodine topical foot soaks",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-07T18:25:22.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 2013,
          "drug_id": 102,
          "indication_name": "Myeloma-related disorder",
          "expected_effects": "Complete resolution of hematologic and globulin abnormalities in 50% of treated cats, generally after chlorambucil was implemented because of toxicosis involving other protocols (melphalan or cyclophosphamide)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-07T18:25:22.000000Z",
          "updated_at": "2020-11-07T18:25:22.000000Z"
      },
      {
          "id": 2014,
          "drug_id": 105,
          "indication_name": "Allergic disorders (e.g., atopic dermatitis)",
          "expected_effects": "54% efficacy in reducing pruritus when given together with omega-3/omega-6 fatty acid supplement",
          "common_combinations": "Omega-3/omega-6 fatty acid supplement (0.5 mL/4.5 kg PO q 24h;contents per mL: 49.5% linoleic acid, 4.2% eicosapentaenoic acid (EPA), 2.8% docosahexaenoic acid (DHA), 1.6% gamma linolenic acid (GLA), 46 IU vitamin E, i.e., DVM DermCaps Liquid)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-07T18:41:01.000000Z",
          "updated_at": "2020-11-07T18:41:01.000000Z"
      },
      {
          "id": 2015,
          "drug_id": 108,
          "indication_name": "Increase in luteinized follicles and progresterone in anestrous bitches",
          "expected_effects": "Induced estrus and ovulation in 64.3% and 83.3% of treated dogs, respectively (similar to cabergoline treatment); 5-fold greater occurrence of follicles with luteinized walls compared to cabergoline or placebo treatment, and presence of cysts (versus none found in cabergoline- or placebo-treated dogs); significantly higher plasma progesterone concentration",
          "common_combinations": "Equine chorionic gonadotropin 20 IU/kg SC q 24h X 5 days",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-07T18:45:08.000000Z",
          "updated_at": "2020-11-07T18:45:08.000000Z"
      },
      {
          "id": 2016,
          "drug_id": 114,
          "indication_name": "Leprosy",
          "expected_effects": "No visible effect on gross cutaneous lesion after 4 days of treatment, but complete rsolution with surgical excision followed by 25 days of clarithromycin postoperatively",
          "common_combinations": "Rifampicin 15.2 mg/kg PO q 24h X 5 days",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-07T18:56:54.000000Z",
          "updated_at": "2020-11-07T18:56:54.000000Z"
      },
      {
          "id": 2017,
          "drug_id": 122,
          "indication_name": "Anxiety-related disorders",
          "expected_effects": "Improvement noted in 69% of treated dogs",
          "common_combinations": "Fluoxetine 1 mg/kg PO q 24h X 10 weeks, and behavioral modification program",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-11-07T19:12:24.000000Z",
          "updated_at": "2020-11-07T19:12:24.000000Z"
      },
      {
          "id": 2018,
          "drug_id": 123,
          "indication_name": "Clotrimazole",
          "expected_effects": "Resolution of clinical signs with single treatment in 68% of cases, and with 1-3 treatments in 94% of cases",
          "common_combinations": "Meticulous surgical debridement; itraconazole 5 mg/kg PO q 24h X 3 months in some cases",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-07T19:17:21.000000Z",
          "updated_at": "2020-11-07T19:17:21.000000Z"
      },
      {
          "id": 2019,
          "drug_id": 124,
          "indication_name": "Inherited selective cobalamin malabsorption",
          "expected_effects": "Marked clinical improvement within 4 days of starting supplementation, with near-complete resolution of physical and hematologic abnormalities by 12 days after starting supplementation and no abnormalities at 8-month recheck in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-08T14:15:22.000000Z",
          "updated_at": "2020-11-08T14:15:22.000000Z"
      },
      {
          "id": 2020,
          "drug_id": 124,
          "indication_name": "Hypocobalaminemia associated with chronic enteropathy",
          "expected_effects": "Significant improvement in clinical signs and marked increase in serum cobalamin concentration both associated with cobalamin supplementation, and both noted to regress with discontinuation of supplementation (suggesting longer-duration treatment should be considered)",
          "common_combinations": "Dietary changes, probiotic administration, and ancillary treatment at clinician's discretion",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T14:15:22.000000Z",
          "updated_at": "2020-11-08T14:15:22.000000Z"
      },
      {
          "id": 2021,
          "drug_id": 124,
          "indication_name": "Cobalamin supplementation",
          "expected_effects": ">96% of cats have serum cobalamin concentrations above the reference interval with this protocol (pretreatment vs. posttreatment median serum cobalamin concentrations: 128 pmol/L vs. 2701 pmol/L)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-08T14:15:22.000000Z",
          "updated_at": "2020-11-08T14:15:22.000000Z"
      },
      {
          "id": 2022,
          "drug_id": 125,
          "indication_name": "Cutaneous analgesia - ineffective",
          "expected_effects": "No difference in thermal threshold compared to placebo",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-08T14:17:16.000000Z",
          "updated_at": "2020-11-08T14:17:16.000000Z"
      },
      {
          "id": 2023,
          "drug_id": 127,
          "indication_name": "Lymphoma (L-CHO, prednisone-free protocol)",
          "expected_effects": "Median progression-free survival=142.5 days (without prednisone) to 292 days (with prednisone), both with L-asparaginase at start of treatment; difference between these 2 groups suggests a trend favoring prednisone but the difference is not statistically significant",
          "common_combinations": "L-asparaginase 400 U/kg once on day 1 of treatment; vincristine 0.7 mg/m2 IV q 14 days beginning on week 1 of treatment; doxorubicin 30 mg/m2 IV or 1 mg/kg IV on weeks 4, 9, 17, and 25 of treatment; +/- prednisone PO q 24h at 2, 1.5, 1, and 0.5 mg/kg X 1 week each, beginning at week 1 of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T14:44:38.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 2024,
          "drug_id": 127,
          "indication_name": "Lymphoma (L-CHOC, prednisolone-free protocol)",
          "expected_effects": "Complete response in 75% of cases with disease-free period=176 days (initial treatment), and complete response in 45% of cases with disease-free period=133 days (rescue treatment); no effect from adding or withholding prednisolone",
          "common_combinations": "L-asparaginase 10 000 U/m2 IM once on day 1 of treatment; doxorubicin 30 mg/m2 IV on days 8, 22, 43, 71, and 92 of treatment; chlorambucil 25 mg/m2 PO over 2 days starting on day 33 of treatment, then chlorambucil 2 mg/m2 PO q 24h from days 127-148 of treatment; vincristine 0.5-0.7 mg/m2 IV once on day 57 of treatment; +/- prednisone PO q 24h at (mg/m2) 50 (starting day 8), 40 (starting day 15), 30 (starting day 22), 25 (starting day 29), 20 (starting at day 43), 15 (starting at day 57), 10 (starting at day 71), 5 (starting at day 85), and 5 q 48h (from days 99-113) of treatment.",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-08T14:44:38.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 2025,
          "drug_id": 127,
          "indication_name": "Lymphoma (L-CHOP protocol, maintenance-free)",
          "expected_effects": "No difference between a 6-month induction phase and no maintenance versus a 6-month induction phase plus a 1.5-year maintenance phase with regard to disease-free interval (216 vs. 184 days), median survival time (375 vs. 304 days), and 6-month (73 vs. 67%), 1-year (50 vs. 39%), and 2-year (24 vs. 21%) survival, respectively.",
          "common_combinations": "Induction phase: vincristine 0.65-0.75 mg/m2 IV on day 1 of cycle; L-asparaginase 10 000 U/m2 IM on day 4 of cycle; cytosine arabinoside 60 mg/m2 SC q 8h X 4 consecutive days (days 20-24 of cycle); doxorubicin 25-30 mg/m2 IV on day 40 of cycle; prednisone first cycle only @ 2 mg/kg PO q 24h (1st week), 1 mg/kg PO q 24h (2nd week), 0.5 mg/kg PO q 24h (3rd week), and 0.5 mg/kg PO q 48h (4th week); 2nd, 3rd, and 4th cycles identical but no prednisone; each cycle has a 2-week no-treatment period before the next cycle begins.",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-08T14:44:38.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 2026,
          "drug_id": 127,
          "indication_name": "Lymphoma (CMOP protocol)",
          "expected_effects": "Median progression-free survival (162 days) and median survival time (242 days) not significantly different from CHOP protocol, but significantly fewer adverse GI effects with CMOP protocol.",
          "common_combinations": "Vincristine 0.7 mg/m2 IV on weeks 1, 3, 6, 8, 11, 15, 19, 23; mitoxantrone 6 mg/m2 IV on weeks 4, 9, 17, and 25; and prednisolone PO q 24h at 2, 1.5, 1, and 0.5 mg/kg X 1 week each, beginning at week 1 of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-08T14:44:38.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 2027,
          "drug_id": 127,
          "indication_name": "Hemangiosarcoma",
          "expected_effects": "Median survival time = 189 days (range: 17-742 days); no difference between dogs with metastatic disease (median survival = 195 days) versus no metastatic disease (median survival = 189 days)",
          "common_combinations": "Doxorubicin 30 mg/m2 IV on day 1 of treatment protocol and q 21 days thereafter, vincristine 0.5-0.75mg/m2 IV on days 8 and 15 of treatment protocol and repeating q 2 of every 3 weeks thereafter (i.e., days 29 and 36, 50 and 57, etc.), and trimethoprim-sulfa 15 mg/kg PO q 12h continuously",
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-08T14:44:38.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 2028,
          "drug_id": 127,
          "indication_name": "Histiocytic sarcoma",
          "expected_effects": "Overall response rate = 58%; median survival time = 185 days (range =18-402 days); median time to tumor progression = 185 days for responders (range = 59-268 days)",
          "common_combinations": "Doxorubicin 30 mg/m2 IV (or 1 mg/kg if <12 kg) q 4 weeks; lomustine 70 mg/m2 PO q 4 weeks staggered with doxorubicin (i.e., lomustine weeks 1, 5, 9, etc. and doxorubicin weeks 3, 7, 11, etc.)",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-08T14:44:38.000000Z",
          "updated_at": "2020-11-08T14:44:38.000000Z"
      },
      {
          "id": 2029,
          "drug_id": 127,
          "indication_name": "Lymphoma (L-CHOP, maintenance-free, 12-week protocol)",
          "expected_effects": "Complete remission in 46% (median duration: 394 days) and partial remission in 27% (median duration: 41 days) of cases; median survival: 454 days (cats with complete remission), 82 days (cats with partial remission)",
          "common_combinations": "L-asparaginase 400 IU/kg SC once on week 1 of treatment; vincristine 0.025 mg/kg IV on weeks 1, 4, 7, and 10 of treatment; doxorubicin 1 mg/kg IV on weeks 3, 6, 9, and 12 of treatment; and prednisolone PO q 24h at 2, 1, and 0.5 mg/kg X 1 week each, beginning at week 1 of treatment",
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-11-08T14:57:59.000000Z",
          "updated_at": "2020-11-08T14:57:59.000000Z"
      },
      {
          "id": 2030,
          "drug_id": 127,
          "indication_name": "Lymphoma, intermediate- to high-grade (L-CHOP, maintenance-free, 25-week protocol)",
          "expected_effects": "Median progression-free interval and survival time = 56 and 97 (range 2-2019) days, respectively; cats with complete response have longer progression-free interval than those with partial or no response (205 vs. 54 vs, 21 days, respectively) and longer median survival time (318 vs. 85 vs. 27 days, respectively)",
          "common_combinations": "Doxorubicin, L-asparaginase, vincristine, and prednisolone per protocol",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-11-08T14:57:59.000000Z",
          "updated_at": "2020-11-08T14:57:59.000000Z"
      },
      {
          "id": 2031,
          "drug_id": 127,
          "indication_name": "Lymphoma (L-CMOP protocol)",
          "expected_effects": "Median progression-free survival time = 65.5 days (median = 364 days in cats showing improvement in physical exam and clinical signs after 1st 5 weeks of treatment [responders] vs. median = 31 days in nonresponders); median overall survival time = 108 days ; median = 591 days in responders vs. median = 73 days in nonresponders)",
          "common_combinations": "L-asparaginase 400 IU/kg SC on weeks 1 and 6 of treatment, vincristine 0.5 mg/m2 IV on weeks 2 and 4 of treatment (continuing q 2 weeks X 6 months if remission achieved), methotrexate 2.5 mg/cat PO on week 5 of treatment (continuing q 4 weeks X 6 months if remission achieved), and prednisone (editors' note: should be prednisolone for cats) 1-2 mg/kg PO q 24h continuously",
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-11-08T14:57:59.000000Z",
          "updated_at": "2020-11-08T14:57:59.000000Z"
      },
      {
          "id": 2032,
          "drug_id": 127,
          "indication_name": "Myeloma-related disorder",
          "expected_effects": "Complete resolution of hematologic and globulin abnormalities in 50% of treated cats and partial resolution in 33% of treated cats, with median survival time = 394 days (range: 174 to >528 days), 67% rate of neutropenia (all mild)",
          "common_combinations": "Prednisolone 5 mg/CAT PO q 24h, tapered as clinically indicated",
          "is_contraindicated": 0,
          "vdi_display_order": 16,
          "created_at": "2020-11-08T14:57:59.000000Z",
          "updated_at": "2020-11-08T14:57:59.000000Z"
      },
      {
          "id": 2033,
          "drug_id": 128,
          "indication_name": "Immune-mediated thrombocytopenia",
          "expected_effects": "94% rate of discharge from the hospital; normalization of platelet count in median of 9 days, similar to mycophenolate treatment; 88% and 82% 30-day and 60-day survival rates, respectively",
          "common_combinations": "Prednisolone 1.92 mg/kg (range: 1.44-3.53 mg/kg) PO q 24h (tapered as indicated)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-08T15:19:12.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 2034,
          "drug_id": 128,
          "indication_name": "Immune-mediated polyarthritis",
          "expected_effects": "70% success rate (improvement in clinical signs after 14 days of treatment and resolution of cytologic synovial fluid abnormalities after 45 days of treatment), similar to prednisone-treated dogs; fewer cyclosporine-treated dogs with PU/PD but more with opportunistic infections (20%) or diarrhea (10%) compared to prednisone",
          "common_combinations": "Carprofen, tramadol, or other analgesic as needed",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T15:19:12.000000Z",
          "updated_at": "2020-11-08T15:19:12.000000Z"
      },
      {
          "id": 2035,
          "drug_id": 130,
          "indication_name": "Cytosine arabinoside",
          "expected_effects": "No difference between a 6-month induction phase and no maintenance versus a 6-month induction phase plus a 1.5-year maintenance phase with regard to disease-free interval (216 vs. 184 days), median survival time (375 vs. 304 days), and 6-month (73 vs. 67%), 1-year (50 vs. 39%), and 2-year (24 vs. 21%) survival, respectively.",
          "common_combinations": "Induction phase: vincristine 0.65-0.75 mg/m2 IV on day 1 of cycle; L-asparaginase 10 000 U/m2 IM on day 4 of cycle; cyclophosphamide 180-200 mg/m2 PO once on day 10 of cycle; doxorubicin 25-30 mg/m2 IV on day 40 of cycle; prednisone first cycle only @ 2 mg/kg PO q 24h (1st week), 1 mg/kg PO q 24h (2nd week), 0.5 mg/kg PO q 24h (3rd week), and 0.5 mg/kg PO q 48h (4th week); 2nd, 3rd, and 4th cycles identical but no prednisone; each cycle has a 2-week no-treatment period before the next cycle begins.",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-08T18:41:41.000000Z",
          "updated_at": "2020-11-08T18:41:41.000000Z"
      },
      {
          "id": 2036,
          "drug_id": 130,
          "indication_name": "Meningoencephalitis",
          "expected_effects": "90% survival 3 months after treatment, compared to 44% in dogs receiving cytosine as intermittent SC injections; significantly greater lesion improvement on MRI with CRI protocol compared to SC\r\n90% survival 3 months after treatment, compared to 44% in dogs receiving cytosine as intermittent SC injections; significantly greater lesion improvement on MRI with CRI protocol compared to SC",
          "common_combinations": "Prednisone 1 mg/kg PO q 12h X 4 weeks, then tapered over the next 30 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-08T18:41:41.000000Z",
          "updated_at": "2020-11-08T18:41:41.000000Z"
      },
      {
          "id": 2039,
          "drug_id": 131,
          "indication_name": "Hemangiosarcoma",
          "expected_effects": "Median time to metastasis (>550 days) and median survival time (>550 days) significantly longer than in dogs receiving doxorubicin-cyclosporine",
          "common_combinations": "Doxorubicin 30 mg/m2 slow IV (20-minute infusion) q 3 weeks X 4 treatments; amoxicillin-clavulanate 12.5-20 mg/kg PO q 12h during period of expected neutrophil nadir",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T18:52:27.000000Z",
          "updated_at": "2020-11-08T18:52:27.000000Z"
      },
      {
          "id": 2040,
          "drug_id": 131,
          "indication_name": "Histiocytic sarcoma (relapsed)",
          "expected_effects": "17.6% response rate (all partial remissions), median event-free survival = 21 days (overall) or 70 days (responders)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-08T19:00:53.000000Z",
          "updated_at": "2020-11-08T19:00:53.000000Z"
      },
      {
          "id": 2041,
          "drug_id": 139,
          "indication_name": "Hemangiosarcoma - questionable efficacy",
          "expected_effects": "Median survival = 150 days, which is not appreciably different from doxorubicin monotherapy-treated dogs",
          "common_combinations": "Doxorubicin 30 mg/m2 IV q 2 weeks X 5 treatments",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T19:25:25.000000Z",
          "updated_at": "2020-11-08T19:25:25.000000Z"
      },
      {
          "id": 2042,
          "drug_id": 493,
          "indication_name": "Hair cycle arrest (alopecia X) in intact male dogs",
          "expected_effects": "Hair regrowth visible within 3 months in 75% of intact male dogs (75%); no hair regrowth noted in any neutered female dogs; overall response to therapy = 60%",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-08T19:34:24.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 2043,
          "drug_id": 493,
          "indication_name": "Postponement of puberty in queens",
          "expected_effects": "Postponement of puberty until at least age 21-36 months in all queens in one small clinical trial",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-08T19:34:24.000000Z",
          "updated_at": "2020-11-08T19:34:24.000000Z"
      },
      {
          "id": 2044,
          "drug_id": 140,
          "indication_name": "Reversal of acetylsalicylic acid-induced bleeding tendency",
          "expected_effects": "Complete normalization of buccal mucosal bleeding time (BMBT) in a small series of ASA-treated preoperative orthopedic patients with markedly prolonged BMBT values at admission; effect occurs as early as 15-30 minutes after desmopressin administration",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-08T19:51:30.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 2045,
          "drug_id": 140,
          "indication_name": "Place this right after current von Willebrand disease indication",
          "expected_effects": "No bleeding noted intra- or postoperatively in any of 16 treated vWD dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T19:51:30.000000Z",
          "updated_at": "2020-11-08T19:51:30.000000Z"
      },
      {
          "id": 2046,
          "drug_id": 143,
          "indication_name": "Morphine 0.1 mg/kg intraarticular once",
          "expected_effects": "Significantly greater analgesia (when combined with morphine 0.1 mg/kg intraarticular simultaneously) compared to placebo",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-08T20:06:29.000000Z",
          "updated_at": "2020-11-08T20:06:29.000000Z"
      },
      {
          "id": 2047,
          "drug_id": 143,
          "indication_name": "Sedation",
          "expected_effects": "Adequate sedation reported in 1 small case series",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-08T20:06:30.000000Z",
          "updated_at": "2020-11-08T20:06:30.000000Z"
      },
      {
          "id": 2048,
          "drug_id": 143,
          "indication_name": "Place this after the first item (Sedation, premedication…)",
          "expected_effects": null,
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-08T20:06:30.000000Z",
          "updated_at": "2020-11-08T20:06:30.000000Z"
      },
      {
          "id": 2049,
          "drug_id": 157,
          "indication_name": "Atrial fibrillation due to degenerative/myxomatous mitral valve disease",
          "expected_effects": "Significant reduction in median heart rate (180 beats/minute with diltiazem vs. 220 beats/minute pre-diltiazem)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-08T20:17:12.000000Z",
          "updated_at": "2020-11-08T20:17:12.000000Z"
      },
      {
          "id": 2050,
          "drug_id": 162,
          "indication_name": "Cytauxzoonosis - ineffective and potentially harmful",
          "expected_effects": "Parasitemia persists despite treatment, and adverse effects common (hypersalivation, monoparesis in the injected limb, proteinuria, and possibly hepatotoxicosis)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-08T20:23:39.000000Z",
          "updated_at": "2020-11-08T20:23:39.000000Z"
      },
      {
          "id": 2051,
          "drug_id": 163,
          "indication_name": "Mast cell tumor intraoperative handling - ineffective",
          "expected_effects": "No difference in circulating histamine concentrations or detectable cardiorespiratory benefit (in fact, occurrence of mild hypotension) with diphenhydramine treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-08T20:27:05.000000Z",
          "updated_at": "2020-11-08T20:27:05.000000Z"
      },
      {
          "id": 2052,
          "drug_id": 168,
          "indication_name": "Demodicosis (generalized)",
          "expected_effects": "94.8% remission rate; 0.5% rate of adverse effects (1 case transient ataxia, 1 case local skin irritation)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-08T20:32:59.000000Z",
          "updated_at": "2020-11-08T20:32:59.000000Z"
      },
      {
          "id": 2053,
          "drug_id": 169,
          "indication_name": "Reversal of acepromazine sedation",
          "expected_effects": "Signficant reduction in sedation (but not complete elimination of sedation) within a median of 5 minutes after doxopram administration",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-08T20:35:57.000000Z",
          "updated_at": "2020-11-08T20:35:57.000000Z"
      },
      {
          "id": 2054,
          "drug_id": 171,
          "indication_name": "Periodontal disease",
          "expected_effects": "Significant improvement in clinical periodontal status, without altering bacterial counts nor inducing antibacterial resistance",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 19,
          "created_at": "2020-11-08T20:50:03.000000Z",
          "updated_at": "2020-11-08T20:50:03.000000Z"
      },
      {
          "id": 2055,
          "drug_id": 177,
          "indication_name": "Laryngeal/pharyngeal edema (severe) immediately post-upper-airway surgery",
          "expected_effects": "Improvement in respiratory effort and resolution of cyanosis in 1 case report of critical laryngeal and pharyngeal edema after soft palate resection, laryngeal sacculectomy, and unilateral laryngeal tieback.",
          "common_combinations": "Dexmedetomidine 1 μg/kg/h IV CRI X 12h to control agitation associated with upper airway obstruction in 1 case report",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-09T20:26:31.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 2056,
          "drug_id": 177,
          "indication_name": "Place this as the 5th (and final dog) indication",
          "expected_effects": "Reduction of tongue size and color from markedly enlarged, unable to be retracted, and cyanotic to normal in size and movement after second treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-09T20:26:31.000000Z",
          "updated_at": "2020-11-09T20:26:31.000000Z"
      },
      {
          "id": 2057,
          "drug_id": 178,
          "indication_name": "Histiocytic sarcoma refractory to lomustine",
          "expected_effects": "Overall response rate = 29%; biological response rate = 71%; median time to progression = 69 days (range: 40-125 days). In the rescue setting, overall response rate = 19% and biological response rate = 63%; median time to progression in rescue treatment = 62 days (range: 40-125 days).",
          "common_combinations": "Lomustine 70 mg/m2 PO q 6 weeks, staggered evenly with doxorubicin to alternate doxorubicin/lomustine q 3 weeks; or epirubicin monotherapy in cases of lomustine toxicosis",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-09T20:45:10.000000Z",
          "updated_at": "2020-11-09T20:45:10.000000Z"
      },
      {
          "id": 2058,
          "drug_id": 178,
          "indication_name": "Injection-site sarcoma (neoadjuvant therapy post-resection)",
          "expected_effects": ">80% survival at 6 years",
          "common_combinations": "Surgical resection of sarcoma",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-09T20:45:10.000000Z",
          "updated_at": "2020-11-09T20:45:10.000000Z"
      },
      {
          "id": 2059,
          "drug_id": 494,
          "indication_name": "Gastric acid suppression",
          "expected_effects": "Gastric pH ≥3 for 88% of 24h period and ≥4 for 83% of 24h period after 5 days of treatment in dogs (compared to 13% and 4%, respectively, without treatment)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-11-11T18:44:41.000000Z",
          "updated_at": "2020-11-11T18:44:41.000000Z"
      },
      {
          "id": 2060,
          "drug_id": 182,
          "indication_name": "Parathyroid nodule ablation",
          "expected_effects": "Complete resolution of hypercalcemia in 85% of cases, almost always (96% of time) within 72h; 25% rate of hypocalcemia (21% subclinical, 4% with overt signs of hypocalcemia) within 2-21 days post-procedure; 8% delayed adverse effects (transient dysphagia, cyst at procedure site)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-11T18:49:45.000000Z",
          "updated_at": "2020-11-11T18:49:45.000000Z"
      },
      {
          "id": 2061,
          "drug_id": 189,
          "indication_name": "Giardiasis (group housing/colony)",
          "expected_effects": "Elimination of Giardia duodenalis shedding in >97% of dogs with one 10-day course of treatment and housing disinfection",
          "common_combinations": "During 10-day fenbendazole treatment period, dogs are bathed on day 5 and moved to new quarters to allow disinfection of prior housing space",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-11T19:38:14.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 2062,
          "drug_id": 189,
          "indication_name": "Dioctophyma renale infection - ineffective",
          "expected_effects": "Resolution of signs, together with surgical resection, associated with E. boehmi aberrant brain migration in 1 case report",
          "common_combinations": "Craniotomy and surgical resection of parasitic granuloma",
          "is_contraindicated": 0,
          "vdi_display_order": 9,
          "created_at": "2020-11-11T19:38:14.000000Z",
          "updated_at": "2020-11-11T19:38:14.000000Z"
      },
      {
          "id": 2063,
          "drug_id": 189,
          "indication_name": "Dioctophyma renale infection - ineffective",
          "expected_effects": "Persistence of parasite intrarenally (no therapeutic effect apparent) in 1 case report",
          "common_combinations": "Ivermectin 0.02 mg/kg SC once",
          "is_contraindicated": 0,
          "vdi_display_order": 10,
          "created_at": "2020-11-11T19:38:15.000000Z",
          "updated_at": "2020-11-11T19:38:15.000000Z"
      },
      {
          "id": 2064,
          "drug_id": 189,
          "indication_name": "Tracheal worm infestation - Oslerus (Filaroides) osleri",
          "expected_effects": "Resolution of clinical signs within 1 week of starting treatment, negative fecal sample 3 weeks after starting treatment, and absence of clinical signs on recheck 6 months after treatment, in 1 case report",
          "common_combinations": "Amoxicillin-clavulanate 20 mg/kg PO q 12h X 2 weeks",
          "is_contraindicated": 0,
          "vdi_display_order": 11,
          "created_at": "2020-11-11T19:38:15.000000Z",
          "updated_at": "2020-11-11T19:38:15.000000Z"
      },
      {
          "id": 2065,
          "drug_id": 189,
          "indication_name": "Lung fluke infestation - Paragonimus kellicotti",
          "expected_effects": "Complete resolution of clinical signs and of most radiographic lung nodules after treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 18,
          "created_at": "2020-11-11T19:38:15.000000Z",
          "updated_at": "2020-11-11T19:38:15.000000Z"
      },
      {
          "id": 2066,
          "drug_id": 192,
          "indication_name": "Pancytopenia associated with chronic canine ehrlichiosis",
          "expected_effects": "Improvement in clinical signs and peripheral blood cell counts during the month following treatment, but also adverse effects (initial worsening of bleeding, thrombocytopenia, and manifestations of bone pain) in 1 case report (https://www.ncbi.nlm.nih.gov/pubmed/28750787)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-11T20:10:32.000000Z",
          "updated_at": "2020-11-11T20:10:32.000000Z"
      },
      {
          "id": 2067,
          "drug_id": 194,
          "indication_name": "Perioperative analgesia for orthopedic surgery",
          "expected_effects": "Adequate analgesia in 60-90% of treated dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-11T20:30:28.000000Z",
          "updated_at": "2020-11-11T20:30:28.000000Z"
      },
      {
          "id": 2068,
          "drug_id": 194,
          "indication_name": "Transitional cell carcinoma",
          "expected_effects": "Remission rate = 20% (versus 57% when combined with cisplatin); all partial remissions, no complete remissions",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-11T20:30:28.000000Z",
          "updated_at": "2020-11-11T20:30:28.000000Z"
      },
      {
          "id": 2069,
          "drug_id": 194,
          "indication_name": "Nasal carcinoma",
          "expected_effects": "Significantly greater appetite, activity, and overall quality of life compared to radiation monotherapy, but no difference in longevity",
          "common_combinations": "Radiation therapy (30 Gy delivered as 5 X 6-Gy fractions twice weekly or 10 X 3-Gy fractions daily if orbit/sinus/intracranial involvement)",
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-11T20:30:29.000000Z",
          "updated_at": "2020-11-11T20:30:29.000000Z"
      },
      {
          "id": 2070,
          "drug_id": 194,
          "indication_name": "Solar dermatitis/actinic keratosis",
          "expected_effects": "Improvement noted in 80% of treated dogs",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-11T20:30:29.000000Z",
          "updated_at": "2020-11-11T20:30:29.000000Z"
      },
      {
          "id": 2071,
          "drug_id": 194,
          "indication_name": "Mammary gland tumor - highly malignant",
          "expected_effects": "Significantly longer disease-free interval (21 +/- 6 months versus 10 +/- 6 months) and overall survival (19 +/- 2 months versus 13 +/- 2 months) in surgery-plus-firocoxib-treated dogs versus surgery-only controls; results for firocoxib also superior to mitoxantrone (14 +/- 9 months and 17 +/- 3 months, respectively)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-11T20:30:29.000000Z",
          "updated_at": "2020-11-11T20:30:29.000000Z"
      },
      {
          "id": 2072,
          "drug_id": 194,
          "indication_name": "Perioperative analgesia (laparotomy) - narrow therapeutic-toxic range",
          "expected_effects": "Singificantly greater analgesia (lower pain scores) compared to placebo and compared to firocoxib 1 mg/kg PO q 24h; 25% incidence of reversible azotemia 72h post-op and 13% incidence of vomiting 48h post-op",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-11T20:30:29.000000Z",
          "updated_at": "2020-11-11T20:30:29.000000Z"
      },
      {
          "id": 2073,
          "drug_id": 195,
          "indication_name": "Cryptococcosis - osseous",
          "expected_effects": "Resolution of bony (radiographic) and gingival (grossly visible) lesions in 1 case report",
          "common_combinations": "Surgical debridement of necrotic gingival tissue",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-11T20:42:59.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 2074,
          "drug_id": 195,
          "indication_name": "Blastomycosis - intracardiac, intraocular",
          "expected_effects": "Resolution of skin and cardiac lesions but enucleation necessary, all in 1 case report",
          "common_combinations": "Itraconazole 5.6 mg/kg PO q 12h X 11 weeks as cotreatment in 1 case report",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-11T20:42:59.000000Z",
          "updated_at": "2020-11-11T20:42:59.000000Z"
      },
      {
          "id": 2075,
          "drug_id": 196,
          "indication_name": "Hyperaldosteronism (primary) - diagnostic testing",
          "expected_effects": "If baseline pre-fludrocortisone urinary aldosterone-to-creatinine-ratio (UACR) is ≤7.5 × 10(-9), primary hyperaldosteronism is very unlikely. If UACR is >7.5 × 10(-9), fludrocortisone suppression test is highly (>90%) effective at discriminating primary hyperaldosteronism (mild or no suppression, ≤50% change in UACR after 4 days of fludrocortisone treatment) from other, non-primary-hyperaldosteronism disorders (>50% reduction in UACR)",
          "common_combinations": "Baseline urinary aldosterone-to-creatinine ratio",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-11T20:58:41.000000Z",
          "updated_at": "2020-11-11T20:58:41.000000Z"
      },
      {
          "id": 2076,
          "drug_id": 197,
          "indication_name": "Reversal of midazolam sedation",
          "expected_effects": "Significantly faster time to head-up response in cats anesthetized with medetomidine + midazolam + ketamine IM",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-11T21:00:58.000000Z",
          "updated_at": "2020-11-11T21:00:58.000000Z"
      },
      {
          "id": 2077,
          "drug_id": 200,
          "indication_name": "Compulsive behavior (tail-chasing)",
          "expected_effects": "Significant reduction in tail chasing compared to placebo, but significantly less of a treatment effect compared to hypericin 0.05 mg/kg PO q 24h",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-11T21:11:47.000000Z",
          "updated_at": "2020-11-11T21:11:47.000000Z"
      },
      {
          "id": 2078,
          "drug_id": 200,
          "indication_name": "Atopic dermatitis - ineffective",
          "expected_effects": "No difference in skin lesion (CADESI-03) and pruritus intensity (PVAS) results between fluoxetine- and placebo-treated dogs in a randomized, double-blind, placebo-controlled, crossover trial.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-11T21:11:47.000000Z",
          "updated_at": "2020-11-11T21:11:47.000000Z"
      },
      {
          "id": 2079,
          "drug_id": 201,
          "indication_name": "Eosinophilic bronchopneumopathy",
          "expected_effects": "Resolution of clinical signs with inhaled fluticasone as monotherapy in 25% of cases, allowing halving or quartering of the dose for long-term maintenance; recurrence of clinical signs with tapering of fluticasone, requiring keeping the original dose without tapering in 25% of cases; remaining 50% of dogs have persistent coughing that may (25%) or may not (25%) be treated with oral glucocorticoids, according to owner and clinician preference",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-11T21:20:11.000000Z",
          "updated_at": "2020-11-11T21:20:11.000000Z"
      },
      {
          "id": 2080,
          "drug_id": 206,
          "indication_name": "Gabapentin",
          "expected_effects": "Significantly less morphine rescue analgesia needed with gabapentin treatment compared to placebo",
          "common_combinations": "Meloxicam 0.2 mg/kg IV immediately pre-op, continuing @ 0.1 mg/kg PO q 24h from 24h post-extubation as needed up to 10 days",
          "is_contraindicated": 0,
          "vdi_display_order": 1,
          "created_at": "2020-11-12T19:10:29.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 2081,
          "drug_id": 206,
          "indication_name": "Chiari-like malformation and syringomyelia",
          "expected_effects": "Significantly greater quality of life scores with treatment, compared to untreated baseline or to topiramate treatment",
          "common_combinations": "Chiari-like malformation and syringomyelia",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-12T19:10:29.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 2082,
          "drug_id": 206,
          "indication_name": "Postoperative analgesia (soft tissue surgery)",
          "expected_effects": "Analgesic effect similar to meloxicam + buprenorphine, marginally superior to buprenorphine monotherapy",
          "common_combinations": "Buprenorphine 0.02 mg/kg IM pre-op",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-12T19:10:29.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 2083,
          "drug_id": 206,
          "indication_name": "Modulation of fear response",
          "expected_effects": "Significantly reduced stress responses, with peak effect 2h after dosing, and lasting 12h; no benefit of 100 mg dose over 50 mg dose",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-12T19:10:29.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 2084,
          "drug_id": 206,
          "indication_name": "Analgesia (musculoskeletal disease) - long-term use",
          "expected_effects": "Subjective reduction in signs of pain (aggression, avoidance of human interaction, hiding)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-12T19:10:29.000000Z",
          "updated_at": "2020-11-12T19:10:29.000000Z"
      },
      {
          "id": 2085,
          "drug_id": 211,
          "indication_name": "Osteoarthritis - ineffective",
          "expected_effects": "No significant change in mobility or other parameters observed by owner or veterinarian; no apparent deterioration when glucosamine is switched to placebo",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-12T20:39:03.000000Z",
          "updated_at": "2020-11-12T20:39:03.000000Z"
      },
      {
          "id": 2086,
          "drug_id": 211,
          "indication_name": "Osteoarthritis - ineffective",
          "expected_effects": "No significant change in mobility or other parameters observed by owner or veterinarian; no apparent deterioration when glucosamine is switched to placebo",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-12T20:39:03.000000Z",
          "updated_at": "2020-11-12T20:39:03.000000Z"
      },
      {
          "id": 2087,
          "drug_id": 218,
          "indication_name": "Heparinized saline for IV catheter flush",
          "expected_effects": "Trend towards superiority of heparinized saline flushes in maintaining peripheral IV catheter patency over time compared to plain saline: 88% of catheters patent at 24h with heparinized saline vs. 75% with plain saline, 91% vs. 64% at 36h, and 90% vs. 50% at 42h.",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-12T20:50:11.000000Z",
          "updated_at": "2020-11-12T20:50:11.000000Z"
      },
      {
          "id": 2088,
          "drug_id": 233,
          "indication_name": "Meningioma",
          "expected_effects": "Improvement in neurologic deficits, and 50% decrease in mass on CT, within 2 weeks of starting treatment, and further 10% reduction in mass size by 8 weeks of treatment, in 1 case report",
          "common_combinations": "Hydroxyurea 50 mg/kg PO q 48h",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-16T01:38:02.000000Z",
          "updated_at": "2020-11-16T01:38:02.000000Z"
      },
      {
          "id": 2089,
          "drug_id": 235,
          "indication_name": "Babesiosis (B. microti-like isolate) - limited efficacy",
          "expected_effects": "Reduction of positive blood smear from 100% (pretreatment) to 82% on day 15 (versus 0% for atovaquone + azithromycin [ATO] and 22% for buparvaquone + azithromycin [BUP]) and 57% on day 45 (versus 19% for ATO and 28% for BUP); clinical relapse in 47% of imidocarb-treated dogs in 12 months following treatment, and persistence of parasitemia (via PCR) on days 90 (94% of cases) and 360 (73%) despite imidocarb treatment (versus 47% and 50% persistence with ATO and 68% and 60% persistence with BUP, respectively), all suggesting inferiority of imidocarb treatment compared to ATO or BUP",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 8,
          "created_at": "2020-11-16T01:48:10.000000Z",
          "updated_at": "2020-11-16T01:48:10.000000Z"
      },
      {
          "id": 2090,
          "drug_id": 235,
          "indication_name": "Hepatozoonosis - ineffective",
          "expected_effects": "Ineffective: persistent of infection at rate of 81-100% 2 weeks after treatment",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 4,
          "created_at": "2020-11-16T01:48:10.000000Z",
          "updated_at": "2020-11-16T01:48:10.000000Z"
      },
      {
          "id": 2091,
          "drug_id": 240,
          "indication_name": "Place as 2nd cat Indication item (=3rd Indication item overall)",
          "expected_effects": "Resolution of ketoacidosis and discharge from hospital in 15/15 cats after hospitalization for 2-5 days (median 4 days) in one study",
          "common_combinations": "Supportive care (potassium, phosphate supplementation as needed, red blood cell transfusion if severe hemolysis)",
          "is_contraindicated": 0,
          "vdi_display_order": 2,
          "created_at": "2020-11-16T02:02:14.000000Z",
          "updated_at": "2020-11-16T02:02:14.000000Z"
      },
      {
          "id": 2092,
          "drug_id": 240,
          "indication_name": "Diabetic ketoacidosis (SC + IM regular insulin protocol)",
          "expected_effects": "Faster normalization of blood glucose concentration and blood pH, and shorter hospitalization duration, compared to IV CRI low-dose regular insulin protocol",
          "common_combinations": "Supportive care (IV fluid resuscitation, potassium, phosphate supplementation as needed, red blood cell transfusion if severe hemolysis)",
          "is_contraindicated": 0,
          "vdi_display_order": 3,
          "created_at": "2020-11-16T02:02:14.000000Z",
          "updated_at": "2020-11-16T02:02:14.000000Z"
      },
      {
          "id": 2093,
          "drug_id": 245,
          "indication_name": "Diabetic ketoacidosis (SC + IM regular insulin protocol)",
          "expected_effects": "Longer time to normalization of blood glucose concentration and blood pH, and longer hospitalization duration, compared to insulin glargine SC + regular insulin IM protocol",
          "common_combinations": "Supportive care (IV fluid resuscitation, potassium, phosphate supplementation as needed, red blood cell transfusion if severe hemolysis)",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-16T02:09:17.000000Z",
          "updated_at": "2020-11-16T02:09:17.000000Z"
      },
      {
          "id": 2094,
          "drug_id": 247,
          "indication_name": "Upper respiratory infection",
          "expected_effects": "All treated cats improve over a 2-week period, and 62% of cats improve substantially (clinical signs very minor or fully resolved by end of 2 weeks); this is somewhat at odds with another study (placebo-controlled) that showed no clinical benefit when interferon is adminstered topically (https://www.ncbi.nlm.nih.gov/pubmed/25457261)",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-16T02:15:06.000000Z",
          "updated_at": "2020-11-16T02:15:06.000000Z"
      },
      {
          "id": 2095,
          "drug_id": 248,
          "indication_name": "Feline immunodeficiency virus infection (SC protocol) - clinical benefit unclear",
          "expected_effects": "Reduction in plasma IL-6 concentration with treatment, but no change in viremia and no appreciable overt clinical benefit",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 7,
          "created_at": "2020-11-16T02:26:50.000000Z",
          "updated_at": "2020-11-16T02:26:50.000000Z"
      },
      {
          "id": 2096,
          "drug_id": 248,
          "indication_name": "Viral keratitis (herpesvirus, calicivirus) - ineffective",
          "expected_effects": "No significant difference in clinical signs nor viral concentration (for either herpesvirus or calicivirus) compared to saline placebo",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 12,
          "created_at": "2020-11-16T02:32:56.000000Z",
          "updated_at": "2020-11-16T02:32:56.000000Z"
      },
      {
          "id": 2097,
          "drug_id": 255,
          "indication_name": "Sporotrichosis (itraconazole + potassium iodide protocol)",
          "expected_effects": "96% cure rate; 33% rate of adverse effects (typically anorexia, weight loss) responding to suspension fo treatment for 7-20 days before resuming",
          "common_combinations": "Potassium iodide 2.5 mg/kg PO q 24h initially, increasing by 2.5 mg/kg q 7 days until clinical improvement noted or maximum of 20 mg/kg reached",
          "is_contraindicated": 0,
          "vdi_display_order": 14,
          "created_at": "2020-11-16T02:56:04.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 2098,
          "drug_id": 255,
          "indication_name": "Pythiosis (pyloric, duodenal)",
          "expected_effects": "Stabilization of vomiting and weight loss X 15 months in 1 case report",
          "common_combinations": "Partial gastrectomy with gastrojejunal anastomosis (Billroth II procedure), partial pancreatectomy, and cholecystoduodenostomy; terbinafine 10 mg/kg PO q 24h; and supportive gastrointestinal medications",
          "is_contraindicated": 0,
          "vdi_display_order": 5,
          "created_at": "2020-11-16T02:56:04.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 2099,
          "drug_id": 255,
          "indication_name": "Disseminated fungal infection (Lecythophora canina, Plectosporium tabacinum)",
          "expected_effects": "Improvement (but not full resolution) of clinical signs during 10 month follow-up in one case report",
          "common_combinations": "Terbinafine 31.25 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 6,
          "created_at": "2020-11-16T02:56:04.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 2100,
          "drug_id": 255,
          "indication_name": "Microsporum canis infection (invasive - oronasal)",
          "expected_effects": "Complete resolution, and lack of recurrence after discontinuation of treatment (>2 months)",
          "common_combinations": "Terbinafine 28 mg/kg PO q 24h",
          "is_contraindicated": 0,
          "vdi_display_order": 15,
          "created_at": "2020-11-16T02:56:04.000000Z",
          "updated_at": "2020-11-16T02:56:04.000000Z"
      },
      {
          "id": 2101,
          "drug_id": 256,
          "indication_name": "Capillaria plica urinary tract parasitosis",
          "expected_effects": "Complete elimination of infection with single dose, where a 5-day course of fenbendazole had been ineffective, in 1 case report",
          "common_combinations": null,
          "is_contraindicated": 0,
          "vdi_display_order": 13,
          "created_at": "2020-11-16T03:01:08.000000Z",
          "updated_at": "2020-11-16T03:01:08.000000Z"
      }
  ];


      let query = "INSERT INTO vdi_treatments (id,drug_id,indication_name,expected_effects,common_combinations,is_contraindicated,vdi_display_order,created_at,updated_at) VALUES";


      for (let i = 0; i < data.length; ++i) {

            query = query + "('"
                  + data[i].id //id
                  + "','"
                  + data[i].drug_id //name
                  + "','"
                  + (data[i].indication_name == null ? null : data[i].indication_name.replace(/[`~!@#$^_?'"\\]/gi, '\\'))
                  + "','"
                  + (data[i].expected_effects == null ? null : data[i].expected_effects.replace(/[`~!@#$^_?'"\\]/gi, '\\'))
                  + "','"
                  + (data[i].common_combinations == null ? null : data[i].common_combinations.replace(/[`~!@#$^_?'"\\]/gi, '\\'))
                  + "','"
                  + data[i].is_contraindicated
                  + "','"
                  + data[i].vdi_display_order
                  + "','"
                  + data[i].created_at //date
                  + "','"
                  + data[i].updated_at //date
                  + "')";
            if (i != data.length - 1) {
                  query = query + ",";
            }
      }
      query = query + ";";
      let treatments = await ExecuteQuery(query, []);;
      console.log('Charles Inserting Treatments.................................')

      console.log('....................................................................');
}

export const insertTreatments = {
      insertTreatmentsToDatabaseAsync
}